CABL001J12301 (ASC4FIRST) and CABL001J12302 (ASC4START): Metaanalysis - AMNOG initial full Dossier Submission

ClinStat GmbH

Sponsor: Novartis

Table of Contents

Table of Contents 2

2. Efficacy 20

Table 2-1.1 Overall Survival (OS): time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 21

Figure 2-1.1 Overall Survival (OS) - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set) 22

Figure 2-1.1.1: Forest-Plot for Overall survival (months) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 23

Table 2-1.2 MMR: time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 24

Figure 2-1.2 MMR - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set) 25

Figure 2-1.2.1: Forest-Plot for Time to MMR (weeks) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 26

Table 2-1.3 MR4.0: time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 27

Figure 2-1.3 MR4.0 - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set) 28

Figure 2-1.3.1: Forest-Plot for Time to MR4.0 (weeks) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 29

Table 2-1.4 MR4.5: time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 30

Figure 2-1.4 MR4.5 - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set) 31

Figure 2-1.4.1: Forest-Plot for Time to MR4.5 (weeks) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 32

Table 2-1.5 Duration of MMR: duration of event - Metaanalysis based on IPD from ASC4FIRST and ASC4START (MMR Responder Set)....33

Figure 2-1.5 Duration of MMR - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (MMR Responder Set)....34

Figure 2-1.5.1: Forest-Plot for Duration of MMR (weeks) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (MMR Responder Set)....35

Table 2-1.6 Duration of MR4.0: duration of event - Metaanalysis based on IPD from ASC4FIRST and ASC4START (MR4.0 Responder Set)....36

Figure 2-1.6 Duration of MR4.0 - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (MR4.0 Responder Set)....37

Figure 2-1.6.1: Forest-Plot for Duration of MR4.0 (weeks) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (MR4.0 Responder Set)....38

Table 2-1.7 Duration of MR4.5: duration of event - Metaanalysis based on IPD from ASC4FIRST and ASC4START (MR4.5 Responder Set)....39

Figure 2-1.7 Duration of MR4.5 - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (MR4.5 Responder Set)....40

Figure 2-1.7.1: Forest-Plot for Duration of MR4.5 (weeks) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (MR4.5 Responder Set)....41

Table 2-1.8 Time to treatment failure: time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)....42

Figure 2-1.8 Time to treatment failure - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)....43

Figure 2-1.8.1: Forest-Plot for Time to treatment failure (months) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)....44

Table 2-1.9 Progression free survival: time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)....45

Figure 2-1.9 Progression free survival - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)....46

Figure 2-1.9.1: Forest-Plot for Progression free survival (months) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 47

Table 2-1.10 Event free survival: time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 48

Figure 2-1.10 Event free survival - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set) 49

Figure 2-1.10.1: Forest-Plot for Event free survival (months) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 50

Table 2-1.12 Progression to blast crisis (BC): time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 51

Figure 2-1.12 Progression to blast crisis (BC) - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set) 52

Figure 2-1.12.1: Forest-Plot for Progression to blast crisis (BC) (months) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 53

Table 2-1.13 MMR - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Competing risks analysis (Full Analysis Set) 54

Figure 2-1.13 MMR - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Competing risks analysis: Plot of cumulative incidence functions (Full Analysis Set) 56

Figure 2-1.13.1: Forest-Plot for competing risks analysis of Time to MMR - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 57

Table 2-2.1 Overall Survival: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 58

Table 2-2.2 MMR: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 59

Figure 2-2.2 MMR: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set) 63

Figure 2-2.2.1: Forest-Plot for Time to MMR (weeks) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 66

Table 2-2.3 Progression free survival: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 72

Figure 2-2.3.1: Forest-Plot for Progression free survival (months) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 76

Table 2-2.4 Progression to blast crisis (BC): Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 82

3. PRO 83

Table 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 84

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set) 92

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 107

Table 3-1.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 122

Figure 3-1.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)..... 126

Figure 3-1.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 132

Table 3-1.3 FACT-ITEM GP5: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 138

Figure 3-1.3 FACT-ITEM GP5: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set) 139

Figure 3-1.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 140

Table 3-1.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 141

Figure 3-1.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set) 145

Figure 3-1.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set).....152

Table 3-1.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 159

Figure 3-1.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set).....163

Figure 3-1.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set).....170

Table 3-1.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set).....177

Figure 3-1.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set) 180

Figure 3-1.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set).....184

Table 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set).....188

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set) 237

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 255

Table 3-2.2 EORTC QLQ-CML24: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set).....345

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 365

Table 3-2.3 FACIT GP5: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set).....401

Figure 3-2.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 405

Table 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 411

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set) 435

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 450

Table 3-2.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 492

Figure 3-2.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set) 515

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 524

Table 3-2.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 566

Figure 3-2.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set) 580

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 583

Table 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set) 607

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)....615

Table 3-4.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)....630

Figure 3-4.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)....634

Table 3-4.3 FACT-ITEM GP5: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)....640

Figure 3-4.3 FACT-ITEM GP5: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)....641

Table 3-4.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)....642

Figure 3-4.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)....646

Table 3-4.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)....653

Figure 3-4.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)....657

Table 3-4.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)....664

Figure 3-4.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set) 667

Table 3-5.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)..... 671

Figure 3-5.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)..... 717

Table 3-5.2 EORTC QLQ-CML24: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set).... 723

Table 3-5.3 FACT-ITEM GP5: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)..... 742

Table 3-5.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set).... 746

Figure 3-5.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)..... 768

Table 3-5.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set).... 774

Figure 3-5.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)..... 796

Table 3-5.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set).... 805

Table 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)..... 818

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set) 826

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 841

Table 3-6.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set) 856

Figure 3-6.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set) 860

Figure 3-6.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 866

Table 3-6.3 FACT-ITEM GP5: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set) 872

Figure 3-6.3 FACT-ITEM GP5: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set) 873

Figure 3-6.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 874

Table 3-6.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set) 875

Figure 3-6.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set) 879

Figure 3-6.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 886

Table 3-6.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set) 893

Figure 3-6.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set) 897

Figure 3-6.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 904

Table 3-6.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set) 911

Figure 3-6.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set) 914

Figure 3-6.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 918

Table 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set) 922

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set) 971

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 986

Table 3-7.2 EORTC QLQ-CML24: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set) 1076

Figure 3-7.2 EORTC QLQ-CML24: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)..... 1096

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 1102

Table 3-7.3 FACIT GP5: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)..... 1138

Figure 3-7.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 1142

Table 3-7.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)..... 1148

Figure 3-7.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)..... 1172

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 1181

Table 3-7.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)..... 1223

Figure 3-7.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)..... 1247

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)..... 1256

Table 3-7.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set) 1298

Figure 3-7.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set) 1312

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set) 1318

4. Safety 1342

Table 4-1.1 Any AE: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1343

Figure 4-1.1 Any AE - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1344

Figure 4-1.1.1: Forest-Plot for Any AE: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1345

Table 4-1.2 Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1346

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1357

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1378

Table 4-1.3 Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1399

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1441

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1524

Table 4-1.4 AE with grade >=3: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1607

Figure 4-1.4 AE with grade >=3 - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1608

Figure 4-1.4.1: Forest-Plot for AE with grade >=3: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1609

Table 4-1.5 AE with grade>=3 by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1610

Figure 4-1.5 AE with grade>=3 by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1615

Figure 4-1.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) ... 1623

Table 4-1.6 AE with grade>=3 by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1631

Figure 4-1.6 AE with grade>=3 by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1636

Figure 4-1.6.1: Forest-Plot for AE with grade>=3 by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) ... 1644

Table 4-1.7 Serious AE: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1652

Figure 4-1.7 Serious AE - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1653

Figure 4-1.7.1: Forest-Plot for Serious AE: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1654

Table 4-1.8 Serious AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1655

Figure 4-1.8 Serious AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1657

Figure 4-1.8.1: Forest-Plot for Serious AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1660

Table 4-1.9 Serious AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1663

Table 4-1.10 AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1664

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1673

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1690

Table 4-1.11 Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1707

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1716

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1733

Table 4-1.12 Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1750

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1759

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1775

Table 4-1.13 Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1791

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1799

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1814

Table 4-1.14 AE leading to discontinuation of treatment: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)... 1829

Figure 4-1.14 AE leading to discontinuation of treatment - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1830

Figure 4-1.14.1: Forest-Plot for AE leading to discontinuation of treatment: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)..... 1831

Table 4-1.15 Severe AE leading to discontinuation of treatment: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)... 1832

Figure 4-1.15 Severe AE leading to discontinuation of treatment - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)..... 1833

Figure 4-1.15.1: Forest-Plot for Severe AE leading to discontinuation of treatment: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)..... 1834

Table 4-1.16 SAE leading to discontinuation of treatment: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)... 1835

Figure 4-1.16 SAE leading to discontinuation of treatment - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set) 1836

Figure 4-1.16.1: Forest-Plot for SAE leading to discontinuation of treatment: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)..... 1837

Table 4-2.1 Time to first any AE: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 1838

Figure 4-2.1 Time to first any AE: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)..... 1842

Figure 4-2.1.1: Forest-Plot for Any AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)... 1845

Table 4-2.2 Time to first any AE by SOC: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)... 1851

Figure 4-2.2 Time to first any AE by SOC: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)....1865

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)...1871

Table 4-2.3 Time to first any AE by PT: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)....1895

Figure 4-2.3 Time to first any AE by PT: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)....1947

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)...1952

Table 4-2.4 Time to first AE with grade >=3: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)...2046

Figure 4-2.4.1: Forest-Plot for AE with grade >=3: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 2050

Table 4-2.5 Time to first AE with grade >=3 by SOC: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)...2056

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 2065

Table 4-2.6 Time to first AE with grade >=3 by PT: Time to event analysis by subgroups (Safety Analysis Set) 2079

Table 4-2.7 Time to first serious AE: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)....2080

Figure 4-2.7 Time to first serious AE: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)....2084

Figure 4-2.7.1: Forest-Plot for Serious AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)...2087

Table 4-2.8 Time to first serious AE by SOC: Time to event analysis by subgroups (Safety Analysis Set)...2093

Table 4-2.9 Time to first serious AE by PT: Time to event analysis by subgroups (Safety Analysis Set)...2094

Table 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)...2095

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)...2138

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 2154

Table 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)...2232

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)...2270

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 2283

Table 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)...2353

Figure 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)...2374

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set) 2386

Table 4-2.13 Time to first serious AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)...2423

Figure 4-2.13.1: Forest-Plot for Serious AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)...2427

Table 4-2.14 Time to first AE leading to discontinuation of treatment: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)....2431

Figure 4-2.14.1: Forest-Plot for AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)....2435

Table 4-2.15 Time to first severe AE leading to discontinuation of treatment: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)....2441

Figure 4-2.15.1: Forest-Plot for Severe AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)....2445

Table 4-2.16 Time to first SAE leading to discontinuation of treatment: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)....2451

Figure 4-2.16.1: Forest-Plot for SAE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)....2455

Table 4-4.1 Discontinuation of treatment due to AE - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Competing risks analysis (Safety Analysis Set)....2461

Figure 4-4.1 Discontinuation of treatment due to AE - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Competing risks analysis: Plot of cumulative incidence functions (Safety Analysis Set)....2463

Figure 4-4.1.1: Forest-Plot for competing risks analysis of Time to discontinuation of treatment due to AE - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)....2464


2. Efficacy

Table 2-1.1 Overall Survival (OS): time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		**Comparison**	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	481	477	0.78	0.347
Number of patients with events, n (%)	4 (0.8)	5 (1.0)	[0.21; 2.91]	
			0.713	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.1 Overall Survival (OS) - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.1.1: Forest-Plot for Overall survival (months) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-1.2 MMR: time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	481	477	1.26	<0.001
Number of patients with events, n (%)	355 (73.8)	317 (66.5)	[1.08; 1.47]	
			0.003	
Percentiles (weeks) [95% CI]				
25th	13.4 [12.6; 23.9]	24.1 [N.E.; N.E.]		
Median	24.6 [24.3; 25.0]	36.0 [25.3; 36.3]		
75th	60.4 [60.1; 72.3]	72.1 [60.3; 73.7]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.2 MMR - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.2.1: Forest-Plot for Time to MMR (weeks) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-1.3 MR4.0: time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	481	477	1.47	0.204
Number of patients with events, n (%)	224 (46.6)	160 (33.5)	[1.20; 1.81]	
			<0.001	
Percentiles (weeks) [95% CI]				
25th	35.6 [24.6; 36.3]	48.3 [47.0; 49.1]		
Median	84.3 [71.3; 96.3]	108.4 [94.9; N.E.]		
75th	132.4 [132.4; N.E.]	N.E. [132.0; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.3 MR4.0 - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.3.1: Forest-Plot for Time to MR4.0 (weeks) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-1.4 MR4.5: time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	481	477	1.48	0.529
Number of patients with events, n (%)	161 (33.5)	103 (21.6)	[1.15; 1.90]	
			0.002	
Percentiles (weeks) [95% CI]				
25th	60.3 [48.1; 72.1]	84.1 [70.0; 96.3]		
Median	121.9 [108.4; 132.3]	131.9 [131.6; N.E.]		
75th	N.E. [132.3; N.E.]	N.E. [N.E.; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.4 MR4.5 - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.4.1: Forest-Plot for Time to MR4.5 (weeks) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-1.5 Duration of MMR: duration of event - Metaanalysis based on IPD from ASC4FIRST and ASC4START (MMR Responder Set)

	Treatment groups		Comparison	
	Asciminib (N = 355)	**Investigator Selected TKI (N = 317)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	355	317	1.77	0.225
Number of patients with events, n (%)	10 (2.8)	4 (1.3)	[0.54; 5.75]	
			0.336	
Percentiles (weeks) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.5 Duration of MMR - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (MMR Responder Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.5.1: Forest-Plot for Duration of MMR (weeks) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (MMR Responder Set)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-1.6 Duration of MR4.0: duration of event - Metaanalysis based on IPD from ASC4FIRST and ASC4START (MR4.0 Responder Set)

	Treatment groups		Comparison	
	Asciminib (N = 224)	**Investigator Selected TKI (N = 160)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	224	160	1.48	0.553
Number of patients with events, n (%)	6 (2.7)	3 (1.9)	[0.37; 5.95]	
			0.582	
Percentiles (weeks) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.6 Duration of MR4.0 - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (MR4.0 Responder Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.6.1: Forest-Plot for Duration of MR4.0 (weeks) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (MR4.0 Responder Set)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-1.7 Duration of MR4.5: duration of event - Metaanalysis based on IPD from ASC4FIRST and ASC4START (MR4.5 Responder Set)

	Treatment groups		Comparison	
	Asciminib (N = 161)	**Investigator Selected TKI (N = 103)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	161	103	0.59	0.968
Number of patients with events, n (%)	3 (1.9)	3 (2.9)	[0.12; 2.97]	
			0.519	
Percentiles (weeks) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.7 Duration of MR4.5 - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (MR4.5 Responder Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.7.1: Forest-Plot for Duration of MR4.5 (weeks) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (MR4.5 Responder Set)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-1.8 Time to treatment failure: time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	481	477	0.51	0.018
Number of patients with events, n (%)	95 (19.8)	158 (33.1)	[0.40; 0.66]	
			<0.001	
Percentiles (months) [95% CI]				
25th	32.9 [21.9; N.E.]	12.4 [11.1; 14.6]		
Median	N.E. [32.9; N.E.]	N.E. [28.4; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.8 Time to treatment failure - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.8.1: Forest-Plot for Time to treatment failure (months) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-1.9 Progression free survival: time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	481	477	0.96	0.185
Number of patients with events, n (%)	11 (2.3)	11 (2.3)	[0.42; 2.22]	
			0.930	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.9 Progression free survival - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.9.1: Forest-Plot for Progression free survival (months) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-1.10 Event free survival: time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	481	477	0.54	0.047
Number of patients with events, n (%)	80 (16.6)	125 (26.2)	[0.41; 0.72]	
			<0.001	
Percentiles (months) [95% CI]				
25th	32.9 [32.9; N.E.]	17.1 [11.3; 22.1]		
Median	N.E. [32.9; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.10 Event free survival - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.10.1: Forest-Plot for Event free survival (months) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-1.12 Progression to blast crisis (BC): time to event analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	481	477	1.87	0.995
Number of patients with events, n (%)	4 (0.8)	2 (0.4)	[0.34; 10.28]	
			0.462	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.12 Progression to blast crisis (BC) - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.12.1: Forest-Plot for Progression to blast crisis (BC) (months) - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Table 2-1.13 MMR - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Competing risks analysis (Full Analysis Set)

	Treatment groups		Comparison			
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**sHR**	**[95%-CI]**	**P-Value**	**Test for Heterogeneity p-Value**
N*	481	477				
Number of patients with events, n (%)	355 (73.8)	317 (66.5)	1.38	[1.19; 1.60]	<0.001	<0.001
Number of patients with competing risk, n (%)	57 (11.9)	114 (23.9)				
Number of patients censored, n (%)	69 (14.3)	46 (9.6)				
Cumulative incidence (%) [95%-CI]						
Week 12	3.5 [2.1; 5.5]	1.1 [0.4; 2.3]				
Week 24	31.9 [27.7; 36.1]	15.0 [11.9; 18.4]				
Week 36	55.4 [50.9; 59.7]	44.7 [40.2; 49.1]				
Week 48	61.1 [56.6; 65.3]	51.5 [46.9; 55.9]				
Week 60	65.5 [61.0; 69.6]	58.1 [53.5; 62.5]				
Week 72	70.7 [66.2; 74.7]	62.5 [57.9; 66.8]				
Week 84	75.2 [70.7; 79.2]	66.0 [61.4; 70.2]				
Week 96	76.0 [71.5; 79.9]	67.1 [62.5; 71.3]				
Week 108	77.0 [72.4; 80.9]	68.2 [63.5; 72.3]				
Week 120	79.9 [75.0; 84.0]	69.5 [64.7; 73.8]				

	Treatment groups		Comparison			
	Asciminib (N = 481)	Investigator Selected TKI (N = 477)	sHR	[95%-CI]	P-Value	Test for Heterogeneity p-Value
Week 132	82.3 [76.9; 86.6]	72.5 [66.9; 77.3]				
Week 144	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]				

sHR: Sub-distribution Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients
IPD: Individual Patient Data
.....
Competing risk for the event of interest (MMR) is the premature discontinuation of study medication for any reason.
Two-sided 95% CI for the cumulative incidence functions are computed by Kaplan-Meier methods.
The sub-distribution HR and 95% CI values are from a stratified Fine-Gray proportional hazard model for competing risk analysis with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
P-Values are from a stratified Gray test for competing risks with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the hetereogeneity test is based on a stratified Fine-Gray proportional hazard model with an additional interaction term between study and treatment arm.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 2-1.13 MMR - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Competing risks analysis: Plot of cumulative incidence functions (Full Analysis Set)



Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-1.13.1: Forest-Plot for competing risks analysis of Time to MMR - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	sHR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	162/197	121/193	1.89	1.50; 2.38	<0.001
ASC4START	193/284	196/284	1.11	0.91; 1.34	0.243
Pooled Analysis	355/481	317/477	1.38	1.19; 1.60	<0.001



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits, sHR: Sub-distribution hazard ratio.
p-value from a stratified Gray test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-2.1 Overall Survival: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

No subgroup analyses were performed, because for every attribute there are not at least 10 patients for every subgroup or not at least 10 events in at least one subgroup.

.....
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-2.2 MMR: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (weeks) [95% CI]	n/N* (%)	Median (weeks) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.633)								
Low	234/291 (80.4)	24.3 [24.1; 24.4]	224/292 (76.7)	24.9 [24.4; 26.9]	1.20	[1.00; 1.45]	0.043	0.017
Intermediate	89/129 (69.0)	25.1 [24.3; 36.3]	69/128 (53.9)	48.1 [36.1; 60.3]	1.43	[1.04; 1.97]	0.026	0.012
High	32/61 (52.5)	48.3 [36.0; 60.4]	24/57 (42.1)	48.3 [36.3; N.E.]	1.25	[0.72; 2.15]	0.407	0.063
Sex								
(Interaction test: p = 0.549)								
Female	134/175 (76.6)	24.3 [24.1; 25.0]	136/201 (67.7)	25.0 [24.4; 36.0]	1.17	[0.91; 1.49]	0.194	0.337
Male	221/306	24.6 [24.3; 35.6]	181/276	36.3 [35.7; 48.1]	1.32	[1.08; 1.62]	0.006	<0.001

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (weeks) [95% CI]	n/N* (%)	Median (weeks) [95% CI]				
	(72.2)		(65.6)					
Race								
(Interaction test: p = 0.484)								
Asian	99/128	24.1 [24.1; 24.6]	89/132	35.6 [24.3; 36.4]	1.37	[1.02; 1.85]	0.027	0.105
	(77.3)		(67.4)					
White	242/333	24.6 [24.4; 26.1]	213/320	36.1 [25.3; 36.4]	1.20	[1.00; 1.45]	0.048	0.003
	(72.7)		(66.6)					
Others	14/20	25.0 [12.6; 48.4]	15/25	25.6 [24.1; N.E.]	1.05	[0.46; 2.38]	0.908	0.991
	(70.0)		(60.0)					
Age groups								
(Interaction test: p = 0.101)								
18 - < 65 years	277/390	24.7 [24.3; 36.1]	269/397	36.1 [25.3; 36.3]	1.17	[0.99; 1.39]	0.053	<0.001
	(71.0)		(67.8)					
65 - < 75 years	61/72	24.3 [24.1; 24.7]	32/53	26.4 [24.1; 37.7]	1.66	[1.05; 2.63]	0.027	0.396
	(84.7)		(60.4)					
>= 75 years	17/19	24.3 [12.6; 24.6]	16/27	36.1 [24.3; 48.1]	2.89	[1.26; 6.63]	0.007	0.067


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (weeks) [95% CI]	n/N* (%)	Median (weeks) [95% CI]				
	(89.5)		(59.3)					
Pre-randomization selection of TKI								
(Interaction test: p = <0.001)								
Imatinib	82/101	24.1 [24.0; 24.6]	59/102	48.6 [36.1; 60.0]	2.29	[1.63; 3.24]	<0.001	N.E.
	(81.2)		(57.8)					
Nilotinib	241/339	24.7 [24.4; 36.1]	229/333	25.1 [24.4; 36.0]	1.02	[0.85; 1.22]	0.803	0.459
	(71.1)		(68.8)					
Dasatinib	32/41	24.3 [24.0; 36.0]	29/42	36.1 [24.4; 60.3]	1.82	[1.07; 3.08]	0.022	N.E.
	(78.0)		(69.0)					
Geographic region								
(Interaction test: p = 0.339)								
Europe excluding Germany	148/202	24.6 [24.3; 36.1]	138/203	35.7 [24.9; 36.7]	1.08	[0.85; 1.37]	0.512	0.085
	(73.3)		(68.0)					
Germany	68/91	24.4 [24.3; 25.3]	45/68	36.3 [25.3; 48.3]	1.39	[0.93; 2.07]	0.092	0.028

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (weeks) [95% CI]	n/N* (%)	Median (weeks) [95% CI]				
Others	(74.7) 139/188 (73.9)	24.3 [24.1; 25.9]	(66.2) 134/206 (65.0)	35.7 [24.6; 36.4]	1.32	[1.03; 1.69]	0.020	0.012

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-2.2 MMR: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-2.2 MMR: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Pre-randomization selection of TKI: Nilotinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-2.2 MMR: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-2.2.1: Forest-Plot for Time to MMR (weeks) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	124/153	99/150	1.68	1.28; 2.20	<0.001
ASC4START	153/237	170/247	0.93	0.74; 1.16	0.532
Pooled Analysis	277/390	269/397	1.17	0.99; 1.39	0.053
65 - < 75 years					
ASC4FIRST	29/34	17/29	2.04	1.06; 3.93	0.029
ASC4START	32/38	15/24	1.38	0.74; 2.57	0.311
Pooled Analysis	61/72	32/53	1.66	1.05; 2.63	0.027
>= 75 years					
ASC4FIRST	9/10	5/14	13.97	1.69; 115.40	0.002
ASC4START	8/9	11/13	1.57	0.58; 4.27	0.326
Pooled Analysis	17/19	16/27	2.89	1.26; 6.63	0.007



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-2.2.1: Forest-Plot for Time to MMR (weeks) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	15/23	6/20	2.78	0.98; 7.93	0.043
ASC4START	17/38	18/37	0.86	0.44; 1.67	0.654
Pooled Analysis	32/61	24/57	1.25	0.72; 2.15	0.407
Intermediate					
ASC4FIRST	39/54	24/53	2.43	1.43; 4.11	<0.001
ASC4START	50/75	45/75	1.03	0.69; 1.54	0.880
Pooled Analysis	89/129	69/128	1.43	1.04; 1.97	0.026
Low					
ASC4FIRST	108/120	91/120	1.56	1.18; 2.08	0.002
ASC4START	126/171	133/172	0.99	0.77; 1.26	0.962
Pooled Analysis	234/291	224/292	1.20	1.00; 1.45	0.043



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-2.2.1: Forest-Plot for Time to MMR (weeks) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	53/64	40/62	1.50	0.96; 2.33	0.073
ASC4START	95/138	98/141	0.94	0.71; 1.25	0.710
Pooled Analysis	148/202	138/203	1.08	0.85; 1.37	0.512
Germany					
ASC4FIRST	16/19	9/15	3.85	1.38; 10.71	0.006
ASC4START	52/72	36/53	1.11	0.71; 1.71	0.621
Pooled Analysis	68/91	45/68	1.39	0.93; 2.07	0.092
Others					
ASC4FIRST	93/114	72/116	1.72	1.25; 2.38	<0.001
ASC4START	46/74	62/90	0.90	0.61; 1.32	0.592
Pooled Analysis	139/188	134/206	1.32	1.03; 1.69	0.020



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-2.2.1: Forest-Plot for Time to MMR (weeks) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	32/41	29/42	1.82	1.07; 3.08	0.022
Pooled Analysis	32/41	29/42	1.82	1.07; 3.08	0.022
Imatinib					
ASC4FIRST	82/101	59/102	2.29	1.63; 3.24	<0.001
Pooled Analysis	82/101	59/102	2.29	1.63; 3.24	<0.001
Nilotinib					
ASC4FIRST	48/55	33/49	1.19	0.75; 1.89	0.400
ASC4START	193/284	196/284	0.99	0.81; 1.20	0.921
Pooled Analysis	241/339	229/333	1.02	0.85; 1.22	0.803



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-2.2.1: Forest-Plot for Time to MMR (weeks) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	27/40	34/46	0.97	0.58; 1.62	0.913
Pooled Analysis	99/128	89/132	1.37	1.02; 1.85	0.027
Asian/Others					
ASC4FIRST	75/91	58/90	1.68	1.17; 2.42	0.003
Others					
ASC4START	11/17	12/21	0.93	0.41; 2.15	0.863
Pooled Analysis	14/20	15/25	1.05	0.46; 2.38	0.908
White					
ASC4FIRST	87/106	63/103	1.86	1.32; 2.61	<0.001
ASC4START	155/227	150/217	0.99	0.79; 1.24	0.961
Pooled Analysis	242/333	213/320	1.20	1.00; 1.45	0.048



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-2.2.1: Forest-Plot for Time to MMR (weeks) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	56/68	49/75	1.36	0.91; 2.04	0.111
ASC4START	78/107	87/126	1.06	0.78; 1.45	0.677
Pooled Analysis	134/175	136/201	1.17	0.91; 1.49	0.194
Male					
ASC4FIRST	106/129	72/118	2.06	1.50; 2.83	<0.001
ASC4START	115/177	109/158	0.96	0.74; 1.25	0.791
Pooled Analysis	221/306	181/276	1.32	1.08; 1.62	0.006



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-2.3 Progression free survival: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.436)								
Low	6/291 (2.1)	N.E. [N.E.; N.E.]	4/292 (1.4)	N.E. [N.E.; N.E.]	1.50	[0.42; 5.33]	0.524	0.214
Intermediate	4/129 (3.1)	N.E. [N.E.; N.E.]	4/128 (3.1)	N.E. [N.E.; N.E.]	0.97	[0.24; 3.89]	0.970	0.994
High	1/61 (1.6)	N.E. [N.E.; N.E.]	3/57 (5.3)	N.E. [N.E.; N.E.]	0.28	[0.03; 2.73]	0.244	0.996
Sex								
(Interaction test: p = 0.867)								
Female	3/175 (1.7)	N.E. [N.E.; N.E.]	3/201 (1.5)	N.E. [N.E.; N.E.]	1.16	[0.23; 5.87]	0.856	0.923

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Male	8/306 (2.6)	N.E. [N.E.; N.E.]	8/276 (2.9)	N.E. [N.E.; N.E.]	0.92	[0.35; 2.46]	0.874	0.149
Race								
(Interaction test: p = 0.966)								
Asian	3/128 (2.3)	N.E. [N.E.; N.E.]	4/132 (3.0)	N.E. [N.E.; N.E.]	0.63	[0.14; 2.86]	0.550	0.996
White	7/333 (2.1)	N.E. [N.E.; N.E.]	7/320 (2.2)	N.E. [N.E.; N.E.]	0.90	[0.31; 2.58]	0.847	0.577
Others	1/20 (5.0)	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	2.77	[0.03; 255.52]	0.337	N.E.
Age groups								
(Interaction test: p = 1.000)								
18 - < 65 years	9/390 (2.3)	N.E. [N.E.; N.E.]	11/397 (2.8)	N.E. [N.E.; N.E.]	0.83	[0.34; 2.00]	0.675	0.206
65 - < 75 years	2/72 (2.8)	N.E. [N.E.; N.E.]	0/53	N.E. [N.E.; N.E.]	5.10	[0.11; 244.03]	0.170	1.000


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
>= 75 years	0/19	N.E. [N.E.; N.E.]	0/27	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Pre-randomization selection of TKI								
(Interaction test: p = 0.624)								
Imatinib	3/101 (3.0)	N.E. [N.E.; N.E.]	6/102 (5.9)	N.E. [N.E.; N.E.]	0.48	[0.12; 1.90]	0.281	N.E.
Nilotinib	6/339 (1.8)	N.E. [N.E.; N.E.]	5/333 (1.5)	N.E. [N.E.; N.E.]	1.13	[0.34; 3.71]	0.837	0.991
Dasatinib	2/41 (4.9)	N.E. [N.E.; N.E.]	0/42	N.E. [N.E.; N.E.]	4.34	[0.09; 216.27]	0.207	N.E.
Geographic region								
(Interaction test: p = 0.548)								
Europe excluding Germany	3/202 (1.5)	N.E. [N.E.; N.E.]	5/203 (2.5)	N.E. [N.E.; N.E.]	0.55	[0.13; 2.34]	0.417	0.711

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Germany	2/91 (2.2)	N.E. [N.E.; N.E.]	2/68 (2.9)	N.E. [N.E.; N.E.]	0.73	[0.10; 5.28]	0.755	N.E.
Others	6/188 (3.2)	N.E. [N.E.; N.E.]	4/206 (1.9)	N.E. [N.E.; N.E.]	1.52	[0.43; 5.40]	0.514	0.993

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-2.3.1: Forest-Plot for Progression free survival (months) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	4/153	8/150	0.51	0.15; 1.68	0.255
ASC4START	5/237	3/247	1.69	0.40; 7.08	0.467
Pooled Analysis	9/390	11/397	0.83	0.34; 2.00	0.675
65 - < 75 years					
ASC4FIRST	1/34	0/29	4.43	0.05; 401.48	0.221
ASC4START	1/38	0/24	1.57	0.02; 152.79	0.480
Pooled Analysis	2/72	0/53	5.10	0.11; 244.03	0.170
>= 75 years					
ASC4FIRST	0/10	0/14	N.E.	N.E.; N.E.	N.E.
ASC4START	0/9	0/13	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/19	0/27	N.E.	N.E.; N.E.	N.E.



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-2.3.1: Forest-Plot for Progression free survival (months) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	1/20	0.76	0.05; 12.15	0.843
ASC4START	0/38	2/37	0.19	0.00; 7.91	0.149
Pooled Analysis	1/61	3/57	0.28	0.03; 2.73	0.244
Intermediate					
ASC4FIRST	2/54	4/53	0.49	0.09; 2.66	0.394
ASC4START	2/75	0/75	4.86	0.12; 200.46	0.163
Pooled Analysis	4/129	4/128	0.97	0.24; 3.89	0.970
Low					
ASC4FIRST	2/120	3/120	0.67	0.11; 4.00	0.656
ASC4START	4/171	1/172	4.01	0.45; 35.90	0.179
Pooled Analysis	6/291	4/292	1.50	0.42; 5.33	0.524



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 2-2.3.1: Forest-Plot for Progression free survival (months) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	2/64	4/62	0.47	0.09; 2.60	0.377
ASC4START	1/138	1/141	0.87	0.05; 14.20	0.925
Pooled Analysis	3/202	5/203	0.55	0.13; 2.34	0.417
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	2/72	2/53	0.73	0.10; 5.28	0.755
Pooled Analysis	2/91	2/68	0.73	0.10; 5.28	0.755
Others					
ASC4FIRST	3/114	4/116	0.73	0.16; 3.28	0.683
ASC4START	3/74	0/90	7.81	0.25; 241.72	0.069
Pooled Analysis	6/188	4/206	1.52	0.43; 5.40	0.514




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-2.3.1: Forest-Plot for Progression free survival (months) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 2-2.3.1: Forest-Plot for Progression free survival (months) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 2-2.3.1: Forest-Plot for Progression free survival (months) - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	2/68	2/75	1.23	0.17; 9.02	0.839
ASC4START	1/107	1/126	1.04	0.06; 16.68	0.978
Pooled Analysis	3/175	3/201	1.16	0.23; 5.87	0.856
Male					
ASC4FIRST	3/129	6/118	0.47	0.12; 1.87	0.269
ASC4START	5/177	2/158	2.27	0.44; 11.72	0.313
Pooled Analysis	8/306	8/276	0.92	0.35; 2.46	0.874



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 2-2.4 Progression to blast crisis (BC): Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

No subgroup analyses were performed, because for every attribute there are not at least 10 patients for every subgroup or not at least 10 events in at least one subgroup.

.....
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

3. PRO

Table 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Global health status/QoL (MID=10)				
N*	481	477	0.81	0.414
Number of patients with events, n (%)	98 (20.4)	112 (23.5)	[0.61; 1.06]	
			0.085	
Percentiles (months) [95% CI]				
25th	4.2 [2.0; 11.1]	1.9 [1.8; 2.8]		
Median	22.1 [22.0; N.E.]	22.1 [11.1; N.E.]		
75th	N.E. [22.2; N.E.]	30.3 [N.E.; N.E.]		
Physical functioning (MID=10)				
N*	481	477	0.75	0.126
Number of patients with events, n (%)	74 (15.4)	87 (18.2)	[0.55; 1.02]	
			0.069	
Percentiles (months) [95% CI]				
25th	8.9 [2.8; 22.1]	2.8 [1.8; 11.0]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [22.1; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Role functioning (MID=10)				
N*	481	477	0.86	0.037
Number of patients with events, n (%)	98 (20.4)	100 (21.0)	[0.65; 1.14]	
			0.350	
Percentiles (months) [95% CI]				
25th	2.8 [1.9; 5.6]	2.7 [1.9; 5.4]		
Median	22.2 [22.1; N.E.]	22.1 [11.8; N.E.]		
75th	N.E. [22.5; N.E.]	N.E. [22.3; N.E.]		
Emotional functioning (MID=10)				
N*	481	477	0.68	0.973
Number of patients with events, n (%)	76 (15.8)	96 (20.1)	[0.50; 0.92]	
			0.031	
Percentiles (months) [95% CI]				
25th	8.3 [2.8; 11.1]	2.8 [2.7; 5.6]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [22.1; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Cognitive functioning (MID=10)				
N*	481	477	0.85	0.398
Number of patients with events, n (%)	115 (23.9)	127 (26.6)	[0.65; 1.09]	
			0.196	
Percentiles (months) [95% CI]				
25th	2.0 [1.9; 2.8]	2.7 [1.9; 2.8]		
Median	22.1 [11.1; N.E.]	11.1 [5.7; 22.1]		
75th	N.E. [N.E.; N.E.]	N.E. [22.2; N.E.]		
Social functioning (MID=10)				
N*	481	477	0.72	0.565
Number of patients with events, n (%)	92 (19.1)	110 (23.1)	[0.54; 0.95]	
			0.024	
Percentiles (months) [95% CI]				
25th	2.7 [1.9; 5.6]	1.9 [1.2; 2.8]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	22.5 [22.1; N.E.]	N.E. [11.1; N.E.]		
75th	N.E. [22.5; N.E.]	N.E. [N.E.; N.E.]		
Fatigue (MID=10)				
N*	481	477	0.68	0.501
Number of patients with events, n (%)	100 (20.8)	120 (25.2)	[0.52; 0.90]	
			0.007	
Percentiles (months) [95% CI]				
25th	1.9 [1.8; 5.5]	1.5 [1.0; 1.9]		
Median	22.2 [22.1; N.E.]	22.0 [5.6; N.E.]		
75th	N.E. [22.2; N.E.]	N.E. [N.E.; N.E.]		
Nausea and vomiting (MID=10)				
N*	481	477	0.59	0.087
Number of patients with events, n (%)	62 (12.9)	89 (18.7)	[0.43; 0.82]	
			0.001	
Percentiles (months) [95% CI]				
25th	11.1 [8.2; N.E.]	2.8 [2.0; 5.6]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	22.2 [22.1; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Pain (MID=10)				
N*	481	477	0.73	0.040
Number of patients with events, n (%)	113 (23.5)	134 (28.1)	[0.57; 0.95]	
			0.009	
Percentiles (months) [95% CI]				
25th	1.9 [1.0; 2.0]	1.1 [1.0; 1.8]		
Median	N.E. [11.1; N.E.]	5.7 [2.8; 16.4]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Dyspnoea (MID=10)				
N*	481	477	0.73	0.188
Number of patients with events, n (%)	70 (14.6)	86 (18.0)	[0.53; 1.00]	
			0.052	
Percentiles (months) [95% CI]				
25th	11.1 [5.4; 22.1]	2.8 [1.9; 5.7]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	22.2 [22.2; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [22.2; N.E.]	N.E. [N.E.; N.E.]		
Insomnia (MID=10)				
N*	481	477	0.69	0.510
Number of patients with events, n (%)	87 (18.1)	104 (21.8)	[0.52; 0.92]	
			0.020	
Percentiles (months) [95% CI]				
25th	5.6 [2.8; 11.1]	1.9 [1.8; 2.8]		
Median	22.5 [22.5; N.E.]	22.2 [11.2; N.E.]		
75th	N.E. [22.5; N.E.]	N.E. [N.E.; N.E.]		
Appetite loss (MID=10)				
N*	481	477	0.59	0.081
Number of patients with events, n (%)	50 (10.4)	72 (15.1)	[0.41; 0.85]	
			0.004	
Percentiles (months) [95% CI]				
25th	22.1 [22.0; N.E.]	5.6 [2.8; 22.1]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [22.2; N.E.]	N.E. [22.2; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Constipation (MID=10)				
N*	481	477	0.69	0.367
Number of patients with events, n (%)	80 (16.6)	95 (19.9)	[0.51; 0.93]	
			0.031	
Percentiles (months) [95% CI]				
25th	11.0 [5.5; 11.1]	2.8 [1.9; 5.5]		
Median	N.E. [N.E.; N.E.]	N.E. [11.8; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Diarrhoea (MID=10)				
N*	481	477	0.60	0.227
Number of patients with events, n (%)	68 (14.1)	98 (20.5)	[0.44; 0.83]	
			<0.001	
Percentiles (months) [95% CI]				
25th	10.9 [3.6; N.E.]	2.8 [2.7; 5.5]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	22.2 [22.0; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Financial difficulties (MID=10)				
N*	481	477	1.13	0.734
Number of patients with events, n (%)	64 (13.3)	56 (11.7)	[0.78; 1.63]	
			0.496	
Percentiles (months) [95% CI]				
25th	11.2 [2.9; N.E.]	22.2 [11.0; 26.4]		
Median	N.E. [N.E.; N.E.]	26.4 [22.3; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [26.4; N.E.]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline score.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)

Global health status/QoL (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	149 (257)	58 (333)	57 (333)	0 (383)	0 (383)	0 (383)
Investigator Selected TKI	477 (0)	120 (260)	50 (319)	41 (328)	4 (362)	1 (365)	0 (365)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Physical functioning (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Role functioning (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)

Emotional functioning (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	162 (256)	61 (344)	61 (344)	0 (405)	0 (405)	0 (405)
Investigator Selected TKI	477 (0)	126 (271)	56 (330)	50 (336)	4 (377)	1 (380)	0 (381)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Cognitive functioning (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Social functioning (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Fatigue (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Nausea and vomiting (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Pain (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Dyspnoea (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)

Insomnia (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	153 (258)	58 (338)	57 (339)	0 (394)	0 (394)	0 (394)
Investigator Selected TKI	477 (0)	116 (269)	47 (331)	43 (335)	5 (368)	1 (372)	0 (373)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Appetite loss (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Constipation (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Diarrhoea (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)

Financial difficulties (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	161 (262)	71 (348)	71 (348)	0 (417)	0 (417)	0 (417)
Investigator Selected TKI	477 (0)	158 (275)	76 (349)	67 (358)	5 (417)	1 (420)	0 (421)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Appetite loss (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Cognitive functioning (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Constipation (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Diarrhoea (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Dyspnoea (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Emotional functioning (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Fatigue (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Financial difficulties (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Global health status/QoL (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Insomnia (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Nausea and vomiting (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Pain (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Physical functioning (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Role functioning (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-1.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Body Image Problems (MID=15)				
N*	481	477	0.88	0.152
Number of patients with events, n (%)	94 (19.5)	96 (20.1)	[0.66; 1.17]	
			0.306	
Percentiles (months) [95% CI]				
25th	2.8 [2.0; 5.6]	2.7 [1.9; 5.5]		
Median	22.2 [22.2; N.E.]	N.E. [16.6; N.E.]		
75th	N.E. [22.2; N.E.]	N.E. [N.E.; N.E.]		
Impact on Daily Life (MID=15)				
N*	481	477	0.59	0.282
Number of patients with events, n (%)	58 (12.1)	86 (18.0)	[0.42; 0.83]	
			0.003	
Percentiles (months) [95% CI]				
25th	11.2 [10.9; N.E.]	2.8 [2.0; 10.9]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [22.1; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Impact on Worry/Mood (MID=15)				
N*	481	477	0.82	0.075
Number of patients with events, n (%)	59 (12.3)	59 (12.4)	[0.57; 1.18]	
			0.451	
Percentiles (months) [95% CI]				
25th	11.8 [8.9; N.E.]	11.1 [5.6; 22.1]		
Median	22.2 [22.2; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [22.2; N.E.]	N.E. [N.E.; N.E.]		
Symptom Burden (MID=15)				
N*	481	477	0.38	0.404
Number of patients with events, n (%)	27 (5.6)	62 (13.0)	[0.24; 0.61]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	11.2 [5.6; 22.1]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	25.7 [22.3; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [25.7; N.E.]		
Satisfaction with Care and Information (MID=15)				
N*	481	477	1.15	0.840
Number of patients with events, n (%)	103 (21.4)	73 (15.3)	[0.84; 1.56]	
			0.066	
Percentiles (months) [95% CI]				
25th	2.8 [1.9; 5.5]	2.8 [1.9; 10.9]		
Median	N.E. [11.1; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Satisfaction with Social Life (MID=15)				
N*	481	477	1.09	0.872
Number of patients with events, n (%)	118 (24.5)	103 (21.6)	[0.83; 1.43]	
			0.560	
Percentiles (months) [95% CI]				
25th	1.8 [1.0; 2.7]	1.9 [1.8; 2.8]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	21.9 [11.0; N.E.]	25.7 [11.1; N.E.]		
75th	N.E. [N.E.; N.E.]	25.7 [N.E.; N.E.]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline score.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)

Body Image Problems (MID=15)




Pts at Risk (censored)

Asciminib	481 (0)	139 (261)	59 (331)	59 (331)	0 (387)	0 (387)	0 (387)
Investigator Selected TKI	477 (0)	115 (276)	48 (337)	41 (343)	2 (379)	0 (381)	0 (381)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Impact on Daily Life (MID=15)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)

Impact on Worry/Mood (MID=15)




Pts at Risk (censored)

Asciminib	481 (0)	164 (271)	66 (360)	65 (361)	0 (422)	0 (422)	0 (422)
Investigator Selected TKI	477 (0)	142 (285)	59 (363)	50 (372)	4 (414)	1 (417)	0 (418)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)

Symptom Burden (MID=15)




Pts at Risk (censored)

Asciminib	481 (0)	181 (279)	75 (382)	74 (383)	0 (454)	0 (454)	0 (454)
Investigator Selected TKI	477 (0)	148 (282)	62 (359)	54 (367)	4 (412)	0 (415)	0 (415)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Satisfaction with Care and Information (MID=15)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Satisfaction with Social Life (MID=15)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Body Image Problems (MID=15)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Impact on Daily Life (MID=15)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Impact on Worry/Mood (MID=15)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Care and Information (MID=15)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Social Life (MID=15)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	39/197	33/193	1.06	0.65; 1.73	0.791
ASC4START	79/284	70/284	1.10	0.80; 1.52	0.599
Pooled Analysis	118/481	103/477	1.09	0.83; 1.43	0.560



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Table 3-1.3 FACT-ITEM GP5: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
V4 (MID=1)				
N*	481	477	0.69	0.015
Number of patients with events, n (%)	156 (32.4)	177 (37.1)	[0.55; 0.85]	
			0.004	
Percentiles (months) [95% CI]				
25th	0.5 [0.5; 0.9]	0.3 [0.3; 0.5]		
Median	2.7 [1.8; 5.6]	1.0 [0.7; 1.9]		
75th	N.E. [N.E.; N.E.]	22.1 [8.3; N.E.]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline score.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.3 FACT-ITEM GP5: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


V4 (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-1.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Headache - Frequency (MID=1)				
N*	481	477	0.70	0.352
Number of patients with events, n (%)	163 (33.9)	180 (37.7)	[0.57; 0.87]	
			0.003	
Percentiles (months) [95% CI]				
25th	0.7 [0.5; 1.0]	0.3 [0.3; 0.5]		
Median	3.7 [2.1; 5.6]	1.7 [1.0; 2.6]		
75th	N.E. [N.E.; N.E.]	18.5 [8.2; N.E.]		
Rash - Presence/Absence (MID=1)				
N*	481	477	0.63	0.320
Number of patients with events, n (%)	138 (28.7)	156 (32.7)	[0.50; 0.80]	
			<0.001	
Percentiles (months) [95% CI]				
25th	1.9 [1.4; 2.9]	0.5 [0.5; 1.0]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	10.2 [5.6; 15.7]	2.8 [1.9; 5.6]		
75th	N.E. [30.5; N.E.]	N.E. [22.1; N.E.]		
Diarrhea - Frequency (MID=1)				
N*	481	477	0.83	0.042
Number of patients with events, n (%)	157 (32.6)	164 (34.4)	[0.67; 1.04]	
			0.091	
Percentiles (months) [95% CI]				
25th	0.7 [0.5; 1.0]	0.5 [0.3; 0.7]		
Median	3.7 [2.1; 6.5]	2.3 [1.4; 3.3]		
75th	N.E. [N.E.; N.E.]	N.E. [17.5; N.E.]		
Vomiting - Frequency (MID=1)				
N*	481	477	0.39	0.745
Number of patients with events, n (%)	46 (9.6)	92 (19.3)	[0.27; 0.56]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [17.5; N.E.]	3.0 [2.0; 4.6]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Nausea - Frequency (MID=1)				
N*	481	477	0.49	0.086
Number of patients with events, n (%)	101 (21.0)	155 (32.5)	[0.38; 0.63]	
			<0.001	
Percentiles (months) [95% CI]				
25th	1.7 [1.0; 3.3]	0.5 [0.3; 0.7]		
Median	N.E. [25.8; N.E.]	3.0 [1.9; 4.9]		
75th	N.E. [N.E.; N.E.]	28.6 [24.9; N.E.]		
Edema - Frequency (MID=1)				
N*	481	477	0.63	<0.001
Number of patients with events, n (%)	107 (22.2)	136 (28.5)	[0.49; 0.82]	
			<0.001	
Percentiles (months) [95% CI]				
25th	2.2 [1.6; 3.5]	0.9 [0.5; 1.4]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [17.5; N.E.]	10.2 [4.2; 13.8]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Muscle Pain - Frequency (MID=1)				
N*	481	477	0.79	0.067
Number of patients with events, n (%)	164 (34.1)	185 (38.8)	[0.64; 0.97]	
			0.022	
Percentiles (months) [95% CI]				
25th	0.5 [0.3; 0.5]	0.3 [0.3; 0.5]		
Median	1.6 [1.0; 3.0]	1.0 [0.7; 1.4]		
75th	N.E. [N.E.; N.E.]	11.8 [5.5; N.E.]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline score.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Headache - Frequency (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Rash - Presence/Absence (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Diarrhea - Frequency (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Vomiting - Frequency (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Nausea - Frequency (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Edema - Frequency (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)

Muscle Pain - Frequency (MID=1)



Pts at Risk (censored)


Asciminib	481 (0)	93 (235)	57 (263)	42 (276)	27 (290)	4 (313)	0 (317)
Investigator Selected TKI	477 (0)	64 (243)	32 (265)	20 (274)	8 (284)	1 (291)	0 (292)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	61/197	72/193	0.62	0.44; 0.89	0.009
ASC4START	96/284	92/284	1.00	0.75; 1.33	0.945
Pooled Analysis	157/481	164/477	0.83	0.67; 1.04	0.091



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	64/197	68/193	0.80	0.56; 1.14	0.287
ASC4START	99/284	112/284	0.65	0.49; 0.85	0.004
Pooled Analysis	163/481	180/477	0.70	0.57; 0.87	0.003




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	59/197	81/193	0.62	0.44; 0.87	0.003
ASC4START	105/284	104/284	0.92	0.70; 1.21	0.568
Pooled Analysis	164/481	185/477	0.79	0.64; 0.97	0.022




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	40/197	75/193	0.38	0.26; 0.56	<0.001
ASC4START	61/284	80/284	0.60	0.43; 0.84	0.003
Pooled Analysis	101/481	155/477	0.49	0.38; 0.63	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Rash - Presence/Absence (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	58/197	66/193	0.72	0.51; 1.04	0.050
ASC4START	80/284	90/284	0.57	0.42; 0.77	0.007
Pooled Analysis	138/481	156/477	0.63	0.50; 0.80	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	22/197	45/193	0.37	0.22; 0.62	<0.001
ASC4START	24/284	47/284	0.42	0.25; 0.68	<0.001
Pooled Analysis	46/481	92/477	0.39	0.27; 0.56	<0.001



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-1.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Fatigue - Severity (MID=1)				
N*	481	477	0.83	0.703
Number of patients with events, n (%)	162 (33.7)	167 (35.0)	[0.66; 1.03]	
			0.199	
Percentiles (months) [95% CI]				
25th	0.5 [0.3; 0.6]	0.5 [0.3; 0.5]		
Median	3.0 [1.8; 9.2]	2.1 [1.1; 3.5]		
75th	N.E. [24.0; N.E.]	N.E. [16.6; N.E.]		
Headache - Severity (MID=1)				
N*	481	477	0.76	0.567
Number of patients with events, n (%)	161 (33.5)	172 (36.1)	[0.61; 0.94]	
			0.035	
Percentiles (months) [95% CI]				
25th	0.7 [0.5; 1.0]	0.3 [0.3; 0.5]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	2.8 [2.1; 4.9]	1.9 [1.1; 3.3]		
75th	N.E. [N.E.; N.E.]	27.6 [14.8; N.E.]		
Vomiting - Severity (MID=1)				
N*	481	477	0.40	0.448
Number of patients with events, n (%)	42 (8.7)	85 (17.8)	[0.27; 0.58]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [22.1; N.E.]	3.5 [2.3; 5.6]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Nausea - Severity (MID=1)				
N*	481	477	0.48	0.083
Number of patients with events, n (%)	98 (20.4)	156 (32.7)	[0.37; 0.62]	
			<0.001	
Percentiles (months) [95% CI]				
25th	2.3 [1.0; 4.2]	0.5 [0.3; 0.8]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [25.8; N.E.]	3.3 [2.1; 5.3]		
75th	N.E. [N.E.; N.E.]	28.6 [24.9; N.E.]		
Edema - Severity (MID=1)				
N*	481	477	0.58	0.002
Number of patients with events, n (%)	89 (18.5)	120 (25.2)	[0.44; 0.77]	
			<0.001	
Percentiles (months) [95% CI]				
25th	3.3 [2.1; 7.4]	1.0 [0.7; 1.5]		
Median	N.E. [N.E.; N.E.]	13.8 [7.4; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Muscle Pain - Severity (MID=1)				
N*	481	477	0.67	0.065
Number of patients with events, n (%)	150 (31.2)	186 (39.0)	[0.54; 0.84]	
			<0.001	
Percentiles (months) [95% CI]				
25th	0.5 [0.3; 0.6]	0.3 [0.3; 0.3]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	3.3 [1.6; 9.2]	1.0 [0.7; 1.4]		
75th	N.E. [N.E.; N.E.]	11.3 [5.6; N.E.]		
Pruritus - Severity (MID=1)				
N*	481	477	0.67	0.031
Number of patients with events, n (%)	152 (31.6)	179 (37.5)	[0.54; 0.84]	
			<0.001	
Percentiles (months) [95% CI]				
25th	1.0 [0.7; 1.2]	0.5 [0.5; 0.7]		
Median	4.6 [2.9; 8.3]	2.3 [1.6; 3.0]		
75th	N.E. [N.E.; N.E.]	16.7 [11.1; 24.0]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline score.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)

Fatigue - Severity (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	110 (234)	65 (266)	45 (281)	23 (297)	4 (315)	0 (319)
Investigator Selected TKI	477 (0)	86 (243)	54 (264)	30 (282)	12 (298)	3 (307)	0 (310)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Headache - Severity (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Vomiting - Severity (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Nausea - Severity (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Edema - Severity (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)

Muscle Pain - Severity (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	106 (237)	66 (269)	45 (287)	28 (303)	4 (327)	0 (331)
Investigator Selected TKI	477 (0)	66 (242)	30 (265)	18 (275)	10 (281)	1 (290)	0 (291)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)

Pruritus - Severity (MID=1)



Pts at Risk (censored)


Asciminib	481 (0)	108 (237)	64 (269)	44 (289)	23 (306)	5 (324)	0 (329)
Investigator Selected TKI	477 (0)	78 (245)	46 (264)	29 (274)	9 (289)	2 (296)	0 (298)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	34/197	65/193	0.35	0.23; 0.54	<0.001
ASC4START	55/284	55/284	0.88	0.60; 1.28	0.512
Pooled Analysis	89/481	120/477	0.58	0.44; 0.77	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	63/197	69/193	0.78	0.55; 1.11	0.186
ASC4START	99/284	98/284	0.86	0.65; 1.14	0.554
Pooled Analysis	162/481	167/477	0.83	0.66; 1.03	0.199




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	64/197	67/193	0.82	0.58; 1.16	0.351
ASC4START	97/284	105/284	0.72	0.54; 1.95	0.051
Pooled Analysis	161/481	172/477	0.76	0.61; 0.94	0.035




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Severity (MID=1)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	54/197	81/193	0.52	0.37; 0.74	<0.001
ASC4START	96/284	105/284	0.79	0.60; 1.05	0.071
Pooled Analysis	150/481	186/477	0.67	0.54; 0.84	<0.001



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Severity (MID=1)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pruritus - Severity (MID=1)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	60/197	65/193	0.94	0.65; 1.35	0.521
ASC4START	92/284	114/284	0.56	0.42; 0.74	<0.001
Pooled Analysis	152/481	179/477	0.67	0.54; 0.84	<0.001



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-1.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Fatigue - Interference (MID=1)				
N*	481	477	0.82	0.007
Number of patients with events, n (%)	160 (33.3)	167 (35.0)	[0.66; 1.02]	
			0.128	
Percentiles (months) [95% CI]				
25th	0.5 [0.5; 0.7]	0.3 [0.3; 0.5]		
Median	3.9 [2.6; 8.3]	1.4 [1.0; 2.8]		
75th	N.E. [N.E.; N.E.]	N.E. [17.5; N.E.]		
Headache - Interference (MID=1)				
N*	481	477	0.76	0.717
Number of patients with events, n (%)	134 (27.9)	145 (30.4)	[0.60; 0.96]	
			0.033	
Percentiles (months) [95% CI]				
25th	1.8 [1.0; 2.1]	0.5 [0.5; 1.0]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	15.7 [5.6; 22.1]	4.2 [2.6; 10.2]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Edema - Interference (MID=1)				
N*	481	477	0.60	0.024
Number of patients with events, n (%)	68 (14.1)	94 (19.7)	[0.44; 0.83]	
			0.002	
Percentiles (months) [95% CI]				
25th	12.9 [4.9; N.E.]	2.8 [1.4; 4.2]		
Median	N.E. [N.E.; N.E.]	N.E. [27.6; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Muscle Pain - Interference (MID=1)				
N*	481	477	0.82	0.163
Number of patients with events, n (%)	142 (29.5)	150 (31.4)	[0.65; 1.03]	
			0.116	
Percentiles (months) [95% CI]				
25th	0.6 [0.5; 1.0]	0.5 [0.3; 0.5]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	5.1 [3.0; 15.7]	2.8 [1.6; 6.5]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline score.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Fatigue - Interference (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)

Headache - Interference (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	130 (238)	82 (278)	57 (297)	26 (322)	6 (341)	0 (347)
Investigator Selected TKI	477 (0)	98 (249)	65 (276)	43 (293)	13 (319)	3 (329)	0 (332)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Edema - Interference (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Full Analysis Set)


Muscle Pain - Interference (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Edema - Interference (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Fatigue - Interference (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Headache - Interference (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-1.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Global health status/QoL (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.138)								
Low	70/291 (24.1)	21.9 [11.1; 22.1]	72/292 (24.7)	22.0 [10.8; N.E.]	0.99	[0.71; 1.38]	0.865	0.418
Intermediate	22/129 (17.1)	22.2 [N.E.; N.E.]	33/128 (25.8)	11.1 [5.4; N.E.]	0.50	[0.28; 0.87]	0.008	0.577
High	6/61 (9.8)	N.E. [N.E.; N.E.]	7/57 (12.3)	N.E. [5.7; N.E.]	0.53	[0.17; 1.63]	0.326	0.331
Sex								
(Interaction test: p = 0.943)								
Female	37/175	N.E. [11.1; N.E.]	44/201	22.1 [5.6; N.E.]	0.85	[0.54; 1.34]	0.398	0.395

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(21.1)		(21.9)					
Male	61/306	22.1 [22.0; N.E.]	68/276	30.3 [11.0; N.E.]	0.83	[0.58; 1.18]	0.134	0.964
	(19.9)		(24.6)					
Race								
(Interaction test: p = 0.922)								
Asian	40/128	N.E. [11.1; N.E.]	52/132	11.1 [5.4; N.E.]	0.76	[0.50; 1.17]	0.111	0.925
	(31.3)		(39.4)					
White	56/333	22.1 [12.4; N.E.]	59/320	22.0 [11.1; N.E.]	0.86	[0.59; 1.26]	0.358	0.405
	(16.8)		(18.4)					
Others	2/20	N.E. [0.9; N.E.]	1/25	N.E. [1.0; N.E.]	2.03	[0.03; 143.02]	0.244	N.E.
	(10.0)		(4.0)					
Age groups								
(Interaction test: p = 0.232)								
18 - < 65 years	84/390	22.1 [12.4; N.E.]	93/397	22.1 [11.1; N.E.]	0.88	[0.65; 1.19]	0.384	0.655
	(21.5)		(23.4)					
65 - < 75 years	11/72	N.E. [11.1; N.E.]	11/53	N.E. [1.5; N.E.]	0.66	[0.24; 1.75]	0.198	0.516

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(15.3)		(20.8)					
>= 75 years	3/19	22.2 [1.0; N.E.]	8/27	1.4 [1.0; 11.1]	0.35	[0.06; 2.20]	0.030	0.998
	(15.8)		(29.6)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.780)								
Imatinib	24/101	22.2 [11.1; N.E.]	25/102	11.1 [1.9; N.E.]	0.66	[0.37; 1.18]	0.125	N.E.
	(23.8)		(24.5)					
Nilotinib	69/339	22.1 [12.4; N.E.]	78/333	N.E. [11.1; N.E.]	0.87	[0.62; 1.21]	0.316	0.749
	(20.4)		(23.4)					
Dasatinib	5/41	N.E. [11.1; N.E.]	9/42	11.1 [2.7; N.E.]	0.73	[0.23; 2.26]	0.512	N.E.
	(12.2)		(21.4)					
Geographic region								
(Interaction test: p = 0.953)								
Europe excluding Germany	40/202	22.2 [22.0; N.E.]	43/203	22.0 [11.0; N.E.]	0.83	[0.53; 1.29]	0.369	0.775

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(19.8)		(21.2)					
Germany	10/91	22.1 [5.6; N.E.]	6/68	N.E. [0.9; N.E.]	0.56	[0.18; 1.74]	0.403	N.E.
	(11.0)		(8.8)					
Others	48/188	N.E. [11.2; N.E.]	63/206	22.1 [5.6; N.E.]	0.82	[0.56; 1.21]	0.149	0.390
	(25.5)		(30.6)					
Physical functioning (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.049)								
Low	38/291	N.E. [N.E.; N.E.]	61/292	22.1 [22.1; N.E.]	0.58	[0.38; 0.87]	0.008	0.513
	(13.1)		(20.9)					
Intermediate	27/129	N.E. [11.1; N.E.]	23/128	N.E. [11.1; N.E.]	0.94	[0.54; 1.66]	0.810	0.083
	(20.9)		(18.0)					
High	9/61	N.E. [N.E.; N.E.]	3/57	N.E. [N.E.; N.E.]	2.34	[0.62; 8.75]	0.147	0.994
	(14.8)		(5.3)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.605)								
Female	34/175 (19.4)	22.1 [11.2; N.E.]	42/201 (20.9)	22.1 [11.1; N.E.]	0.90	[0.57; 1.44]	0.601	0.500
Male	40/306 (13.1)	N.E. [N.E.; N.E.]	45/276 (16.3)	N.E. [22.1; N.E.]	0.72	[0.47; 1.11]	0.147	0.282
Race								
(Interaction test: p = 0.511)								
Asian	31/128 (24.2)	N.E. [22.1; N.E.]	36/132 (27.3)	22.1 [22.1; N.E.]	0.76	[0.46; 1.26]	0.297	0.090
White	40/333 (12.0)	N.E. [N.E.; N.E.]	50/320 (15.6)	N.E. [11.8; N.E.]	0.73	[0.48; 1.11]	0.130	0.652
Others	3/20 (15.0)	N.E. [0.9; N.E.]	1/25 (4.0)	11.1 [N.E.; N.E.]	1.94	[0.04; 87.12]	0.343	N.E.
Age groups								
(Interaction test: p = 0.045)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	62/390 (15.9)	N.E. [N.E.; N.E.]	74/397 (18.6)	22.1 [22.1; N.E.]	0.77	[0.55; 1.08]	0.142	0.080
65 - < 75 years	6/72 (8.3)	N.E. [N.E.; N.E.]	11/53 (20.8)	N.E. [1.9; N.E.]	0.35	[0.12; 0.98]	0.036	0.629
>= 75 years	6/19 (31.6)	11.1 [0.9; N.E.]	2/27 (7.4)	N.E. [5.4; N.E.]	6.86	[0.78; 60.13]	0.050	0.998
Pre-randomization selection of TKI								
(Interaction test: p = 0.315)								
Imatinib	14/101 (13.9)	N.E. [22.1; N.E.]	20/102 (19.6)	22.1 [5.5; N.E.]	0.53	[0.26; 1.06]	0.068	N.E.
Nilotinib	55/339 (16.2)	N.E. [N.E.; N.E.]	57/333 (17.1)	N.E. [22.1; N.E.]	0.89	[0.62; 1.30]	0.555	0.854
Dasatinib	5/41 (12.2)	N.E. [22.1; N.E.]	10/42 (23.8)	11.0 [1.0; N.E.]	0.43	[0.13; 1.38]	0.146	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.415)								
Europe excluding Germany	33/202 (16.3)	N.E. [N.E.; N.E.]	38/203 (18.7)	N.E. [11.1; N.E.]	0.75	[0.47; 1.20]	0.208	0.696
Germany	6/91 (6.6)	N.E. [11.1; N.E.]	7/68 (10.3)	5.6 [1.0; N.E.]	0.38	[0.11; 1.28]	0.137	N.E.
Others	35/188 (18.6)	N.E. [22.1; N.E.]	42/206 (20.4)	22.1 [22.1; N.E.]	0.85	[0.53; 1.34]	0.486	0.021
Role functioning (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.761)								
Low	59/291 (20.3)	22.5 [22.1; N.E.]	64/292 (21.9)	N.E. [11.1; N.E.]	0.86	[0.60; 1.23]	0.471	0.044
Intermediate	32/129 (24.8)	22.2 [5.6; N.E.]	32/128 (25.0)	12.0 [5.6; N.E.]	0.82	[0.49; 1.36]	0.418	0.278

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
High	7/61 (11.5)	N.E. [N.E.; N.E.]	4/57 (7.0)	N.E. [N.E.; N.E.]	1.13	[0.33; 3.88]	0.711	0.995
Sex								
(Interaction test: p = 0.742)								
Female	39/175 (22.3)	N.E. [11.1; N.E.]	45/201 (22.4)	11.8 [5.7; N.E.]	0.96	[0.62; 1.49]	0.664	0.121
Male	59/306 (19.3)	22.2 [22.1; N.E.]	55/276 (19.9)	22.3 [22.1; N.E.]	0.85	[0.58; 1.24]	0.534	0.172
Race								
(Interaction test: p = 0.373)								
Asian	31/128 (24.2)	N.E. [N.E.; N.E.]	41/132 (31.1)	22.3 [11.1; N.E.]	0.66	[0.41; 1.06]	0.099	0.320
White	63/333 (18.9)	22.1 [11.1; N.E.]	57/320 (17.8)	22.1 [11.1; N.E.]	1.01	[0.70; 1.46]	0.880	0.165
Others	4/20 (20.0)	N.E. [1.0; N.E.]	2/25 (8.0)	N.E. [2.8; N.E.]	0.60	[0.07; 4.88]	0.692	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Age groups								
(Interaction test: p = 0.544)								
18 - < 65 years	83/390 (21.3)	22.5 [22.1; N.E.]	83/397 (20.9)	22.3 [11.8; N.E.]	0.93	[0.68; 1.27]	0.805	0.027
65 - < 75 years	10/72 (13.9)	N.E. [11.1; N.E.]	11/53 (20.8)	12.0 [2.8; N.E.]	0.43	[0.16; 1.18]	0.055	0.451
>= 75 years	5/19 (26.3)	22.1 [0.9; N.E.]	6/27 (22.2)	11.1 [1.0; N.E.]	0.64	[0.15; 2.79]	0.483	0.079
Pre-randomization selection of TKI								
(Interaction test: p = 0.030)								
Imatinib	16/101 (15.8)	22.2 [22.2; N.E.]	23/102 (22.5)	11.1 [2.8; N.E.]	0.42	[0.22; 0.81]	0.008	N.E.
Nilotinib	76/339 (22.4)	22.5 [11.2; N.E.]	67/333 (20.1)	22.3 [22.1; N.E.]	1.10	[0.79; 1.55]	0.455	0.764
Dasatinib	6/41	N.E. [5.6; N.E.]	10/42	5.4 [1.0; N.E.]	0.40	[0.12; 1.30]	0.096	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(14.6)		(23.8)					
Geographic region								
(Interaction test: p = 0.310)								
Europe excluding Germany	48/202	22.2 [11.1; N.E.]	42/203	22.1 [11.1; N.E.]	0.98	[0.63; 1.51]	0.939	0.447
	(23.8)		(20.7)					
Germany	11/91	22.1 [1.9; N.E.]	9/68	2.7 [0.9; N.E.]	0.36	[0.12; 1.02]	0.222	N.E.
	(12.1)		(13.2)					
Others	39/188	N.E. [N.E.; N.E.]	49/206	22.3 [12.0; N.E.]	0.75	[0.49; 1.15]	0.230	0.022
	(20.7)		(23.8)					
Emotional functioning (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.711)								
Low	42/291	N.E. [N.E.; N.E.]	62/292	N.E. [11.8; N.E.]	0.61	[0.41; 0.90]	0.038	0.866

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(14.4)		(21.2)					
Intermediate	26/129	N.E. [11.1; N.E.]	26/128	N.E. [11.0; N.E.]	0.85	[0.49; 1.47]	0.578	0.368
	(20.2)		(20.3)					
High	8/61	N.E. [N.E.; N.E.]	8/57	N.E. [11.0; N.E.]	0.62	[0.23; 1.71]	0.430	0.365
	(13.1)		(14.0)					
Sex								
(Interaction test: p = 0.981)								
Female	34/175	N.E. [11.2; N.E.]	46/201	11.8 [5.6; N.E.]	0.69	[0.44; 1.08]	0.114	0.751
	(19.4)		(22.9)					
Male	42/306	N.E. [N.E.; N.E.]	50/276	N.E. [22.1; N.E.]	0.65	[0.43; 0.99]	0.124	0.838
	(13.7)		(18.1)					
Race								
(Interaction test: p = 0.395)								
Asian	26/128	N.E. [N.E.; N.E.]	36/132	N.E. [22.1; N.E.]	0.62	[0.37; 1.03]	0.104	0.359
	(20.3)		(27.3)					
White	45/333	N.E. [N.E.; N.E.]	59/320	22.0 [11.0; N.E.]	0.67	[0.45; 0.99]	0.066	0.549

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(13.5)		(18.4)					
Others	5/20	5.6 [0.9; N.E.]	1/25	N.E. [5.6; N.E.]	3.79	[0.09; 152.79]	0.212	N.E.
	(25.0)		(4.0)					
Age groups								
(Interaction test: p = 0.870)								
18 - < 65 years	64/390	N.E. [N.E.; N.E.]	81/397	N.E. [22.1; N.E.]	0.69	[0.49; 0.96]	0.081	0.792
	(16.4)		(20.4)					
65 - < 75 years	9/72	N.E. [11.1; N.E.]	11/53	22.0 [2.8; N.E.]	0.58	[0.20; 1.65]	0.199	0.283
	(12.5)		(20.8)					
>= 75 years	3/19	N.E. [0.9; N.E.]	4/27	11.1 [1.0; N.E.]	0.79	[0.16; 3.91]	0.538	0.349
	(15.8)		(14.8)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.284)								
Imatinib	15/101	N.E. [N.E.; N.E.]	21/102	22.1 [11.0; N.E.]	0.60	[0.30; 1.17]	0.110	N.E.
	(14.9)		(20.6)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Nilotinib	58/339 (17.1)	N.E. [N.E.; N.E.]	66/333 (19.8)	N.E. [22.0; N.E.]	0.73	[0.51; 1.05]	0.279	0.141
Dasatinib	3/41 (7.3)	N.E. [N.E.; N.E.]	9/42 (21.4)	11.0 [1.9; N.E.]	0.19	[0.04; 0.90]	0.029	N.E.
Geographic region (Interaction test: p = 0.894)								
Europe excluding Germany	36/202 (17.8)	N.E. [N.E.; N.E.]	45/203 (22.2)	11.8 [5.8; N.E.]	0.65	[0.41; 1.02]	0.091	0.364
Germany	4/91 (4.4)	N.E. [11.1; N.E.]	4/68 (5.9)	N.E. [2.7; N.E.]	0.73	[0.17; 3.19]	0.662	N.E.
Others	36/188 (19.1)	N.E. [N.E.; N.E.]	47/206 (22.8)	N.E. [22.1; N.E.]	0.75	[0.48; 1.17]	0.314	0.743
Cognitive functioning (MID=10)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.260)								
Low	61/291 (21.0)	22.1 [11.1; N.E.]	83/292 (28.4)	11.1 [5.6; 22.1]	0.72	[0.52; 1.01]	0.057	0.222
Intermediate	40/129 (31.0)	10.8 [4.2; N.E.]	32/128 (25.0)	11.1 [5.6; N.E.]	1.18	[0.74; 1.89]	0.490	0.587
High	14/61 (23.0)	22.1 [11.1; N.E.]	12/57 (21.1)	11.1 [2.8; N.E.]	0.80	[0.36; 1.79]	0.523	0.311
Sex								
(Interaction test: p = 0.128)								
Female	51/175 (29.1)	11.1 [5.6; 22.1]	52/201 (25.9)	11.1 [5.6; 11.8]	1.15	[0.77; 1.71]	0.510	0.161
Male	64/306 (20.9)	N.E. [22.1; N.E.]	75/276 (27.2)	11.1 [5.6; N.E.]	0.72	[0.51; 1.01]	0.053	0.822

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.795)								
Asian	42/128 (32.8)	N.E. [11.0; N.E.]	53/132 (40.2)	11.1 [5.6; 22.2]	0.78	[0.52; 1.18]	0.236	0.554
White	69/333 (20.7)	22.1 [11.1; 22.1]	69/320 (21.6)	11.1 [5.6; N.E.]	0.87	[0.62; 1.22]	0.406	0.374
Others	4/20 (20.0)	5.6 [0.9; N.E.]	5/25 (20.0)	5.6 [1.0; N.E.]	1.08	[0.15; 7.87]	0.409	N.E.
Age groups								
(Interaction test: p = 0.544)								
18 - < 65 years	95/390 (24.4)	22.1 [11.1; N.E.]	112/397 (28.2)	11.1 [5.6; 22.1]	0.81	[0.61; 1.06]	0.126	0.329
65 - < 75 years	15/72 (20.8)	22.1 [5.6; N.E.]	11/53 (20.8)	11.0 [5.6; N.E.]	0.88	[0.38; 2.06]	0.776	0.936
>= 75 years	5/19 (26.3)	5.6 [1.6; N.E.]	4/27 (14.8)	11.1 [1.0; N.E.]	2.85	[0.38; 21.66]	0.403	0.997

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.176)								
Imatinib	16/101 (15.8)	N.E. [22.1; N.E.]	25/102 (24.5)	11.1 [5.5; 22.2]	0.43	[0.22; 0.85]	0.011	N.E.
Nilotinib	91/339 (26.8)	11.1 [11.0; N.E.]	93/333 (27.9)	11.1 [5.6; 22.1]	0.95	[0.71; 1.27]	0.753	0.629
Dasatinib	8/41 (19.5)	N.E. [1.9; N.E.]	9/42 (21.4)	22.1 [2.8; N.E.]	1.14	[0.41; 3.18]	0.872	N.E.
Geographic region								
(Interaction test: p = 0.955)								
Europe excluding Germany	49/202 (24.3)	22.1 [11.1; N.E.]	50/203 (24.6)	11.1 [5.6; N.E.]	0.84	[0.56; 1.27]	0.398	0.689
Germany	14/91 (15.4)	11.0 [1.9; N.E.]	9/68 (13.2)	2.8 [0.9; N.E.]	0.70	[0.27; 1.81]	0.845	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	52/188 (27.7)	N.E. [11.0; N.E.]	68/206 (33.0)	11.1 [5.7; 22.1]	0.83	[0.57; 1.19]	0.300	0.425
Social functioning (MID=10)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.389)								
Low	50/291 (17.2)	22.5 [22.1; N.E.]	72/292 (24.7)	22.1 [5.6; N.E.]	0.62	[0.43; 0.89]	0.008	0.156
Intermediate	31/129 (24.0)	N.E. [8.3; N.E.]	30/128 (23.4)	N.E. [2.8; N.E.]	0.90	[0.54; 1.49]	0.725	0.680
High	11/61 (18.0)	N.E. [8.9; N.E.]	8/57 (14.0)	N.E. [2.8; N.E.]	0.89	[0.35; 2.26]	0.993	0.890
Sex (Interaction test: p = 0.829)								
Female	33/175	N.E. [N.E.; N.E.]	47/201	11.1 [2.8; N.E.]	0.76	[0.48; 1.20]	0.130	0.585

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(18.9)		(23.4)					
Male	59/306	22.5 [22.1; N.E.]	63/276	N.E. [11.1; N.E.]	0.76	[0.53; 1.09]	0.183	0.977
	(19.3)		(22.8)					
Race								
(Interaction test: p = 0.262)								
Asian	39/128	N.E. [22.1; N.E.]	45/132	N.E. [10.9; N.E.]	0.84	[0.54; 1.30]	0.406	0.880
	(30.5)		(34.1)					
White	50/333	22.5 [22.1; N.E.]	64/320	N.E. [3.0; N.E.]	0.64	[0.44; 0.94]	0.034	0.329
	(15.0)		(20.0)					
Others	3/20	N.E. [0.9; N.E.]	1/25	N.E. [2.8; N.E.]	2.68	[0.06; 128.64]	0.343	N.E.
	(15.0)		(4.0)					
Age groups								
(Interaction test: p = 0.915)								
18 - < 65 years	79/390	22.5 [22.1; N.E.]	95/397	N.E. [11.0; N.E.]	0.72	[0.53; 0.98]	0.049	0.355
	(20.3)		(23.9)					
65 - < 75 years	10/72	N.E. [N.E.; N.E.]	11/53	N.E. [2.7; N.E.]	0.53	[0.21; 1.35]	0.173	0.587

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(13.9)		(20.8)					
>= 75 years	3/19	N.E. [0.9; N.E.]	4/27	11.1 [1.0; N.E.]	2.97	[0.29; 30.97]	0.770	0.799
	(15.8)		(14.8)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.753)								
Imatinib	19/101	N.E. [5.7; N.E.]	26/102	11.0 [2.8; N.E.]	0.61	[0.34; 1.12]	0.088	N.E.
	(18.8)		(25.5)					
Nilotinib	69/339	22.5 [22.1; N.E.]	76/333	N.E. [11.1; N.E.]	0.77	[0.55; 1.08]	0.179	0.903
	(20.4)		(22.8)					
Dasatinib	4/41	N.E. [N.E.; N.E.]	8/42	N.E. [1.8; N.E.]	0.49	[0.13; 1.86]	0.169	N.E.
	(9.8)		(19.0)					
Geographic region								
(Interaction test: p = 0.106)								
Europe excluding Germany	41/202	22.5 [22.5; N.E.]	49/203	11.1 [2.8; N.E.]	0.70	[0.45; 1.06]	0.104	0.630

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(20.3)		(24.1)					
Germany	5/91	22.1 [N.E.; N.E.]	7/68	N.E. [1.0; N.E.]	0.21	[0.05; 0.82]	0.024	N.E.
	(5.5)		(10.3)					
Others	46/188	N.E. [22.1; N.E.]	54/206	N.E. [22.1; N.E.]	0.89	[0.60; 1.34]	0.584	0.236
	(24.5)		(26.2)					
Fatigue (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.409)								
Low	56/291	22.2 [21.9; N.E.]	81/292	11.1 [2.8; 22.1]	0.61	[0.43; 0.87]	0.004	0.536
	(19.2)		(27.7)					
Intermediate	34/129	22.1 [5.6; N.E.]	30/128	22.0 [5.4; N.E.]	0.88	[0.53; 1.45]	0.688	0.238
	(26.4)		(23.4)					
High	10/61	N.E. [11.1; N.E.]	9/57	N.E. [11.0; N.E.]	0.61	[0.23; 1.58]	0.470	0.428
	(16.4)		(15.8)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.677)								
Female	38/175 (21.7)	22.1 [11.2; N.E.]	47/201 (23.4)	11.1 [2.8; N.E.]	0.80	[0.51; 1.27]	0.137	0.396
Male	62/306 (20.3)	N.E. [11.1; N.E.]	73/276 (26.4)	22.0 [5.6; N.E.]	0.65	[0.46; 0.92]	0.023	0.932
Race								
(Interaction test: p = 0.902)								
Asian	42/128 (32.8)	N.E. [11.1; N.E.]	58/132 (43.9)	5.5 [1.9; 22.0]	0.61	[0.40; 0.91]	0.012	0.614
White	53/333 (15.9)	22.2 [11.2; N.E.]	62/320 (19.4)	22.0 [5.8; N.E.]	0.73	[0.50; 1.07]	0.069	0.990
Others	5/20 (25.0)	7.6 [0.9; N.E.]	0/25	N.E. [N.E.; N.E.]	6.75	[0.15; 300.69]	0.074	N.E.
Age groups								
(Interaction test: p = 0.541)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	83/390 (21.3)	22.2 [21.9; N.E.]	99/397 (24.9)	22.0 [5.8; N.E.]	0.69	[0.51; 0.93]	0.024	0.630
65 - < 75 years	12/72 (16.7)	N.E. [2.8; N.E.]	16/53 (30.2)	2.8 [1.9; 22.0]	0.42	[0.17; 1.04]	0.040	0.666
>= 75 years	5/19 (26.3)	22.1 [1.6; N.E.]	5/27 (18.5)	11.1 [1.0; N.E.]	1.21	[0.28; 5.32]	0.973	0.996
Pre-randomization selection of TKI								
(Interaction test: p = 0.912)								
Imatinib	26/101 (25.7)	21.9 [1.9; N.E.]	31/102 (30.4)	2.8 [1.8; 11.1]	0.63	[0.37; 1.08]	0.039	N.E.
Nilotinib	67/339 (19.8)	N.E. [22.1; N.E.]	77/333 (23.1)	22.1 [11.1; N.E.]	0.71	[0.51; 1.00]	0.123	0.592
Dasatinib	7/41 (17.1)	N.E. [1.8; N.E.]	12/42 (28.6)	2.8 [0.9; N.E.]	0.67	[0.26; 1.75]	0.305	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.993)								
Europe excluding Germany	42/202 (20.8)	22.1 [11.2; N.E.]	46/203 (22.7)	22.0 [5.6; N.E.]	0.69	[0.45; 1.07]	0.044	0.888
Germany	7/91 (7.7)	N.E. [5.6; N.E.]	6/68 (8.8)	22.0 [1.9; N.E.]	0.41	[0.11; 1.50]	0.491	N.E.
Others	51/188 (27.1)	N.E. [11.1; N.E.]	68/206 (33.0)	11.1 [2.8; N.E.]	0.66	[0.45; 0.96]	0.031	0.306
Nausea and vomiting (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.087)								
Low	36/291 (12.4)	N.E. [N.E.; N.E.]	55/292 (18.8)	22.2 [22.1; N.E.]	0.60	[0.39; 0.92]	0.013	0.088
Intermediate	13/129	N.E. [N.E.; N.E.]	26/128	N.E. [5.6; N.E.]	0.37	[0.18; 0.73]	0.002	0.278

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(10.1)		(20.3)					
High	13/61	22.1 [11.1; N.E.]	8/57	N.E. [11.0; N.E.]	1.19	[0.48; 2.97]	0.556	0.266
	(21.3)		(14.0)					
Sex								
(Interaction test: p = 0.654)								
Female	29/175	N.E. [22.1; N.E.]	44/201	22.1 [11.0; N.E.]	0.55	[0.33; 0.91]	0.014	0.061
	(16.6)		(21.9)					
Male	33/306	N.E. [N.E.; N.E.]	45/276	N.E. [22.1; N.E.]	0.62	[0.39; 0.98]	0.027	0.497
	(10.8)		(16.3)					
Race								
(Interaction test: p = 0.918)								
Asian	26/128	N.E. [N.E.; N.E.]	44/132	22.1 [11.0; N.E.]	0.54	[0.33; 0.89]	0.015	0.082
	(20.3)		(33.3)					
White	34/333	N.E. [22.1; N.E.]	45/320	22.2 [22.0; N.E.]	0.62	[0.39; 0.99]	0.026	0.537
	(10.2)		(14.1)					
Others	2/20	N.E. [2.8; N.E.]	0/25	N.E. [N.E.; N.E.]	1.40	[0.01; 222.25]	0.527	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(10.0)							
Age groups								
(Interaction test: p = 0.878)								
18 - < 65 years	54/390 (13.8)	N.E. [N.E.; N.E.]	78/397 (19.6)	N.E. [22.1; N.E.]	0.57	[0.40; 0.81]	0.001	0.156
65 - < 75 years	5/72 (6.9)	N.E. [22.1; N.E.]	5/53 (9.4)	22.2 [22.2; N.E.]	0.60	[0.13; 2.83]	0.523	0.430
>= 75 years	3/19 (15.8)	N.E. [1.0; N.E.]	6/27 (22.2)	2.8 [1.0; N.E.]	0.31	[0.06; 1.56]	0.073	0.489
Pre-randomization selection of TKI								
(Interaction test: p = 0.048)								
Imatinib	10/101 (9.9)	N.E. [N.E.; N.E.]	26/102 (25.5)	10.9 [2.8; 22.1]	0.26	[0.12; 0.56]	<0.001	N.E.
Nilotinib	47/339 (13.9)	N.E. [N.E.; N.E.]	57/333 (17.1)	N.E. [22.1; N.E.]	0.79	[0.53; 1.16]	0.213	0.688

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	5/41 (12.2)	N.E. [6.0; N.E.]	6/42 (14.3)	N.E. [1.8; N.E.]	0.41	[0.10; 1.75]	0.237	N.E.
Geographic region (Interaction test: p = 0.683)								
Europe excluding Germany	27/202 (13.4)	N.E. [22.1; N.E.]	32/203 (15.8)	22.2 [22.0; N.E.]	0.63	[0.36; 1.08]	0.068	0.622
Germany	3/91 (3.3)	N.E. [11.1; N.E.]	5/68 (7.4)	N.E. [2.8; N.E.]	0.20	[0.04; 1.08]	0.029	N.E.
Others	32/188 (17.0)	N.E. [N.E.; N.E.]	52/206 (25.2)	22.1 [22.1; N.E.]	0.58	[0.37; 0.91]	0.017	0.014
Pain (MID=10)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.255)								
Low	62/291	N.E. [11.1; N.E.]	87/292	5.6 [2.8; 11.1]	0.63	[0.45; 0.87]	0.005	0.263

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(21.3)		(29.8)					
Intermediate	37/129	11.1 [4.2; N.E.]	34/128	11.1 [2.7; N.E.]	0.89	[0.55; 1.43]	0.551	0.044
	(28.7)		(26.6)					
High	14/61	N.E. [2.9; N.E.]	13/57	5.7 [2.7; N.E.]	1.13	[0.53; 2.43]	0.815	0.684
	(23.0)		(22.8)					
Sex								
(Interaction test: p = 0.419)								
Female	49/175	10.8 [2.8; N.E.]	60/201	2.8 [1.9; 11.1]	0.88	[0.60; 1.30]	0.313	0.020
	(28.0)		(29.9)					
Male	64/306	N.E. [22.0; N.E.]	74/276	11.1 [2.8; N.E.]	0.70	[0.49; 0.98]	0.034	0.703
	(20.9)		(26.8)					
Race								
(Interaction test: p = 0.138)								
Asian	40/128	N.E. [11.1; N.E.]	59/132	2.9 [2.3; 11.1]	0.57	[0.38; 0.86]	0.005	0.085
	(31.3)		(44.7)					
White	69/333	22.0 [10.8; N.E.]	73/320	11.1 [2.8; N.E.]	0.87	[0.62; 1.21]	0.312	0.964

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(20.7)		(22.8)					
Others	4/20 (20.0)	7.6 [0.9; N.E.]	2/25 (8.0)	N.E. [1.0; N.E.]	0.50	[0.03; 7.55]	0.937	N.E.
Age groups (Interaction test: p = 0.318)								
18 - < 65 years	95/390 (24.4)	N.E. [11.1; N.E.]	115/397 (29.0)	6.7 [2.8; N.E.]	0.76	[0.57; 1.00]	0.035	0.025
65 - < 75 years	12/72 (16.7)	N.E. [10.8; N.E.]	14/53 (26.4)	5.7 [2.8; N.E.]	0.43	[0.17; 1.05]	0.030	0.747
>= 75 years	6/19 (31.6)	1.8 [1.0; N.E.]	5/27 (18.5)	11.1 [1.0; N.E.]	1.54	[0.39; 6.09]	0.909	0.788
Pre-randomization selection of TKI (Interaction test: p = 0.563)								
Imatinib	22/101 (21.8)	N.E. [5.6; N.E.]	30/102 (29.4)	2.8 [1.9; 11.0]	0.55	[0.31; 0.96]	0.020	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Nilotinib	85/339 (25.1)	N.E. [11.0; N.E.]	95/333 (28.5)	11.1 [2.9; N.E.]	0.82	[0.61; 1.10]	0.155	0.117
Dasatinib	6/41 (14.6)	N.E. [1.9; N.E.]	9/42 (21.4)	2.7 [1.0; N.E.]	0.61	[0.21; 1.77]	0.312	N.E.
Geographic region (Interaction test: p = 0.666)								
Europe excluding Germany	46/202 (22.8)	N.E. [11.1; N.E.]	51/203 (25.1)	11.1 [2.8; N.E.]	0.75	[0.50; 1.12]	0.110	0.478
Germany	12/91 (13.2)	5.1 [1.0; N.E.]	8/68 (11.8)	2.8 [1.0; N.E.]	1.20	[0.45; 3.22]	0.568	N.E.
Others	55/188 (29.3)	N.E. [11.0; N.E.]	75/206 (36.4)	5.6 [2.8; 11.1]	0.69	[0.48; 0.98]	0.024	0.005
Dyspnoea (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.361)								
Low	45/291 (15.5)	22.2 [22.1; N.E.]	60/292 (20.5)	N.E. [11.8; N.E.]	0.73	[0.49; 1.08]	0.119	0.363
Intermediate	18/129 (14.0)	N.E. [N.E.; N.E.]	23/128 (18.0)	N.E. [11.1; N.E.]	0.60	[0.32; 1.13]	0.103	0.749
High	7/61 (11.5)	N.E. [22.1; N.E.]	3/57 (5.3)	N.E. [N.E.; N.E.]	1.68	[0.42; 6.75]	0.479	0.154
Sex								
(Interaction test: p = 0.967)								
Female	31/175 (17.7)	22.2 [22.1; N.E.]	40/201 (19.9)	22.1 [11.1; N.E.]	0.72	[0.44; 1.17]	0.168	0.020
Male	39/306 (12.7)	N.E. [22.1; N.E.]	46/276 (16.7)	N.E. [N.E.; N.E.]	0.77	[0.50; 1.18]	0.268	0.986
Race								
(Interaction test: p = 0.925)								
Asian	28/128	N.E. [N.E.; N.E.]	39/132	N.E. [11.3; N.E.]	0.70	[0.43; 1.16]	0.170	0.432

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(21.9)		(29.5)					
White	39/333	22.2 [22.1; N.E.]	45/320	N.E. [N.E.; N.E.]	0.75	[0.48; 1.16]	0.231	0.402
	(11.7)		(14.1)					
Others	3/20	N.E. [0.9; N.E.]	2/25	N.E. [1.0; N.E.]	0.23	[0.02; 3.03]	0.567	N.E.
	(15.0)		(8.0)					
Age groups								
(Interaction test: p = 0.355)								
18 - < 65 years	58/390	22.2 [22.1; N.E.]	74/397	N.E. [N.E.; N.E.]	0.72	[0.50; 1.02]	0.073	0.411
	(14.9)		(18.6)					
65 - < 75 years	9/72	N.E. [N.E.; N.E.]	10/53	N.E. [2.8; N.E.]	0.52	[0.19; 1.43]	0.231	0.357
	(12.5)		(18.9)					
>= 75 years	3/19	N.E. [1.9; N.E.]	2/27	N.E. [5.4; N.E.]	4.35	[0.16; 119.05]	0.352	0.999
	(15.8)		(7.4)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.676)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Imatinib	14/101 (13.9)	22.2 [N.E.; N.E.]	19/102 (18.6)	N.E. [6.7; N.E.]	0.50	[0.24; 1.04]	0.042	N.E.
Nilotinib	51/339 (15.0)	N.E. [22.1; N.E.]	61/333 (18.3)	N.E. [N.E.; N.E.]	0.84	[0.58; 1.23]	0.404	0.819
Dasatinib	5/41 (12.2)	N.E. [3.2; N.E.]	6/42 (14.3)	N.E. [1.5; N.E.]	0.71	[0.19; 2.59]	0.487	N.E.
Geographic region (Interaction test: p = 0.838)								
Europe excluding Germany	31/202 (15.3)	22.2 [22.2; N.E.]	38/203 (18.7)	N.E. [11.1; N.E.]	0.66	[0.40; 1.08]	0.114	0.434
Germany	5/91 (5.5)	22.1 [N.E.; N.E.]	4/68 (5.9)	N.E. [2.8; N.E.]	0.74	[0.15; 3.68]	0.738	N.E.
Others	34/188 (18.1)	N.E. [N.E.; N.E.]	44/206 (21.4)	N.E. [N.E.; N.E.]	0.79	[0.50; 1.24]	0.311	0.259
Insomnia (MID=10)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.462)								
Low	49/291 (16.8)	22.5 [22.5; N.E.]	64/292 (21.9)	22.2 [22.0; N.E.]	0.69	[0.47; 1.00]	0.110	0.784
Intermediate	25/129 (19.4)	N.E. [11.2; N.E.]	32/128 (25.0)	11.2 [2.8; N.E.]	0.57	[0.33; 0.98]	0.015	0.577
High	13/61 (21.3)	N.E. [5.6; N.E.]	8/57 (14.0)	N.E. [5.6; N.E.]	1.13	[0.46; 2.76]	0.494	0.979
Sex								
(Interaction test: p = 0.179)								
Female	36/175 (20.6)	N.E. [11.2; N.E.]	41/201 (20.4)	22.2 [11.1; N.E.]	0.91	[0.57; 1.45]	0.782	0.349
Male	51/306 (16.7)	22.5 [N.E.; N.E.]	63/276 (22.8)	22.1 [22.0; N.E.]	0.58	[0.40; 0.85]	0.009	0.840

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.466)								
Asian	34/128 (26.6)	N.E. [N.E.; N.E.]	41/132 (31.1)	N.E. [11.1; N.E.]	0.67	[0.42; 1.08]	0.174	0.680
White	49/333 (14.7)	22.5 [11.2; N.E.]	61/320 (19.1)	22.0 [11.1; N.E.]	0.61	[0.42; 0.91]	0.019	0.367
Others	4/20 (20.0)	5.6 [1.0; N.E.]	2/25 (8.0)	N.E. [1.0; N.E.]	0.65	[0.10; 4.09]	0.729	N.E.
Age groups								
(Interaction test: p = 0.138)								
18 - < 65 years	72/390 (18.5)	22.5 [22.5; N.E.]	89/397 (22.4)	22.1 [11.2; N.E.]	0.66	[0.48; 0.90]	0.019	0.475
65 - < 75 years	14/72 (19.4)	N.E. [5.6; N.E.]	10/53 (18.9)	22.2 [5.5; N.E.]	1.04	[0.40; 2.67]	0.816	0.583
>= 75 years	1/19 (5.3)	N.E. [1.9; N.E.]	5/27 (18.5)	11.1 [1.0; N.E.]	0.11	[0.00; 4.09]	0.017	0.998

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.200)								
Imatinib	12/101 (11.9)	N.E. [N.E.; N.E.]	21/102 (20.6)	22.0 [5.5; N.E.]	0.50	[0.24; 1.02]	0.014	N.E.
Nilotinib	67/339 (19.8)	22.5 [11.2; N.E.]	78/333 (23.4)	22.2 [11.1; N.E.]	0.69	[0.49; 0.97]	0.052	0.304
Dasatinib	8/41 (19.5)	N.E. [1.8; N.E.]	5/42 (11.9)	N.E. [1.5; N.E.]	1.59	[0.50; 5.01]	0.226	N.E.
Geographic region								
(Interaction test: p = 0.847)								
Europe excluding Germany	42/202 (20.8)	22.5 [11.2; N.E.]	48/203 (23.6)	22.0 [5.6; 22.2]	0.64	[0.41; 0.98]	0.022	0.665
Germany	4/91 (4.4)	N.E. [N.E.; N.E.]	5/68 (7.4)	N.E. [1.9; N.E.]	0.34	[0.08; 1.41]	0.101	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	41/188 (21.8)	N.E. [N.E.; N.E.]	51/206 (24.8)	N.E. [11.2; N.E.]	0.73	[0.48; 1.11]	0.269	0.240
Appetite loss (MID=10)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.443)								
Low	33/291 (11.3)	N.E. [22.1; N.E.]	43/292 (14.7)	N.E. [22.2; N.E.]	0.73	[0.46; 1.15]	0.189	0.033
Intermediate	12/129 (9.3)	22.2 [N.E.; N.E.]	22/128 (17.2)	N.E. [22.1; N.E.]	0.34	[0.16; 0.71]	0.004	0.497
High	5/61 (8.2)	N.E. [N.E.; N.E.]	7/57 (12.3)	22.1 [16.6; N.E.]	0.76	[0.22; 2.61]	0.272	0.994
Sex (Interaction test: p = 0.253)								
Female	25/175	N.E. [N.E.; N.E.]	32/201	22.2 [22.1; N.E.]	0.79	[0.46; 1.35]	0.259	0.575

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(14.3)		(15.9)					
Male	25/306	N.E. [22.2; N.E.]	40/276	N.E. [22.1; N.E.]	0.47	[0.28; 0.80]	0.005	0.088
	(8.2)		(14.5)					
Race								
(Interaction test: p = 0.021)								
Asian	16/128	N.E. [N.E.; N.E.]	38/132	N.E. [22.1; N.E.]	0.32	[0.18; 0.59]	<0.001	0.630
	(12.5)		(28.8)					
White	30/333	22.2 [22.1; N.E.]	32/320	N.E. [22.2; N.E.]	0.88	[0.53; 1.46]	0.557	0.756
	(9.0)		(10.0)					
Others	4/20	7.6 [2.0; N.E.]	2/25	11.1 [2.8; N.E.]	2.16	[0.18; 25.80]	0.588	N.E.
	(20.0)		(8.0)					
Age groups								
(Interaction test: p = 0.251)								
18 - < 65 years	41/390	N.E. [N.E.; N.E.]	55/397	N.E. [N.E.; N.E.]	0.67	[0.45; 1.01]	0.065	0.243
	(10.5)		(13.9)					
65 - < 75 years	5/72	N.E. [N.E.; N.E.]	11/53	22.2 [1.7; N.E.]	0.28	[0.08; 0.93]	0.025	0.898

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(6.9)		(20.8)					
>= 75 years	4/19	22.2 [1.0; N.E.]	6/27	5.6 [1.4; N.E.]	0.58	[0.12; 2.88]	0.349	0.997
	(21.1)		(22.2)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.691)								
Imatinib	12/101	N.E. [22.1; N.E.]	18/102	22.1 [11.1; N.E.]	0.46	[0.22; 0.99]	0.035	N.E.
	(11.9)		(17.6)					
Nilotinib	34/339	N.E. [N.E.; N.E.]	47/333	N.E. [22.2; N.E.]	0.67	[0.43; 1.06]	0.070	0.090
	(10.0)		(14.1)					
Dasatinib	4/41	N.E. [22.0; N.E.]	7/42	N.E. [1.5; N.E.]	0.39	[0.10; 1.52]	0.181	N.E.
	(9.8)		(16.7)					
Geographic region								
(Interaction test: p = 0.238)								
Europe excluding Germany	22/202	N.E. [22.2; N.E.]	22/203	N.E. [22.1; N.E.]	0.86	[0.47; 1.60]	0.597	0.989

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(10.9)		(10.8)					
Germany	3/91	22.1 [N.E.; N.E.]	4/68	N.E. [5.6; N.E.]	0.38	[0.07; 2.15]	0.209	N.E.
	(3.3)		(5.9)					
Others	25/188	N.E. [N.E.; N.E.]	46/206	N.E. [22.1; N.E.]	0.46	[0.28; 0.75]	0.003	0.061
	(13.3)		(22.3)					
Constipation (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.852)								
Low	47/291	N.E. [N.E.; N.E.]	61/292	N.E. [11.1; N.E.]	0.69	[0.47; 1.02]	0.112	0.487
	(16.2)		(20.9)					
Intermediate	25/129	N.E. [21.4; N.E.]	27/128	N.E. [5.5; N.E.]	0.63	[0.36; 1.10]	0.119	0.808
	(19.4)		(21.1)					
High	8/61	N.E. [N.E.; N.E.]	7/57	N.E. [N.E.; N.E.]	0.91	[0.33; 2.52]	0.825	0.424
	(13.1)		(12.3)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.462)								
Female	31/175 (17.7)	N.E. [21.4; N.E.]	38/201 (18.9)	N.E. [11.0; N.E.]	0.83	[0.51; 1.34]	0.473	0.068
Male	49/306 (16.0)	N.E. [N.E.; N.E.]	57/276 (20.7)	N.E. [11.1; N.E.]	0.63	[0.43; 0.94]	0.051	0.940
Race								
(Interaction test: p = 0.396)								
Asian	34/128 (26.6)	N.E. [N.E.; N.E.]	45/132 (34.1)	N.E. [11.0; N.E.]	0.62	[0.39; 0.98]	0.067	0.114
White	42/333 (12.6)	N.E. [22.1; N.E.]	49/320 (15.3)	N.E. [11.8; N.E.]	0.70	[0.46; 1.07]	0.123	0.840
Others	4/20 (20.0)	7.6 [1.9; N.E.]	1/25 (4.0)	N.E. [5.6; N.E.]	5.07	[0.10; 245.53]	0.110	N.E.
Age groups								
(Interaction test: p = 0.072)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	64/390 (16.4)	N.E. [N.E.; N.E.]	85/397 (21.4)	N.E. [11.1; N.E.]	0.63	[0.45; 0.88]	0.012	0.576
65 - < 75 years	15/72 (20.8)	21.4 [5.5; N.E.]	7/53 (13.2)	N.E. [5.5; N.E.]	1.75	[0.63; 4.85]	0.260	0.307
>= 75 years	1/19 (5.3)	N.E. [1.0; N.E.]	3/27 (11.1)	N.E. [1.0; N.E.]	0.17	[0.01; 5.20]	0.257	1.000
Pre-randomization selection of TKI								
(Interaction test: p = 0.075)								
Imatinib	20/101 (19.8)	N.E. [11.0; N.E.]	12/102 (11.8)	N.E. [N.E.; N.E.]	1.45	[0.70; 2.98]	0.345	N.E.
Nilotinib	53/339 (15.6)	N.E. [22.1; N.E.]	75/333 (22.5)	N.E. [11.1; N.E.]	0.58	[0.41; 0.84]	0.007	0.443
Dasatinib	7/41 (17.1)	N.E. [5.4; N.E.]	8/42 (19.0)	N.E. [1.2; N.E.]	0.61	[0.20; 1.88]	0.353	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.044)								
Europe excluding Germany	34/202 (16.8)	N.E. [21.4; N.E.]	31/203 (15.3)	N.E. [N.E.; N.E.]	0.89	[0.54; 1.47]	0.740	0.544
Germany	2/91 (2.2)	N.E. [N.E.; N.E.]	7/68 (10.3)	2.8 [0.9; N.E.]	0.15	[0.03; 0.77]	0.005	N.E.
Others	44/188 (23.4)	N.E. [18.2; N.E.]	57/206 (27.7)	N.E. [11.1; N.E.]	0.70	[0.47; 1.05]	0.161	0.654
Diarrhoea (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.495)								
Low	38/291 (13.1)	N.E. [N.E.; N.E.]	64/292 (21.9)	22.2 [11.1; N.E.]	0.52	[0.35; 0.79]	0.002	0.306
Intermediate	23/129 (17.8)	N.E. [N.E.; N.E.]	28/128 (21.9)	N.E. [5.5; N.E.]	0.79	[0.45; 1.39]	0.123	0.811

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
High	7/61 (11.5)	N.E. [22.0; N.E.]	6/57 (10.5)	N.E. [11.1; N.E.]	0.82	[0.27; 2.50]	0.764	0.333
Sex								
(Interaction test: p = 0.564)								
Female	23/175 (13.1)	N.E. [N.E.; N.E.]	32/201 (15.9)	22.2 [22.2; N.E.]	0.76	[0.44; 1.32]	0.268	0.401
Male	45/306 (14.7)	N.E. [N.E.; N.E.]	66/276 (23.9)	22.1 [11.1; N.E.]	0.56	[0.38; 0.82]	0.002	0.669
Race								
(Interaction test: p = 0.768)								
Asian	26/128 (20.3)	N.E. [N.E.; N.E.]	40/132 (30.3)	N.E. [11.1; N.E.]	0.61	[0.37; 1.00]	0.039	0.793
White	39/333 (11.7)	N.E. [N.E.; N.E.]	56/320 (17.5)	22.2 [11.1; N.E.]	0.60	[0.39; 0.91]	0.013	0.105
Others	3/20 (15.0)	N.E. [2.8; N.E.]	2/25 (8.0)	N.E. [1.6; N.E.]	0.38	[0.05; 2.76]	0.149	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Age groups								
(Interaction test: p = 0.539)								
18 - < 65 years	57/390 (14.6)	N.E. [N.E.; N.E.]	84/397 (21.2)	N.E. [22.0; N.E.]	0.61	[0.43; 0.86]	0.003	0.345
65 - < 75 years	9/72 (12.5)	N.E. [N.E.; N.E.]	9/53 (17.0)	22.2 [2.8; N.E.]	0.76	[0.26; 2.23]	0.622	0.132
>= 75 years	2/19 (10.5)	N.E. [2.8; N.E.]	5/27 (18.5)	11.1 [1.0; N.E.]	0.27	[0.05; 1.47]	0.125	0.998
Pre-randomization selection of TKI								
(Interaction test: p = 0.123)								
Imatinib	16/101 (15.8)	N.E. [N.E.; N.E.]	28/102 (27.5)	6.7 [2.8; 22.0]	0.34	[0.18; 0.65]	0.002	N.E.
Nilotinib	45/339 (13.3)	N.E. [N.E.; N.E.]	63/333 (18.9)	N.E. [22.2; N.E.]	0.68	[0.46; 1.00]	0.018	0.456
Dasatinib	7/41	N.E. [1.8; N.E.]	7/42	N.E. [2.8; N.E.]	1.12	[0.38; 3.33]	0.545	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(17.1)		(16.7)					
Geographic region								
(Interaction test: p = 0.395)								
Europe excluding Germany	31/202	N.E. [N.E.; N.E.]	43/203	22.0 [10.8; N.E.]	0.59	[0.36; 0.95]	0.024	0.112
	(15.3)		(21.2)					
Germany	3/91	N.E. [22.0; N.E.]	6/68	N.E. [1.9; N.E.]	0.16	[0.03; 0.91]	0.010	N.E.
	(3.3)		(8.8)					
Others	34/188	N.E. [N.E.; N.E.]	49/206	N.E. [22.1; N.E.]	0.70	[0.44; 1.09]	0.086	0.323
	(18.1)		(23.8)					
Financial difficulties (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.131)								
Low	33/291	N.E. [N.E.; N.E.]	37/292	N.E. [22.2; N.E.]	0.94	[0.59; 1.50]	0.802	0.485

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(11.3)		(12.7)					
Intermediate	26/129	N.E. [N.E.; N.E.]	14/128	26.4 [22.3; N.E.]	2.01	[1.01; 4.00]	0.043	0.604
	(20.2)		(10.9)					
High	5/61	N.E. [22.1; N.E.]	5/57	N.E. [N.E.; N.E.]	0.45	[0.11; 1.82]	0.298	0.501
	(8.2)		(8.8)					
Sex								
(Interaction test: p = 0.949)								
Female	24/175	N.E. [N.E.; N.E.]	23/201	N.E. [22.2; N.E.]	1.09	[0.60; 1.99]	0.782	0.220
	(13.7)		(11.4)					
Male	40/306	N.E. [N.E.; N.E.]	33/276	26.4 [22.3; N.E.]	1.15	[0.72; 1.85]	0.549	0.570
	(13.1)		(12.0)					
Race								
(Interaction test: p = 0.422)								
Asian	30/128	N.E. [N.E.; N.E.]	24/132	N.E. [22.3; N.E.]	1.18	[0.67; 2.06]	0.395	0.721
	(23.4)		(18.2)					
White	30/333	N.E. [N.E.; N.E.]	31/320	26.4 [22.2; N.E.]	0.92	[0.55; 1.55]	0.809	0.515

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(9.0)		(9.7)					
Others	4/20 (20.0)	N.E. [1.0; N.E.]	1/25 (4.0)	N.E. [2.8; N.E.]	3.38	[0.12; 98.70]	0.212	N.E.
Age groups (Interaction test: p = 0.169)								
18 - < 65 years	56/390 (14.4)	N.E. [N.E.; N.E.]	48/397 (12.1)	N.E. [22.2; N.E.]	1.24	[0.84; 1.83]	0.271	0.997
65 - < 75 years	5/72 (6.9)	N.E. [22.1; N.E.]	7/53 (13.2)	26.4 [N.E.; N.E.]	0.37	[0.08; 1.67]	0.062	0.996
>= 75 years	3/19 (15.8)	N.E. [1.0; N.E.]	1/27 (3.7)	N.E. [2.8; N.E.]	7.53	[0.18; 314.65]	0.055	1.000
Pre-randomization selection of TKI (Interaction test: p = 0.940)								
Imatinib	13/101 (12.9)	N.E. [22.1; N.E.]	10/102 (9.8)	N.E. [N.E.; N.E.]	0.99	[0.42; 2.34]	0.940	N.E.


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Nilotinib	47/339 (13.9)	N.E. [N.E.; N.E.]	42/333 (12.6)	26.4 [22.3; N.E.]	1.17	[0.76; 1.79]	0.472	0.902
Dasatinib	4/41 (9.8)	N.E. [N.E.; N.E.]	4/42 (9.5)	N.E. [11.0; N.E.]	1.07	[0.26; 4.38]	0.877	N.E.
Geographic region (Interaction test: p = 0.401)								
Europe excluding Germany	23/202 (11.4)	N.E. [N.E.; N.E.]	23/203 (11.3)	N.E. [22.2; N.E.]	0.90	[0.50; 1.64]	0.767	0.296
Germany	4/91 (4.4)	N.E. [N.E.; N.E.]	5/68 (7.4)	26.4 [1.0; N.E.]	0.70	[0.17; 2.93]	0.572	N.E.
Others	37/188 (19.7)	N.E. [N.E.; N.E.]	28/206 (13.6)	N.E. [22.3; N.E.]	1.40	[0.85; 2.32]	0.130	0.872

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				

MID: Minimally important difference
N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not more than 10 events per subgroup per treatment arm, no subgroup analyses were performed for the corresponding attribute.
If there are not more than 10 events per subgroup per treatment arm, no Cox PH hazard analysis is carried out.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline PRO score.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT) and Pre-Randomization selection TKI (IRT).
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Physical functioning (MID=10): Stratification factor: ELTS based on randomization data from IRT: Low



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Physical functioning (MID=10): Stratification factor: ELTS based on randomization data from IRT: Intermediate



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Physical functioning (MID=10): Stratification factor: ELTS based on randomization data from IRT: High



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Physical functioning (MID=10): Age groups: 18 - < 65 years




Pts at Risk (censored)

Asciminib	390 (0)	134 (202)	56 (273)	56 (273)	0 (328)	0 (328)	0 (328)
Investigator Selected TKI	397 (0)	120 (215)	47 (279)	39 (287)	2 (321)	0 (323)	0 (323)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Physical functioning (MID=10): Age groups: 65 - < 75 years




Pts at Risk (censored)

Asciminib	72 (0)	20 (46)	10 (56)	10 (56)	0 (66)	0 (66)	0 (66)
Investigator Selected TKI	53 (0)	13 (30)	6 (36)	4 (38)	0 (42)	0 (42)	0 (42)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Physical functioning (MID=10): Age groups: >= 75 years



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Role functioning (MID=10): Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Role functioning (MID=10): Pre-randomization selection of TKI: Nilotinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Role functioning (MID=10): Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Nausea and vomiting (MID=10): Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Nausea and vomiting (MID=10): Pre-randomization selection of TKI: Nilotinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Nausea and vomiting (MID=10): Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Appetite loss (MID=10): Race: Asian




Pts at Risk (censored)

Asciminib	128 (0)	72 (42)	45 (69)	45 (69)	0 (112)	0 (112)	0 (112)
Investigator Selected TKI	132 (0)	58 (40)	33 (64)	32 (65)	1 (93)	0 (94)	0 (94)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Appetite loss (MID=10): Race: White



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Appetite loss (MID=10): Race: Others



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Constipation (MID=10): Geographic region: Europe excluding Germany




Pts at Risk (censored)

Asciminib	202 (0)	67 (111)	22 (148)	21 (149)	0 (168)	0 (168)	0 (168)
Investigator Selected TKI	203 (0)	48 (127)	16 (156)	12 (160)	1 (171)	0 (172)	0 (172)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Constipation (MID=10): Geographic region: Germany




Pts at Risk (censored)

Asciminib	91 (0)	18 (71)	5 (84)	5 (84)	0 (89)	0 (89)	0 (89)
Investigator Selected TKI	68 (0)	5 (56)	4 (57)	2 (59)	1 (60)	0 (61)	0 (61)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Constipation (MID=10): Geographic region: Others



Pts at Risk (censored)


Asciminib	188 (0)	73 (81)	33 (112)	33 (112)	0 (144)	0 (144)	0 (144)
Investigator Selected TKI	206 (0)	69 (91)	28 (121)	28 (121)	0 (149)	0 (149)	0 (149)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Appetite loss (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	15/153	23/150	0.50	0.26; 0.97	0.047
ASC4START	26/237	32/247	0.82	0.49; 1.38	0.437
Pooled Analysis	41/390	55/397	0.67	0.45; 1.01	0.065
65 - < 75 years					
ASC4FIRST	3/34	6/29	0.30	0.06; 1.57	0.138
ASC4START	2/38	5/24	0.25	0.04; 1.39	0.088
Pooled Analysis	5/72	11/53	0.28	0.08; 0.93	0.025
>= 75 years					
ASC4FIRST	1/10	4/14	0.17	0.00; 6.39	0.072
ASC4START	3/9	2/13	1.89	0.18; 19.47	0.629
Pooled Analysis	4/19	6/27	0.58	0.12; 2.88	0.349



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Appetite loss (MID=10)




Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	0/20	5.58	0.12; 270.43	0.192
ASC4START	3/38	7/37	0.40	0.09; 1.73	0.072
Pooled Analysis	5/61	7/57	0.76	0.22; 2.61	0.272
Intermediate					
ASC4FIRST	6/54	10/53	0.26	0.08; 0.80	0.021
ASC4START	6/75	12/75	0.43	0.16; 1.16	0.063
Pooled Analysis	12/129	22/128	0.34	0.16; 0.71	0.004
Low					
ASC4FIRST	11/120	23/120	0.40	0.20; 0.84	0.011
ASC4START	22/171	20/172	1.14	0.62; 2.10	0.600
Pooled Analysis	33/291	43/292	0.73	0.46; 1.15	0.189

n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Appetite loss (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	9/64	5/62	0.84	0.26; 2.75	0.950
ASC4START	13/138	17/141	0.85	0.41; 1.77	0.506
Pooled Analysis	22/202	22/203	0.86	0.47; 1.60	0.597
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	3/72	4/53	0.38	0.07; 2.15	0.209
Pooled Analysis	3/91	4/68	0.38	0.07; 2.15	0.209
Others					
ASC4FIRST	10/114	28/116	0.28	0.13; 0.59	<0.001
ASC4START	15/74	18/90	0.74	0.37; 1.49	0.580
Pooled Analysis	25/188	46/206	0.46	0.28; 0.75	0.003



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Appetite loss (MID=10)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Appetite loss (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	6/40	13/46	0.39	0.15; 1.04	0.057
Pooled Analysis	16/128	38/132	0.32	0.18; 0.59	<0.001
Asian/Others					
ASC4FIRST	11/91	25/90	0.31	0.15; 0.65	0.001
Others					
ASC4START	3/17	2/21	2.16	0.18; 25.80	0.588
Pooled Analysis	4/20	2/25	2.16	0.18; 25.80	0.588
White					
ASC4FIRST	8/106	8/103	0.77	0.27; 2.21	0.727
ASC4START	22/227	24/217	0.92	0.52; 1.66	0.633
Pooled Analysis	30/333	32/320	0.88	0.53; 1.46	0.557




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Appetite loss (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	8/68	10/75	0.63	0.24; 1.65	0.318
ASC4START	17/107	22/126	0.90	0.47; 1.72	0.492
Pooled Analysis	25/175	32/201	0.79	0.46; 1.35	0.259
Male					
ASC4FIRST	11/129	23/118	0.28	0.13; 0.63	0.002
ASC4START	14/177	17/158	0.73	0.36; 1.48	0.366
Pooled Analysis	25/306	40/276	0.47	0.28; 0.80	0.005




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Cognitive functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	31/153	41/150	0.66	0.41; 1.07	0.085
ASC4START	64/237	71/247	0.88	0.63; 1.24	0.519
Pooled Analysis	95/390	112/397	0.81	0.61; 1.06	0.126
65 - < 75 years					
ASC4FIRST	8/34	6/29	0.83	0.24; 2.86	0.968
ASC4START	7/38	5/24	0.81	0.25; 2.65	0.723
Pooled Analysis	15/72	11/53	0.88	0.38; 2.06	0.776
>= 75 years					
ASC4FIRST	1/10	3/14	1.45	0.08; 25.36	0.549
ASC4START	4/9	1/13	4.98	0.14; 177.70	0.105
Pooled Analysis	5/19	4/27	2.85	0.38; 21.66	0.403




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Cognitive functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	4/23	4/20	0.34	0.06; 1.94	0.219
ASC4START	10/38	8/37	1.01	0.40; 2.58	0.993
Pooled Analysis	14/61	12/57	0.80	0.36; 1.79	0.523
Intermediate					
ASC4FIRST	17/54	12/53	1.39	0.66; 2.94	0.415
ASC4START	23/75	20/75	1.06	0.58; 1.94	0.822
Pooled Analysis	40/129	32/128	1.18	0.74; 1.89	0.490
Low					
ASC4FIRST	19/120	34/120	0.54	0.31; 0.96	0.033
ASC4START	42/171	49/172	0.84	0.56; 1.28	0.436
Pooled Analysis	61/291	83/292	0.72	0.52; 1.01	0.057




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Cognitive functioning (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	15/64	11/62	0.72	0.31; 1.66	0.415
ASC4START	34/138	39/141	0.88	0.55; 1.40	0.603
Pooled Analysis	49/202	50/203	0.84	0.56; 1.27	0.398
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	14/72	9/53	0.70	0.27; 1.81	0.845
Pooled Analysis	14/91	9/68	0.70	0.27; 1.81	0.845
Others					
ASC4FIRST	25/114	39/116	0.72	0.43; 1.19	0.192
ASC4START	27/74	29/90	0.98	0.57; 1.68	0.910
Pooled Analysis	52/188	68/206	0.83	0.57; 1.19	0.300



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Cognitive functioning (MID=10)




Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	8/41	9/42	1.14	0.41; 3.18	0.872
Pooled Analysis	8/41	9/42	1.14	0.41; 3.18	0.872
Imatinib					
ASC4FIRST	16/101	25/102	0.43	0.22; 0.85	0.011
Pooled Analysis	16/101	25/102	0.43	0.22; 0.85	0.011
Nilotinib					
ASC4FIRST	16/55	16/49	1.11	0.54; 2.28	0.746
ASC4START	75/284	77/284	0.92	0.67; 1.26	0.626
Pooled Analysis	91/339	93/333	0.95	0.71; 1.27	0.753

n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Cognitive functioning (MID=10)




Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	16/40	17/46	0.94	0.47; 1.89	0.846
Pooled Analysis	42/128	53/132	0.78	0.52; 1.18	0.236
Asian/Others					
ASC4FIRST	27/91	36/90	0.74	0.44; 1.22	0.216
Others					
ASC4START	3/17	5/21	1.08	0.15; 7.87	0.409
Pooled Analysis	4/20	5/25	1.08	0.15; 7.87	0.409
White					
ASC4FIRST	13/106	14/103	0.60	0.26; 1.40	0.235
ASC4START	56/227	55/217	0.93	0.64; 1.35	0.708
Pooled Analysis	69/333	69/320	0.87	0.62; 1.22	0.406

n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Cognitive functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	13/68	19/75	0.72	0.33; 1.55	0.342
ASC4START	38/107	33/126	1.38	0.85; 2.22	0.165
Pooled Analysis	51/175	52/201	1.15	0.77; 1.71	0.510
Male					
ASC4FIRST	27/129	31/118	0.75	0.44; 1.27	0.266
ASC4START	37/177	44/158	0.69	0.45; 1.07	0.112
Pooled Analysis	64/306	75/276	0.72	0.51; 1.01	0.053




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Constipation (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	27/153	29/150	0.70	0.40; 1.20	0.276
ASC4START	37/237	56/247	0.60	0.39; 0.91	0.020
Pooled Analysis	64/390	85/397	0.63	0.45; 0.88	0.012
65 - < 75 years					
ASC4FIRST	9/34	4/29	2.77	0.70; 10.87	0.154
ASC4START	6/38	3/24	1.00	0.24; 4.14	0.939
Pooled Analysis	15/72	7/53	1.75	0.63; 4.85	0.260
>= 75 years					
ASC4FIRST	0/10	2/14	0.26	0.01; 11.61	0.225
ASC4START	1/9	1/13	0.34	0.00; 23.19	0.739
Pooled Analysis	1/19	3/27	0.17	0.01; 5.20	0.257




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Constipation (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	4/23	2/20	1.56	0.28; 8.57	0.628
ASC4START	4/38	5/37	0.65	0.17; 2.42	0.495
Pooled Analysis	8/61	7/57	0.91	0.33; 2.52	0.825
Intermediate					
ASC4FIRST	12/54	11/53	0.65	0.26; 1.63	0.363
ASC4START	13/75	16/75	0.63	0.30; 1.32	0.204
Pooled Analysis	25/129	27/128	0.63	0.36; 1.10	0.119
Low					
ASC4FIRST	20/120	22/120	0.83	0.45; 1.54	0.679
ASC4START	27/171	39/172	0.62	0.38; 1.02	0.089
Pooled Analysis	47/291	61/292	0.69	0.47; 1.02	0.112




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Constipation (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	9/64	4/62	1.21	0.35; 4.13	0.713
ASC4START	25/138	27/141	0.84	0.48; 1.46	0.589
Pooled Analysis	34/202	31/203	0.89	0.54; 1.47	0.740
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	2/72	7/53	0.15	0.03; 0.77	0.005
Pooled Analysis	2/91	7/68	0.15	0.03; 0.77	0.005
Others					
ASC4FIRST	27/114	31/116	0.76	0.44; 1.30	0.434
ASC4START	17/74	26/90	0.63	0.34; 1.18	0.216
Pooled Analysis	44/188	57/206	0.70	0.47; 1.05	0.161




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Constipation (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	7/41	8/42	0.61	0.20; 1.88	0.353
Pooled Analysis	7/41	8/42	0.61	0.20; 1.88	0.353
Imatinib					
ASC4FIRST	20/101	12/102	1.45	0.70; 2.98	0.345
Pooled Analysis	20/101	12/102	1.45	0.70; 2.98	0.345
Nilotinib					
ASC4FIRST	9/55	15/49	0.34	0.13; 0.90	0.111
ASC4START	44/284	60/284	0.63	0.42; 0.93	0.026
Pooled Analysis	53/339	75/333	0.58	0.41; 0.84	0.007



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Constipation (MID=10)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Constipation (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	14/68	11/75	1.55	0.66; 3.64	0.315
ASC4START	17/107	27/126	0.60	0.33; 1.11	0.102
Pooled Analysis	31/175	38/201	0.83	0.51; 1.34	0.473
Male					
ASC4FIRST	22/129	24/118	0.64	0.35; 1.19	0.223
ASC4START	27/177	33/158	0.63	0.38; 1.05	0.126
Pooled Analysis	49/306	57/276	0.63	0.43; 0.94	0.051




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	23/153	34/150	0.50	0.29; 0.87	0.023
ASC4START	34/237	50/247	0.70	0.45; 1.09	0.044
Pooled Analysis	57/390	84/397	0.61	0.43; 0.86	0.003
65 - < 75 years					
ASC4FIRST	4/34	7/29	0.35	0.07; 1.77	0.143
ASC4START	5/38	2/24	3.24	0.34; 30.58	0.322
Pooled Analysis	9/72	9/53	0.76	0.26; 2.23	0.622
>= 75 years					
ASC4FIRST	2/10	4/14	0.37	0.06; 2.13	0.249
ASC4START	0/9	1/13	0.17	0.00; 18.51	0.221
Pooled Analysis	2/19	5/27	0.27	0.05; 1.47	0.125




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	2/20	0.25	0.02; 3.59	0.341
ASC4START	6/38	4/37	1.10	0.31; 3.92	0.867
Pooled Analysis	7/61	6/57	0.82	0.27; 2.50	0.764
Intermediate					
ASC4FIRST	12/54	16/53	0.77	0.36; 1.66	0.109
ASC4START	11/75	12/75	0.84	0.37; 1.90	0.588
Pooled Analysis	23/129	28/128	0.79	0.45; 1.39	0.123
Low					
ASC4FIRST	16/120	27/120	0.43	0.22; 0.83	0.028
ASC4START	22/171	37/172	0.65	0.38; 1.10	0.033
Pooled Analysis	38/291	64/292	0.52	0.35; 0.79	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	9/64	12/62	0.32	0.13; 0.82	0.018
ASC4START	22/138	31/141	0.75	0.43; 1.31	0.221
Pooled Analysis	31/202	43/203	0.59	0.36; 0.95	0.024
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	3/72	6/53	0.16	0.03; 0.91	0.010
Pooled Analysis	3/91	6/68	0.16	0.03; 0.91	0.010
Others					
ASC4FIRST	20/114	33/116	0.59	0.33; 1.04	0.072
ASC4START	14/74	16/90	0.95	0.45; 1.97	0.641
Pooled Analysis	34/188	49/206	0.70	0.44; 1.09	0.086




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	7/41	7/42	1.12	0.38; 3.33	0.545
Pooled Analysis	7/41	7/42	1.12	0.38; 3.33	0.545
Imatinib					
ASC4FIRST	16/101	28/102	0.34	0.18; 0.65	0.002
Pooled Analysis	16/101	28/102	0.34	0.18; 0.65	0.002
Nilotinib					
ASC4FIRST	6/55	10/49	0.44	0.14; 1.34	0.116
ASC4START	39/284	53/284	0.72	0.48; 1.09	0.055
Pooled Analysis	45/339	63/333	0.68	0.46; 1.00	0.018




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	7/40	11/46	0.70	0.27; 1.82	0.276
Pooled Analysis	26/128	40/132	0.61	0.37; 1.00	0.039
Asian/Others					
ASC4FIRST	20/91	29/90	0.60	0.33; 1.08	0.097
Others					
ASC4START	2/17	2/21	0.38	0.05; 2.76	0.149
Pooled Analysis	3/20	2/25	0.38	0.05; 2.76	0.149
White					
ASC4FIRST	9/106	16/103	0.33	0.14; 0.80	0.015
ASC4START	30/227	40/217	0.73	0.46; 1.19	0.138
Pooled Analysis	39/333	56/320	0.60	0.39; 0.91	0.013




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	7/68	13/75	0.54	0.20; 1.44	0.258
ASC4START	16/107	19/126	0.90	0.45; 1.77	0.583
Pooled Analysis	23/175	32/201	0.76	0.44; 1.32	0.268
Male					
ASC4FIRST	22/129	32/118	0.51	0.29; 0.90	0.024
ASC4START	23/177	34/158	0.61	0.36; 1.04	0.039
Pooled Analysis	45/306	66/276	0.56	0.38; 0.82	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Dyspnoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	20/153	26/150	0.58	0.31; 1.08	0.085
ASC4START	38/237	48/247	0.79	0.52; 1.22	0.331
Pooled Analysis	58/390	74/397	0.72	0.50; 1.02	0.073
65 - < 75 years					
ASC4FIRST	4/34	8/29	0.31	0.07; 1.32	0.112
ASC4START	5/38	2/24	1.15	0.21; 6.27	0.940
Pooled Analysis	9/72	10/53	0.52	0.19; 1.43	0.231
>= 75 years					
ASC4FIRST	1/10	2/14	5.92	0.07; 537.99	1.000
ASC4START	2/9	0/13	1.83	0.02; 199.10	0.199
Pooled Analysis	3/19	2/27	4.35	0.16; 119.05	0.352




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Dyspnoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	2/20	0.41	0.04; 4.55	0.446
ASC4START	5/38	1/37	4.23	0.49; 36.35	0.161
Pooled Analysis	7/61	3/57	1.68	0.42; 6.75	0.479
Intermediate					
ASC4FIRST	8/54	10/53	0.54	0.21; 1.39	0.191
ASC4START	10/75	13/75	0.66	0.29; 1.51	0.304
Pooled Analysis	18/129	23/128	0.60	0.32; 1.13	0.103
Low					
ASC4FIRST	15/120	24/120	0.57	0.29; 1.11	0.071
ASC4START	30/171	36/172	0.83	0.51; 1.36	0.559
Pooled Analysis	45/291	60/292	0.73	0.49; 1.08	0.119




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Dyspnoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	7/64	7/62	0.43	0.13; 1.40	0.139
ASC4START	24/138	31/141	0.72	0.42; 1.23	0.283
Pooled Analysis	31/202	38/203	0.66	0.40; 1.08	0.114
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	5/72	4/53	0.74	0.15; 3.68	0.738
Pooled Analysis	5/91	4/68	0.74	0.15; 3.68	0.738
Others					
ASC4FIRST	18/114	29/116	0.63	0.35; 1.15	0.125
ASC4START	16/74	15/90	1.08	0.53; 2.22	0.775
Pooled Analysis	34/188	44/206	0.79	0.50; 1.24	0.311




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Dyspnoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	5/41	6/42	0.71	0.19; 2.59	0.487
Pooled Analysis	5/41	6/42	0.71	0.19; 2.59	0.487
Imatinib					
ASC4FIRST	14/101	19/102	0.50	0.24; 1.04	0.042
Pooled Analysis	14/101	19/102	0.50	0.24; 1.04	0.042
Nilotinib					
ASC4FIRST	6/55	11/49	0.76	0.28; 2.07	0.525
ASC4START	45/284	50/284	0.86	0.57; 1.29	0.524
Pooled Analysis	51/339	61/333	0.84	0.58; 1.23	0.404




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Dyspnoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	10/40	11/46	0.96	0.40; 2.34	0.961
Pooled Analysis	28/128	39/132	0.70	0.43; 1.16	0.170
Asian/Others					
ASC4FIRST	19/91	28/90	0.64	0.35; 1.16	0.126
Others					
ASC4START	2/17	2/21	0.23	0.02; 3.03	0.567
Pooled Analysis	3/20	2/25	0.23	0.02; 3.03	0.567
White					
ASC4FIRST	6/106	8/103	0.47	0.13; 1.65	0.204
ASC4START	33/227	37/217	0.80	0.50; 1.29	0.431
Pooled Analysis	39/333	45/320	0.75	0.48; 1.16	0.231




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Dyspnoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	8/68	15/75	0.23	0.08; 0.65	0.004
ASC4START	23/107	25/126	1.04	0.58; 1.83	0.845
Pooled Analysis	31/175	40/201	0.72	0.44; 1.17	0.168
Male					
ASC4FIRST	17/129	21/118	0.76	0.40; 1.47	0.460
ASC4START	22/177	25/158	0.76	0.43; 1.36	0.409
Pooled Analysis	39/306	46/276	0.77	0.50; 1.18	0.268




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Emotional functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	24/153	27/150	0.74	0.42; 1.29	0.342
ASC4START	40/237	54/247	0.64	0.42; 0.97	0.142
Pooled Analysis	64/390	81/397	0.69	0.49; 0.96	0.081
65 - < 75 years					
ASC4FIRST	4/34	7/29	0.32	0.07; 1.55	0.123
ASC4START	5/38	4/24	1.06	0.22; 5.08	0.851
Pooled Analysis	9/72	11/53	0.58	0.20; 1.65	0.199
>= 75 years					
ASC4FIRST	1/10	3/14	0.34	0.03; 3.61	0.352
ASC4START	2/9	1/13	13.27	0.09; >1000	0.739
Pooled Analysis	3/19	4/27	0.79	0.16; 3.91	0.538




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Emotional functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	4/23	2/20	1.24	0.22; 6.99	0.759
ASC4START	4/38	6/37	0.42	0.11; 1.55	0.223
Pooled Analysis	8/61	8/57	0.62	0.23; 1.71	0.430
Intermediate					
ASC4FIRST	9/54	12/53	0.58	0.24; 1.41	0.217
ASC4START	17/75	14/75	0.99	0.48; 2.03	0.777
Pooled Analysis	26/129	26/128	0.85	0.49; 1.47	0.578
Low					
ASC4FIRST	16/120	23/120	0.65	0.34; 1.23	0.236
ASC4START	26/171	39/172	0.58	0.35; 0.95	0.088
Pooled Analysis	42/291	62/292	0.61	0.41; 0.90	0.038




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Emotional functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	10/64	14/62	0.46	0.19; 1.08	0.048
ASC4START	26/138	31/141	0.72	0.43; 1.23	0.431
Pooled Analysis	36/202	45/203	0.65	0.41; 1.02	0.091
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	4/72	4/53	0.73	0.17; 3.19	0.662
Pooled Analysis	4/91	4/68	0.73	0.17; 3.19	0.662
Others					
ASC4FIRST	19/114	23/116	0.82	0.44; 1.51	0.643
ASC4START	17/74	24/90	0.67	0.35; 1.26	0.334
Pooled Analysis	36/188	47/206	0.75	0.48; 1.17	0.314




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Emotional functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	3/41	9/42	0.19	0.04; 0.90	0.029
Pooled Analysis	3/41	9/42	0.19	0.04; 0.90	0.029
Imatinib					
ASC4FIRST	15/101	21/102	0.60	0.30; 1.17	0.110
Pooled Analysis	15/101	21/102	0.60	0.30; 1.17	0.110
Nilotinib					
ASC4FIRST	11/55	7/49	1.46	0.55; 3.89	0.340
ASC4START	47/284	59/284	0.65	0.44; 0.96	0.120
Pooled Analysis	58/339	66/333	0.73	0.51; 1.05	0.279




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Emotional functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	8/40	15/46	0.43	0.18; 1.03	0.089
Pooled Analysis	26/128	36/132	0.62	0.37; 1.03	0.104
Asian/Others					
ASC4FIRST	19/91	21/90	0.78	0.42; 1.47	0.548
Others					
ASC4START	4/17	1/21	3.79	0.09; 152.79	0.212
Pooled Analysis	5/20	1/25	3.79	0.09; 152.79	0.212
White					
ASC4FIRST	10/106	16/103	0.54	0.24; 1.22	0.129
ASC4START	35/227	43/217	0.70	0.45; 1.10	0.205
Pooled Analysis	45/333	59/320	0.67	0.45; 0.99	0.066




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Emotional functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	14/68	20/75	0.63	0.31; 1.28	0.173
ASC4START	20/107	26/126	0.71	0.39; 1.28	0.356
Pooled Analysis	34/175	46/201	0.69	0.44; 1.08	0.114
Male					
ASC4FIRST	15/129	17/118	0.70	0.34; 1.43	0.371
ASC4START	27/177	33/158	0.61	0.36; 1.02	0.211
Pooled Analysis	42/306	50/276	0.65	0.43; 0.99	0.124




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	41/153	47/150	0.64	0.42; 0.99	0.047
ASC4START	42/237	52/247	0.73	0.49; 1.11	0.218
Pooled Analysis	83/390	99/397	0.69	0.51; 0.93	0.024
65 - < 75 years					
ASC4FIRST	6/34	10/29	0.33	0.08; 1.28	0.032
ASC4START	6/38	6/24	0.48	0.12; 1.89	0.495
Pooled Analysis	12/72	16/53	0.42	0.17; 1.04	0.040
>= 75 years					
ASC4FIRST	3/10	5/14	0.62	0.12; 3.33	0.505
ASC4START	2/9	0/13	10.18	0.12; 884.59	0.199
Pooled Analysis	5/19	5/27	1.21	0.28; 5.32	0.973




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	5/23	2/20	1.39	0.25; 7.61	0.607
ASC4START	5/38	7/37	0.48	0.14; 1.68	0.199
Pooled Analysis	10/61	9/57	0.61	0.23; 1.58	0.470
Intermediate					
ASC4FIRST	19/54	20/53	0.69	0.37; 1.32	0.293
ASC4START	15/75	10/75	1.22	0.54; 2.74	0.520
Pooled Analysis	34/129	30/128	0.88	0.53; 1.45	0.688
Low					
ASC4FIRST	26/120	40/120	0.55	0.33; 0.91	0.006
ASC4START	30/171	41/172	0.68	0.42; 1.09	0.164
Pooled Analysis	56/291	81/292	0.61	0.43; 0.87	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	17/64	13/62	0.64	0.29; 1.44	0.140
ASC4START	25/138	33/141	0.68	0.40; 1.15	0.149
Pooled Analysis	42/202	46/203	0.69	0.45; 1.07	0.044
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	7/72	6/53	0.41	0.11; 1.50	0.491
Pooled Analysis	7/91	6/68	0.41	0.11; 1.50	0.491
Others					
ASC4FIRST	33/114	49/116	0.58	0.37; 0.91	0.015
ASC4START	18/74	19/90	0.87	0.45; 1.70	0.810
Pooled Analysis	51/188	68/206	0.66	0.45; 0.96	0.031




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	7/41	12/42	0.67	0.26; 1.75	0.305
Pooled Analysis	7/41	12/42	0.67	0.26; 1.75	0.305
Imatinib					
ASC4FIRST	26/101	31/102	0.63	0.37; 1.08	0.039
Pooled Analysis	26/101	31/102	0.63	0.37; 1.08	0.039
Nilotinib					
ASC4FIRST	17/55	19/49	0.65	0.31; 1.33	0.344
ASC4START	50/284	58/284	0.74	0.51; 1.09	0.214
Pooled Analysis	67/339	77/333	0.71	0.51; 1.00	0.123



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue (MID=10)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	17/68	23/75	0.64	0.31; 1.31	0.069
ASC4START	21/107	24/126	0.94	0.52; 1.71	0.695
Pooled Analysis	38/175	47/201	0.80	0.51; 1.27	0.137
Male					
ASC4FIRST	33/129	39/118	0.63	0.39; 1.02	0.047
ASC4START	29/177	34/158	0.63	0.38; 1.05	0.224
Pooled Analysis	62/306	73/276	0.65	0.46; 0.92	0.023




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Financial difficulties (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	21/153	15/150	1.23	0.63; 2.41	0.492
ASC4START	35/237	33/247	1.23	0.76; 2.00	0.388
Pooled Analysis	56/390	48/397	1.24	0.84; 1.83	0.271
65 - < 75 years					
ASC4FIRST	2/34	3/29	0.06	0.00; 2.53	0.047
ASC4START	3/38	4/24	1.13	0.12; 11.05	0.397
Pooled Analysis	5/72	7/53	0.37	0.08; 1.67	0.062
>= 75 years					
ASC4FIRST	1/10	1/14	5.90	0.07; 535.35	0.157
ASC4START	2/9	0/13	3.00	0.04; 207.39	0.182
Pooled Analysis	3/19	1/27	7.53	0.18; 314.65	0.055




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Financial difficulties (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	1/20	4.15	0.09; 195.48	0.943
ASC4START	2/38	4/37	0.31	0.06; 1.71	0.192
Pooled Analysis	5/61	5/57	0.45	0.11; 1.82	0.298
Intermediate					
ASC4FIRST	12/54	6/53	1.68	0.62; 4.57	0.298
ASC4START	14/75	8/75	2.42	0.92; 6.35	0.072
Pooled Analysis	26/129	14/128	2.01	1.01; 4.00	0.043
Low					
ASC4FIRST	9/120	12/120	0.72	0.30; 1.72	0.476
ASC4START	24/171	25/172	1.05	0.60; 1.83	0.865
Pooled Analysis	33/291	37/292	0.94	0.59; 1.50	0.802




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Financial difficulties (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	5/64	5/62	0.49	0.13; 1.89	0.276
ASC4START	18/138	18/141	1.05	0.54; 2.04	0.838
Pooled Analysis	23/202	23/203	0.90	0.50; 1.64	0.767
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	4/72	5/53	0.70	0.17; 2.93	0.572
Pooled Analysis	4/91	5/68	0.70	0.17; 2.93	0.572
Others					
ASC4FIRST	19/114	14/116	1.36	0.67; 2.76	0.319
ASC4START	18/74	14/90	1.45	0.71; 2.98	0.252
Pooled Analysis	37/188	28/206	1.40	0.85; 2.32	0.130




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Financial difficulties (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	4/41	4/42	1.07	0.26; 4.38	0.877
Pooled Analysis	4/41	4/42	1.07	0.26; 4.38	0.877
Imatinib					
ASC4FIRST	13/101	10/102	0.99	0.42; 2.34	0.940
Pooled Analysis	13/101	10/102	0.99	0.42; 2.34	0.940
Nilotinib					
ASC4FIRST	7/55	5/49	1.09	0.33; 3.57	0.874
ASC4START	40/284	37/284	1.18	0.75; 1.86	0.477
Pooled Analysis	47/339	42/333	1.17	0.76; 1.79	0.472




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Financial difficulties (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	12/40	10/46	1.27	0.53; 3.06	0.413
Pooled Analysis	30/128	24/132	1.18	0.67; 2.06	0.395
Asian/Others					
ASC4FIRST	19/91	14/90	1.10	0.54; 2.26	0.650
Others					
ASC4START	3/17	1/21	3.38	0.12; 98.70	0.212
Pooled Analysis	4/20	1/25	3.38	0.12; 98.70	0.212
White					
ASC4FIRST	5/106	5/103	0.62	0.16; 2.35	0.472
ASC4START	25/227	26/217	0.98	0.56; 1.73	0.968
Pooled Analysis	30/333	31/320	0.92	0.55; 1.55	0.809




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Financial difficulties (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	8/68	10/75	0.68	0.25; 1.86	0.448
ASC4START	16/107	13/126	1.47	0.69; 3.14	0.357
Pooled Analysis	24/175	23/201	1.09	0.60; 1.99	0.782
Male					
ASC4FIRST	16/129	9/118	1.33	0.57; 3.10	0.419
ASC4START	24/177	24/158	1.04	0.58; 1.86	0.875
Pooled Analysis	40/306	33/276	1.15	0.72; 1.85	0.549




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Global health status/QoL (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	32/153	36/150	0.80	0.49; 1.32	0.355
ASC4START	52/237	57/247	0.93	0.63; 1.35	0.701
Pooled Analysis	84/390	93/397	0.88	0.65; 1.19	0.384
65 - < 75 years					
ASC4FIRST	6/34	7/29	0.67	0.16; 2.87	0.223
ASC4START	5/38	4/24	0.29	0.04; 1.98	0.567
Pooled Analysis	11/72	11/53	0.66	0.24; 1.75	0.198
>= 75 years					
ASC4FIRST	1/10	6/14	0.11	0.00; 4.24	0.017
ASC4START	2/9	2/13	0.88	0.08; 9.40	0.701
Pooled Analysis	3/19	8/27	0.35	0.06; 2.20	0.030




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Global health status/QoL (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	1/20	1.49	0.13; 17.26	0.792
ASC4START	4/38	6/37	0.39	0.11; 1.41	0.206
Pooled Analysis	6/61	7/57	0.53	0.17; 1.63	0.326
Intermediate					
ASC4FIRST	10/54	17/53	0.42	0.18; 0.96	0.016
ASC4START	12/75	16/75	0.57	0.27; 1.22	0.160
Pooled Analysis	22/129	33/128	0.50	0.28; 0.87	0.008
Low					
ASC4FIRST	27/120	31/120	0.85	0.50; 1.44	0.389
ASC4START	43/171	41/172	1.11	0.72; 1.70	0.627
Pooled Analysis	70/291	72/292	0.99	0.71; 1.38	0.865




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Global health status/QoL (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	12/64	10/62	0.71	0.29; 1.73	0.360
ASC4START	28/138	33/141	0.86	0.51; 1.43	0.606
Pooled Analysis	40/202	43/203	0.83	0.53; 1.29	0.369
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	10/72	6/53	0.56	0.18; 1.74	0.403
Pooled Analysis	10/91	6/68	0.56	0.18; 1.74	0.403
Others					
ASC4FIRST	27/114	39/116	0.72	0.43; 1.21	0.091
ASC4START	21/74	24/90	0.99	0.55; 1.81	0.813
Pooled Analysis	48/188	63/206	0.82	0.56; 1.21	0.149




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Global health status/QoL (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	5/41	9/42	0.73	0.23; 2.26	0.512
Pooled Analysis	5/41	9/42	0.73	0.23; 2.26	0.512
Imatinib					
ASC4FIRST	24/101	25/102	0.66	0.37; 1.18	0.125
Pooled Analysis	24/101	25/102	0.66	0.37; 1.18	0.125
Nilotinib					
ASC4FIRST	10/55	15/49	0.77	0.31; 1.94	0.281
ASC4START	59/284	63/284	0.89	0.62; 1.27	0.529
Pooled Analysis	69/339	78/333	0.87	0.62; 1.21	0.316




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Global health status/QoL (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	13/40	18/46	0.74	0.36; 1.54	0.403
Pooled Analysis	40/128	52/132	0.76	0.50; 1.17	0.111
Asian/Others					
ASC4FIRST	27/91	34/90	0.76	0.45; 1.29	0.148
Others					
ASC4START	2/17	1/21	2.03	0.03; 143.02	0.244
Pooled Analysis	2/20	1/25	2.03	0.03; 143.02	0.244
White					
ASC4FIRST	12/106	15/103	0.62	0.27; 1.43	0.205
ASC4START	44/227	44/217	0.94	0.61; 1.43	0.698
Pooled Analysis	56/333	59/320	0.86	0.59; 1.26	0.358




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Global health status/QoL (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	14/68	19/75	0.68	0.31; 1.48	0.192
ASC4START	23/107	25/126	0.99	0.56; 1.75	0.962
Pooled Analysis	37/175	44/201	0.85	0.54; 1.34	0.398
Male					
ASC4FIRST	25/129	30/118	0.83	0.47; 1.47	0.178
ASC4START	36/177	38/158	0.82	0.52; 1.30	0.407
Pooled Analysis	61/306	68/276	0.83	0.58; 1.18	0.134




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Insomnia (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	26/153	32/150	0.56	0.33; 0.95	0.087
ASC4START	46/237	57/247	0.72	0.48; 1.06	0.097
Pooled Analysis	72/390	89/397	0.66	0.48; 0.90	0.019
65 - < 75 years					
ASC4FIRST	6/34	5/29	0.87	0.15; 4.97	0.720
ASC4START	8/38	5/24	1.38	0.39; 4.86	0.531
Pooled Analysis	14/72	10/53	1.04	0.40; 2.67	0.816
>= 75 years					
ASC4FIRST	0/10	3/14	0.17	0.00; 6.39	0.072
ASC4START	1/9	2/13	0.56	0.00; 126.83	0.116
Pooled Analysis	1/19	5/27	0.11	0.00; 4.09	0.017



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Insomnia (MID=10)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Insomnia (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	10/64	10/62	0.55	0.21; 1.43	0.123
ASC4START	32/138	38/141	0.66	0.41; 1.09	0.075
Pooled Analysis	42/202	48/203	0.64	0.41; 0.98	0.022
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	4/72	5/53	0.34	0.08; 1.41	0.101
Pooled Analysis	4/91	5/68	0.34	0.08; 1.41	0.101
Others					
ASC4FIRST	22/114	30/116	0.58	0.33; 1.03	0.146
ASC4START	19/74	21/90	0.97	0.51; 1.84	0.982
Pooled Analysis	41/188	51/206	0.73	0.48; 1.11	0.269



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Insomnia (MID=10)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Insomnia (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	11/40	14/46	0.78	0.35; 1.75	0.630
Pooled Analysis	34/128	41/132	0.67	0.42; 1.08	0.174
Asian/Others					
ASC4FIRST	24/91	27/90	0.65	0.37; 1.14	0.216
Others					
ASC4START	3/17	2/21	0.65	0.10; 4.09	0.729
Pooled Analysis	4/20	2/25	0.65	0.10; 4.09	0.729
White					
ASC4FIRST	8/106	13/103	0.42	0.16; 1.13	0.052
ASC4START	41/227	48/217	0.67	0.44; 1.03	0.090
Pooled Analysis	49/333	61/320	0.61	0.42; 1.91	0.019




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Insomnia (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	11/68	16/75	0.65	0.28; 1.48	0.519
ASC4START	25/107	25/126	1.06	0.60; 1.87	0.907
Pooled Analysis	36/175	41/201	0.91	0.57; 1.45	0.782
Male					
ASC4FIRST	21/129	24/118	0.61	0.33; 1.13	0.128
ASC4START	30/177	39/158	0.57	0.35; 0.92	0.033
Pooled Analysis	51/306	63/276	0.58	0.40; 0.85	0.009




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea and vomiting (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	20/153	34/150	0.42	0.24; 0.73	0.002
ASC4START	34/237	44/247	0.70	0.44; 1.10	0.107
Pooled Analysis	54/390	78/397	0.57	0.40; 0.81	0.001
65 - < 75 years					
ASC4FIRST	2/34	3/29	0.32	0.03; 3.27	0.317
ASC4START	3/38	2/24	1.26	0.11; 14.42	0.850
Pooled Analysis	5/72	5/53	0.60	0.13; 2.83	0.523
>= 75 years					
ASC4FIRST	1/10	5/14	0.20	0.02; 1.78	0.065
ASC4START	2/9	1/13	0.71	0.04; 11.79	0.695
Pooled Analysis	3/19	6/27	0.31	0.06; 1.56	0.073




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea and vomiting (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	5/23	2/20	2.36	0.42; 13.11	0.227
ASC4START	8/38	6/37	0.84	0.28; 2.48	0.886
Pooled Analysis	13/61	8/57	1.19	0.48; 2.97	0.556
Intermediate					
ASC4FIRST	5/54	13/53	0.23	0.08; 0.68	0.004
ASC4START	8/75	13/75	0.55	0.23; 1.34	0.114
Pooled Analysis	13/129	26/128	0.37	0.18; 0.73	0.002
Low					
ASC4FIRST	13/120	27/120	0.40	0.20; 0.78	0.003
ASC4START	23/171	28/172	0.83	0.48; 1.45	0.509
Pooled Analysis	36/291	55/292	0.60	0.39; 0.92	0.013




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea and vomiting (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	9/64	8/62	0.50	0.17; 1.48	0.139
ASC4START	18/138	24/141	0.68	0.36; 1.28	0.210
Pooled Analysis	27/202	32/203	0.63	0.36; 1.08	0.068
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	3/72	5/53	0.20	0.04; 1.08	0.029
Pooled Analysis	3/91	5/68	0.20	0.04; 1.08	0.029
Others					
ASC4FIRST	14/114	34/116	0.34	0.18; 0.65	<0.001
ASC4START	18/74	18/90	1.09	0.56; 2.13	0.815
Pooled Analysis	32/188	52/206	0.58	0.37; 0.91	0.017



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Nausea and vomiting (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea and vomiting (MID=10)




Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	Hazard Ratio and 95% CL	HR	95% CL	P-value
Race	**n/N**	**n/N**				
Asian						
ASC4START	13/40	15/46		0.91	0.42; 1.96	0.841
Pooled Analysis	26/128	44/132		0.54	0.33; 0.89	0.015
Asian/Others						
ASC4FIRST	14/91	29/90		0.39	0.20; 0.75	0.004
Others						
ASC4START	1/17	0/21		1.40	0.01; 222.25	0.527
Pooled Analysis	2/20	0/25		1.40	0.01; 222.25	0.527
White						
ASC4FIRST	9/106	13/103		0.49	0.19; 1.23	0.072
ASC4START	25/227	32/217		0.68	0.40; 1.16	0.127
Pooled Analysis	34/333	45/320		0.62	0.39; 0.99	0.026

n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea and vomiting (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	9/68	20/75	0.26	0.10; 0.66	0.002
ASC4START	20/107	24/126	0.78	0.43; 1.44	0.433
Pooled Analysis	29/175	44/201	0.55	0.33; 0.91	0.014
Male					
ASC4FIRST	14/129	22/118	0.52	0.26; 1.03	0.052
ASC4START	19/177	23/158	0.69	0.38; 1.28	0.219
Pooled Analysis	33/306	45/276	0.62	0.39; 0.98	0.027




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pain (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	28/153	44/150	0.48	0.29; 0.78	0.002
ASC4START	67/237	71/247	0.95	0.68; 1.33	0.661
Pooled Analysis	95/390	115/397	0.76	0.57; 1.00	0.035
65 - < 75 years					
ASC4FIRST	6/34	7/29	0.34	0.08; 1.38	0.067
ASC4START	6/38	7/24	0.47	0.13; 1.65	0.199
Pooled Analysis	12/72	14/53	0.43	0.17; 1.05	0.030
>= 75 years					
ASC4FIRST	3/10	4/14	1.17	0.21; 6.69	0.574
ASC4START	3/9	1/13	2.12	0.19; 23.50	0.485
Pooled Analysis	6/19	5/27	1.54	0.39; 6.09	0.909




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pain (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	3/20	0.68	0.10; 4.47	0.459
ASC4START	12/38	10/37	1.24	0.53; 2.88	0.921
Pooled Analysis	14/61	13/57	1.13	0.53; 2.43	0.815
Intermediate					
ASC4FIRST	15/54	17/53	0.51	0.25; 1.04	0.083
ASC4START	22/75	17/75	1.38	0.73; 2.60	0.475
Pooled Analysis	37/129	34/128	0.89	0.55; 1.43	0.551
Low					
ASC4FIRST	20/120	35/120	0.48	0.27; 0.83	0.006
ASC4START	42/171	52/172	0.72	0.48; 1.08	0.141
Pooled Analysis	62/291	87/292	0.63	0.45; 0.87	0.005




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pain (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	15/64	11/62	0.85	0.37; 1.92	0.599
ASC4START	31/138	40/141	0.69	0.43; 1.10	0.124
Pooled Analysis	46/202	51/203	0.75	0.50; 1.12	0.110
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	12/72	8/53	1.20	0.45; 3.22	0.568
Pooled Analysis	12/91	8/68	1.20	0.45; 3.22	0.568
Others					
ASC4FIRST	22/114	44/116	0.40	0.24; 0.68	<0.001
ASC4START	33/74	31/90	1.14	0.69; 1.87	0.681
Pooled Analysis	55/188	75/206	0.69	0.48; 0.98	0.024




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pain (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	6/41	9/42	0.61	0.21; 1.77	0.312
Pooled Analysis	6/41	9/42	0.61	0.21; 1.77	0.312
Imatinib					
ASC4FIRST	22/101	30/102	0.55	0.31; 0.96	0.020
Pooled Analysis	22/101	30/102	0.55	0.31; 0.96	0.020
Nilotinib					
ASC4FIRST	9/55	16/49	0.42	0.17; 1.01	0.045
ASC4START	76/284	79/284	0.90	0.66; 1.23	0.453
Pooled Analysis	85/339	95/333	0.82	0.61; 1.10	0.155




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pain (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	19/40	20/46	0.88	0.47; 1.65	0.639
Pooled Analysis	40/128	59/132	0.57	0.38; 0.86	0.005
Asian/Others					
ASC4FIRST	22/91	39/90	0.43	0.25; 0.74	0.001
Others					
ASC4START	3/17	2/21	0.50	0.03; 7.55	0.937
Pooled Analysis	4/20	2/25	0.50	0.03; 7.55	0.937
White					
ASC4FIRST	15/106	16/103	0.86	0.42; 1.76	0.567
ASC4START	54/227	57/217	0.87	0.60; 1.26	0.398
Pooled Analysis	69/333	73/320	0.87	0.62; 1.21	0.312




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pain (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	12/68	25/75	0.41	0.20; 0.85	0.009
ASC4START	37/107	35/126	1.22	0.76; 1.96	0.560
Pooled Analysis	49/175	60/201	0.88	0.60; 1.30	0.313
Male					
ASC4FIRST	25/129	30/118	0.63	0.36; 1.11	0.104
ASC4START	39/177	44/158	0.74	0.48; 1.14	0.156
Pooled Analysis	64/306	74/276	0.70	0.49; 0.98	0.034




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Physical functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	18/153	29/150	0.50	0.27; 0.91	0.023
ASC4START	44/237	45/247	0.95	0.63; 1.45	0.853
Pooled Analysis	62/390	74/397	0.77	0.55; 1.08	0.142
65 - < 75 years					
ASC4FIRST	3/34	6/29	0.45	0.11; 1.92	0.232
ASC4START	3/38	5/24	0.28	0.07; 1.21	0.071
Pooled Analysis	6/72	11/53	0.35	0.12; 0.98	0.036
>= 75 years					
ASC4FIRST	4/10	2/14	5.00	0.41; 61.09	0.132
ASC4START	2/9	0/13	3.29	0.09; 121.85	0.199
Pooled Analysis	6/19	2/27	6.86	0.78; 60.13	0.050




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Physical functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	0/20	4.24	0.04; 512.30	0.317
ASC4START	8/38	3/37	2.01	0.52; 7.75	0.226
Pooled Analysis	9/61	3/57	2.34	0.62; 8.75	0.147
Intermediate					
ASC4FIRST	12/54	14/53	0.61	0.28; 1.35	0.183
ASC4START	15/75	9/75	1.75	0.76; 4.04	0.315
Pooled Analysis	27/129	23/128	0.94	0.54; 1.66	0.810
Low					
ASC4FIRST	12/120	23/120	0.48	0.23; 0.97	0.035
ASC4START	26/171	38/172	0.64	0.39; 1.05	0.081
Pooled Analysis	38/291	61/292	0.58	0.38; 0.87	0.008




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Physical functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	12/64	12/62	0.63	0.28; 1.43	0.271
ASC4START	21/138	26/141	0.80	0.45; 1.43	0.440
Pooled Analysis	33/202	38/203	0.75	0.47; 1.20	0.208
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	6/72	7/53	0.38	0.11; 1.28	0.137
Pooled Analysis	6/91	7/68	0.38	0.11; 1.28	0.137
Others					
ASC4FIRST	13/114	25/116	0.47	0.23; 0.94	0.032
ASC4START	22/74	17/90	1.44	0.75; 2.75	0.257
Pooled Analysis	35/188	42/206	0.85	0.53; 1.34	0.486




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Physical functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	5/41	10/42	0.43	0.13; 1.38	0.146
Pooled Analysis	5/41	10/42	0.43	0.13; 1.38	0.146
Imatinib					
ASC4FIRST	14/101	20/102	0.53	0.26; 1.06	0.068
Pooled Analysis	14/101	20/102	0.53	0.26; 1.06	0.068
Nilotinib					
ASC4FIRST	6/55	7/49	0.82	0.26; 2.57	0.725
ASC4START	49/284	50/284	0.91	0.61; 1.35	0.616
Pooled Analysis	55/339	57/333	0.89	0.62; 1.30	0.555




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Physical functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	17/40	14/46	1.21	0.58; 2.52	0.584
Pooled Analysis	31/128	36/132	0.76	0.46; 1.26	0.297
Asian/Others					
ASC4FIRST	15/91	22/90	0.53	0.27; 1.06	0.073
Others					
ASC4START	2/17	1/21	1.94	0.04; 87.12	0.343
Pooled Analysis	3/20	1/25	1.94	0.04; 87.12	0.343
White					
ASC4FIRST	10/106	15/103	0.62	0.27; 1.43	0.247
ASC4START	30/227	35/217	0.78	0.47; 1.27	0.282
Pooled Analysis	40/333	50/320	0.73	0.48; 1.11	0.130




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Physical functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	10/68	16/75	0.66	0.28; 1.56	0.391
ASC4START	24/107	26/126	1.02	0.58; 1.78	0.961
Pooled Analysis	34/175	42/201	0.90	0.57; 1.44	0.601
Male					
ASC4FIRST	15/129	21/118	0.54	0.27; 1.08	0.081
ASC4START	25/177	24/158	0.88	0.50; 1.54	0.663
Pooled Analysis	40/306	45/276	0.72	0.47; 1.11	0.147




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Role functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	24/153	31/150	0.57	0.33; 0.97	0.043
ASC4START	59/237	52/247	1.19	0.82; 1.74	0.264
Pooled Analysis	83/390	83/397	0.93	0.68; 1.27	0.805
65 - < 75 years					
ASC4FIRST	7/34	6/29	0.58	0.15; 2.23	0.373
ASC4START	3/38	5/24	0.30	0.07; 1.34	0.056
Pooled Analysis	10/72	11/53	0.43	0.16; 1.18	0.055
>= 75 years					
ASC4FIRST	3/10	4/14	0.29	0.02; 3.78	0.198
ASC4START	2/9	2/13	14.16	0.12; >1000	0.541
Pooled Analysis	5/19	6/27	0.64	0.15; 2.79	0.483




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Role functioning (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	0/20	3.13	0.07; 137.19	0.265
ASC4START	5/38	4/37	0.83	0.22; 3.13	0.915
Pooled Analysis	7/61	4/57	1.13	0.33; 3.88	0.711
Intermediate					
ASC4FIRST	15/54	14/53	0.62	0.28; 1.33	0.197
ASC4START	17/75	18/75	1.07	0.54; 2.12	0.959
Pooled Analysis	32/129	32/128	0.82	0.49; 1.36	0.418
Low					
ASC4FIRST	17/120	27/120	0.52	0.28; 0.96	0.034
ASC4START	42/171	37/172	1.14	0.73; 1.78	0.498
Pooled Analysis	59/291	64/292	0.86	0.60; 1.23	0.471



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Role functioning (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Role functioning (MID=10)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Role functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	12/40	15/46	0.89	0.41; 1.93	0.809
Pooled Analysis	31/128	41/132	0.66	0.41; 1.06	0.099
Asian/Others					
ASC4FIRST	21/91	26/90	0.59	0.32; 1.06	0.085
Others					
ASC4START	2/17	2/21	0.60	0.07; 4.88	0.692
Pooled Analysis	4/20	2/25	0.60	0.07; 4.88	0.692
White					
ASC4FIRST	13/106	15/103	0.61	0.27; 1.37	0.250
ASC4START	50/227	42/217	1.16	0.76; 1.76	0.442
Pooled Analysis	63/333	57/320	1.01	0.70; 1.46	0.880




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Role functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	11/68	17/75	0.53	0.23; 1.21	0.097
ASC4START	28/107	28/126	1.22	0.72; 2.08	0.549
Pooled Analysis	39/175	45/201	0.96	0.62; 1.49	0.664
Male					
ASC4FIRST	23/129	24/118	0.61	0.34; 1.12	0.130
ASC4START	36/177	31/158	1.06	0.65; 1.75	0.666
Pooled Analysis	59/306	55/276	0.85	0.58; 1.24	0.534




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	27/153	37/150	0.59	0.36; 0.99	0.039
ASC4START	52/237	58/247	0.79	0.54; 1.16	0.367
Pooled Analysis	79/390	95/397	0.72	0.53; 0.98	0.049
65 - < 75 years					
ASC4FIRST	5/34	6/29	0.68	0.18; 2.63	0.527
ASC4START	5/38	5/24	0.43	0.12; 1.59	0.186
Pooled Analysis	10/72	11/53	0.53	0.21; 1.35	0.173
>= 75 years					
ASC4FIRST	2/10	3/14	2.92	0.26; 32.93	0.549
ASC4START	1/9	1/13	1.55	0.00; 874.00	0.739
Pooled Analysis	3/19	4/27	2.97	0.29; 30.97	0.770




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	4/23	2/20	1.01	0.17; 6.10	0.645
ASC4START	7/38	6/37	0.84	0.28; 2.51	0.747
Pooled Analysis	11/61	8/57	0.89	0.35; 2.26	0.993
Intermediate					
ASC4FIRST	15/54	13/53	1.00	0.46; 2.17	0.935
ASC4START	16/75	17/75	0.82	0.41; 1.62	0.581
Pooled Analysis	31/129	30/128	0.90	0.54; 1.49	0.725
Low					
ASC4FIRST	15/120	31/120	0.41	0.22; 0.77	0.004
ASC4START	35/171	41/172	0.74	0.47; 1.17	0.265
Pooled Analysis	50/291	72/292	0.62	0.43; 0.89	0.008




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	11/64	12/62	0.56	0.24; 1.33	0.168
ASC4START	30/138	37/141	0.73	0.45; 1.20	0.274
Pooled Analysis	41/202	49/203	0.70	0.45; 1.06	0.104
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	5/72	7/53	0.21	0.05; 0.82	0.024
Pooled Analysis	5/91	7/68	0.21	0.05; 0.82	0.024
Others					
ASC4FIRST	23/114	34/116	0.72	0.42; 1.24	0.229
ASC4START	23/74	20/90	1.18	0.64; 2.18	0.579
Pooled Analysis	46/188	54/206	0.89	0.60; 1.34	0.584




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	4/41	8/42	0.49	0.13; 1.86	0.169
Pooled Analysis	4/41	8/42	0.49	0.13; 1.86	0.169
Imatinib					
ASC4FIRST	19/101	26/102	0.61	0.34; 1.12	0.088
Pooled Analysis	19/101	26/102	0.61	0.34; 1.12	0.088
Nilotinib					
ASC4FIRST	11/55	12/49	0.81	0.34; 1.96	0.660
ASC4START	58/284	64/284	0.76	0.53; 1.09	0.203
Pooled Analysis	69/339	76/333	0.77	0.55; 1.08	0.179




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	15/40	15/46	0.88	0.43; 1.82	0.736
Pooled Analysis	39/128	45/132	0.84	0.54; 1.30	0.406
Asian/Others					
ASC4FIRST	25/91	30/90	0.83	0.48; 1.43	0.464
Others					
ASC4START	2/17	1/21	2.68	0.06; 128.64	0.343
Pooled Analysis	3/20	1/25	2.68	0.06; 128.64	0.343
White					
ASC4FIRST	9/106	16/103	0.44	0.19; 1.03	0.054
ASC4START	41/227	48/217	0.70	0.46; 1.07	0.162
Pooled Analysis	50/333	64/320	0.64	0.44; 0.94	0.034




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	10/68	20/75	0.57	0.25; 1.29	0.132
ASC4START	23/107	27/126	0.84	0.48; 1.47	0.440
Pooled Analysis	33/175	47/201	0.76	0.48; 1.20	0.130
Male					
ASC4FIRST	24/129	26/118	0.76	0.43; 1.35	0.345
ASC4START	35/177	37/158	0.76	0.47; 1.21	0.343
Pooled Analysis	59/306	63/276	0.76	0.53; 1.09	0.183



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-2.2 EORTC QLQ-CML24: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Body Image Problems (MID=15)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.401)								
Low	54/291 (18.6)	22.2 [22.0; N.E.]	54/292 (18.5)	N.E. [22.1; N.E.]	0.98	[0.67; 1.43]	0.960	0.166
Intermediate	28/129 (21.7)	N.E. [11.1; N.E.]	35/128 (27.3)	11.1 [2.8; N.E.]	0.70	[0.42; 1.15]	0.071	0.297
High	12/61 (19.7)	N.E. [11.1; N.E.]	7/57 (12.3)	N.E. [5.6; N.E.]	1.06	[0.41; 2.75]	0.879	0.333
Sex								
(Interaction test: p = 0.744)								
Female	39/175	22.2 [10.9; N.E.]	43/201	16.6 [5.6; N.E.]	1.00	[0.63; 1.57]	0.651	0.510

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(22.3)		(21.4)					
Male	55/306	N.E. [22.0; N.E.]	53/276	N.E. [22.1; N.E.]	0.86	[0.58; 1.26]	0.436	0.351
	(18.0)		(19.2)					
Race								
(Interaction test: p = 0.977)								
Asian	36/128	N.E. [N.E.; N.E.]	39/132	N.E. [5.6; N.E.]	0.84	[0.53; 1.33]	0.455	0.360
	(28.1)		(29.5)					
White	55/333	22.2 [11.1; N.E.]	54/320	22.1 [11.1; N.E.]	0.94	[0.64; 1.39]	0.619	0.434
	(16.5)		(16.9)					
Others	3/20	N.E. [1.8; N.E.]	3/25	11.1 [2.8; N.E.]	2.11	[0.05; 82.83]	0.343	N.E.
	(15.0)		(12.0)					
Age groups								
(Interaction test: p = 0.916)								
18 - < 65 years	81/390	22.2 [22.0; N.E.]	85/397	22.1 [16.6; N.E.]	0.86	[0.63; 1.18]	0.389	0.207
	(20.8)		(21.4)					
65 - < 75 years	8/72	N.E. [N.E.; N.E.]	7/53	N.E. [11.1; N.E.]	1.20	[0.37; 3.93]	0.767	0.113

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(11.1)		(13.2)					
>= 75 years	5/19	2.8 [1.0; N.E.]	4/27	11.1 [1.4; N.E.]	1.39	[0.23; 8.20]	0.564	0.997
	(26.3)		(14.8)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.473)								
Imatinib	17/101	22.2 [22.0; N.E.]	21/102	22.1 [5.4; N.E.]	0.61	[0.32; 1.17]	0.117	N.E.
	(16.8)		(20.6)					
Nilotinib	73/339	N.E. [11.1; N.E.]	69/333	N.E. [16.6; N.E.]	1.01	[0.72; 1.40]	0.981	0.725
	(21.5)		(20.7)					
Dasatinib	4/41	N.E. [N.E.; N.E.]	6/42	N.E. [1.2; N.E.]	0.75	[0.19; 3.00]	0.233	N.E.
	(9.8)		(14.3)					
Geographic region								
(Interaction test: p = 0.785)								
Europe excluding Germany	39/202	22.2 [11.1; N.E.]	41/203	16.6 [10.9; N.E.]	0.81	[0.51; 1.28]	0.201	0.148

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(19.3)		(20.2)					
Germany	11/91	11.1 [2.8; N.E.]	6/68	N.E. [1.0; N.E.]	0.79	[0.27; 2.32]	0.984	N.E.
	(12.1)		(8.8)					
Others	44/188	N.E. [N.E.; N.E.]	49/206	N.E. [22.1; N.E.]	0.90	[0.59; 1.36]	0.605	0.209
	(23.4)		(23.8)					
Impact on Daily Life (MID=15)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.567)								
Low	37/291	N.E. [N.E.; N.E.]	55/292	N.E. [22.0; N.E.]	0.64	[0.42; 0.98]	0.052	0.054
	(12.7)		(18.8)					
Intermediate	15/129	N.E. [N.E.; N.E.]	27/128	N.E. [11.0; N.E.]	0.47	[0.25; 0.90]	0.013	0.453
	(11.6)		(21.1)					
High	6/61	N.E. [N.E.; N.E.]	4/57	N.E. [N.E.; N.E.]	0.66	[0.18; 2.44]	0.834	0.995
	(9.8)		(7.0)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.338)								
Female	23/175 (13.1)	N.E. [N.E.; N.E.]	46/201 (22.9)	11.3 [4.6; N.E.]	0.54	[0.33; 0.90]	0.006	0.310
Male	35/306 (11.4)	N.E. [N.E.; N.E.]	40/276 (14.5)	N.E. [N.E.; N.E.]	0.71	[0.45; 1.13]	0.241	0.568
Race								
(Interaction test: p = 0.284)								
Asian	24/128 (18.8)	N.E. [N.E.; N.E.]	30/132 (22.7)	N.E. [N.E.; N.E.]	0.79	[0.46; 1.36]	0.379	0.106
White	30/333 (9.0)	N.E. [N.E.; N.E.]	53/320 (16.6)	22.0 [11.3; N.E.]	0.48	[0.30; 0.75]	0.002	0.109
Others	4/20 (20.0)	N.E. [1.0; N.E.]	3/25 (12.0)	11.1 [1.0; N.E.]	0.32	[0.02; 5.17]	0.624	N.E.
Age groups								
(Interaction test: p = 0.916)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	51/390 (13.1)	N.E. [N.E.; N.E.]	74/397 (18.6)	N.E. [22.0; N.E.]	0.60	[0.42; 0.86]	0.011	0.283
65 - < 75 years	5/72 (6.9)	N.E. [N.E.; N.E.]	7/53 (13.2)	N.E. [11.0; N.E.]	0.61	[0.18; 2.12]	0.385	0.224
>= 75 years	2/19 (10.5)	N.E. [1.0; N.E.]	5/27 (18.5)	11.1 [1.0; N.E.]	0.15	[0.01; 1.48]	0.110	0.998
Pre-randomization selection of TKI								
(Interaction test: p = 0.353)								
Imatinib	7/101 (6.9)	N.E. [N.E.; N.E.]	19/102 (18.6)	22.1 [5.6; N.E.]	0.33	[0.14; 0.80]	0.006	N.E.
Nilotinib	51/339 (15.0)	N.E. [N.E.; N.E.]	61/333 (18.3)	N.E. [16.6; N.E.]	0.70	[0.48; 1.03]	0.125	0.549
Dasatinib	0/41	N.E. [N.E.; N.E.]	6/42 (14.3)	N.E. [1.8; N.E.]	0.08	[0.00; 1.90]	0.017	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.245)								
Europe excluding Germany	25/202 (12.4)	N.E. [N.E.; N.E.]	45/203 (22.2)	11.8 [11.0; N.E.]	0.48	[0.30; 0.79]	0.003	0.426
Germany	3/91 (3.3)	N.E. [N.E.; N.E.]	3/68 (4.4)	N.E. [11.0; N.E.]	0.49	[0.08; 2.87]	0.600	N.E.
Others	30/188 (16.0)	N.E. [N.E.; N.E.]	38/206 (18.4)	N.E. [N.E.; N.E.]	0.82	[0.50; 1.32]	0.413	0.095
Impact on Worry/Mood (MID=15)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.391)								
Low	33/291 (11.3)	22.2 [22.2; N.E.]	41/292 (14.0)	N.E. [N.E.; N.E.]	0.72	[0.45; 1.14]	0.194	0.059
Intermediate	22/129	N.E. [22.1; N.E.]	14/128	N.E. [22.1; N.E.]	1.14	[0.57; 2.26]	0.497	0.644

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(17.1)		(10.9)					
High	4/61	N.E. [N.E.; N.E.]	4/57	N.E. [N.E.; N.E.]	0.66	[0.16; 2.72]	0.703	0.795
	(6.6)		(7.0)					
Sex								
(Interaction test: p = 0.263)								
Female	27/175	22.2 [22.2; N.E.]	25/201	N.E. [22.1; N.E.]	1.20	[0.68; 2.13]	0.753	0.054
	(15.4)		(12.4)					
Male	32/306	N.E. [N.E.; N.E.]	34/276	N.E. [N.E.; N.E.]	0.70	[0.43; 1.15]	0.298	0.770
	(10.5)		(12.3)					
Race								
(Interaction test: p = 0.386)								
Asian	31/128	N.E. [22.1; N.E.]	29/132	N.E. [22.1; N.E.]	0.93	[0.55; 1.56]	0.904	0.090
	(24.2)		(22.0)					
White	24/333	22.2 [22.2; N.E.]	29/320	N.E. [N.E.; N.E.]	0.74	[0.43; 1.29]	0.379	0.300
	(7.2)		(9.1)					
Others	4/20	11.0 [2.8; N.E.]	1/25	N.E. [5.6; N.E.]	2.99	[0.09; 95.46]	0.267	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(20.0)		(4.0)					
Age groups								
(Interaction test: p = 0.994)								
18 - < 65 years	55/390	22.2 [22.2; N.E.]	53/397	N.E. [N.E.; N.E.]	0.87	[0.59; 1.29]	0.750	0.063
	(14.1)		(13.4)					
65 - < 75 years	4/72	N.E. [N.E.; N.E.]	4/53	N.E. [N.E.; N.E.]	0.72	[0.10; 5.02]	0.699	0.643
	(5.6)		(7.5)					
>= 75 years	0/19	N.E. [N.E.; N.E.]	2/27	N.E. [1.4; N.E.]	0.26	[0.01; 11.61]	0.225	N.E.
			(7.4)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.361)								
Imatinib	11/101	22.2 [N.E.; N.E.]	16/102	22.1 [22.0; N.E.]	0.51	[0.23; 1.13]	0.104	N.E.
	(10.9)		(15.7)					
Nilotinib	42/339	N.E. [N.E.; N.E.]	35/333	N.E. [N.E.; N.E.]	0.95	[0.60; 1.52]	0.835	0.183
	(12.4)		(10.5)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	6/41 (14.6)	N.E. [8.3; N.E.]	8/42 (19.0)	N.E. [1.2; N.E.]	0.78	[0.27; 2.26]	0.619	N.E.
Geographic region (Interaction test: p = 0.289)								
Europe excluding Germany	21/202 (10.4)	22.2 [22.2; N.E.]	20/203 (9.9)	N.E. [N.E.; N.E.]	0.91	[0.49; 1.70]	0.846	0.303
Germany	2/91 (2.2)	N.E. [N.E.; N.E.]	4/68 (5.9)	N.E. [1.9; N.E.]	0.08	[0.01; 0.77]	0.028	N.E.
Others	36/188 (19.1)	N.E. [22.1; N.E.]	35/206 (17.0)	N.E. [22.1; N.E.]	0.91	[0.56; 1.46]	0.930	0.036
Symptom Burden (MID=15)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.535)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Low	16/291 (5.5)	N.E. [N.E.; N.E.]	43/292 (14.7)	25.7 [N.E.; N.E.]	0.36	[0.20; 0.65]	<0.001	0.773
Intermediate	7/129 (5.4)	N.E. [N.E.; N.E.]	16/128 (12.5)	22.3 [22.0; N.E.]	0.33	[0.13; 0.82]	0.012	0.356
High	4/61 (6.6)	N.E. [N.E.; N.E.]	3/57 (5.3)	N.E. [11.2; N.E.]	0.81	[0.17; 3.82]	0.844	0.605
Sex (Interaction test: p = 0.113)								
Female	11/175 (6.3)	N.E. [N.E.; N.E.]	35/201 (17.4)	22.1 [11.2; N.E.]	0.26	[0.13; 0.53]	<0.001	0.141
Male	16/306 (5.2)	N.E. [N.E.; N.E.]	27/276 (9.8)	25.7 [22.3; N.E.]	0.52	[0.27; 0.99]	0.047	0.893
Race (Interaction test: p = 0.956)								
Asian	11/128 (8.6)	N.E. [N.E.; N.E.]	32/132 (24.2)	25.7 [22.1; N.E.]	0.33	[0.16; 0.68]	0.001	0.354

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
White	13/333 (3.9)	N.E. [N.E.; N.E.]	30/320 (9.4)	N.E. [22.3; N.E.]	0.34	[0.17; 0.68]	0.001	0.818
Others	3/20 (15.0)	N.E. [0.9; N.E.]	0/25	N.E. [N.E.; N.E.]	1.78	[0.01; 242.14]	0.343	N.E.
Age groups (Interaction test: p = 0.965)								
18 - < 65 years	26/390 (6.7)	N.E. [N.E.; N.E.]	53/397 (13.4)	25.7 [N.E.; N.E.]	0.44	[0.27; 0.71]	<0.001	0.324
65 - < 75 years	0/72	N.E. [N.E.; N.E.]	5/53 (9.4)	N.E. [11.2; N.E.]	0.08	[0.00; 1.73]	0.012	1.000
>= 75 years	1/19 (5.3)	N.E. [22.1; N.E.]	4/27 (14.8)	22.3 [1.0; N.E.]	0.16	[0.01; 2.67]	0.303	N.E.
Pre-randomization selection of TKI (Interaction test: p = 0.587)								
Imatinib	6/101	N.E. [N.E.; N.E.]	18/102	22.1 [11.1; N.E.]	0.25	[0.10; 0.62]	0.001	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(5.9)		(17.6)					
Nilotinib	17/339	N.E. [N.E.; N.E.]	36/333	N.E. [22.3; N.E.]	0.47	[0.26; 0.84]	0.010	0.976
	(5.0)		(10.8)					
Dasatinib	4/41	N.E. [22.1; N.E.]	8/42	25.7 [1.2; N.E.]	0.25	[0.05; 1.33]	0.107	N.E.
	(9.8)		(19.0)					
Geographic region								
(Interaction test: p = 0.911)								
Europe excluding Germany	13/202	N.E. [N.E.; N.E.]	24/203	N.E. [N.E.; N.E.]	0.38	[0.18; 0.78]	0.007	0.801
	(6.4)		(11.8)					
Germany	1/91	N.E. [N.E.; N.E.]	2/68	N.E. [5.4; N.E.]	0.05	[0.00; 4.29]	0.212	N.E.
	(1.1)		(2.9)					
Others	13/188	N.E. [N.E.; N.E.]	36/206	22.3 [22.1; N.E.]	0.37	[0.19; 0.70]	0.001	0.176
	(6.9)		(17.5)					
Satisfaction with Care and Information (MID=15)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.794)								
Low	52/291 (17.9)	N.E. [11.2; N.E.]	44/292 (15.1)	N.E. [N.E.; N.E.]	1.13	[0.75; 1.69]	0.290	0.904
Intermediate	35/129 (27.1)	11.1 [6.0; N.E.]	23/128 (18.0)	N.E. [10.9; N.E.]	1.05	[0.60; 1.82]	0.311	0.811
High	16/61 (26.2)	N.E. [2.8; N.E.]	6/57 (10.5)	N.E. [N.E.; N.E.]	1.64	[0.62; 4.34]	0.167	0.813
Sex								
(Interaction test: p = 0.818)								
Female	40/175 (22.9)	11.2 [11.0; N.E.]	26/201 (12.9)	N.E. [N.E.; N.E.]	1.05	[0.62; 1.78]	0.129	0.931
Male	63/306 (20.6)	N.E. [11.1; N.E.]	47/276 (17.0)	N.E. [N.E.; N.E.]	1.11	[0.75; 1.65]	0.303	0.660

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.637)								
Asian	60/128 (46.9)	5.6 [2.7; 11.0]	37/132 (28.0)	N.E. [N.E.; N.E.]	1.14	[0.74; 1.76]	0.022	0.616
White	41/333 (12.3)	N.E. [13.1; N.E.]	32/320 (10.0)	N.E. [N.E.; N.E.]	1.23	[0.76; 1.98]	0.605	0.816
Others	2/20 (10.0)	N.E. [1.0; N.E.]	4/25 (16.0)	5.6 [1.9; N.E.]	0.20	[0.02; 2.02]	0.151	N.E.
Age groups								
(Interaction test: p = 0.195)								
18 - < 65 years	90/390 (23.1)	N.E. [11.0; N.E.]	61/397 (15.4)	N.E. [N.E.; N.E.]	1.27	[0.91; 1.78]	0.017	0.770
65 - < 75 years	11/72 (15.3)	N.E. [11.1; N.E.]	10/53 (18.9)	N.E. [1.8; N.E.]	0.51	[0.18; 1.43]	0.289	0.687
>= 75 years	2/19 (10.5)	N.E. [1.8; N.E.]	2/27 (7.4)	N.E. [1.0; N.E.]	1.44	[0.12; 17.78]	0.790	1.000

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.275)								
Imatinib	22/101 (21.8)	N.E. [5.4; N.E.]	19/102 (18.6)	N.E. [1.9; N.E.]	0.91	[0.47; 1.73]	0.925	N.E.
Nilotinib	72/339 (21.2)	N.E. [11.2; N.E.]	48/333 (14.4)	N.E. [N.E.; N.E.]	1.36	[0.94; 1.96]	0.064	0.180
Dasatinib	9/41 (22.0)	6.0 [1.8; N.E.]	6/42 (14.3)	N.E. [0.9; N.E.]	0.48	[0.11; 2.04]	0.476	N.E.
Geographic region								
(Interaction test: p = 0.481)								
Europe excluding Germany	29/202 (14.4)	N.E. [13.1; N.E.]	26/203 (12.8)	N.E. [N.E.; N.E.]	0.91	[0.52; 1.59]	0.542	0.665
Germany	6/91 (6.6)	N.E. [11.1; N.E.]	2/68 (2.9)	N.E. [11.1; N.E.]	2.16	[0.42; 11.09]	0.391	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	68/188 (36.2)	6.0 [2.8; 11.1]	45/206 (21.8)	N.E. [N.E.; N.E.]	1.24	[0.84; 1.84]	0.009	0.549
Satisfaction with Social Life (MID=15)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.557)								
Low	66/291 (22.7)	22.1 [11.0; N.E.]	61/292 (20.9)	25.7 [11.1; N.E.]	1.14	[0.80; 1.62]	0.421	0.260
Intermediate	34/129 (26.4)	11.1 [5.6; N.E.]	34/128 (26.6)	11.1 [2.8; N.E.]	0.94	[0.58; 1.54]	0.539	0.171
High	18/61 (29.5)	11.1 [2.7; N.E.]	8/57 (14.0)	N.E. [1.9; N.E.]	1.11	[0.44; 2.78]	0.356	0.082
Sex (Interaction test: p = 0.931)								
Female	49/175	11.0 [2.9; N.E.]	40/201	N.E. [5.6; N.E.]	1.08	[0.70; 1.67]	0.239	0.151

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(28.0)		(19.9)					
Male	69/306	N.E. [11.1; N.E.]	63/276	25.7 [11.0; N.E.]	1.05	[0.74; 1.50]	0.915	0.487
	(22.5)		(22.8)					
Race								
(Interaction test: p = 0.978)								
Asian	48/128	21.9 [5.6; N.E.]	40/132	25.7 [10.9; N.E.]	1.17	[0.75; 1.82]	0.316	0.633
	(37.5)		(30.3)					
White	66/333	11.2 [11.0; N.E.]	59/320	22.1 [8.3; N.E.]	1.06	[0.74; 1.53]	0.974	0.810
	(19.8)		(18.4)					
Others	4/20	11.1 [0.9; N.E.]	4/25	5.6 [1.0; N.E.]	0.42	[0.07; 2.62]	0.107	N.E.
	(20.0)		(16.0)					
Age groups								
(Interaction test: p = 0.929)								
18 - < 65 years	102/390	11.2 [9.2; N.E.]	91/397	25.7 [10.9; N.E.]	1.12	[0.84; 1.50]	0.349	0.593
	(26.2)		(22.9)					
65 - < 75 years	14/72	N.E. [5.6; N.E.]	10/53	N.E. [2.8; N.E.]	0.91	[0.38; 2.18]	0.518	0.169

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(19.4)		(18.9)					
>= 75 years	2/19	N.E. [1.0; N.E.]	2/27	N.E. [1.0; N.E.]	1.62	[0.14; 18.31]	0.688	1.000
	(10.5)		(7.4)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.816)								
Imatinib	19/101	N.E. [11.0; N.E.]	17/102	N.E. [5.5; N.E.]	0.99	[0.50; 1.96]	0.911	N.E.
	(18.8)		(16.7)					
Nilotinib	90/339	11.1 [5.6; N.E.]	79/333	22.1 [5.6; N.E.]	1.11	[0.82; 1.51]	0.583	0.903
	(26.5)		(23.7)					
Dasatinib	9/41	11.0 [1.8; N.E.]	7/42	25.7 [1.9; N.E.]	0.73	[0.22; 2.42]	0.438	N.E.
	(22.0)		(16.7)					
Geographic region								
(Interaction test: p = 0.249)								
Europe excluding Germany	50/202	11.2 [5.6; N.E.]	44/203	22.1 [3.0; N.E.]	1.22	[0.80; 1.85]	0.801	0.635


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(24.8)		(21.7)					
Germany	9/91	N.E. [5.6; N.E.]	9/68	2.8 [1.0; N.E.]	0.45	[0.14; 1.50]	0.448	N.E.
	(9.9)		(13.2)					
Others	59/188	21.9 [5.6; N.E.]	50/206	25.7 [N.E.; N.E.]	1.13	[0.76; 1.68]	0.278	0.955
	(31.4)		(24.3)					

MID: Minimally important difference
N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not more than 10 events per subgroup per treatment arm, no subgroup analyses were performed for the corresponding attribute.
If there are not more than 10 events per subgroup per treatment arm, no Cox PH hazard analysis is carried out.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline PRO score.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT) and Pre-Randomization selection TKI (IRT).
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Body Image Problems (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	27/153	31/150	0.66	0.39; 1.12	0.087
ASC4START	54/237	54/247	1.00	0.68; 1.47	0.866
Pooled Analysis	81/390	85/397	0.86	0.63; 1.18	0.389
65 - < 75 years					
ASC4FIRST	3/34	5/29	0.40	0.06; 2.69	0.304
ASC4START	5/38	2/24	4.74	0.54; 41.95	0.532
Pooled Analysis	8/72	7/53	1.20	0.37; 3.93	0.767
>= 75 years					
ASC4FIRST	2/10	3/14	0.76	0.10; 5.99	0.946
ASC4START	3/9	1/13	1.45	0.12; 17.57	0.455
Pooled Analysis	5/19	4/27	1.39	0.23; 8.20	0.564




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Body Image Problems (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	1/20	3.18	0.32; 31.86	0.555
ASC4START	9/38	6/37	0.82	0.29; 2.36	0.890
Pooled Analysis	12/61	7/57	1.06	0.41; 2.75	0.879
Intermediate					
ASC4FIRST	10/54	14/53	0.49	0.21; 1.14	0.063
ASC4START	18/75	21/75	0.85	0.45; 1.60	0.391
Pooled Analysis	28/129	35/128	0.70	0.42; 1.15	0.071
Low					
ASC4FIRST	19/120	24/120	0.70	0.38; 1.29	0.209
ASC4START	35/171	30/172	1.22	0.75; 1.99	0.347
Pooled Analysis	54/291	54/292	0.98	0.67; 1.43	0.960




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Body Image Problems (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	10/64	9/62	0.42	0.15; 1.15	0.068
ASC4START	29/138	32/141	0.95	0.57; 1.59	0.588
Pooled Analysis	39/202	41/203	0.81	0.51; 1.28	0.201
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	11/72	6/53	0.79	0.27; 2.32	0.984
Pooled Analysis	11/91	6/68	0.79	0.27; 2.32	0.984
Others					
ASC4FIRST	22/114	30/116	0.71	0.40; 1.25	0.169
ASC4START	22/74	19/90	1.23	0.66; 2.29	0.440
Pooled Analysis	44/188	49/206	0.90	0.59; 1.36	0.605




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Body Image Problems (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	4/41	6/42	0.75	0.19; 3.00	0.233
Pooled Analysis	4/41	6/42	0.75	0.19; 3.00	0.233
Imatinib					
ASC4FIRST	17/101	21/102	0.61	0.32; 1.17	0.117
Pooled Analysis	17/101	21/102	0.61	0.32; 1.17	0.117
Nilotinib					
ASC4FIRST	11/55	12/49	0.87	0.37; 2.03	0.669
ASC4START	62/284	57/284	1.03	0.72; 1.48	0.874
Pooled Analysis	73/339	69/333	1.01	0.72; 1.40	0.981




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Body Image Problems (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	15/40	13/46	1.13	0.54; 2.40	0.724
Pooled Analysis	36/128	39/132	0.84	0.53; 1.33	0.455
Asian/Others					
ASC4FIRST	22/91	26/90	0.72	0.40; 1.29	0.260
Others					
ASC4START	2/17	3/21	2.11	0.05; 82.83	0.343
Pooled Analysis	3/20	3/25	2.11	0.05; 82.83	0.343
White					
ASC4FIRST	10/106	13/103	0.63	0.25; 1.60	0.273
ASC4START	45/227	41/217	1.02	0.66; 1.56	0.978
Pooled Analysis	55/333	54/320	0.94	0.64; 1.39	0.619




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Body Image Problems (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	9/68	14/75	0.76	0.30; 1.93	0.185
ASC4START	30/107	29/126	1.09	0.64; 1.84	0.785
Pooled Analysis	39/175	43/201	1.00	0.63; 1.57	0.651
Male					
ASC4FIRST	23/129	25/118	0.69	0.38; 1.24	0.221
ASC4START	32/177	28/158	1.01	0.60; 1.68	0.977
Pooled Analysis	55/306	53/276	0.86	0.58; 1.26	0.436




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Daily Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	13/153	24/150	0.43	0.22; 0.86	0.012
ASC4START	38/237	50/247	0.67	0.44; 1.04	0.162
Pooled Analysis	51/390	74/397	0.60	0.42; 0.86	0.011
65 - < 75 years					
ASC4FIRST	2/34	3/29	1.26	0.19; 8.21	0.853
ASC4START	3/38	4/24	0.08	0.00; 1.44	0.175
Pooled Analysis	5/72	7/53	0.61	0.18; 2.12	0.385
>= 75 years					
ASC4FIRST	1/10	5/14	0.10	0.01; 1.34	0.045
ASC4START	1/9	0/13	27.00	0.00; >1000	0.480
Pooled Analysis	2/19	5/27	0.15	0.01; 1.48	0.110




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Daily Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	0/20	1.37	0.01; 130.71	0.480
ASC4START	5/38	4/37	0.56	0.14; 2.18	0.651
Pooled Analysis	6/61	4/57	0.66	0.18; 2.44	0.834
Intermediate					
ASC4FIRST	8/54	11/53	0.62	0.24; 1.59	0.243
ASC4START	7/75	16/75	0.38	0.15; 0.92	0.022
Pooled Analysis	15/129	27/128	0.47	0.25; 0.90	0.013
Low					
ASC4FIRST	7/120	21/120	0.31	0.13; 0.72	0.004
ASC4START	30/171	34/172	0.82	0.50; 1.35	0.667
Pooled Analysis	37/291	55/292	0.64	0.42; 0.98	0.052




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Daily Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	5/64	11/62	0.33	0.11; 0.97	0.017
ASC4START	20/138	34/141	0.54	0.31; 0.95	0.035
Pooled Analysis	25/202	45/203	0.48	0.30; 0.79	0.003
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	3/72	3/53	0.49	0.08; 2.87	0.600
Pooled Analysis	3/91	3/68	0.49	0.08; 2.87	0.600
Others					
ASC4FIRST	11/114	21/116	0.51	0.24; 1.06	0.060
ASC4START	19/74	17/90	1.18	0.61; 2.30	0.511
Pooled Analysis	30/188	38/206	0.82	0.50; 1.32	0.413




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Daily Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	0/41	6/42	0.08	0.00; 1.90	0.017
Pooled Analysis	0/41	6/42	0.08	0.00; 1.90	0.017
Imatinib					
ASC4FIRST	7/101	19/102	0.33	0.14; 0.80	0.006
Pooled Analysis	7/101	19/102	0.33	0.14; 0.80	0.006
Nilotinib					
ASC4FIRST	9/55	7/49	0.96	0.34; 2.69	0.936
ASC4START	42/284	54/284	0.67	0.44; 1.00	0.106
Pooled Analysis	51/339	61/333	0.70	0.48; 1.03	0.125




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Daily Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	12/40	10/46	1.31	0.56; 3.07	0.447
Pooled Analysis	24/128	30/132	0.79	0.46; 1.36	0.379
Asian/Others					
ASC4FIRST	14/91	20/90	0.60	0.30; 1.21	0.137
Others					
ASC4START	2/17	3/21	0.32	0.02; 5.17	0.624
Pooled Analysis	4/20	3/25	0.32	0.02; 5.17	0.624
White					
ASC4FIRST	2/106	12/103	0.15	0.03; 0.68	0.003
ASC4START	28/227	41/217	0.56	0.35; 0.92	0.036
Pooled Analysis	30/333	53/320	0.48	0.30; 0.75	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Daily Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	4/68	15/75	0.30	0.10; 0.96	0.011
ASC4START	19/107	31/126	0.63	0.36; 1.13	0.094
Pooled Analysis	23/175	46/201	0.54	0.33; 0.90	0.006
Male					
ASC4FIRST	12/129	17/118	0.60	0.28; 1.28	0.178
ASC4START	23/177	23/158	0.75	0.42; 1.36	0.661
Pooled Analysis	35/306	40/276	0.71	0.45; 1.13	0.241




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Worry/Mood (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	25/153	30/150	0.60	0.35; 1.05	0.112
ASC4START	30/237	23/247	1.23	0.71; 2.14	0.264
Pooled Analysis	55/390	53/397	0.87	0.59; 1.29	0.750
65 - < 75 years					
ASC4FIRST	3/34	3/29	1.13	0.09; 14.19	0.971
ASC4START	1/38	1/24	0.58	0.03; 10.86	0.485
Pooled Analysis	4/72	4/53	0.72	0.10; 5.02	0.699
>= 75 years					
ASC4FIRST	0/10	2/14	0.26	0.01; 11.61	0.225
ASC4START	0/9	0/13	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/19	2/27	0.26	0.01; 11.61	0.225




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Worry/Mood (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	2/20	0.54	0.05; 6.32	0.583
ASC4START	3/38	2/37	0.79	0.13; 4.86	0.956
Pooled Analysis	4/61	4/57	0.66	0.16; 2.72	0.703
Intermediate					
ASC4FIRST	12/54	7/53	0.99	0.37; 2.60	0.771
ASC4START	10/75	7/75	1.29	0.49; 3.41	0.500
Pooled Analysis	22/129	14/128	1.14	0.57; 2.26	0.497
Low					
ASC4FIRST	15/120	26/120	0.47	0.24; 0.90	0.021
ASC4START	18/171	15/172	1.17	0.59; 2.34	0.561
Pooled Analysis	33/291	41/292	0.72	0.45; 1.14	0.194




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Worry/Mood (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	7/64	8/62	0.58	0.20; 1.70	0.260
ASC4START	14/138	12/141	1.17	0.54; 2.54	0.568
Pooled Analysis	21/202	20/203	0.91	0.49; 1.70	0.846
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	2/72	4/53	0.08	0.01; 0.77	0.028
Pooled Analysis	2/91	4/68	0.08	0.01; 0.77	0.028
Others					
ASC4FIRST	21/114	27/116	0.63	0.35; 1.14	0.196
ASC4START	15/74	8/90	1.92	0.80; 4.60	0.090
Pooled Analysis	36/188	35/206	0.91	0.56; 1.46	0.930




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Worry/Mood (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	6/41	8/42	0.78	0.27; 2.26	0.619
Pooled Analysis	6/41	8/42	0.78	0.27; 2.26	0.619
Imatinib					
ASC4FIRST	11/101	16/102	0.51	0.23; 1.13	0.104
Pooled Analysis	11/101	16/102	0.51	0.23; 1.13	0.104
Nilotinib					
ASC4FIRST	11/55	11/49	0.55	0.21; 1.40	0.331
ASC4START	31/284	24/284	1.15	0.67; 1.97	0.417
Pooled Analysis	42/339	35/333	0.95	0.60; 1.52	0.835




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Worry/Mood (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	10/40	5/46	1.91	0.63; 5.72	0.140
Pooled Analysis	31/128	29/132	0.93	0.55; 1.56	0.904
Asian/Others					
ASC4FIRST	22/91	24/90	0.74	0.41; 1.34	0.376
Others					
ASC4START	3/17	1/21	2.99	0.09; 95.46	0.267
Pooled Analysis	4/20	1/25	2.99	0.09; 95.46	0.267
White					
ASC4FIRST	6/106	11/103	0.46	0.16; 1.35	0.161
ASC4START	18/227	18/217	0.91	0.47; 1.75	0.892
Pooled Analysis	24/333	29/320	0.74	0.43; 1.29	0.379




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Worry/Mood (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	11/68	17/75	0.63	0.28; 1.44	0.178
ASC4START	16/107	8/126	2.15	0.91; 5.06	0.067
Pooled Analysis	27/175	25/201	1.20	0.68; 2.13	0.753
Male					
ASC4FIRST	17/129	18/118	0.65	0.33; 1.31	0.343
ASC4START	15/177	16/158	0.76	0.37; 1.55	0.606
Pooled Analysis	32/306	34/276	0.70	0.43; 1.15	0.298




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Care and Information (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	44/153	28/150	1.14	0.68; 1.89	0.065
ASC4START	46/237	33/247	1.36	0.86; 2.13	0.126
Pooled Analysis	90/390	61/397	1.27	0.91; 1.78	0.017
65 - < 75 years					
ASC4FIRST	6/34	5/29	0.37	0.06; 2.42	0.647
ASC4START	5/38	5/24	0.59	0.17; 2.10	0.305
Pooled Analysis	11/72	10/53	0.51	0.18; 1.43	0.289
>= 75 years					
ASC4FIRST	1/10	1/14	2.79	0.08; 93.28	0.808
ASC4START	1/9	1/13	0.71	0.03; 17.62	0.515
Pooled Analysis	2/19	2/27	1.44	0.12; 17.78	0.790




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Care and Information (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	6/23	2/20	1.33	0.20; 8.92	0.250
ASC4START	10/38	4/37	1.76	0.55; 5.64	0.378
Pooled Analysis	16/61	6/57	1.64	0.62; 4.34	0.167
Intermediate					
ASC4FIRST	17/54	9/53	0.88	0.36; 2.18	0.231
ASC4START	18/75	14/75	1.11	0.55; 2.25	0.772
Pooled Analysis	35/129	23/128	1.05	0.60; 1.82	0.311
Low					
ASC4FIRST	28/120	23/120	1.13	0.64; 1.98	0.399
ASC4START	24/171	21/172	1.13	0.63; 2.02	0.516
Pooled Analysis	52/291	44/292	1.13	0.75; 1.69	0.290




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Care and Information (MID=15)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	9/64	5/62	1.20	0.29; 5.01	0.922
ASC4START	20/138	21/141	0.85	0.46; 1.58	0.521
Pooled Analysis	29/202	26/203	0.91	0.52; 1.59	0.542
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	6/72	2/53	2.16	0.42; 11.09	0.391
Pooled Analysis	6/91	2/68	2.16	0.42; 11.09	0.391
Others					
ASC4FIRST	42/114	29/116	1.06	0.64; 1.77	0.055
ASC4START	26/74	16/90	1.55	0.82; 2.94	0.074
Pooled Analysis	68/188	45/206	1.24	0.84; 1.84	0.009



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Care and Information (MID=15)




Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	Hazard Ratio and 95% CL	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**				
Dasatinib						
ASC4FIRST	9/41	6/42		0.48	0.11; 2.04	0.476
Pooled Analysis	9/41	6/42		0.48	0.11; 2.04	0.476
Imatinib						
ASC4FIRST	22/101	19/102		0.91	0.47; 1.73	0.925
Pooled Analysis	22/101	19/102		0.91	0.47; 1.73	0.925
Nilotinib						
ASC4FIRST	20/55	9/49		2.19	0.97; 4.95	0.038
ASC4START	52/284	39/284		1.19	0.78; 1.80	0.332
Pooled Analysis	72/339	48/333		1.36	0.94; 1.96	0.064

n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Care and Information (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	18/40	10/46	1.49	0.67; 3.34	0.101
Pooled Analysis	60/128	37/132	1.14	0.74; 1.76	0.022
Asian/Others					
ASC4FIRST	42/91	27/90	1.01	0.60; 1.71	0.124
Others					
ASC4START	2/17	4/21	0.20	0.02; 2.02	0.151
Pooled Analysis	2/20	4/25	0.20	0.02; 2.02	0.151
White					
ASC4FIRST	9/106	7/103	1.58	0.46; 5.46	0.927
ASC4START	32/227	25/217	1.18	0.70; 2.01	0.593
Pooled Analysis	41/333	32/320	1.23	0.76; 1.98	0.605




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Care and Information (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	15/68	7/75	0.67	0.19; 2.43	0.111
ASC4START	25/107	19/126	1.10	0.60; 2.01	0.453
Pooled Analysis	40/175	26/201	1.05	0.62; 1.78	0.129
Male					
ASC4FIRST	36/129	27/118	0.98	0.57; 1.69	0.397
ASC4START	27/177	20/158	1.20	0.67; 2.14	0.551
Pooled Analysis	63/306	47/276	1.11	0.75; 1.65	0.303




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Social Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	32/153	26/150	1.32	0.75; 2.33	0.532
ASC4START	70/237	65/247	1.08	0.76; 1.51	0.476
Pooled Analysis	102/390	91/397	1.12	0.84; 1.50	0.349
65 - < 75 years					
ASC4FIRST	7/34	6/29	0.52	0.14; 1.88	0.511
ASC4START	7/38	4/24	2.50	0.57; 11.00	0.802
Pooled Analysis	14/72	10/53	0.91	0.38; 2.18	0.518
>= 75 years					
ASC4FIRST	0/10	1/14	0.59	0.00; 89.10	0.317
ASC4START	2/9	1/13	1.62	0.14; 18.31	0.861
Pooled Analysis	2/19	2/27	1.62	0.14; 18.31	0.688




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Social Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	7/23	4/20	0.25	0.03; 2.01	0.869
ASC4START	11/38	4/37	1.83	0.58; 5.75	0.298
Pooled Analysis	18/61	8/57	1.11	0.44; 2.78	0.356
Intermediate					
ASC4FIRST	9/54	10/53	0.54	0.21; 1.37	0.257
ASC4START	25/75	24/75	1.14	0.64; 2.03	0.987
Pooled Analysis	34/129	34/128	0.94	0.58; 1.54	0.539
Low					
ASC4FIRST	23/120	19/120	1.56	0.83; 2.91	0.310
ASC4START	43/171	42/172	0.99	0.65; 1.52	0.786
Pooled Analysis	66/291	61/292	1.14	0.80; 1.62	0.421




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Social Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	10/64	6/62	0.92	0.30; 2.85	0.917
ASC4START	40/138	38/141	1.26	0.80; 1.98	0.751
Pooled Analysis	50/202	44/203	1.22	0.80; 1.85	0.801
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	9/72	9/53	0.45	0.14; 1.50	0.448
Pooled Analysis	9/91	9/68	0.45	0.14; 1.50	0.448
Others					
ASC4FIRST	29/114	27/116	1.16	0.66; 2.04	0.624
ASC4START	30/74	23/90	1.14	0.65; 1.99	0.294
Pooled Analysis	59/188	50/206	1.13	0.76; 1.68	0.278




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Social Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	9/41	7/42	0.73	0.22; 2.42	0.438
Pooled Analysis	9/41	7/42	0.73	0.22; 2.42	0.438
Imatinib					
ASC4FIRST	19/101	17/102	0.99	0.50; 1.96	0.911
Pooled Analysis	19/101	17/102	0.99	0.50; 1.96	0.911
Nilotinib					
ASC4FIRST	11/55	9/49	1.30	0.50; 3.40	0.873
ASC4START	79/284	70/284	1.10	0.80; 1.52	0.599
Pooled Analysis	90/339	79/333	1.11	0.82; 1.51	0.583




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Social Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	20/40	14/46	1.45	0.71; 2.95	0.142
Pooled Analysis	48/128	40/132	1.17	0.75; 1.82	0.316
Asian/Others					
ASC4FIRST	28/91	26/90	1.10	0.62; 1.95	0.989
Others					
ASC4START	4/17	4/21	0.42	0.07; 2.62	0.107
Pooled Analysis	4/20	4/25	0.42	0.07; 2.62	0.107
White					
ASC4FIRST	11/106	7/103	1.17	0.41; 3.35	0.679
ASC4START	55/227	52/217	1.04	0.71; 1.53	0.899
Pooled Analysis	66/333	59/320	1.06	0.74; 1.53	0.974




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Social Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	15/68	13/75	0.62	0.27; 1.42	0.956
ASC4START	34/107	27/126	1.32	0.79; 2.21	0.171
Pooled Analysis	49/175	40/201	1.08	0.70; 1.67	0.239
Male					
ASC4FIRST	24/129	20/118	1.30	0.68; 2.51	0.665
ASC4START	45/177	43/158	0.96	0.63; 1.47	0.672
Pooled Analysis	69/306	63/276	1.05	0.74; 1.50	0.915




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	13/153	30/150	0.35	0.18; 0.69	0.001
ASC4START	13/237	23/247	0.55	0.28; 1.10	0.110
Pooled Analysis	26/390	53/397	0.44	0.27; 0.71	<0.001
65 - < 75 years					
ASC4FIRST	0/34	2/29	0.32	0.00; 21.17	0.320
ASC4START	0/38	3/24	0.01	0.00; 6.84	0.015
Pooled Analysis	0/72	5/53	0.08	0.00; 1.73	0.012
>= 75 years					
ASC4FIRST	1/10	4/14	0.16	0.01; 2.67	0.303
ASC4START	0/9	0/13	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	1/19	4/27	0.16	0.01; 2.67	0.303




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	2/20	0.56	0.07; 4.19	0.593
ASC4START	2/38	1/37	1.22	0.11; 13.97	0.768
Pooled Analysis	4/61	3/57	0.81	0.17; 3.82	0.844
Intermediate					
ASC4FIRST	3/54	9/53	0.21	0.05; 0.82	0.015
ASC4START	4/75	7/75	0.50	0.15; 1.71	0.250
Pooled Analysis	7/129	16/128	0.33	0.13; 0.82	0.012
Low					
ASC4FIRST	9/120	25/120	0.34	0.16; 0.73	0.004
ASC4START	7/171	18/172	0.40	0.16; 0.96	0.035
Pooled Analysis	16/291	43/292	0.36	0.20; 0.65	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	7/64	10/62	0.35	0.12; 1.02	0.039
ASC4START	6/138	14/141	0.42	0.16; 1.10	0.071
Pooled Analysis	13/202	24/203	0.38	0.18; 0.78	0.007
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	1/72	2/53	0.05	0.00; 4.29	0.212
Pooled Analysis	1/91	2/68	0.05	0.00; 4.29	0.212
Others					
ASC4FIRST	7/114	26/116	0.26	0.11; 0.63	<0.001
ASC4START	6/74	10/90	0.62	0.22; 1.78	0.408
Pooled Analysis	13/188	36/206	0.37	0.19; 0.70	0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	4/41	8/42	0.25	0.05; 1.33	0.107
Pooled Analysis	4/41	8/42	0.25	0.05; 1.33	0.107
Imatinib					
ASC4FIRST	6/101	18/102	0.25	0.10; 0.62	0.001
Pooled Analysis	6/101	18/102	0.25	0.10; 0.62	0.001
Nilotinib					
ASC4FIRST	4/55	10/49	0.49	0.15; 1.64	0.200
ASC4START	13/284	26/284	0.46	0.24; 0.91	0.026
Pooled Analysis	17/339	36/333	0.47	0.26; 0.84	0.010




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	4/40	9/46	0.52	0.16; 1.72	0.285
Pooled Analysis	11/128	32/132	0.33	0.16; 0.68	0.001
Asian/Others					
ASC4FIRST	8/91	23/90	0.30	0.13; 0.72	0.003
Others					
ASC4START	2/17	0/21	1.78	0.01; 242.14	0.343
Pooled Analysis	3/20	0/25	1.78	0.01; 242.14	0.343
White					
ASC4FIRST	6/106	13/103	0.31	0.10; 0.91	0.024
ASC4START	7/227	17/217	0.36	0.15; 0.89	0.023
Pooled Analysis	13/333	30/320	0.34	0.17; 0.68	0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	4/68	18/75	0.12	0.03; 0.42	<0.001
ASC4START	7/107	17/126	0.42	0.17; 1.02	0.046
Pooled Analysis	11/175	35/201	0.26	0.13; 0.53	<0.001
Male					
ASC4FIRST	10/129	18/118	0.50	0.22; 1.14	0.096
ASC4START	6/177	9/158	0.53	0.18; 1.51	0.276
Pooled Analysis	16/306	27/276	0.52	0.27; 0.99	0.047



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-2.3 FACIT GP5: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
V4 (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.742)								
Low	92/291 (31.6)	2.2 [1.0; 4.4]	108/292 (37.0)	1.0 [0.5; 2.1]	0.74	[0.56; 0.98]	0.072	0.062
Intermediate	43/129 (33.3)	3.7 [1.7; N.E.]	53/128 (41.4)	1.2 [0.5; 2.8]	0.59	[0.39; 0.89]	0.026	0.222
High	21/61 (34.4)	1.9 [1.0; N.E.]	16/57 (28.1)	1.9 [0.5; N.E.]	0.69	[0.35; 1.34]	0.433	0.397
Sex								
(Interaction test: p = 0.943)								
Female	58/175	1.2 [0.7; 3.5]	75/201	1.0 [0.5; 1.9]	0.75	[0.53; 1.08]	0.180	0.470

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(33.1)		(37.3)					
Male	98/306	4.2 [2.1; 13.8]	102/276	1.2 [0.7; 3.3]	0.70	[0.52; 0.93]	0.039	0.016
	(32.0)		(37.0)					
Race								
(Interaction test: p = 0.921)								
Asian	53/128	4.0 [1.6; N.E.]	71/132	1.4 [0.7; 2.8]	0.62	[0.43; 0.90]	0.009	0.030
	(41.4)		(53.8)					
White	97/333	2.1 [1.0; 4.4]	100/320	1.0 [0.5; 1.9]	0.70	[0.53; 0.93]	0.050	0.244
	(29.1)		(31.3)					
Others	6/20	2.1 [0.3; N.E.]	6/25	1.0 [0.1; N.E.]	0.15	[0.02; 1.34]	0.102	N.E.
	(30.0)		(24.0)					
Age groups								
(Interaction test: p = 0.387)								
18 - < 65 years	133/390	2.6 [1.7; 5.6]	144/397	1.4 [0.6; 2.6]	0.74	[0.58; 0.94]	0.078	0.027
	(34.1)		(36.3)					
65 - < 75 years	18/72	3.7 [0.7; N.E.]	24/53	1.0 [0.5; 2.1]	0.51	[0.25; 1.04]	0.082	0.679

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(25.0)		(45.3)					
>= 75 years	5/19	1.6 [0.3; N.E.]	9/27	0.7 [0.3; 1.4]	0.89	[0.23; 3.37]	0.209	0.549
	(26.3)		(33.3)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.849)								
Imatinib	32/101	2.1 [1.0; 18.4]	40/102	1.0 [0.5; 3.0]	0.65	[0.40; 1.04]	0.105	N.E.
	(31.7)		(39.2)					
Nilotinib	112/339	3.5 [1.9; 11.0]	123/333	1.2 [0.7; 2.6]	0.73	[0.56; 0.95]	0.055	0.003
	(33.0)		(36.9)					
Dasatinib	12/41	3.3 [0.5; N.E.]	14/42	0.7 [0.3; 6.5]	0.57	[0.25; 1.29]	0.223	N.E.
	(29.3)		(33.3)					
Geographic region								
(Interaction test: p = 0.206)								
Europe excluding Germany	68/202	2.6 [1.0; 13.8]	78/203	1.0 [0.5; 1.4]	0.63	[0.45; 0.87]	0.006	0.522


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(33.7)		(38.4)					
Germany	16/91	2.2 [0.5; 7.4]	12/68	0.3 [0.3; 0.8]	0.36	[0.15; 0.87]	0.035	N.E.
	(17.6)		(17.6)					
Others	72/188	2.8 [1.6; 18.4]	87/206	2.6 [1.0; 3.7]	0.78	[0.56; 1.07]	0.294	<0.001
	(38.3)		(42.2)					

MID: Minimally important difference
N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not more than 10 events per subgroup per treatment arm, no subgroup analyses were performed for the corresponding attribute.
If there are not more than 10 events per subgroup per treatment arm, no Cox PH hazard analysis is carried out.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline PRO score.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT) and Pre-Randomization selection TKI (IRT).
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	42/153	55/150	0.50	0.33; 0.75	0.005
ASC4START	91/237	89/247	0.91	0.68; 1.22	0.881
Pooled Analysis	133/390	144/397	0.74	0.58; 0.94	0.078
65 - < 75 years					
ASC4FIRST	8/34	16/29	0.45	0.16; 1.25	0.120
ASC4START	10/38	8/24	0.58	0.22; 1.58	0.365
Pooled Analysis	18/72	24/53	0.51	0.25; 1.04	0.082
>= 75 years					
ASC4FIRST	3/10	6/14	0.65	0.12; 3.60	0.350
ASC4START	2/9	3/13	1.62	0.14; 18.31	0.397
Pooled Analysis	5/19	9/27	0.89	0.23; 3.37	0.209




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	4/20	0.32	0.05; 1.83	0.136
ASC4START	18/38	12/37	0.77	0.37; 1.61	0.838
Pooled Analysis	21/61	16/57	0.69	0.35; 1.34	0.433
Intermediate					
ASC4FIRST	19/54	28/53	0.43	0.24; 0.80	0.013
ASC4START	24/75	25/75	0.76	0.44; 1.34	0.458
Pooled Analysis	43/129	53/128	0.59	0.39; 0.89	0.026
Low					
ASC4FIRST	31/120	45/120	0.52	0.32; 0.82	0.012
ASC4START	61/171	63/172	0.91	0.64; 1.29	0.748
Pooled Analysis	92/291	108/292	0.74	0.56; 0.98	0.072




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	16/64	19/62	0.51	0.25; 1.03	0.037
ASC4START	52/138	59/141	0.66	0.45; 0.97	0.047
Pooled Analysis	68/202	78/203	0.63	0.45; 0.87	0.006
Germany					
ASC4FIRST	1/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	15/72	12/53	0.36	0.15; 0.87	0.035
Pooled Analysis	16/91	12/68	0.36	0.15; 0.87	0.035
Others					
ASC4FIRST	36/114	58/116	0.48	0.31; 0.74	0.003
ASC4START	36/74	29/90	1.50	0.91; 2.48	0.065
Pooled Analysis	72/188	87/206	0.78	0.56; 1.07	0.294




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	12/41	14/42	0.57	0.25; 1.29	0.223
Pooled Analysis	12/41	14/42	0.57	0.25; 1.29	0.223
Imatinib					
ASC4FIRST	32/101	40/102	0.65	0.40; 1.04	0.105
Pooled Analysis	32/101	40/102	0.65	0.40; 1.04	0.105
Nilotinib					
ASC4FIRST	9/55	23/49	0.23	0.10; 0.52	<0.001
ASC4START	103/284	100/284	0.85	0.65; 1.12	0.484
Pooled Analysis	112/339	123/333	0.73	0.56; 0.95	0.055




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	19/40	19/46	1.16	0.59; 2.28	0.799
Pooled Analysis	53/128	71/132	0.62	0.43; 0.90	0.009
Asian/Others					
ASC4FIRST	35/91	52/90	0.48	0.31; 0.75	0.001
Others					
ASC4START	5/17	6/21	0.15	0.02; 1.34	0.102
Pooled Analysis	6/20	6/25	0.15	0.02; 1.34	0.102
White					
ASC4FIRST	18/106	25/103	0.47	0.24; 0.92	0.040
ASC4START	79/227	75/217	0.77	0.56; 1.06	0.234
Pooled Analysis	97/333	100/320	0.70	0.53; 0.93	0.050




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration -Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	19/68	29/75	0.62	0.33; 1.16	0.178
ASC4START	39/107	46/126	0.83	0.54; 1.27	0.485
Pooled Analysis	58/175	75/201	0.75	0.53; 1.08	0.180
Male					
ASC4FIRST	34/129	48/118	0.43	0.27; 0.69	0.002
ASC4START	64/177	54/158	0.92	0.64; 1.33	0.870
Pooled Analysis	98/306	102/276	0.70	0.52; 0.93	0.039



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Headache - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.303)								
Low	90/291 (30.9)	4.2 [2.1; 7.4]	115/292 (39.4)	1.4 [0.7; 2.8]	0.63	[0.48; 0.83]	0.004	0.770
Intermediate	48/129 (37.2)	2.6 [1.0; 10.2]	47/128 (36.7)	2.3 [1.2; 5.4]	0.92	[0.62; 1.39]	0.597	0.432
High	25/61 (41.0)	4.2 [1.9; 9.0]	18/57 (31.6)	0.7 [0.5; 3.9]	0.60	[0.31; 1.15]	0.188	0.672
Sex								
(Interaction test: p = 0.824)								
Female	63/175	2.6 [1.0; 5.1]	78/201	1.2 [0.5; 2.6]	0.71	[0.50; 1.00]	0.060	0.809

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(36.0)		(38.8)					
Male	100/306	4.4 [2.3; 9.0]	102/276	2.1 [1.0; 4.2]	0.70	[0.52; 0.92]	0.029	0.361
	(32.7)		(37.0)					
Race								
(Interaction test: p = 0.279)								
Asian	57/128	4.9 [1.8; N.E.]	72/132	1.9 [1.0; 3.5]	0.66	[0.46; 0.94]	0.031	0.267
	(44.5)		(54.5)					
White	101/333	2.8 [1.9; 4.6]	101/320	1.5 [0.7; 2.8]	0.78	[0.58; 1.04]	0.124	0.543
	(30.3)		(31.6)					
Others	5/20	13.8 [0.3; N.E.]	7/25	0.5 [0.1; 3.7]	0.23	[0.04; 1.25]	0.068	N.E.
	(25.0)		(28.0)					
Age groups								
(Interaction test: p = 0.302)								
18 - < 65 years	138/390	3.7 [2.1; 5.6]	153/397	1.4 [0.8; 2.3]	0.69	[0.54; 0.87]	0.007	0.315
	(35.4)		(38.5)					
65 - < 75 years	19/72	5.8 [1.2; N.E.]	21/53	2.8 [0.5; 7.4]	0.61	[0.31; 1.22]	0.146	0.822

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(26.4)		(39.6)					
>= 75 years	6/19	1.0 [0.3; N.E.]	6/27	3.1 [0.7; N.E.]	2.86	[0.66; 12.30]	0.276	0.488
	(31.6)		(22.2)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.168)								
Imatinib	33/101	2.1 [1.0; 14.8]	35/102	3.0 [1.2; 7.4]	1.05	[0.65; 1.70]	0.980	N.E.
	(32.7)		(34.3)					
Nilotinib	120/339	3.7 [2.1; 5.6]	133/333	1.5 [0.7; 2.6]	0.65	[0.51; 0.84]	0.004	0.824
	(35.4)		(39.9)					
Dasatinib	10/41	19.4 [1.6; N.E.]	12/42	0.7 [0.3; N.E.]	0.41	[0.16; 1.06]	0.142	N.E.
	(24.4)		(28.6)					
Geographic region								
(Interaction test: p = 0.240)								
Europe excluding Germany	74/202	3.5 [1.9; 6.4]	73/203	1.6 [0.8; 5.4]	0.77	[0.55; 1.08]	0.202	0.219

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(36.6)		(36.0)					
Germany	14/91	5.1 [2.3; N.E.]	11/68	0.4 [0.3; 9.2]	0.36	[0.13; 0.94]	0.048	N.E.
	(15.4)		(16.2)					
Others	75/188	2.8 [1.8; 7.4]	96/206	1.9 [1.0; 2.8]	0.72	[0.53; 0.99]	0.045	0.867
	(39.9)		(46.6)					
Rash - Presence/Absence (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.377)								
Low	85/291	8.3 [4.4; 12.0]	96/292	2.6 [1.4; 7.4]	0.70	[0.52; 0.93]	0.076	0.777
	(29.2)		(32.9)					
Intermediate	38/129	10.1 [4.2; N.E.]	45/128	2.9 [1.6; 6.3]	0.61	[0.39; 0.95]	0.019	0.052
	(29.5)		(35.2)					
High	15/61	N.E. [6.5; N.E.]	15/57	3.9 [0.7; N.E.]	0.36	[0.17; 0.77]	0.022	0.824
	(24.6)		(26.3)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.705)								
Female	60/175 (34.3)	5.1 [2.3; 11.2]	67/201 (33.3)	2.7 [1.2; 5.6]	0.69	[0.48; 1.00]	0.234	0.302
Male	78/306 (25.5)	15.7 [7.4; N.E.]	89/276 (32.2)	3.0 [1.9; 12.0]	0.61	[0.45; 0.83]	0.002	0.074
Race								
(Interaction test: p = 0.763)								
Asian	55/128 (43.0)	10.2 [4.0; N.E.]	65/132 (49.2)	2.9 [1.4; 9.2]	0.60	[0.42; 0.88]	0.026	0.235
White	80/333 (24.0)	9.2 [5.1; 19.3]	85/320 (26.6)	2.8 [1.6; 6.5]	0.64	[0.47; 0.88]	0.020	0.677
Others	3/20 (15.0)	N.E. [0.3; N.E.]	6/25 (24.0)	2.5 [0.5; N.E.]	0.57	[0.10; 3.22]	0.223	N.E.
Age groups								
(Interaction test: p = 0.611)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	119/390 (30.5)	10.2 [5.6; 14.8]	131/397 (33.0)	2.8 [1.9; 5.6]	0.61	[0.47; 0.79]	0.003	0.493
65 - < 75 years	14/72 (19.4)	N.E. [3.0; N.E.]	19/53 (35.8)	2.1 [1.2; 19.4]	0.60	[0.28; 1.30]	0.149	0.686
>= 75 years	5/19 (26.3)	5.6 [0.7; N.E.]	6/27 (22.2)	3.5 [0.3; N.E.]	0.43	[0.08; 2.44]	0.276	0.999
Pre-randomization selection of TKI								
(Interaction test: p = 0.447)								
Imatinib	29/101 (28.7)	10.1 [4.4; N.E.]	30/102 (29.4)	5.6 [2.1; N.E.]	0.84	[0.50; 1.42]	0.388	N.E.
Nilotinib	97/339 (28.6)	11.1 [5.4; N.E.]	111/333 (33.3)	2.8 [1.6; 5.6]	0.57	[0.43; 0.76]	0.002	0.947
Dasatinib	12/41 (29.3)	10.2 [1.0; N.E.]	15/42 (35.7)	1.2 [0.7; 4.7]	0.59	[0.26; 1.38]	0.240	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.686)								
Europe excluding Germany	60/202 (29.7)	9.2 [4.4; N.E.]	62/203 (30.5)	3.3 [1.6; 12.9]	0.62	[0.43; 0.90]	0.060	0.746
Germany	10/91 (11.0)	N.E. [1.9; N.E.]	10/68 (14.7)	1.8 [0.3; N.E.]	0.47	[0.18; 1.22]	0.074	N.E.
Others	68/188 (36.2)	10.2 [4.9; N.E.]	84/206 (40.8)	2.8 [1.4; 5.6]	0.64	[0.46; 0.89]	0.019	0.227
Diarrhea - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.907)								
Low	93/291 (32.0)	2.3 [1.4; 5.3]	106/292 (36.3)	1.9 [1.2; 3.3]	0.88	[0.66; 1.16]	0.317	0.640
Intermediate	44/129	5.6 [2.4; 17.5]	44/128	2.8 [1.4; 9.2]	0.75	[0.49; 1.15]	0.146	0.041

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(34.1)		(34.4)					
High	20/61	4.0 [1.2; N.E.]	14/57	2.8 [1.4; N.E.]	0.84	[0.41; 1.70]	0.655	0.127
	(32.8)		(24.6)					
Sex								
(Interaction test: p = 0.917)								
Female	55/175	5.3 [2.3; 15.7]	67/201	2.3 [1.4; 6.5]	0.81	[0.55; 1.19]	0.197	0.307
	(31.4)		(33.3)					
Male	102/306	2.9 [1.7; 5.6]	97/276	2.6 [1.4; 3.5]	0.84	[0.63; 1.11]	0.265	0.078
	(33.3)		(35.1)					
Race								
(Interaction test: p = 0.869)								
Asian	61/128	5.6 [2.6; 15.7]	63/132	2.3 [1.4; 6.5]	0.86	[0.60; 1.23]	0.353	0.332
	(47.7)		(47.7)					
White	89/333	2.6 [1.7; 5.6]	96/320	2.3 [1.4; 3.5]	0.80	[0.59; 1.07]	0.130	0.024
	(26.7)		(30.0)					
Others	7/20	2.1 [0.3; N.E.]	5/25	1.4 [0.3; N.E.]	1.12	[0.24; 5.23]	0.933	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(35.0)		(20.0)					
Age groups								
(Interaction test: p = 0.462)								
18 - < 65 years	130/390	3.7 [2.1; 7.4]	137/397	2.6 [1.6; 4.6]	0.88	[0.69; 1.13]	0.248	0.295
	(33.3)		(34.5)					
65 - < 75 years	19/72	11.1 [1.7; N.E.]	20/53	1.4 [0.7; 6.5]	0.69	[0.35; 1.37]	0.295	0.054
	(26.4)		(37.7)					
>= 75 years	8/19	1.2 [0.3; 5.6]	7/27	1.0 [0.3; N.E.]	0.73	[0.18; 2.85]	0.678	0.251
	(42.1)		(25.9)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.031)								
Imatinib	31/101	5.6 [1.0; 19.4]	43/102	1.0 [0.5; 2.1]	0.50	[0.31; 0.80]	0.002	N.E.
	(30.7)		(42.2)					
Nilotinib	113/339	3.5 [2.1; 7.4]	107/333	3.0 [2.1; 9.2]	1.00	[0.77; 1.31]	0.969	0.962
	(33.3)		(32.1)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	13/41 (31.7)	1.7 [0.3; N.E.]	14/42 (33.3)	1.0 [0.3; 12.8]	0.71	[0.32; 1.56]	0.488	N.E.
Geographic region (Interaction test: p = 0.031)								
Europe excluding Germany	73/202 (36.1)	2.0 [1.2; 3.7]	69/203 (34.0)	2.1 [1.0; 3.5]	0.94	[0.66; 1.33]	0.674	0.008
Germany	8/91 (8.8)	N.E. [4.6; N.E.]	11/68 (16.2)	1.1 [0.3; 9.2]	0.20	[0.06; 0.63]	0.006	N.E.
Others	76/188 (40.4)	5.2 [2.1; 13.7]	84/206 (40.8)	2.8 [1.6; 6.5]	0.91	[0.66; 1.25]	0.480	0.045
Vomiting - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.942)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Low	25/291 (8.6)	N.E. [N.E.; N.E.]	55/292 (18.8)	N.E. [N.E.; N.E.]	0.38	[0.23; 0.61]	<0.001	0.783
Intermediate	16/129 (12.4)	N.E. [N.E.; N.E.]	29/128 (22.7)	N.E. [5.5; N.E.]	0.37	[0.20; 0.69]	0.002	0.539
High	5/61 (8.2)	N.E. [N.E.; N.E.]	8/57 (14.0)	N.E. [3.5; N.E.]	0.47	[0.15; 1.48]	0.173	0.263
Sex								
(Interaction test: p = 0.558)								
Female	20/175 (11.4)	N.E. [N.E.; N.E.]	47/201 (23.4)	N.E. [4.6; N.E.]	0.36	[0.21; 0.62]	<0.001	0.781
Male	26/306 (8.5)	N.E. [N.E.; N.E.]	45/276 (16.3)	N.E. [N.E.; N.E.]	0.44	[0.27; 0.72]	<0.001	0.468
Race								
(Interaction test: p = 0.933)								
Asian	23/128 (18.0)	N.E. [N.E.; N.E.]	45/132 (34.1)	N.E. [5.3; N.E.]	0.40	[0.24; 0.66]	<0.001	0.740

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
White	21/333 (6.3)	N.E. [N.E.; N.E.]	42/320 (13.1)	N.E. [N.E.; N.E.]	0.40	[0.24; 0.69]	<0.001	0.468
Others	2/20 (10.0)	N.E. [0.3; N.E.]	5/25 (20.0)	15.7 [1.2; N.E.]	0.87	[0.05; 13.95]	0.857	N.E.
Age groups (Interaction test: p = 0.751)								
18 - < 65 years	39/390 (10.0)	N.E. [N.E.; N.E.]	77/397 (19.4)	N.E. [N.E.; N.E.]	0.40	[0.27; 0.59]	<0.001	0.967
65 - < 75 years	4/72 (5.6)	N.E. [N.E.; N.E.]	10/53 (18.9)	N.E. [1.6; N.E.]	0.24	[0.06; 0.93]	0.026	0.677
>= 75 years	3/19 (15.8)	22.1 [3.3; N.E.]	5/27 (18.5)	6.9 [1.0; N.E.]	0.42	[0.07; 2.41]	0.317	0.997
Pre-randomization selection of TKI (Interaction test: p = 0.266)								
Imatinib	10/101	N.E. [N.E.; N.E.]	29/102	5.6 [1.6; N.E.]	0.26	[0.13; 0.54]	<0.001	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(9.9)		(28.4)					
Nilotinib	31/339	N.E. [N.E.; N.E.]	57/333	N.E. [N.E.; N.E.]	0.43	[0.28; 0.67]	<0.001	0.737
	(9.1)		(17.1)					
Dasatinib	5/41	N.E. [N.E.; N.E.]	6/42	N.E. [3.0; N.E.]	0.82	[0.25; 2.69]	0.740	N.E.
	(12.2)		(14.3)					
Geographic region								
(Interaction test: p = 0.962)								
Europe excluding Germany	17/202	N.E. [N.E.; N.E.]	32/203	N.E. [N.E.; N.E.]	0.39	[0.21; 0.72]	0.002	0.659
	(8.4)		(15.8)					
Germany	1/91	N.E. [N.E.; N.E.]	1/68	N.E. [N.E.; N.E.]	0.55	[0.03; 8.78]	0.666	N.E.
	(1.1)		(1.5)					
Others	28/188	N.E. [N.E.; N.E.]	59/206	N.E. [5.5; N.E.]	0.38	[0.24; 0.61]	<0.001	0.988
	(14.9)		(28.6)					
Nausea - Frequency (MID=1)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.294)								
Low	63/291 (21.6)	N.E. [11.1; N.E.]	96/292 (32.9)	2.3 [1.2; 10.7]	0.54	[0.39; 0.75]	<0.001	0.206
Intermediate	24/129 (18.6)	N.E. [22.1; N.E.]	47/128 (36.7)	2.8 [1.4; 4.6]	0.32	[0.19; 0.53]	<0.001	0.492
High	14/61 (23.0)	N.E. [3.5; N.E.]	12/57 (21.1)	11.1 [2.3; N.E.]	0.73	[0.33; 1.60]	0.568	0.738
Sex								
(Interaction test: p = 0.980)								
Female	46/175 (26.3)	15.7 [3.9; N.E.]	72/201 (35.8)	1.4 [0.7; 2.3]	0.53	[0.36; 0.78]	0.001	0.570
Male	55/306 (18.0)	N.E. [25.8; N.E.]	83/276 (30.1)	4.6 [2.8; 18.5]	0.49	[0.35; 0.69]	<0.001	0.118

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.857)								
Asian	40/128 (31.3)	N.E. [18.4; N.E.]	65/132 (49.2)	2.6 [1.4; 5.6]	0.45	[0.30; 0.68]	<0.001	0.175
White	58/333 (17.4)	25.8 [22.1; N.E.]	86/320 (26.9)	3.3 [1.6; 8.3]	0.53	[0.37; 0.75]	<0.001	0.334
Others	3/20 (15.0)	N.E. [0.3; N.E.]	4/25 (16.0)	18.4 [0.3; N.E.]	0.52	[0.07; 3.86]	0.596	N.E.
Age groups								
(Interaction test: p = 0.400)								
18 - < 65 years	87/390 (22.3)	N.E. [25.8; N.E.]	128/397 (32.2)	3.5 [1.9; 10.7]	0.53	[0.40; 0.70]	<0.001	0.082
65 - < 75 years	10/72 (13.9)	N.E. [15.7; N.E.]	21/53 (39.6)	1.9 [0.5; 3.9]	0.18	[0.07; 0.47]	<0.001	0.783
>= 75 years	4/19 (21.1)	22.1 [0.5; N.E.]	6/27 (22.2)	1.2 [0.3; N.E.]	0.46	[0.08; 2.62]	0.214	0.701

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.024)								
Imatinib	17/101 (16.8)	N.E. [13.9; N.E.]	45/102 (44.1)	1.0 [0.5; 1.6]	0.25	[0.14; 0.44]	<0.001	N.E.
Nilotinib	75/339 (22.1)	25.8 [22.1; N.E.]	97/333 (29.1)	8.3 [3.0; 22.1]	0.62	[0.46; 0.84]	0.003	0.617
Dasatinib	9/41 (22.0)	N.E. [0.7; N.E.]	13/42 (31.0)	1.9 [0.5; 28.6]	0.49	[0.20; 1.20]	0.156	N.E.
Geographic region								
(Interaction test: p = 0.952)								
Europe excluding Germany	43/202 (21.3)	N.E. [15.7; N.E.]	65/203 (32.0)	2.1 [1.2; 8.3]	0.47	[0.32; 0.71]	<0.001	0.515
Germany	9/91 (9.9)	25.8 [2.4; N.E.]	9/68 (13.2)	3.9 [0.3; N.E.]	0.60	[0.22; 1.62]	0.273	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	49/188 (26.1)	N.E. [18.4; N.E.]	81/206 (39.3)	3.3 [1.8; 5.6]	0.50	[0.35; 0.72]	<0.001	0.053
Edema - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.790)								
Low	61/291 (21.0)	N.E. [12.0; N.E.]	82/292 (28.1)	11.1 [5.4; 24.9]	0.66	[0.47; 0.92]	0.013	0.084
Intermediate	31/129 (24.0)	22.1 [11.0; N.E.]	42/128 (32.8)	4.6 [2.0; 22.1]	0.53	[0.33; 0.85]	0.007	0.005
High	15/61 (24.6)	N.E. [3.3; N.E.]	12/57 (21.1)	4.2 [1.0; N.E.]	0.82	[0.37; 1.78]	0.536	0.197
Sex (Interaction test: p = 0.768)								
Female	51/175	9.2 [3.3; N.E.]	68/201	2.8 [1.0; 5.4]	0.61	[0.42; 0.91]	0.011	0.002

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(29.1)		(33.8)					
Male	56/306	N.E. [N.E.; N.E.]	68/276	16.6 [11.1; N.E.]	0.67	[0.47; 0.96]	0.033	0.033
	(18.3)		(24.6)					
Race								
(Interaction test: p = 0.020)								
Asian	42/128	N.E. [8.3; N.E.]	70/132	2.1 [1.2; 4.2]	0.45	[0.30; 0.66]	<0.001	0.147
	(32.8)		(53.0)					
White	59/333	24.9 [17.5; N.E.]	62/320	24.9 [11.1; N.E.]	0.82	[0.57; 1.19]	0.251	0.038
	(17.7)		(19.4)					
Others	6/20	2.8 [0.3; N.E.]	4/25	15.7 [0.3; N.E.]	1.38	[0.29; 6.54]	0.440	N.E.
	(30.0)		(16.0)					
Age groups								
(Interaction test: p = 0.354)								
18 - < 65 years	87/390	N.E. [22.1; N.E.]	114/397	11.1 [4.9; 15.7]	0.61	[0.46; 0.82]	<0.001	0.003
	(22.3)		(28.7)					
65 - < 75 years	15/72	N.E. [2.1; N.E.]	18/53	2.0 [0.5; N.E.]	0.45	[0.21; 0.97]	0.071	0.073

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(20.8)		(34.0)					
>= 75 years	5/19	16.1 [0.3; N.E.]	4/27	N.E. [1.0; N.E.]	1.20	[0.20; 7.26]	0.861	0.998
	(26.3)		(14.8)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.009)								
Imatinib	24/101	24.9 [6.4; N.E.]	44/102	1.2 [0.8; 2.1]	0.37	[0.22; 0.62]	<0.001	N.E.
	(23.8)		(43.1)					
Nilotinib	77/339	N.E. [17.5; N.E.]	80/333	22.1 [11.1; N.E.]	0.88	[0.64; 1.21]	0.431	0.307
	(22.7)		(24.0)					
Dasatinib	6/41	N.E. [11.0; N.E.]	12/42	1.6 [0.3; N.E.]	0.22	[0.07; 0.68]	0.003	N.E.
	(14.6)		(28.6)					
Geographic region								
(Interaction test: p = 0.583)								
Europe excluding Germany	43/202	N.E. [17.5; N.E.]	48/203	14.8 [11.1; N.E.]	0.72	[0.47; 1.10]	0.108	0.051

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(21.3)		(23.6)					
Germany	9/91	22.1 [2.8; N.E.]	6/68	N.E. [1.8; N.E.]	0.74	[0.24; 2.32]	0.813	N.E.
	(9.9)		(8.8)					
Others	55/188	N.E. [10.2; N.E.]	82/206	3.0 [1.7; 10.2]	0.58	[0.41; 0.83]	0.002	0.005
	(29.3)		(39.8)					
Muscle Pain - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.794)								
Low	95/291	1.7 [0.8; 4.9]	117/292	0.8 [0.5; 1.4]	0.75	[0.57; 0.99]	0.038	0.204
	(32.6)		(40.1)					
Intermediate	50/129	1.5 [1.0; 3.3]	51/128	1.1 [0.7; 3.0]	0.86	[0.58; 1.28]	0.422	0.211
	(38.8)		(39.8)					
High	19/61	8.3 [0.7; N.E.]	17/57	1.6 [0.7; 2.8]	0.78	[0.40; 1.53]	0.429	0.670
	(31.1)		(29.8)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.769)								
Female	63/175 (36.0)	1.0 [0.5; 1.9]	82/201 (40.8)	1.0 [0.7; 1.4]	0.84	[0.60; 1.18]	0.153	0.678
Male	101/306 (33.0)	2.3 [1.2; 7.4]	103/276 (37.3)	1.1 [0.5; 2.8]	0.78	[0.59; 1.04]	0.105	0.067
Race								
(Interaction test: p = 0.084)								
Asian	59/128 (46.1)	3.0 [1.0; 19.4]	85/132 (64.4)	0.7 [0.5; 1.2]	0.58	[0.41; 0.82]	<0.001	0.998
White	98/333 (29.4)	1.4 [1.0; 2.2]	96/320 (30.0)	1.2 [0.7; 2.8]	0.93	[0.70; 1.24]	0.635	0.255
Others	7/20 (35.0)	0.5 [0.3; N.E.]	4/25 (16.0)	N.E. [0.3; N.E.]	1.69	[0.31; 9.26]	0.349	N.E.
Age groups								
(Interaction test: p = 0.501)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	134/390 (34.4)	1.9 [1.0; 5.5]	155/397 (39.0)	1.0 [0.7; 1.4]	0.76	[0.60; 0.96]	0.025	0.048
65 - < 75 years	22/72 (30.6)	1.3 [0.6; 8.3]	24/53 (45.3)	1.2 [0.5; 2.8]	0.72	[0.37; 1.39]	0.223	0.985
>= 75 years	8/19 (42.1)	1.0 [0.3; 2.1]	6/27 (22.2)	1.1 [0.3; N.E.]	1.22	[0.29; 5.11]	0.647	0.085
Pre-randomization selection of TKI								
(Interaction test: p = 0.248)								
Imatinib	30/101 (29.7)	2.8 [0.5; N.E.]	44/102 (43.1)	0.8 [0.5; 1.4]	0.58	[0.36; 0.93]	0.016	N.E.
Nilotinib	123/339 (36.3)	1.4 [1.0; 2.2]	128/333 (38.4)	1.2 [0.7; 2.1]	0.89	[0.69; 1.15]	0.354	0.512
Dasatinib	11/41 (26.8)	8.3 [0.7; N.E.]	13/42 (31.0)	1.0 [0.3; 6.5]	0.54	[0.22; 1.28]	0.150	N.E.
Geographic region								


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.432)								
Europe excluding Germany	71/202 (35.1)	1.6 [1.0; 3.3]	68/203 (33.5)	1.2 [0.7; 3.0]	0.97	[0.69; 1.36]	0.847	0.268
Germany	14/91 (15.4)	1.2 [0.5; N.E.]	10/68 (14.7)	0.4 [0.3; N.E.]	0.71	[0.28; 1.80]	0.524	N.E.
Others	79/188 (42.0)	1.4 [0.8; 7.4]	107/206 (51.9)	0.9 [0.5; 1.4]	0.68	[0.51; 0.92]	0.006	0.364

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				

MID: Minimally important difference
N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not more than 10 events per subgroup per treatment arm, no subgroup analyses were performed for the corresponding attribute.
If there are not more than 10 events per subgroup per treatment arm, no Cox PH hazard analysis is carried out.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline PRO score.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT) and Pre-Randomization selection TKI (IRT).
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Diarrhea - Frequency (MID=1): Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Diarrhea - Frequency (MID=1): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	72 (164)	44 (186)	25 (201)	11 (215)	2 (224)	0 (226)
Investigator Selected TKI	333 (0)	73 (166)	41 (190)	26 (202)	12 (215)	2 (224)	0 (226)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Diarrhea - Frequency (MID=1): Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Diarrhea - Frequency (MID=1): Geographic region: Europe excluding Germany




Pts at Risk (censored)

Asciminib	202 (0)	35 (97)	23 (108)	12 (117)	7 (122)	1 (128)	0 (129)
Investigator Selected TKI	203 (0)	33 (108)	13 (123)	5 (129)	2 (132)	1 (133)	0 (134)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Diarrhea - Frequency (MID=1): Geographic region: Germany




Pts at Risk (censored)

Asciminib	91 (0)	13 (72)	7 (76)	6 (77)	1 (82)	0 (83)	0 (83)
Investigator Selected TKI	68 (0)	3 (55)	2 (55)	1 (56)	1 (56)	0 (57)	0 (57)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Diarrhea - Frequency (MID=1): Geographic region: Others




Pts at Risk (censored)

Asciminib	188 (0)	51 (71)	38 (80)	25 (88)	15 (97)	4 (108)	0 (112)
Investigator Selected TKI	206 (0)	51 (81)	35 (93)	27 (98)	12 (111)	2 (120)	0 (122)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Nausea - Frequency (MID=1): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	101 (0)	31 (55)	25 (60)	23 (61)	12 (72)	3 (81)	0 (84)
Investigator Selected TKI	102 (0)	9 (49)	6 (51)	6 (51)	3 (54)	0 (57)	0 (57)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Nausea - Frequency (MID=1): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	114 (163)	64 (205)	34 (233)	17 (249)	3 (261)	0 (264)
Investigator Selected TKI	333 (0)	77 (170)	48 (193)	27 (212)	8 (229)	2 (234)	0 (236)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Nausea - Frequency (MID=1): Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Frequency (MID=1): Race: Asian



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Edema - Frequency (MID=1): Race: White




Pts at Risk (censored)

Asciminib	333 (0)	90 (195)	56 (224)	30 (247)	14 (261)	3 (271)	0 (274)
Investigator Selected TKI	320 (0)	77 (196)	46 (216)	25 (234)	8 (251)	2 (256)	0 (258)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Edema - Frequency (MID=1): Race: Others




Pts at Risk (censored)

Asciminib	20 (0)	3 (12)	1 (13)	0 (14)	0 (14)	0 (14)	0 (14)
Investigator Selected TKI	25 (0)	5 (17)	2 (20)	1 (20)	0 (21)	0 (21)	0 (21)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Frequency (MID=1): Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Edema - Frequency (MID=1): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	110 (164)	64 (202)	35 (229)	17 (245)	3 (259)	0 (262)
Investigator Selected TKI	333 (0)	96 (172)	55 (203)	30 (225)	10 (244)	2 (251)	0 (253)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Edema - Frequency (MID=1): Pre-randomization selection of TKI: Dasatinib




Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	50/153	53/150	0.74	0.50; 1.11	0.133
ASC4START	80/237	84/247	0.97	0.71; 1.32	0.757
Pooled Analysis	130/390	137/397	0.88	0.69; 1.13	0.248
65 - < 75 years					
ASC4FIRST	7/34	14/29	0.33	0.11; 0.96	0.033
ASC4START	12/38	6/24	1.41	0.51; 3.92	0.518
Pooled Analysis	19/72	20/53	0.69	0.35; 1.37	0.295
>= 75 years					
ASC4FIRST	4/10	5/14	0.19	0.02; 2.21	0.270
ASC4START	4/9	2/13	1.69	0.27; 10.49	0.636
Pooled Analysis	8/19	7/27	0.73	0.18; 2.85	0.678




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	5/23	5/20	0.38	0.08; 1.89	0.122
ASC4START	15/38	9/37	1.16	0.50; 2.65	0.726
Pooled Analysis	20/61	14/57	0.84	0.41; 1.70	0.655
Intermediate					
ASC4FIRST	19/54	25/53	0.48	0.25; 0.89	0.006
ASC4START	25/75	19/75	1.15	0.64; 2.10	0.565
Pooled Analysis	44/129	44/128	0.75	0.49; 1.15	0.146
Low					
ASC4FIRST	37/120	42/120	0.78	0.50; 1.23	0.390
ASC4START	56/171	64/172	0.91	0.63; 1.31	0.551
Pooled Analysis	93/291	106/292	0.88	0.66; 1.16	0.317




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	21/64	20/62	0.41	0.21; 0.82	0.009
ASC4START	52/138	49/141	1.23	0.83; 1.82	0.334
Pooled Analysis	73/202	69/203	0.94	0.66; 1.33	0.674
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	8/72	11/53	0.20	0.06; 0.63	0.006
Pooled Analysis	8/91	11/68	0.20	0.06; 0.63	0.006
Others					
ASC4FIRST	40/114	52/116	0.69	0.45; 1.05	0.071
ASC4START	36/74	32/90	1.29	0.79; 2.10	0.324
Pooled Analysis	76/188	84/206	0.91	0.66; 1.25	0.480




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	13/41	14/42	0.71	0.32; 1.56	0.488
Pooled Analysis	13/41	14/42	0.71	0.32; 1.56	0.488
Imatinib					
ASC4FIRST	31/101	43/102	0.50	0.31; 0.80	0.002
Pooled Analysis	31/101	43/102	0.50	0.31; 0.80	0.002
Nilotinib					
ASC4FIRST	17/55	15/49	0.99	0.47; 2.10	0.943
ASC4START	96/284	92/284	1.00	0.75; 1.33	0.945
Pooled Analysis	113/339	107/333	1.00	0.77; 1.31	0.969




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	21/40	19/46	1.05	0.55; 2.01	0.833
Pooled Analysis	61/128	63/132	0.86	0.60; 1.23	0.353
Asian/Others					
ASC4FIRST	42/91	44/90	0.77	0.50; 1.19	0.231
Others					
ASC4START	5/17	5/21	1.12	0.24; 5.23	0.933
Pooled Analysis	7/20	5/25	1.12	0.24; 5.23	0.933
White					
ASC4FIRST	19/106	28/103	0.40	0.21; 0.75	0.006
ASC4START	70/227	68/217	0.96	0.69; 1.34	0.795
Pooled Analysis	89/333	96/320	0.80	0.59; 1.07	0.130




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	21/68	26/75	0.68	0.36; 1.29	0.098
ASC4START	34/107	41/126	0.92	0.57; 1.48	0.695
Pooled Analysis	55/175	67/201	0.81	0.55; 1.19	0.197
Male					
ASC4FIRST	40/129	46/118	0.60	0.38; 0.94	0.054
ASC4START	62/177	51/158	1.03	0.71; 1.50	0.881
Pooled Analysis	102/306	97/276	0.84	0.63; 1.11	0.265




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	32/153	55/150	0.36	0.23; 0.57	<0.001
ASC4START	55/237	59/247	0.88	0.61; 1.28	0.521
Pooled Analysis	87/390	114/397	0.61	0.46; 0.82	<0.001
65 - < 75 years					
ASC4FIRST	6/34	14/29	0.23	0.07; 0.70	0.008
ASC4START	9/38	4/24	1.02	0.29; 3.57	0.764
Pooled Analysis	15/72	18/53	0.45	0.21; 0.97	0.071
>= 75 years					
ASC4FIRST	4/10	4/14	0.88	0.12; 6.66	0.770
ASC4START	1/9	0/13	2.99	0.03; 275.43	0.317
Pooled Analysis	5/19	4/27	1.20	0.20; 7.26	0.861




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	5/20	0.07	0.00; 1.15	0.090
ASC4START	13/38	7/37	1.06	0.42; 2.67	0.802
Pooled Analysis	15/61	12/57	0.82	0.37; 1.78	0.536
Intermediate					
ASC4FIRST	15/54	29/53	0.30	0.15; 0.56	<0.001
ASC4START	16/75	13/75	1.20	0.57; 2.52	0.701
Pooled Analysis	31/129	42/128	0.53	0.33; 0.85	0.007
Low					
ASC4FIRST	25/120	39/120	0.47	0.28; 0.78	0.003
ASC4START	36/171	43/172	0.85	0.55; 1.33	0.462
Pooled Analysis	61/291	82/292	0.66	0.47; 1.92	0.013




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	13/64	18/62	0.38	0.18; 0.81	0.010
ASC4START	30/138	30/141	0.97	0.58; 1.62	0.813
Pooled Analysis	43/202	48/203	0.72	0.47; 1.10	0.108
Germany					
ASC4FIRST	1/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	8/72	6/53	0.74	0.24; 2.32	0.813
Pooled Analysis	9/91	6/68	0.74	0.24; 2.32	0.813
Others					
ASC4FIRST	28/114	55/116	0.38	0.24; 0.62	<0.001
ASC4START	27/74	27/90	1.07	0.62; 1.85	0.771
Pooled Analysis	55/188	82/206	0.58	0.41; 0.83	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	6/41	12/42	0.22	0.07; 0.68	0.003
Pooled Analysis	6/41	12/42	0.22	0.07; 0.68	0.003
Imatinib					
ASC4FIRST	24/101	44/102	0.37	0.22; 0.62	<0.001
Pooled Analysis	24/101	44/102	0.37	0.22; 0.62	<0.001
Nilotinib					
ASC4FIRST	12/55	17/49	0.62	0.29; 1.34	0.221
ASC4START	65/284	63/284	0.95	0.67; 1.35	0.762
Pooled Analysis	77/339	80/333	0.88	0.64; 1.21	0.431




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	15/40	20/46	0.67	0.34; 1.32	0.232
Pooled Analysis	42/128	70/132	0.45	0.30; 0.66	<0.001
Asian/Others					
ASC4FIRST	28/91	50/90	0.38	0.23; 0.62	<0.001
Others					
ASC4START	5/17	4/21	1.38	0.29; 6.54	0.440
Pooled Analysis	6/20	4/25	1.38	0.29; 6.54	0.440
White					
ASC4FIRST	14/106	23/103	0.43	0.21; 0.87	0.016
ASC4START	45/227	39/217	1.06	0.69; 1.63	0.882
Pooled Analysis	59/333	62/320	0.82	0.57; 1.19	0.251




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	17/68	32/75	0.27	0.14; 0.53	<0.001
ASC4START	34/107	36/126	1.00	0.62; 1.61	0.876
Pooled Analysis	51/175	68/201	0.61	0.42; 0.91	0.011
Male					
ASC4FIRST	25/129	41/118	0.46	0.27; 0.76	0.002
ASC4START	31/177	27/158	1.00	0.59; 1.67	0.953
Pooled Analysis	56/306	68/276	0.67	0.47; 0.96	0.033




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	54/153	51/150	0.80	0.54; 1.20	0.573
ASC4START	84/237	102/247	0.63	0.47; 0.85	0.004
Pooled Analysis	138/390	153/397	0.69	0.54; 0.87	0.007
65 - < 75 years					
ASC4FIRST	8/34	13/29	0.52	0.17; 1.60	0.211
ASC4START	11/38	8/24	0.64	0.24; 1.73	0.426
Pooled Analysis	19/72	21/53	0.61	0.31; 1.22	0.146
>= 75 years					
ASC4FIRST	2/10	4/14	1.72	0.24; 12.50	0.786
ASC4START	4/9	2/13	5.96	0.47; 76.09	0.202
Pooled Analysis	6/19	6/27	2.86	0.66; 12.30	0.276




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	7/23	5/20	0.78	0.19; 3.18	0.729
ASC4START	18/38	13/37	0.56	0.27; 1.16	0.191
Pooled Analysis	25/61	18/57	0.60	0.31; 1.15	0.188
Intermediate					
ASC4FIRST	22/54	20/53	1.14	0.61; 2.13	0.900
ASC4START	26/75	27/75	0.80	0.47; 1.38	0.412
Pooled Analysis	48/129	47/128	0.92	0.62; 1.39	0.597
Low					
ASC4FIRST	35/120	43/120	0.66	0.42; 1.04	0.177
ASC4START	55/171	72/172	0.61	0.43; 0.87	0.010
Pooled Analysis	90/291	115/292	0.63	0.48; 0.83	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	22/64	15/62	1.18	0.58; 2.40	0.924
ASC4START	52/138	58/141	0.70	0.48; 1.03	0.130
Pooled Analysis	74/202	73/203	0.77	0.55; 1.08	0.202
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	14/72	11/53	0.36	0.13; 0.94	0.048
Pooled Analysis	14/91	11/68	0.36	0.13; 0.94	0.048
Others					
ASC4FIRST	42/114	53/116	0.75	0.49; 1.13	0.241
ASC4START	33/74	43/90	0.71	0.45; 1.12	0.091
Pooled Analysis	75/188	96/206	0.72	0.53; 1.09	0.045




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	10/41	12/42	0.41	0.16; 1.06	0.142
Pooled Analysis	10/41	12/42	0.41	0.16; 1.06	0.142
Imatinib					
ASC4FIRST	33/101	35/102	1.05	0.65; 1.70	0.980
Pooled Analysis	33/101	35/102	1.05	0.65; 1.70	0.980
Nilotinib					
ASC4FIRST	21/55	21/49	0.64	0.33; 1.23	0.565
ASC4START	99/284	112/284	0.65	0.49; 0.85	0.004
Pooled Analysis	120/339	133/333	0.65	0.51; 0.84	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	17/40	28/46	0.50	0.27; 0.92	0.019
Pooled Analysis	57/128	72/132	0.66	0.46; 0.94	0.031
Asian/Others					
ASC4FIRST	42/91	44/90	0.79	0.51; 1.22	0.418
Others					
ASC4START	3/17	7/21	0.23	0.04; 1.25	0.068
Pooled Analysis	5/20	7/25	0.23	0.04; 1.25	0.068
White					
ASC4FIRST	22/106	24/103	0.96	0.51; 1.84	0.583
ASC4START	79/227	77/217	0.75	0.54; 1.03	0.148
Pooled Analysis	101/333	101/320	0.78	0.58; 1.04	0.124




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	23/68	27/75	0.75	0.42; 1.35	0.409
ASC4START	40/107	51/126	0.69	0.45; 1.05	0.085
Pooled Analysis	63/175	78/201	0.71	0.50; 1.00	0.060
Male					
ASC4FIRST	41/129	41/118	0.82	0.52; 1.29	0.495
ASC4START	59/177	61/158	0.63	0.44; 0.90	0.024
Pooled Analysis	100/306	102/276	0.70	0.52; 0.92	0.029




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	47/153	63/150	0.56	0.38; 0.82	0.003
ASC4START	87/237	92/247	0.91	0.68; 1.23	0.587
Pooled Analysis	134/390	155/397	0.76	0.60; 0.96	0.025
65 - < 75 years					
ASC4FIRST	9/34	14/29	0.64	0.24; 1.71	0.367
ASC4START	13/38	10/24	0.72	0.29; 1.81	0.411
Pooled Analysis	22/72	24/53	0.72	0.37; 1.39	0.223
>= 75 years					
ASC4FIRST	3/10	4/14	3.79	0.49; 29.38	0.378
ASC4START	5/9	2/13	0.55	0.06; 4.67	0.863
Pooled Analysis	8/19	6/27	1.22	0.29; 5.11	0.647




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	4/23	5/20	0.58	0.14; 2.37	0.430
ASC4START	15/38	12/37	0.85	0.40; 1.83	0.643
Pooled Analysis	19/61	17/57	0.78	0.40; 1.53	0.429
Intermediate					
ASC4FIRST	19/54	23/53	0.63	0.34; 1.18	0.166
ASC4START	31/75	28/75	1.05	0.63; 1.76	0.912
Pooled Analysis	50/129	51/128	0.86	0.58; 1.28	0.422
Low					
ASC4FIRST	36/120	53/120	0.61	0.39; 0.94	0.011
ASC4START	59/171	64/172	0.87	0.61; 1.25	0.545
Pooled Analysis	95/291	117/292	0.75	0.57; 0.99	0.038




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	16/64	18/62	0.75	0.37; 1.52	0.183
ASC4START	55/138	50/141	1.08	0.74; 1.60	0.612
Pooled Analysis	71/202	68/203	0.97	0.69; 1.36	0.847
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	14/72	10/53	0.71	0.28; 1.80	0.524
Pooled Analysis	14/91	10/68	0.71	0.28; 1.80	0.524
Others					
ASC4FIRST	43/114	63/116	0.60	0.41; 0.90	0.014
ASC4START	36/74	44/90	0.80	0.51; 1.25	0.177
Pooled Analysis	79/188	107/206	0.68	0.51; 0.92	0.006




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	11/41	13/42	0.54	0.22; 1.28	0.150
Pooled Analysis	11/41	13/42	0.54	0.22; 1.28	0.150
Imatinib					
ASC4FIRST	30/101	44/102	0.58	0.36; 0.93	0.016
Pooled Analysis	30/101	44/102	0.58	0.36; 0.93	0.016
Nilotinib					
ASC4FIRST	18/55	24/49	0.72	0.38; 1.39	0.298
ASC4START	105/284	104/284	0.92	0.70; 1.21	0.568
Pooled Analysis	123/339	128/333	0.89	0.69; 1.15	0.354




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	18/40	29/46	0.59	0.32; 1.08	0.033
Pooled Analysis	59/128	85/132	0.58	0.41; 0.82	<0.001
Asian/Others					
ASC4FIRST	42/91	56/90	0.59	0.39; 0.89	0.009
Others					
ASC4START	6/17	4/21	1.69	0.31; 9.26	0.349
Pooled Analysis	7/20	4/25	1.69	0.31; 9.26	0.349
White					
ASC4FIRST	17/106	25/103	0.68	0.36; 1.30	0.163
ASC4START	81/227	71/217	1.01	0.73; 1.40	0.866
Pooled Analysis	98/333	96/320	0.93	0.70; 1.24	0.635




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	20/68	32/75	0.78	0.43; 1.41	0.168
ASC4START	43/107	50/126	0.88	0.58; 1.33	0.444
Pooled Analysis	63/175	82/201	0.84	0.60; 1.18	0.153
Male					
ASC4FIRST	39/129	49/118	0.58	0.37; 0.89	0.012
ASC4START	62/177	54/158	0.98	0.68; 1.41	0.981
Pooled Analysis	101/306	103/276	0.78	0.59; 1.04	0.105




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	34/153	56/150	0.39	0.25; 0.61	<0.001
ASC4START	53/237	72/247	0.65	0.45; 0.93	0.020
Pooled Analysis	87/390	128/397	0.53	0.40; 0.70	<0.001
65 - < 75 years					
ASC4FIRST	4/34	14/29	0.14	0.03; 0.69	0.005
ASC4START	6/38	7/24	0.19	0.05; 0.69	0.015
Pooled Analysis	10/72	21/53	0.18	0.07; 0.47	<0.001
>= 75 years					
ASC4FIRST	2/10	5/14	0.35	0.03; 3.54	0.212
ASC4START	2/9	1/13	0.71	0.04; 11.79	0.695
Pooled Analysis	4/19	6/27	0.46	0.08; 2.62	0.214




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	4/20	0.51	0.09; 2.88	0.363
ASC4START	12/38	8/37	0.79	0.32; 1.94	0.887
Pooled Analysis	14/61	12/57	0.73	0.33; 1.60	0.568
Intermediate					
ASC4FIRST	11/54	25/53	0.27	0.13; 0.55	<0.001
ASC4START	13/75	22/75	0.38	0.19; 0.78	0.006
Pooled Analysis	24/129	47/128	0.32	0.19; 0.53	<0.001
Low					
ASC4FIRST	27/120	46/120	0.43	0.27; 0.70	<0.001
ASC4START	36/171	50/172	0.65	0.42; 1.00	0.056
Pooled Analysis	63/291	96/292	0.54	0.39; 0.75	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	12/64	20/62	0.39	0.18; 0.87	0.005
ASC4START	31/138	45/141	0.51	0.32; 0.82	0.004
Pooled Analysis	43/202	65/203	0.47	0.32; 0.71	<0.001
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	9/72	9/53	0.60	0.22; 1.62	0.273
Pooled Analysis	9/91	9/68	0.60	0.22; 1.62	0.273
Others					
ASC4FIRST	28/114	55/116	0.38	0.24; 0.60	<0.001
ASC4START	21/74	26/90	0.79	0.44; 1.42	0.492
Pooled Analysis	49/188	81/206	0.50	0.35; 0.72	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	9/41	13/42	0.49	0.20; 1.20	0.156
Pooled Analysis	9/41	13/42	0.49	0.20; 1.20	0.156
Imatinib					
ASC4FIRST	17/101	45/102	0.25	0.14; 0.44	<0.001
Pooled Analysis	17/101	45/102	0.25	0.14; 0.44	<0.001
Nilotinib					
ASC4FIRST	14/55	17/49	0.69	0.33; 1.44	0.475
ASC4START	61/284	80/284	0.60	0.43; 0.84	0.003
Pooled Analysis	75/339	97/333	0.62	0.46; 0.84	0.003




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	13/40	17/46	0.70	0.34; 1.46	0.382
Pooled Analysis	40/128	65/132	0.45	0.30; 0.68	<0.001
Asian/Others					
ASC4FIRST	28/91	48/90	0.39	0.24; 0.63	<0.001
Others					
ASC4START	2/17	4/21	0.52	0.07; 3.86	0.596
Pooled Analysis	3/20	4/25	0.52	0.07; 3.86	0.596
White					
ASC4FIRST	12/106	27/103	0.39	0.19; 0.83	0.003
ASC4START	46/227	59/217	0.58	0.39; 0.86	0.007
Pooled Analysis	58/333	86/320	0.53	0.37; 0.75	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	15/68	31/75	0.43	0.22; 0.86	0.006
ASC4START	31/107	41/126	0.57	0.35; 0.93	0.047
Pooled Analysis	46/175	72/201	0.53	0.36; 0.78	0.001
Male					
ASC4FIRST	25/129	44/118	0.36	0.22; 0.60	<0.001
ASC4START	30/177	39/158	0.64	0.39; 1.03	0.050
Pooled Analysis	55/306	83/276	0.49	0.35; 0.69	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Rash - Presence/Absence (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	48/153	50/150	0.68	0.45; 1.02	0.061
ASC4START	71/237	81/247	0.57	0.41; 0.79	0.019
Pooled Analysis	119/390	131/397	0.61	0.47; 0.79	0.003
65 - < 75 years					
ASC4FIRST	7/34	12/29	0.71	0.24; 2.05	0.400
ASC4START	7/38	7/24	0.52	0.18; 1.51	0.227
Pooled Analysis	14/72	19/53	0.60	0.28; 1.30	0.149
>= 75 years					
ASC4FIRST	3/10	4/14	1.00	0.13; 7.51	0.946
ASC4START	2/9	2/13	0.13	0.00; 5.13	0.039
Pooled Analysis	5/19	6/27	0.43	0.08; 2.44	0.276




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Rash - Presence/Absence (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	4/20	0.30	0.05; 1.84	0.133
ASC4START	13/38	11/37	0.38	0.16; 0.86	0.073
Pooled Analysis	15/61	15/57	0.36	0.17; 0.77	0.022
Intermediate					
ASC4FIRST	19/54	17/53	1.01	0.52; 1.98	0.861
ASC4START	19/75	28/75	0.42	0.23; 0.75	0.003
Pooled Analysis	38/129	45/128	0.61	0.39; 0.95	0.019
Low					
ASC4FIRST	37/120	45/120	0.66	0.43; 1.03	0.059
ASC4START	48/171	51/172	0.72	0.49; 1.07	0.489
Pooled Analysis	85/291	96/292	0.70	0.52; 0.93	0.076




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Rash - Presence/Absence (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	16/64	15/62	0.70	0.32; 1.50	0.232
ASC4START	44/138	47/141	0.60	0.40; 0.92	0.136
Pooled Analysis	60/202	62/203	0.62	0.43; 0.90	0.060
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	10/72	10/53	0.47	0.18; 1.22	0.074
Pooled Analysis	10/91	10/68	0.47	0.18; 1.22	0.074
Others					
ASC4FIRST	42/114	51/116	0.75	0.49; 1.13	0.136
ASC4START	26/74	33/90	0.49	0.28; 0.85	0.056
Pooled Analysis	68/188	84/206	0.64	0.46; 0.89	0.019




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Rash - Presence/Absence (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	12/41	15/42	0.59	0.26; 1.38	0.240
Pooled Analysis	12/41	15/42	0.59	0.26; 1.38	0.240
Imatinib					
ASC4FIRST	29/101	30/102	0.84	0.50; 1.42	0.388
Pooled Analysis	29/101	30/102	0.84	0.50; 1.42	0.388
Nilotinib					
ASC4FIRST	17/55	21/49	0.58	0.30; 1.13	0.132
ASC4START	80/284	90/284	0.57	0.42; 0.77	0.007
Pooled Analysis	97/339	111/333	0.57	0.43; 0.76	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Rash - Presence/Absence (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	14/40	19/46	0.41	0.20; 0.86	0.103
Pooled Analysis	55/128	65/132	0.60	0.42; 0.88	0.026
Asian/Others					
ASC4FIRST	42/91	46/90	0.70	0.45; 1.07	0.120
Others					
ASC4START	2/17	6/21	0.57	0.10; 3.22	0.223
Pooled Analysis	3/20	6/25	0.57	0.10; 3.22	0.223
White					
ASC4FIRST	16/106	20/103	0.74	0.35; 1.55	0.193
ASC4START	64/227	65/217	0.62	0.44; 0.88	0.052
Pooled Analysis	80/333	85/320	0.64	0.47; 0.88	0.020




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Rash - Presence/Absence (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	19/68	26/75	0.52	0.27; 1.00	0.085
ASC4START	41/107	41/126	0.79	0.51; 1.24	0.810
Pooled Analysis	60/175	67/201	0.69	0.48; 1.00	0.234
Male					
ASC4FIRST	39/129	40/118	0.83	0.52; 1.30	0.243
ASC4START	39/177	49/158	0.47	0.31; 0.72	0.001
Pooled Analysis	78/306	89/276	0.61	0.45; 0.83	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	18/153	33/150	0.40	0.22; 0.71	0.001
ASC4START	21/237	44/247	0.40	0.24; 0.68	<0.001
Pooled Analysis	39/390	77/397	0.40	0.27; 0.59	<0.001
65 - < 75 years					
ASC4FIRST	2/34	7/29	0.17	0.02; 1.44	0.068
ASC4START	2/38	3/24	0.32	0.05; 2.09	0.201
Pooled Analysis	4/72	10/53	0.24	0.06; 0.93	0.026
>= 75 years					
ASC4FIRST	2/10	5/14	0.19	0.02; 1.83	0.116
ASC4START	1/9	0/13	2.99	0.03; 275.43	0.317
Pooled Analysis	3/19	5/27	0.42	0.07; 2.41	0.317




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	2/20	1.03	0.14; 7.68	0.764
ASC4START	3/38	6/37	0.28	0.07; 1.21	0.067
Pooled Analysis	5/61	8/57	0.47	0.15; 1.48	0.173
Intermediate					
ASC4FIRST	9/54	19/53	0.32	0.14; 0.71	0.004
ASC4START	7/75	10/75	0.45	0.16; 1.24	0.186
Pooled Analysis	16/129	29/128	0.37	0.20; 0.69	0.002
Low					
ASC4FIRST	11/120	24/120	0.35	0.17; 0.71	0.003
ASC4START	14/171	31/172	0.40	0.21; 0.76	0.004
Pooled Analysis	25/291	55/292	0.38	0.23; 0.61	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	6/64	11/62	0.32	0.11; 0.94	0.029
ASC4START	11/138	21/141	0.44	0.21; 0.91	0.024
Pooled Analysis	17/202	32/203	0.39	0.21; 0.72	0.002
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	1/72	1/53	0.55	0.03; 8.78	0.666
Pooled Analysis	1/91	1/68	0.55	0.03; 8.78	0.666
Others					
ASC4FIRST	16/114	34/116	0.38	0.21; 0.70	0.001
ASC4START	12/74	25/90	0.38	0.19; 0.79	0.006
Pooled Analysis	28/188	59/206	0.38	0.24; 0.61	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	5/41	6/42	0.82	0.25; 2.69	0.740
Pooled Analysis	5/41	6/42	0.82	0.25; 2.69	0.740
Imatinib					
ASC4FIRST	10/101	29/102	0.26	0.13; 0.54	<0.001
Pooled Analysis	10/101	29/102	0.26	0.13; 0.54	<0.001
Nilotinib					
ASC4FIRST	7/55	10/49	0.49	0.18; 1.35	0.180
ASC4START	24/284	47/284	0.42	0.25; 0.68	<0.001
Pooled Analysis	31/339	57/333	0.43	0.28; 0.67	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	7/40	14/46	0.45	0.18; 1.13	0.077
Pooled Analysis	23/128	45/132	0.40	0.24; 0.66	<0.001
Asian/Others					
ASC4FIRST	17/91	31/90	0.39	0.21; 0.72	0.002
Others					
ASC4START	1/17	5/21	0.87	0.05; 13.95	0.857
Pooled Analysis	2/20	5/25	0.87	0.05; 13.95	0.857
White					
ASC4FIRST	5/106	14/103	0.28	0.09; 0.88	0.022
ASC4START	16/227	28/217	0.45	0.24; 0.84	0.011
Pooled Analysis	21/333	42/320	0.40	0.24; 0.69	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	8/68	18/75	0.41	0.17; 0.99	0.033
ASC4START	12/107	29/126	0.34	0.17; 0.68	0.001
Pooled Analysis	20/175	47/201	0.36	0.21; 0.62	<0.001
Male					
ASC4FIRST	14/129	27/118	0.37	0.19; 0.72	0.003
ASC4START	12/177	18/158	0.54	0.26; 1.13	0.095
Pooled Analysis	26/306	45/276	0.44	0.27; 0.72	<0.001



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-2.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Fatigue - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.844)								
Low	96/291 (33.0)	2.3 [1.0; 7.5]	105/292 (36.0)	1.7 [1.0; 3.3]	0.86	[0.65; 1.14]	0.551	0.263
Intermediate	50/129 (38.8)	3.0 [1.0; 15.7]	49/128 (38.3)	2.8 [0.7; 6.0]	0.82	[0.55; 1.22]	0.316	0.416
High	16/61 (26.2)	N.E. [3.5; N.E.]	13/57 (22.8)	11.0 [0.5; N.E.]	0.67	[0.31; 1.42]	0.351	0.970
Sex								
(Interaction test: p = 0.362)								
Female	58/175	4.9 [1.0; 13.8]	73/201	2.1 [1.0; 3.9]	0.78	[0.54; 1.12]	0.350	0.180

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(33.1)		(36.3)					
Male	104/306	3.0 [1.7; 10.2]	94/276	2.1 [1.0; 5.6]	0.92	[0.69; 1.23]	0.720	0.760
	(34.0)		(34.1)					
Race								
(Interaction test: p = 0.337)								
Asian	61/128	2.8 [1.0; 22.1]	68/132	2.1 [0.7; 5.6]	0.82	[0.57; 1.17]	0.232	0.880
	(47.7)		(51.5)					
White	94/333	4.9 [1.6; 11.1]	96/320	1.9 [1.0; 3.5]	0.77	[0.57; 1.03]	0.179	0.390
	(28.2)		(30.0)					
Others	7/20	1.2 [0.3; N.E.]	3/25	N.E. [0.3; N.E.]	0.39	[0.01; 11.08]	0.148	N.E.
	(35.0)		(12.0)					
Age groups								
(Interaction test: p = 0.302)								
18 - < 65 years	139/390	2.8 [1.4; 9.0]	137/397	2.8 [1.2; 5.5]	0.88	[0.69; 1.12]	0.696	0.888
	(35.6)		(34.5)					
65 - < 75 years	16/72	17.5 [1.4; N.E.]	24/53	0.7 [0.3; 2.8]	0.65	[0.32; 1.30]	0.099	0.512

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(22.2)		(45.3)					
>= 75 years	7/19	1.0 [0.3; N.E.]	6/27	2.1 [0.3; N.E.]	5.35	[0.57; 50.55]	0.452	0.643
	(36.8)		(22.2)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.359)								
Imatinib	33/101	1.2 [0.5; 13.8]	33/102	1.9 [0.5; 13.8]	1.09	[0.67; 1.78]	0.900	N.E.
	(32.7)		(32.4)					
Nilotinib	115/339	4.6 [2.1; 11.1]	118/333	2.8 [1.0; 4.6]	0.81	[0.62; 1.05]	0.263	0.258
	(33.9)		(35.4)					
Dasatinib	14/41	8.3 [0.3; 26.7]	16/42	0.5 [0.3; 8.3]	0.55	[0.25; 1.24]	0.158	N.E.
	(34.1)		(38.1)					
Geographic region								
(Interaction test: p = 0.626)								
Europe excluding Germany	69/202	3.0 [1.0; 11.2]	71/203	1.7 [1.0; 3.5]	0.77	[0.54; 1.08]	0.264	0.881

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(34.2)		(35.0)					
Germany	16/91	8.3 [0.3; 13.0]	9/68	1.9 [0.3; N.E.]	0.72	[0.28; 1.86]	0.850	N.E.
	(17.6)		(13.2)					
Others	77/188	2.8 [1.4; 17.5]	87/206	2.8 [1.2; 6.5]	0.92	[0.67; 1.26]	0.599	0.271
	(41.0)		(42.2)					
Headache - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.795)								
Low	93/291	2.8 [2.0; 5.6]	109/292	1.8 [1.0; 4.0]	0.74	[0.56; 0.97]	0.117	0.713
	(32.0)		(37.3)					
Intermediate	45/129	2.8 [1.6; N.E.]	46/128	2.3 [0.9; 5.3]	0.85	[0.56; 1.29]	0.378	0.246
	(34.9)		(35.9)					
High	23/61	4.2 [1.9; N.E.]	17/57	2.1 [0.5; 9.3]	0.66	[0.35; 1.25]	0.204	0.610
	(37.7)		(29.8)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.264)								
Female	65/175 (37.1)	2.1 [1.2; 3.5]	71/201 (35.3)	1.8 [0.7; 3.0]	0.89	[0.63; 1.25]	0.665	0.576
Male	96/306 (31.4)	4.4 [2.6; 13.8]	101/276 (36.6)	2.3 [1.1; 5.6]	0.69	[0.52; 0.92]	0.022	0.901
Race								
(Interaction test: p = 0.180)								
Asian	58/128 (45.3)	4.9 [1.8; N.E.]	70/132 (53.0)	2.0 [1.0; 4.2]	0.71	[0.50; 1.01]	0.072	0.507
White	99/333 (29.7)	2.6 [2.0; 4.2]	95/320 (29.7)	1.9 [1.0; 5.1]	0.86	[0.64; 1.15]	0.478	0.505
Others	4/20 (20.0)	13.8 [0.3; N.E.]	7/25 (28.0)	1.8 [0.1; 5.3]	0.22	[0.03; 1.63]	0.094	N.E.
Age groups								
(Interaction test: p = 0.078)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	138/390 (35.4)	2.8 [2.1; 4.9]	150/397 (37.8)	1.6 [1.0; 2.8]	0.74	[0.58; 0.94]	0.039	0.748
65 - < 75 years	17/72 (23.6)	7.5 [1.9; N.E.]	18/53 (34.0)	4.4 [0.5; 19.4]	0.68	[0.32; 1.47]	0.307	0.814
>= 75 years	6/19 (31.6)	1.0 [0.3; N.E.]	4/27 (14.8)	9.3 [0.7; N.E.]	6.87	[0.79; 60.01]	0.119	0.998
Pre-randomization selection of TKI								
(Interaction test: p = 0.381)								
Imatinib	31/101 (30.7)	2.3 [1.6; 16.6]	33/102 (32.4)	2.3 [1.2; 12.9]	1.04	[0.63; 1.71]	0.895	N.E.
Nilotinib	119/339 (35.1)	2.8 [2.1; 5.6]	128/333 (38.4)	1.7 [1.0; 3.3]	0.71	[0.55; 0.92]	0.039	0.877
Dasatinib	11/41 (26.8)	6.4 [1.4; N.E.]	11/42 (26.2)	1.2 [0.3; N.E.]	0.69	[0.28; 1.72]	0.455	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.600)								
Europe excluding Germany	70/202 (34.7)	2.8 [1.9; 7.4]	69/203 (34.0)	1.9 [1.0; 7.4]	0.78	[0.55; 1.10]	0.248	0.282
Germany	16/91 (17.6)	4.4 [2.1; 9.0]	10/68 (14.7)	0.5 [0.3; N.E.]	0.42	[0.15; 1.14]	0.227	N.E.
Others	75/188 (39.9)	2.8 [1.8; 11.0]	93/206 (45.1)	2.1 [1.2; 3.7]	0.78	[0.57; 1.06]	0.129	0.961
Vomiting - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.964)								
Low	24/291 (8.2)	N.E. [N.E.; N.E.]	51/292 (17.5)	N.E. [N.E.; N.E.]	0.40	[0.25; 0.66]	<0.001	0.621
Intermediate	13/129	N.E. [N.E.; N.E.]	27/128	N.E. [6.9; N.E.]	0.34	[0.17; 0.67]	0.001	0.334

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(10.1)		(21.1)					
High	5/61	N.E. [N.E.; N.E.]	7/57	N.E. [3.5; N.E.]	0.61	[0.19; 1.96]	0.387	0.388
	(8.2)		(12.3)					
Sex								
(Interaction test: p = 0.987)								
Female	19/175	N.E. [N.E.; N.E.]	41/201	N.E. [9.2; N.E.]	0.40	[0.23; 0.70]	0.001	0.548
	(10.9)		(20.4)					
Male	23/306	N.E. [N.E.; N.E.]	44/276	N.E. [N.E.; N.E.]	0.40	[0.24; 0.67]	<0.001	0.571
	(7.5)		(15.9)					
Race								
(Interaction test: p = 0.930)								
Asian	19/128	N.E. [N.E.; N.E.]	41/132	N.E. [12.0; N.E.]	0.38	[0.22; 0.66]	<0.001	0.446
	(14.8)		(31.1)					
White	21/333	N.E. [N.E.; N.E.]	40/320	N.E. [N.E.; N.E.]	0.43	[0.25; 0.74]	0.002	0.559
	(6.3)		(12.5)					
Others	2/20	N.E. [0.3; N.E.]	4/25	17.1 [1.2; N.E.]	0.87	[0.05; 13.95]	0.857	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(10.0)		(16.0)					
Age groups								
(Interaction test: p = 0.654)								
18 - < 65 years	36/390	N.E. [N.E.; N.E.]	71/397	N.E. [N.E.; N.E.]	0.41	[0.27; 0.62]	<0.001	0.771
	(9.2)		(17.9)					
65 - < 75 years	3/72	N.E. [N.E.; N.E.]	9/53	N.E. [2.8; N.E.]	0.31	[0.08; 1.21]	0.067	0.396
	(4.2)		(17.0)					
>= 75 years	3/19	22.1 [3.3; N.E.]	5/27	6.9 [1.0; N.E.]	0.42	[0.07; 2.41]	0.317	0.997
	(15.8)		(18.5)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.397)								
Imatinib	9/101	N.E. [N.E.; N.E.]	27/102	5.6 [2.3; N.E.]	0.25	[0.12; 0.54]	<0.001	N.E.
	(8.9)		(26.5)					
Nilotinib	30/339	N.E. [N.E.; N.E.]	52/333	N.E. [N.E.; N.E.]	0.47	[0.30; 0.74]	<0.001	0.733
	(8.8)		(15.6)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	3/41 (7.3)	N.E. [N.E.; N.E.]	6/42 (14.3)	N.E. [3.0; N.E.]	0.43	[0.11; 1.72]	0.217	N.E.
Geographic region (Interaction test: p = 0.912)								
Europe excluding Germany	17/202 (8.4)	N.E. [N.E.; N.E.]	30/203 (14.8)	N.E. [N.E.; N.E.]	0.42	[0.23; 0.78]	0.005	0.725
Germany	1/91 (1.1)	N.E. [N.E.; N.E.]	1/68 (1.5)	N.E. [N.E.; N.E.]	0.55	[0.03; 8.78]	0.666	N.E.
Others	24/188 (12.8)	N.E. [N.E.; N.E.]	54/206 (26.2)	N.E. [12.0; N.E.]	0.37	[0.22; 0.60]	<0.001	0.585
Nausea - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.344)								
Low	62/291	N.E. [11.1; N.E.]	97/292	2.6 [1.4; 7.4]	0.54	[0.39; 0.75]	<0.001	0.221

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(21.3)		(33.2)					
Intermediate	23/129	N.E. [25.8; N.E.]	46/128	3.3 [1.6; 5.5]	0.31	[0.19; 0.52]	<0.001	0.371
	(17.8)		(35.9)					
High	13/61	N.E. [3.7; N.E.]	13/57	4.9 [2.3; N.E.]	0.66	[0.30; 1.45]	0.296	0.720
	(21.3)		(22.8)					
Sex								
(Interaction test: p = 0.674)								
Female	46/175	18.4 [4.2; N.E.]	71/201	1.9 [0.8; 3.3]	0.57	[0.39; 0.84]	0.005	0.443
	(26.3)		(35.3)					
Male	52/306	N.E. [N.E.; N.E.]	85/276	4.6 [2.8; 14.8]	0.46	[0.32; 0.65]	<0.001	0.170
	(17.0)		(30.8)					
Race								
(Interaction test: p = 0.862)								
Asian	37/128	N.E. [18.4; N.E.]	63/132	3.3 [1.8; 5.8]	0.44	[0.29; 0.67]	<0.001	0.210
	(28.9)		(47.7)					
White	58/333	N.E. [22.1; N.E.]	89/320	3.3 [1.6; 7.4]	0.52	[0.37; 0.72]	<0.001	0.329

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(17.4)		(27.8)					
Others	3/20	N.E. [0.3; N.E.]	4/25	18.4 [0.3; N.E.]	0.50	[0.07; 3.76]	0.648	N.E.
	(15.0)		(16.0)					
Age groups								
(Interaction test: p = 0.151)								
18 - < 65 years	85/390	N.E. [25.8; N.E.]	130/397	3.5 [2.3; 5.6]	0.52	[0.39; 0.68]	<0.001	0.180
	(21.8)		(32.7)					
65 - < 75 years	7/72	N.E. [N.E.; N.E.]	20/53	2.3 [0.9; 10.2]	0.15	[0.05; 0.43]	<0.001	0.309
	(9.7)		(37.7)					
>= 75 years	6/19	3.5 [0.5; N.E.]	6/27	1.2 [0.3; N.E.]	0.32	[0.05; 1.98]	0.214	0.627
	(31.6)		(22.2)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.014)								
Imatinib	17/101	N.E. [15.7; N.E.]	44/102	1.0 [0.5; 1.6]	0.26	[0.14; 0.46]	<0.001	N.E.
	(16.8)		(43.1)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Nilotinib	74/339 (21.8)	N.E. [22.1; N.E.]	99/333 (29.7)	5.6 [3.3; 18.4]	0.63	[0.46; 0.85]	0.002	0.352
Dasatinib	7/41 (17.1)	N.E. [1.4; N.E.]	13/42 (31.0)	1.9 [0.5; 28.6]	0.34	[0.13; 0.91]	0.035	N.E.
Geographic region (Interaction test: p = 0.849)								
Europe excluding Germany	42/202 (20.8)	N.E. [22.1; N.E.]	67/203 (33.0)	2.3 [1.2; 7.4]	0.44	[0.30; 0.67]	<0.001	0.562
Germany	9/91 (9.9)	N.E. [2.3; N.E.]	10/68 (14.7)	3.3 [0.3; N.E.]	0.56	[0.22; 1.44]	0.246	N.E.
Others	47/188 (25.0)	N.E. [18.4; N.E.]	79/206 (38.3)	3.5 [2.1; 5.8]	0.50	[0.34; 0.72]	<0.001	0.040
Edema - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.534)								
Low	53/291 (18.2)	N.E. [24.9; N.E.]	71/292 (24.3)	16.6 [10.2; N.E.]	0.65	[0.45; 0.93]	0.019	0.040
Intermediate	25/129 (19.4)	N.E. [22.1; N.E.]	39/128 (30.5)	4.9 [2.0; N.E.]	0.47	[0.28; 0.78]	0.002	0.029
High	11/61 (18.0)	N.E. [16.6; N.E.]	10/57 (17.5)	N.E. [1.7; N.E.]	0.60	[0.25; 1.44]	0.270	0.405
Sex								
(Interaction test: p = 0.348)								
Female	42/175 (24.0)	24.9 [5.6; N.E.]	63/201 (31.3)	3.7 [1.5; 10.2]	0.55	[0.36; 0.82]	0.004	0.001
Male	47/306 (15.4)	N.E. [N.E.; N.E.]	57/276 (20.7)	N.E. [22.1; N.E.]	0.67	[0.46; 1.00]	0.051	0.142
Race								
(Interaction test: p = 0.088)								
Asian	36/128	N.E. [N.E.; N.E.]	62/132	2.2 [1.4; 10.2]	0.42	[0.28; 0.64]	<0.001	0.467

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(28.1)		(47.0)					
White	48/333	N.E. [24.9; N.E.]	54/320	N.E. [13.8; N.E.]	0.75	[0.51; 1.12]	0.157	0.010
	(14.4)		(16.9)					
Others	5/20	11.1 [0.3; N.E.]	4/25	7.4 [0.3; N.E.]	0.92	[0.21; 3.97]	0.834	N.E.
	(25.0)		(16.0)					
Age groups								
(Interaction test: p = 0.115)								
18 - < 65 years	75/390	N.E. [N.E.; N.E.]	96/397	22.1 [11.1; N.E.]	0.62	[0.45; 0.84]	0.003	0.005
	(19.2)		(24.2)					
65 - < 75 years	10/72	N.E. [5.6; N.E.]	19/53	1.2 [0.5; 10.2]	0.29	[0.12; 0.67]	0.004	0.116
	(13.9)		(35.8)					
>= 75 years	4/19	N.E. [0.3; N.E.]	5/27	3.7 [0.5; N.E.]	0.75	[0.16; 3.47]	0.699	0.997
	(21.1)		(18.5)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.004)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Imatinib	16/101 (15.8)	N.E. [24.9; N.E.]	41/102 (40.2)	1.6 [1.0; 2.2]	0.25	[0.14; 0.44]	<0.001	N.E.
Nilotinib	67/339 (19.8)	N.E. [22.1; N.E.]	69/333 (20.7)	N.E. [22.1; N.E.]	0.87	[0.62; 1.22]	0.419	0.850
Dasatinib	6/41 (14.6)	N.E. [2.9; N.E.]	10/42 (23.8)	2.1 [0.3; N.E.]	0.31	[0.10; 0.97]	0.115	N.E.
Geographic region (Interaction test: p = 0.937)								
Europe excluding Germany	34/202 (16.8)	N.E. [N.E.; N.E.]	43/203 (21.2)	N.E. [11.1; N.E.]	0.61	[0.39; 0.97]	0.034	0.020
Germany	7/91 (7.7)	22.1 [9.2; N.E.]	6/68 (8.8)	N.E. [1.8; N.E.]	0.68	[0.21; 2.20]	0.677	N.E.
Others	48/188 (25.5)	N.E. [19.4; N.E.]	71/206 (34.5)	5.6 [2.0; N.E.]	0.55	[0.38; 0.81]	0.002	0.026

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Muscle Pain - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.593)								
Low	88/291 (30.2)	3.0 [1.2; 9.2]	118/292 (40.4)	1.0 [0.5; 1.4]	0.65	[0.49; 0.86]	<0.001	0.276
Intermediate	46/129 (35.7)	2.1 [1.2; 14.8]	51/128 (39.8)	1.0 [0.5; 3.0]	0.75	[0.50; 1.13]	0.149	0.086
High	16/61 (26.2)	N.E. [1.0; N.E.]	17/57 (29.8)	1.6 [0.5; 2.8]	0.58	[0.29; 1.16]	0.103	0.630
Sex								
(Interaction test: p = 0.623)								
Female	58/175 (33.1)	1.2 [0.6; 5.6]	82/201 (40.8)	1.0 [0.7; 1.4]	0.73	[0.52; 1.03]	0.027	0.805
Male	92/306	6.2 [2.3; 19.4]	104/276	1.0 [0.5; 2.8]	0.66	[0.50; 0.88]	0.004	0.040

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(30.1)		(37.7)					
Race								
(Interaction test: p = 0.225)								
Asian	54/128	9.2 [1.9; N.E.]	83/132	0.8 [0.5; 1.4]	0.52	[0.37; 0.75]	<0.001	0.759
	(42.2)		(62.9)					
White	89/333	2.1 [1.2; 5.6]	97/320	1.2 [0.6; 2.6]	0.78	[0.59; 1.05]	0.087	0.224
	(26.7)		(30.3)					
Others	7/20	0.5 [0.3; N.E.]	6/25	3.8 [0.3; N.E.]	1.49	[0.25; 8.73]	0.761	N.E.
	(35.0)		(24.0)					
Age groups								
(Interaction test: p = 0.418)								
18 - < 65 years	124/390	4.4 [1.9; 12.0]	157/397	0.8 [0.5; 1.4]	0.64	[0.51; 0.82]	<0.001	0.052
	(31.8)		(39.5)					
65 - < 75 years	18/72	4.4 [0.7; N.E.]	22/53	2.1 [0.6; 2.8]	0.53	[0.25; 1.12]	0.066	0.584
	(25.0)		(41.5)					
>= 75 years	8/19	1.0 [0.3; 2.1]	7/27	1.0 [0.3; 15.7]	1.65	[0.43; 6.29]	0.356	0.570

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(42.1)		(25.9)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.121)								
Imatinib	26/101	14.8 [1.0; N.E.]	45/102	0.6 [0.5; 1.0]	0.47	[0.28; 0.76]	<0.001	N.E.
	(25.7)		(44.1)					
Nilotinib	115/339	2.4 [1.4; 6.2]	127/333	1.4 [0.7; 2.8]	0.77	[0.60; 1.00]	0.039	0.607
	(33.9)		(38.1)					
Dasatinib	9/41	N.E. [0.3; N.E.]	14/42	1.0 [0.3; 2.3]	0.35	[0.13; 0.96]	0.030	N.E.
	(22.0)		(33.3)					
Geographic region								
(Interaction test: p = 0.513)								
Europe excluding Germany	64/202	2.3 [1.2; N.E.]	69/203	1.4 [0.7; 3.1]	0.80	[0.56; 1.13]	0.197	0.288
	(31.7)		(34.0)					
Germany	13/91	2.2 [0.5; N.E.]	11/68	0.4 [0.3; 5.5]	0.66	[0.28; 1.55]	0.304	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(14.3)		(16.2)					
Others	73/188	5.2 [1.4; 15.7]	106/206	0.9 [0.5; 1.4]	0.61	[0.45; 0.82]	<0.001	0.235
	(38.8)		(51.5)					
Pruritus - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.380)								
Low	92/291	3.9 [2.2; 7.4]	116/292	2.1 [1.2; 3.0]	0.69	[0.53; 0.91]	0.011	0.375
	(31.6)		(39.7)					
Intermediate	42/129	5.6 [2.6; N.E.]	45/128	3.1 [2.1; 16.7]	0.73	[0.47; 1.13]	0.193	0.077
	(32.6)		(35.2)					
High	18/61	N.E. [1.4; N.E.]	18/57	2.1 [0.7; 5.3]	0.45	[0.23; 0.87]	0.019	0.105
	(29.5)		(31.6)					
Sex								
(Interaction test: p = 0.891)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Female	59/175 (33.7)	3.0 [1.6; 5.6]	77/201 (38.3)	1.9 [0.8; 2.8]	0.69	[0.48; 0.98]	0.026	0.127
Male	93/306 (30.4)	6.1 [3.5; 22.1]	102/276 (37.0)	2.8 [1.9; 5.6]	0.65	[0.48; 0.87]	0.011	0.193
Race								
(Interaction test: p = 0.939)								
Asian	52/128 (40.6)	8.3 [2.8; N.E.]	68/132 (51.5)	2.8 [1.4; 5.6]	0.65	[0.45; 0.94]	0.033	0.081
White	92/333 (27.6)	4.0 [2.2; 7.4]	103/320 (32.2)	2.1 [1.2; 3.3]	0.68	[0.50; 0.90]	0.009	0.197
Others	8/20 (40.0)	1.9 [0.3; 5.6]	8/25 (32.0)	0.8 [0.3; 2.6]	0.76	[0.19; 2.97]	0.597	N.E.
Age groups								
(Interaction test: p = 0.998)								
18 - < 65 years	127/390 (32.6)	5.3 [3.0; 8.3]	151/397 (38.0)	2.3 [1.4; 3.3]	0.65	[0.51; 0.83]	0.001	0.257


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
65 - < 75 years	18/72 (25.0)	4.6 [1.6; N.E.]	20/53 (37.7)	3.0 [1.2; 5.6]	0.78	[0.37; 1.61]	0.494	0.026
>= 75 years	7/19 (36.8)	1.4 [0.5; N.E.]	8/27 (29.6)	2.1 [0.5; 3.7]	1.08	[0.25; 4.72]	0.808	0.995
Pre-randomization selection of TKI								
(Interaction test: p = 0.006)								
Imatinib	32/101 (31.7)	2.8 [1.2; 10.2]	31/102 (30.4)	5.6 [2.8; 24.0]	1.47	[0.88; 2.46]	0.439	N.E.
Nilotinib	108/339 (31.9)	5.3 [3.0; 19.4]	137/333 (41.1)	1.9 [1.0; 2.6]	0.55	[0.42; 0.71]	<0.001	0.738
Dasatinib	12/41 (29.3)	3.7 [0.5; N.E.]	11/42 (26.2)	1.4 [0.3; N.E.]	0.78	[0.32; 1.90]	0.636	N.E.
Geographic region								
(Interaction test: p = 0.144)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Europe excluding Germany	69/202 (34.2)	3.9 [1.9; 7.4]	76/203 (37.4)	2.3 [1.2; 3.5]	0.70	[0.50; 0.99]	0.043	0.046
Germany	12/91 (13.2)	19.4 [1.2; N.E.]	12/68 (17.6)	0.7 [0.3; 2.0]	0.39	[0.16; 0.96]	0.033	N.E.
Others	71/188 (37.8)	5.8 [2.8; 22.1]	91/206 (44.2)	2.8 [1.8; 5.5]	0.73	[0.53; 1.01]	0.045	0.456

MID: Minimally important difference
N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not more than 10 events per subgroup per treatment arm, no subgroup analyses were performed for the corresponding attribute.
If there are not more than 10 events per subgroup per treatment arm, no Cox PH hazard analysis is carried out.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline PRO score.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT) and Pre-Randomization selection TKI (IRT).
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Nausea - Severity (MID=1): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	101 (0)	31 (55)	27 (58)	25 (59)	14 (70)	3 (81)	0 (84)
Investigator Selected TKI	102 (0)	10 (49)	6 (52)	6 (52)	3 (55)	0 (58)	0 (58)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Nausea - Severity (MID=1): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	115 (164)	61 (208)	32 (235)	17 (249)	3 (262)	0 (265)
Investigator Selected TKI	333 (0)	79 (167)	48 (192)	28 (210)	7 (228)	2 (232)	0 (234)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Nausea - Severity (MID=1): Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Severity (MID=1): Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Severity (MID=1): Pre-randomization selection of TKI: Nilotinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Severity (MID=1): Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Pruritus - Severity (MID=1): Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Pruritus - Severity (MID=1): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	83 (159)	45 (189)	27 (207)	13 (218)	3 (228)	0 (231)
Investigator Selected TKI	333 (0)	52 (164)	26 (177)	13 (186)	3 (193)	1 (195)	0 (196)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Pruritus - Severity (MID=1): Pre-randomization selection of TKI: Dasatinib




Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	27/153	47/150	0.37	0.22; 0.60	<0.001
ASC4START	48/237	49/247	0.90	0.60; 1.35	0.664
Pooled Analysis	75/390	96/397	0.62	0.45; 0.84	0.003
65 - < 75 years					
ASC4FIRST	3/34	14/29	0.12	0.03; 0.56	0.001
ASC4START	7/38	5/24	0.59	0.18; 2.01	0.402
Pooled Analysis	10/72	19/53	0.29	0.12; 0.67	0.004
>= 75 years					
ASC4FIRST	4/10	4/14	1.33	0.21; 8.37	0.933
ASC4START	0/9	1/13	0.57	0.00; 107.73	0.221
Pooled Analysis	4/19	5/27	0.75	0.16; 3.47	0.699




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	3/20	0.15	0.01; 2.32	0.116
ASC4START	10/38	7/37	0.71	0.27; 1.87	0.642
Pooled Analysis	11/61	10/57	0.60	0.25; 1.44	0.270
Intermediate					
ASC4FIRST	11/54	25/53	0.27	0.13; 0.56	<0.001
ASC4START	14/75	14/75	0.90	0.43; 1.88	0.634
Pooled Analysis	25/129	39/128	0.47	0.28; 0.78	0.002
Low					
ASC4FIRST	22/120	37/120	0.43	0.25; 0.74	0.002
ASC4START	31/171	34/172	0.93	0.57; 1.51	0.758
Pooled Analysis	53/291	71/292	0.65	0.45; 0.93	0.019




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	8/64	16/62	0.25	0.10; 0.61	0.002
ASC4START	26/138	27/141	0.87	0.51; 1.51	0.621
Pooled Analysis	34/202	43/203	0.61	0.39; 0.97	0.034
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	7/72	6/53	0.68	0.21; 2.20	0.677
Pooled Analysis	7/91	6/68	0.68	0.21; 2.20	0.677
Others					
ASC4FIRST	26/114	49/116	0.39	0.24; 0.64	<0.001
ASC4START	22/74	22/90	0.94	0.52; 1.73	0.928
Pooled Analysis	48/188	71/206	0.55	0.38; 0.81	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	6/41	10/42	0.31	0.10; 0.97	0.115
Pooled Analysis	6/41	10/42	0.31	0.10; 0.97	0.115
Imatinib					
ASC4FIRST	16/101	41/102	0.25	0.14; 0.44	<0.001
Pooled Analysis	16/101	41/102	0.25	0.14; 0.44	<0.001
Nilotinib					
ASC4FIRST	12/55	14/49	0.91	0.41; 2.01	0.612
ASC4START	55/284	55/284	0.88	0.60; 1.28	0.512
Pooled Analysis	67/339	69/333	0.87	0.62; 1.22	0.419




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	11/40	17/46	0.54	0.25; 1.17	0.118
Pooled Analysis	36/128	62/132	0.42	0.28; 0.64	<0.001
Asian/Others					
ASC4FIRST	26/91	45/90	0.40	0.24; 0.65	<0.001
Others					
ASC4START	4/17	4/21	0.92	0.21; 3.97	0.834
Pooled Analysis	5/20	4/25	0.92	0.21; 3.97	0.834
White					
ASC4FIRST	8/106	20/103	0.29	0.12; 0.67	0.003
ASC4START	40/227	34/217	1.03	0.65; 1.64	0.920
Pooled Analysis	48/333	54/320	0.75	0.51; 1.12	0.157




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	11/68	30/75	0.21	0.10; 0.45	<0.001
ASC4START	31/107	33/126	0.91	0.55; 1.51	0.789
Pooled Analysis	42/175	63/201	0.55	0.36; 0.82	0.004
Male					
ASC4FIRST	23/129	35/118	0.52	0.30; 0.89	0.016
ASC4START	24/177	22/158	0.93	0.52; 1.67	0.785
Pooled Analysis	47/306	57/276	0.67	0.46; 1.00	0.051




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	53/153	48/150	0.85	0.57; 1.27	0.669
ASC4START	86/237	89/247	0.89	0.66; 1.20	0.863
Pooled Analysis	139/390	137/397	0.88	0.69; 1.12	0.696
65 - < 75 years					
ASC4FIRST	7/34	16/29	0.52	0.20; 1.39	0.091
ASC4START	9/38	8/24	0.83	0.30; 2.32	0.570
Pooled Analysis	16/72	24/53	0.65	0.32; 1.30	0.099
>= 75 years					
ASC4FIRST	3/10	5/14	5.48	0.49; 60.90	0.579
ASC4START	4/9	1/13	1.25	0.08; 19.72	0.610
Pooled Analysis	7/19	6/27	5.35	0.57; 50.55	0.452




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	4/20	0.65	0.12; 3.44	0.306
ASC4START	13/38	9/37	0.67	0.28; 1.59	0.609
Pooled Analysis	16/61	13/57	0.67	0.31; 1.42	0.351
Intermediate					
ASC4FIRST	24/54	22/53	0.95	0.52; 1.74	0.930
ASC4START	26/75	27/75	0.70	0.41; 1.21	0.155
Pooled Analysis	50/129	49/128	0.82	0.55; 1.22	0.316
Low					
ASC4FIRST	36/120	43/120	0.71	0.45; 1.11	0.142
ASC4START	60/171	62/172	0.98	0.69; 1.41	0.692
Pooled Analysis	96/291	105/292	0.86	0.65; 1.14	0.551




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	20/64	17/62	0.79	0.39; 1.58	0.683
ASC4START	49/138	54/141	0.76	0.51; 1.13	0.292
Pooled Analysis	69/202	71/203	0.77	0.54; 1.08	0.264
Germany					
ASC4FIRST	1/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	15/72	9/53	0.72	0.28; 1.86	0.850
Pooled Analysis	16/91	9/68	0.72	0.28; 1.86	0.850
Others					
ASC4FIRST	42/114	52/116	0.79	0.52; 1.20	0.231
ASC4START	35/74	35/90	1.13	0.69; 1.83	0.568
Pooled Analysis	77/188	87/206	0.92	0.67; 1.26	0.599




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	14/41	16/42	0.55	0.25; 1.24	0.158
Pooled Analysis	14/41	16/42	0.55	0.25; 1.24	0.158
Imatinib					
ASC4FIRST	33/101	33/102	1.09	0.67; 1.78	0.900
Pooled Analysis	33/101	33/102	1.09	0.67; 1.78	0.900
Nilotinib					
ASC4FIRST	16/55	20/49	0.55	0.28; 1.11	0.131
ASC4START	99/284	98/284	0.86	0.65; 1.14	0.554
Pooled Analysis	115/339	118/333	0.81	0.62; 1.05	0.263




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	20/40	23/46	0.75	0.40; 1.41	0.681
Pooled Analysis	61/128	68/132	0.82	0.57; 1.17	0.232
Asian/Others					
ASC4FIRST	43/91	45/90	0.85	0.55; 1.31	0.294
Others					
ASC4START	5/17	3/21	0.39	0.01; 11.08	0.148
Pooled Analysis	7/20	3/25	0.39	0.01; 11.08	0.148
White					
ASC4FIRST	20/106	24/103	0.56	0.29; 1.09	0.255
ASC4START	74/227	72/217	0.83	0.59; 1.15	0.353
Pooled Analysis	94/333	96/320	0.77	0.57; 1.03	0.179




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	16/68	28/75	0.53	0.27; 1.05	0.072
ASC4START	42/107	45/126	0.93	0.60; 1.45	0.961
Pooled Analysis	58/175	73/201	0.78	0.54; 1.12	0.350
Male					
ASC4FIRST	47/129	41/118	0.97	0.63; 1.50	0.956
ASC4START	57/177	53/158	0.89	0.61; 1.30	0.603
Pooled Analysis	104/306	94/276	0.92	0.69; 1.23	0.720




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	56/153	55/150	0.79	0.54; 1.16	0.360
ASC4START	82/237	95/247	0.71	0.53; 0.97	0.057
Pooled Analysis	138/390	150/397	0.74	0.58; 0.94	0.039
65 - < 75 years					
ASC4FIRST	6/34	10/29	0.85	0.27; 2.70	0.337
ASC4START	11/38	8/24	0.69	0.24; 1.99	0.623
Pooled Analysis	17/72	18/53	0.68	0.32; 1.47	0.307
>= 75 years					
ASC4FIRST	2/10	2/14	3.41	0.29; 39.81	0.364
ASC4START	4/9	2/13	5.48	0.29; 104.41	0.202
Pooled Analysis	6/19	4/27	6.87	0.79; 60.01	0.119




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	6/23	4/20	0.92	0.24; 3.55	0.752
ASC4START	17/38	13/37	0.60	0.29; 1.25	0.201
Pooled Analysis	23/61	17/57	0.66	0.35; 1.25	0.204
Intermediate					
ASC4FIRST	22/54	19/53	1.13	0.60; 2.13	0.843
ASC4START	23/75	27/75	0.68	0.39; 1.19	0.174
Pooled Analysis	45/129	46/128	0.85	0.56; 1.29	0.378
Low					
ASC4FIRST	36/120	44/120	0.69	0.44; 1.08	0.220
ASC4START	57/171	65/172	0.77	0.54; 1.10	0.305
Pooled Analysis	93/291	109/292	0.74	0.56; 0.97	0.117




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	21/64	16/62	1.07	0.52; 2.19	0.797
ASC4START	49/138	53/141	0.70	0.47; 1.04	0.238
Pooled Analysis	70/202	69/203	0.78	0.55; 1.10	0.248
Germany					
ASC4FIRST	1/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	15/72	10/53	0.42	0.15; 1.14	0.227
Pooled Analysis	16/91	10/68	0.42	0.15; 1.14	0.227
Others					
ASC4FIRST	42/114	51/116	0.76	0.50; 1.15	0.324
ASC4START	33/74	42/90	0.78	0.49; 1.23	0.241
Pooled Analysis	75/188	93/206	0.78	0.57; 1.06	0.129




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	11/41	11/42	0.69	0.28; 1.72	0.455
Pooled Analysis	11/41	11/42	0.69	0.28; 1.72	0.455
Imatinib					
ASC4FIRST	31/101	33/102	1.04	0.63; 1.71	0.895
Pooled Analysis	31/101	33/102	1.04	0.63; 1.71	0.895
Nilotinib					
ASC4FIRST	22/55	23/49	0.69	0.37; 1.30	0.490
ASC4START	97/284	105/284	0.72	0.54; 0.95	0.051
Pooled Analysis	119/339	128/333	0.71	0.55; 0.92	0.039




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	18/40	27/46	0.60	0.32; 1.09	0.084
Pooled Analysis	58/128	70/132	0.71	0.50; 1.01	0.072
Asian/Others					
ASC4FIRST	42/91	43/90	0.78	0.50; 1.20	0.401
Others					
ASC4START	2/17	7/21	0.22	0.03; 1.63	0.094
Pooled Analysis	4/20	7/25	0.22	0.03; 1.63	0.094
White					
ASC4FIRST	22/106	24/103	1.04	0.54; 2.00	0.804
ASC4START	77/227	71/217	0.81	0.59; 1.13	0.504
Pooled Analysis	99/333	95/320	0.86	0.64; 1.15	0.478




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	23/68	22/75	1.04	0.57; 1.93	0.724
ASC4START	42/107	49/126	0.82	0.54; 1.25	0.446
Pooled Analysis	65/175	71/201	0.89	0.63; 1.25	0.665
Male					
ASC4FIRST	41/129	45/118	0.71	0.45; 1.10	0.120
ASC4START	55/177	56/158	0.68	0.46; 1.09	0.090
Pooled Analysis	96/306	101/276	0.69	0.52; 0.92	0.022




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	44/153	63/150	0.47	0.32; 0.70	<0.001
ASC4START	80/237	94/247	0.77	0.57; 1.04	0.069
Pooled Analysis	124/390	157/397	0.64	0.51; 0.82	<0.001
65 - < 75 years					
ASC4FIRST	7/34	13/29	0.65	0.23; 1.85	0.331
ASC4START	11/38	9/24	0.42	0.14; 1.23	0.104
Pooled Analysis	18/72	22/53	0.53	0.25; 1.12	0.066
>= 75 years					
ASC4FIRST	3/10	5/14	1.18	0.21; 6.59	0.879
ASC4START	5/9	2/13	2.84	0.24; 33.24	0.261
Pooled Analysis	8/19	7/27	1.65	0.43; 6.29	0.356




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	5/20	0.42	0.09; 1.91	0.228
ASC4START	13/38	12/37	0.63	0.29; 1.40	0.232
Pooled Analysis	16/61	17/57	0.58	0.29; 1.16	0.103
Intermediate					
ASC4FIRST	18/54	25/53	0.50	0.27; 0.93	0.029
ASC4START	28/75	26/75	1.04	0.61; 1.78	0.988
Pooled Analysis	46/129	51/128	0.75	0.50; 1.13	0.149
Low					
ASC4FIRST	33/120	51/120	0.55	0.35; 0.86	0.002
ASC4START	55/171	67/172	0.73	0.51; 1.05	0.076
Pooled Analysis	88/291	118/292	0.65	0.49; 1.13	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	15/64	19/62	0.56	0.28; 1.14	0.073
ASC4START	49/138	50/141	0.89	0.60; 1.33	0.634
Pooled Analysis	64/202	69/203	0.80	0.56; 1.13	0.197
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	13/72	11/53	0.66	0.28; 1.55	0.304
Pooled Analysis	13/91	11/68	0.66	0.28; 1.55	0.304
Others					
ASC4FIRST	39/114	62/116	0.52	0.34; 0.78	<0.001
ASC4START	34/74	44/90	0.74	0.47; 1.17	0.092
Pooled Analysis	73/188	106/206	0.61	0.45; 0.82	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	9/41	14/42	0.35	0.13; 0.96	0.030
Pooled Analysis	9/41	14/42	0.35	0.13; 0.96	0.030
Imatinib					
ASC4FIRST	26/101	45/102	0.47	0.28; 0.76	<0.001
Pooled Analysis	26/101	45/102	0.47	0.28; 0.76	<0.001
Nilotinib					
ASC4FIRST	19/55	22/49	0.63	0.32; 1.24	0.306
ASC4START	96/284	105/284	0.79	0.60; 1.05	0.071
Pooled Analysis	115/339	127/333	0.77	0.60; 1.00	0.039




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	16/40	28/46	0.56	0.29; 1.06	0.021
Pooled Analysis	54/128	83/132	0.52	0.37; 0.75	<0.001
Asian/Others					
ASC4FIRST	39/91	55/90	0.51	0.34; 0.78	<0.001
Others					
ASC4START	6/17	6/21	1.49	0.25; 8.73	0.761
Pooled Analysis	7/20	6/25	1.49	0.25; 8.73	0.761
White					
ASC4FIRST	15/106	26/103	0.54	0.28; 1.05	0.044
ASC4START	74/227	71/217	0.86	0.62; 1.20	0.369
Pooled Analysis	89/333	97/320	0.78	0.59; 1.05	0.087




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	19/68	32/75	0.69	0.38; 1.25	0.096
ASC4START	39/107	50/126	0.75	0.49; 1.15	0.125
Pooled Analysis	58/175	82/201	0.73	0.52; 1.03	0.027
Male					
ASC4FIRST	35/129	49/118	0.46	0.29; 0.72	<0.001
ASC4START	57/177	55/158	0.85	0.58; 1.23	0.355
Pooled Analysis	92/306	104/276	0.66	0.50; 0.88	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	34/153	55/150	0.41	0.26; 0.63	<0.001
ASC4START	51/237	75/247	0.60	0.42; 0.86	0.004
Pooled Analysis	85/390	130/397	0.52	0.39; 0.68	<0.001
65 - < 75 years					
ASC4FIRST	2/34	14/29	0.08	0.01; 0.59	<0.001
ASC4START	5/38	6/24	0.27	0.06; 1.18	0.054
Pooled Analysis	7/72	20/53	0.15	0.05; 0.43	<0.001
>= 75 years					
ASC4FIRST	3/10	5/14	0.26	0.02; 2.92	0.212
ASC4START	3/9	1/13	0.42	0.02; 8.07	0.695
Pooled Analysis	6/19	6/27	0.32	0.05; 1.98	0.214




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	4/20	0.48	0.08; 2.74	0.363
ASC4START	11/38	9/37	0.72	0.30; 1.75	0.492
Pooled Analysis	13/61	13/57	0.66	0.30; 1.45	0.296
Intermediate					
ASC4FIRST	10/54	24/53	0.25	0.12; 0.53	<0.001
ASC4START	13/75	22/75	0.37	0.18; 0.76	0.006
Pooled Analysis	23/129	46/128	0.31	0.19; 0.52	<0.001
Low					
ASC4FIRST	27/120	46/120	0.44	0.27; 0.71	<0.001
ASC4START	35/171	51/172	0.65	0.42; 1.00	0.047
Pooled Analysis	62/291	97/292	0.54	0.39; 0.75	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	12/64	20/62	0.40	0.18; 0.87	0.006
ASC4START	30/138	47/141	0.47	0.30; 0.76	0.002
Pooled Analysis	42/202	67/203	0.44	0.30; 0.67	<0.001
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	9/72	10/53	0.56	0.22; 1.44	0.246
Pooled Analysis	9/91	10/68	0.56	0.22; 1.44	0.246
Others					
ASC4FIRST	27/114	54/116	0.37	0.23; 0.59	<0.001
ASC4START	20/74	25/90	0.82	0.46; 1.49	0.524
Pooled Analysis	47/188	79/206	0.50	0.34; 0.72	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	7/41	13/42	0.34	0.13; 0.91	0.035
Pooled Analysis	7/41	13/42	0.34	0.13; 0.91	0.035
Imatinib					
ASC4FIRST	17/101	44/102	0.26	0.14; 0.46	<0.001
Pooled Analysis	17/101	44/102	0.26	0.14; 0.46	<0.001
Nilotinib					
ASC4FIRST	15/55	17/49	0.85	0.42; 1.73	0.677
ASC4START	59/284	82/284	0.59	0.42; 0.82	0.002
Pooled Analysis	74/339	99/333	0.63	0.46; 0.85	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	11/40	16/46	0.68	0.31; 1.47	0.311
Pooled Analysis	37/128	63/132	0.44	0.29; 0.67	<0.001
Asian/Others					
ASC4FIRST	27/91	47/90	0.38	0.24; 0.63	<0.001
Others					
ASC4START	2/17	4/21	0.50	0.07; 3.76	0.648
Pooled Analysis	3/20	4/25	0.50	0.07; 3.76	0.648
White					
ASC4FIRST	12/106	27/103	0.40	0.20; 0.84	0.004
ASC4START	46/227	62/217	0.57	0.38; 0.83	0.003
Pooled Analysis	58/333	89/320	0.52	0.37; 0.72	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	16/68	30/75	0.50	0.26; 0.95	0.017
ASC4START	30/107	41/126	0.64	0.40; 1.04	0.084
Pooled Analysis	46/175	71/201	0.57	0.39; 0.84	0.005
Male					
ASC4FIRST	23/129	44/118	0.35	0.21; 0.59	<0.001
ASC4START	29/177	41/158	0.57	0.35; 0.92	0.013
Pooled Analysis	52/306	85/276	0.46	0.32; 0.65	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pruritus - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	47/153	49/150	0.80	0.53; 1.22	0.249
ASC4START	80/237	102/247	0.59	0.44; 0.80	0.001
Pooled Analysis	127/390	151/397	0.65	0.51; 0.83	0.001
65 - < 75 years					
ASC4FIRST	9/34	11/29	1.97	0.70; 5.54	0.264
ASC4START	9/38	9/24	0.34	0.12; 0.94	0.031
Pooled Analysis	18/72	20/53	0.78	0.37; 1.61	0.494
>= 75 years					
ASC4FIRST	4/10	5/14	8.61	0.72; 102.67	0.039
ASC4START	3/9	3/13	0.05	0.00; 2.45	0.014
Pooled Analysis	7/19	8/27	1.08	0.25; 4.72	0.808




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pruritus - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	6/23	3/20	1.27	0.30; 5.38	0.696
ASC4START	12/38	15/37	0.33	0.15; 0.70	0.003
Pooled Analysis	18/61	18/57	0.45	0.23; 0.87	0.019
Intermediate					
ASC4FIRST	17/54	18/53	1.23	0.60; 2.51	0.883
ASC4START	25/75	27/75	0.54	0.31; 0.95	0.072
Pooled Analysis	42/129	45/128	0.73	0.47; 1.13	0.193
Low					
ASC4FIRST	37/120	44/120	0.82	0.53; 1.28	0.314
ASC4START	55/171	72/172	0.63	0.44; 0.90	0.014
Pooled Analysis	92/291	116/292	0.69	0.53; 0.91	0.011




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pruritus - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	20/64	15/62	1.31	0.64; 2.67	0.480
ASC4START	49/138	61/141	0.58	0.39; 0.86	0.007
Pooled Analysis	69/202	76/203	0.70	0.50; 0.99	0.043
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	12/72	12/53	0.39	0.16; 0.96	0.033
Pooled Analysis	12/91	12/68	0.39	0.16; 0.96	0.033
Others					
ASC4FIRST	40/114	50/116	0.83	0.54; 1.28	0.260
ASC4START	31/74	41/90	0.64	0.40; 1.04	0.080
Pooled Analysis	71/188	91/206	0.73	0.53; 1.01	0.045




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pruritus - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	12/41	11/42	0.78	0.32; 1.90	0.636
Pooled Analysis	12/41	11/42	0.78	0.32; 1.90	0.636
Imatinib					
ASC4FIRST	32/101	31/102	1.47	0.88; 2.46	0.439
Pooled Analysis	32/101	31/102	1.47	0.88; 2.46	0.439
Nilotinib					
ASC4FIRST	16/55	23/49	0.49	0.25; 0.96	0.052
ASC4START	92/284	114/284	0.56	0.42; 0.74	<0.001
Pooled Analysis	108/339	137/333	0.55	0.42; 0.71	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pruritus - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	13/40	24/46	0.39	0.20; 0.79	0.014
Pooled Analysis	52/128	68/132	0.65	0.45; 0.94	0.033
Asian/Others					
ASC4FIRST	40/91	44/90	0.83	0.53; 1.29	0.394
Others					
ASC4START	7/17	8/21	0.76	0.19; 2.97	0.597
Pooled Analysis	8/20	8/25	0.76	0.19; 2.97	0.597
White					
ASC4FIRST	20/106	21/103	1.02	0.53; 1.98	0.928
ASC4START	72/227	82/217	0.62	0.44; 0.85	0.004
Pooled Analysis	92/333	103/320	0.68	0.50; 0.90	0.009




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pruritus - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	21/68	26/75	1.08	0.58; 2.02	0.837
ASC4START	38/107	51/126	0.57	0.37; 0.88	0.010
Pooled Analysis	59/175	77/201	0.69	0.48; 0.98	0.026
Male					
ASC4FIRST	39/129	39/118	0.84	0.52; 1.36	0.467
ASC4START	54/177	63/158	0.57	0.39; 0.82	0.007
Pooled Analysis	93/306	102/276	0.65	0.48; 0.87	0.011




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	16/153	30/150	0.38	0.20; 0.70	0.002
ASC4START	20/237	41/247	0.43	0.25; 0.74	0.002
Pooled Analysis	36/390	71/397	0.41	0.27; 0.62	<0.001
65 - < 75 years					
ASC4FIRST	1/34	7/29	0.17	0.02; 1.44	0.068
ASC4START	2/38	2/24	0.63	0.08; 5.12	0.555
Pooled Analysis	3/72	9/53	0.31	0.08; 1.21	0.067
>= 75 years					
ASC4FIRST	2/10	5/14	0.19	0.02; 1.83	0.116
ASC4START	1/9	0/13	2.99	0.03; 275.43	0.317
Pooled Analysis	3/19	5/27	0.42	0.07; 2.41	0.317




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	2/20	1.03	0.14; 7.68	0.764
ASC4START	3/38	5/37	0.39	0.09; 1.75	0.210
Pooled Analysis	5/61	7/57	0.61	0.19; 1.96	0.387
Intermediate					
ASC4FIRST	7/54	18/53	0.26	0.11; 0.64	0.002
ASC4START	6/75	9/75	0.44	0.15; 1.32	0.190
Pooled Analysis	13/129	27/128	0.34	0.17; 0.67	0.001
Low					
ASC4FIRST	10/120	22/120	0.35	0.16; 0.74	0.005
ASC4START	14/171	29/172	0.45	0.24; 0.85	0.011
Pooled Analysis	24/291	51/292	0.40	0.25; 0.66	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	6/64	10/62	0.36	0.12; 1.07	0.055
ASC4START	11/138	20/141	0.46	0.22; 0.97	0.036
Pooled Analysis	17/202	30/203	0.42	0.23; 0.78	0.005
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	1/72	1/53	0.55	0.03; 8.78	0.666
Pooled Analysis	1/91	1/68	0.55	0.03; 8.78	0.666
Others					
ASC4FIRST	13/114	32/116	0.32	0.17; 0.62	<0.001
ASC4START	11/74	22/90	0.43	0.20; 0.91	0.025
Pooled Analysis	24/188	54/206	0.37	0.22; 0.60	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	3/41	6/42	0.43	0.11; 1.72	0.217
Pooled Analysis	3/41	6/42	0.43	0.11; 1.72	0.217
Imatinib					
ASC4FIRST	9/101	27/102	0.25	0.12; 0.54	<0.001
Pooled Analysis	9/101	27/102	0.25	0.12; 0.54	<0.001
Nilotinib					
ASC4FIRST	7/55	9/49	0.54	0.19; 1.52	0.258
ASC4START	23/284	43/284	0.45	0.27; 0.75	0.002
Pooled Analysis	30/339	52/333	0.47	0.30; 0.74	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	6/40	12/46	0.54	0.20; 1.50	0.216
Pooled Analysis	19/128	41/132	0.38	0.22; 0.66	<0.001
Asian/Others					
ASC4FIRST	14/91	29/90	0.34	0.18; 0.66	0.001
Others					
ASC4START	1/17	4/21	0.87	0.05; 13.95	0.857
Pooled Analysis	2/20	4/25	0.87	0.05; 13.95	0.857
White					
ASC4FIRST	5/106	13/103	0.32	0.10; 1.02	0.044
ASC4START	16/227	27/217	0.47	0.25; 0.88	0.016
Pooled Analysis	21/333	40/320	0.43	0.25; 0.74	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	7/68	17/75	0.32	0.13; 0.79	0.015
ASC4START	12/107	24/126	0.46	0.23; 0.93	0.025
Pooled Analysis	19/175	41/201	0.40	0.23; 0.70	0.001
Male					
ASC4FIRST	12/129	25/118	0.35	0.17; 0.71	0.002
ASC4START	11/177	19/158	0.47	0.22; 0.99	0.039
Pooled Analysis	23/306	44/276	0.40	0.24; 0.67	<0.001



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-2.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Fatigue - Interference (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.664)								
Low	97/291 (33.3)	3.0 [1.4; 7.5]	103/292 (35.3)	1.2 [1.0; 2.8]	0.85	[0.64; 1.13]	0.406	0.011
Intermediate	48/129 (37.2)	3.3 [1.2; 11.1]	51/128 (39.8)	1.4 [0.5; 8.3]	0.82	[0.55; 1.22]	0.329	0.293
High	15/61 (24.6)	N.E. [3.7; N.E.]	13/57 (22.8)	11.0 [0.7; N.E.]	0.66	[0.31; 1.44]	0.249	0.423
Sex								
(Interaction test: p = 0.985)								
Female	59/175	4.6 [1.4; 9.2]	70/201	2.1 [1.0; 3.0]	0.85	[0.59; 1.22]	0.482	0.018

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(33.7)		(34.8)					
Male	101/306	3.8 [2.3; 11.0]	97/276	1.1 [0.7; 3.3]	0.86	[0.64; 1.14]	0.378	0.174
	(33.0)		(35.1)					
Race								
(Interaction test: p = 0.477)								
Asian	58/128	4.4 [1.8; 23.1]	72/132	1.2 [0.7; 2.8]	0.71	[0.50; 1.02]	0.127	0.180
	(45.3)		(54.5)					
White	97/333	3.7 [2.1; 8.3]	91/320	1.7 [0.7; 3.3]	0.92	[0.69; 1.24]	0.664	0.033
	(29.1)		(28.4)					
Others	5/20	2.8 [0.3; N.E.]	4/25	N.E. [0.3; N.E.]	0.42	[0.06; 2.90]	0.924	N.E.
	(25.0)		(16.0)					
Age groups								
(Interaction test: p = 0.572)								
18 - < 65 years	139/390	3.7 [2.4; 7.5]	139/397	1.5 [1.0; 3.0]	0.85	[0.67; 1.09]	0.445	0.007
	(35.6)		(35.0)					
65 - < 75 years	16/72	14.8 [1.0; N.E.]	21/53	1.0 [0.5; 2.1]	0.54	[0.25; 1.14]	0.061	0.356

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(22.2)		(39.6)					
>= 75 years	5/19	1.2 [0.5; N.E.]	7/27	2.1 [0.3; 16.6]	11.01	[0.85; 142.30]	0.972	0.826
	(26.3)		(25.9)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.329)								
Imatinib	34/101	1.2 [0.5; 17.5]	40/102	0.5 [0.5; 2.1]	0.74	[0.46; 1.17]	0.146	N.E.
	(33.7)		(39.2)					
Nilotinib	116/339	4.4 [2.6; 8.3]	114/333	2.6 [1.0; 8.3]	0.89	[0.69; 1.16]	0.645	0.005
	(34.2)		(34.2)					
Dasatinib	10/41	N.E. [0.5; N.E.]	13/42	0.5 [0.3; 2.1]	0.50	[0.20; 1.21]	0.176	N.E.
	(24.4)		(31.0)					
Geographic region								
(Interaction test: p = 0.269)								
Europe excluding Germany	73/202	3.0 [1.0; 8.3]	66/203	1.7 [0.7; 3.3]	0.98	[0.70; 1.38]	0.939	0.220

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(36.1)		(32.5)					
Germany	17/91	3.6 [1.6; 11.1]	9/68	1.9 [0.3; N.E.]	0.63	[0.24; 1.64]	0.779	N.E.
	(18.7)		(13.2)					
Others	70/188	5.8 [2.7; 23.1]	92/206	1.4 [0.7; 2.8]	0.70	[0.51; 0.96]	0.039	0.056
	(37.2)		(44.7)					
Headache - Interference (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.897)								
Low	81/291	10.2 [3.8; 21.2]	95/292	3.0 [1.9; 10.2]	0.72	[0.54; 0.98]	0.069	0.984
	(27.8)		(32.5)					
Intermediate	32/129	N.E. [8.3; N.E.]	36/128	5.4 [2.8; N.E.]	0.73	[0.45; 1.18]	0.177	0.798
	(24.8)		(28.1)					
High	21/61	9.0 [2.1; 22.1]	14/57	4.6 [1.0; 22.1]	0.96	[0.48; 1.94]	0.984	0.445
	(34.4)		(24.6)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.627)								
Female	58/175 (33.1)	3.8 [2.1; 16.6]	65/201 (32.3)	2.6 [1.8; 5.4]	0.84	[0.58; 1.21]	0.481	0.592
Male	76/306 (24.8)	23.0 [12.0; N.E.]	80/276 (29.0)	8.3 [3.5; 19.4]	0.73	[0.53; 1.01]	0.069	0.618
Race								
(Interaction test: p = 0.470)								
Asian	48/128 (37.5)	24.9 [5.6; N.E.]	59/132 (44.7)	4.9 [2.3; 19.4]	0.72	[0.49; 1.07]	0.107	0.682
White	83/333 (24.9)	11.2 [3.8; 18.4]	81/320 (25.3)	4.0 [2.1; 13.8]	0.82	[0.60; 1.13]	0.271	0.769
Others	3/20 (15.0)	N.E. [0.3; N.E.]	5/25 (20.0)	2.6 [0.1; N.E.]	0.20	[0.03; 1.47]	0.165	N.E.
Age groups								
(Interaction test: p = 0.245)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	114/390 (29.2)	12.9 [4.6; 22.1]	132/397 (33.2)	3.3 [2.1; 5.4]	0.69	[0.54; 0.89]	0.008	0.904
65 - < 75 years	15/72 (20.8)	16.6 [2.3; N.E.]	9/53 (17.0)	N.E. [4.2; N.E.]	1.28	[0.52; 3.15]	0.554	0.641
>= 75 years	5/19 (26.3)	19.4 [0.3; N.E.]	4/27 (14.8)	14.8 [0.7; N.E.]	0.65	[0.11; 3.68]	0.489	0.622
Pre-randomization selection of TKI								
(Interaction test: p = 0.538)								
Imatinib	25/101 (24.8)	21.2 [3.5; N.E.]	26/102 (25.5)	12.9 [3.5; N.E.]	0.88	[0.50; 1.54]	0.651	N.E.
Nilotinib	101/339 (29.8)	9.0 [4.4; 22.1]	108/333 (32.4)	3.3 [2.1; 7.4]	0.76	[0.57; 1.00]	0.073	0.572
Dasatinib	8/41 (19.5)	N.E. [1.0; N.E.]	11/42 (26.2)	2.1 [0.3; N.E.]	0.62	[0.23; 1.69]	0.348	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.192)								
Europe excluding Germany	63/202 (31.2)	10.2 [2.8; 18.4]	58/203 (28.6)	4.0 [2.1; 18.5]	0.88	[0.61; 1.27]	0.624	0.186
Germany	12/91 (13.2)	14.2 [4.4; N.E.]	10/68 (14.7)	2.3 [0.3; 5.6]	0.29	[0.11; 0.75]	0.010	N.E.
Others	59/188 (31.4)	24.9 [5.6; N.E.]	77/206 (37.4)	4.4 [2.3; 13.8]	0.71	[0.50; 1.00]	0.060	0.661
Edema - Interference (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.849)								
Low	37/291 (12.7)	N.E. [N.E.; N.E.]	60/292 (20.5)	N.E. [18.5; N.E.]	0.56	[0.37; 0.84]	0.005	0.072
Intermediate	24/129	N.E. [17.5; N.E.]	28/128	N.E. [5.6; N.E.]	0.67	[0.38; 1.18]	0.209	0.081

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(18.6)		(21.9)					
High	7/61	N.E. [N.E.; N.E.]	6/57	N.E. [N.E.; N.E.]	0.52	[0.17; 1.55]	0.355	0.995
	(11.5)		(10.5)					
Sex								
(Interaction test: p = 0.404)								
Female	30/175	N.E. [N.E.; N.E.]	49/201	11.1 [4.2; N.E.]	0.54	[0.33; 0.86]	0.008	0.051
	(17.1)		(24.4)					
Male	38/306	N.E. [N.E.; N.E.]	45/276	N.E. [27.6; N.E.]	0.68	[0.44; 1.06]	0.094	0.116
	(12.4)		(16.3)					
Race								
(Interaction test: p = 0.165)								
Asian	31/128	N.E. [N.E.; N.E.]	49/132	11.1 [4.2; N.E.]	0.50	[0.32; 0.79]	0.003	0.956
	(24.2)		(37.1)					
White	32/333	N.E. [N.E.; N.E.]	43/320	27.6 [27.6; N.E.]	0.63	[0.39; 1.00]	0.051	0.006
	(9.6)		(13.4)					
Others	5/20	7.4 [0.3; N.E.]	2/25	N.E. [0.3; N.E.]	2.06	[0.30; 13.90]	0.394	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(25.0)		(8.0)					
Age groups								
(Interaction test: p = 0.449)								
18 - < 65 years	57/390	N.E. [N.E.; N.E.]	76/397	N.E. [27.6; N.E.]	0.64	[0.45; 0.90]	0.012	0.065
	(14.6)		(19.1)					
65 - < 75 years	7/72	N.E. [N.E.; N.E.]	13/53	N.E. [1.2; N.E.]	0.41	[0.15; 1.08]	0.068	0.184
	(9.7)		(24.5)					
>= 75 years	4/19	22.1 [0.3; N.E.]	5/27	3.1 [0.5; N.E.]	0.45	[0.08; 2.40]	0.246	0.999
	(21.1)		(18.5)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.023)								
Imatinib	12/101	N.E. [N.E.; N.E.]	33/102	3.1 [1.4; 11.1]	0.27	[0.14; 0.53]	<0.001	N.E.
	(11.9)		(32.4)					
Nilotinib	50/339	N.E. [N.E.; N.E.]	54/333	N.E. [27.6; N.E.]	0.81	[0.55; 1.20]	0.302	0.646
	(14.7)		(16.2)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	6/41 (14.6)	N.E. [8.2; N.E.]	7/42 (16.7)	N.E. [0.5; N.E.]	0.64	[0.20; 2.09]	0.417	N.E.
Geographic region (Interaction test: p = 0.519)								
Europe excluding Germany	26/202 (12.9)	N.E. [N.E.; N.E.]	35/203 (17.2)	N.E. [18.5; N.E.]	0.54	[0.32; 0.93]	0.029	0.014
Germany	5/91 (5.5)	N.E. [9.2; N.E.]	2/68 (2.9)	N.E. [N.E.; N.E.]	0.73	[0.12; 4.65]	0.911	N.E.
Others	37/188 (19.7)	N.E. [N.E.; N.E.]	57/206 (27.7)	27.6 [10.7; N.E.]	0.58	[0.38; 0.89]	0.014	0.365
Muscle Pain - Interference (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.150)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Low	79/291 (27.1)	8.3 [3.3; 24.9]	97/292 (33.2)	1.9 [1.0; 6.5]	0.71	[0.53; 0.96]	0.032	0.468
Intermediate	47/129 (36.4)	1.9 [1.0; 14.8]	40/128 (31.3)	4.6 [1.6; N.E.]	1.16	[0.76; 1.78]	0.504	0.068
High	16/61 (26.2)	N.E. [2.1; N.E.]	13/57 (22.8)	2.8 [0.7; N.E.]	0.66	[0.31; 1.39]	0.385	0.785
Sex								
(Interaction test: p = 0.230)								
Female	58/175 (33.1)	1.6 [1.0; 8.3]	63/201 (31.3)	1.9 [1.0; 3.1]	1.01	[0.70; 1.45]	0.985	0.716
Male	84/306 (27.5)	14.8 [4.4; N.E.]	87/276 (31.5)	4.6 [1.4; 13.8]	0.74	[0.54; 1.00]	0.076	0.123
Race								
(Interaction test: p = 0.140)								
Asian	58/128 (45.3)	4.6 [1.4; 24.9]	61/132 (46.2)	3.3 [1.4; 10.2]	0.88	[0.61; 1.27]	0.552	0.716

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
White	77/333 (23.1)	11.1 [3.0; N.E.]	86/320 (26.9)	2.7 [1.1; 6.7]	0.74	[0.54; 1.01]	0.070	0.060
Others	7/20 (35.0)	0.5 [0.3; N.E.]	3/25 (12.0)	N.E. [0.3; N.E.]	1.90	[0.32; 11.41]	0.322	N.E.
Age groups (Interaction test: p = 0.998)								
18 - < 65 years	118/390 (30.3)	5.2 [3.1; 24.9]	125/397 (31.5)	2.8 [1.2; 7.3]	0.80	[0.62; 1.03]	0.114	0.144
65 - < 75 years	17/72 (23.6)	8.3 [1.0; N.E.]	18/53 (34.0)	3.7 [1.6; 13.9]	0.62	[0.29; 1.32]	0.337	0.535
>= 75 years	7/19 (36.8)	1.5 [0.3; N.E.]	7/27 (25.9)	1.0 [0.3; N.E.]	0.43	[0.09; 2.13]	0.525	0.281
Pre-randomization selection of TKI (Interaction test: p = 0.213)								
Imatinib	24/101	24.9 [1.9; N.E.]	37/102	2.3 [0.5; 4.6]	0.53	[0.31; 0.89]	0.010	N.E.


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(23.8)		(36.3)					
Nilotinib	108/339	3.9 [2.1; 11.0]	104/333	2.8 [1.4; 13.8]	0.91	[0.69; 1.19]	0.599	0.593
	(31.9)		(31.2)					
Dasatinib	10/41	N.E. [0.5; N.E.]	9/42	13.8 [0.3; N.E.]	0.97	[0.37; 2.53]	0.994	N.E.
	(24.4)		(21.4)					
Geographic region								
(Interaction test: p = 0.450)								
Europe excluding Germany	57/202	12.0 [2.1; N.E.]	61/203	2.7 [1.2; 13.8]	0.78	[0.54; 1.12]	0.205	0.154
	(28.2)		(30.0)					
Germany	13/91	5.1 [0.5; N.E.]	10/68	0.5 [0.3; N.E.]	0.68	[0.27; 1.69]	0.347	N.E.
	(14.3)		(14.7)					
Others	72/188	4.6 [1.6; 24.9]	79/206	3.3 [1.6; 10.2]	0.91	[0.66; 1.26]	0.626	0.226
	(38.3)		(38.3)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				

MID: Minimally important difference
N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not more than 10 events per subgroup per treatment arm, no subgroup analyses were performed for the corresponding attribute.
If there are not more than 10 events per subgroup per treatment arm, no Cox PH hazard analysis is carried out.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline PRO score.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT) and Pre-Randomization selection TKI (IRT).
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Interference (MID=1): Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Interference (MID=1): Pre-randomization selection of TKI: Nilotinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Full Analysis Set)

Edema - Interference (MID=1): Pre-randomization selection of TKI: Dasatinib




Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	21/153	36/150	0.43	0.25; 0.75	0.002
ASC4START	36/237	40/247	0.85	0.54; 1.33	0.476
Pooled Analysis	57/390	76/397	0.64	0.45; 0.90	0.012
65 - < 75 years					
ASC4FIRST	2/34	10/29	0.19	0.04; 0.95	0.028
ASC4START	5/38	3/24	0.84	0.19; 3.64	0.820
Pooled Analysis	7/72	13/53	0.41	0.15; 1.08	0.068
>= 75 years					
ASC4FIRST	3/10	4/14	0.52	0.09; 2.94	0.452
ASC4START	1/9	1/13	0.57	0.00; 107.73	0.221
Pooled Analysis	4/19	5/27	0.45	0.08; 2.40	0.246




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	0/20	1.34	0.01; 130.28	0.513
ASC4START	6/38	6/37	0.45	0.14; 1.39	0.252
Pooled Analysis	7/61	6/57	0.52	0.17; 1.55	0.355
Intermediate					
ASC4FIRST	11/54	19/53	0.46	0.21; 0.99	0.026
ASC4START	13/75	9/75	1.26	0.52; 3.05	0.536
Pooled Analysis	24/129	28/128	0.67	0.38; 1.18	0.209
Low					
ASC4FIRST	14/120	31/120	0.36	0.19; 0.68	0.001
ASC4START	23/171	29/172	0.79	0.46; 1.36	0.397
Pooled Analysis	37/291	60/292	0.56	0.37; 1.84	0.005




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	6/64	14/62	0.16	0.05; 0.49	<0.001
ASC4START	20/138	21/141	0.88	0.47; 1.65	0.708
Pooled Analysis	26/202	35/203	0.54	0.32; 0.93	0.029
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	5/72	2/53	0.73	0.12; 4.65	0.911
Pooled Analysis	5/91	2/68	0.73	0.12; 4.65	0.911
Others					
ASC4FIRST	20/114	36/116	0.52	0.30; 0.92	0.013
ASC4START	17/74	21/90	0.73	0.38; 1.40	0.396
Pooled Analysis	37/188	57/206	0.58	0.38; 0.89	0.014




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	6/41	7/42	0.64	0.20; 2.09	0.417
Pooled Analysis	6/41	7/42	0.64	0.20; 2.09	0.417
Imatinib					
ASC4FIRST	12/101	33/102	0.27	0.14; 0.53	<0.001
Pooled Analysis	12/101	33/102	0.27	0.14; 0.53	<0.001
Nilotinib					
ASC4FIRST	8/55	10/49	0.74	0.28; 1.97	0.402
ASC4START	42/284	44/284	0.85	0.55; 1.30	0.450
Pooled Analysis	50/339	54/333	0.81	0.55; 1.20	0.302




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	10/40	16/46	0.49	0.21; 1.11	0.083
Pooled Analysis	31/128	49/132	0.50	0.32; 0.79	0.003
Asian/Others					
ASC4FIRST	22/91	33/90	0.56	0.32; 0.97	0.023
Others					
ASC4START	4/17	2/21	2.06	0.30; 13.90	0.394
Pooled Analysis	5/20	2/25	2.06	0.30; 13.90	0.394
White					
ASC4FIRST	4/106	17/103	0.16	0.05; 0.50	<0.001
ASC4START	28/227	26/217	0.95	0.55; 1.63	0.848
Pooled Analysis	32/333	43/320	0.63	0.39; 1.00	0.051




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	8/68	22/75	0.26	0.11; 0.63	0.002
ASC4START	22/107	27/126	0.76	0.43; 1.36	0.356
Pooled Analysis	30/175	49/201	0.54	0.33; 0.86	0.008
Male					
ASC4FIRST	18/129	28/118	0.54	0.29; 1.01	0.020
ASC4START	20/177	17/158	1.02	0.53; 1.94	0.964
Pooled Analysis	38/306	45/276	0.68	0.44; 1.06	0.094




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	47/153	58/150	0.56	0.38; 0.84	0.007
ASC4START	92/237	81/247	1.09	0.81; 1.48	0.293
Pooled Analysis	139/390	139/397	0.85	0.67; 1.09	0.445
65 - < 75 years					
ASC4FIRST	7/34	14/29	0.34	0.10; 1.11	0.038
ASC4START	9/38	7/24	0.76	0.26; 2.21	0.610
Pooled Analysis	16/72	21/53	0.54	0.25; 1.14	0.061
>= 75 years					
ASC4FIRST	3/10	5/14	7.60	0.57; 101.53	0.500
ASC4START	2/9	2/13	11.34	0.07; >1000	0.464
Pooled Analysis	5/19	7/27	11.01	0.85; 142.30	0.972




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	5/20	0.29	0.05; 1.75	0.088
ASC4START	13/38	8/37	0.78	0.32; 1.89	0.714
Pooled Analysis	15/61	13/57	0.66	0.31; 1.44	0.249
Intermediate					
ASC4FIRST	21/54	24/53	0.65	0.36; 1.18	0.198
ASC4START	27/75	27/75	1.00	0.58; 1.71	0.857
Pooled Analysis	48/129	51/128	0.82	0.55; 1.22	0.329
Low					
ASC4FIRST	34/120	48/120	0.55	0.35; 0.85	0.007
ASC4START	63/171	55/172	1.15	0.80; 1.65	0.261
Pooled Analysis	97/291	103/292	0.85	0.64; 1.13	0.406




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	20/64	19/62	0.66	0.34; 1.28	0.134
ASC4START	53/138	47/141	1.11	0.74; 1.66	0.448
Pooled Analysis	73/202	66/203	0.98	0.70; 1.38	0.939
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	17/72	9/53	0.63	0.24; 1.64	0.779
Pooled Analysis	17/91	9/68	0.63	0.24; 1.64	0.779
Others					
ASC4FIRST	37/114	58/116	0.54	0.36; 0.82	0.006
ASC4START	33/74	34/90	1.02	0.62; 1.66	0.981
Pooled Analysis	70/188	92/206	0.70	0.51; 0.96	0.039




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	10/41	13/42	0.50	0.20; 1.21	0.176
Pooled Analysis	10/41	13/42	0.50	0.20; 1.21	0.176
Imatinib					
ASC4FIRST	34/101	40/102	0.74	0.46; 1.17	0.146
Pooled Analysis	34/101	40/102	0.74	0.46; 1.17	0.146
Nilotinib					
ASC4FIRST	13/55	24/49	0.37	0.18; 0.74	0.005
ASC4START	103/284	90/284	1.05	0.79; 1.40	0.505
Pooled Analysis	116/339	114/333	0.89	0.69; 1.16	0.645




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	21/40	23/46	0.99	0.53; 1.85	0.717
Pooled Analysis	58/128	72/132	0.71	0.50; 1.02	0.127
Asian/Others					
ASC4FIRST	38/91	49/90	0.61	0.40; 0.95	0.037
Others					
ASC4START	4/17	4/21	0.42	0.06; 2.90	0.924
Pooled Analysis	5/20	4/25	0.42	0.06; 2.90	0.924
White					
ASC4FIRST	19/106	28/103	0.50	0.27; 0.94	0.020
ASC4START	78/227	63/217	1.10	0.79; 1.54	0.485
Pooled Analysis	97/333	91/320	0.92	0.69; 1.24	0.664




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	16/68	29/75	0.44	0.23; 0.85	0.011
ASC4START	43/107	41/126	1.16	0.74; 1.80	0.410
Pooled Analysis	59/175	70/201	0.85	0.59; 1.22	0.482
Male					
ASC4FIRST	41/129	48/118	0.69	0.45; 1.06	0.093
ASC4START	60/177	49/158	1.02	0.69; 1.50	0.763
Pooled Analysis	101/306	97/276	0.86	0.64; 1.14	0.378




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	44/153	47/150	0.71	0.47; 1.09	0.154
ASC4START	70/237	85/247	0.68	0.50; 0.94	0.024
Pooled Analysis	114/390	132/397	0.69	0.54; 0.89	0.008
65 - < 75 years					
ASC4FIRST	6/34	6/29	1.10	0.31; 3.88	0.937
ASC4START	9/38	3/24	1.78	0.43; 7.45	0.357
Pooled Analysis	15/72	9/53	1.28	0.52; 3.15	0.554
>= 75 years					
ASC4FIRST	2/10	2/14	1.03	0.09; 11.55	0.782
ASC4START	3/9	2/13	0.43	0.04; 4.84	0.485
Pooled Analysis	5/19	4/27	0.65	0.11; 3.68	0.489




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	6/23	4/20	1.33	0.35; 5.05	0.540
ASC4START	15/38	10/37	0.82	0.37; 1.84	0.694
Pooled Analysis	21/61	14/57	0.96	0.48; 1.94	0.984
Intermediate					
ASC4FIRST	16/54	17/53	0.80	0.39; 1.64	0.444
ASC4START	16/75	19/75	0.68	0.35; 1.33	0.257
Pooled Analysis	32/129	36/128	0.73	0.45; 1.18	0.177
Low					
ASC4FIRST	30/120	34/120	0.74	0.45; 1.22	0.332
ASC4START	51/171	61/172	0.72	0.49; 1.04	0.122
Pooled Analysis	81/291	95/292	0.72	0.54; 0.98	0.069




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	20/64	12/62	1.37	0.63; 2.97	0.403
ASC4START	43/138	46/141	0.76	0.50; 1.16	0.304
Pooled Analysis	63/202	58/203	0.88	0.61; 1.27	0.624
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	12/72	10/53	0.29	0.11; 0.75	0.010
Pooled Analysis	12/91	10/68	0.29	0.11; 0.75	0.010
Others					
ASC4FIRST	32/114	43/116	0.65	0.41; 1.04	0.101
ASC4START	27/74	34/90	0.77	0.47; 1.28	0.318
Pooled Analysis	59/188	77/206	0.71	0.50; 1.00	0.060




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	8/41	11/42	0.62	0.23; 1.69	0.348
Pooled Analysis	8/41	11/42	0.62	0.23; 1.69	0.348
Imatinib					
ASC4FIRST	25/101	26/102	0.88	0.50; 1.54	0.651
Pooled Analysis	25/101	26/102	0.88	0.50; 1.54	0.651
Nilotinib					
ASC4FIRST	19/55	18/49	0.90	0.46; 1.78	0.904
ASC4START	82/284	90/284	0.73	0.54; 0.99	0.055
Pooled Analysis	101/339	108/333	0.76	0.57; 1.00	0.073




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	16/40	24/46	0.67	0.36; 1.28	0.170
Pooled Analysis	48/128	59/132	0.72	0.49; 1.07	0.107
Asian/Others					
ASC4FIRST	33/91	35/90	0.76	0.47; 1.25	0.374
Others					
ASC4START	2/17	5/21	0.20	0.03; 1.47	0.165
Pooled Analysis	3/20	5/25	0.20	0.03; 1.47	0.165
White					
ASC4FIRST	19/106	20/103	0.89	0.44; 1.81	0.699
ASC4START	64/227	61/217	0.80	0.56; 1.14	0.299
Pooled Analysis	83/333	81/320	0.82	0.60; 1.13	0.271




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	18/68	20/75	1.08	0.54; 2.17	0.779
ASC4START	40/107	45/126	0.78	0.51; 1.20	0.317
Pooled Analysis	58/175	65/201	0.84	0.58; 1.21	0.481
Male					
ASC4FIRST	34/129	35/118	0.81	0.50; 1.32	0.366
ASC4START	42/177	45/158	0.69	0.45; 1.05	0.104
Pooled Analysis	76/306	80/276	0.73	0.53; 1.01	0.069




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	42/153	51/150	0.62	0.41; 0.94	0.035
ASC4START	76/237	74/247	0.93	0.67; 1.28	0.715
Pooled Analysis	118/390	125/397	0.80	0.62; 1.03	0.114
65 - < 75 years					
ASC4FIRST	7/34	9/29	0.81	0.27; 2.43	0.636
ASC4START	10/38	9/24	0.48	0.17; 1.34	0.383
Pooled Analysis	17/72	18/53	0.62	0.29; 1.32	0.337
>= 75 years					
ASC4FIRST	2/10	5/14	0.77	0.12; 4.81	0.713
ASC4START	5/9	2/13	0.10	0.00; 3.88	0.586
Pooled Analysis	7/19	7/27	0.43	0.09; 2.13	0.525




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	2/20	0.73	0.10; 5.32	0.863
ASC4START	14/38	11/37	0.64	0.29; 1.42	0.386
Pooled Analysis	16/61	13/57	0.66	0.31; 1.39	0.385
Intermediate					
ASC4FIRST	18/54	21/53	0.74	0.39; 1.41	0.360
ASC4START	29/75	19/75	1.64	0.92; 2.94	0.087
Pooled Analysis	47/129	40/128	1.16	0.76; 1.78	0.504
Low					
ASC4FIRST	31/120	42/120	0.62	0.39; 0.99	0.049
ASC4START	48/171	55/172	0.78	0.53; 1.15	0.246
Pooled Analysis	79/291	97/292	0.71	0.53; 0.96	0.032




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	14/64	18/62	0.50	0.24; 1.06	0.038
ASC4START	43/138	43/141	0.91	0.59; 1.41	0.789
Pooled Analysis	57/202	61/203	0.78	0.54; 1.12	0.205
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	13/72	10/53	0.68	0.27; 1.69	0.347
Pooled Analysis	13/91	10/68	0.68	0.27; 1.69	0.347
Others					
ASC4FIRST	37/114	47/116	0.75	0.49; 1.17	0.270
ASC4START	35/74	32/90	1.13	0.70; 1.83	0.617
Pooled Analysis	72/188	79/206	0.91	0.66; 1.26	0.626




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	10/41	9/42	0.97	0.37; 2.53	0.994
Pooled Analysis	10/41	9/42	0.97	0.37; 2.53	0.994
Imatinib					
ASC4FIRST	24/101	37/102	0.53	0.31; 0.89	0.010
Pooled Analysis	24/101	37/102	0.53	0.31; 0.89	0.010
Nilotinib					
ASC4FIRST	17/55	19/49	0.73	0.36; 1.48	0.553
ASC4START	91/284	85/284	0.94	0.70; 1.26	0.751
Pooled Analysis	108/339	104/333	0.91	0.69; 1.19	0.599




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	21/40	22/46	0.95	0.52; 1.74	0.904
Pooled Analysis	58/128	61/132	0.88	0.61; 1.27	0.552
Asian/Others					
ASC4FIRST	38/91	39/90	0.83	0.53; 1.31	0.553
Others					
ASC4START	6/17	3/21	1.90	0.32; 11.41	0.322
Pooled Analysis	7/20	3/25	1.90	0.32; 11.41	0.322
White					
ASC4FIRST	13/106	26/103	0.40	0.20; 0.82	0.007
ASC4START	64/227	60/217	0.87	0.61; 1.24	0.519
Pooled Analysis	77/333	86/320	0.74	0.54; 1.01	0.070




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-2.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	18/68	23/75	0.94	0.49; 1.80	0.765
ASC4START	40/107	40/126	1.06	0.68; 1.65	0.822
Pooled Analysis	58/175	63/201	1.01	0.70; 1.45	0.985
Male					
ASC4FIRST	33/129	42/118	0.56	0.35; 0.89	0.018
ASC4START	51/177	45/158	0.91	0.61; 1.36	0.757
Pooled Analysis	84/306	87/276	0.74	0.54; 1.00	0.076



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Global health status/QoL (MID=10)				
N*	481	477	0.86	0.540
Number of patients with events, n (%)	185 (38.5)	202 (42.3)	[0.69; 1.08]	
			0.128	
Percentiles (months) [95% CI]				
25th	1.9 [1.2; 2.6]	1.2 [0.9; 1.5]		
Median	22.2 [21.9; 22.4]	11.3 [5.2; 17.4]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Physical functioning (MID=10)				
N*	481	477	0.76	0.921
Number of patients with events, n (%)	139 (28.9)	157 (32.9)	[0.59; 0.98]	
			0.106	
Percentiles (months) [95% CI]				
25th	3.1 [-0.3; 6.5]	1.9 [1.1; 2.7]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	Investigator Selected TKI (N = 477)	HR [95% CI] p-value	Test for Heterogeneity p-Value
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Role functioning (MID=10)				
N*	481	477	0.77	0.564
Number of patients with events, n (%)	184 (38.3)	204 (42.8)	[0.62; 0.95]	
			0.103	
Percentiles (months) [95% CI]				
25th	1.9 [1.2; 2.6]	1.2 [0.9; 1.5]		
Median	22.5 [22.1; 22.9]	11.2 [4.2; 18.3]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Emotional functioning (MID=10)				
N*	481	477	0.75	0.707
Number of patients with events, n (%)	160 (33.3)	177 (37.1)	[0.58; 0.96]	
			0.213	
Percentiles (months) [95% CI]				
25th	2.8 [1.2; 4.4]	2.0 [1.3; 2.7]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Median	N.E. [N.E.; N.E.]	22.1 [22.0; 22.2]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Cognitive functioning (MID=10)				
N*	481	477	0.82	0.752
Number of patients with events, n (%)	212 (44.1)	227 (47.6)	[0.68; 1.00]	
			0.157	
Percentiles (months) [95% CI]				
25th	1.9 [1.5; 2.4]	1.9 [1.5; 2.3]		
Median	11.2 [6.1; 16.4]	11.0 [8.5; 13.6]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Social functioning (MID=10)				
N*	481	477	0.70	0.982
Number of patients with events, n (%)	176 (36.6)	211 (44.2)	[0.56; 0.87]	
			0.004	
Percentiles (months) [95% CI]				
25th	1.9 [1.2; 2.6]	1.1 [0.8; 1.4]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Median	22.5 [22.4; 22.6]	11.1 [3.5; 18.7]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Fatigue (MID=10)				
N*	481	477	0.77	0.729
Number of patients with events, n (%)	187 (38.9)	210 (44.0)	[0.62; 0.95]	
			0.050	
Percentiles (months) [95% CI]				
25th	1.8 [1.5; 2.2]	1.1 [0.8; 1.3]		
Median	22.2 [21.8; 22.7]	11.1 [2.7; 19.6]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Nausea and vomiting (MID=10)				
N*	481	477	0.63	0.714
Number of patients with events, n (%)	115 (23.9)	157 (32.9)	[0.49; 0.80]	
			<0.001	
Percentiles (months) [95% CI]				
25th	11.1 [5.4; 16.9]	2.8 [1.3; 4.3]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Median	24.8 [24.7; 24.8]	22.2 [22.1; 22.3]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Pain (MID=10)				
N*	481	477	0.82	0.373
Number of patients with events, n (%)	202 (42.0)	230 (48.2)	[0.67; 1.00]	
			0.037	
Percentiles (months) [95% CI]				
25th	1.2 [0.9; 1.6]	1.0 [1.0; 1.1]		
Median	22.2 [12.1; 32.3]	5.7 [1.6; 9.8]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Dyspnoea (MID=10)				
N*	481	477	0.79	0.299
Number of patients with events, n (%)	147 (30.6)	167 (35.0)	[0.63; 1.00]	
			0.113	
Percentiles (months) [95% CI]				
25th	3.1 [-0.8; 7.0]	1.9 [1.2; 2.6]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Median	22.2 [21.9; 22.6]	22.4 [22.1; 22.7]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Insomnia (MID=10)				
N*	481	477	0.79	0.571
Number of patients with events, n (%)	176 (36.6)	182 (38.2)	[0.63; 1.00]	
			0.260	
Percentiles (months) [95% CI]				
25th	2.8 [1.3; 4.3]	1.9 [1.3; 2.5]		
Median	22.3 [21.9; 22.6]	22.1 [15.4; 28.9]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Appetite loss (MID=10)				
N*	481	477	0.61	0.254
Number of patients with events, n (%)	103 (21.4)	139 (29.1)	[0.46; 0.81]	
			0.002	
Percentiles (months) [95% CI]				
25th	22.0 [15.5; 28.6]	2.8 [0.9; 4.8]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Median	N.E. [N.E.; N.E.]	22.4 [22.0; 22.8]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Constipation (MID=10)				
N*	481	477	0.68	0.126
Number of patients with events, n (%)	135 (28.1)	162 (34.0)	[0.54; 0.87]	
			0.012	
Percentiles (months) [95% CI]				
25th	5.7 [2.3; 9.2]	2.3 [1.9; 2.8]		
Median	22.5 [22.4; 22.6]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Diarrhoea (MID=10)				
N*	481	477	0.91	0.451
Number of patients with events, n (%)	155 (32.2)	160 (33.5)	[0.72; 1.14]	
			0.682	
Percentiles (months) [95% CI]				
25th	2.8 [1.6; 4.1]	2.8 [1.7; 4.0]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Median	N.E. [N.E.; N.E.]	22.4 [21.9; 22.9]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Financial difficulties (MID=10)				
N*	481	477	1.00	0.911
Number of patients with events, n (%)	122 (25.4)	118 (24.7)	[0.76; 1.30]	
			0.473	
Percentiles (months) [95% CI]				
25th	5.6 [-2.4; 13.5]	5.7 [-2.3; 13.8]		
Median	N.E. [N.E.; N.E.]	26.4 [26.4; 26.5]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event. The number of patients is the mean number over all imputations rounded to the nearest integer
IPD: Individual Patient Data
.....
Missing baseline values are multiply imputed by simple imputation using 10 repetitions under a MAR assumption.
Two-sided 95% CI for KM percentiles are derived by the approach outlined in Moscovici and Ratitch (2017).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates baseline score and treatment arm.
P-Values for comparison of treatments are based on stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
Test results are combined using the Wilson-Hilferty transformation.
P-Values for test of heterogeneity are from the stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Test results are combined using the Wilson-Hilferty transformation.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Global health status/QoL (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	227 (98)	89 (217)	87 (218)	3 (293)	0 (296)	0 (296)
Investigator Selected TKI	477 (0)	177 (119)	67 (213)	56 (223)	4 (272)	1 (275)	0 (275)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Physical functioning (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	250 (110)	103 (242)	101 (244)	3 (340)	0 (342)	0 (342)
Investigator Selected TKI	477 (0)	205 (132)	77 (246)	66 (257)	2 (318)	0 (320)	0 (320)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Role functioning (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	221 (97)	93 (211)	91 (212)	2 (295)	0 (297)	0 (297)
Investigator Selected TKI	477 (0)	174 (119)	62 (215)	55 (222)	2 (271)	0 (273)	0 (273)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Emotional functioning (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	246 (97)	94 (231)	93 (231)	3 (318)	0 (321)	0 (321)
Investigator Selected TKI	477 (0)	189 (133)	76 (230)	69 (236)	4 (296)	1 (299)	0 (300)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Cognitive functioning (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	201 (97)	81 (197)	77 (199)	1 (267)	0 (269)	0 (269)
Investigator Selected TKI	477 (0)	155 (120)	51 (204)	48 (207)	1 (249)	0 (250)	0 (250)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Social functioning (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	228 (92)	98 (214)	96 (215)	2 (303)	0 (305)	0 (305)
Investigator Selected TKI	477 (0)	163 (116)	66 (204)	58 (212)	2 (264)	1 (265)	0 (266)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Fatigue (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	211 (103)	73 (227)	71 (228)	2 (293)	0 (294)	0 (294)
Investigator Selected TKI	477 (0)	163 (118)	54 (217)	47 (225)	2 (265)	0 (267)	0 (267)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Nausea and vomiting (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	273 (114)	112 (260)	108 (262)	3 (363)	0 (366)	0 (366)
Investigator Selected TKI	477 (0)	199 (141)	73 (252)	65 (260)	3 (317)	0 (320)	0 (320)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Pain (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	206 (95)	86 (196)	85 (197)	3 (276)	0 (279)	0 (279)
Investigator Selected TKI	477 (0)	150 (116)	56 (193)	50 (198)	1 (246)	0 (247)	0 (247)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Dyspnoea (MID=10)



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Insomnia (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	231 (103)	88 (225)	86 (227)	3 (303)	0 (305)	0 (305)
Investigator Selected TKI	477 (0)	178 (134)	65 (235)	61 (240)	5 (290)	1 (294)	0 (295)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Appetite loss (MID=10)



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Constipation (MID=10)




Pts at Risk (censored)

Asciminib	481 (0)	259 (114)	99 (253)	95 (256)	2 (344)	0 (346)	0 (346)
Investigator Selected TKI	477 (0)	190 (147)	68 (249)	61 (255)	2 (313)	0 (315)	0 (315)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Diarrhoea (MID=10)




Pts at Risk (censored)							
Asciminib	481 (0)	234 (107)	85 (245)	84 (246)	1 (325)	0 (326)	0 (326)
Investigator Selected TKI	477 (0)	197 (140)	65 (256)	60 (261)	4 (313)	0 (317)	0 (317)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Financial difficulties (MID=10)



Pts at Risk (censored)

Asciminib	481 (0)	257 (110)	114 (248)	111 (250)	4 (355)	0 (359)	0 (359)
Investigator Selected TKI	477 (0)	231 (144)	97 (267)	87 (277)	5 (355)	1 (358)	0 (359)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-4.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Body Image Problems (MID=15)				
N*	481	477	0.84	0.677
Number of patients with events, n (%)	186 (39.0)	194 (40.7)	[0.68; 1.04]	
			0.278	
Percentiles (months) [95% CI]				
25th	2.0 [1.6; 2.4]	1.9 [1.5; 2.3]		
Median	22.2 [22.1; 22.3]	16.7 [10.8; 22.5]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Impact on Daily Life (MID=15)				
N*	481	477	0.65	0.606
Number of patients with events, n (%)	122 (25.6)	160 (33.5)	[0.50; 0.85]	
			0.009	
Percentiles (months) [95% CI]				
25th	11.0 [2.0; 20.0]	2.7 [2.0; 3.4]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Impact on Worry/Mood (MID=15)				
N*	481	477	0.80	0.671
Number of patients with events, n (%)	123 (25.8)	126 (26.4)	[0.61; 1.06]	
			0.622	
Percentiles (months) [95% CI]				
25th	9.0 [0.2; 17.7]	5.6 [1.9; 9.3]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Symptom Burden (MID=15)				
N*	481	477	0.49	0.804
Number of patients with events, n (%)	74 (15.5)	126 (26.4)	[0.35; 0.68]	
			<0.001	
Percentiles (months) [95% CI]				
25th	22.6 [21.6; 23.5]	5.6 [1.9; 9.4]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Median	N.E. [N.E.; N.E.]	22.4 [20.6; 24.3]		
75th	N.E. [N.E.; N.E.]	25.7 [25.6; 25.7]		
Satisfaction with Care and Information (MID=15)				
N*	481	477	1.12	0.841
Number of patients with events, n (%)	180 (37.7)	141 (29.6)	[0.86; 1.44]	
			0.308	
Percentiles (months) [95% CI]				
25th	2.0 [1.5; 2.4]	2.8 [1.3; 4.3]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Satisfaction with Social Life (MID=15)				
N*	481	477	1.01	0.641
Number of patients with events, n (%)	211 (44.2)	192 (40.3)	[0.81; 1.26]	
			0.755	
Percentiles (months) [95% CI]				
25th	1.1 [0.8; 1.5]	1.9 [1.6; 2.2]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Median	11.2 [9.1; 13.3]	22.1 [10.0; 34.3]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event. The number of patients is the mean number over all imputations rounded to the nearest integer
IPD: Individual Patient Data
.....
Missing baseline values are multiply imputed by simple imputation using 500 repetitions under a MAR assumption.
Two-sided 95% CI for KM percentiles are derived by the approach outlined in Moscovici and Ratitch (2017).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates baseline score and treatment arm.
P-Values for comparison of treatments are based on stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
Test results are combined using the Wilson-Hilferty transformation.
P-Values for test of heterogeneity are from the stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Test results are combined using the Wilson-Hilferty transformation.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Body Image Problems (MID=15)




Pts at Risk (censored)

Asciminib	481 (0)	216 (100)	92 (210)	91 (211)	3 (292)	0 (295)	0 (295)
Investigator Selected TKI	477 (0)	176 (127)	67 (222)	58 (231)	2 (281)	0 (283)	0 (283)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Impact on Daily Life (MID=15)




Pts at Risk (censored)

Asciminib	481 (0)	268 (107)	115 (245)	114 (246)	3 (356)	0 (359)	0 (359)
Investigator Selected TKI	477 (0)	205 (131)	81 (239)	71 (249)	3 (314)	1 (316)	0 (317)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Impact on Worry/Mood (MID=15)




Pts at Risk (censored)

Asciminib	481 (0)	265 (112)	107 (257)	105 (259)	3 (355)	0 (358)	0 (358)
Investigator Selected TKI	477 (0)	220 (147)	82 (274)	71 (285)	4 (347)	1 (350)	0 (351)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Symptom Burden (MID=15)



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Satisfaction with Care and Information (MID=15)




Pts at Risk (censored)

Asciminib	481 (0)	219 (106)	71 (232)	69 (233)	3 (298)	0 (301)	0 (301)
Investigator Selected TKI	477 (0)	200 (147)	73 (264)	62 (275)	5 (331)	1 (335)	0 (336)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Satisfaction with Social Life (MID=15)



Pts at Risk (censored)

Asciminib	481 (0)	200 (92)	80 (192)	78 (194)	4 (267)	0 (270)	0 (270)
Investigator Selected TKI	477 (0)	169 (129)	69 (219)	60 (226)	1 (285)	0 (285)	0 (285)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Table 3-4.3 FACT-ITEM GP5: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
V4 (MID=1)				
N*	481	477	0.66	0.163
Number of patients with events, n (%)	278 (58.3)	321 (67.3)	[0.55; 0.78]	
			0.001	
Percentiles (months) [95% CI]				
25th	0.5 [0.4; 0.6]	0.3 [0.3; 0.3]		
Median	2.6 [1.3; 3.9]	1.0 [0.7; 1.3]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event. The number of patients is the mean number over all imputations rounded to the nearest integer
IPD: Individual Patient Data
.....
Missing baseline values are multiply imputed by simple imputation using 500 repetitions under a MAR assumption.
Two-sided 95% CI for KM percentiles are derived by the approach outlined in Moscovici and Ratitch (2017).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates baseline score and treatment arm.
P-Values for comparison of treatments are based on stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
Test results are combined using the Wilson-Hilferty transformation.
P-Values for test of heterogeneity are from the stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Test results are combined using the Wilson-Hilferty transformation.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.3 FACT-ITEM GP5: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

V4 (MID=1)



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-4.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Headache - Frequency (MID=1)				
N*	481	477	0.72	0.471
Number of patients with events, n (%)	290 (60.3)	320 (67.1)	[0.61; 0.86]	
			0.010	
Percentiles (months) [95% CI]				
25th	0.5 [0.3; 0.7]	0.3 [0.3; 0.4]		
Median	3.1 [1.9; 4.2]	1.5 [0.9; 2.1]		
75th	N.E. [N.E.; N.E.]	19.4 [8.9; 29.8]		
Rash - Presence/Absence (MID=1)				
N*	481	477	0.68	0.724
Number of patients with events, n (%)	254 (52.8)	286 (60.0)	[0.57; 0.81]	
			<0.001	
Percentiles (months) [95% CI]				
25th	1.7 [1.2; 2.1]	0.6 [0.5; 0.7]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	Investigator Selected TKI (N = 477)	HR [95% CI] p-value	Test for Heterogeneity p-Value
Median	8.3 [5.4; 11.3]	2.9 [1.7; 4.1]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Diarrhea - Frequency (MID=1)				
N*	481	477	0.95	0.073
Number of patients with events, n (%)	288 (59.9)	286 (60.0)	[0.80; 1.13]	
			0.859	
Percentiles (months) [95% CI]				
25th	0.5 [0.4; 0.7]	0.5 [0.4; 0.7]		
Median	2.6 [1.4; 3.8]	2.6 [1.8; 3.4]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Vomiting - Frequency (MID=1)				
N*	481	477	0.53	0.797
Number of patients with events, n (%)	96 (20.0)	152 (31.9)	[0.41; 0.69]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	3.7 [2.3; 5.2]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	Investigator Selected TKI (N = 477)	HR [95% CI] p-value	Test for Heterogeneity p-Value
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Nausea - Frequency (MID=1)				
N*	481	477	0.60	0.076
Number of patients with events, n (%)	204 (42.4)	279 (58.5)	[0.50; 0.73]	
			<0.001	
Percentiles (months) [95% CI]				
25th	1.2 [0.6; 1.9]	0.5 [0.4; 0.7]		
Median	N.E. [N.E.; N.E.]	3.3 [1.9; 4.7]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Edema - Frequency (MID=1)				
N*	481	477	0.70	0.012
Number of patients with events, n (%)	192 (39.9)	232 (48.6)	[0.57; 0.86]	
			0.002	
Percentiles (months) [95% CI]				
25th	2.2 [1.5; 2.9]	1.2 [0.9; 1.6]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	Investigator Selected TKI (N = 477)	HR [95% CI] p-value	Test for Heterogeneity p-Value
Median	N.E. [N.E.; N.E.]	11.1 [7.3; 15.0]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Muscle Pain - Frequency (MID=1)				
N*	481	477	0.81	0.097
Number of patients with events, n (%)	298 (62.0)	331 (69.4)	[0.69; 0.96]	
			0.090	
Percentiles (months) [95% CI]				
25th	0.4 [0.3; 0.4]	0.3 [0.3; 0.4]		
Median	1.2 [0.8; 1.7]	1.1 [0.7; 1.4]		
75th	31.9 [31.8; 32.0]	13.9 [7.6; 20.1]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event. The number of patients is the mean number over all imputations rounded to the nearest integer
IPD: Individual Patient Data
.....
Missing baseline values are multiply imputed by simple imputation using 500 repetitions under a MAR assumption.
Two-sided 95% CI for KM percentiles are derived by the approach outlined in Moscovici and Ratitch (2017).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates baseline score and treatment arm.
P-Values for comparison of treatments are based on stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
Test results are combined using the Wilson-Hilferty transformation.
P-Values for test of heterogeneity are from the stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Test results are combined using the Wilson-Hilferty transformation.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Headache - Frequency (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	167 (47)	111 (91)	80 (116)	40 (151)	10 (181)	0 (191)
Investigator Selected TKI	477 (0)	127 (59)	78 (90)	50 (112)	20 (137)	1 (155)	0 (157)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Rash - Presence/Absence (MID=1)



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Diarrhea - Frequency (MID=1)



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Vomiting - Frequency (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	336 (69)	246 (151)	165 (223)	83 (302)	19 (366)	0 (385)
Investigator Selected TKI	477 (0)	261 (88)	173 (161)	102 (227)	45 (280)	8 (317)	0 (325)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Nausea - Frequency (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	247 (55)	165 (121)	111 (171)	59 (220)	13 (265)	0 (277)
Investigator Selected TKI	477 (0)	164 (64)	102 (108)	64 (142)	24 (178)	6 (192)	0 (198)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Edema - Frequency (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	259 (60)	177 (122)	115 (181)	62 (228)	15 (274)	0 (289)
Investigator Selected TKI	477 (0)	208 (79)	120 (142)	68 (181)	27 (220)	6 (239)	0 (245)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Muscle Pain - Frequency (MID=1)



Pts at Risk (censored)

Asciminib	481 (0)	156 (46)	105 (85)	72 (113)	41 (143)	11 (173)	0 (183)
Investigator Selected TKI	477 (0)	117 (51)	64 (89)	41 (108)	18 (129)	2 (145)	0 (146)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-4.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Fatigue - Severity (MID=1)				
N*	481	477	0.81	0.802
Number of patients with events, n (%)	284 (59.0)	296 (62.1)	[0.68; 0.97]	
			0.455	
Percentiles (months) [95% CI]				
25th	0.4 [0.3; 0.4]	0.3 [0.3; 0.4]		
Median	2.6 [-0.6; 5.8]	1.7 [0.8; 2.6]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Headache - Severity (MID=1)				
N*	481	477	0.76	0.551
Number of patients with events, n (%)	286 (59.5)	309 (64.8)	[0.64; 0.90]	
			0.044	
Percentiles (months) [95% CI]				
25th	0.5 [0.3; 0.8]	0.3 [0.3; 0.4]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Median	2.8 [1.6; 4.0]	1.8 [0.9; 2.6]		
75th	N.E. [N.E.; N.E.]	27.7 [15.3; 40.0]		
Vomiting - Severity (MID=1)				
N*	481	477	0.51	0.234
Number of patients with events, n (%)	86 (17.9)	141 (29.6)	[0.39; 0.67]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	4.7 [2.0; 7.4]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Nausea - Severity (MID=1)				
N*	481	477	0.58	0.045
Number of patients with events, n (%)	193 (40.1)	275 (57.7)	[0.48; 0.71]	
			<0.001	
Percentiles (months) [95% CI]				
25th	1.4 [0.8; 2.1]	0.6 [0.4; 0.7]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	Investigator Selected TKI (N = 477)	HR [95% CI] p-value	Test for Heterogeneity p-Value
Median	N.E. [N.E.; N.E.]	3.5 [2.0; 5.0]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Edema - Severity (MID=1)				
N*	481	477	0.68	0.032
Number of patients with events, n (%)	166 (34.5)	208 (43.6)	[0.55; 0.84]	
			0.001	
Percentiles (months) [95% CI]				
25th	3.1 [1.7; 4.4]	1.5 [1.0; 2.0]		
Median	N.E. [N.E.; N.E.]	14.9 [7.1; 22.8]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Muscle Pain - Severity (MID=1)				
N*	481	477	0.75	0.069
Number of patients with events, n (%)	277 (57.6)	329 (69.0)	[0.63; 0.89]	
			0.004	
Percentiles (months) [95% CI]				
25th	0.4 [0.3; 0.4]	0.3 [0.3; 0.4]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Median	1.9 [0.3; 3.5]	1.1 [0.6; 1.5]		
75th	N.E. [N.E.; N.E.]	15.7 [8.4; 23.1]		
Pruritus - Severity (MID=1)				
N*	481	477	0.69	0.133
Number of patients with events, n (%)	285 (59.3)	327 (68.6)	[0.59; 0.82]	
			<0.001	
Percentiles (months) [95% CI]				
25th	0.8 [0.6; 1.0]	0.5 [0.5; 0.6]		
Median	3.9 [2.5; 5.2]	2.1 [1.7; 2.6]		
75th	N.E. [N.E.; N.E.]	16.7 [10.5; 22.8]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event. The number of patients is the mean number over all imputations rounded to the nearest integer
IPD: Individual Patient Data
.....
Missing baseline values are multiply imputed by simple imputation using 500 repetitions under a MAR assumption.
Two-sided 95% CI for KM percentiles are derived by the approach outlined in Moscovici and Ratitch (2017).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates baseline score and treatment arm.
P-Values for comparison of treatments are based on stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
Test results are combined using the Wilson-Hilferty transformation.
P-Values for test of heterogeneity are from the stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Test results are combined using the Wilson-Hilferty transformation.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Fatigue - Severity (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	188 (44)	125 (90)	83 (124)	39 (160)	8 (188)	0 (197)
Investigator Selected TKI	477 (0)	151 (56)	96 (95)	54 (129)	22 (159)	5 (176)	0 (181)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Headache - Severity (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	171 (46)	111 (95)	78 (121)	42 (154)	10 (185)	0 (195)
Investigator Selected TKI	477 (0)	141 (59)	89 (95)	54 (120)	23 (146)	1 (167)	0 (168)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Vomiting - Severity (MID=1)



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Nausea - Severity (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	254 (58)	172 (124)	116 (175)	63 (225)	12 (275)	0 (288)
Investigator Selected TKI	477 (0)	170 (62)	102 (112)	65 (145)	23 (182)	6 (195)	0 (202)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Edema - Severity (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	279 (62)	191 (133)	125 (196)	65 (251)	15 (300)	0 (315)
Investigator Selected TKI	477 (0)	219 (82)	130 (150)	75 (196)	31 (238)	6 (263)	0 (269)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Muscle Pain - Severity (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	174 (49)	118 (94)	78 (129)	43 (162)	11 (194)	0 (204)
Investigator Selected TKI	477 (0)	120 (52)	62 (91)	37 (113)	19 (129)	2 (146)	0 (148)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Pruritus - Severity (MID=1)



Pts at Risk (censored)

Asciminib	481 (0)	181 (49)	108 (100)	71 (132)	35 (161)	9 (187)	0 (196)
Investigator Selected TKI	477 (0)	126 (60)	72 (94)	47 (109)	18 (132)	3 (146)	0 (150)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-4.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Fatigue - Interference (MID=1)				
N*	481	477	0.81	0.124
Number of patients with events, n (%)	285 (59.3)	297 (62.3)	[0.67; 0.97]	
			0.293	
Percentiles (months) [95% CI]				
25th	0.5 [0.4; 0.6]	0.3 [0.3; 0.4]		
Median	3.1 [1.1; 5.0]	1.4 [0.6; 2.2]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Headache - Interference (MID=1)				
N*	481	477	0.78	0.731
Number of patients with events, n (%)	247 (51.4)	264 (55.3)	[0.65; 0.94]	
			0.051	
Percentiles (months) [95% CI]				
25th	1.4 [1.0; 1.9]	0.6 [0.3; 0.8]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	Investigator Selected TKI (N = 477)	HR [95% CI] p-value	Test for Heterogeneity p-Value
Median	11.1 [4.9; 17.4]	4.2 [1.5; 6.9]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Edema - Interference (MID=1)				
N*	481	477	0.64	0.304
Number of patients with events, n (%)	123 (25.6)	162 (34.0)	[0.51; 0.82]	
			0.001	
Percentiles (months) [95% CI]				
25th	11.0 [3.8; 18.2]	3.1 [1.7; 4.4]		
Median	32.8 [32.7; 32.8]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Muscle Pain - Interference (MID=1)				
N*	481	477	0.85	0.162
Number of patients with events, n (%)	257 (53.4)	276 (57.9)	[0.71; 1.02]	
			0.301	
Percentiles (months) [95% CI]				
25th	0.5 [0.4; 0.7]	0.5 [0.5; 0.6]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-Value**
Median	4.7 [-1.2; 10.5]	2.8 [1.3; 4.3]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event. The number of patients is the mean number over all imputations rounded to the nearest integer
IPD: Individual Patient Data
.....
Missing baseline values are multiply imputed by simple imputation using 500 repetitions under a MAR assumption.
Two-sided 95% CI for KM percentiles are derived by the approach outlined in Moscovici and Ratitch (2017).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates baseline score and treatment arm.
P-Values for comparison of treatments are based on stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
Test results are combined using the Wilson-Hilferty transformation.
P-Values for test of heterogeneity are from the stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Test results are combined using the Wilson-Hilferty transformation.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Fatigue - Interference (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	180 (46)	120 (89)	83 (120)	39 (158)	11 (185)	0 (196)
Investigator Selected TKI	477 (0)	145 (57)	94 (96)	57 (127)	23 (157)	3 (177)	0 (180)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Headache - Interference (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	218 (53)	147 (106)	99 (144)	44 (192)	12 (222)	0 (234)
Investigator Selected TKI	477 (0)	174 (69)	114 (114)	69 (149)	25 (188)	5 (207)	0 (213)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Edema - Interference (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	313 (68)	225 (143)	148 (215)	77 (282)	20 (338)	0 (358)
Investigator Selected TKI	477 (0)	248 (93)	158 (168)	93 (225)	44 (273)	7 (308)	0 (315)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-4.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Muscle Pain - Interference (MID=1)



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-5.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Global health status/QoL (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.402)								
Low	129/291 (44.3)	21.9 [13.8; 30.1]	133/292 (45.5)	11.1 [-0.6; 22.8]	0.96	[0.73; 1.25]	0.930	0.544
Intermediate	41/129 (31.8)	22.2 [22.2; 22.3]	54/128 (42.2)	11.1 [-6.6; 28.7]	0.61	[0.39; 0.96]	0.059	0.687
High	15/61 (24.6)	N.E. [N.E.; N.E.]	16/57 (28.1)	N.E. [N.E.; N.E.]	0.79	[0.35; 1.76]	0.976	0.897
Sex								
(Interaction test p = 0.667)								
Female	73/175	22.5 [4.9; 40.1]	86/201	11.1 [-0.6; 22.9]	0.86	[0.60; 1.23]	0.717	0.670

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(41.7)		(42.8)					
Male	112/306	22.2 [22.1; 22.3]	116/276	22.0 [13.0; 31.0]	0.87	[0.65; 1.17]	0.249	0.798
	(36.6)		(42.0)					
Race								
(Interaction test p = 0.792)								
White	129/333	22.1 [22.0; 22.3]	131/320	22.0 [11.3; 32.7]	0.90	[0.69; 1.18]	0.495	0.640
	(38.7)		(40.9)					
Asian	50/128	N.E. [N.E.; N.E.]	64/132	11.1 [-3.0; 25.1]	0.76	[0.51; 1.12]	0.170	0.883
	(39.1)		(48.5)					
Others	6/20	N.E. [N.E.; N.E.]	7/25	N.E. [N.E.; N.E.]	0.82	[0.17; 3.97]	0.808	0.113
	(30.0)		(28.0)					
Age groups								
(Interaction test p = 0.954)								
18 - < 65 years	149/390	22.2 [21.9; 22.5]	170/397	22.0 [14.7; 29.3]	0.84	[0.66; 1.07]	0.213	0.546
	(38.2)		(42.8)					
65 - < 75 years	28/72	N.E. [N.E.; N.E.]	20/53	N.E. [N.E.; N.E.]	1.10	[0.53; 2.26]	0.682	0.866

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(38.9)		(37.7)					
>= 75 years	8/19	N.E. [N.E.; N.E.]	12/27	5.6 [5.3; 6.0]	0.69	[0.18; 2.61]	0.552	0.799
	(42.1)		(44.4)					
Pre-randomization selection of TKI								
(Interaction test p = 0.400)								
Imatinib	44/101	22.1 [12.7; 31.4]	43/102	11.1 [-5.4; 27.6]	0.84	[0.53; 1.33]	0.688	N.E.
	(43.6)		(42.2)					
Nilotinib	128/339	22.2 [21.9; 22.5]	138/333	22.0 [8.3; 35.8]	0.85	[0.65; 1.10]	0.353	0.490
	(37.8)		(41.4)					
Dasatinib	13/41	N.E. [N.E.; N.E.]	21/42	11.1 [-6.8; 29.0]	0.79	[0.36; 1.74]	0.528	N.E.
	(31.7)		(50.0)					
Geographic region								
(Interaction test p = 0.508)								
Europe excluding Germany	73/202	22.2 [22.0; 22.4]	84/203	22.0 [10.3; 33.7]	0.83	[0.59; 1.18]	0.440	0.813
	(36.1)		(41.4)					
Germany	41/91	11.2 [3.7; 18.7]	29/68	11.1 [-11.2; 33.5]	0.70	[0.39; 1.25]	0.768	0.838

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(45.1)		(42.6)					
Others	71/188	22.5 [21.6; 23.4]	90/206	11.1 [3.4; 18.9]	0.83	[0.59; 1.18]	0.254	0.469
	(37.8)		(43.7)					
Physical functioning (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.196)								
Low	78/291	N.E. [N.E.; N.E.]	109/292	22.2 [22.1; 22.2]	0.64	[0.46; 0.88]	0.012	0.695
	(26.8)		(37.3)					
Intermediate	47/129	N.E. [N.E.; N.E.]	38/128	N.E. [N.E.; N.E.]	1.09	[0.69; 1.73]	0.652	0.237
	(36.4)		(29.7)					
High	14/61	N.E. [N.E.; N.E.]	10/57	N.E. [N.E.; N.E.]	1.11	[0.43; 2.84]	0.932	0.896
	(23.0)		(17.5)					
Sex								
(Interaction test p = 0.528)								
Female	61/175	N.E. [N.E.; N.E.]	79/201	22.1 [12.9; 31.4]	0.82	[0.57; 1.19]	0.525	0.841

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(34.9)		(39.3)					
Male	78/306	N.E. [N.E.; N.E.]	78/276	N.E. [N.E.; N.E.]	0.81	[0.58; 1.14]	0.493	0.520
	(25.5)		(28.3)					
Race								
(Interaction test p = 0.721)								
White	97/333	N.E. [N.E.; N.E.]	103/320	N.E. [N.E.; N.E.]	0.83	[0.61; 1.13]	0.450	0.623
	(29.1)		(32.2)					
Asian	37/128	N.E. [N.E.; N.E.]	46/132	22.2 [22.1; 22.2]	0.72	[0.46; 1.14]	0.322	0.498
	(28.9)		(34.8)					
Others	4/20	N.E. [N.E.; N.E.]	8/25	11.1 [11.1; 11.2]	0.50	[0.11; 2.33]	0.928	0.379
	(20.0)		(32.0)					
Age groups								
(Interaction test p = 0.507)								
18 - < 65 years	107/390	N.E. [N.E.; N.E.]	131/397	N.E. [N.E.; N.E.]	0.74	[0.56; 0.98]	0.099	0.872
	(27.4)		(33.0)					
65 - < 75 years	22/72	N.E. [N.E.; N.E.]	19/53	N.E. [N.E.; N.E.]	0.80	[0.39; 1.63]	0.724	0.777

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(30.6)		(35.8)					
>= 75 years	11/19	5.9 [-3.4; 15.1]	7/27	N.E. [N.E.; N.E.]	2.32	[0.61; 8.89]	0.412	0.758
	(57.9)		(25.9)					
Pre-randomization selection of TKI								
(Interaction test p = 0.846)								
Imatinib	29/101	N.E. [N.E.; N.E.]	36/102	22.1 [-0.3; 44.5]	0.65	[0.38; 1.11]	0.228	N.E.
	(28.7)		(35.3)					
Nilotinib	95/339	N.E. [N.E.; N.E.]	100/333	N.E. [N.E.; N.E.]	0.85	[0.63; 1.16]	0.712	0.507
	(28.0)		(30.0)					
Dasatinib	15/41	27.7 [27.5; 27.8]	21/42	11.3 [-2.8; 25.4]	0.75	[0.36; 1.59]	0.713	N.E.
	(36.6)		(50.0)					
Geographic region								
(Interaction test p = 0.583)								
Europe excluding Germany	54/202	N.E. [N.E.; N.E.]	68/203	N.E. [N.E.; N.E.]	0.72	[0.48; 1.06]	0.181	0.722
	(26.7)		(33.5)					
Germany	33/91	N.E. [N.E.; N.E.]	26/68	N.E. [N.E.; N.E.]	0.71	[0.38; 1.35]	0.926	0.272

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(36.3)		(38.2)					
Others	52/188	N.E. [N.E.; N.E.]	63/206	N.E. [N.E.; N.E.]	0.84	[0.57; 1.25]	0.815	0.271
	(27.7)		(30.6)					
Role functioning (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.705)								
Low	117/291	22.5 [22.0; 23.0]	134/292	11.1 [1.6; 20.6]	0.76	[0.58; 0.99]	0.171	0.754
	(40.2)		(45.9)					
Intermediate	54/129	22.1 [16.1; 28.1]	54/128	11.1 [7.8; 14.5]	0.89	[0.59; 1.35]	0.838	0.974
	(41.9)		(42.2)					
High	14/61	N.E. [N.E.; N.E.]	15/57	N.E. [N.E.; N.E.]	0.65	[0.29; 1.47]	0.841	0.699
	(23.0)		(26.3)					
Sex								
(Interaction test p = 0.572)								
Female	73/175	22.5 [7.7; 37.3]	94/201	6.8 [2.9; 10.7]	0.82	[0.59; 1.15]	0.328	0.715

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(41.7)		(46.8)					
Male	111/306	22.2 [21.9; 22.5]	110/276	22.2 [16.1; 28.3]	0.78	[0.59; 1.04]	0.472	0.886
	(36.3)		(39.9)					
Race								
(Interaction test p = 0.795)								
White	137/333	22.2 [12.6; 31.8]	138/320	11.1 [0.4; 21.8]	0.86	[0.66; 1.11]	0.759	0.853
	(41.1)		(43.1)					
Asian	38/128	N.E. [N.E.; N.E.]	54/132	22.2 [17.8; 26.5]	0.61	[0.39; 0.94]	0.058	0.911
	(29.7)		(40.9)					
Others	9/20	2.8 [2.8; 2.9]	12/25	5.7 [0.1; 11.3]	0.39	[0.12; 1.24]	0.443	0.138
	(45.0)		(48.0)					
Age groups								
(Interaction test p = 0.888)								
18 - < 65 years	146/390	22.5 [21.9; 23.1]	171/397	11.3 [6.1; 16.6]	0.76	[0.60; 0.97]	0.139	0.210
	(37.4)		(43.1)					
65 - < 75 years	29/72	N.E. [N.E.; N.E.]	20/53	12.0 [10.0; 14.0]	0.95	[0.48; 1.85]	0.824	0.870

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(40.3)		(37.7)					
>= 75 years	9/19	22.1 [43.6; 0.7]	13/27	5.5 [-0.5; 11.4]	0.65	[0.20; 2.12]	0.977	0.886
	(47.4)		(48.1)					
Pre-randomization selection of TKI								
(Interaction test p = 0.440)								
Imatinib	36/101	N.E. [N.E.; N.E.]	46/102	10.8 [2.5; 19.2]	0.56	[0.35; 0.89]	0.047	N.E.
	(35.6)		(45.1)					
Nilotinib	131/339	22.5 [15.2; 29.8]	133/333	22.2 [16.1; 28.3]	0.87	[0.67; 1.13]	0.919	0.993
	(38.6)		(39.9)					
Dasatinib	17/41	N.E. [N.E.; N.E.]	25/42	3.0 [-0.1; 6.1]	0.74	[0.38; 1.46]	0.666	N.E.
	(41.5)		(59.5)					
Geographic region								
(Interaction test p = 0.498)								
Europe excluding Germany	80/202	22.2 [21.9; 22.5]	89/203	11.1 [-1.4; 23.6]	0.80	[0.57; 1.11]	0.533	0.853
	(39.6)		(43.8)					
Germany	46/91	11.0 [2.2; 19.9]	35/68	2.7 [-1.3; 6.7]	0.68	[0.39; 1.16]	0.764	0.693

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(50.5)		(51.5)					
Others	59/188	22.5 [22.5; 22.6]	80/206	22.2 [18.0; 26.4]	0.68	[0.47; 0.97]	0.118	0.494
	(31.4)		(38.8)					
Emotional functioning (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.860)								
Low	101/291	22.5 [21.7; 23.3]	119/292	22.1 [10.7; 33.5]	0.72	[0.54; 0.96]	0.246	0.992
	(34.7)		(40.8)					
Intermediate	45/129	N.E. [N.E.; N.E.]	42/128	22.4 [21.5; 23.3]	0.94	[0.60; 1.48]	0.577	0.890
	(34.9)		(32.8)					
High	14/61	N.E. [N.E.; N.E.]	16/57	N.E. [N.E.; N.E.]	0.68	[0.31; 1.49]	0.691	0.842
	(23.0)		(28.1)					
Sex								
(Interaction test p = 0.583)								
Female	66/175	22.3 [21.4; 23.1]	82/201	11.8 [3.0; 20.7]	0.77	[0.53; 1.10]	0.450	0.608

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(37.7)		(40.8)					
Male	93/306	N.E. [N.E.; N.E.]	94/276	N.E. [N.E.; N.E.]	0.78	[0.57; 1.06]	0.574	0.638
	(30.4)		(34.1)					
Race								
(Interaction test p = 0.549)								
White	115/333	N.E. [N.E.; N.E.]	122/320	22.1 [10.0; 34.2]	0.79	[0.59; 1.05]	0.479	0.621
	(34.5)		(38.1)					
Asian	36/128	N.E. [N.E.; N.E.]	45/132	N.E. [N.E.; N.E.]	0.69	[0.43; 1.10]	0.371	0.529
	(28.1)		(34.1)					
Others	9/20	11.2 [2.7; 19.7]	9/25	N.E. [N.E.; N.E.]	0.79	[0.21; 3.01]	0.793	0.412
	(45.0)		(36.0)					
Age groups								
(Interaction test p = 0.561)								
18 - < 65 years	131/390	N.E. [N.E.; N.E.]	151/397	22.1 [9.0; 35.2]	0.75	[0.58; 0.97]	0.298	0.651
	(33.6)		(38.0)					
65 - < 75 years	23/72	N.E. [N.E.; N.E.]	18/53	N.E. [N.E.; N.E.]	0.92	[0.42; 2.01]	0.826	0.834

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(31.9)		(34.0)					
>= 75 years	6/19	N.E. [N.E.; N.E.]	8/27	11.1 [11.0; 11.2]	0.89	[0.22; 3.64]	0.853	0.886
	(31.6)		(29.6)					
Pre-randomization selection of TKI								
(Interaction test p = 0.999)								
Imatinib	34/101	N.E. [N.E.; N.E.]	37/102	22.1 [22.1; 22.2]	0.79	[0.47; 1.32]	0.599	N.E.
	(33.7)		(36.3)					
Nilotinib	115/339	N.E. [N.E.; N.E.]	119/333	N.E. [N.E.; N.E.]	0.79	[0.60; 1.05]	0.853	0.435
	(33.9)		(35.7)					
Dasatinib	12/41	N.E. [N.E.; N.E.]	21/42	11.0 [-12.2; 34.2]	0.53	[0.23; 1.19]	0.270	N.E.
	(29.3)		(50.0)					
Geographic region								
(Interaction test p = 0.587)								
Europe excluding Germany	66/202	N.E. [N.E.; N.E.]	80/203	11.6 [10.6; 12.6]	0.70	[0.49; 1.00]	0.231	0.645
	(32.7)		(39.4)					
Germany	35/91	N.E. [N.E.; N.E.]	26/68	22.1 [-2.5; 46.7]	0.84	[0.45; 1.57]	0.753	0.919

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(38.5)		(38.2)					
Others	59/188	N.E. [N.E.; N.E.]	70/206	N.E. [N.E.; N.E.]	0.80	[0.55; 1.17]	0.817	0.582
	(31.4)		(34.0)					
Cognitive functioning (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.111)								
Low	125/291	22.1 [14.5; 29.7]	152/292	5.6 [2.1; 9.1]	0.72	[0.56; 0.92]	0.031	0.910
	(43.0)		(52.1)					
Intermediate	67/129	5.6 [0.4; 10.8]	54/128	11.1 [6.8; 15.4]	1.22	[0.83; 1.78]	0.730	0.995
	(51.9)		(42.2)					
High	21/61	22.1 [22.0; 22.2]	22/57	11.2 [11.1; 11.3]	0.70	[0.36; 1.36]	0.568	0.647
	(34.4)		(38.6)					
Sex								
(Interaction test p = 0.789)								
Female	90/175	11.1 [7.3; 14.8]	99/201	5.7 [1.4; 10.0]	0.97	[0.71; 1.32]	0.600	0.750

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(51.4)		(49.3)					
Male	123/306	22.1 [16.4; 27.9]	128/276	11.0 [7.7; 14.3]	0.78	[0.60; 1.01]	0.127	0.469
	(40.2)		(46.4)					
Race								
(Interaction test p = 0.774)								
White	149/333	11.2 [5.2; 17.2]	150/320	5.6 [0.8; 10.4]	0.83	[0.64; 1.06]	0.312	0.898
	(44.7)		(46.9)					
Asian	56/128	N.E. [N.E.; N.E.]	64/132	11.1 [3.7; 18.6]	0.87	[0.60; 1.27]	0.939	0.476
	(43.8)		(48.5)					
Others	8/20	N.E. [N.E.; N.E.]	13/25	5.6 [-11.4; 22.6]	0.67	[0.22; 2.09]	0.777	0.155
	(40.0)		(52.0)					
Age groups								
(Interaction test p = 0.824)								
18 - < 65 years	171/390	11.2 [5.6; 16.9]	198/397	5.7 [3.0; 8.4]	0.79	[0.63; 0.98]	0.079	0.838
	(43.8)		(49.9)					
65 - < 75 years	33/72	13.9 [1.4; 26.4]	19/53	N.E. [N.E.; N.E.]	1.14	[0.59; 2.19]	0.812	0.533

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(45.8)		(35.8)					
>= 75 years	9/19	5.6 [1.1; 10.2]	10/27	11.1 [0.8; 21.4]	0.90	[0.27; 2.97]	0.571	0.660
	(47.4)		(37.0)					
Pre-randomization selection of TKI								
(Interaction test p = 0.973)								
Imatinib	39/101	22.1 [22.0; 22.3]	46/102	11.0 [5.0; 17.1]	0.71	[0.45; 1.13]	0.205	N.E.
	(38.6)		(45.1)					
Nilotinib	156/339	11.2 [11.0; 11.3]	157/333	11.0 [8.4; 13.7]	0.89	[0.70; 1.12]	0.778	0.781
	(46.0)		(47.1)					
Dasatinib	17/41	22.2 [21.1; 23.3]	24/42	5.6 [5.4; 5.7]	0.64	[0.33; 1.27]	0.517	N.E.
	(41.5)		(57.1)					
Geographic region								
(Interaction test p = 0.509)								
Europe excluding Germany	87/202	11.2 [2.9; 19.6]	94/203	11.1 [7.2; 15.0]	0.83	[0.60; 1.14]	0.502	0.960
	(43.1)		(46.3)					
Germany	47/91	5.8 [0.1; 11.6]	36/68	2.8 [2.0; 3.6]	0.66	[0.39; 1.10]	0.562	0.678

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(51.6)		(52.9)					
Others	78/188	N.E. [N.E.; N.E.]	98/206	11.1 [7.1; 15.0]	0.84	[0.61; 1.15]	0.531	0.425
	(41.5)		(47.6)					
Social functioning (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.731)								
Low	106/291	22.5 [22.4; 22.6]	143/292	5.7 [-4.7; 16.0]	0.63	[0.49; 0.83]	0.002	0.580
	(36.4)		(49.0)					
Intermediate	51/129	N.E. [N.E.; N.E.]	51/128	11.1 [1.1; 21.1]	0.84	[0.56; 1.26]	0.976	0.740
	(39.5)		(39.8)					
High	19/61	N.E. [N.E.; N.E.]	16/57	N.E. [N.E.; N.E.]	0.89	[0.44; 1.81]	0.531	0.948
	(31.1)		(28.1)					
Sex								
(Interaction test p = 0.888)								
Female	66/175	22.5 [22.4; 22.6]	97/201	3.1 [-1.8; 7.9]	0.66	[0.48; 0.93]	0.017	0.570

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(37.7)		(48.3)					
Male	110/306	22.6 [22.0; 23.2]	114/276	22.1 [7.2; 37.0]	0.75	[0.57; 1.00]	0.163	0.888
	(35.9)		(41.3)					
Race								
(Interaction test p = 0.950)								
White	119/333	22.5 [22.1; 22.9]	145/320	5.7 [0.9; 10.4]	0.66	[0.51; 0.85]	0.009	0.873
	(35.7)		(45.3)					
Asian	48/128	N.E. [N.E.; N.E.]	56/132	22.1 [9.1; 35.1]	0.83	[0.55; 1.24]	0.617	0.409
	(37.5)		(42.4)					
Others	9/20	5.6 [5.5; 5.7]	11/25	N.E. [N.E.; N.E.]	0.76	[0.25; 2.33]	0.810	0.264
	(45.0)		(44.0)					
Age groups								
(Interaction test p = 0.782)								
18 - < 65 years	141/390	22.5 [22.1; 22.9]	182/397	11.1 [0.3; 21.9]	0.66	[0.52; 0.84]	0.002	0.456
	(36.2)		(45.8)					
65 - < 75 years	28/72	N.E. [N.E.; N.E.]	19/53	N.E. [N.E.; N.E.]	0.94	[0.48; 1.84]	0.576	0.599

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(38.9)		(35.8)					
>= 75 years	7/19	N.E. [N.E.; N.E.]	10/27	5.7 [-0.3; 11.7]	1.09	[0.29; 4.13]	0.554	0.357
	(36.8)		(37.0)					
Pre-randomization selection of TKI								
(Interaction test p = 0.278)								
Imatinib	40/101	N.E. [N.E.; N.E.]	46/102	5.6 [-1.8; 13.0]	0.72	[0.46; 1.13]	0.247	N.E.
	(39.6)		(45.1)					
Nilotinib	122/339	22.5 [22.1; 22.9]	142/333	11.4 [4.6; 18.2]	0.70	[0.55; 0.90]	0.033	0.457
	(36.0)		(42.6)					
Dasatinib	14/41	N.E. [N.E.; N.E.]	23/42	5.5 [1.5; 9.4]	0.69	[0.33; 1.43]	0.377	N.E.
	(34.1)		(54.8)					
Geographic region								
(Interaction test p = 0.467)								
Europe excluding Germany	67/202	22.6 [22.5; 22.6]	96/203	5.6 [-0.0; 11.3]	0.59	[0.42; 0.82]	0.006	0.531
	(33.2)		(47.3)					
Germany	38/91	22.2 [3.3; 41.0]	31/68	2.8 [-1.0; 6.7]	0.62	[0.36; 1.08]	0.347	0.913

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(41.8)		(45.6)					
Others	71/188	22.5 [22.4; 22.6]	85/206	22.1 [10.6; 33.6]	0.84	[0.60; 1.17]	0.584	0.416
	(37.8)		(41.3)					
Fatigue (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.533)								
Low	114/291	22.2 [21.7; 22.8]	144/292	5.7 [1.0; 10.3]	0.70	[0.54; 0.92]	0.020	0.599
	(39.2)		(49.3)					
Intermediate	56/129	22.1 [5.5; 38.8]	48/128	22.1 [2.0; 42.2]	1.03	[0.67; 1.56]	0.726	0.638
	(43.4)		(37.5)					
High	17/61	N.E. [N.E.; N.E.]	18/57	N.E. [N.E.; N.E.]	0.69	[0.32; 1.46]	0.661	0.739
	(27.9)		(31.6)					
Sex								
(Interaction test p = 0.598)								
Female	71/175	22.1 [22.0; 22.3]	90/201	11.1 [5.6; 16.5]	0.80	[0.55; 1.14]	0.232	0.781

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(40.6)		(44.8)					
Male	115/306	N.E. [N.E.; N.E.]	120/276	22.0 [11.1; 33.0]	0.78	[0.59; 1.04]	0.237	0.563
	(37.6)		(43.5)					
Race								
(Interaction test p = 0.806)								
White	126/333	22.2 [21.8; 22.6]	131/320	11.8 [2.1; 21.5]	0.84	[0.64; 1.11]	0.366	0.597
	(37.8)		(40.9)					
Asian	52/128	N.E. [N.E.; N.E.]	71/132	5.5 [-1.8; 12.8]	0.62	[0.42; 0.91]	0.022	0.971
	(40.6)		(53.8)					
Others	9/20	8.3 [2.3; 14.4]	8/25	N.E. [N.E.; N.E.]	0.58	[0.14; 2.44]	0.785	0.519
	(45.0)		(32.0)					
Age groups								
(Interaction test p = 0.655)								
18 - < 65 years	148/390	22.2 [21.8; 22.7]	175/397	11.2 [2.2; 20.3]	0.74	[0.58; 0.95]	0.067	0.818
	(37.9)		(44.1)					
65 - < 75 years	28/72	N.E. [N.E.; N.E.]	25/53	5.6 [-0.5; 11.6]	0.79	[0.40; 1.54]	0.773	0.608

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(38.9)		(47.2)					
>= 75 years	10/19	5.6 [-0.6; 11.8]	10/27	11.1 [1.4; 20.9]	1.35	[0.42; 4.37]	0.672	0.701
	(52.6)		(37.0)					
Pre-randomization selection of TKI								
(Interaction test p = 0.617)								
Imatinib	49/101	5.9 [-16.1; 27.8]	53/102	2.0 [1.1; 2.9]	0.81	[0.52; 1.24]	0.340	N.E.
	(48.5)		(52.0)					
Nilotinib	120/339	22.5 [21.6; 23.4]	129/333	22.1 [9.6; 34.7]	0.78	[0.59; 1.02]	0.364	0.767
	(35.4)		(38.7)					
Dasatinib	18/41	N.E. [N.E.; N.E.]	28/42	1.6 [-0.7; 3.8]	0.66	[0.34; 1.27]	0.308	N.E.
	(43.9)		(66.7)					
Geographic region								
(Interaction test p = 0.664)								
Europe excluding Germany	76/202	22.1 [22.0; 22.3]	89/203	11.2 [-0.6; 23.1]	0.74	[0.52; 1.05]	0.135	0.570
	(37.6)		(43.8)					
Germany	37/91	22.2 [-5.7; 50.1]	26/68	22.1 [22.0; 22.2]	0.84	[0.44; 1.60]	0.827	0.730

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(40.7)		(38.2)					
Others	73/188	22.5 [22.4; 22.6]	95/206	11.1 [0.2; 22.0]	0.70	[0.51; 0.98]	0.079	0.707
	(38.8)		(46.1)					
Nausea and vomiting (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.523)								
Low	68/291	N.E. [N.E.; N.E.]	103/292	22.2 [22.1; 22.4]	0.57	[0.42; 0.79]	0.001	0.652
	(23.4)		(35.3)					
Intermediate	29/129	N.E. [N.E.; N.E.]	39/128	N.E. [N.E.; N.E.]	0.64	[0.38; 1.06]	0.094	0.610
	(22.5)		(30.5)					
High	19/61	22.1 [22.1; 22.2]	15/57	N.E. [N.E.; N.E.]	0.98	[0.48; 1.99]	0.306	0.666
	(31.1)		(26.3)					
Sex								
(Interaction test p = 0.377)								
Female	53/175	N.E. [N.E.; N.E.]	79/201	19.4 [10.7; 28.2]	0.63	[0.43; 0.92]	0.016	0.410

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(30.3)		(39.3)					
Male	62/306	N.E. [N.E.; N.E.]	78/276	N.E. [N.E.; N.E.]	0.63	[0.45; 0.90]	0.011	0.416
	(20.3)		(28.3)					
Race								
(Interaction test p = 0.364)								
White	78/333	24.8 [24.7; 24.8]	96/320	22.2 [22.1; 22.3]	0.69	[0.50; 0.95]	0.016	0.916
	(23.4)		(30.0)					
Asian	30/128	N.E. [N.E.; N.E.]	54/132	22.2 [22.0; 22.3]	0.50	[0.31; 0.79]	0.006	0.159
	(23.4)		(40.9)					
Others	7/20	N.E. [N.E.; N.E.]	7/25	N.E. [N.E.; N.E.]	1.10	[0.29; 4.25]	0.487	0.121
	(35.0)		(28.0)					
Age groups								
(Interaction test p = 0.508)								
18 - < 65 years	95/390	N.E. [N.E.; N.E.]	133/397	N.E. [N.E.; N.E.]	0.61	[0.47; 0.81]	<0.001	0.900
	(24.4)		(33.5)					
65 - < 75 years	14/72	N.E. [N.E.; N.E.]	13/53	22.2 [22.2; 22.3]	0.76	[0.31; 1.84]	1.000	0.891

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(19.4)		(24.5)					
>= 75 years	6/19	N.E. [N.E.; N.E.]	11/27	5.7 [5.4; 5.9]	0.50	[0.15; 1.69]	0.303	0.446
	(31.6)		(40.7)					
Pre-randomization selection of TKI								
(Interaction test p = 0.085)								
Imatinib	23/101	N.E. [N.E.; N.E.]	46/102	5.7 [0.4; 11.0]	0.35	[0.21; 0.61]	<0.001	N.E.
	(22.8)		(45.1)					
Nilotinib	77/339	N.E. [N.E.; N.E.]	94/333	22.2 [22.1; 22.3]	0.74	[0.54; 1.01]	0.091	0.979
	(22.7)		(28.2)					
Dasatinib	15/41	N.E. [N.E.; N.E.]	17/42	N.E. [N.E.; N.E.]	0.83	[0.40; 1.72]	0.844	N.E.
	(36.6)		(40.5)					
Geographic region								
(Interaction test p = 0.508)								
Europe excluding Germany	45/202	24.8 [24.7; 24.8]	60/203	22.2 [21.9; 22.5]	0.63	[0.41; 0.95]	0.026	0.951
	(22.3)		(29.6)					
Germany	18/91	N.E. [N.E.; N.E.]	17/68	N.E. [N.E.; N.E.]	0.74	[0.35; 1.55]	0.765	0.535

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(19.8)		(25.0)					
Others	52/188	N.E. [N.E.; N.E.]	81/206	22.2 [22.0; 22.3]	0.58	[0.40; 0.84]	0.007	0.234
	(27.7)		(39.3)					
Pain (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.246)								
Low	120/291	22.5 [0.6; 44.4]	153/292	5.5 [1.3; 9.7]	0.69	[0.53; 0.89]	0.009	0.996
	(41.2)		(52.4)					
Intermediate	61/129	11.1 [6.5; 15.7]	53/128	11.1 [1.4; 20.9]	1.09	[0.73; 1.61]	0.649	0.403
	(47.3)		(41.4)					
High	22/61	N.E. [N.E.; N.E.]	24/57	5.7 [5.4; 5.9]	0.97	[0.52; 1.82]	0.906	0.758
	(36.1)		(42.1)					
Sex								
(Interaction test p = 0.951)								
Female	86/175	8.3 [-6.7; 23.2]	106/201	2.9 [0.8; 4.9]	0.91	[0.66; 1.25]	0.550	0.149

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(49.1)		(52.7)					
Male	117/306	N.E. [N.E.; N.E.]	124/276	11.1 [2.1; 20.1]	0.78	[0.60; 1.03]	0.111	0.489
	(38.2)		(44.9)					
Race								
(Interaction test p = 0.201)								
White	145/333	11.2 [4.5; 17.9]	148/320	11.0 [7.4; 14.7]	0.92	[0.72; 1.19]	0.711	0.899
	(43.5)		(46.3)					
Asian	48/128	N.E. [N.E.; N.E.]	71/132	2.9 [0.5; 5.2]	0.58	[0.39; 0.84]	0.005	0.227
	(37.5)		(53.8)					
Others	8/20	7.6 [7.5; 7.7]	11/25	3.0 [-0.3; 6.3]	0.68	[0.21; 2.21]	0.984	0.197
	(40.0)		(44.0)					
Age groups								
(Interaction test p = 0.300)								
18 - < 65 years	162/390	22.5 [3.6; 41.4]	195/397	5.6 [1.8; 9.4]	0.77	[0.62; 0.97]	0.037	0.181
	(41.5)		(49.1)					
65 - < 75 years	29/72	22.2 [-10.6; 55.0]	25/53	5.7 [-1.8; 13.3]	0.81	[0.44; 1.51]	0.772	0.557

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(40.3)		(47.2)					
>= 75 years	11/19	1.5 [0.2; 2.9]	11/27	5.7 [5.4; 6.0]	2.17	[0.66; 7.09]	0.948	0.764
	(57.9)		(40.7)					
Pre-randomization selection of TKI								
(Interaction test p = 0.998)								
Imatinib	42/101	22.2 [-0.1; 44.4]	51/102	2.8 [-0.5; 6.2]	0.66	[0.42; 1.02]	0.091	N.E.
	(41.6)		(50.0)					
Nilotinib	146/339	11.3 [4.0; 18.6]	158/333	11.1 [7.6; 14.7]	0.85	[0.67; 1.08]	0.358	0.793
	(43.1)		(47.4)					
Dasatinib	15/41	N.E. [N.E.; N.E.]	21/42	2.8 [0.0; 5.5]	0.69	[0.33; 1.44]	0.445	N.E.
	(36.6)		(50.0)					
Geographic region								
(Interaction test p = 0.702)								
Europe excluding Germany	81/202	22.2 [3.6; 40.7]	96/203	6.8 [1.0; 12.5]	0.78	[0.57; 1.08]	0.204	0.594
	(40.1)		(47.3)					
Germany	43/91	8.4 [-15.8; 32.5]	31/68	5.7 [-5.3; 16.7]	0.92	[0.52; 1.63]	0.816	0.878

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(47.3)		(45.6)					
Others	78/188	22.5 [-2.7; 47.7]	103/206	5.6 [1.3; 9.8]	0.75	[0.54; 1.02]	0.089	0.043
	(41.5)		(50.0)					
Dyspnoea (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.454)								
Low	97/291	22.2 [22.1; 22.3]	114/292	22.4 [-5.5; 50.4]	0.81	[0.61; 1.07]	0.345	0.994
	(33.3)		(39.0)					
Intermediate	37/129	22.2 [22.1; 22.3]	42/128	22.3 [22.3; 22.4]	0.71	[0.45; 1.14]	0.348	0.757
	(28.7)		(32.8)					
High	12/61	N.E. [N.E.; N.E.]	11/57	N.E. [N.E.; N.E.]	0.91	[0.37; 2.23]	0.614	0.319
	(19.7)		(19.3)					
Sex								
(Interaction test p = 0.969)								
Female	58/175	22.2 [22.1; 22.3]	78/201	11.8 [1.7; 22.0]	0.71	[0.49; 1.03]	0.134	0.608

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(33.1)		(38.8)					
Male	89/306	N.E. [N.E.; N.E.]	89/276	N.E. [N.E.; N.E.]	0.86	[0.63; 1.17]	0.831	0.468
	(29.1)		(32.2)					
Race								
(Interaction test p = 0.534)								
White	102/333	22.2 [21.9; 22.6]	106/320	N.E. [N.E.; N.E.]	0.81	[0.61; 1.10]	0.399	0.502
	(30.6)		(33.1)					
Asian	37/128	22.2 [22.2; 22.3]	49/132	22.3 [22.3; 22.4]	0.70	[0.45; 1.10]	0.274	0.702
	(28.9)		(37.1)					
Others	8/20	N.E. [N.E.; N.E.]	11/25	6.4 [5.0; 7.9]	0.71	[0.25; 2.00]	0.771	0.720
	(40.0)		(44.0)					
Age groups								
(Interaction test p = 0.417)								
18 - < 65 years	118/390	22.2 [22.1; 22.3]	142/397	22.3 [21.8; 22.9]	0.77	[0.59; 0.99]	0.130	0.422
	(30.3)		(35.8)					
65 - < 75 years	23/72	N.E. [N.E.; N.E.]	17/53	N.E. [N.E.; N.E.]	0.85	[0.43; 1.71]	0.711	0.896

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(31.9)		(32.1)					
>= 75 years	6/19	N.E. [N.E.; N.E.]	7/27	N.E. [N.E.; N.E.]	0.66	[0.12; 3.50]	0.619	0.685
	(31.6)		(25.9)					
Pre-randomization selection of TKI								
(Interaction test p = 0.408)								
Imatinib	33/101	22.2 [22.2; 22.3]	36/102	22.3 [21.5; 23.2]	0.80	[0.48; 1.32]	0.697	N.E.
	(32.7)		(35.3)					
Nilotinib	103/339	N.E. [N.E.; N.E.]	110/333	N.E. [N.E.; N.E.]	0.86	[0.65; 1.14]	0.755	0.750
	(30.4)		(33.0)					
Dasatinib	11/41	N.E. [N.E.; N.E.]	21/42	5.5 [-22.1; 33.1]	0.42	[0.19; 0.92]	0.058	N.E.
	(26.8)		(50.0)					
Geographic region								
(Interaction test p = 0.384)								
Europe excluding Germany	60/202	22.2 [22.2; 22.3]	74/203	N.E. [N.E.; N.E.]	0.74	[0.51; 1.07]	0.227	0.851
	(29.7)		(36.5)					
Germany	34/91	22.2 [6.4; 38.0]	24/68	22.4 [-12.1; 57.0]	0.94	[0.50; 1.75]	0.689	0.885

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(37.4)		(35.3)					
Others	52/188	22.2 [21.8; 22.7]	68/206	22.3 [22.3; 22.4]	0.75	[0.51; 1.10]	0.332	0.629
	(27.7)		(33.0)					
Insomnia (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.897)								
Low	108/291	22.3 [22.1; 22.5]	119/292	22.1 [14.4; 29.8]	0.76	[0.57; 1.01]	0.312	0.495
	(37.1)		(40.8)					
Intermediate	45/129	N.E. [N.E.; N.E.]	47/128	22.4 [-1.6; 46.4]	0.82	[0.53; 1.27]	0.534	0.535
	(34.9)		(36.7)					
High	23/61	N.E. [N.E.; N.E.]	16/57	N.E. [N.E.; N.E.]	1.09	[0.53; 2.24]	0.950	0.520
	(37.7)		(28.1)					
Sex								
(Interaction test p = 0.655)								
Female	72/175	22.4 [-2.2; 47.0]	81/201	11.2 [4.5; 17.9]	0.87	[0.61; 1.23]	0.879	0.952

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(41.1)		(40.3)					
Male	104/306	22.3 [22.1; 22.5]	101/276	22.4 [21.9; 22.9]	0.79	[0.59; 1.07]	0.387	0.587
	(34.0)		(36.6)					
Race								
(Interaction test p = 0.309)								
White	123/333	22.2 [13.5; 30.8]	125/320	22.0 [14.5; 29.6]	0.78	[0.59; 1.04]	0.273	0.569
	(36.9)		(39.1)					
Asian	45/128	N.E. [N.E.; N.E.]	48/132	N.E. [N.E.; N.E.]	0.81	[0.53; 1.24]	0.888	0.440
	(35.2)		(36.4)					
Others	8/20	N.E. [N.E.; N.E.]	10/25	N.E. [N.E.; N.E.]	0.68	[0.21; 2.20]	0.849	0.367
	(40.0)		(40.0)					
Age groups								
(Interaction test p = 0.444)								
18 - < 65 years	139/390	22.3 [22.0; 22.6]	155/397	22.1 [13.5; 30.7]	0.75	[0.59; 0.96]	0.146	0.637
	(35.6)		(39.0)					
65 - < 75 years	30/72	24.9 [-5.8; 55.6]	18/53	22.2 [22.2; 22.3]	1.44	[0.69; 3.01]	0.872	0.791

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(41.7)		(34.0)					
>= 75 years	6/19	N.E. [N.E.; N.E.]	9/27	11.1 [11.0; 11.2]	0.65	[0.15; 2.82]	0.617	0.588
	(31.6)		(33.3)					
Pre-randomization selection of TKI								
(Interaction test p = 0.578)								
Imatinib	32/101	N.E. [N.E.; N.E.]	41/102	11.2 [1.1; 21.2]	0.66	[0.40; 1.09]	0.101	N.E.
	(31.7)		(40.2)					
Nilotinib	126/339	22.2 [18.1; 26.2]	126/333	22.2 [7.5; 37.0]	0.82	[0.63; 1.07]	0.619	0.697
	(37.2)		(37.8)					
Dasatinib	18/41	22.0 [10.3; 33.7]	15/42	N.E. [N.E.; N.E.]	1.29	[0.61; 2.75]	0.659	N.E.
	(43.9)		(35.7)					
Geographic region								
(Interaction test p = 0.669)								
Europe excluding Germany	76/202	22.2 [21.6; 22.8]	83/203	11.6 [5.3; 17.9]	0.79	[0.56; 1.11]	0.260	0.904
	(37.6)		(40.9)					
Germany	32/91	22.3 [8.3; 36.3]	27/68	22.4 [-21.7; 66.4]	0.59	[0.31; 1.14]	0.412	0.553

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(35.2)		(39.7)					
Others	68/188	22.4 [22.3; 22.5]	73/206	N.E. [N.E.; N.E.]	0.85	[0.60; 1.22]	0.721	0.691
	(36.2)		(35.4)					
Appetite loss (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.782)								
Low	67/291	N.E. [N.E.; N.E.]	90/292	22.4 [22.0; 22.9]	0.63	[0.45; 0.88]	0.025	0.352
	(23.0)		(30.8)					
Intermediate	24/129	N.E. [N.E.; N.E.]	35/128	N.E. [N.E.; N.E.]	0.55	[0.31; 0.95]	0.070	0.843
	(18.6)		(27.3)					
High	12/61	N.E. [N.E.; N.E.]	14/57	N.E. [N.E.; N.E.]	0.85	[0.36; 1.99]	0.849	0.450
	(19.7)		(24.6)					
Sex								
(Interaction test p = 0.437)								
Female	46/175	22.5 [22.4; 22.6]	68/201	22.2 [21.9; 22.5]	0.68	[0.46; 1.01]	0.065	0.710

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(26.3)		(33.8)					
Male	57/306	N.E. [N.E.; N.E.]	71/276	N.E. [N.E.; N.E.]	0.62	[0.42; 0.90]	0.031	0.166
	(18.6)		(25.7)					
Race								
(Interaction test p = 0.097)								
White	75/333	N.E. [N.E.; N.E.]	83/320	22.4 [22.3; 22.6]	0.76	[0.54; 1.06]	0.210	0.829
	(22.5)		(25.9)					
Asian	21/128	N.E. [N.E.; N.E.]	46/132	N.E. [N.E.; N.E.]	0.35	[0.20; 0.60]	<0.001	0.465
	(16.4)		(34.8)					
Others	7/20	N.E. [N.E.; N.E.]	9/25	11.1 [11.1; 11.2]	0.87	[0.23; 3.32]	0.778	0.186
	(35.0)		(36.0)					
Age groups								
(Interaction test p = 0.442)								
18 - < 65 years	78/390	N.E. [N.E.; N.E.]	107/397	N.E. [N.E.; N.E.]	0.64	[0.47; 0.87]	0.014	0.465
	(20.0)		(27.0)					
65 - < 75 years	18/72	N.E. [N.E.; N.E.]	20/53	22.2 [22.0; 22.5]	0.62	[0.30; 1.28]	0.360	0.573

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(25.0)		(37.7)					
>= 75 years	6/19	22.2 [22.2; 22.3]	12/27	5.6 [-0.7; 11.9]	0.60	[0.17; 2.20]	0.725	0.672
	(31.6)		(44.4)					
Pre-randomization selection of TKI								
(Interaction test p = 0.885)								
Imatinib	25/101	N.E. [N.E.; N.E.]	36/102	22.1 [22.0; 22.2]	0.49	[0.28; 0.84]	0.027	N.E.
	(24.8)		(35.3)					
Nilotinib	66/339	N.E. [N.E.; N.E.]	85/333	N.E. [N.E.; N.E.]	0.71	[0.51; 1.00]	0.070	0.798
	(19.5)		(25.5)					
Dasatinib	12/41	N.E. [N.E.; N.E.]	18/42	22.4 [22.3; 22.5]	0.58	[0.26; 1.28]	0.487	N.E.
	(29.3)		(42.9)					
Geographic region								
(Interaction test p = 0.651)								
Europe excluding Germany	39/202	N.E. [N.E.; N.E.]	48/203	22.2 [22.1; 22.3]	0.69	[0.44; 1.09]	0.249	0.356
	(19.3)		(23.6)					
Germany	21/91	N.E. [N.E.; N.E.]	18/68	N.E. [N.E.; N.E.]	0.96	[0.45; 2.04]	0.636	0.719

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(23.1)		(26.5)					
Others	43/188	22.5 [22.5; 22.6]	73/206	N.E. [N.E.; N.E.]	0.49	[0.33; 0.74]	0.002	0.562
	(22.9)		(35.4)					
Constipation (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.306)								
Low	80/291	22.5 [22.4; 22.6]	110/292	N.E. [N.E.; N.E.]	0.59	[0.43; 0.79]	0.007	0.245
	(27.5)		(37.7)					
Intermediate	39/129	N.E. [N.E.; N.E.]	41/128	22.1 [-11.9; 56.2]	0.73	[0.46; 1.15]	0.515	0.917
	(30.2)		(32.0)					
High	16/61	N.E. [N.E.; N.E.]	11/57	N.E. [N.E.; N.E.]	1.31	[0.59; 2.93]	0.899	0.920
	(26.2)		(19.3)					
Sex								
(Interaction test p = 0.581)								
Female	56/175	22.3 [22.1; 22.5]	74/201	19.4 [7.8; 31.0]	0.71	[0.49; 1.03]	0.233	0.136

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(32.0)		(36.8)					
Male	79/306	N.E. [N.E.; N.E.]	88/276	N.E. [N.E.; N.E.]	0.65	[0.47; 0.90]	0.059	0.546
	(25.8)		(31.9)					
Race								
(Interaction test p = 0.420)								
White	84/333	22.5 [22.4; 22.6]	99/320	N.E. [N.E.; N.E.]	0.67	[0.49; 0.91]	0.062	0.338
	(25.2)		(30.9)					
Asian	45/128	N.E. [N.E.; N.E.]	54/132	N.E. [N.E.; N.E.]	0.68	[0.45; 1.03]	0.274	0.264
	(35.2)		(40.9)					
Others	5/20	N.E. [N.E.; N.E.]	9/25	11.7 [11.6; 11.8]	0.37	[0.09; 1.55]	0.854	0.171
	(25.0)		(36.0)					
Age groups								
(Interaction test p = 0.026)								
18 - < 65 years	102/390	22.5 [22.4; 22.6]	141/397	N.E. [N.E.; N.E.]	0.60	[0.46; 0.78]	0.002	0.234
	(26.2)		(35.5)					
65 - < 75 years	29/72	21.4 [3.9; 39.0]	12/53	N.E. [N.E.; N.E.]	1.93	[0.90; 4.11]	0.223	0.772

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(40.3)		(22.6)					
>= 75 years	4/19	N.E. [N.E.; N.E.]	8/27	N.E. [N.E.; N.E.]	0.47	[0.10; 2.31]	0.747	0.472
	(21.1)		(29.6)					
Pre-randomization selection of TKI								
(Interaction test p = 0.020)								
Imatinib	36/101	N.E. [N.E.; N.E.]	22/102	N.E. [N.E.; N.E.]	1.46	[0.83; 2.57]	0.364	N.E.
	(35.6)		(21.6)					
Nilotinib	86/339	22.5 [22.1; 22.9]	119/333	22.1 [6.6; 37.7]	0.57	[0.43; 0.77]	0.002	0.538
	(25.4)		(35.7)					
Dasatinib	13/41	N.E. [N.E.; N.E.]	21/42	10.6 [-2.9; 24.2]	0.55	[0.27; 1.15]	0.192	N.E.
	(31.7)		(50.0)					
Geographic region								
(Interaction test p = 0.675)								
Europe excluding Germany	51/202	N.E. [N.E.; N.E.]	60/203	N.E. [N.E.; N.E.]	0.69	[0.47; 1.02]	0.206	0.840
	(25.2)		(29.6)					
Germany	18/91	22.5 [22.4; 22.6]	21/68	N.E. [N.E.; N.E.]	0.44	[0.22; 0.90]	0.115	0.762

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(19.8)		(30.9)					
Others	65/188	N.E. [N.E.; N.E.]	80/206	19.4 [11.0; 27.8]	0.74	[0.52; 1.05]	0.375	0.564
	(34.6)		(38.8)					
Diarrhoea (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.409)								
Low	97/291	N.E. [N.E.; N.E.]	107/292	22.2 [21.9; 22.5]	0.88	[0.66; 1.18]	0.847	0.471
	(33.3)		(36.6)					
Intermediate	42/129	N.E. [N.E.; N.E.]	40/128	N.E. [N.E.; N.E.]	1.04	[0.66; 1.64]	0.766	0.390
	(32.6)		(31.3)					
High	16/61	N.E. [N.E.; N.E.]	13/57	N.E. [N.E.; N.E.]	0.95	[0.43; 2.09]	0.502	0.631
	(26.2)		(22.8)					
Sex								
(Interaction test p = 0.765)								
Female	57/175	N.E. [N.E.; N.E.]	62/201	22.2 [22.0; 22.4]	1.04	[0.71; 1.53]	0.504	0.902

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(32.6)		(30.8)					
Male	98/306	N.E. [N.E.; N.E.]	98/276	N.E. [N.E.; N.E.]	0.86	[0.64; 1.15]	0.675	0.893
	(32.0)		(35.5)					
Race								
(Interaction test p = 0.630)								
White	111/333	N.E. [N.E.; N.E.]	109/320	22.2 [14.6; 29.8]	0.91	[0.69; 1.20]	0.991	0.369
	(33.3)		(34.1)					
Asian	36/128	N.E. [N.E.; N.E.]	46/132	N.E. [N.E.; N.E.]	0.75	[0.48; 1.18]	0.362	0.491
	(28.1)		(34.8)					
Others	7/20	N.E. [N.E.; N.E.]	5/25	N.E. [N.E.; N.E.]	1.61	[0.43; 6.05]	0.961	0.192
	(35.0)		(20.0)					
Age groups								
(Interaction test p = 0.462)								
18 - < 65 years	126/390	N.E. [N.E.; N.E.]	132/397	22.4 [22.4; 22.5]	0.95	[0.74; 1.23]	0.856	0.998
	(32.3)		(33.2)					
65 - < 75 years	22/72	N.E. [N.E.; N.E.]	16/53	22.2 [22.1; 22.3]	1.03	[0.50; 2.09]	0.499	0.060

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(30.6)		(30.2)					
>= 75 years	6/19	N.E. [N.E.; N.E.]	11/27	5.6 [1.6; 9.7]	0.35	[0.10; 1.17]	0.269	0.110
	(31.6)		(40.7)					
Pre-randomization selection of TKI								
(Interaction test p = 0.060)								
Imatinib	38/101	N.E. [N.E.; N.E.]	50/102	5.6 [4.3; 6.8]	0.55	[0.35; 0.86]	0.059	N.E.
	(37.6)		(49.0)					
Nilotinib	97/339	N.E. [N.E.; N.E.]	94/333	N.E. [N.E.; N.E.]	1.05	[0.78; 1.40]	0.481	0.402
	(28.6)		(28.2)					
Dasatinib	20/41	11.1 [-4.7; 26.8]	16/42	22.4 [22.4; 22.5]	1.29	[0.64; 2.61]	0.661	N.E.
	(48.8)		(38.1)					
Geographic region								
(Interaction test p = 0.567)								
Europe excluding Germany	67/202	N.E. [N.E.; N.E.]	73/203	22.0 [14.5; 29.5]	0.83	[0.58; 1.18]	0.641	0.057
	(33.2)		(36.0)					
Germany	27/91	N.E. [N.E.; N.E.]	19/68	22.4 [22.4; 22.5]	1.14	[0.58; 2.27]	0.590	0.632

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(29.7)		(27.9)					
Others	61/188	N.E. [N.E.; N.E.]	68/206	N.E. [N.E.; N.E.]	0.93	[0.65; 1.34]	0.744	0.343
	(32.4)		(33.0)					
Financial difficulties (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.667)								
Low	75/291	N.E. [N.E.; N.E.]	80/292	N.E. [N.E.; N.E.]	0.93	[0.67; 1.30]	0.779	0.945
	(25.8)		(27.4)					
Intermediate	37/129	N.E. [N.E.; N.E.]	28/128	26.4 [26.4; 26.5]	1.37	[0.81; 2.34]	0.517	0.548
	(28.7)		(21.9)					
High	11/61	N.E. [N.E.; N.E.]	11/57	N.E. [N.E.; N.E.]	0.74	[0.29; 1.86]	0.752	0.537
	(18.0)		(19.3)					
Sex								
(Interaction test p = 0.405)								
Female	46/175	N.E. [N.E.; N.E.]	51/201	N.E. [N.E.; N.E.]	1.03	[0.68; 1.57]	0.431	0.660

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(26.3)		(25.4)					
Male	77/306	N.E. [N.E.; N.E.]	67/276	26.4 [26.4; 26.5]	1.00	[0.71; 1.42]	0.480	0.878
	(25.2)		(24.3)					
Race								
(Interaction test p = 0.958)								
White	75/333	N.E. [N.E.; N.E.]	78/320	26.4 [26.4; 26.5]	0.91	[0.65; 1.28]	0.954	0.594
	(22.5)		(24.4)					
Asian	37/128	N.E. [N.E.; N.E.]	33/132	N.E. [N.E.; N.E.]	1.08	[0.65; 1.79]	0.980	0.450
	(28.9)		(25.0)					
Others	10/20	5.6 [-31.6; 42.8]	8/25	N.E. [N.E.; N.E.]	2.15	[0.63; 7.36]	0.539	N.E.
	(50.0)		(32.0)					
Age groups								
(Interaction test p = 0.720)								
18 - < 65 years	106/390	N.E. [N.E.; N.E.]	101/397	N.E. [N.E.; N.E.]	1.06	[0.80; 1.41]	0.687	0.745
	(27.2)		(25.4)					
65 - < 75 years	13/72	N.E. [N.E.; N.E.]	12/53	N.E. [N.E.; N.E.]	0.78	[0.29; 2.14]	0.592	0.909


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(18.1)		(22.6)					
>= 75 years	4/19	N.E. [N.E.; N.E.]	5/27	N.E. [N.E.; N.E.]	2.33	[0.35; 15.58]	0.784	0.452
	(21.1)		(18.5)					
Pre-randomization selection of TKI								
(Interaction test p = 0.342)								
Imatinib	24/101	N.E. [N.E.; N.E.]	19/102	N.E. [N.E.; N.E.]	1.07	[0.56; 2.03]	0.619	N.E.
	(23.8)		(18.6)					
Nilotinib	87/339	N.E. [N.E.; N.E.]	86/333	N.E. [N.E.; N.E.]	1.00	[0.73; 1.37]	0.447	0.439
	(25.7)		(25.8)					
Dasatinib	11/41	N.E. [N.E.; N.E.]	13/42	N.E. [N.E.; N.E.]	0.89	[0.38; 2.09]	0.573	N.E.
	(26.8)		(31.0)					
Geographic region								
(Interaction test p = 0.722)								
Europe excluding Germany	38/202	N.E. [N.E.; N.E.]	47/203	N.E. [N.E.; N.E.]	0.79	[0.50; 1.24]	0.524	0.549
	(18.8)		(23.2)					
Germany	27/91	N.E. [N.E.; N.E.]	20/68	N.E. [N.E.; N.E.]	0.87	[0.45; 1.71]	0.703	0.620

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	(29.7) 57/188 (30.3)	N.E. [N.E.; N.E.]	(29.4) 51/206 (24.8)	N.E. [N.E.; N.E.]	1.16	[0.77; 1.74]	0.610	0.489

MID: Minimal important difference
N*: Number of patients included in the analysis
n: Number of patients with event. The number of patients is the mean number over all imputations rounded to the nearest integer
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
.....
Missing baseline values are multiply imputed by simple imputation using 500 repetitions under a MAR assumption.
Two-sided 95% CI for KM percentiles are derived by the approach outlined in Moscovici and Ratitch (2017).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates baseline score and treatment arm.
P-Values are based on stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
Test results are combined using the Wilson-Hilferty transformation.
P-Values for test of heterogeneity are from the stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Test results are combined using the Wilson-Hilferty transformation.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Constipation (MID=10): Age groups: 18 - < 65 years




Pts at Risk (censored)							
Asciminib	390 (0)	218 (95)	82 (211)	79 (214)	0 (288)	0 (288)	0 (288)
Investigator Selected TKI	397 (0)	164 (111)	59 (198)	54 (203)	1 (255)	0 (256)	0 (256)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Constipation (MID=10): Age groups: 65 - < 75 years




Pts at Risk (censored)

Asciminib	72 (0)	32 (13)	13 (32)	12 (32)	1 (41)	0 (43)	0 (43)
Investigator Selected TKI	53 (0)	21 (21)	7 (33)	6 (34)	1 (40)	0 (41)	0 (41)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Constipation (MID=10): Age groups: >= 75 years



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Constipation (MID=10): Pre-randomization selection of TKI: Imatinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Constipation (MID=10): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	187 (86)	52 (206)	48 (209)	0 (252)	0 (253)	0 (253)
Investigator Selected TKI	333 (0)	137 (96)	38 (178)	32 (183)	2 (212)	0 (214)	0 (214)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Constipation (MID=10): Pre-randomization selection of TKI: Dasatinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-5.2 EORTC QLQ-CML24: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Body Image Problems (MID=15)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.729)								
Low	114/291 (39.2)	22.2 [22.1; 22.3]	121/292 (41.4)	22.1 [10.7; 33.5]	0.84	[0.64; 1.10]	0.721	0.610
Intermediate	51/129 (39.5)	24.7 [-0.2; 49.6]	55/128 (43.0)	11.0 [5.9; 16.0]	0.78	[0.52; 1.17]	0.349	0.262
High	21/61 (34.4)	N.E. [N.E.; N.E.]	18/57 (31.6)	N.E. [N.E.; N.E.]	1.11	[0.55; 2.23]	0.657	0.792
Sex								
(Interaction test p = 0.710)								
Female	76/175 (43.4)	22.2 [3.3; 41.1]	87/201 (43.3)	11.2 [1.9; 20.5]	0.94	[0.67; 1.31]	0.848	0.772

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	110/306 (35.9)	22.3 [20.1; 24.5]	107/276 (38.8)	22.1 [8.4; 35.9]	0.83	[0.63; 1.10]	0.490	0.924
Race (Interaction test p = 0.558)								
White	132/333 (39.6)	22.2 [13.4; 31.0]	129/320 (40.3)	11.4 [5.3; 17.5]	0.87	[0.67; 1.13]	0.693	0.928
Asian	48/128 (37.5)	N.E. [N.E.; N.E.]	54/132 (40.9)	N.E. [N.E.; N.E.]	0.80	[0.53; 1.21]	0.574	0.781
Others	5/20 (25.0)	N.E. [N.E.; N.E.]	10/25 (40.0)	11.1 [11.1; 11.2]	0.69	[0.15; 3.26]	0.907	0.979
Age groups (Interaction test p = 0.603)								
18 - < 65 years	154/390 (39.5)	22.2 [22.0; 22.4]	167/397 (42.1)	11.6 [4.8; 18.3]	0.82	[0.65; 1.04]	0.310	0.826
65 - < 75 years	24/72 (33.3)	24.7 [24.6; 24.8]	17/53 (32.1)	N.E. [N.E.; N.E.]	1.07	[0.52; 2.24]	0.727	0.305

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	9/19 (47.4)	2.9 [2.6; 3.2]	9/27 (33.3)	11.1 [2.0; 20.2]	1.28	[0.36; 4.53]	0.873	0.733
Pre-randomization selection of TKI (Interaction test p = 0.911)								
Imatinib	38/101 (37.6)	22.2 [22.1; 22.3]	42/102 (41.2)	11.1 [-0.5; 22.7]	0.66	[0.41; 1.07]	0.247	N.E.
Nilotinib	134/339 (39.5)	22.2 [-2.8; 47.2]	132/333 (39.6)	16.7 [9.1; 24.2]	0.91	[0.70; 1.17]	0.871	0.469
Dasatinib	14/41 (34.1)	N.E. [N.E.; N.E.]	20/42 (47.6)	11.1 [11.0; 11.2]	0.85	[0.41; 1.77]	0.730	N.E.
Geographic region (Interaction test p = 0.431)								
Europe excluding Germany	74/202 (36.6)	22.2 [22.1; 22.4]	84/203 (41.4)	11.4 [7.3; 15.4]	0.79	[0.56; 1.10]	0.208	0.458
Germany	43/91 (47.3)	11.1 [4.5; 17.7]	28/68 (41.2)	11.1 [1.5; 20.8]	0.83	[0.48; 1.44]	0.692	0.406

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	69/188 (36.7)	24.7 [24.6; 24.8]	82/206 (39.8)	22.1 [6.6; 37.6]	0.82	[0.59; 1.16]	0.539	0.790
Impact on Daily Life (MID=15)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.507)								
Low	79/291 (27.1)	N.E. [N.E.; N.E.]	105/292 (36.0)	N.E. [N.E.; N.E.]	0.67	[0.49; 0.93]	0.074	0.613
Intermediate	32/129 (24.8)	N.E. [N.E.; N.E.]	42/128 (32.8)	22.3 [8.1; 36.6]	0.67	[0.40; 1.10]	0.172	0.541
High	10/61 (16.4)	N.E. [N.E.; N.E.]	13/57 (22.8)	N.E. [N.E.; N.E.]	0.50	[0.19; 1.29]	0.602	0.786
Sex (Interaction test p = 0.817)								
Female	49/175 (28.0)	N.E. [N.E.; N.E.]	80/201 (39.8)	11.8 [10.9; 12.7]	0.65	[0.43; 0.97]	0.033	0.641

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	73/306 (23.9)	N.E. [N.E.; N.E.]	80/276 (29.0)	N.E. [N.E.; N.E.]	0.72	[0.50; 1.02]	0.325	0.600
Race (Interaction test p = 0.701)								
White	84/333 (25.2)	N.E. [N.E.; N.E.]	111/320 (34.7)	N.E. [N.E.; N.E.]	0.61	[0.44; 0.84]	0.018	0.829
Asian	32/128 (25.0)	N.E. [N.E.; N.E.]	41/132 (31.1)	N.E. [N.E.; N.E.]	0.78	[0.47; 1.29]	0.597	0.294
Others	6/20 (30.0)	N.E. [N.E.; N.E.]	9/25 (36.0)	11.1 [11.1; 11.2]	0.53	[0.11; 2.57]	0.994	0.644
Age groups (Interaction test p = 0.923)								
18 - < 65 years	102/390 (26.2)	N.E. [N.E.; N.E.]	137/397 (34.5)	N.E. [N.E.; N.E.]	0.66	[0.49; 0.87]	0.026	0.626
65 - < 75 years	15/72 (20.8)	N.E. [N.E.; N.E.]	13/53 (24.5)	N.E. [N.E.; N.E.]	0.82	[0.32; 2.04]	0.965	0.794

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	5/19 (26.3)	N.E. [N.E.; N.E.]	11/27 (40.7)	10.8 [-1.5; 23.2]	0.32	[0.08; 1.23]	0.114	0.830
Pre-randomization selection of TKI (Interaction test p = 0.961)								
Imatinib	23/101 (22.8)	N.E. [N.E.; N.E.]	34/102 (33.3)	22.1 [21.8; 22.5]	0.62	[0.34; 1.12]	0.148	N.E.
Nilotinib	93/339 (27.4)	N.E. [N.E.; N.E.]	111/333 (33.3)	N.E. [N.E.; N.E.]	0.69	[0.51; 0.94]	0.128	0.936
Dasatinib	6/41 (14.6)	N.E. [N.E.; N.E.]	15/42 (35.7)	N.E. [N.E.; N.E.]	0.41	[0.13; 1.23]	0.130	N.E.
Geographic region (Interaction test p = 0.496)								
Europe excluding Germany	48/202 (23.8)	N.E. [N.E.; N.E.]	80/203 (39.4)	11.8 [2.1; 21.5]	0.53	[0.36; 0.79]	0.004	0.782
Germany	26/91 (28.6)	N.E. [N.E.; N.E.]	19/68 (27.9)	N.E. [N.E.; N.E.]	0.74	[0.35; 1.57]	0.838	0.526

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	48/188 (25.5)	N.E. [N.E.; N.E.]	62/206 (30.1)	N.E. [N.E.; N.E.]	0.82	[0.55; 1.25]	0.678	0.510
Impact on Worry/Mood (MID=15)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.211)								
Low	77/291 (26.5)	N.E. [N.E.; N.E.]	88/292 (30.1)	N.E. [N.E.; N.E.]	0.73	[0.52; 1.03]	0.389	0.843
Intermediate	37/129 (28.7)	N.E. [N.E.; N.E.]	25/128 (19.5)	N.E. [N.E.; N.E.]	1.26	[0.73; 2.21]	0.633	0.700
High	9/61 (14.8)	N.E. [N.E.; N.E.]	13/57 (22.8)	N.E. [N.E.; N.E.]	0.48	[0.19; 1.23]	0.269	0.674
Sex (Interaction test p = 0.641)								
Female	52/175 (29.7)	N.E. [N.E.; N.E.]	54/201 (26.9)	N.E. [N.E.; N.E.]	1.05	[0.68; 1.61]	0.635	0.917

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	71/306 (23.2)	N.E. [N.E.; N.E.]	72/276 (26.1)	N.E. [N.E.; N.E.]	0.74	[0.51; 1.07]	0.593	0.795
Race (Interaction test p = 0.458)								
White	76/333 (22.8)	N.E. [N.E.; N.E.]	77/320 (24.1)	N.E. [N.E.; N.E.]	0.79	[0.55; 1.14]	0.864	0.687
Asian	40/128 (31.3)	N.E. [N.E.; N.E.]	42/132 (31.8)	N.E. [N.E.; N.E.]	0.85	[0.53; 1.36]	0.841	0.255
Others	6/20 (30.0)	N.E. [N.E.; N.E.]	7/25 (28.0)	N.E. [N.E.; N.E.]	1.16	[0.21; 6.50]	0.990	0.643
Age groups (Interaction test p = 0.696)								
18 - < 65 years	105/390 (26.9)	N.E. [N.E.; N.E.]	111/397 (28.0)	N.E. [N.E.; N.E.]	0.81	[0.60; 1.09]	0.842	0.375
65 - < 75 years	14/72 (19.4)	N.E. [N.E.; N.E.]	10/53 (18.9)	N.E. [N.E.; N.E.]	1.02	[0.36; 2.92]	0.719	0.796

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	4/19 (21.1)	N.E. [N.E.; N.E.]	5/27 (18.5)	N.E. [N.E.; N.E.]	0.75	[0.08; 6.93]	0.871	N.E.
Pre-randomization selection of TKI (Interaction test p = 0.686)								
Imatinib	31/101 (30.7)	22.2 [22.2; 22.3]	34/102 (33.3)	22.1 [22.0; 22.2]	0.74	[0.43; 1.29]	0.706	N.E.
Nilotinib	79/339 (23.3)	N.E. [N.E.; N.E.]	73/333 (21.9)	N.E. [N.E.; N.E.]	0.85	[0.60; 1.21]	0.742	0.896
Dasatinib	13/41 (31.7)	N.E. [N.E.; N.E.]	19/42 (45.2)	22.4 [-5.0; 49.8]	0.69	[0.32; 1.51]	0.622	N.E.
Geographic region (Interaction test p = 0.739)								
Europe excluding Germany	41/202 (20.3)	N.E. [N.E.; N.E.]	46/203 (22.7)	N.E. [N.E.; N.E.]	0.78	[0.48; 1.26]	0.951	0.839
Germany	25/91 (27.5)	N.E. [N.E.; N.E.]	21/68 (30.9)	N.E. [N.E.; N.E.]	0.59	[0.28; 1.27]	0.728	0.841

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	57/188 (30.3)	N.E. [N.E.; N.E.]	60/206 (29.1)	N.E. [N.E.; N.E.]	0.85	[0.56; 1.27]	0.843	0.217
Symptom Burden (MID=15)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.884)								
Low	46/291 (15.8)	N.E. [N.E.; N.E.]	88/292 (30.1)	N.E. [N.E.; N.E.]	0.45	[0.30; 0.67]	<0.001	0.948
Intermediate	20/129 (15.5)	N.E. [N.E.; N.E.]	27/128 (21.1)	22.3 [22.3; 22.4]	0.63	[0.33; 1.21]	0.324	0.779
High	8/61 (13.1)	N.E. [N.E.; N.E.]	11/57 (19.3)	N.E. [N.E.; N.E.]	0.51	[0.18; 1.46]	0.455	0.469
Sex (Interaction test p = 0.744)								
Female	32/175 (18.3)	N.E. [N.E.; N.E.]	67/201 (33.3)	22.1 [21.8; 22.4]	0.45	[0.28; 0.73]	0.001	0.945

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	42/306 (13.7)	N.E. [N.E.; N.E.]	59/276 (21.4)	25.7 [22.8; 28.6]	0.58	[0.37; 0.92]	0.059	0.612
Race (Interaction test p = 0.843)								
White	54/333 (16.2)	N.E. [N.E.; N.E.]	78/320 (24.4)	22.4 [22.2; 22.7]	0.56	[0.37; 0.84]	0.014	0.692
Asian	17/128 (13.3)	N.E. [N.E.; N.E.]	42/132 (31.8)	22.3 [22.3; 22.4]	0.38	[0.20; 0.71]	0.003	0.931
Others	4/20 (20.0)	N.E. [N.E.; N.E.]	6/25 (24.0)	N.E. [N.E.; N.E.]	0.44	[0.05; 3.48]	0.689	0.816
Age groups (Interaction test p = 0.571)								
18 - < 65 years	60/390 (15.4)	N.E. [N.E.; N.E.]	106/397 (26.7)	N.E. [N.E.; N.E.]	0.49	[0.34; 0.70]	<0.001	0.848
65 - < 75 years	9/72 (12.5)	N.E. [N.E.; N.E.]	12/53 (22.6)	N.E. [N.E.; N.E.]	0.57	[0.20; 1.61]	0.465	0.662

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	5/19 (26.3)	N.E. [N.E.; N.E.]	8/27 (29.6)	N.E. [N.E.; N.E.]	0.73	[0.15; 3.63]	0.969	N.E.
Pre-randomization selection of TKI (Interaction test p = 0.384)								
Imatinib	21/101 (20.8)	N.E. [N.E.; N.E.]	34/102 (33.3)	22.1 [22.0; 22.3]	0.47	[0.25; 0.87]	0.027	N.E.
Nilotinib	44/339 (13.0)	N.E. [N.E.; N.E.]	73/333 (21.9)	N.E. [N.E.; N.E.]	0.51	[0.34; 0.78]	0.008	0.817
Dasatinib	9/41 (22.0)	N.E. [N.E.; N.E.]	19/42 (45.2)	22.4 [21.6; 23.3]	0.52	[0.22; 1.24]	0.161	N.E.
Geographic region (Interaction test p = 0.580)								
Europe excluding Germany	26/202 (12.9)	N.E. [N.E.; N.E.]	51/203 (25.1)	N.E. [N.E.; N.E.]	0.43	[0.25; 0.74]	0.004	0.661
Germany	20/91 (22.0)	N.E. [N.E.; N.E.]	17/68 (25.0)	N.E. [N.E.; N.E.]	0.74	[0.32; 1.73]	0.914	0.484

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	28/188 (14.9)	N.E. [N.E.; N.E.]	58/206 (28.2)	22.3 [22.3; 22.4]	0.45	[0.27; 0.74]	0.004	0.886
Satisfaction with Care and Information (MID=15)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.481)								
Low	105/291 (36.1)	N.E. [N.E.; N.E.]	93/292 (31.8)	N.E. [N.E.; N.E.]	1.09	[0.79; 1.50]	0.816	0.656
Intermediate	52/129 (40.3)	13.2 [0.5; 25.9]	34/128 (26.6)	N.E. [N.E.; N.E.]	1.14	[0.70; 1.85]	0.406	0.790
High	22/61 (36.1)	N.E. [N.E.; N.E.]	14/57 (24.6)	N.E. [N.E.; N.E.]	1.24	[0.57; 2.68]	0.838	0.949
Sex (Interaction test p = 0.678)								
Female	69/175	N.E. [N.E.; N.E.]	54/201	N.E. [N.E.; N.E.]	1.09	[0.72; 1.66]	0.412	0.756

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(39.4)		(26.9)					
Male	111/306	N.E. [N.E.; N.E.]	87/276	N.E. [N.E.; N.E.]	1.13	[0.81; 1.58]	0.725	0.873
	(36.3)		(31.5)					
Race								
(Interaction test p = 0.611)								
White	101/333	N.E. [N.E.; N.E.]	84/320	N.E. [N.E.; N.E.]	1.11	[0.78; 1.58]	0.902	0.922
	(30.3)		(26.3)					
Asian	73/128	5.6 [0.7; 10.5]	48/132	N.E. [N.E.; N.E.]	1.16	[0.77; 1.74]	0.060	0.766
	(57.0)		(36.4)					
Others	7/20	N.E. [N.E.; N.E.]	9/25	11.1 [11.0; 11.3]	0.82	[0.19; 3.51]	0.736	N.E.
	(35.0)		(36.0)					
Age groups								
(Interaction test p = 0.793)								
18 - < 65 years	152/390	N.E. [N.E.; N.E.]	122/397	N.E. [N.E.; N.E.]	1.14	[0.87; 1.50]	0.255	0.790
	(39.0)		(30.7)					
65 - < 75 years	24/72	N.E. [N.E.; N.E.]	16/53	N.E. [N.E.; N.E.]	0.90	[0.41; 1.95]	0.714	0.608

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(33.3)		(30.2)					
>= 75 years	4/19	N.E. [N.E.; N.E.]	4/27	N.E. [N.E.; N.E.]	2.06	[0.24; 17.61]	0.753	0.604
	(21.1)		(14.8)					
Pre-randomization selection of TKI								
(Interaction test p = 0.641)								
Imatinib	40/101	N.E. [N.E.; N.E.]	36/102	N.E. [N.E.; N.E.]	0.99	[0.58; 1.69]	0.874	N.E.
	(39.6)		(35.3)					
Nilotinib	121/339	N.E. [N.E.; N.E.]	89/333	N.E. [N.E.; N.E.]	1.24	[0.92; 1.68]	0.150	0.874
	(35.7)		(26.7)					
Dasatinib	18/41	N.E. [N.E.; N.E.]	16/42	N.E. [N.E.; N.E.]	0.74	[0.30; 1.80]	0.948	N.E.
	(43.9)		(38.1)					
Geographic region								
(Interaction test p = 0.702)								
Europe excluding Germany	58/202	N.E. [N.E.; N.E.]	58/203	N.E. [N.E.; N.E.]	0.92	[0.59; 1.43]	0.949	0.938
	(28.7)		(28.6)					
Germany	28/91	N.E. [N.E.; N.E.]	17/68	N.E. [N.E.; N.E.]	1.17	[0.55; 2.48]	0.877	0.945

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(30.8)		(25.0)					
Others	93/188	8.5 [4.6; 12.5]	67/206	N.E. [N.E.; N.E.]	1.32	[0.92; 1.88]	0.034	0.394
	(49.5)		(32.5)					
Satisfaction with Social Life (MID=15)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.430)								
Low	127/291	21.9 [7.8; 36.1]	121/292	22.1 [4.1; 40.2]	0.99	[0.75; 1.31]	0.754	0.252
	(43.6)		(41.4)					
Intermediate	58/129	11.1 [1.5; 20.7]	52/128	11.1 [0.8; 21.4]	1.07	[0.71; 1.63]	0.657	0.206
	(45.0)		(40.6)					
High	26/61	11.1 [10.1; 12.1]	20/57	N.E. [N.E.; N.E.]	0.96	[0.49; 1.87]	0.722	0.754
	(42.6)		(35.1)					
Sex								
(Interaction test p = 0.778)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Female	82/175 (46.9)	11.1 [5.6; 16.6]	81/201 (40.3)	11.2 [1.9; 20.5]	0.95	[0.67; 1.35]	0.816	0.882
Male	129/306 (42.2)	22.1 [8.1; 36.2]	111/276 (40.2)	N.E. [N.E.; N.E.]	1.07	[0.80; 1.42]	0.703	0.809
Race (Interaction test p = 0.824)								
White	142/333 (42.6)	11.2 [8.5; 13.9]	129/320 (40.3)	16.6 [5.5; 27.7]	0.94	[0.72; 1.24]	0.841	0.766
Asian	60/128 (46.9)	21.9 [2.2; 41.7]	52/132 (39.4)	N.E. [N.E.; N.E.]	1.18	[0.78; 1.76]	0.743	0.806
Others	9/20 (45.0)	11.1 [5.9; 16.3]	11/25 (44.0)	5.7 [-3.5; 14.9]	0.79	[0.22; 2.82]	0.902	N.E.
Age groups (Interaction test p = 0.751)								
18 - < 65 years	176/390 (45.1)	11.2 [7.9; 14.4]	164/397 (41.3)	22.1 [9.7; 34.6]	1.04	[0.82; 1.32]	0.863	0.904

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
65 - < 75 years	30/72 (41.7)	N.E. [N.E.; N.E.]	20/53 (37.7)	N.E. [N.E.; N.E.]	0.92	[0.47; 1.80]	0.731	0.149
>= 75 years	5/19 (26.3)	N.E. [N.E.; N.E.]	9/27 (33.3)	N.E. [N.E.; N.E.]	0.85	[0.20; 3.52]	0.966	0.795
Pre-randomization selection of TKI (Interaction test p = 0.770)								
Imatinib	37/101 (36.6)	N.E. [N.E.; N.E.]	32/102 (31.4)	N.E. [N.E.; N.E.]	1.06	[0.62; 1.82]	0.775	N.E.
Nilotinib	155/339 (45.7)	11.1 [0.6; 21.7]	141/333 (42.3)	11.3 [0.1; 22.5]	1.03	[0.80; 1.32]	0.740	0.730
Dasatinib	19/41 (46.3)	N.E. [N.E.; N.E.]	19/42 (45.2)	N.E. [N.E.; N.E.]	0.81	[0.38; 1.72]	0.794	N.E.
Geographic region (Interaction test p = 0.842)								
Europe excluding Germany	88/202 (43.6)	11.2 [11.0; 11.4]	87/203 (42.9)	11.1 [0.5; 21.7]	0.95	[0.68; 1.33]	0.935	0.959

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Germany	38/91 (41.8)	12.0 [5.7; 18.3]	28/68 (41.2)	11.3 [-1.4; 24.0]	0.82	[0.44; 1.55]	0.823	0.749
Others	84/188 (44.7)	21.9 [3.1; 40.8]	78/206 (37.9)	N.E. [N.E.; N.E.]	1.17	[0.84; 1.64]	0.639	0.510

MID: Minimal important difference
N*: Number of patients included in the analysis
n: Number of patients with event. The number of patients is the mean number over all imputations rounded to the nearest integer
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
.....
Missing baseline values are multiply imputed by simple imputation using 500 repetitions under a MAR assumption.
Two-sided 95% CI for KM percentiles are derived by the approach outlined in Moscovici and Ratitch (2017).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates baseline score and treatment arm.
P-Values are based on stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
Test results are combined using the Wilson-Hilferty transformation.
P-Values for test of heterogeneity are from the stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Test results are combined using the Wilson-Hilferty transformation.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-5.3 FACT-ITEM GP5: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
V4 (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.443)								
Low	173/291 (59.5)	2.4 [0.7; 4.1]	203/292 (69.5)	1.0 [0.6; 1.3]	0.67	[0.54; 0.83]	0.019	0.247
Intermediate	73/129 (56.6)	3.3 [-2.2; 8.8]	85/128 (66.4)	1.1 [0.1; 2.2]	0.61	[0.44; 0.84]	0.032	0.319
High	32/61 (52.5)	1.9 [-1.9; 5.8]	34/57 (59.6)	1.9 [0.2; 3.5]	0.68	[0.40; 1.13]	0.786	0.994
Sex								
(Interaction test p = 0.601)								
Female	109/175 (62.3)	1.1 [0.4; 1.9]	138/201 (68.7)	0.8 [0.4; 1.2]	0.72	[0.55; 0.94]	0.176	0.532

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	168/306 (54.9)	3.5 [-0.4; 7.4]	184/276 (66.7)	1.1 [0.4; 1.7]	0.65	[0.52; 0.81]	0.009	0.086
Race (Interaction test p = 0.307)								
White	197/333 (59.2)	2.1 [1.0; 3.3]	217/320 (67.8)	0.9 [0.6; 1.2]	0.65	[0.53; 0.80]	0.024	0.986
Asian	68/128 (53.1)	8.2 [-9.3; 25.7]	89/132 (67.4)	1.4 [0.4; 2.5]	0.61	[0.43; 0.85]	0.007	0.083
Others	12/20 (60.0)	1.9 [0.1; 3.7]	15/25 (60.0)	1.0 [0.2; 1.8]	0.52	[0.19; 1.46]	0.854	0.809
Age groups (Interaction test p = 0.971)								
18 - < 65 years	226/390 (57.9)	2.8 [1.2; 4.3]	262/397 (66.0)	1.1 [0.5; 1.6]	0.68	[0.56; 0.82]	0.016	0.177
65 - < 75 years	43/72 (59.7)	2.1 [0.1; 4.1]	41/53 (77.4)	1.0 [0.8; 1.2]	0.60	[0.36; 0.99]	0.152	0.458

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	9/19 (47.4)	2.4 [-7.1; 11.8]	18/27 (66.7)	0.8 [0.6; 0.9]	0.46	[0.16; 1.37]	0.174	0.764
Pre-randomization selection of TKI (Interaction test p = 0.365)								
Imatinib	56/101 (55.4)	2.4 [0.5; 4.2]	70/102 (68.6)	1.0 [0.5; 1.6]	0.66	[0.45; 0.95]	0.212	N.E.
Nilotinib	198/339 (58.4)	2.8 [1.2; 4.3]	224/333 (67.3)	1.0 [0.7; 1.3]	0.67	[0.55; 0.82]	0.010	0.034
Dasatinib	24/41 (58.5)	3.3 [-2.0; 8.7]	28/42 (66.7)	1.4 [-1.1; 4.0]	0.58	[0.32; 1.04]	0.598	N.E.
Geographic region (Interaction test p = 0.655)								
Europe excluding Germany	117/202 (57.9)	2.4 [0.4; 4.3]	146/203 (71.9)	0.8 [0.5; 1.1]	0.61	[0.47; 0.80]	0.009	0.732
Germany	55/91 (60.4)	1.7 [-0.2; 3.7]	46/68 (67.6)	0.6 [0.3; 0.9]	0.56	[0.36; 0.89]	0.273	0.907

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	106/188 (56.4)	3.5 [-1.2; 8.3]	130/206 (63.1)	2.1 [1.0; 3.3]	0.73	[0.56; 0.96]	0.184	0.038

MID: Minimal important difference
N*: Number of patients included in the analysis
n: Number of patients with event. The number of patients is the mean number over all imputations rounded to the nearest integer
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
.....
Missing baseline values are multiply imputed by simple imputation using 500 repetitions under a MAR assumption.
Two-sided 95% CI for KM percentiles are derived by the approach outlined in Moscovici and Ratitch (2017).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates baseline score and treatment arm.
P-Values are based on stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
Test results are combined using the Wilson-Hilferty transformation.
P-Values for test of heterogeneity are from the stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Test results are combined using the Wilson-Hilferty transformation.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-5.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Headache - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.109)								
Low	172/291 (59.1)	3.3 [1.2; 5.4]	209/292 (71.6)	1.1 [0.4; 1.7]	0.63	[0.51; 0.78]	0.003	0.551
Intermediate	81/129 (62.8)	2.4 [1.2; 3.6]	75/128 (58.6)	2.6 [1.3; 3.9]	1.01	[0.73; 1.40]	0.566	0.443
High	37/61 (60.7)	4.3 [1.9; 6.7]	36/57 (63.2)	1.7 [-0.7; 4.2]	0.72	[0.44; 1.18]	0.771	0.477
Sex								
(Interaction test p = 0.804)								
Female	114/175 (65.1)	2.1 [0.4; 3.8]	136/201 (67.7)	1.2 [0.3; 2.1]	0.80	[0.61; 1.06]	0.373	0.553

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	176/306 (57.5)	3.8 [1.9; 5.7]	184/276 (66.7)	1.7 [0.7; 2.7]	0.69	[0.56; 0.86]	0.025	0.436
Race (Interaction test p = 0.174)								
White	206/333 (61.9)	2.4 [1.1; 3.7]	212/320 (66.3)	1.4 [0.7; 2.1]	0.80	[0.65; 0.99]	0.253	0.581
Asian	74/128 (57.8)	4.2 [1.9; 6.5]	90/132 (68.2)	1.9 [0.7; 3.1]	0.65	[0.47; 0.90]	0.046	0.846
Others	10/20 (50.0)	5.8 [-2.0; 13.6]	18/25 (72.0)	0.6 [0.3; 0.8]	0.42	[0.14; 1.23]	0.407	0.823
Age groups (Interaction test p = 0.568)								
18 - < 65 years	238/390 (61.0)	3.2 [1.8; 4.6]	271/397 (68.3)	1.4 [0.8; 2.1]	0.70	[0.58; 0.84]	0.015	0.728
65 - < 75 years	40/72 (55.6)	3.6 [-1.9; 9.1]	36/53 (67.9)	1.7 [-0.3; 3.8]	0.73	[0.43; 1.22]	0.389	0.480

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	12/19 (63.2)	1.4 [0.3; 2.6]	13/27 (48.1)	2.1 [0.5; 3.8]	2.13	[0.68; 6.71]	0.618	0.729
Pre-randomization selection of TKI (Interaction test p = 0.986)								
Imatinib	59/101 (58.4)	2.8 [1.0; 4.6]	65/102 (63.7)	1.8 [0.1; 3.4]	0.87	[0.60; 1.26]	0.815	N.E.
Nilotinib	209/339 (61.7)	2.9 [1.6; 4.1]	227/333 (68.2)	1.5 [0.7; 2.2]	0.70	[0.57; 0.86]	0.027	0.643
Dasatinib	22/41 (53.7)	6.4 [-13.8; 26.6]	28/42 (66.7)	1.2 [-0.9; 3.3]	0.65	[0.35; 1.21]	0.453	N.E.
Geographic region (Interaction test p = 0.868)								
Europe excluding Germany	129/202 (63.9)	2.6 [1.0; 4.2]	138/203 (68.0)	1.2 [0.2; 2.2]	0.79	[0.61; 1.03]	0.438	0.575
Germany	51/91 (56.0)	4.4 [1.4; 7.5]	42/68 (61.8)	1.3 [0.1; 2.6]	0.66	[0.40; 1.08]	0.514	0.377

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	110/188 (58.5)	3.1 [1.1; 5.0]	140/206 (68.0)	1.9 [1.1; 2.7]	0.69	[0.53; 0.90]	0.033	0.407
Rash - Presence/Absence (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.621)								
Low	165/291 (56.7)	6.6 [3.2; 10.0]	180/292 (61.6)	2.5 [1.0; 4.1]	0.71	[0.57; 0.88]	0.043	0.674
Intermediate	67/129 (51.9)	7.6 [-2.2; 17.4]	75/128 (58.6)	3.0 [0.7; 5.4]	0.71	[0.50; 1.00]	0.076	0.305
High	22/61 (36.1)	N.E. [N.E.; N.E.]	30/57 (52.6)	4.0 [0.2; 7.7]	0.44	[0.25; 0.80]	0.044	0.695
Sex (Interaction test p = 0.604)								
Female	102/175 (58.3)	5.4 [0.8; 10.0]	124/201 (61.7)	2.4 [1.5; 3.3]	0.60	[0.46; 0.80]	0.028	0.985

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	152/306 (49.7)	10.2 [4.4; 16.0]	162/276 (58.7)	4.0 [1.8; 6.2]	0.74	[0.59; 0.93]	0.026	0.290
Race (Interaction test p = 0.504)								
White	178/333 (53.5)	6.7 [3.4; 10.1]	190/320 (59.4)	2.8 [1.5; 4.1]	0.69	[0.56; 0.86]	0.013	0.545
Asian	70/128 (54.7)	10.2 [6.2; 14.1]	81/132 (61.4)	4.0 [1.2; 6.7]	0.64	[0.46; 0.90]	0.047	0.299
Others	6/20 (30.0)	N.E. [N.E.; N.E.]	14/25 (56.0)	3.4 [-5.8; 12.6]	0.68	[0.22; 2.06]	0.866	0.106
Age groups (Interaction test p = 0.875)								
18 - < 65 years	216/390 (55.4)	6.8 [3.8; 9.8]	239/397 (60.2)	2.9 [1.6; 4.2]	0.70	[0.58; 0.85]	0.013	0.891
65 - < 75 years	29/72 (40.3)	N.E. [N.E.; N.E.]	33/53 (62.3)	2.4 [-1.1; 6.0]	0.57	[0.33; 1.00]	0.044	0.473

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	9/19 (47.4)	6.5 [4.2; 8.9]	13/27 (48.1)	3.5 [-3.4; 10.4]	0.63	[0.20; 2.02]	0.731	0.631
Pre-randomization selection of TKI (Interaction test p = 0.653)								
Imatinib	52/101 (51.5)	8.3 [1.5; 15.2]	56/102 (54.9)	6.4 [1.2; 11.7]	0.84	[0.57; 1.24]	0.483	N.E.
Nilotinib	178/339 (52.5)	8.3 [4.6; 12.1]	198/333 (59.5)	2.7 [1.4; 4.0]	0.62	[0.50; 0.76]	0.003	0.819
Dasatinib	24/41 (58.5)	8.8 [0.7; 16.9]	31/42 (73.8)	1.8 [0.7; 2.8]	0.75	[0.43; 1.31]	0.330	N.E.
Geographic region (Interaction test p = 0.141)								
Europe excluding Germany	110/202 (54.5)	6.5 [2.6; 10.5]	121/203 (59.6)	2.9 [1.9; 3.9]	0.69	[0.53; 0.90]	0.089	0.525
Germany	49/91 (53.8)	6.1 [-3.3; 15.5]	42/68 (61.8)	2.4 [-0.2; 4.9]	0.74	[0.46; 1.18]	0.510	0.398

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	95/188 (50.5)	10.2 [5.9; 14.4]	123/206 (59.7)	3.6 [1.5; 5.8]	0.67	[0.50; 0.88]	0.015	0.280
Diarrhea - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.627)								
Low	181/291 (62.2)	1.9 [1.1; 2.8]	188/292 (64.4)	2.2 [1.4; 3.0]	0.98	[0.79; 1.21]	0.700	0.487
Intermediate	71/129 (55.0)	5.1 [-2.6; 12.9]	69/128 (53.9)	3.7 [-1.3; 8.8]	0.84	[0.59; 1.20]	0.797	0.177
High	35/61 (57.4)	3.7 [-3.4; 10.9]	30/57 (52.6)	3.3 [-0.4; 7.0]	1.03	[0.60; 1.75]	0.689	0.718
Sex (Interaction test p = 0.634)								
Female	103/175 (58.9)	3.1 [0.7; 5.5]	120/201 (59.7)	2.4 [1.5; 3.2]	0.90	[0.68; 1.21]	0.735	0.851

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	184/306 (60.1)	2.1 [1.0; 3.3]	167/276 (60.5)	2.6 [1.7; 3.6]	0.97	[0.78; 1.21]	0.616	0.041
Race (Interaction test p = 0.808)								
White	199/333 (59.8)	2.0 [1.2; 2.8]	195/320 (60.9)	2.6 [1.8; 3.4]	0.95	[0.77; 1.18]	0.744	0.312
Asian	75/128 (58.6)	5.2 [-0.4; 10.8]	79/132 (59.8)	2.8 [0.4; 5.1]	0.89	[0.64; 1.24]	0.869	0.368
Others	13/20 (65.0)	1.9 [1.4; 2.5]	12/25 (48.0)	3.2 [-12.3; 18.6]	1.54	[0.55; 4.29]	0.755	0.400
Age groups (Interaction test p = 0.392)								
18 - < 65 years	235/390 (60.3)	2.4 [1.1; 3.6]	236/397 (59.4)	2.8 [1.5; 4.1]	1.02	[0.84; 1.23]	0.676	0.603
65 - < 75 years	40/72 (55.6)	5.7 [-5.6; 17.0]	35/53 (66.0)	1.9 [0.9; 3.0]	0.73	[0.44; 1.21]	0.425	0.072

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	13/19 (68.4)	2.2 [0.9; 3.4]	15/27 (55.6)	1.0 [0.2; 1.9]	0.54	[0.19; 1.51]	0.711	0.974
Pre-randomization selection of TKI (Interaction test p = 0.082)								
Imatinib	61/101 (60.4)	2.2 [0.1; 4.3]	75/102 (73.5)	1.0 [0.5; 1.5]	0.65	[0.45; 0.93]	0.087	N.E.
Nilotinib	201/339 (59.3)	2.8 [1.3; 4.3]	184/333 (55.3)	3.3 [-0.3; 6.8]	1.09	[0.88; 1.35]	0.956	0.415
Dasatinib	25/41 (61.0)	1.9 [0.1; 3.7]	28/42 (66.7)	2.4 [-3.2; 8.0]	0.81	[0.45; 1.45]	0.660	N.E.
Geographic region (Interaction test p = 0.268)								
Europe excluding Germany	133/202 (65.8)	1.7 [1.1; 2.2]	132/203 (65.0)	2.1 [1.4; 2.9]	0.97	[0.74; 1.26]	0.661	0.023
Germany	43/91 (47.3)	12.0 [-14.4; 38.4]	32/68 (47.1)	9.3 [-5.4; 24.0]	1.02	[0.60; 1.73]	0.715	0.613

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	111/188 (59.0)	3.7 [1.3; 6.2]	122/206 (59.2)	2.8 [0.9; 4.8]	0.96	[0.73; 1.26]	0.696	0.173
Vomiting - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.568)								
Low	55/291 (18.9)	N.E. [N.E.; N.E.]	96/292 (32.9)	N.E. [N.E.; N.E.]	0.49	[0.35; 0.69]	<0.001	0.395
Intermediate	32/129 (24.8)	N.E. [N.E.; N.E.]	41/128 (32.0)	N.E. [N.E.; N.E.]	0.61	[0.38; 0.99]	0.084	0.319
High	9/61 (14.8)	N.E. [N.E.; N.E.]	15/57 (26.3)	N.E. [N.E.; N.E.]	0.51	[0.21; 1.21]	0.226	0.371
Sex								
(Interaction test p = 0.881)								
Female	42/175 (24.0)	N.E. [N.E.; N.E.]	77/201 (38.3)	N.E. [N.E.; N.E.]	0.49	[0.33; 0.73]	<0.001	0.938

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	53/306 (17.3)	N.E. [N.E.; N.E.]	75/276 (27.2)	N.E. [N.E.; N.E.]	0.60	[0.42; 0.86]	0.010	0.185
Race (Interaction test p = 0.680)								
White	63/333 (18.9)	N.E. [N.E.; N.E.]	87/320 (27.2)	N.E. [N.E.; N.E.]	0.62	[0.44; 0.86]	0.010	0.751
Asian	29/128 (22.7)	N.E. [N.E.; N.E.]	54/132 (40.9)	N.E. [N.E.; N.E.]	0.41	[0.26; 0.65]	<0.001	0.923
Others	4/20 (20.0)	N.E. [N.E.; N.E.]	11/25 (44.0)	15.7 [13.4; 18.0]	0.65	[0.17; 2.54]	0.929	0.110
Age groups (Interaction test p = 0.153)								
18 - < 65 years	75/390 (19.2)	N.E. [N.E.; N.E.]	127/397 (32.0)	N.E. [N.E.; N.E.]	0.53	[0.40; 0.71]	<0.001	0.864
65 - < 75 years	14/72 (19.4)	N.E. [N.E.; N.E.]	15/53 (28.3)	N.E. [N.E.; N.E.]	0.57	[0.26; 1.26]	0.323	0.405

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	7/19 (36.8)	24.0 [23.9; 24.0]	10/27 (37.0)	7.0 [6.8; 7.1]	0.44	[0.13; 1.50]	0.361	0.830
Pre-randomization selection of TKI (Interaction test p = 0.736)								
Imatinib	19/101 (18.8)	N.E. [N.E.; N.E.]	42/102 (41.2)	N.E. [N.E.; N.E.]	0.38	[0.22; 0.66]	<0.001	N.E.
Nilotinib	66/339 (19.5)	N.E. [N.E.; N.E.]	92/333 (27.6)	N.E. [N.E.; N.E.]	0.60	[0.44; 0.83]	0.004	0.301
Dasatinib	10/41 (24.4)	N.E. [N.E.; N.E.]	17/42 (40.5)	N.E. [N.E.; N.E.]	0.55	[0.25; 1.22]	0.282	N.E.
Geographic region (Interaction test p = 0.446)								
Europe excluding Germany	41/202 (20.3)	N.E. [N.E.; N.E.]	52/203 (25.6)	N.E. [N.E.; N.E.]	0.69	[0.45; 1.06]	0.186	0.551
Germany	13/91 (14.3)	N.E. [N.E.; N.E.]	15/68 (22.1)	N.E. [N.E.; N.E.]	0.63	[0.28; 1.43]	0.568	0.387

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	42/188 (22.3)	N.E. [N.E.; N.E.]	85/206 (41.3)	N.E. [N.E.; N.E.]	0.42	[0.29; 0.62]	<0.001	0.398
Nausea - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.676)								
Low	132/291 (45.4)	25.9 [9.0; 42.7]	177/292 (60.6)	2.4 [0.9; 3.8]	0.61	[0.48; 0.78]	<0.001	0.083
Intermediate	49/129 (38.0)	N.E. [N.E.; N.E.]	73/128 (57.0)	4.0 [2.3; 5.8]	0.52	[0.35; 0.76]	<0.001	0.824
High	23/61 (37.7)	N.E. [N.E.; N.E.]	29/57 (50.9)	4.9 [-2.3; 12.1]	0.66	[0.37; 1.18]	0.393	0.578
Sex (Interaction test p = 0.703)								
Female	85/175 (48.6)	13.9 [2.6; 25.1]	131/201 (65.2)	1.4 [0.7; 2.2]	0.57	[0.43; 0.77]	<0.001	0.898

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	119/306 (38.9)	N.E. [N.E.; N.E.]	148/276 (53.6)	6.6 [1.9; 11.3]	0.64	[0.49; 0.82]	0.002	0.057
Race (Interaction test p = 0.559)								
White	144/333 (43.2)	25.9 [7.5; 44.2]	185/320 (57.8)	3.5 [1.3; 5.7]	0.66	[0.52; 0.83]	<0.001	0.638
Asian	50/128 (39.1)	N.E. [N.E.; N.E.]	80/132 (60.6)	3.3 [1.4; 5.2]	0.47	[0.33; 0.69]	<0.001	0.263
Others	10/20 (50.0)	2.4 [1.0; 3.7]	14/25 (56.0)	3.1 [-6.3; 12.4]	0.56	[0.20; 1.59]	0.956	0.848
Age groups (Interaction test p = 0.810)								
18 - < 65 years	167/390 (42.8)	N.E. [N.E.; N.E.]	230/397 (57.9)	3.8 [1.6; 6.0]	0.62	[0.51; 0.77]	<0.001	0.101
65 - < 75 years	29/72 (40.3)	N.E. [N.E.; N.E.]	35/53 (66.0)	2.1 [1.0; 3.2]	0.47	[0.26; 0.83]	0.024	0.652

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	7/19 (36.8)	22.1 [22.1; 22.2]	15/27 (55.6)	1.0 [0.7; 1.4]	0.25	[0.06; 1.02]	0.048	0.385
Pre-randomization selection of TKI (Interaction test p = 0.006)								
Imatinib	31/101 (30.7)	N.E. [N.E.; N.E.]	73/102 (71.6)	1.1 [0.7; 1.6]	0.30	[0.19; 0.48]	<0.001	N.E.
Nilotinib	152/339 (44.8)	25.8 [9.6; 42.1]	176/333 (52.9)	5.4 [1.2; 9.6]	0.71	[0.57; 0.90]	0.013	0.359
Dasatinib	21/41 (51.2)	3.2 [-25.2; 31.6]	30/42 (71.4)	3.1 [-1.9; 8.0]	0.71	[0.40; 1.28]	0.636	N.E.
Geographic region (Interaction test p = 0.499)								
Europe excluding Germany	89/202 (44.1)	N.E. [N.E.; N.E.]	122/203 (60.1)	2.4 [0.5; 4.3]	0.63	[0.47; 0.85]	0.004	0.618
Germany	39/91 (42.9)	25.9 [3.0; 48.7]	39/68 (57.4)	5.9 [0.8; 11.0]	0.67	[0.40; 1.11]	0.210	0.925

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	75/188 (39.9)	N.E. [N.E.; N.E.]	118/206 (57.3)	3.5 [1.5; 5.5]	0.55	[0.41; 0.75]	<0.001	0.177
Edema - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.293)								
Low	115/291 (39.5)	N.E. [N.E.; N.E.]	148/292 (50.7)	11.1 [6.9; 15.3]	0.69	[0.53; 0.88]	0.012	0.439
Intermediate	56/129 (43.4)	22.1 [20.2; 24.1]	58/128 (45.3)	11.1 [-0.2; 22.4]	0.76	[0.51; 1.11]	0.355	0.049
High	21/61 (34.4)	N.E. [N.E.; N.E.]	25/57 (43.9)	16.7 [11.4; 21.9]	0.70	[0.38; 1.29]	0.538	0.164
Sex (Interaction test p = 0.875)								
Female	86/175 (49.1)	11.2 [-1.8; 24.2]	112/201 (55.7)	4.2 [1.7; 6.7]	0.67	[0.50; 0.91]	0.027	0.009

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	106/306 (34.6)	N.E. [N.E.; N.E.]	120/276 (43.5)	15.7 [9.4; 22.0]	0.74	[0.56; 0.97]	0.083	0.395
Race (Interaction test p = 0.206)								
White	129/333 (38.7)	N.E. [N.E.; N.E.]	138/320 (43.1)	14.8 [8.2; 21.4]	0.82	[0.64; 1.05]	0.284	0.085
Asian	57/128 (44.5)	N.E. [N.E.; N.E.]	82/132 (62.1)	2.8 [0.7; 4.9]	0.54	[0.38; 0.77]	0.001	0.261
Others	6/20 (30.0)	N.E. [N.E.; N.E.]	12/25 (48.0)	14.2 [13.7; 14.7]	0.58	[0.19; 1.77]	0.990	0.771
Age groups (Interaction test p = 0.505)								
18 - < 65 years	152/390 (39.0)	N.E. [N.E.; N.E.]	193/397 (48.6)	12.0 [8.5; 15.6]	0.69	[0.56; 0.87]	0.005	0.022
65 - < 75 years	31/72 (43.1)	N.E. [N.E.; N.E.]	28/53 (52.8)	4.5 [-3.0; 12.0]	0.63	[0.35; 1.11]	0.410	0.112

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	9/19 (47.4)	22.1 [5.6; 38.7]	10/27 (37.0)	2.6 [0.8; 4.4]	1.04	[0.35; 3.13]	0.545	0.510
Pre-randomization selection of TKI (Interaction test p = 0.046)								
Imatinib	43/101 (42.6)	24.9 [8.0; 41.8]	66/102 (64.7)	2.1 [0.5; 3.7]	0.46	[0.31; 0.70]	<0.001	N.E.
Nilotinib	135/339 (39.8)	N.E. [N.E.; N.E.]	143/333 (42.9)	15.7 [8.6; 22.8]	0.85	[0.67; 1.09]	0.564	0.720
Dasatinib	14/41 (34.1)	N.E. [N.E.; N.E.]	23/42 (54.8)	6.7 [-5.2; 18.6]	0.49	[0.24; 0.98]	0.071	N.E.
Geographic region (Interaction test p = 0.723)								
Europe excluding Germany	70/202 (34.7)	N.E. [N.E.; N.E.]	93/203 (45.8)	13.0 [9.1; 16.8]	0.65	[0.47; 0.90]	0.020	0.023
Germany	38/91 (41.8)	22.1 [-4.5; 48.8]	29/68 (42.6)	14.9 [7.2; 22.6]	1.06	[0.62; 1.82]	0.734	0.772

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	83/188 (44.1)	24.0 [5.0; 43.0]	110/206 (53.4)	5.6 [0.3; 10.9]	0.69	[0.51; 0.93]	0.031	0.160
Muscle Pain - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.952)								
Low	182/291 (62.5)	1.1 [0.3; 1.8]	212/292 (72.6)	0.8 [0.4; 1.2]	0.78	[0.63; 0.96]	0.107	0.423
Intermediate	84/129 (65.1)	1.4 [0.9; 2.0]	82/128 (64.1)	1.4 [-0.0; 2.9]	0.94	[0.68; 1.30]	0.709	0.217
High	32/61 (52.5)	2.2 [-10.9; 15.3]	37/57 (64.9)	1.4 [0.4; 2.5]	0.71	[0.43; 1.19]	0.493	0.924
Sex (Interaction test p = 0.438)								
Female	117/175 (66.9)	1.0 [0.5; 1.4]	142/201 (70.6)	1.0 [0.6; 1.4]	0.94	[0.72; 1.23]	0.887	0.694

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	181/306 (59.2)	1.7 [0.3; 3.1]	189/276 (68.5)	1.1 [0.5; 1.7]	0.76	[0.61; 0.95]	0.095	0.069
Race (Interaction test p = 0.099)								
White	211/333 (63.4)	1.1 [0.5; 1.6]	210/320 (65.6)	1.2 [0.6; 1.8]	0.93	[0.75; 1.14]	0.907	0.738
Asian	74/128 (57.8)	3.1 [-1.9; 8.0]	105/132 (79.5)	0.8 [0.4; 1.1]	0.57	[0.42; 0.78]	<0.001	0.839
Others	12/20 (60.0)	1.0 [-2.6; 4.5]	15/25 (60.0)	0.6 [-1.8; 3.1]	0.76	[0.29; 1.98]	0.747	0.555
Age groups (Interaction test p = 0.919)								
18 - < 65 years	239/390 (61.3)	1.3 [0.7; 1.9]	278/397 (70.0)	1.0 [0.6; 1.3]	0.79	[0.66; 0.95]	0.089	0.057
65 - < 75 years	45/72 (62.5)	1.1 [0.4; 1.7]	40/53 (75.5)	1.3 [0.4; 2.3]	0.80	[0.48; 1.31]	0.615	0.589


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	14/19 (73.7)	1.2 [0.6; 1.9]	14/27 (51.9)	1.4 [-0.7; 3.6]	1.11	[0.38; 3.27]	0.996	0.431
Pre-randomization selection of TKI (Interaction test p = 0.766)								
Imatinib	57/101 (56.4)	1.9 [-0.5; 4.4]	72/102 (70.6)	0.8 [0.5; 1.2]	0.68	[0.47; 0.99]	0.180	N.E.
Nilotinib	217/339 (64.0)	1.1 [0.7; 1.5]	229/333 (68.8)	1.1 [0.6; 1.7]	0.86	[0.71; 1.05]	0.485	0.293
Dasatinib	23/41 (56.1)	5.6 [-2.8; 13.9]	30/42 (71.4)	1.0 [0.5; 1.4]	0.64	[0.36; 1.15]	0.324	N.E.
Geographic region (Interaction test p = 0.646)								
Europe excluding Germany	128/202 (63.4)	1.2 [0.8; 1.7]	136/203 (67.0)	1.2 [0.5; 1.9]	0.92	[0.71; 1.19]	0.931	0.415
Germany	55/91 (60.4)	1.0 [-0.3; 2.2]	42/68 (61.8)	1.1 [-0.2; 2.3]	0.92	[0.57; 1.48]	0.812	0.768

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	115/188 (61.2)	1.5 [-0.1; 3.1]	153/206 (74.3)	1.0 [0.7; 1.3]	0.69	[0.53; 0.89]	0.013	0.551

MID: Minimal important difference
N*: Number of patients included in the analysis
n: Number of patients with event. The number of patients is the mean number over all imputations rounded to the nearest integer
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
.....
Missing baseline values are multiply imputed by simple imputation using 500 repetitions under a MAR assumption.
Two-sided 95% CI for KM percentiles are derived by the approach outlined in Moscovici and Ratitch (2017).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates baseline score and treatment arm.
P-Values are based on stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
Test results are combined using the Wilson-Hilferty transformation.
P-Values for test of heterogeneity are from the stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Test results are combined using the Wilson-Hilferty transformation.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Nausea - Frequency (MID=1): Pre-randomization selection of TKI: Imatinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Nausea - Frequency (MID=1): Pre-randomization selection of TKI: Nilotinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Nausea - Frequency (MID=1): Pre-randomization selection of TKI: Dasatinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Edema - Frequency (MID=1): Pre-randomization selection of TKI: Imatinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Edema - Frequency (MID=1): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	182 (38)	115 (94)	59 (148)	24 (181)	4 (200)	0 (204)
Investigator Selected TKI	333 (0)	159 (61)	90 (112)	44 (149)	14 (178)	3 (187)	0 (190)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Edema - Frequency (MID=1): Pre-randomization selection of TKI: Dasatinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-5.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Fatigue - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.605)								
Low	176/291 (60.5)	2.2 [-0.2; 4.5]	189/292 (64.7)	1.2 [0.5; 2.0]	0.81	[0.65; 1.02]	0.648	0.532
Intermediate	81/129 (62.8)	2.4 [-0.7; 5.4]	78/128 (60.9)	2.8 [0.7; 5.0]	0.87	[0.62; 1.22]	0.871	0.951
High	27/61 (44.3)	N.E. [N.E.; N.E.]	29/57 (50.9)	11.1 [-5.3; 27.4]	0.69	[0.39; 1.23]	0.615	0.626
Sex								
(Interaction test p = 0.796)								
Female	101/175 (57.7)	4.7 [-3.5; 12.8]	127/201 (63.2)	1.9 [0.5; 3.3]	0.76	[0.56; 1.02]	0.430	0.647

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	183/306 (59.8)	2.5 [0.5; 4.4]	169/276 (61.2)	1.6 [0.3; 2.9]	0.87	[0.70; 1.09]	0.996	0.525
Race (Interaction test p = 0.533)								
White	199/333 (59.8)	2.5 [-0.7; 5.6]	200/320 (62.5)	1.4 [0.4; 2.5]	0.82	[0.66; 1.03]	0.782	0.723
Asian	73/128 (57.0)	4.5 [-7.4; 16.4]	84/132 (63.6)	1.9 [0.1; 3.7]	0.75	[0.54; 1.05]	0.212	0.555
Others	12/20 (60.0)	1.2 [-0.4; 2.9]	12/25 (48.0)	12.9 [0.7; 25.1]	0.60	[0.13; 2.70]	0.964	0.627
Age groups (Interaction test p = 0.692)								
18 - < 65 years	233/390 (59.7)	2.6 [-0.3; 5.5]	245/397 (61.7)	1.9 [0.6; 3.2]	0.83	[0.68; 1.01]	0.866	0.932
65 - < 75 years	38/72 (52.8)	5.7 [-10.8; 22.1]	38/53 (71.7)	1.2 [-0.4; 2.8]	0.74	[0.43; 1.26]	0.274	0.639

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	13/19 (68.4)	2.2 [-5.8; 10.2]	13/27 (48.1)	2.1 [-6.0; 10.3]	0.82	[0.24; 2.77]	0.871	0.949
Pre-randomization selection of TKI (Interaction test p = 0.726)								
Imatinib	60/101 (59.4)	1.4 [-0.0; 2.9]	60/102 (58.8)	1.7 [0.3; 3.0]	0.96	[0.66; 1.42]	0.805	N.E.
Nilotinib	199/339 (58.7)	3.1 [-0.8; 6.9]	204/333 (61.3)	2.1 [0.7; 3.6]	0.81	[0.65; 1.00]	0.574	0.640
Dasatinib	26/41 (63.4)	5.2 [-7.2; 17.5]	32/42 (76.2)	1.0 [-0.3; 2.3]	0.60	[0.33; 1.07]	0.456	N.E.
Geographic region (Interaction test p = 0.573)								
Europe excluding Germany	121/202 (59.9)	2.4 [-1.0; 5.7]	129/203 (63.5)	1.3 [0.4; 2.3]	0.80	[0.60; 1.05]	0.797	0.587
Germany	57/91 (62.6)	1.2 [-1.1; 3.5]	41/68 (60.3)	1.0 [-1.8; 3.8]	0.69	[0.41; 1.17]	0.972	0.980

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	106/188 (56.4)	4.2 [-4.8; 13.3]	126/206 (61.2)	2.4 [-0.0; 4.7]	0.82	[0.62; 1.08]	0.492	0.864
Headache - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.416)								
Low	174/291 (59.8)	2.8 [1.2; 4.5]	202/292 (69.2)	1.3 [0.7; 1.9]	0.68	[0.55; 0.85]	0.025	0.909
Intermediate	77/129 (59.7)	2.6 [1.1; 4.1]	73/128 (57.0)	2.9 [0.9; 4.8]	0.96	[0.69; 1.35]	0.677	0.734
High	36/61 (59.0)	3.7 [1.5; 6.0]	33/57 (57.9)	2.1 [-0.5; 4.8]	0.80	[0.48; 1.32]	0.971	0.621
Sex (Interaction test p = 0.298)								
Female	115/175 (65.7)	1.9 [0.8; 3.0]	128/201 (63.7)	1.7 [0.9; 2.6]	0.91	[0.69; 1.20]	0.922	0.659

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	171/306 (55.9)	3.7 [0.2; 7.3]	180/276 (65.2)	1.9 [0.5; 3.3]	0.69	[0.55; 0.86]	0.018	0.905
Race (Interaction test p = 0.198)								
White	202/333 (60.7)	2.4 [1.2; 3.6]	204/320 (63.8)	1.7 [0.6; 2.8]	0.83	[0.67; 1.03]	0.387	0.558
Asian	75/128 (58.6)	4.2 [0.7; 7.7]	87/132 (65.9)	2.0 [0.9; 3.2]	0.69	[0.50; 0.96]	0.121	0.606
Others	9/20 (45.0)	13.9 [0.7; 27.1]	17/25 (68.0)	1.4 [-1.2; 4.1]	0.37	[0.12; 1.15]	0.379	0.919
Age groups (Interaction test p = 0.376)								
18 - < 65 years	236/390 (60.5)	2.8 [1.6; 4.1]	266/397 (67.0)	1.5 [0.9; 2.1]	0.73	[0.61; 0.88]	0.043	0.808
65 - < 75 years	37/72 (51.4)	3.8 [-6.1; 13.8]	31/53 (58.5)	4.4 [-1.2; 10.1]	0.83	[0.47; 1.44]	0.836	0.515

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	12/19 (63.2)	1.4 [0.2; 2.7]	11/27 (40.7)	9.3 [-3.1; 21.7]	2.61	[0.61; 11.06]	0.411	0.980
Pre-randomization selection of TKI (Interaction test p = 0.624)								
Imatinib	56/101 (55.4)	2.4 [1.0; 3.8]	64/102 (62.7)	2.0 [1.0; 2.9]	0.87	[0.59; 1.27]	0.600	N.E.
Nilotinib	207/339 (61.1)	2.8 [1.5; 4.2]	219/333 (65.8)	1.7 [0.7; 2.8]	0.74	[0.61; 0.91]	0.111	0.553
Dasatinib	22/41 (53.7)	6.4 [-12.5; 25.3]	26/42 (61.9)	1.9 [-2.2; 6.1]	0.72	[0.39; 1.35]	0.766	N.E.
Geographic region (Interaction test p = 0.681)								
Europe excluding Germany	122/202 (60.4)	2.6 [1.2; 4.0]	131/203 (64.5)	1.7 [0.2; 3.2]	0.81	[0.62; 1.05]	0.450	0.483
Germany	56/91 (61.5)	3.7 [1.6; 5.9]	42/68 (61.8)	1.2 [0.5; 2.0]	0.68	[0.42; 1.11]	0.667	0.385

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	108/188 (57.4)	3.1 [0.8; 5.3]	136/206 (66.0)	2.0 [1.1; 3.0]	0.73	[0.56; 0.95]	0.101	0.712
Vomiting - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.196)								
Low	51/291 (17.5)	N.E. [N.E.; N.E.]	90/292 (30.8)	N.E. [N.E.; N.E.]	0.49	[0.35; 0.69]	<0.001	0.813
Intermediate	26/129 (20.2)	N.E. [N.E.; N.E.]	38/128 (29.7)	N.E. [N.E.; N.E.]	0.52	[0.32; 0.87]	0.022	0.092
High	9/61 (14.8)	N.E. [N.E.; N.E.]	13/57 (22.8)	N.E. [N.E.; N.E.]	0.57	[0.24; 1.38]	0.415	0.743
Sex (Interaction test p = 0.448)								
Female	39/175 (22.3)	N.E. [N.E.; N.E.]	69/201 (34.3)	N.E. [N.E.; N.E.]	0.50	[0.33; 0.74]	0.002	0.311

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	47/306 (15.4)	N.E. [N.E.; N.E.]	72/276 (26.1)	N.E. [N.E.; N.E.]	0.54	[0.37; 0.79]	0.003	0.064
Race (Interaction test p = 0.895)								
White	58/333 (17.4)	N.E. [N.E.; N.E.]	83/320 (25.9)	N.E. [N.E.; N.E.]	0.58	[0.41; 0.81]	0.003	0.889
Asian	24/128 (18.8)	N.E. [N.E.; N.E.]	49/132 (37.1)	N.E. [N.E.; N.E.]	0.39	[0.23; 0.65]	<0.001	0.219
Others	4/20 (20.0)	N.E. [N.E.; N.E.]	9/25 (36.0)	18.5 [18.4; 18.5]	0.71	[0.17; 2.92]	0.935	0.109
Age groups (Interaction test p = 0.175)								
18 - < 65 years	67/390 (17.2)	N.E. [N.E.; N.E.]	118/397 (29.7)	N.E. [N.E.; N.E.]	0.52	[0.38; 0.70]	<0.001	0.685
65 - < 75 years	13/72 (18.1)	N.E. [N.E.; N.E.]	14/53 (26.4)	N.E. [N.E.; N.E.]	0.65	[0.29; 1.43]	0.582	0.200

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	6/19 (31.6)	24.0 [23.9; 24.0]	10/27 (37.0)	7.0 [3.7; 10.3]	0.36	[0.10; 1.32]	0.193	0.966
Pre-randomization selection of TKI (Interaction test p = 0.207)								
Imatinib	18/101 (17.8)	N.E. [N.E.; N.E.]	40/102 (39.2)	N.E. [N.E.; N.E.]	0.36	[0.21; 0.64]	0.001	N.E.
Nilotinib	63/339 (18.6)	N.E. [N.E.; N.E.]	84/333 (25.2)	N.E. [N.E.; N.E.]	0.63	[0.45; 0.88]	0.013	0.385
Dasatinib	5/41 (12.2)	N.E. [N.E.; N.E.]	17/42 (40.5)	N.E. [N.E.; N.E.]	0.26	[0.10; 0.72]	0.012	N.E.
Geographic region (Interaction test p = 0.362)								
Europe excluding Germany	39/202 (19.3)	N.E. [N.E.; N.E.]	48/203 (23.6)	N.E. [N.E.; N.E.]	0.69	[0.44; 1.07]	0.193	0.805
Germany	11/91 (12.1)	N.E. [N.E.; N.E.]	14/68 (20.6)	N.E. [N.E.; N.E.]	0.55	[0.24; 1.29]	0.334	0.994

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	36/188 (19.1)	N.E. [N.E.; N.E.]	79/206 (38.3)	N.E. [N.E.; N.E.]	0.39	[0.26; 0.58]	<0.001	0.677
Nausea - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.635)								
Low	124/291 (42.6)	N.E. [N.E.; N.E.]	176/292 (60.3)	2.6 [1.3; 3.9]	0.59	[0.46; 0.75]	<0.001	0.063
Intermediate	47/129 (36.4)	N.E. [N.E.; N.E.]	71/128 (55.5)	4.7 [3.2; 6.2]	0.51	[0.35; 0.75]	<0.001	0.523
High	22/61 (36.1)	N.E. [N.E.; N.E.]	29/57 (50.9)	4.9 [-2.5; 12.3]	0.66	[0.37; 1.18]	0.322	0.552
Sex (Interaction test p = 0.508)								
Female	84/175 (48.0)	15.7 [1.3; 30.1]	128/201 (63.7)	1.9 [0.9; 2.9]	0.60	[0.45; 0.80]	0.002	0.896

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	110/306 (35.9)	N.E. [N.E.; N.E.]	147/276 (53.3)	6.5 [1.7; 11.4]	0.59	[0.45; 0.76]	<0.001	0.033
Race (Interaction test p = 0.503)								
White	138/333 (41.4)	N.E. [N.E.; N.E.]	183/320 (57.2)	3.5 [1.3; 5.7]	0.63	[0.50; 0.80]	<0.001	0.434
Asian	45/128 (35.2)	N.E. [N.E.; N.E.]	78/132 (59.1)	3.5 [1.7; 5.3]	0.45	[0.31; 0.66]	<0.001	0.266
Others	10/20 (50.0)	2.8 [-5.7; 11.3]	15/25 (60.0)	3.1 [0.9; 5.2]	0.66	[0.23; 1.89]	0.837	0.717
Age groups (Interaction test p = 0.583)								
18 - < 65 years	159/390 (40.8)	N.E. [N.E.; N.E.]	229/397 (57.7)	3.8 [1.9; 5.7]	0.60	[0.48; 0.74]	<0.001	0.123
65 - < 75 years	25/72 (34.7)	N.E. [N.E.; N.E.]	33/53 (62.3)	2.8 [-0.3; 5.9]	0.47	[0.26; 0.85]	0.023	0.507

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	10/19 (52.6)	3.5 [-21.6; 28.6]	14/27 (51.9)	1.2 [0.8; 1.6]	0.27	[0.07; 1.10]	0.146	0.467
Pre-randomization selection of TKI (Interaction test p = 0.007)								
Imatinib	31/101 (30.7)	N.E. [N.E.; N.E.]	72/102 (70.6)	1.2 [0.8; 1.6]	0.30	[0.19; 0.47]	<0.001	N.E.
Nilotinib	144/339 (42.5)	N.E. [N.E.; N.E.]	174/333 (52.3)	5.6 [1.5; 9.7]	0.71	[0.56; 0.89]	0.008	0.358
Dasatinib	18/41 (43.9)	N.E. [N.E.; N.E.]	30/42 (71.4)	2.8 [-2.0; 7.6]	0.57	[0.31; 1.06]	0.179	N.E.
Geographic region (Interaction test p = 0.281)								
Europe excluding Germany	84/202 (41.6)	N.E. [N.E.; N.E.]	120/203 (59.1)	2.9 [0.9; 5.0]	0.60	[0.44; 0.81]	0.001	0.389
Germany	37/91 (40.7)	N.E. [N.E.; N.E.]	40/68 (58.8)	5.9 [2.0; 9.8]	0.63	[0.38; 1.03]	0.120	0.993

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	72/188 (38.3)	N.E. [N.E.; N.E.]	116/206 (56.3)	3.5 [1.8; 5.2]	0.54	[0.40; 0.74]	<0.001	0.108
Edema - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.160)								
Low	101/291 (34.7)	N.E. [N.E.; N.E.]	132/292 (45.2)	14.9 [10.4; 19.3]	0.69	[0.53; 0.90]	0.015	0.363
Intermediate	47/129 (36.4)	N.E. [N.E.; N.E.]	56/128 (43.8)	13.0 [3.8; 22.2]	0.68	[0.45; 1.01]	0.108	0.111
High	18/61 (29.5)	N.E. [N.E.; N.E.]	21/57 (36.8)	N.E. [N.E.; N.E.]	0.70	[0.36; 1.37]	0.677	0.875
Sex (Interaction test p = 0.912)								
Female	75/175 (42.9)	N.E. [N.E.; N.E.]	104/201 (51.7)	5.6 [1.3; 9.8]	0.64	[0.47; 0.88]	0.021	0.010

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	91/306 (29.7)	N.E. [N.E.; N.E.]	105/276 (38.0)	N.E. [N.E.; N.E.]	0.73	[0.55; 0.98]	0.070	0.935
Race (Interaction test p = 0.333)								
White	112/333 (33.6)	N.E. [N.E.; N.E.]	125/320 (39.1)	26.7 [8.0; 45.5]	0.79	[0.60; 1.03]	0.174	0.119
Asian	49/128 (38.3)	N.E. [N.E.; N.E.]	73/132 (55.3)	4.9 [-1.9; 11.6]	0.52	[0.36; 0.76]	0.001	0.723
Others	5/20 (25.0)	N.E. [N.E.; N.E.]	10/25 (40.0)	14.2 [14.1; 14.3]	0.53	[0.17; 1.72]	0.635	0.852
Age groups (Interaction test p = 0.826)								
18 - < 65 years	134/390 (34.4)	N.E. [N.E.; N.E.]	168/397 (42.3)	22.1 [11.6; 32.6]	0.72	[0.57; 0.90]	0.016	0.069
65 - < 75 years	25/72 (34.7)	N.E. [N.E.; N.E.]	29/53 (54.7)	4.4 [-1.7; 10.5]	0.50	[0.27; 0.92]	0.067	0.092

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	7/19 (36.8)	N.E. [N.E.; N.E.]	11/27 (40.7)	2.7 [-0.5; 5.8]	0.74	[0.24; 2.24]	0.877	0.662
Pre-randomization selection of TKI (Interaction test p = 0.013)								
Imatinib	32/101 (31.7)	N.E. [N.E.; N.E.]	60/102 (58.8)	3.7 [1.1; 6.4]	0.37	[0.23; 0.59]	<0.001	N.E.
Nilotinib	121/339 (35.7)	N.E. [N.E.; N.E.]	129/333 (38.7)	N.E. [N.E.; N.E.]	0.85	[0.66; 1.10]	0.509	0.335
Dasatinib	13/41 (31.7)	N.E. [N.E.; N.E.]	20/42 (47.6)	22.2 [4.7; 39.7]	0.56	[0.27; 1.16]	0.211	N.E.
Geographic region (Interaction test p = 0.845)								
Europe excluding Germany	57/202 (28.2)	N.E. [N.E.; N.E.]	83/203 (40.9)	N.E. [N.E.; N.E.]	0.61	[0.42; 0.86]	0.010	0.041
Germany	35/91 (38.5)	N.E. [N.E.; N.E.]	28/68 (41.2)	16.7 [7.1; 26.2]	0.97	[0.56; 1.68]	0.566	0.583

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	75/188 (39.9)	N.E. [N.E.; N.E.]	97/206 (47.1)	12.3 [0.8; 23.8]	0.67	[0.49; 0.92]	0.030	0.421
Muscle Pain - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.980)								
Low	171/291 (58.8)	1.9 [-0.3; 4.2]	212/292 (72.6)	1.0 [0.6; 1.4]	0.72	[0.58; 0.89]	0.009	0.382
Intermediate	78/129 (60.5)	1.5 [0.6; 2.3]	83/128 (64.8)	1.7 [0.4; 3.1]	0.86	[0.62; 1.19]	0.695	0.104
High	28/61 (45.9)	16.8 [-13.0; 46.5]	35/57 (61.4)	1.7 [-0.2; 3.6]	0.64	[0.37; 1.09]	0.283	0.804
Sex (Interaction test p = 0.576)								
Female	109/175 (62.3)	1.1 [0.5; 1.7]	143/201 (71.1)	1.1 [0.6; 1.5]	0.84	[0.64; 1.10]	0.235	0.497

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	169/306 (55.2)	3.7 [0.2; 7.3]	187/276 (67.8)	1.1 [0.3; 1.8]	0.70	[0.56; 0.88]	0.011	0.024
Race (Interaction test p = 0.179)								
White	196/333 (58.9)	1.5 [0.7; 2.4]	210/320 (65.6)	1.2 [0.6; 1.9]	0.84	[0.68; 1.04]	0.387	0.519
Asian	69/128 (53.9)	7.6 [-3.0; 18.2]	102/132 (77.3)	1.0 [0.6; 1.4]	0.54	[0.39; 0.74]	<0.001	0.899
Others	12/20 (60.0)	1.0 [-2.2; 4.2]	17/25 (68.0)	2.1 [-0.4; 4.7]	0.70	[0.27; 1.80]	0.921	0.629
Age groups (Interaction test p = 0.784)								
18 - < 65 years	224/390 (57.4)	2.4 [0.0; 4.7]	277/397 (69.8)	1.0 [0.7; 1.4]	0.73	[0.60; 0.88]	0.005	0.045
65 - < 75 years	40/72 (55.6)	1.5 [-3.2; 6.2]	37/53 (69.8)	2.1 [0.9; 3.4]	0.78	[0.46; 1.32]	0.503	0.595

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	14/19 (73.7)	1.2 [0.4; 2.0]	15/27 (55.6)	1.4 [0.2; 2.7]	1.01	[0.37; 2.75]	0.836	0.708
Pre-randomization selection of TKI (Interaction test p = 0.350)								
Imatinib	51/101 (50.5)	5.6 [-13.4; 24.5]	74/102 (72.5)	0.8 [0.4; 1.2]	0.58	[0.39; 0.85]	0.016	N.E.
Nilotinib	205/339 (60.5)	1.7 [0.5; 2.9]	225/333 (67.6)	1.4 [0.8; 2.1]	0.82	[0.67; 1.00]	0.140	0.415
Dasatinib	21/41 (51.2)	7.6 [-13.9; 29.1]	30/42 (71.4)	1.0 [0.4; 1.7]	0.58	[0.32; 1.06]	0.129	N.E.
Geographic region (Interaction test p = 0.856)								
Europe excluding Germany	118/202 (58.4)	1.7 [-0.5; 3.9]	135/203 (66.5)	1.3 [0.4; 2.1]	0.82	[0.62; 1.06]	0.348	0.388
Germany	54/91 (59.3)	0.8 [-1.0; 2.7]	45/68 (66.2)	1.1 [0.3; 1.8]	0.88	[0.55; 1.40]	0.941	0.698

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	106/188 (56.4)	3.7 [-0.6; 7.9]	150/206 (72.8)	1.0 [0.5; 1.5]	0.65	[0.50; 0.84]	0.002	0.352
Pruritus - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.708)								
Low	179/291 (61.5)	3.9 [2.2; 5.5]	210/292 (71.9)	1.8 [1.1; 2.4]	0.69	[0.56; 0.85]	0.006	0.613
Intermediate	76/129 (58.9)	3.3 [1.1; 5.5]	78/128 (60.9)	2.8 [2.1; 3.5]	0.81	[0.58; 1.13]	0.477	0.261
High	30/61 (49.2)	9.3 [-11.7; 30.3]	39/57 (68.4)	2.1 [1.1; 3.0]	0.53	[0.32; 0.87]	0.058	0.704
Sex (Interaction test p = 0.383)								
Female	110/175 (62.9)	3.3 [2.1; 4.5]	141/201 (70.1)	1.9 [1.1; 2.6]	0.71	[0.55; 0.93]	0.033	0.040

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	175/306 (57.2)	4.5 [1.8; 7.1]	187/276 (67.8)	2.1 [1.4; 2.8]	0.69	[0.55; 0.86]	0.015	0.678
Race (Interaction test p = 0.660)								
White	208/333 (62.5)	3.3 [2.0; 4.5]	226/320 (70.6)	1.9 [1.4; 2.4]	0.72	[0.59; 0.88]	0.010	0.320
Asian	66/128 (51.6)	8.3 [-5.0; 21.7]	85/132 (64.4)	2.9 [0.7; 5.0]	0.62	[0.44; 0.87]	0.034	0.153
Others	11/20 (55.0)	3.4 [0.0; 6.7]	17/25 (68.0)	1.3 [-0.7; 3.4]	0.67	[0.25; 1.79]	0.971	0.548
Age groups (Interaction test p = 0.167)								
18 - < 65 years	229/390 (58.7)	4.2 [2.3; 6.2]	270/397 (68.0)	1.9 [1.4; 2.4]	0.69	[0.57; 0.82]	0.002	0.844
65 - < 75 years	42/72 (58.3)	3.8 [1.8; 5.7]	39/53 (73.6)	2.6 [1.8; 3.4]	0.89	[0.53; 1.48]	0.958	0.027


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	13/19 (68.4)	2.2 [1.9; 2.5]	18/27 (66.7)	2.1 [2.0; 2.2]	0.73	[0.31; 1.71]	0.901	0.110
Pre-randomization selection of TKI (Interaction test p = 0.004)								
Imatinib	59/101 (58.4)	3.8 [0.3; 7.4]	56/102 (54.9)	4.7 [1.8; 7.6]	1.32	[0.90; 1.94]	0.994	N.E.
Nilotinib	200/339 (59.0)	4.0 [2.3; 5.6]	243/333 (73.0)	1.5 [1.0; 2.0]	0.59	[0.48; 0.72]	<0.001	0.447
Dasatinib	25/41 (61.0)	3.8 [1.9; 5.7]	29/42 (69.0)	2.4 [0.7; 4.0]	0.80	[0.46; 1.38]	0.963	N.E.
Geographic region (Interaction test p = 0.609)								
Europe excluding Germany	124/202 (61.4)	3.5 [2.0; 5.1]	146/203 (71.9)	1.9 [1.3; 2.6]	0.71	[0.55; 0.91]	0.032	0.349
Germany	56/91 (61.5)	3.5 [0.2; 6.9]	49/68 (72.1)	1.5 [0.8; 2.1]	0.67	[0.44; 1.04]	0.269	0.602

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	105/188 (55.9)	5.6 [2.6; 8.5]	133/206 (64.6)	2.8 [1.6; 4.0]	0.74	[0.56; 0.97]	0.071	0.705

MID: Minimal important difference
N*: Number of patients included in the analysis
n: Number of patients with event. The number of patients is the mean number over all imputations rounded to the nearest integer
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
.....
Missing baseline values are multiply imputed by simple imputation using 500 repetitions under a MAR assumption.
Two-sided 95% CI for KM percentiles are derived by the approach outlined in Moscovici and Ratitch (2017).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates baseline score and treatment arm.
P-Values are based on stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
Test results are combined using the Wilson-Hilferty transformation.
P-Values for test of heterogeneity are from the stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Test results are combined using the Wilson-Hilferty transformation.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Nausea - Severity (MID=1): Pre-randomization selection of TKI: Imatinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Nausea - Severity (MID=1): Pre-randomization selection of TKI: Nilotinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Nausea - Severity (MID=1): Pre-randomization selection of TKI: Dasatinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Edema - Severity (MID=1): Pre-randomization selection of TKI: Imatinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Edema - Severity (MID=1): Pre-randomization selection of TKI: Nilotinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Edema - Severity (MID=1): Pre-randomization selection of TKI: Dasatinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)


Pruritus - Severity (MID=1): Pre-randomization selection of TKI: Imatinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Pruritus - Severity (MID=1): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	131 (29)	71 (75)	38 (104)	18 (121)	4 (134)	0 (139)
Investigator Selected TKI	333 (0)	78 (38)	37 (61)	19 (75)	5 (86)	1 (89)	0 (90)

Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-5.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values): Kaplan-Meier plot (Full Analysis Set)

Pruritus - Severity (MID=1): Pre-randomization selection of TKI: Dasatinib



Note: The number of patients at risk and the number censored at a timepoint are the mean numbers over all imputations rounded to the nearest integer
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-5.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Sensitivity analysis (multiple imputation of missing baseline values) (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Fatigue - Interference (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test p = 0.688)								
Low	182/291 (62.5)	2.6 [0.9; 4.3]	190/292 (65.1)	1.2 [0.5; 1.9]	0.83	[0.66; 1.03]	0.648	0.165
Intermediate	78/129 (60.5)	2.4 [-0.1; 5.0]	80/128 (62.5)	1.4 [-0.5; 3.4]	0.83	[0.59; 1.15]	0.832	0.946
High	25/61 (41.0)	N.E. [N.E.; N.E.]	28/57 (49.1)	7.5 [-10.6; 25.5]	0.63	[0.35; 1.15]	0.428	0.944
Sex								
(Interaction test p = 0.562)								
Female	104/175 (59.4)	3.7 [0.3; 7.1]	125/201 (62.2)	1.9 [0.4; 3.3]	0.82	[0.61; 1.10]	0.668	0.236

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	181/306 (59.2)	2.8 [0.9; 4.8]	173/276 (62.7)	1.2 [0.4; 1.9]	0.83	[0.66; 1.04]	0.587	0.547
Race (Interaction test p = 0.402)								
White	203/333 (61.0)	2.6 [0.6; 4.6]	195/320 (60.9)	1.4 [0.3; 2.6]	0.89	[0.72; 1.12]	0.985	0.595
Asian	72/128 (56.3)	5.8 [-0.3; 11.9]	88/132 (66.7)	1.4 [0.4; 2.5]	0.67	[0.48; 0.93]	0.079	0.461
Others	10/20 (50.0)	2.2 [1.1; 3.3]	13/25 (52.0)	1.4 [-3.0; 5.9]	0.55	[0.18; 1.69]	0.768	0.767
Age groups (Interaction test p = 0.446)								
18 - < 65 years	237/390 (60.8)	2.9 [1.1; 4.7]	248/397 (62.5)	1.4 [0.4; 2.4]	0.82	[0.67; 1.00]	0.659	0.067
65 - < 75 years	38/72 (52.8)	5.0 [-9.0; 18.9]	36/53 (67.9)	1.0 [0.3; 1.7]	0.73	[0.42; 1.27]	0.389	0.561

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	10/19 (52.6)	2.2 [-3.3; 7.6]	14/27 (51.9)	2.1 [-0.8; 5.1]	0.95	[0.29; 3.16]	0.990	0.760
Pre-randomization selection of TKI (Interaction test p = 0.800)								
Imatinib	62/101 (61.4)	1.5 [-1.2; 4.2]	67/102 (65.7)	0.8 [0.0; 1.5]	0.77	[0.53; 1.12]	0.561	N.E.
Nilotinib	200/339 (59.0)	3.5 [1.5; 5.5]	201/333 (60.4)	2.1 [0.9; 3.4]	0.83	[0.67; 1.03]	0.615	0.033
Dasatinib	23/41 (56.1)	4.4 [-4.2; 13.1]	29/42 (69.0)	0.6 [-0.6; 1.8]	0.66	[0.36; 1.20]	0.635	N.E.
Geographic region (Interaction test p = 0.491)								
Europe excluding Germany	125/202 (61.9)	2.4 [-0.1; 4.8]	126/203 (62.1)	1.4 [0.2; 2.6]	0.92	[0.70; 1.21]	0.782	0.446
Germany	58/91 (63.7)	2.0 [-0.6; 4.6]	39/68 (57.4)	1.1 [-1.6; 3.9]	0.72	[0.43; 1.21]	0.924	0.739

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	102/188 (54.3)	5.8 [-0.3; 12.0]	132/206 (64.1)	1.4 [0.6; 2.3]	0.69	[0.52; 0.90]	0.036	0.476
Headache - Interference (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.743)								
Low	156/291 (53.6)	9.1 [3.2; 14.9]	180/292 (61.6)	2.8 [1.3; 4.3]	0.72	[0.57; 0.90]	0.031	0.487
Intermediate	62/129 (48.1)	16.6 [1.3; 31.9]	59/128 (46.1)	8.3 [0.3; 16.4]	0.94	[0.65; 1.36]	0.800	0.803
High	29/61 (47.5)	11.2 [-0.4; 22.8]	25/57 (43.9)	14.8 [4.9; 24.7]	0.90	[0.51; 1.57]	0.487	0.460
Sex (Interaction test p = 0.933)								
Female	105/175 (60.0)	3.9 [1.0; 6.9]	117/201 (58.2)	2.8 [1.4; 4.3]	0.87	[0.65; 1.15]	0.972	0.482

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	142/306 (46.4)	16.6 [8.5; 24.7]	148/276 (53.6)	7.4 [1.8; 12.9]	0.76	[0.60; 0.97]	0.075	0.942
Race (Interaction test p = 0.430)								
White	176/333 (52.9)	10.2 [3.5; 16.9]	176/320 (55.0)	4.4 [-0.1; 8.9]	0.85	[0.68; 1.06]	0.347	0.640
Asian	65/128 (50.8)	13.9 [-1.2; 29.0]	74/132 (56.1)	4.4 [0.8; 7.9]	0.75	[0.53; 1.07]	0.327	0.500
Others	6/20 (30.0)	N.E. [N.E.; N.E.]	14/25 (56.0)	3.7 [-0.3; 7.8]	0.45	[0.15; 1.32]	0.409	0.922
Age groups (Interaction test p = 0.451)								
18 - < 65 years	203/390 (52.1)	10.3 [4.3; 16.2]	234/397 (58.9)	3.3 [1.7; 4.9]	0.74	[0.61; 0.90]	0.021	0.812
65 - < 75 years	35/72 (48.6)	11.1 [-4.7; 26.8]	21/53 (39.6)	N.E. [N.E.; N.E.]	1.11	[0.60; 2.08]	0.676	0.704

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	9/19 (47.4)	19.4 [16.1; 22.6]	10/27 (37.0)	14.8 [6.4; 23.2]	0.63	[0.20; 2.04]	0.878	0.536
Pre-randomization selection of TKI (Interaction test p = 0.941)								
Imatinib	48/101 (47.5)	18.5 [7.2; 29.9]	54/102 (52.9)	4.9 [-4.0; 13.9]	0.75	[0.50; 1.14]	0.327	N.E.
Nilotinib	182/339 (53.7)	7.4 [2.9; 11.9]	184/333 (55.3)	4.2 [1.5; 6.9]	0.82	[0.67; 1.02]	0.350	0.480
Dasatinib	18/41 (43.9)	N.E. [N.E.; N.E.]	26/42 (61.9)	2.1 [-2.6; 6.9]	0.57	[0.30; 1.09]	0.173	N.E.
Geographic region (Interaction test p = 0.841)								
Europe excluding Germany	108/202 (53.5)	10.2 [2.4; 17.9]	110/203 (54.2)	5.2 [-1.1; 11.5]	0.87	[0.66; 1.16]	0.896	0.494
Germany	49/91 (53.8)	5.7 [-0.4; 11.7]	40/68 (58.8)	1.9 [-1.8; 5.6]	0.66	[0.41; 1.06]	0.295	0.839

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	90/188 (47.9)	17.5 [4.6; 30.5]	114/206 (55.3)	4.2 [1.2; 7.3]	0.71	[0.53; 0.96]	0.073	0.835
Edema - Interference (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.702)								
Low	73/291 (25.1)	32.8 [32.7; 32.8]	104/292 (35.6)	N.E. [N.E.; N.E.]	0.64	[0.47; 0.86]	0.008	0.701
Intermediate	40/129 (31.0)	N.E. [N.E.; N.E.]	43/128 (33.6)	N.E. [N.E.; N.E.]	0.74	[0.47; 1.16]	0.379	0.546
High	11/61 (18.0)	N.E. [N.E.; N.E.]	16/57 (28.1)	N.E. [N.E.; N.E.]	0.49	[0.22; 1.09]	0.246	0.647
Sex (Interaction test p = 0.548)								
Female	51/175 (29.1)	N.E. [N.E.; N.E.]	79/201 (39.3)	N.E. [N.E.; N.E.]	0.58	[0.40; 0.84]	0.008	0.090

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Male	73/306 (23.9)	32.8 [32.7; 32.8]	83/276 (30.1)	N.E. [N.E.; N.E.]	0.72	[0.52; 1.00]	0.108	0.410
Race (Interaction test p = 0.618)								
White	77/333 (23.1)	N.E. [N.E.; N.E.]	98/320 (30.6)	N.E. [N.E.; N.E.]	0.65	[0.48; 0.90]	0.017	0.301
Asian	41/128 (32.0)	N.E. [N.E.; N.E.]	57/132 (43.2)	N.E. [N.E.; N.E.]	0.58	[0.38; 0.87]	0.019	0.649
Others	5/20 (25.0)	N.E. [N.E.; N.E.]	7/25 (28.0)	N.E. [N.E.; N.E.]	0.87	[0.24; 3.15]	0.402	0.553
Age groups (Interaction test p = 0.770)								
18 - < 65 years	98/390 (25.1)	32.8 [32.7; 32.8]	130/397 (32.7)	N.E. [N.E.; N.E.]	0.68	[0.52; 0.89]	0.012	0.416
65 - < 75 years	18/72 (25.0)	N.E. [N.E.; N.E.]	21/53 (39.6)	N.E. [N.E.; N.E.]	0.47	[0.23; 0.95]	0.087	0.300

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
>= 75 years	8/19 (42.1)	22.1 [22.1; 22.2]	11/27 (40.7)	2.7 [0.9; 4.4]	0.61	[0.20; 1.80]	0.720	0.855
Pre-randomization selection of TKI (Interaction test p = 0.156)								
Imatinib	25/101 (24.8)	N.E. [N.E.; N.E.]	47/102 (46.1)	11.1 [-1.5; 23.7]	0.39	[0.24; 0.65]	<0.001	N.E.
Nilotinib	86/339 (25.4)	N.E. [N.E.; N.E.]	101/333 (30.3)	27.7 [27.6; 27.7]	0.75	[0.56; 1.01]	0.114	0.365
Dasatinib	12/41 (29.3)	32.8 [32.7; 32.8]	14/42 (33.3)	N.E. [N.E.; N.E.]	0.78	[0.35; 1.72]	0.848	N.E.
Geographic region (Interaction test p = 0.781)								
Europe excluding Germany	42/202 (20.8)	N.E. [N.E.; N.E.]	66/203 (32.5)	27.6 [27.5; 27.7]	0.54	[0.36; 0.81]	0.004	0.121
Germany	24/91 (26.4)	N.E. [N.E.; N.E.]	18/68 (26.5)	N.E. [N.E.; N.E.]	0.94	[0.48; 1.82]	0.492	0.934

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	57/188 (30.3)	N.E. [N.E.; N.E.]	78/206 (37.9)	N.E. [N.E.; N.E.]	0.66	[0.47; 0.95]	0.058	0.690
Muscle Pain - Interference (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test p = 0.262)								
Low	156/291 (53.6)	5.1 [-2.0; 12.3]	179/292 (61.3)	1.9 [0.6; 3.2]	0.78	[0.62; 0.98]	0.122	0.524
Intermediate	77/129 (59.7)	1.9 [0.9; 3.0]	68/128 (53.1)	4.3 [1.2; 7.4]	1.15	[0.82; 1.61]	0.873	0.379
High	24/61 (39.3)	N.E. [N.E.; N.E.]	29/57 (50.9)	4.5 [0.6; 8.3]	0.69	[0.39; 1.24]	0.675	0.719
Sex (Interaction test p = 0.216)								
Female	105/175	1.5 [0.6; 2.5]	116/201	1.9 [0.8; 3.0]	1.05	[0.79; 1.40]	0.711	0.723

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(60.0)		(57.7)					
Male	151/306	12.0 [1.1; 23.0]	160/276	3.7 [0.9; 6.6]	0.77	[0.61; 0.97]	0.118	0.122
	(49.3)		(58.0)					
Race								
(Interaction test p = 0.402)								
White	174/333	4.7 [-2.9; 12.3]	186/320	2.7 [0.7; 4.7]	0.85	[0.68; 1.07]	0.512	0.331
	(52.3)		(58.1)					
Asian	73/128	4.7 [-2.4; 11.7]	78/132	3.1 [1.2; 5.0]	0.84	[0.60; 1.17]	0.693	0.983
	(57.0)		(59.1)					
Others	10/20	3.3 [-5.3; 11.9]	12/25	5.5 [-4.7; 15.7]	0.95	[0.33; 2.73]	0.573	0.451
	(50.0)		(48.0)					
Age groups								
(Interaction test p = 0.424)								
18 - < 65 years	206/390	5.0 [-1.6; 11.6]	230/397	2.6 [0.8; 4.4]	0.83	[0.68; 1.01]	0.298	0.061
	(52.8)		(57.9)					
65 - < 75 years	38/72	4.7 [-5.4; 14.9]	32/53	3.7 [1.8; 5.7]	0.80	[0.46; 1.38]	0.781	0.582

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
	(52.8)		(60.4)					
>= 75 years	13/19	2.1 [1.3; 2.9]	13/27	2.6 [-0.3; 5.5]	0.65	[0.22; 1.90]	0.725	0.808
	(68.4)		(48.1)					
Pre-randomization selection of TKI								
(Interaction test p = 0.334)								
Imatinib	45/101	22.2 [8.3; 36.1]	63/102	1.7 [-0.6; 3.9]	0.60	[0.40; 0.91]	0.031	N.E.
	(44.6)		(61.8)					
Nilotinib	192/339	3.3 [1.4; 5.2]	191/333	2.8 [0.8; 4.9]	0.93	[0.75; 1.14]	0.792	0.767
	(56.6)		(57.4)					
Dasatinib	20/41	21.3 [-1.7; 44.4]	22/42	4.7 [-8.2; 17.5]	0.83	[0.44; 1.57]	0.908	N.E.
	(48.8)		(52.4)					
Geographic region								
(Interaction test p = 0.387)								
Europe excluding Germany	104/202	7.6 [-2.3; 17.5]	120/203	2.6 [0.4; 4.8]	0.82	[0.62; 1.08]	0.455	0.272
	(51.5)		(59.1)					
Germany	50/91	3.7 [-0.4; 7.9]	39/68	1.7 [-0.3; 3.7]	0.91	[0.57; 1.47]	0.682	0.588

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				Test for Heterogeneity p-value
Others	(54.9) 102/188 (54.3)	4.7 [-1.3; 10.7]	(57.4) 117/206 (56.8)	3.4 [0.9; 5.8]	0.89	[0.67; 1.17]	0.886	0.604

MID: Minimal important difference
N*: Number of patients included in the analysis
n: Number of patients with event. The number of patients is the mean number over all imputations rounded to the nearest integer
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
.....
Missing baseline values are multiply imputed by simple imputation using 500 repetitions under a MAR assumption.
Two-sided 95% CI for KM percentiles are derived by the approach outlined in Moscovici and Ratitch (2017).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates baseline score and treatment arm.
P-Values are based on stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
Test results are combined using the Wilson-Hilferty transformation.
P-Values for test of heterogeneity are from the stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Test results are combined using the Wilson-Hilferty transformation.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Global health status/QoL (MID=10)				
N*	481	477	0.80	0.322
Number of patients with events, n (%)	113 (23.5)	129 (27.0)	[0.62; 1.04]	
			0.042	
Percentiles (months) [95% CI]				
25th	5.3 [2.7; 11.1]	2.0 [1.9; 2.8]		
Median	22.5 [22.1; N.E.]	22.1 [11.1; N.E.]		
75th	N.E. [N.E.; N.E.]	30.3 [N.E.; N.E.]		
Physical functioning (MID=10)				
N*	481	477	0.74	0.139
Number of patients with events, n (%)	82 (17.0)	97 (20.3)	[0.55; 0.99]	
			0.038	
Percentiles (months) [95% CI]				
25th	11.1 [3.6; 22.1]	4.2 [1.9; 11.0]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	27.6 [27.6; N.E.]	N.E. [22.1; N.E.]		
75th	N.E. [27.6; N.E.]	N.E. [N.E.; N.E.]		
Role functioning (MID=10)				
N*	481	477	0.78	0.004
Number of patients with events, n (%)	111 (23.1)	123 (25.8)	[0.60; 1.01]	
			0.060	
Percentiles (months) [95% CI]				
25th	2.8 [1.9; 5.6]	2.7 [1.9; 2.9]		
Median	22.5 [22.2; N.E.]	22.1 [11.2; N.E.]		
75th	N.E. [22.5; N.E.]	N.E. [22.3; N.E.]		
Emotional functioning (MID=10)				
N*	481	477	0.72	0.941
Number of patients with events, n (%)	90 (18.7)	111 (23.3)	[0.54; 0.95]	
			0.025	
Percentiles (months) [95% CI]				
25th	11.0 [2.9; 11.2]	5.4 [2.8; 5.6]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [22.5; N.E.]	N.E. [22.1; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Cognitive functioning (MID=10)				
N*	481	477	0.82	0.242
Number of patients with events, n (%)	137 (28.5)	151 (31.7)	[0.65; 1.03]	
			0.075	
Percentiles (months) [95% CI]				
25th	2.8 [1.9; 5.5]	2.7 [1.9; 2.8]		
Median	22.1 [11.1; 22.5]	11.1 [5.7; 11.6]		
75th	N.E. [22.5; N.E.]	N.E. [22.2; N.E.]		
Social functioning (MID=10)				
N*	481	477	0.68	0.343
Number of patients with events, n (%)	105 (21.8)	130 (27.3)	[0.52; 0.88]	
			0.003	
Percentiles (months) [95% CI]				
25th	2.8 [1.9; 5.7]	1.9 [1.7; 2.8]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	22.5 [22.2; N.E.]	22.1 [11.1; N.E.]		
75th	N.E. [22.5; N.E.]	N.E. [N.E.; N.E.]		
Fatigue (MID=10)				
N*	481	477	0.70	0.690
Number of patients with events, n (%)	121 (25.2)	141 (29.6)	[0.55; 0.90]	
			0.008	
Percentiles (months) [95% CI]				
25th	1.9 [1.8; 4.2]	1.8 [1.1; 1.9]		
Median	22.2 [22.1; N.E.]	22.0 [5.6; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Nausea and vomiting (MID=10)				
N*	481	477	0.61	0.230
Number of patients with events, n (%)	77 (16.0)	106 (22.2)	[0.45; 0.82]	
			<0.001	
Percentiles (months) [95% CI]				
25th	11.1 [6.0; 24.7]	2.8 [2.7; 5.6]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	24.7 [22.3; N.E.]	22.2 [22.1; N.E.]		
75th	N.E. [24.7; N.E.]	N.E. [N.E.; N.E.]		
Pain (MID=10)				
N*	481	477	0.77	0.074
Number of patients with events, n (%)	132 (27.4)	153 (32.1)	[0.60; 0.97]	
			0.009	
Percentiles (months) [95% CI]				
25th	1.9 [1.7; 2.0]	1.2 [1.0; 1.9]		
Median	22.5 [22.0; N.E.]	11.1 [5.5; 16.4]		
75th	N.E. [24.7; N.E.]	N.E. [22.2; N.E.]		
Dyspnoea (MID=10)				
N*	481	477	0.67	0.091
Number of patients with events, n (%)	79 (16.4)	104 (21.8)	[0.50; 0.90]	
			0.006	
Percentiles (months) [95% CI]				
25th	22.1 [5.6; 22.1]	2.8 [1.9; 5.7]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	22.5 [22.2; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Insomnia (MID=10)				
N*	481	477	0.77	0.709
Number of patients with events, n (%)	106 (22.0)	117 (24.5)	[0.59; 1.00]	
			0.081	
Percentiles (months) [95% CI]				
25th	5.5 [2.8; 10.8]	2.8 [1.9; 2.8]		
Median	22.5 [22.5; N.E.]	22.2 [15.2; N.E.]		
75th	N.E. [22.5; N.E.]	N.E. [N.E.; N.E.]		
Appetite loss (MID=10)				
N*	481	477	0.55	0.028
Number of patients with events, n (%)	57 (11.9)	86 (18.0)	[0.39; 0.77]	
			<0.001	
Percentiles (months) [95% CI]				
25th	22.2 [22.1; N.E.]	5.6 [2.8; 16.6]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [22.5; N.E.]	N.E. [22.2; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Constipation (MID=10)				
N*	481	477	0.67	0.421
Number of patients with events, n (%)	92 (19.1)	114 (23.9)	[0.51; 0.88]	
			0.007	
Percentiles (months) [95% CI]				
25th	11.0 [5.5; 11.1]	2.8 [1.9; 3.0]		
Median	N.E. [22.5; N.E.]	N.E. [11.6; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Diarrhoea (MID=10)				
N*	481	477	0.66	0.569
Number of patients with events, n (%)	89 (18.5)	121 (25.4)	[0.50; 0.87]	
			0.001	
Percentiles (months) [95% CI]				
25th	5.6 [2.8; 11.2]	2.8 [2.6; 3.0]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	22.2 [11.2; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Financial difficulties (MID=10)				
N*	481	477	1.18	0.866
Number of patients with events, n (%)	74 (15.4)	64 (13.4)	[0.84; 1.66]	
			0.333	
Percentiles (months) [95% CI]				
25th	21.9 [5.6; N.E.]	22.2 [11.0; 26.4]		
Median	N.E. [N.E.; N.E.]	26.4 [22.3; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [26.4; N.E.]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
In this sensitivity analysis a missing assessment before randomization is substituted by the last assessment before or on the day of treatment start, if such an assessment is available.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline score.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Global health status/QoL (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Physical functioning (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Role functioning (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Emotional functioning (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Cognitive functioning (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Social functioning (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Fatigue (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Nausea and vomiting (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Pain (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Dyspnoea (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Insomnia (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Appetite loss (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Constipation (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Diarrhoea (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1 EORTC QLQ-C30: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Financial difficulties (MID=10)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Appetite loss (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Cognitive functioning (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Constipation (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhoea (MID=10)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Dyspnoea (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	34/197	52/193	0.51	0.33; 0.79	0.001
ASC4START	45/284	52/284	0.85	0.57; 1.27	0.460
Pooled Analysis	79/481	104/477	0.67	0.50; 0.90	0.006



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Emotional functioning (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Fatigue (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Financial difficulties (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Global health status/QoL (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Insomnia (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Nausea and vomiting (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Pain (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Physical functioning (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Role functioning (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Table 3-6.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Body Image Problems (MID=15)				
N*	481	477	0.95	0.208
Number of patients with events, n (%)	117 (24.3)	112 (23.5)	[0.73; 1.24]	
			0.599	
Percentiles (months) [95% CI]				
25th	2.8 [1.9; 5.5]	2.8 [1.9; 5.5]		
Median	22.2 [22.1; N.E.]	N.E. [16.6; N.E.]		
75th	24.7 [22.5; N.E.]	N.E. [N.E.; N.E.]		
Impact on Daily Life (MID=15)				
N*	481	477	0.64	0.353
Number of patients with events, n (%)	70 (14.6)	98 (20.5)	[0.47; 0.87]	
			0.004	
Percentiles (months) [95% CI]				
25th	11.1 [8.5; N.E.]	2.9 [2.7; 10.9]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [22.1; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Impact on Worry/Mood (MID=15)				
N*	481	477	0.88	0.082
Number of patients with events, n (%)	70 (14.6)	69 (14.5)	[0.63; 1.23]	
			0.501	
Percentiles (months) [95% CI]				
25th	11.8 [8.3; N.E.]	11.1 [5.6; 22.1]		
Median	N.E. [22.2; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Symptom Burden (MID=15)				
N*	481	477	0.36	0.303
Number of patients with events, n (%)	31 (6.4)	73 (15.3)	[0.24; 0.55]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	11.2 [5.6; 22.1]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	25.7 [22.3; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [25.7; N.E.]		
Satisfaction with Care and Information (MID=15)				
N*	481	477	1.17	0.755
Number of patients with events, n (%)	120 (24.9)	83 (17.4)	[0.87; 1.55]	
			0.022	
Percentiles (months) [95% CI]				
25th	2.7 [1.9; 2.8]	3.0 [1.9; 11.1]		
Median	N.E. [11.2; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Satisfaction with Social Life (MID=15)				
N*	481	477	1.16	0.766
Number of patients with events, n (%)	136 (28.3)	113 (23.7)	[0.89; 1.49]	
			0.210	
Percentiles (months) [95% CI]				
25th	1.9 [1.1; 2.6]	2.7 [1.9; 2.8]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	22.1 [11.1; N.E.]	25.7 [16.6; N.E.]		
75th	N.E. [N.E.; N.E.]	25.7 [N.E.; N.E.]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
In this sensitivity analysis a missing assessment before randomization is substituted by the last assessment before or on the day of treatment start, if such an assessment is available.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline score.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)

Body Image Problems (MID=15)




Pts at Risk (censored)

Asciminib	481 (0)	157 (223)	74 (296)	74 (296)	2 (363)	0 (364)	0 (364)
Investigator Selected TKI	477 (0)	137 (241)	57 (312)	48 (320)	2 (363)	0 (365)	0 (365)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Impact on Daily Life (MID=15)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)

Impact on Worry/Mood (MID=15)




Pts at Risk (censored)

Asciminib	481 (0)	191 (234)	85 (330)	84 (331)	4 (407)	0 (411)	0 (411)
Investigator Selected TKI	477 (0)	166 (254)	69 (344)	58 (355)	4 (404)	1 (407)	0 (408)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Symptom Burden (MID=15)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)

Satisfaction with Care and Information (MID=15)




Pts at Risk (censored)							
Asciminib	481 (0)	149 (230)	48 (314)	47 (314)	3 (358)	0 (361)	0 (361)
Investigator Selected TKI	477 (0)	148 (251)	60 (334)	50 (344)	5 (389)	1 (393)	0 (394)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.2 EORTC QLQ-CML24: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)

Satisfaction with Social Life (MID=15)




Pts at Risk (censored)

Asciminib	481 (0)	142 (221)	60 (287)	59 (288)	2 (343)	0 (345)	0 (345)
Investigator Selected TKI	477 (0)	133 (243)	60 (307)	52 (314)	1 (364)	0 (364)	0 (364)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Body Image Problems (MID=15)




Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	Hazard Ratio and 95% CL	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**				
ASC4FIRST	52/197	53/193		0.79	0.54; 1.17	0.207
ASC4START	65/284	59/284		1.11	0.78; 1.58	0.662
Pooled Analysis	117/481	112/477		0.95	0.73; 1.24	0.599

n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Daily Life (MID=15)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	26/197	42/193	0.53	0.32; 0.87	0.007
ASC4START	44/284	56/284	0.71	0.48; 1.06	0.144
Pooled Analysis	70/481	98/477	0.64	0.47; 0.87	0.004



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Impact on Worry/Mood (MID=15)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Satisfaction with Care and Information (MID=15)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Satisfaction with Social Life (MID=15)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference


Table 3-6.3 FACT-ITEM GP5: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
V4 (MID=1)				
N*	481	477	0.63	0.071
Number of patients with events, n (%)	220 (45.7)	259 (54.3)	[0.53; 0.76]	
			<0.001	
Percentiles (months) [95% CI]				
25th	0.5 [0.4; 0.6]	0.3 [0.3; 0.3]		
Median	2.1 [1.6; 3.7]	0.8 [0.5; 1.0]		
75th	N.E. [N.E.; N.E.]	13.0 [6.0; N.E.]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
In this sensitivity analysis a missing assessment before randomization is substituted by the last assessment before or on the day of treatment start, if such an assessment is available.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline score.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.3 FACT-ITEM GP5: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


V4 (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Table 3-6.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Headache - Frequency (MID=1)				
N*	481	477	0.71	0.567
Number of patients with events, n (%)	230 (47.8)	252 (52.8)	[0.60; 0.86]	
			0.002	
Percentiles (months) [95% CI]				
25th	0.7 [0.5; 1.0]	0.3 [0.3; 0.5]		
Median	3.4 [2.3; 4.4]	1.8 [1.2; 2.6]		
75th	N.E. [N.E.; N.E.]	19.4 [9.2; N.E.]		
Rash - Presence/Absence (MID=1)				
N*	481	477	0.66	0.590
Number of patients with events, n (%)	191 (39.7)	217 (45.5)	[0.54; 0.81]	
			<0.001	
Percentiles (months) [95% CI]				
25th	1.9 [1.4; 2.4]	0.6 [0.5; 1.0]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	10.2 [6.1; 14.8]	3.3 [2.3; 5.6]		
75th	N.E. [30.5; N.E.]	N.E. [22.1; N.E.]		
Diarrhea - Frequency (MID=1)				
N*	481	477	0.82	0.103
Number of patients with events, n (%)	216 (44.9)	240 (50.3)	[0.68; 0.99]	
			0.020	
Percentiles (months) [95% CI]				
25th	0.7 [0.5; 0.9]	0.5 [0.4; 0.6]		
Median	3.1 [2.2; 5.6]	2.2 [1.5; 2.8]		
75th	N.E. [N.E.; N.E.]	24.0 [17.5; N.E.]		
Vomiting - Frequency (MID=1)				
N*	481	477	0.46	0.676
Number of patients with events, n (%)	71 (14.8)	128 (26.8)	[0.35; 0.62]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [14.8; N.E.]	3.0 [2.2; 4.6]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Nausea - Frequency (MID=1)				
N*	481	477	0.57	0.058
Number of patients with events, n (%)	158 (32.8)	224 (47.0)	[0.46; 0.70]	
			<0.001	
Percentiles (months) [95% CI]				
25th	1.4 [0.8; 2.2]	0.5 [0.3; 0.7]		
Median	25.8 [13.9; N.E.]	2.8 [1.8; 3.9]		
75th	N.E. [N.E.; N.E.]	28.6 [22.1; N.E.]		
Edema - Frequency (MID=1)				
N*	481	477	0.61	<0.001
Number of patients with events, n (%)	145 (30.1)	193 (40.5)	[0.49; 0.76]	
			<0.001	
Percentiles (months) [95% CI]				
25th	2.8 [1.9; 3.5]	1.0 [0.7; 1.5]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [22.1; N.E.]	9.2 [4.5; 12.9]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Muscle Pain - Frequency (MID=1)				
N*	481	477	0.78	0.413
Number of patients with events, n (%)	232 (48.2)	271 (56.8)	[0.65; 0.93]	
			0.004	
Percentiles (months) [95% CI]				
25th	0.4 [0.3; 0.5]	0.3 [0.3; 0.5]		
Median	1.2 [1.0; 1.9]	1.0 [0.7; 1.4]		
75th	N.E. [N.E.; N.E.]	7.2 [3.7; 22.2]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
In this sensitivity analysis a missing assessment before randomization is substituted by the last assessment before or on the day of treatment start, if such an assessment is available.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline score.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)

Headache - Frequency (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	126 (142)	82 (178)	58 (197)	29 (222)	6 (245)	0 (251)
Investigator Selected TKI	477 (0)	96 (150)	58 (176)	38 (191)	14 (211)	0 (225)	0 (225)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Rash - Presence/Absence (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Diarrhea - Frequency (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Vomiting - Frequency (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Nausea - Frequency (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Edema - Frequency (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.4 PRO-CTCAE - Frequency: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)

Muscle Pain - Frequency (MID=1)




Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	84/197	103/193	0.68	0.50; 0.91	0.011
ASC4START	132/284	137/284	0.93	0.73; 1.18	0.352
Pooled Analysis	216/481	240/477	0.82	0.68; 0.99	0.020



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	86/197	92/193	0.76	0.56; 1.03	0.225
ASC4START	144/284	160/284	0.69	0.55; 1.86	0.004
Pooled Analysis	230/481	252/477	0.71	0.60; 0.86	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	86/197	110/193	0.71	0.53; 0.94	0.019
ASC4START	146/284	161/284	0.82	0.66; 1.03	0.063
Pooled Analysis	232/481	271/477	0.78	0.65; 0.93	0.004



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Nausea - Frequency (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Rash - Presence/Absence (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Table 3-6.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Fatigue - Severity (MID=1)				
N*	481	477	0.77	0.440
Number of patients with events, n (%)	218 (45.3)	239 (50.1)	[0.64; 0.92]	
			0.020	
Percentiles (months) [95% CI]				
25th	0.5 [0.3; 0.7]	0.5 [0.3; 0.5]		
Median	3.8 [2.1; 9.0]	1.9 [1.0; 2.8]		
75th	N.E. [26.7; N.E.]	N.E. [14.0; N.E.]		
Headache - Severity (MID=1)				
N*	481	477	0.78	0.994
Number of patients with events, n (%)	227 (47.2)	243 (50.9)	[0.65; 0.93]	
			0.029	
Percentiles (months) [95% CI]				
25th	0.7 [0.5; 1.0]	0.4 [0.3; 0.5]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	2.8 [2.2; 4.2]	1.9 [1.2; 2.8]		
75th	N.E. [N.E.; N.E.]	27.6 [15.7; N.E.]		
Vomiting - Severity (MID=1)				
N*	481	477	0.43	0.248
Number of patients with events, n (%)	61 (12.7)	120 (25.2)	[0.31; 0.58]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [22.1; N.E.]	3.5 [2.8; 5.5]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Nausea - Severity (MID=1)				
N*	481	477	0.53	0.038
Number of patients with events, n (%)	148 (30.8)	223 (46.8)	[0.43; 0.66]	
			<0.001	
Percentiles (months) [95% CI]				
25th	1.6 [1.0; 2.6]	0.6 [0.5; 0.8]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [22.1; N.E.]	3.3 [2.3; 4.6]		
75th	N.E. [N.E.; N.E.]	28.6 [22.0; N.E.]		
Edema - Severity (MID=1)				
N*	481	477	0.57	0.004
Number of patients with events, n (%)	123 (25.6)	173 (36.3)	[0.45; 0.73]	
			<0.001	
Percentiles (months) [95% CI]				
25th	3.5 [2.6; 7.4]	1.2 [0.9; 1.6]		
Median	N.E. [N.E.; N.E.]	12.0 [6.5; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Muscle Pain - Severity (MID=1)				
N*	481	477	0.67	0.181
Number of patients with events, n (%)	216 (44.9)	273 (57.2)	[0.56; 0.81]	
			<0.001	
Percentiles (months) [95% CI]				
25th	0.5 [0.3; 0.5]	0.3 [0.3; 0.4]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	2.3 [1.4; 5.6]	1.0 [0.7; 1.4]		
75th	N.E. [N.E.; N.E.]	6.7 [4.6; 15.7]		
Pruritus - Severity (MID=1)				
N*	481	477	0.66	0.104
Number of patients with events, n (%)	217 (45.1)	257 (53.9)	[0.55; 0.80]	
			<0.001	
Percentiles (months) [95% CI]				
25th	1.0 [0.7; 1.2]	0.5 [0.5; 0.7]		
Median	4.1 [3.0; 5.6]	2.1 [1.4; 2.4]		
75th	N.E. [N.E.; N.E.]	16.7 [9.2; 24.0]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
In this sensitivity analysis a missing assessment before randomization is substituted by the last assessment before or on the day of treatment start, if such an assessment is available.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline score.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)

Fatigue - Severity (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	154 (141)	95 (184)	63 (211)	29 (235)	6 (257)	0 (263)
Investigator Selected TKI	477 (0)	110 (152)	67 (181)	35 (206)	15 (223)	3 (235)	0 (238)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)

Headache - Severity (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	130 (139)	81 (180)	54 (202)	29 (225)	6 (248)	0 (254)
Investigator Selected TKI	477 (0)	107 (150)	68 (178)	43 (196)	19 (216)	0 (234)	0 (234)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Vomiting - Severity (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Nausea - Severity (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Edema - Severity (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Muscle Pain - Severity (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.5 PRO-CTCAE - Severity: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)

Pruritus - Severity (MID=1)




Pts at Risk (censored)

Asciminib	481 (0)	143 (142)	85 (185)	55 (213)	26 (238)	6 (258)	0 (264)
Investigator Selected TKI	477 (0)	98 (149)	57 (175)	37 (188)	14 (206)	3 (217)	0 (220)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Edema - Severity (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Fatigue - Severity (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Headache - Severity (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Muscle Pain - Severity (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Nausea - Severity (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Pruritus - Severity (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Table 3-6.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Fatigue - Interference (MID=1)				
N*	481	477	0.73	0.002
Number of patients with events, n (%)	217 (45.1)	245 (51.4)	[0.61; 0.88]	
			0.002	
Percentiles (months) [95% CI]				
25th	0.6 [0.5; 0.8]	0.3 [0.3; 0.5]		
Median	4.2 [2.6; 8.3]	1.3 [1.0; 2.1]		
75th	N.E. [N.E.; N.E.]	19.4 [16.5; N.E.]		
Headache - Interference (MID=1)				
N*	481	477	0.77	0.905
Number of patients with events, n (%)	194 (40.3)	211 (44.2)	[0.63; 0.94]	
			0.017	
Percentiles (months) [95% CI]				
25th	1.8 [1.0; 2.1]	0.7 [0.5; 1.0]		


	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	10.3 [4.9; 18.4]	4.2 [2.8; 8.3]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Edema - Interference (MID=1)				
N*	481	477	0.57	0.070
Number of patients with events, n (%)	93 (19.3)	135 (28.3)	[0.43; 0.74]	
			<0.001	
Percentiles (months) [95% CI]				
25th	12.9 [5.6; 22.1]	2.6 [1.7; 4.2]		
Median	N.E. [N.E.; N.E.]	27.6 [27.6; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Muscle Pain - Interference (MID=1)				
N*	481	477	0.77	0.253
Number of patients with events, n (%)	198 (41.2)	229 (48.0)	[0.63; 0.93]	
			0.006	
Percentiles (months) [95% CI]				
25th	0.6 [0.5; 0.8]	0.5 [0.3; 0.5]		

	Treatment groups		Comparison	
	Asciminib (N = 481)	**Investigator Selected TKI (N = 477)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	4.7 [3.0; 15.6]	1.9 [1.3; 3.2]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

MID: Minimal important difference
HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
In this sensitivity analysis a missing assessment before randomization is substituted by the last assessment before or on the day of treatment start, if such an assessment is available.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline score.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Fatigue - Interference (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Headache - Interference (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Edema - Interference (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.6 PRO-CTCAE - Interference: Time to first deterioration - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot (Full Analysis Set)


Muscle Pain - Interference (MID=1)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-6.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Edema - Interference (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Fatigue - Interference (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)


Headache - Interference (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Figure 3-6.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference

Table 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Global health status/QoL (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.113)								
Low	79/291 (27.1)	22.0 [11.2; N.E.]	83/292 (28.4)	22.1 [11.1; N.E.]	0.99	[0.73; 1.35]	0.691	0.321
Intermediate	26/129 (20.2)	22.2 [22.2; N.E.]	38/128 (29.7)	11.1 [5.4; N.E.]	0.50	[0.30; 0.84]	0.004	0.605
High	8/61 (13.1)	N.E. [22.1; N.E.]	8/57 (14.0)	N.E. [5.7; N.E.]	0.49	[0.17; 1.40]	0.370	0.562
Sex								
(Interaction test: p = 0.636)								
Female	46/175	22.5 [11.1; N.E.]	54/201	22.1 [5.7; N.E.]	0.88	[0.59; 1.32]	0.413	0.502

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(26.3)		(26.9)					
Male	67/306	22.2 [22.1; N.E.]	75/276	22.1 [11.1; N.E.]	0.80	[0.57; 1.12]	0.057	0.757
	(21.9)		(27.2)					
Race								
(Interaction test: p = 0.731)								
Asian	43/128	N.E. [11.2; N.E.]	55/132	11.1 [5.4; N.E.]	0.76	[0.50; 1.14]	0.090	0.961
	(33.6)		(41.7)					
White	68/333	22.2 [22.0; N.E.]	73/320	22.1 [11.2; N.E.]	0.84	[0.60; 1.19]	0.174	0.434
	(20.4)		(22.8)					
Others	2/20	N.E. [0.9; N.E.]	1/25	N.E. [N.E.; N.E.]	3.52	[0.07; 172.12]	0.134	N.E.
	(10.0)		(4.0)					
Age groups								
(Interaction test: p = 0.181)								
18 - < 65 years	94/390	22.5 [22.0; N.E.]	106/397	22.1 [11.2; N.E.]	0.85	[0.64; 1.13]	0.196	0.334
	(24.1)		(26.7)					
65 - < 75 years	15/72	N.E. [11.1; N.E.]	14/53	N.E. [1.9; N.E.]	0.80	[0.34; 1.87]	0.326	0.171

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(20.8)		(26.4)					
>= 75 years	4/19	22.2 [2.0; N.E.]	9/27	4.1 [1.0; 11.1]	0.32	[0.08; 1.36]	0.026	0.297
	(21.1)		(33.3)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.494)								
Imatinib	32/101	22.2 [11.1; N.E.]	32/102	22.0 [2.8; N.E.]	0.74	[0.45; 1.22]	0.191	N.E.
	(31.7)		(31.4)					
Nilotinib	76/339	22.1 [12.4; N.E.]	84/333	N.E. [11.1; N.E.]	0.87	[0.63; 1.19]	0.250	0.543
	(22.4)		(25.2)					
Dasatinib	5/41	N.E. [N.E.; N.E.]	13/42	22.1 [5.4; N.E.]	0.38	[0.13; 1.11]	0.045	N.E.
	(12.2)		(31.0)					
Geographic region								
(Interaction test: p = 0.996)								
Europe excluding Germany	47/202	22.2 [22.0; N.E.]	53/203	22.0 [11.0; N.E.]	0.88	[0.58; 1.32]	0.413	0.873

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(23.3)		(26.1)					
Germany	12/91	22.1 [11.1; N.E.]	7/68	N.E. [2.8; N.E.]	0.69	[0.24; 2.01]	0.520	0.993
	(13.2)		(10.3)					
Others	54/188	22.5 [21.9; N.E.]	69/206	22.1 [5.7; N.E.]	0.78	[0.54; 1.13]	0.073	0.238
	(28.7)		(33.5)					
Physical functioning (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.257)								
Low	44/291	N.E. [N.E.; N.E.]	66/292	N.E. [22.1; N.E.]	0.64	[0.43; 0.94]	0.020	0.868
	(15.1)		(22.6)					
Intermediate	30/129	27.6 [22.1; N.E.]	27/128	N.E. [11.1; N.E.]	0.83	[0.49; 1.42]	0.429	0.038
	(23.3)		(21.1)					
High	8/61	N.E. [N.E.; N.E.]	4/57	N.E. [N.E.; N.E.]	1.42	[0.42; 4.81]	0.455	0.560
	(13.1)		(7.0)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.763)								
Female	38/175 (21.7)	N.E. [22.1; N.E.]	50/201 (24.9)	22.1 [11.1; N.E.]	0.85	[0.56; 1.31]	0.402	0.313
Male	44/306 (14.4)	27.6 [27.6; N.E.]	47/276 (17.0)	N.E. [22.1; N.E.]	0.74	[0.49; 1.13]	0.143	0.423
Race								
(Interaction test: p = 0.310)								
Asian	32/128 (25.0)	N.E. [N.E.; N.E.]	37/132 (28.0)	N.E. [22.1; N.E.]	0.73	[0.45; 1.20]	0.230	0.137
White	47/333 (14.1)	27.6 [27.6; N.E.]	59/320 (18.4)	N.E. [N.E.; N.E.]	0.67	[0.45; 1.00]	0.032	0.425
Others	3/20 (15.0)	N.E. [0.9; N.E.]	1/25 (4.0)	N.E. [11.1; N.E.]	4.39	[0.11; 182.44]	0.180	N.E.
Age groups								
(Interaction test: p = 0.401)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	66/390 (16.9)	N.E. [N.E.; N.E.]	80/397 (20.2)	N.E. [22.1; N.E.]	0.77	[0.56; 1.07]	0.130	0.112
65 - < 75 years	10/72 (13.9)	27.6 [N.E.; N.E.]	13/53 (24.5)	N.E. [5.6; N.E.]	0.46	[0.19; 1.11]	0.059	0.332
>= 75 years	6/19 (31.6)	22.1 [1.0; N.E.]	4/27 (14.8)	N.E. [2.6; N.E.]	1.42	[0.35; 5.80]	0.635	0.997
Pre-randomization selection of TKI								
(Interaction test: p = 0.260)								
Imatinib	17/101 (16.8)	N.E. [N.E.; N.E.]	24/102 (23.5)	N.E. [11.1; N.E.]	0.50	[0.27; 0.95]	0.035	N.E.
Nilotinib	58/339 (17.1)	N.E. [N.E.; N.E.]	61/333 (18.3)	N.E. [22.1; N.E.]	0.89	[0.62; 1.28]	0.517	0.992
Dasatinib	7/41 (17.1)	27.6 [22.1; N.E.]	12/42 (28.6)	22.1 [1.9; N.E.]	0.41	[0.15; 1.14]	0.103	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.770)								
Europe excluding Germany	34/202 (16.8)	N.E. [N.E.; N.E.]	43/203 (21.2)	N.E. [11.8; N.E.]	0.75	[0.47; 1.19]	0.191	0.804
Germany	10/91 (11.0)	27.6 [21.9; N.E.]	8/68 (11.8)	N.E. [1.9; N.E.]	0.52	[0.18; 1.53]	0.210	0.367
Others	38/188 (20.2)	N.E. [N.E.; N.E.]	46/206 (22.3)	N.E. [22.1; N.E.]	0.79	[0.51; 1.23]	0.297	0.024
Role functioning (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.784)								
Low	68/291 (23.4)	22.5 [22.1; N.E.]	79/292 (27.1)	22.1 [11.1; N.E.]	0.79	[0.57; 1.10]	0.167	0.009
Intermediate	35/129 (27.1)	22.2 [11.1; N.E.]	39/128 (30.5)	11.1 [5.6; 22.1]	0.72	[0.45; 1.17]	0.136	0.120

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
High	8/61 (13.1)	N.E. [N.E.; N.E.]	5/57 (8.8)	N.E. [N.E.; N.E.]	0.89	[0.28; 2.83]	0.861	0.814
Sex								
(Interaction test: p = 0.507)								
Female	48/175 (27.4)	22.5 [11.2; N.E.]	57/201 (28.4)	11.2 [6.7; N.E.]	0.87	[0.59; 1.30]	0.360	0.040
Male	63/306 (20.6)	22.5 [22.2; N.E.]	66/276 (23.9)	22.1 [22.1; N.E.]	0.75	[0.53; 1.07]	0.139	0.038
Race								
(Interaction test: p = 0.337)								
Asian	33/128 (25.8)	N.E. [N.E.; N.E.]	44/132 (33.3)	22.1 [11.1; N.E.]	0.66	[0.41; 1.04]	0.083	0.270
White	74/333 (22.2)	22.5 [22.1; N.E.]	77/320 (24.1)	11.8 [11.1; N.E.]	0.83	[0.60; 1.15]	0.223	0.010
Others	4/20 (20.0)	N.E. [1.0; N.E.]	2/25 (8.0)	N.E. [5.7; N.E.]	1.00	[0.14; 7.24]	0.964	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Age groups								
(Interaction test: p = 0.317)								
18 - < 65 years	93/390 (23.8)	22.5 [22.5; N.E.]	100/397 (25.2)	22.1 [11.8; N.E.]	0.86	[0.65; 1.15]	0.362	0.005
65 - < 75 years	13/72 (18.1)	N.E. [N.E.; N.E.]	15/53 (28.3)	12.0 [2.9; N.E.]	0.52	[0.21; 1.26]	0.043	0.516
>= 75 years	5/19 (26.3)	22.2 [1.0; N.E.]	8/27 (29.6)	10.8 [1.4; N.E.]	0.36	[0.08; 1.56]	0.110	0.021
Pre-randomization selection of TKI								
(Interaction test: p = 0.004)								
Imatinib	22/101 (21.8)	N.E. [22.2; N.E.]	35/102 (34.3)	11.1 [2.9; 22.1]	0.38	[0.22; 0.67]	<0.001	N.E.
Nilotinib	82/339 (24.2)	22.5 [22.1; 22.5]	73/333 (21.9)	22.3 [22.1; N.E.]	1.08	[0.78; 1.49]	0.563	0.736
Dasatinib	7/41	N.E. [22.1; N.E.]	15/42	5.6 [1.9; N.E.]	0.41	[0.16; 1.06]	0.024	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(17.1)		(35.7)					
Geographic region								
(Interaction test: p = 0.656)								
Europe excluding Germany	53/202	22.2 [11.2; N.E.]	56/203	11.2 [11.1; N.E.]	0.88	[0.59; 1.30]	0.513	0.273
	(26.2)		(27.6)					
Germany	15/91	22.1 [8.9; N.E.]	11/68	5.6 [1.9; N.E.]	0.58	[0.24; 1.36]	0.231	0.563
	(16.5)		(16.2)					
Others	43/188	N.E. [22.5; N.E.]	56/206	22.3 [12.0; N.E.]	0.68	[0.45; 1.02]	0.069	0.004
	(22.9)		(27.2)					
Emotional functioning (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.878)								
Low	51/291	22.5 [22.2; N.E.]	70/292	N.E. [22.1; N.E.]	0.68	[0.47; 0.97]	0.058	0.745

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(17.5)		(24.0)					
Intermediate	29/129	N.E. [N.E.; N.E.]	30/128	N.E. [11.0; N.E.]	0.85	[0.51; 1.43]	0.493	0.318
	(22.5)		(23.4)					
High	10/61	N.E. [22.1; N.E.]	11/57	N.E. [11.0; N.E.]	0.58	[0.25; 1.38]	0.207	0.592
	(16.4)		(19.3)					
Sex								
(Interaction test: p = 0.640)								
Female	41/175	22.5 [22.5; N.E.]	55/201	11.8 [11.0; N.E.]	0.77	[0.51; 1.16]	0.129	0.821
	(23.4)		(27.4)					
Male	49/306	N.E. [22.2; N.E.]	56/276	N.E. [22.1; N.E.]	0.67	[0.45; 1.00]	0.103	0.936
	(16.0)		(20.3)					
Race								
(Interaction test: p = 0.237)								
Asian	29/128	N.E. [22.2; N.E.]	38/132	N.E. [22.1; N.E.]	0.63	[0.39; 1.04]	0.122	0.374
	(22.7)		(28.8)					
White	56/333	N.E. [22.5; N.E.]	72/320	22.0 [11.1; N.E.]	0.70	[0.49; 1.00]	0.027	0.702

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(16.8)		(22.5)					
Others	5/20	11.2 [0.9; N.E.]	1/25	N.E. [5.6; N.E.]	8.31	[0.26; 270.24]	0.060	N.E.
	(25.0)		(4.0)					
Age groups								
(Interaction test: p = 0.944)								
18 - < 65 years	75/390	22.5 [22.2; N.E.]	92/397	N.E. [22.1; N.E.]	0.75	[0.55; 1.01]	0.102	0.767
	(19.2)		(23.2)					
65 - < 75 years	11/72	N.E. [N.E.; N.E.]	12/53	N.E. [11.0; N.E.]	0.70	[0.26; 1.89]	0.229	0.511
	(15.3)		(22.6)					
>= 75 years	4/19	N.E. [1.0; N.E.]	7/27	10.8 [1.0; N.E.]	0.65	[0.15; 2.77]	0.338	0.334
	(21.1)		(25.9)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.100)								
Imatinib	23/101	N.E. [22.1; N.E.]	25/102	N.E. [11.1; N.E.]	0.81	[0.46; 1.44]	0.326	N.E.
	(22.8)		(24.5)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Nilotinib	62/339 (18.3)	22.5 [22.5; N.E.]	72/333 (21.6)	N.E. [11.8; N.E.]	0.76	[0.54; 1.07]	0.230	0.506
Dasatinib	5/41 (12.2)	N.E. [N.E.; N.E.]	14/42 (33.3)	11.0 [1.9; N.E.]	0.23	[0.08; 0.69]	0.006	N.E.
Geographic region (Interaction test: p = 0.953)								
Europe excluding Germany	41/202 (20.3)	N.E. [22.1; N.E.]	53/203 (26.1)	11.6 [11.0; N.E.]	0.75	[0.49; 1.15]	0.170	0.970
Germany	7/91 (7.7)	N.E. [11.1; N.E.]	7/68 (10.3)	N.E. [2.9; N.E.]	0.85	[0.25; 2.84]	0.859	0.852
Others	42/188 (22.3)	22.5 [22.2; N.E.]	51/206 (24.8)	N.E. [22.1; N.E.]	0.75	[0.50; 1.14]	0.315	0.942
Cognitive functioning (MID=10)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.484)								
Low	77/291 (26.5)	22.1 [11.1; N.E.]	99/292 (33.9)	11.1 [5.6; 11.8]	0.73	[0.54; 0.98]	0.035	0.239
Intermediate	43/129 (33.3)	11.1 [5.6; N.E.]	38/128 (29.7)	11.1 [5.6; N.E.]	1.04	[0.67; 1.62]	0.939	0.908
High	17/61 (27.9)	22.1 [11.1; N.E.]	14/57 (24.6)	11.1 [2.9; N.E.]	0.81	[0.39; 1.66]	0.596	0.495
Sex								
(Interaction test: p = 0.212)								
Female	61/175 (34.9)	11.1 [5.6; 22.1]	67/201 (33.3)	11.1 [5.6; 11.3]	1.01	[0.71; 1.45]	0.911	0.114
Male	76/306 (24.8)	22.2 [22.1; N.E.]	84/276 (30.4)	11.1 [5.6; 22.2]	0.73	[0.54; 1.00]	0.053	0.995

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.914)								
Asian	45/128 (35.2)	N.E. [11.0; N.E.]	57/132 (43.2)	11.1 [5.6; 22.1]	0.78	[0.53; 1.16]	0.211	0.463
White	88/333 (26.4)	22.1 [11.1; 22.1]	88/320 (27.5)	11.1 [5.6; 11.6]	0.83	[0.62; 1.12]	0.202	0.361
Others	4/20 (20.0)	N.E. [0.9; N.E.]	6/25 (24.0)	5.6 [1.0; N.E.]	1.36	[0.21; 8.80]	0.548	N.E.
Age groups								
(Interaction test: p = 0.781)								
18 - < 65 years	112/390 (28.7)	22.1 [11.1; N.E.]	132/397 (33.2)	11.1 [5.6; 11.6]	0.79	[0.61; 1.02]	0.057	0.244
65 - < 75 years	20/72 (27.8)	22.1 [5.6; N.E.]	13/53 (24.5)	N.E. [5.6; N.E.]	0.96	[0.46; 2.03]	0.898	0.803
>= 75 years	5/19 (26.3)	N.E. [1.9; N.E.]	6/27 (22.2)	11.1 [1.0; N.E.]	0.78	[0.19; 3.23]	0.863	0.997

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.189)								
Imatinib	26/101 (25.7)	N.E. [22.1; N.E.]	34/102 (33.3)	11.1 [5.5; N.E.]	0.59	[0.35; 0.99]	0.033	N.E.
Nilotinib	99/339 (29.2)	11.1 [11.0; 22.5]	100/333 (30.0)	11.1 [5.6; 11.8]	0.94	[0.71; 1.25]	0.674	0.814
Dasatinib	12/41 (29.3)	22.2 [5.6; N.E.]	17/42 (40.5)	5.6 [2.8; 22.1]	0.51	[0.23; 1.12]	0.090	N.E.
Geographic region								
(Interaction test: p = 0.868)								
Europe excluding Germany	56/202 (27.7)	22.1 [11.1; 22.2]	62/203 (30.5)	11.1 [5.6; 11.8]	0.79	[0.54; 1.16]	0.224	0.429
Germany	19/91 (20.9)	12.0 [5.5; 22.1]	14/68 (20.6)	2.9 [1.0; 11.1]	0.62	[0.28; 1.38]	0.304	0.264

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	62/188 (33.0)	N.E. [11.0; N.E.]	75/206 (36.4)	11.1 [5.7; 22.1]	0.84	[0.60; 1.19]	0.312	0.386
Social functioning (MID=10)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.423)								
Low	59/291 (20.3)	22.5 [22.2; N.E.]	86/292 (29.5)	22.1 [5.7; N.E.]	0.59	[0.42; 0.83]	0.002	0.174
Intermediate	34/129 (26.4)	N.E. [11.1; N.E.]	35/128 (27.3)	11.3 [2.8; N.E.]	0.81	[0.50; 1.31]	0.375	0.905
High	12/61 (19.7)	N.E. [N.E.; N.E.]	9/57 (15.8)	N.E. [N.E.; N.E.]	0.85	[0.35; 2.04]	0.871	0.933
Sex (Interaction test: p = 0.832)								
Female	41/175	22.5 [22.5; N.E.]	57/201	11.2 [5.4; N.E.]	0.71	[0.47; 1.07]	0.046	0.628

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(23.4)		(28.4)					
Male	64/306	22.5 [22.2; N.E.]	73/276	N.E. [11.1; N.E.]	0.69	[0.49; 0.97]	0.034	0.448
	(20.9)		(26.4)					
Race								
(Interaction test: p = 0.198)								
Asian	40/128	N.E. [N.E.; N.E.]	48/132	N.E. [10.9; N.E.]	0.78	[0.51; 1.20]	0.231	0.606
	(31.3)		(36.4)					
White	62/333	22.5 [22.2; N.E.]	81/320	11.3 [5.6; N.E.]	0.62	[0.44; 0.87]	0.005	0.535
	(18.6)		(25.3)					
Others	3/20	N.E. [0.9; N.E.]	1/25	N.E. [N.E.; N.E.]	5.53	[0.11; 274.09]	0.180	N.E.
	(15.0)		(4.0)					
Age groups								
(Interaction test: p = 0.935)								
18 - < 65 years	89/390	22.5 [22.2; N.E.]	112/397	22.1 [11.0; N.E.]	0.67	[0.51; 0.89]	0.007	0.180
	(22.8)		(28.2)					
65 - < 75 years	12/72	N.E. [N.E.; N.E.]	13/53	N.E. [2.8; N.E.]	0.52	[0.21; 1.27]	0.130	0.797

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(16.7)		(24.5)					
>= 75 years	4/19	N.E. [0.9; N.E.]	5/27	11.1 [1.4; N.E.]	2.46	[0.32; 19.15]	0.799	0.826
	(21.1)		(18.5)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.187)								
Imatinib	26/101	22.2 [22.1; N.E.]	35/102	11.1 [2.8; N.E.]	0.58	[0.34; 0.97]	0.027	N.E.
	(25.7)		(34.3)					
Nilotinib	75/339	22.5 [22.1; 22.5]	82/333	N.E. [11.2; N.E.]	0.77	[0.56; 1.06]	0.130	0.869
	(22.1)		(24.6)					
Dasatinib	4/41	N.E. [N.E.; N.E.]	13/42	5.6 [2.8; N.E.]	0.29	[0.09; 0.94]	0.009	N.E.
	(9.8)		(31.0)					
Geographic region								
(Interaction test: p = 0.478)								
Europe excluding Germany	46/202	22.5 [22.1; N.E.]	61/203	11.1 [3.0; N.E.]	0.71	[0.48; 1.05]	0.102	0.977

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(22.8)		(30.0)					
Germany	8/91	22.2 [22.1; N.E.]	8/68	N.E. [1.9; N.E.]	0.24	[0.07; 0.80]	0.016	0.888
	(8.8)		(11.8)					
Others	51/188	22.5 [22.5; N.E.]	61/206	N.E. [11.1; N.E.]	0.79	[0.54; 1.16]	0.180	0.046
	(27.1)		(29.6)					
Fatigue (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.670)								
Low	72/291	22.2 [11.2; N.E.]	95/292	11.1 [2.8; 22.1]	0.67	[0.49; 0.92]	0.016	0.940
	(24.7)		(32.5)					
Intermediate	38/129	N.E. [5.8; N.E.]	35/128	22.0 [2.9; N.E.]	0.83	[0.52; 1.32]	0.369	0.201
	(29.5)		(27.3)					
High	11/61	N.E. [11.1; N.E.]	11/57	N.E. [3.0; N.E.]	0.55	[0.23; 1.32]	0.335	0.656
	(18.0)		(19.3)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.230)								
Female	50/175 (28.6)	22.1 [11.0; N.E.]	59/201 (29.4)	11.1 [2.9; N.E.]	0.87	[0.59; 1.28]	0.210	0.916
Male	71/306 (23.2)	N.E. [21.9; N.E.]	82/276 (29.7)	22.0 [5.6; N.E.]	0.64	[0.46; 0.88]	0.012	0.708
Race								
(Interaction test: p = 0.202)								
Asian	47/128 (36.7)	N.E. [5.6; N.E.]	61/132 (46.2)	5.5 [1.9; N.E.]	0.63	[0.43; 0.92]	0.021	0.618
White	69/333 (20.7)	22.2 [22.1; N.E.]	79/320 (24.7)	22.0 [5.7; N.E.]	0.71	[0.51; 0.98]	0.024	0.927
Others	5/20 (25.0)	8.3 [0.9; N.E.]	1/25 (4.0)	N.E. [2.8; N.E.]	1.98	[0.12; 31.50]	0.149	N.E.
Age groups								
(Interaction test: p = 0.704)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	99/390 (25.4)	22.2 [21.9; N.E.]	115/397 (29.0)	22.0 [5.7; N.E.]	0.73	[0.55; 0.95]	0.048	0.943
65 - < 75 years	16/72 (22.2)	N.E. [5.6; N.E.]	19/53 (35.8)	2.8 [1.9; N.E.]	0.42	[0.19; 0.93]	0.025	0.513
>= 75 years	6/19 (31.6)	22.1 [1.6; N.E.]	7/27 (25.9)	5.4 [1.0; N.E.]	0.92	[0.24; 3.47]	0.496	0.996
Pre-randomization selection of TKI								
(Interaction test: p = 0.839)								
Imatinib	36/101 (35.6)	21.9 [2.8; N.E.]	41/102 (40.2)	2.8 [1.8; 22.0]	0.67	[0.42; 1.05]	0.058	N.E.
Nilotinib	75/339 (22.1)	N.E. [22.1; N.E.]	83/333 (24.9)	22.1 [11.8; N.E.]	0.73	[0.53; 1.01]	0.173	0.858
Dasatinib	10/41 (24.4)	N.E. [2.8; N.E.]	17/42 (40.5)	3.0 [1.2; N.E.]	0.63	[0.29; 1.40]	0.156	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.984)								
Europe excluding Germany	50/202 (24.8)	22.2 [11.2; N.E.]	57/203 (28.1)	11.8 [5.6; N.E.]	0.72	[0.48; 1.06]	0.075	0.666
Germany	10/91 (11.0)	N.E. [11.1; N.E.]	9/68 (13.2)	22.0 [2.7; N.E.]	0.82	[0.28; 2.43]	0.423	0.089
Others	61/188 (32.4)	N.E. [11.0; N.E.]	75/206 (36.4)	11.1 [2.8; N.E.]	0.66	[0.47; 0.94]	0.025	0.284
Nausea and vomiting (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.102)								
Low	46/291 (15.8)	24.7 [22.3; N.E.]	67/292 (22.9)	22.2 [22.1; N.E.]	0.61	[0.42; 0.90]	0.012	0.223
Intermediate	16/129	N.E. [N.E.; N.E.]	29/128	N.E. [11.1; N.E.]	0.41	[0.22; 0.76]	0.002	0.442

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(12.4)		(22.7)					
High	15/61	22.1 [11.1; N.E.]	10/57	N.E. [11.0; N.E.]	1.16	[0.51; 2.60]	0.723	0.425
	(24.6)		(17.5)					
Sex								
(Interaction test: p = 0.823)								
Female	37/175	22.3 [22.1; N.E.]	56/201	22.0 [6.7; N.E.]	0.56	[0.36; 0.87]	0.007	0.244
	(21.1)		(27.9)					
Male	40/306	24.7 [24.7; N.E.]	50/276	N.E. [22.1; N.E.]	0.62	[0.41; 0.94]	0.024	0.469
	(13.1)		(18.1)					
Race								
(Interaction test: p = 0.618)								
Asian	26/128	N.E. [N.E.; N.E.]	47/132	22.1 [11.0; N.E.]	0.50	[0.30; 0.81]	0.005	0.035
	(20.3)		(35.6)					
White	48/333	24.7 [22.3; N.E.]	59/320	22.2 [22.0; N.E.]	0.66	[0.45; 0.98]	0.026	0.711
	(14.4)		(18.4)					
Others	3/20	N.E. [1.0; N.E.]	0/25	N.E. [N.E.; N.E.]	2.73	[0.02; 467.59]	0.371	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(15.0)							
Age groups								
(Interaction test: p = 0.829)								
18 - < 65 years	66/390 (16.9)	24.7 [22.3; N.E.]	90/397 (22.7)	N.E. [22.1; N.E.]	0.60	[0.44; 0.83]	0.002	0.513
65 - < 75 years	6/72 (8.3)	N.E. [N.E.; N.E.]	9/53 (17.0)	22.2 [22.2; N.E.]	0.30	[0.08; 1.20]	0.050	0.135
>= 75 years	5/19 (26.3)	22.1 [1.0; N.E.]	7/27 (25.9)	3.0 [1.0; N.E.]	0.53	[0.15; 1.93]	0.249	0.823
Pre-randomization selection of TKI								
(Interaction test: p = 0.008)								
Imatinib	14/101 (13.9)	24.7 [N.E.; N.E.]	35/102 (34.3)	10.9 [5.4; 22.1]	0.25	[0.13; 0.48]	<0.001	N.E.
Nilotinib	52/339 (15.3)	N.E. [N.E.; N.E.]	62/333 (18.6)	N.E. [22.1; N.E.]	0.79	[0.54; 1.15]	0.207	0.439

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	11/41 (26.8)	22.3 [11.0; N.E.]	9/42 (21.4)	N.E. [3.0; N.E.]	1.00	[0.40; 2.46]	0.988	N.E.
Geographic region (Interaction test: p = 0.942)								
Europe excluding Germany	31/202 (15.3)	24.7 [22.1; N.E.]	43/203 (21.2)	22.2 [11.3; N.E.]	0.56	[0.34; 0.92]	0.017	0.597
Germany	5/91 (5.5)	N.E. [N.E.; N.E.]	5/68 (7.4)	N.E. [11.1; N.E.]	0.35	[0.09; 1.38]	0.133	0.994
Others	41/188 (21.8)	22.3 [22.3; N.E.]	58/206 (28.2)	N.E. [22.1; N.E.]	0.63	[0.42; 0.95]	0.023	0.021
Pain (MID=10)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.204)								
Low	74/291	22.5 [22.0; N.E.]	101/292	10.9 [2.8; 11.2]	0.66	[0.48; 0.89]	0.004	0.360

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(25.4)		(34.6)					
Intermediate	42/129	24.7 [5.6; N.E.]	37/128	16.4 [2.8; N.E.]	1.02	[0.65; 1.60]	0.705	0.093
	(32.6)		(28.9)					
High	16/61	N.E. [8.2; N.E.]	15/57	5.7 [2.8; N.E.]	0.99	[0.48; 2.01]	0.602	0.498
	(26.2)		(26.3)					
Sex								
(Interaction test: p = 0.496)								
Female	59/175	11.2 [2.9; N.E.]	73/201	5.5 [2.8; 11.2]	0.87	[0.61; 1.25]	0.259	0.027
	(33.7)		(36.3)					
Male	73/306	24.7 [22.1; N.E.]	80/276	11.1 [5.6; N.E.]	0.75	[0.54; 1.04]	0.050	0.937
	(23.9)		(29.0)					
Race								
(Interaction test: p = 0.061)								
Asian	42/128	N.E. [N.E.; N.E.]	61/132	5.5 [2.7; N.E.]	0.59	[0.39; 0.87]	0.006	0.079
	(32.8)		(46.2)					
White	86/333	22.1 [11.1; 24.7]	90/320	11.1 [5.5; N.E.]	0.86	[0.64; 1.17]	0.125	0.969

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(25.8)		(28.1)					
Others	4/20	N.E. [0.9; N.E.]	2/25	N.E. [1.0; N.E.]	2.05	[0.20; 21.07]	0.435	N.E.
	(20.0)		(8.0)					
Age groups								
(Interaction test: p = 0.500)								
18 - < 65 years	109/390	22.5 [11.2; N.E.]	125/397	11.1 [5.5; N.E.]	0.82	[0.63; 1.06]	0.095	0.110
	(27.9)		(31.5)					
65 - < 75 years	16/72	24.7 [11.1; N.E.]	20/53	5.7 [2.8; N.E.]	0.51	[0.25; 1.06]	0.020	0.813
	(22.2)		(37.7)					
>= 75 years	7/19	2.3 [1.0; N.E.]	8/27	2.6 [1.0; N.E.]	1.75	[0.49; 6.22]	0.571	0.858
	(36.8)		(29.6)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.380)								
Imatinib	31/101	24.7 [5.6; N.E.]	43/102	2.8 [1.9; 11.0]	0.54	[0.34; 0.87]	0.006	N.E.
	(30.7)		(42.2)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Nilotinib	90/339 (26.5)	22.5 [11.1; N.E.]	97/333 (29.1)	11.1 [5.6; N.E.]	0.87	[0.65; 1.16]	0.241	0.274
Dasatinib	11/41 (26.8)	N.E. [3.2; N.E.]	13/42 (31.0)	N.E. [1.0; N.E.]	0.75	[0.32; 1.76]	0.339	N.E.
Geographic region (Interaction test: p = 0.693)								
Europe excluding Germany	53/202 (26.2)	N.E. [11.1; N.E.]	62/203 (30.5)	11.2 [5.5; N.E.]	0.77	[0.53; 1.13]	0.159	0.501
Germany	14/91 (15.4)	N.E. [1.8; N.E.]	10/68 (14.7)	N.E. [2.0; N.E.]	1.29	[0.52; 3.22]	0.804	0.360
Others	65/188 (34.6)	22.5 [11.1; N.E.]	81/206 (39.3)	5.6 [2.8; 11.1]	0.71	[0.50; 0.99]	0.027	0.002
Dyspnoea (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.438)								
Low	50/291 (17.2)	22.5 [22.2; N.E.]	73/292 (25.0)	N.E. [11.6; N.E.]	0.67	[0.47; 0.97]	0.019	0.208
Intermediate	21/129 (16.3)	22.2 [22.1; N.E.]	27/128 (21.1)	N.E. [11.1; N.E.]	0.56	[0.31; 1.01]	0.046	0.597
High	8/61 (13.1)	N.E. [22.1; N.E.]	4/57 (7.0)	N.E. [N.E.; N.E.]	1.33	[0.39; 4.52]	0.419	0.131
Sex								
(Interaction test: p = 0.771)								
Female	36/175 (20.6)	22.2 [22.1; N.E.]	50/201 (24.9)	22.1 [11.1; N.E.]	0.70	[0.45; 1.09]	0.103	0.067
Male	43/306 (14.1)	N.E. [22.2; N.E.]	54/276 (19.6)	N.E. [N.E.; N.E.]	0.68	[0.45; 1.02]	0.054	0.471
Race								
(Interaction test: p = 0.901)								
Asian	30/128	22.2 [22.2; N.E.]	41/132	N.E. [11.3; N.E.]	0.68	[0.42; 1.10]	0.129	0.339

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(23.4)		(31.1)					
White	46/333	22.5 [22.1; N.E.]	60/320	N.E. [N.E.; N.E.]	0.63	[0.43; 0.93]	0.020	0.111
	(13.8)		(18.8)					
Others	3/20	N.E. [0.9; N.E.]	3/25	N.E. [2.8; N.E.]	0.65	[0.11; 4.03]	0.676	N.E.
	(15.0)		(12.0)					
Age groups								
(Interaction test: p = 0.437)								
18 - < 65 years	66/390	22.5 [22.2; N.E.]	87/397	N.E. [N.E.; N.E.]	0.69	[0.50; 0.95]	0.023	0.349
	(16.9)		(21.9)					
65 - < 75 years	9/72	N.E. [N.E.; N.E.]	14/53	N.E. [2.8; N.E.]	0.43	[0.17; 1.10]	0.068	0.199
	(12.5)		(26.4)					
>= 75 years	4/19	22.2 [2.8; N.E.]	3/27	N.E. [5.4; N.E.]	0.47	[0.04; 5.68]	0.801	1.000
	(21.1)		(11.1)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.480)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Imatinib	19/101 (18.8)	22.2 [22.2; N.E.]	26/102 (25.5)	N.E. [11.1; N.E.]	0.56	[0.31; 1.02]	0.044	N.E.
Nilotinib	54/339 (15.9)	22.5 [22.5; N.E.]	67/333 (20.1)	N.E. [N.E.; N.E.]	0.79	[0.55; 1.13]	0.175	0.383
Dasatinib	6/41 (14.6)	N.E. [22.1; N.E.]	11/42 (26.2)	N.E. [1.9; N.E.]	0.30	[0.10; 0.95]	0.036	N.E.
Geographic region (Interaction test: p = 0.919)								
Europe excluding Germany	35/202 (17.3)	22.2 [22.1; N.E.]	47/203 (23.2)	N.E. [11.6; N.E.]	0.65	[0.42; 1.03]	0.060	0.520
Germany	6/91 (6.6)	N.E. [22.1; N.E.]	7/68 (10.3)	N.E. [2.8; N.E.]	0.72	[0.20; 2.62]	0.369	0.871
Others	38/188 (20.2)	22.5 [22.2; N.E.]	50/206 (24.3)	N.E. [N.E.; N.E.]	0.70	[0.46; 1.08]	0.108	0.131
Insomnia (MID=10)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.616)								
Low	64/291 (22.0)	22.5 [22.5; N.E.]	74/292 (25.3)	22.2 [11.5; N.E.]	0.79	[0.56; 1.10]	0.340	0.964
Intermediate	28/129 (21.7)	N.E. [22.1; N.E.]	34/128 (26.6)	N.E. [2.8; N.E.]	0.65	[0.39; 1.08]	0.032	0.778
High	14/61 (23.0)	N.E. [8.9; N.E.]	9/57 (15.8)	N.E. [11.1; N.E.]	1.01	[0.43; 2.37]	0.691	0.715
Sex								
(Interaction test: p = 0.249)								
Female	44/175 (25.1)	N.E. [11.2; N.E.]	49/201 (24.4)	22.2 [11.1; N.E.]	0.97	[0.64; 1.48]	0.972	0.362
Male	62/306 (20.3)	22.5 [22.5; N.E.]	68/276 (24.6)	N.E. [22.0; N.E.]	0.69	[0.49; 0.99]	0.047	0.537

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.329)								
Asian	36/128 (28.1)	N.E. [N.E.; N.E.]	43/132 (32.6)	N.E. [11.1; N.E.]	0.70	[0.45; 1.11]	0.209	0.647
White	66/333 (19.8)	22.5 [21.5; N.E.]	72/320 (22.5)	22.0 [11.2; N.E.]	0.75	[0.53; 1.06]	0.109	0.716
Others	4/20 (20.0)	N.E. [1.0; N.E.]	2/25 (8.0)	N.E. [1.0; N.E.]	1.11	[0.17; 7.23]	0.752	N.E.
Age groups								
(Interaction test: p = 0.084)								
18 - < 65 years	86/390 (22.1)	22.5 [22.5; N.E.]	100/397 (25.2)	22.1 [11.5; N.E.]	0.73	[0.54; 0.97]	0.052	0.559
65 - < 75 years	18/72 (25.0)	N.E. [5.6; N.E.]	11/53 (20.8)	22.2 [11.1; N.E.]	1.56	[0.64; 3.80]	0.442	0.815
>= 75 years	2/19 (10.5)	N.E. [2.9; N.E.]	6/27 (22.2)	11.1 [1.4; N.E.]	0.03	[0.00; 1.66]	0.004	0.998

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.202)								
Imatinib	19/101 (18.8)	N.E. [N.E.; N.E.]	27/102 (26.5)	22.1 [11.1; N.E.]	0.58	[0.32; 1.06]	0.051	N.E.
Nilotinib	76/339 (22.4)	22.5 [11.2; N.E.]	82/333 (24.6)	22.2 [11.2; N.E.]	0.75	[0.54; 1.04]	0.134	0.389
Dasatinib	11/41 (26.8)	N.E. [2.9; N.E.]	8/42 (19.0)	N.E. [11.5; N.E.]	1.76	[0.70; 4.43]	0.277	N.E.
Geographic region								
(Interaction test: p = 0.780)								
Europe excluding Germany	46/202 (22.8)	22.5 [11.2; N.E.]	56/203 (27.6)	22.0 [11.1; 22.2]	0.71	[0.47; 1.07]	0.058	0.836
Germany	9/91 (9.9)	N.E. [12.0; N.E.]	6/68 (8.8)	N.E. [5.6; N.E.]	0.75	[0.22; 2.47]	0.668	0.995

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	51/188 (27.1)	N.E. [N.E.; N.E.]	55/206 (26.7)	N.E. [11.5; N.E.]	0.84	[0.57; 1.24]	0.553	0.360
Appetite loss (MID=10)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.496)								
Low	38/291 (13.1)	N.E. [22.5; N.E.]	53/292 (18.2)	N.E. [22.2; N.E.]	0.64	[0.42; 0.98]	0.062	0.011
Intermediate	13/129 (10.1)	N.E. [22.2; N.E.]	24/128 (18.8)	N.E. [22.1; N.E.]	0.35	[0.18; 0.72]	0.003	0.446
High	6/61 (9.8)	N.E. [N.E.; N.E.]	9/57 (15.8)	22.1 [16.6; N.E.]	0.47	[0.16; 1.37]	0.135	0.289
Sex (Interaction test: p = 0.536)								
Female	27/175	N.E. [22.5; N.E.]	41/201	N.E. [22.1; N.E.]	0.67	[0.41; 1.10]	0.066	0.351

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(15.4)		(20.4)					
Male	30/306	N.E. [N.E.; N.E.]	45/276	N.E. [N.E.; N.E.]	0.48	[0.30; 0.78]	0.004	0.048
	(9.8)		(16.3)					
Race								
(Interaction test: p = 0.018)								
Asian	16/128	N.E. [N.E.; N.E.]	39/132	N.E. [22.1; N.E.]	0.31	[0.17; 0.57]	<0.001	0.501
	(12.5)		(29.5)					
White	37/333	N.E. [22.5; N.E.]	45/320	N.E. [22.1; N.E.]	0.71	[0.45; 1.11]	0.126	0.203
	(11.1)		(14.1)					
Others	4/20	7.6 [2.0; N.E.]	2/25	11.1 [11.1; N.E.]	3.74	[0.33; 42.12]	0.293	N.E.
	(20.0)		(8.0)					
Age groups								
(Interaction test: p = 0.299)								
18 - < 65 years	46/390	N.E. [22.5; N.E.]	64/397	N.E. [N.E.; N.E.]	0.63	[0.43; 0.92]	0.026	0.108
	(11.8)		(16.1)					
65 - < 75 years	6/72	N.E. [N.E.; N.E.]	14/53	22.2 [2.8; N.E.]	0.23	[0.07; 0.71]	0.005	0.689

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(8.3)		(26.4)					
>= 75 years	5/19	22.2 [1.0; N.E.]	8/27	5.6 [1.4; N.E.]	0.57	[0.14; 2.35]	0.395	0.193
	(26.3)		(29.6)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.384)								
Imatinib	15/101	N.E. [22.2; N.E.]	26/102	22.1 [11.1; N.E.]	0.36	[0.19; 0.71]	0.004	N.E.
	(14.9)		(25.5)					
Nilotinib	37/339	N.E. [22.5; N.E.]	51/333	N.E. [22.2; N.E.]	0.67	[0.44; 1.03]	0.054	0.096
	(10.9)		(15.3)					
Dasatinib	5/41	N.E. [N.E.; N.E.]	9/42	N.E. [3.0; N.E.]	0.35	[0.11; 1.17]	0.088	N.E.
	(12.2)		(21.4)					
Geographic region								
(Interaction test: p = 0.345)								
Europe excluding Germany	25/202	N.E. [22.2; N.E.]	31/203	22.2 [22.1; N.E.]	0.72	[0.41; 1.25]	0.305	0.443

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(12.4)		(15.3)					
Germany	3/91	N.E. [22.1; N.E.]	5/68	N.E. [16.6; N.E.]	0.34	[0.06; 1.99]	0.180	N.E.
	(3.3)		(7.4)					
Others	29/188	N.E. [22.5; N.E.]	50/206	N.E. [22.1; N.E.]	0.46	[0.29; 0.73]	0.002	0.032
	(15.4)		(24.3)					
Constipation (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.786)								
Low	55/291	22.5 [22.5; N.E.]	76/292	N.E. [11.2; N.E.]	0.64	[0.45; 0.91]	0.027	0.675
	(18.9)		(26.0)					
Intermediate	28/129	N.E. [22.1; N.E.]	30/128	N.E. [5.5; N.E.]	0.68	[0.40; 1.14]	0.132	0.583
	(21.7)		(23.4)					
High	9/61	N.E. [N.E.; N.E.]	8/57	N.E. [N.E.; N.E.]	0.87	[0.33; 2.25]	0.700	0.508
	(14.8)		(14.0)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.651)								
Female	37/175 (21.1)	22.5 [22.5; N.E.]	50/201 (24.9)	N.E. [11.1; N.E.]	0.73	[0.47; 1.13]	0.158	0.137
Male	55/306 (18.0)	N.E. [N.E.; N.E.]	64/276 (23.2)	N.E. [11.5; N.E.]	0.65	[0.45; 0.93]	0.037	0.950
Race								
(Interaction test: p = 0.275)								
Asian	36/128 (28.1)	N.E. [N.E.; N.E.]	48/132 (36.4)	N.E. [10.9; N.E.]	0.61	[0.39; 0.95]	0.044	0.170
White	52/333 (15.6)	22.5 [22.5; N.E.]	65/320 (20.3)	N.E. [11.5; N.E.]	0.66	[0.46; 0.96]	0.037	0.695
Others	4/20 (20.0)	7.6 [1.9; N.E.]	1/25 (4.0)	N.E. [5.6; N.E.]	5.39	[0.12; 234.85]	0.079	N.E.
Age groups								
(Interaction test: p = 0.150)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	73/390 (18.7)	22.5 [22.5; N.E.]	100/397 (25.2)	N.E. [11.2; N.E.]	0.62	[0.46; 0.85]	0.004	0.538
65 - < 75 years	17/72 (23.6)	N.E. [11.1; N.E.]	10/53 (18.9)	N.E. [5.5; N.E.]	1.51	[0.61; 3.74]	0.649	0.461
>= 75 years	2/19 (10.5)	N.E. [2.8; N.E.]	4/27 (14.8)	N.E. [1.4; N.E.]	0.44	[0.07; 2.72]	0.337	0.710
Pre-randomization selection of TKI								
(Interaction test: p = 0.092)								
Imatinib	26/101 (25.7)	N.E. [18.2; N.E.]	19/102 (18.6)	N.E. [N.E.; N.E.]	1.21	[0.67; 2.20]	0.630	N.E.
Nilotinib	56/339 (16.5)	22.5 [22.5; N.E.]	81/333 (24.3)	N.E. [11.1; N.E.]	0.57	[0.40; 0.80]	0.003	0.501
Dasatinib	10/41 (24.4)	N.E. [5.6; N.E.]	14/42 (33.3)	10.6 [1.9; N.E.]	0.59	[0.25; 1.36]	0.195	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.049)								
Europe excluding Germany	37/202 (18.3)	N.E. [22.1; N.E.]	42/203 (20.7)	N.E. [11.6; N.E.]	0.76	[0.48; 1.19]	0.267	0.925
Germany	3/91 (3.3)	22.5 [22.5; N.E.]	9/68 (13.2)	N.E. [1.9; N.E.]	0.11	[0.02; 0.52]	<0.001	0.995
Others	52/188 (27.7)	N.E. [N.E.; N.E.]	63/206 (30.6)	N.E. [11.1; N.E.]	0.71	[0.49; 1.04]	0.128	0.793
Diarrhoea (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.226)								
Low	49/291 (16.8)	N.E. [N.E.; N.E.]	82/292 (28.1)	22.1 [11.0; N.E.]	0.56	[0.39; 0.80]	<0.001	0.484
Intermediate	30/129 (23.3)	N.E. [22.1; N.E.]	30/128 (23.4)	N.E. [11.1; N.E.]	0.94	[0.56; 1.57]	0.334	0.745

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
High	10/61 (16.4)	N.E. [11.2; N.E.]	9/57 (15.8)	N.E. [11.0; N.E.]	0.76	[0.30; 1.94]	0.734	0.480
Sex								
(Interaction test: p = 0.535)								
Female	34/175 (19.4)	N.E. [N.E.; N.E.]	48/201 (23.9)	22.2 [11.2; N.E.]	0.79	[0.50; 1.25]	0.201	0.510
Male	55/306 (18.0)	N.E. [N.E.; N.E.]	73/276 (26.4)	N.E. [11.1; N.E.]	0.61	[0.43; 0.87]	0.004	0.883
Race								
(Interaction test: p = 0.650)								
Asian	30/128 (23.4)	N.E. [N.E.; N.E.]	44/132 (33.3)	N.E. [11.1; N.E.]	0.62	[0.39; 0.99]	0.028	0.953
White	56/333 (16.8)	N.E. [22.1; N.E.]	75/320 (23.4)	22.0 [11.1; N.E.]	0.65	[0.46; 0.92]	0.010	0.500
Others	3/20 (15.0)	N.E. [2.8; N.E.]	2/25 (8.0)	N.E. [2.8; N.E.]	1.03	[0.14; 7.42]	0.747	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Age groups								
(Interaction test: p = 0.263)								
18 - < 65 years	71/390 (18.2)	N.E. [N.E.; N.E.]	100/397 (25.2)	N.E. [11.2; N.E.]	0.67	[0.50; 0.92]	0.005	0.863
65 - < 75 years	15/72 (20.8)	22.1 [11.1; N.E.]	14/53 (26.4)	22.2 [2.8; N.E.]	0.91	[0.42; 1.97]	0.806	0.208
>= 75 years	3/19 (15.8)	N.E. [2.8; N.E.]	7/27 (25.9)	3.0 [1.0; N.E.]	0.30	[0.07; 1.24]	0.048	0.999
Pre-randomization selection of TKI								
(Interaction test: p = 0.024)								
Imatinib	24/101 (23.8)	N.E. [22.1; N.E.]	42/102 (41.2)	5.6 [2.8; 11.1]	0.40	[0.24; 0.67]	<0.001	N.E.
Nilotinib	51/339 (15.0)	N.E. [N.E.; N.E.]	69/333 (20.7)	N.E. [22.2; N.E.]	0.73	[0.50; 1.05]	0.040	0.931
Dasatinib	14/41	10.9 [1.9; N.E.]	10/42	N.E. [5.6; N.E.]	1.47	[0.64; 3.38]	0.276	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(34.1)		(23.8)					
Geographic region								
(Interaction test: p = 0.165)								
Europe excluding Germany	38/202	N.E. [N.E.; N.E.]	57/203	11.3 [6.7; N.E.]	0.58	[0.38; 0.88]	0.007	0.120
	(18.8)		(28.1)					
Germany	4/91	N.E. [22.0; N.E.]	8/68	N.E. [2.8; N.E.]	0.14	[0.03; 0.81]	0.018	1.000
	(4.4)		(11.8)					
Others	47/188	N.E. [N.E.; N.E.]	56/206	N.E. [22.1; N.E.]	0.82	[0.55; 1.22]	0.228	0.618
	(25.0)		(27.2)					
Financial difficulties (MID=10)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.202)								
Low	42/291	N.E. [N.E.; N.E.]	42/292	N.E. [22.2; N.E.]	1.07	[0.70; 1.64]	0.769	0.820

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(14.4)		(14.4)					
Intermediate	27/129	N.E. [N.E.; N.E.]	16/128	26.4 [22.3; N.E.]	1.82	[0.95; 3.48]	0.068	0.558
	(20.9)		(12.5)					
High	5/61	N.E. [22.1; N.E.]	6/57	N.E. [N.E.; N.E.]	0.54	[0.16; 1.82]	0.341	0.370
	(8.2)		(10.5)					
Sex								
(Interaction test: p = 0.640)								
Female	28/175	N.E. [N.E.; N.E.]	30/201	N.E. [22.2; N.E.]	1.09	[0.64; 1.84]	0.814	0.465
	(16.0)		(14.9)					
Male	46/306	N.E. [N.E.; N.E.]	34/276	26.4 [22.3; N.E.]	1.29	[0.82; 2.03]	0.260	0.303
	(15.0)		(12.3)					
Race								
(Interaction test: p = 0.344)								
Asian	30/128	N.E. [N.E.; N.E.]	26/132	N.E. [22.3; N.E.]	1.07	[0.62; 1.84]	0.592	0.483
	(23.4)		(19.7)					
White	40/333	N.E. [N.E.; N.E.]	37/320	26.4 [26.4; N.E.]	1.06	[0.67; 1.67]	0.801	0.438

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(12.0)		(11.6)					
Others	4/20	N.E. [1.0; N.E.]	1/25	N.E. [N.E.; N.E.]	9.86	[0.29; 336.31]	0.078	N.E.
	(20.0)		(4.0)					
Age groups								
(Interaction test: p = 0.340)								
18 - < 65 years	64/390	N.E. [N.E.; N.E.]	53/397	N.E. [22.3; N.E.]	1.30	[0.90; 1.87]	0.160	0.713
	(16.4)		(13.4)					
65 - < 75 years	7/72	N.E. [N.E.; N.E.]	9/53	26.4 [N.E.; N.E.]	0.63	[0.18; 2.20]	0.150	0.745
	(9.7)		(17.0)					
>= 75 years	3/19	N.E. [1.0; N.E.]	2/27	N.E. [2.8; N.E.]	3.42	[0.34; 34.43]	0.289	0.998
	(15.8)		(7.4)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.995)								
Imatinib	15/101	N.E. [N.E.; N.E.]	12/102	N.E. [N.E.; N.E.]	1.10	[0.51; 2.37]	0.790	N.E.
	(14.9)		(11.8)					


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Nilotinib	51/339 (15.0)	N.E. [N.E.; N.E.]	46/333 (13.8)	26.4 [22.3; N.E.]	1.18	[0.78; 1.76]	0.444	0.831
Dasatinib	8/41 (19.5)	N.E. [21.9; N.E.]	6/42 (14.3)	N.E. [N.E.; N.E.]	1.38	[0.47; 4.08]	0.548	N.E.
Geographic region (Interaction test: p = 0.358)								
Europe excluding Germany	25/202 (12.4)	N.E. [N.E.; N.E.]	28/203 (13.8)	N.E. [22.2; N.E.]	0.88	[0.50; 1.54]	0.702	0.378
Germany	7/91 (7.7)	N.E. [21.9; N.E.]	6/68 (8.8)	26.4 [N.E.; N.E.]	0.93	[0.24; 3.59]	0.927	0.998
Others	42/188 (22.3)	N.E. [N.E.; N.E.]	30/206 (14.6)	N.E. [22.3; N.E.]	1.46	[0.90; 2.35]	0.078	0.980

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				

MID: Minimally important difference
N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
In this sensitivity analysis a missing assessment before randomization is substituted by the last assessment before or on the day of treatment start, if such an assessment is available.
If there are not at least 10 patients in every subgroup or not more than 10 events per subgroup per treatment arm, no subgroup analyses were performed for the corresponding attribute.
If there are not more than 10 events per subgroup per treatment arm, no Cox PH hazard analysis is carried out.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline PRO score.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates. P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT) and Pre-Randomization selection TKI (IRT).
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)


Role functioning (MID=10): Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Role functioning (MID=10): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	107 (162)	32 (229)	32 (229)	0 (257)	0 (257)	0 (257)
Investigator Selected TKI	333 (0)	106 (164)	34 (228)	27 (235)	2 (258)	0 (260)	0 (260)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Role functioning (MID=10): Pre-randomization selection of TKI: Dasatinib




Pts at Risk (censored)

Asciminib	41 (0)	19 (16)	15 (20)	15 (20)	2 (32)	0 (34)	0 (34)
Investigator Selected TKI	42 (0)	11 (17)	9 (19)	8 (20)	0 (27)	0 (27)	0 (27)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)


Nausea and vomiting (MID=10): Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Nausea and vomiting (MID=10): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	129 (171)	37 (253)	35 (254)	0 (287)	0 (287)	0 (287)
Investigator Selected TKI	333 (0)	111 (170)	39 (235)	32 (242)	2 (269)	0 (271)	0 (271)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Nausea and vomiting (MID=10): Pre-randomization selection of TKI: Dasatinib




Pts at Risk (censored)

Asciminib	41 (0)	17 (16)	13 (19)	13 (19)	1 (29)	0 (30)	0 (30)
Investigator Selected TKI	42 (0)	14 (19)	12 (21)	11 (22)	1 (32)	0 (33)	0 (33)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Appetite loss (MID=10): Race: Asian




Pts at Risk (censored)

Asciminib	128 (0)	79 (35)	51 (63)	51 (63)	0 (112)	0 (112)	0 (112)
Investigator Selected TKI	132 (0)	62 (35)	36 (60)	35 (61)	1 (92)	0 (93)	0 (93)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Appetite loss (MID=10): Race: White




Pts at Risk (censored)

Asciminib	333 (0)	124 (178)	50 (250)	49 (251)	3 (293)	0 (296)	0 (296)
Investigator Selected TKI	320 (0)	97 (186)	36 (243)	26 (252)	3 (272)	1 (274)	0 (275)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)


Appetite loss (MID=10): Race: Others



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Constipation (MID=10): Geographic region: Europe excluding Germany




Pts at Risk (censored)

Asciminib	202 (0)	80 (96)	30 (137)	29 (138)	1 (164)	0 (165)	0 (165)
Investigator Selected TKI	203 (0)	58 (108)	18 (143)	14 (147)	1 (160)	0 (161)	0 (161)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Constipation (MID=10): Geographic region: Germany




Pts at Risk (censored)

Asciminib	91 (0)	25 (64)	9 (80)	9 (80)	1 (87)	0 (88)	0 (88)
Investigator Selected TKI	68 (0)	9 (50)	7 (52)	4 (55)	1 (58)	0 (59)	0 (59)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Constipation (MID=10): Geographic region: Others




Pts at Risk (censored)

Asciminib	188 (0)	85 (62)	41 (96)	41 (96)	1 (135)	0 (136)	0 (136)
Investigator Selected TKI	206 (0)	75 (80)	31 (112)	30 (113)	0 (143)	0 (143)	0 (143)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Diarrhoea (MID=10): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	101 (0)	44 (37)	33 (45)	33 (45)	1 (76)	0 (77)	0 (77)
Investigator Selected TKI	102 (0)	22 (46)	9 (53)	9 (53)	0 (60)	0 (60)	0 (60)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Diarrhoea (MID=10): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	123 (170)	32 (257)	32 (257)	0 (288)	0 (288)	0 (288)
Investigator Selected TKI	333 (0)	106 (164)	34 (231)	29 (236)	3 (261)	0 (264)	0 (264)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1 EORTC QLQ-C30: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Diarrhoea (MID=10): Pre-randomization selection of TKI: Dasatinib



Pts at Risk (censored)


Asciminib	41 (0)	12 (17)	8 (19)	8 (19)	1 (26)	0 (27)	0 (27)
Investigator Selected TKI	42 (0)	14 (20)	10 (22)	9 (23)	1 (31)	0 (32)	0 (32)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Appetite loss (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	19/153	30/150	0.44	0.24; 0.79	0.013
ASC4START	27/237	34/247	0.83	0.50; 1.37	0.434
Pooled Analysis	46/390	64/397	0.63	0.43; 0.92	0.026
65 - < 75 years					
ASC4FIRST	4/34	9/29	0.19	0.04; 0.90	0.016
ASC4START	2/38	5/24	0.29	0.05; 1.60	0.127
Pooled Analysis	6/72	14/53	0.23	0.07; 0.71	0.005
>= 75 years					
ASC4FIRST	2/10	6/14	0.19	0.02; 1.93	0.122
ASC4START	3/9	2/13	1.89	0.18; 19.47	0.629
Pooled Analysis	5/19	8/27	0.57	0.14; 2.35	0.395




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Appetite loss (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	2/20	1.18	0.18; 7.67	0.980
ASC4START	3/38	7/37	0.40	0.09; 1.74	0.064
Pooled Analysis	6/61	9/57	0.47	0.16; 1.37	0.135
Intermediate					
ASC4FIRST	7/54	12/53	0.27	0.10; 0.74	0.010
ASC4START	6/75	12/75	0.47	0.18; 1.27	0.093
Pooled Analysis	13/129	24/128	0.35	0.18; 0.72	0.003
Low					
ASC4FIRST	15/120	31/120	0.36	0.19; 0.68	0.002
ASC4START	23/171	22/172	1.11	0.62; 2.01	0.675
Pooled Analysis	38/291	53/292	0.64	0.42; 0.98	0.062




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Appetite loss (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	11/64	12/62	0.53	0.21; 1.31	0.423
ASC4START	14/138	19/141	0.84	0.42; 1.70	0.503
Pooled Analysis	25/202	31/203	0.72	0.41; 1.25	0.305
Germany					
ASC4FIRST	0/19	1/15	N.E.	N.E.; N.E.	N.E.
ASC4START	3/72	4/53	0.37	0.06; 2.13	0.180
Pooled Analysis	3/91	5/68	0.34	0.06; 1.99	0.180
Others					
ASC4FIRST	14/114	32/116	0.29	0.15; 0.56	<0.001
ASC4START	15/74	18/90	0.82	0.41; 1.64	0.757
Pooled Analysis	29/188	50/206	0.46	0.29; 0.73	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Appetite loss (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	5/41	9/42	0.35	0.11; 1.17	0.088
Pooled Analysis	5/41	9/42	0.35	0.11; 1.17	0.088
Imatinib					
ASC4FIRST	15/101	26/102	0.36	0.19; 0.71	0.004
Pooled Analysis	15/101	26/102	0.36	0.19; 0.71	0.004
Nilotinib					
ASC4FIRST	5/55	10/49	0.27	0.09; 0.84	0.037
ASC4START	32/284	41/284	0.79	0.50; 1.26	0.239
Pooled Analysis	37/339	51/333	0.67	0.44; 1.03	0.054




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Appetite loss (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	6/40	13/46	0.41	0.16; 1.08	0.067
Pooled Analysis	16/128	39/132	0.31	0.17; 0.57	<0.001
Asian/Others					
ASC4FIRST	11/91	26/90	0.29	0.14; 0.59	<0.001
Others					
ASC4START	3/17	2/21	3.74	0.33; 42.12	0.293
Pooled Analysis	4/20	2/25	3.74	0.33; 42.12	0.293
White					
ASC4FIRST	14/106	19/103	0.49	0.24; 1.03	0.086
ASC4START	23/227	26/217	0.90	0.51; 1.59	0.553
Pooled Analysis	37/333	45/320	0.71	0.45; 1.11	0.126




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Appetite loss (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	10/68	17/75	0.49	0.22; 1.09	0.068
ASC4START	17/107	24/126	0.85	0.45; 1.61	0.374
Pooled Analysis	27/175	41/201	0.67	0.41; 1.10	0.066
Male					
ASC4FIRST	15/129	28/118	0.31	0.16; 0.59	<0.001
ASC4START	15/177	17/158	0.81	0.40; 1.62	0.528
Pooled Analysis	30/306	45/276	0.48	0.30; 0.78	0.004



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Cognitive functioning (MID=10)




Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	Hazard Ratio and 95% CL	HR	95% CL	P-value
Age groups	**n/N**	**n/N**				
18 - < 65 years						
ASC4FIRST	46/153	58/150		0.66	0.44; 0.97	0.029
ASC4START	66/237	74/247		0.90	0.64; 1.25	0.521
Pooled Analysis	112/390	132/397		0.79	0.61; 1.02	0.057
65 - < 75 years						
ASC4FIRST	13/34	8/29		1.03	0.39; 2.73	0.917
ASC4START	7/38	5/24		0.82	0.25; 2.65	0.743
Pooled Analysis	20/72	13/53		0.96	0.46; 2.03	0.898
>= 75 years						
ASC4FIRST	1/10	5/14		0.24	0.03; 2.24	0.086
ASC4START	4/9	1/13		4.98	0.14; 177.70	0.105
Pooled Analysis	5/19	6/27		0.78	0.19; 3.23	0.863

n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Cognitive functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	7/23	6/20	0.64	0.20; 2.04	0.478
ASC4START	10/38	8/37	0.98	0.38; 2.49	0.923
Pooled Analysis	17/61	14/57	0.81	0.39; 1.66	0.596
Intermediate					
ASC4FIRST	20/54	17/53	1.03	0.53; 2.00	0.873
ASC4START	23/75	21/75	1.07	0.59; 1.94	0.803
Pooled Analysis	43/129	38/128	1.04	0.67; 1.62	0.939
Low					
ASC4FIRST	33/120	48/120	0.60	0.38; 0.94	0.021
ASC4START	44/171	51/172	0.86	0.57; 1.29	0.460
Pooled Analysis	77/291	99/292	0.73	0.54; 0.98	0.035




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Cognitive functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	21/64	21/62	0.63	0.32; 1.24	0.174
ASC4START	35/138	41/141	0.88	0.56; 1.39	0.583
Pooled Analysis	56/202	62/203	0.79	0.54; 1.16	0.224
Germany					
ASC4FIRST	4/19	5/15	0.19	0.02; 1.89	0.119
ASC4START	15/72	9/53	0.76	0.31; 1.86	0.671
Pooled Analysis	19/91	14/68	0.62	0.28; 1.38	0.304
Others					
ASC4FIRST	35/114	45/116	0.75	0.48; 1.18	0.172
ASC4START	27/74	30/90	1.04	0.61; 1.77	0.947
Pooled Analysis	62/188	75/206	0.84	0.60; 1.19	0.312




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Cognitive functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	12/41	17/42	0.51	0.23; 1.12	0.090
Pooled Analysis	12/41	17/42	0.51	0.23; 1.12	0.090
Imatinib					
ASC4FIRST	26/101	34/102	0.59	0.35; 0.99	0.033
Pooled Analysis	26/101	34/102	0.59	0.35; 0.99	0.033
Nilotinib					
ASC4FIRST	22/55	20/49	1.01	0.54; 1.86	0.995
ASC4START	77/284	80/284	0.93	0.68; 1.27	0.633
Pooled Analysis	99/339	100/333	0.94	0.71; 1.25	0.674




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Cognitive functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	16/40	17/46	0.99	0.49; 1.99	0.943
Pooled Analysis	45/128	57/132	0.78	0.53; 1.16	0.211
Asian/Others					
ASC4FIRST	30/91	40/90	0.72	0.45; 1.17	0.156
Others					
ASC4START	3/17	6/21	1.36	0.21; 8.80	0.548
Pooled Analysis	4/20	6/25	1.36	0.21; 8.80	0.548
White					
ASC4FIRST	30/106	31/103	0.68	0.41; 1.14	0.126
ASC4START	58/227	57/217	0.92	0.64; 1.33	0.635
Pooled Analysis	88/333	88/320	0.83	0.62; 1.12	0.202




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Cognitive functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	22/68	31/75	0.72	0.41; 1.27	0.161
ASC4START	39/107	36/126	1.28	0.81; 2.04	0.302
Pooled Analysis	61/175	67/201	1.01	0.71; 1.45	0.911
Male					
ASC4FIRST	38/129	40/118	0.73	0.47; 1.15	0.171
ASC4START	38/177	44/158	0.73	0.47; 1.13	0.173
Pooled Analysis	76/306	84/276	0.73	0.54; 1.00	0.053




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Constipation (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	36/153	41/150	0.69	0.44; 1.08	0.129
ASC4START	37/237	59/247	0.58	0.38; 0.88	0.012
Pooled Analysis	73/390	100/397	0.62	0.46; 0.85	0.004
65 - < 75 years					
ASC4FIRST	11/34	7/29	1.97	0.63; 6.16	0.675
ASC4START	6/38	3/24	0.99	0.24; 4.12	0.841
Pooled Analysis	17/72	10/53	1.51	0.61; 3.74	0.649
>= 75 years					
ASC4FIRST	1/10	3/14	0.34	0.03; 3.85	0.346
ASC4START	1/9	1/13	0.34	0.00; 23.19	0.739
Pooled Analysis	2/19	4/27	0.44	0.07; 2.72	0.337




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Constipation (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	5/23	3/20	1.24	0.29; 5.24	0.834
ASC4START	4/38	5/37	0.64	0.17; 2.38	0.468
Pooled Analysis	9/61	8/57	0.87	0.33; 2.25	0.700
Intermediate					
ASC4FIRST	15/54	13/53	0.84	0.39; 1.81	0.409
ASC4START	13/75	17/75	0.63	0.30; 1.30	0.197
Pooled Analysis	28/129	30/128	0.68	0.40; 1.14	0.132
Low					
ASC4FIRST	28/120	35/120	0.69	0.42; 1.14	0.201
ASC4START	27/171	41/172	0.60	0.37; 0.97	0.065
Pooled Analysis	55/291	76/292	0.64	0.45; 0.91	0.027




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Constipation (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	12/64	12/62	0.74	0.32; 1.70	0.446
ASC4START	25/138	30/141	0.78	0.45; 1.33	0.408
Pooled Analysis	37/202	42/203	0.76	0.48; 1.19	0.267
Germany					
ASC4FIRST	1/19	2/15	0.16	0.00; 6.69	0.074
ASC4START	2/72	7/53	0.13	0.03; 0.67	0.004
Pooled Analysis	3/91	9/68	0.11	0.02; 0.52	<0.001
Others					
ASC4FIRST	35/114	37/116	0.73	0.46; 1.18	0.245
ASC4START	17/74	26/90	0.68	0.36; 1.27	0.326
Pooled Analysis	52/188	63/206	0.71	0.49; 1.04	0.128




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Constipation (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	10/41	14/42	0.59	0.25; 1.36	0.195
Pooled Analysis	10/41	14/42	0.59	0.25; 1.36	0.195
Imatinib					
ASC4FIRST	26/101	19/102	1.21	0.67; 2.20	0.630
Pooled Analysis	26/101	19/102	1.21	0.67; 2.20	0.630
Nilotinib					
ASC4FIRST	12/55	18/49	0.42	0.20; 0.89	0.057
ASC4START	44/284	63/284	0.61	0.41; 0.90	0.018
Pooled Analysis	56/339	81/333	0.57	0.40; 0.80	0.003



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Constipation (MID=10)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Constipation (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	20/68	20/75	1.06	0.56; 2.03	0.940
ASC4START	17/107	30/126	0.55	0.30; 1.00	0.048
Pooled Analysis	37/175	50/201	0.73	0.47; 1.13	0.158
Male					
ASC4FIRST	28/129	31/118	0.65	0.39; 1.10	0.122
ASC4START	27/177	33/158	0.65	0.39; 1.09	0.159
Pooled Analysis	55/306	64/276	0.65	0.45; 0.93	0.037




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	36/153	47/150	0.66	0.42; 1.02	0.061
ASC4START	35/237	53/247	0.70	0.45; 1.08	0.040
Pooled Analysis	71/390	100/397	0.67	0.50; 0.92	0.005
65 - < 75 years					
ASC4FIRST	10/34	12/29	0.68	0.28; 1.67	0.385
ASC4START	5/38	2/24	3.55	0.39; 32.61	0.269
Pooled Analysis	15/72	14/53	0.91	0.42; 1.97	0.806
>= 75 years					
ASC4FIRST	3/10	6/14	0.37	0.08; 1.64	0.100
ASC4START	0/9	1/13	0.17	0.00; 18.51	0.221
Pooled Analysis	3/19	7/27	0.30	0.07; 1.24	0.048




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	4/23	5/20	0.48	0.12; 1.96	0.524
ASC4START	6/38	4/37	1.08	0.30; 3.84	0.893
Pooled Analysis	10/61	9/57	0.76	0.30; 1.94	0.734
Intermediate					
ASC4FIRST	19/54	17/53	1.03	0.53; 2.01	0.439
ASC4START	11/75	13/75	0.83	0.37; 1.86	0.560
Pooled Analysis	30/129	30/128	0.94	0.56; 1.57	0.334
Low					
ASC4FIRST	26/120	43/120	0.50	0.31; 0.82	0.009
ASC4START	23/171	39/172	0.66	0.39; 1.10	0.035
Pooled Analysis	49/291	82/292	0.56	0.39; 0.80	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	15/64	24/62	0.39	0.20; 0.75	0.004
ASC4START	23/138	33/141	0.77	0.45; 1.32	0.239
Pooled Analysis	38/202	57/203	0.58	0.38; 0.88	0.007
Germany					
ASC4FIRST	1/19	2/15	0.39	0.00; 97.21	0.617
ASC4START	3/72	6/53	0.14	0.03; 0.81	0.008
Pooled Analysis	4/91	8/68	0.14	0.03; 0.81	0.018
Others					
ASC4FIRST	33/114	39/116	0.76	0.48; 1.23	0.245
ASC4START	14/74	17/90	0.97	0.47; 1.99	0.671
Pooled Analysis	47/188	56/206	0.82	0.55; 1.22	0.228




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	14/41	10/42	1.47	0.64; 3.38	0.276
Pooled Analysis	14/41	10/42	1.47	0.64; 3.38	0.276
Imatinib					
ASC4FIRST	24/101	42/102	0.40	0.24; 0.67	<0.001
Pooled Analysis	24/101	42/102	0.40	0.24; 0.67	<0.001
Nilotinib					
ASC4FIRST	11/55	13/49	0.74	0.33; 1.69	0.488
ASC4START	40/284	56/284	0.72	0.48; 1.09	0.052
Pooled Analysis	51/339	69/333	0.73	0.50; 1.05	0.040




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	7/40	12/46	0.66	0.26; 1.69	0.206
Pooled Analysis	30/128	44/132	0.62	0.39; 0.99	0.028
Asian/Others					
ASC4FIRST	24/91	32/90	0.62	0.36; 1.07	0.079
Others					
ASC4START	2/17	2/21	1.03	0.14; 7.42	0.747
Pooled Analysis	3/20	2/25	1.03	0.14; 7.42	0.747
White					
ASC4FIRST	25/106	33/103	0.57	0.34; 0.96	0.033
ASC4START	31/227	42/217	0.73	0.45; 1.16	0.121
Pooled Analysis	56/333	75/320	0.65	0.46; 0.92	0.010




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	17/68	27/75	0.68	0.36; 1.29	0.206
ASC4START	17/107	21/126	0.91	0.47; 1.75	0.596
Pooled Analysis	34/175	48/201	0.79	0.50; 1.25	0.201
Male					
ASC4FIRST	32/129	38/118	0.62	0.38; 1.02	0.045
ASC4START	23/177	35/158	0.60	0.35; 1.02	0.033
Pooled Analysis	55/306	73/276	0.61	0.43; 0.87	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Dyspnoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	28/153	37/150	0.57	0.35; 0.95	0.027
ASC4START	38/237	50/247	0.79	0.51; 1.20	0.267
Pooled Analysis	66/390	87/397	0.69	0.50; 0.95	0.023
65 - < 75 years					
ASC4FIRST	4/34	12/29	0.25	0.06; 0.98	0.018
ASC4START	5/38	2/24	1.34	0.24; 7.42	0.792
Pooled Analysis	9/72	14/53	0.43	0.17; 1.10	0.068
>= 75 years					
ASC4FIRST	2/10	3/14	0.47	0.04; 5.68	0.426
ASC4START	2/9	0/13	1.83	0.02; 199.10	0.199
Pooled Analysis	4/19	3/27	0.47	0.04; 5.68	0.801




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Dyspnoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	3/20	0.49	0.08; 2.87	0.821
ASC4START	5/38	1/37	4.06	0.47; 34.87	0.171
Pooled Analysis	8/61	4/57	1.33	0.39; 4.52	0.419
Intermediate					
ASC4FIRST	11/54	13/53	0.48	0.21; 1.09	0.078
ASC4START	10/75	14/75	0.66	0.29; 1.48	0.285
Pooled Analysis	21/129	27/128	0.56	0.31; 1.01	0.046
Low					
ASC4FIRST	20/120	36/120	0.52	0.30; 0.90	0.006
ASC4START	30/171	37/172	0.83	0.51; 1.35	0.508
Pooled Analysis	50/291	73/292	0.67	0.47; 0.97	0.019




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Dyspnoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	11/64	15/62	0.51	0.22; 1.22	0.077
ASC4START	24/138	32/141	0.72	0.42; 1.22	0.264
Pooled Analysis	35/202	47/203	0.65	0.42; 1.03	0.060
Germany					
ASC4FIRST	1/19	3/15	0.38	0.02; 6.82	0.320
ASC4START	5/72	4/53	0.78	0.16; 3.84	0.663
Pooled Analysis	6/91	7/68	0.72	0.20; 2.62	0.369
Others					
ASC4FIRST	22/114	34/116	0.54	0.31; 0.94	0.025
ASC4START	16/74	16/90	1.08	0.54; 2.19	0.763
Pooled Analysis	38/188	50/206	0.70	0.46; 1.08	0.108




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Dyspnoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	6/41	11/42	0.30	0.10; 0.95	0.036
Pooled Analysis	6/41	11/42	0.30	0.10; 0.95	0.036
Imatinib					
ASC4FIRST	19/101	26/102	0.56	0.31; 1.02	0.044
Pooled Analysis	19/101	26/102	0.56	0.31; 1.02	0.044
Nilotinib					
ASC4FIRST	9/55	15/49	0.56	0.24; 1.29	0.119
ASC4START	45/284	52/284	0.85	0.57; 1.27	0.460
Pooled Analysis	54/339	67/333	0.79	0.55; 1.13	0.175




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Dyspnoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	10/40	11/46	1.00	0.41; 2.43	0.979
Pooled Analysis	30/128	41/132	0.68	0.42; 1.10	0.129
Asian/Others					
ASC4FIRST	21/91	30/90	0.59	0.33; 1.05	0.078
Others					
ASC4START	2/17	3/21	0.65	0.11; 4.03	0.676
Pooled Analysis	3/20	3/25	0.65	0.11; 4.03	0.676
White					
ASC4FIRST	13/106	22/103	0.39	0.19; 0.80	0.005
ASC4START	33/227	38/217	0.79	0.49; 1.26	0.354
Pooled Analysis	46/333	60/320	0.63	0.43; 0.93	0.020




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Dyspnoea (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	13/68	23/75	0.41	0.20; 0.85	0.014
ASC4START	23/107	27/126	0.98	0.56; 1.71	0.933
Pooled Analysis	36/175	50/201	0.70	0.45; 1.09	0.103
Male					
ASC4FIRST	21/129	29/118	0.59	0.33; 1.04	0.051
ASC4START	22/177	25/158	0.79	0.45; 1.40	0.448
Pooled Analysis	43/306	54/276	0.68	0.45; 1.02	0.054




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Emotional functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	34/153	36/150	0.79	0.49; 1.26	0.351
ASC4START	41/237	56/247	0.68	0.45; 1.03	0.175
Pooled Analysis	75/390	92/397	0.75	0.55; 1.01	0.102
65 - < 75 years					
ASC4FIRST	6/34	8/29	0.51	0.13; 2.04	0.170
ASC4START	5/38	4/24	1.03	0.22; 4.93	0.837
Pooled Analysis	11/72	12/53	0.70	0.26; 1.89	0.229
>= 75 years					
ASC4FIRST	2/10	6/14	0.30	0.05; 1.81	0.215
ASC4START	2/9	1/13	13.27	0.09; >1000	0.739
Pooled Analysis	4/19	7/27	0.65	0.15; 2.77	0.338




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Emotional functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	6/23	5/20	0.72	0.22; 2.39	0.590
ASC4START	4/38	6/37	0.42	0.11; 1.53	0.209
Pooled Analysis	10/61	11/57	0.58	0.25; 1.38	0.207
Intermediate					
ASC4FIRST	12/54	15/53	0.60	0.28; 1.31	0.157
ASC4START	17/75	15/75	1.04	0.52; 2.11	0.722
Pooled Analysis	29/129	30/128	0.85	0.51; 1.43	0.493
Low					
ASC4FIRST	24/120	30/120	0.73	0.43; 1.25	0.276
ASC4START	27/171	40/172	0.61	0.37; 1.00	0.116
Pooled Analysis	51/291	70/292	0.68	0.47; 0.97	0.058




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Emotional functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	15/64	20/62	0.71	0.34; 1.48	0.239
ASC4START	26/138	33/141	0.75	0.45; 1.26	0.397
Pooled Analysis	41/202	53/203	0.75	0.49; 1.15	0.170
Germany					
ASC4FIRST	2/19	3/15	0.27	0.01; 8.95	0.829
ASC4START	5/72	4/53	0.77	0.19; 3.08	0.739
Pooled Analysis	7/91	7/68	0.85	0.25; 2.84	0.859
Others					
ASC4FIRST	25/114	27/116	0.77	0.45; 1.34	0.479
ASC4START	17/74	24/90	0.71	0.37; 1.34	0.473
Pooled Analysis	42/188	51/206	0.75	0.50; 1.14	0.315




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Emotional functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	5/41	14/42	0.23	0.08; 0.69	0.006
Pooled Analysis	5/41	14/42	0.23	0.08; 0.69	0.006
Imatinib					
ASC4FIRST	23/101	25/102	0.81	0.46; 1.44	0.326
Pooled Analysis	23/101	25/102	0.81	0.46; 1.44	0.326
Nilotinib					
ASC4FIRST	14/55	11/49	1.05	0.47; 2.34	0.856
ASC4START	48/284	61/284	0.69	0.47; 1.02	0.156
Pooled Analysis	62/339	72/333	0.76	0.54; 1.07	0.230




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Emotional functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	8/40	15/46	0.44	0.18; 1.07	0.101
Pooled Analysis	29/128	38/132	0.63	0.39; 1.04	0.122
Asian/Others					
ASC4FIRST	22/91	23/90	0.77	0.43; 1.39	0.529
Others					
ASC4START	4/17	1/21	8.31	0.26; 270.24	0.060
Pooled Analysis	5/20	1/25	8.31	0.26; 270.24	0.060
White					
ASC4FIRST	20/106	27/103	0.58	0.32; 1.06	0.051
ASC4START	36/227	45/217	0.73	0.47; 1.14	0.194
Pooled Analysis	56/333	72/320	0.70	0.49; 1.00	0.027




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Emotional functioning (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	20/68	27/75	0.68	0.38; 1.24	0.168
ASC4START	21/107	28/126	0.79	0.45; 1.41	0.437
Pooled Analysis	41/175	55/201	0.77	0.51; 1.16	0.129
Male					
ASC4FIRST	22/129	23/118	0.69	0.38; 1.26	0.247
ASC4START	27/177	33/158	0.63	0.38; 1.06	0.248
Pooled Analysis	49/306	56/276	0.67	0.45; 1.00	0.103



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue (MID=10)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	6/23	4/20	0.74	0.19; 2.80	0.963
ASC4START	5/38	7/37	0.47	0.14; 1.64	0.178
Pooled Analysis	11/61	11/57	0.55	0.23; 1.32	0.335
Intermediate					
ASC4FIRST	23/54	24/53	0.65	0.37; 1.17	0.115
ASC4START	15/75	11/75	1.20	0.55; 2.63	0.566
Pooled Analysis	38/129	35/128	0.83	0.52; 1.32	0.369
Low					
ASC4FIRST	41/120	52/120	0.66	0.44; 1.01	0.055
ASC4START	31/171	43/172	0.68	0.43; 1.08	0.146
Pooled Analysis	72/291	95/292	0.67	0.49; 0.92	0.016




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	24/64	22/62	0.78	0.42; 1.44	0.324
ASC4START	26/138	35/141	0.67	0.40; 1.12	0.136
Pooled Analysis	50/202	57/203	0.72	0.48; 1.06	0.075
Germany					
ASC4FIRST	3/19	3/15	2.47	0.10; 61.29	0.863
ASC4START	7/72	6/53	0.41	0.11; 1.51	0.407
Pooled Analysis	10/91	9/68	0.82	0.28; 2.43	0.423
Others					
ASC4FIRST	43/114	55/116	0.59	0.40; 0.89	0.011
ASC4START	18/74	20/90	0.90	0.46; 1.73	0.867
Pooled Analysis	61/188	75/206	0.66	0.47; 1.04	0.025




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	10/41	17/42	0.63	0.29; 1.40	0.156
Pooled Analysis	10/41	17/42	0.63	0.29; 1.40	0.156
Imatinib					
ASC4FIRST	36/101	41/102	0.67	0.42; 1.05	0.058
Pooled Analysis	36/101	41/102	0.67	0.42; 1.05	0.058
Nilotinib					
ASC4FIRST	24/55	22/49	0.74	0.40; 1.37	0.668
ASC4START	51/284	61/284	0.74	0.51; 1.07	0.181
Pooled Analysis	75/339	83/333	0.73	0.53; 1.01	0.173




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	9/40	15/46	0.50	0.21; 1.18	0.128
Pooled Analysis	47/128	61/132	0.63	0.43; 0.92	0.021
Asian/Others					
ASC4FIRST	39/91	46/90	0.65	0.42; 1.01	0.064
Others					
ASC4START	4/17	1/21	1.98	0.12; 31.50	0.149
Pooled Analysis	5/20	1/25	1.98	0.12; 31.50	0.149
White					
ASC4FIRST	31/106	34/103	0.68	0.41; 1.13	0.071
ASC4START	38/227	45/217	0.71	0.46; 1.10	0.156
Pooled Analysis	69/333	79/320	0.71	0.51; 0.98	0.024




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	28/68	32/75	0.85	0.50; 1.45	0.279
ASC4START	22/107	27/126	0.88	0.50; 1.56	0.500
Pooled Analysis	50/175	59/201	0.87	0.59; 1.28	0.210
Male					
ASC4FIRST	42/129	48/118	0.61	0.40; 0.92	0.019
ASC4START	29/177	34/158	0.65	0.40; 1.08	0.261
Pooled Analysis	71/306	82/276	0.64	0.46; 0.88	0.012




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Financial difficulties (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	29/153	19/150	1.41	0.79; 2.52	0.230
ASC4START	35/237	34/247	1.22	0.76; 1.97	0.410
Pooled Analysis	64/390	53/397	1.30	0.90; 1.87	0.160
65 - < 75 years					
ASC4FIRST	4/34	4/29	0.52	0.09; 3.14	0.472
ASC4START	3/38	5/24	0.64	0.10; 3.98	0.193
Pooled Analysis	7/72	9/53	0.63	0.18; 2.20	0.150
>= 75 years					
ASC4FIRST	1/10	2/14	1.41	0.08; 23.57	0.808
ASC4START	2/9	0/13	3.00	0.04; 207.39	0.182
Pooled Analysis	3/19	2/27	3.42	0.34; 34.43	0.289




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Financial difficulties (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	2/20	1.51	0.19; 12.00	0.950
ASC4START	2/38	4/37	0.30	0.05; 1.66	0.178
Pooled Analysis	5/61	6/57	0.54	0.16; 1.82	0.341
Intermediate					
ASC4FIRST	13/54	7/53	1.51	0.60; 3.80	0.383
ASC4START	14/75	9/75	2.23	0.89; 5.57	0.090
Pooled Analysis	27/129	16/128	1.82	0.95; 3.48	0.068
Low					
ASC4FIRST	18/120	16/120	1.15	0.59; 2.26	0.720
ASC4START	24/171	26/172	1.02	0.58; 1.78	0.934
Pooled Analysis	42/291	42/292	1.07	0.70; 1.64	0.769




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Financial difficulties (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	7/64	9/62	0.59	0.20; 1.75	0.346
ASC4START	18/138	19/141	1.03	0.53; 1.97	0.887
Pooled Analysis	25/202	28/203	0.88	0.50; 1.54	0.702
Germany					
ASC4FIRST	3/19	1/15	2.40	0.04; 153.75	0.302
ASC4START	4/72	5/53	0.71	0.17; 2.94	0.539
Pooled Analysis	7/91	6/68	0.93	0.24; 3.59	0.927
Others					
ASC4FIRST	24/114	15/116	1.46	0.76; 2.80	0.188
ASC4START	18/74	15/90	1.46	0.72; 2.95	0.242
Pooled Analysis	42/188	30/206	1.46	0.90; 2.35	0.078




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Financial difficulties (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	8/41	6/42	1.38	0.47; 4.08	0.548
Pooled Analysis	8/41	6/42	1.38	0.47; 4.08	0.548
Imatinib					
ASC4FIRST	15/101	12/102	1.10	0.51; 2.37	0.790
Pooled Analysis	15/101	12/102	1.10	0.51; 2.37	0.790
Nilotinib					
ASC4FIRST	11/55	7/49	1.29	0.50; 3.36	0.590
ASC4START	40/284	39/284	1.15	0.73; 1.80	0.556
Pooled Analysis	51/339	46/333	1.18	0.78; 1.76	0.444




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Financial difficulties (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	12/40	10/46	1.31	0.54; 3.15	0.369
Pooled Analysis	30/128	26/132	1.07	0.62; 1.84	0.592
Asian/Others					
ASC4FIRST	19/91	16/90	0.93	0.47; 1.85	0.997
Others					
ASC4START	3/17	1/21	9.86	0.29; 336.31	0.078
Pooled Analysis	4/20	1/25	9.86	0.29; 336.31	0.078
White					
ASC4FIRST	15/106	9/103	1.40	0.60; 3.22	0.435
ASC4START	25/227	28/217	0.92	0.53; 1.59	0.823
Pooled Analysis	40/333	37/320	1.06	0.67; 1.67	0.801




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Financial difficulties (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	12/68	15/75	0.88	0.41; 1.90	0.747
ASC4START	16/107	15/126	1.35	0.65; 2.80	0.527
Pooled Analysis	28/175	30/201	1.09	0.64; 1.84	0.814
Male					
ASC4FIRST	22/129	10/118	1.72	0.80; 3.67	0.136
ASC4START	24/177	24/158	1.06	0.60; 1.90	0.819
Pooled Analysis	46/306	34/276	1.29	0.82; 2.03	0.260




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Global health status/QoL (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	40/153	47/150	0.73	0.47; 1.12	0.092
ASC4START	54/237	59/247	0.96	0.66; 1.39	0.803
Pooled Analysis	94/390	106/397	0.85	0.64; 1.13	0.196
65 - < 75 years					
ASC4FIRST	10/34	9/29	1.19	0.40; 3.58	0.568
ASC4START	5/38	5/24	0.29	0.06; 1.46	0.387
Pooled Analysis	15/72	14/53	0.80	0.34; 1.87	0.326
>= 75 years					
ASC4FIRST	2/10	7/14	0.12	0.01; 1.29	0.015
ASC4START	2/9	2/13	0.88	0.08; 9.40	0.701
Pooled Analysis	4/19	9/27	0.32	0.08; 1.36	0.026




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Global health status/QoL (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	4/23	2/20	1.02	0.17; 6.24	0.810
ASC4START	4/38	6/37	0.39	0.11; 1.41	0.189
Pooled Analysis	8/61	8/57	0.49	0.17; 1.40	0.370
Intermediate					
ASC4FIRST	14/54	21/53	0.44	0.22; 0.89	0.008
ASC4START	12/75	17/75	0.57	0.27; 1.21	0.151
Pooled Analysis	26/129	38/128	0.50	0.30; 0.84	0.004
Low					
ASC4FIRST	34/120	40/120	0.85	0.54; 1.36	0.219
ASC4START	45/171	43/172	1.14	0.75; 1.74	0.559
Pooled Analysis	79/291	83/292	0.99	0.73; 1.35	0.691




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Global health status/QoL (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	18/64	18/62	0.87	0.42; 1.80	0.511
ASC4START	29/138	35/141	0.86	0.52; 1.42	0.588
Pooled Analysis	47/202	53/203	0.88	0.58; 1.32	0.413
Germany					
ASC4FIRST	1/19	1/15	0.14	0.00; 121.52	0.617
ASC4START	11/72	6/53	0.60	0.20; 1.83	0.437
Pooled Analysis	12/91	7/68	0.69	0.24; 2.01	0.520
Others					
ASC4FIRST	33/114	44/116	0.68	0.42; 1.08	0.029
ASC4START	21/74	25/90	1.03	0.57; 1.87	0.905
Pooled Analysis	54/188	69/206	0.78	0.54; 1.13	0.073




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Global health status/QoL (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	5/41	13/42	0.38	0.13; 1.11	0.045
Pooled Analysis	5/41	13/42	0.38	0.13; 1.11	0.045
Imatinib					
ASC4FIRST	32/101	32/102	0.74	0.45; 1.22	0.191
Pooled Analysis	32/101	32/102	0.74	0.45; 1.22	0.191
Nilotinib					
ASC4FIRST	15/55	18/49	0.70	0.32; 1.49	0.145
ASC4START	61/284	66/284	0.91	0.64; 1.29	0.571
Pooled Analysis	76/339	84/333	0.87	0.63; 1.19	0.250




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Global health status/QoL (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	13/40	18/46	0.76	0.37; 1.60	0.460
Pooled Analysis	43/128	55/132	0.76	0.50; 1.14	0.090
Asian/Others					
ASC4FIRST	30/91	37/90	0.74	0.45; 1.21	0.102
Others					
ASC4START	2/17	1/21	3.52	0.07; 172.12	0.134
Pooled Analysis	2/20	1/25	3.52	0.07; 172.12	0.134
White					
ASC4FIRST	22/106	26/103	0.69	0.37; 1.26	0.102
ASC4START	46/227	47/217	0.93	0.62; 1.40	0.595
Pooled Analysis	68/333	73/320	0.84	0.60; 1.19	0.174




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Global health status/QoL (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	21/68	26/75	0.77	0.43; 1.41	0.252
ASC4START	25/107	28/126	1.00	0.58; 1.73	0.956
Pooled Analysis	46/175	54/201	0.88	0.59; 1.32	0.413
Male					
ASC4FIRST	31/129	37/118	0.75	0.45; 1.25	0.045
ASC4START	36/177	38/158	0.84	0.53; 1.33	0.465
Pooled Analysis	67/306	75/276	0.80	0.57; 1.12	0.057




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Insomnia (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	37/153	42/150	0.66	0.42; 1.02	0.123
ASC4START	49/237	58/247	0.78	0.53; 1.15	0.214
Pooled Analysis	86/390	100/397	0.73	0.54; 0.97	0.052
65 - < 75 years					
ASC4FIRST	10/34	6/29	2.47	0.54; 11.33	0.628
ASC4START	8/38	5/24	1.41	0.42; 4.77	0.547
Pooled Analysis	18/72	11/53	1.56	0.64; 3.80	0.442
>= 75 years					
ASC4FIRST	1/10	4/14	0.03	0.00; 3.49	0.013
ASC4START	1/9	2/13	0.56	0.00; 126.83	0.116
Pooled Analysis	2/19	6/27	0.03	0.00; 1.66	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Insomnia (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	4/23	3/20	0.75	0.16; 3.60	0.972
ASC4START	10/38	6/37	1.13	0.41; 3.15	0.617
Pooled Analysis	14/61	9/57	1.01	0.43; 2.37	0.691
Intermediate					
ASC4FIRST	14/54	15/53	0.60	0.29; 1.26	0.120
ASC4START	14/75	19/75	0.69	0.34; 1.40	0.139
Pooled Analysis	28/129	34/128	0.65	0.39; 1.08	0.032
Low					
ASC4FIRST	30/120	34/120	0.78	0.48; 1.28	0.526
ASC4START	34/171	40/172	0.80	0.50; 1.27	0.476
Pooled Analysis	64/291	74/292	0.79	0.56; 1.10	0.340




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Insomnia (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	13/64	17/62	0.69	0.32; 1.48	0.251
ASC4START	33/138	39/141	0.72	0.44; 1.17	0.130
Pooled Analysis	46/202	56/203	0.71	0.47; 1.07	0.058
Germany					
ASC4FIRST	3/19	1/15	11.51	0.27; 492.52	0.098
ASC4START	6/72	5/53	0.38	0.10; 1.43	0.114
Pooled Analysis	9/91	6/68	0.75	0.22; 2.47	0.668
Others					
ASC4FIRST	32/114	34/116	0.73	0.45; 1.19	0.360
ASC4START	19/74	21/90	1.06	0.56; 2.00	0.829
Pooled Analysis	51/188	55/206	0.84	0.57; 1.24	0.553




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Insomnia (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	11/41	8/42	1.76	0.70; 4.43	0.277
Pooled Analysis	11/41	8/42	1.76	0.70; 4.43	0.277
Imatinib					
ASC4FIRST	19/101	27/102	0.58	0.32; 1.06	0.051
Pooled Analysis	19/101	27/102	0.58	0.32; 1.06	0.051
Nilotinib					
ASC4FIRST	18/55	17/49	0.58	0.28; 1.22	0.281
ASC4START	58/284	65/284	0.81	0.56; 1.15	0.254
Pooled Analysis	76/339	82/333	0.75	0.54; 1.04	0.134




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Insomnia (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	11/40	14/46	0.82	0.37; 1.85	0.701
Pooled Analysis	36/128	43/132	0.70	0.45; 1.11	0.209
Asian/Others					
ASC4FIRST	26/91	29/90	0.67	0.39; 1.15	0.238
Others					
ASC4START	3/17	2/21	1.11	0.17; 7.23	0.752
Pooled Analysis	4/20	2/25	1.11	0.17; 7.23	0.752
White					
ASC4FIRST	22/106	23/103	0.84	0.46; 1.53	0.423
ASC4START	44/227	49/217	0.72	0.47; 1.10	0.164
Pooled Analysis	66/333	72/320	0.75	0.53; 1.06	0.109




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Insomnia (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	18/68	23/75	0.78	0.41; 1.48	0.708
ASC4START	26/107	26/126	1.15	0.66; 2.02	0.703
Pooled Analysis	44/175	49/201	0.97	0.64; 1.48	0.972
Male					
ASC4FIRST	30/129	29/118	0.79	0.47; 1.32	0.318
ASC4START	32/177	39/158	0.63	0.39; 1.02	0.076
Pooled Analysis	62/306	68/276	0.69	0.49; 0.99	0.047




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea and vomiting (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	32/153	43/150	0.54	0.34; 0.86	0.009
ASC4START	34/237	47/247	0.67	0.43; 1.05	0.072
Pooled Analysis	66/390	90/397	0.60	0.44; 0.83	0.002
65 - < 75 years					
ASC4FIRST	3/34	7/29	0.14	0.02; 1.18	0.013
ASC4START	3/38	2/24	1.41	0.12; 16.05	0.793
Pooled Analysis	6/72	9/53	0.30	0.08; 1.20	0.050
>= 75 years					
ASC4FIRST	3/10	6/14	0.49	0.11; 2.12	0.274
ASC4START	2/9	1/13	0.71	0.04; 11.79	0.695
Pooled Analysis	5/19	7/27	0.53	0.15; 1.93	0.249




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea and vomiting (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	7/23	4/20	1.58	0.45; 5.52	0.469
ASC4START	8/38	6/37	0.82	0.28; 2.44	0.860
Pooled Analysis	15/61	10/57	1.16	0.51; 2.60	0.723
Intermediate					
ASC4FIRST	8/54	15/53	0.31	0.13; 0.76	0.005
ASC4START	8/75	14/75	0.55	0.23; 1.32	0.104
Pooled Analysis	16/129	29/128	0.41	0.22; 0.76	0.002
Low					
ASC4FIRST	23/120	37/120	0.49	0.29; 0.84	0.007
ASC4START	23/171	30/172	0.79	0.46; 1.37	0.402
Pooled Analysis	46/291	67/292	0.61	0.42; 0.90	0.012




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea and vomiting (MID=10)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	13/64	16/62	0.47	0.21; 1.05	0.057
ASC4START	18/138	27/141	0.63	0.34; 1.16	0.118
Pooled Analysis	31/202	43/203	0.56	0.34; 0.92	0.017
Germany					
ASC4FIRST	2/19	0/15	2.69	0.05; 136.18	0.302
ASC4START	3/72	5/53	0.19	0.04; 0.99	0.022
Pooled Analysis	5/91	5/68	0.35	0.09; 1.38	0.133
Others					
ASC4FIRST	23/114	40/116	0.43	0.26; 0.73	0.001
ASC4START	18/74	18/90	1.17	0.60; 2.28	0.658
Pooled Analysis	41/188	58/206	0.63	0.42; 0.95	0.023



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea and vomiting (MID=10)




Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	Hazard Ratio and 95% CL	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**				
Dasatinib						
ASC4FIRST	11/41	9/42		1.00	0.40; 2.46	0.988
Pooled Analysis	11/41	9/42		1.00	0.40; 2.46	0.988
Imatinib						
ASC4FIRST	14/101	35/102		0.25	0.13; 0.48	<0.001
Pooled Analysis	14/101	35/102		0.25	0.13; 0.48	<0.001
Nilotinib						
ASC4FIRST	13/55	12/49		1.04	0.46; 2.34	0.848
ASC4START	39/284	50/284		0.73	0.48; 1.11	0.126
Pooled Analysis	52/339	62/333		0.79	0.54; 1.15	0.207

n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea and vomiting (MID=10)




Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	Hazard Ratio and 95% CL	HR	95% CL	P-value
Race	**n/N**	**n/N**				
Asian						
ASC4START	13/40	15/46		0.95	0.44; 2.04	0.907
Pooled Analysis	26/128	47/132		0.50	0.30; 0.81	0.005
Asian/Others						
ASC4FIRST	15/91	32/90		0.37	0.20; 0.69	0.001
Others						
ASC4START	1/17	0/21		2.73	0.02; 467.59	0.371
Pooled Analysis	3/20	0/25		2.73	0.02; 467.59	0.371
White						
ASC4FIRST	23/106	24/103		0.71	0.39; 1.28	0.225
ASC4START	25/227	35/217		0.62	0.37; 1.05	0.059
Pooled Analysis	48/333	59/320		0.66	0.45; 0.98	0.026

n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea and vomiting (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	17/68	29/75	0.41	0.21; 0.79	0.006
ASC4START	20/107	27/126	0.72	0.40; 1.31	0.277
Pooled Analysis	37/175	56/201	0.56	0.36; 0.87	0.007
Male					
ASC4FIRST	21/129	27/118	0.52	0.29; 0.93	0.043
ASC4START	19/177	23/158	0.71	0.39; 1.31	0.250
Pooled Analysis	40/306	50/276	0.62	0.41; 0.94	0.024




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pain (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	42/153	53/150	0.63	0.42; 0.95	0.024
ASC4START	67/237	72/247	0.98	0.70; 1.37	0.761
Pooled Analysis	109/390	125/397	0.82	0.63; 1.06	0.095
65 - < 75 years					
ASC4FIRST	10/34	13/29	0.47	0.18; 1.23	0.048
ASC4START	6/38	7/24	0.59	0.18; 1.90	0.215
Pooled Analysis	16/72	20/53	0.51	0.25; 1.06	0.020
>= 75 years					
ASC4FIRST	4/10	7/14	1.57	0.33; 7.45	0.305
ASC4START	3/9	1/13	2.12	0.19; 23.50	0.485
Pooled Analysis	7/19	8/27	1.75	0.49; 6.22	0.571




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pain (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	4/23	5/20	0.62	0.16; 2.39	0.342
ASC4START	12/38	10/37	1.21	0.52; 2.83	0.990
Pooled Analysis	16/61	15/57	0.99	0.48; 2.01	0.602
Intermediate					
ASC4FIRST	20/54	20/53	0.67	0.35; 1.28	0.126
ASC4START	22/75	17/75	1.49	0.79; 2.82	0.332
Pooled Analysis	42/129	37/128	1.02	0.65; 1.60	0.705
Low					
ASC4FIRST	32/120	48/120	0.55	0.35; 0.87	0.007
ASC4START	42/171	53/172	0.74	0.50; 1.12	0.164
Pooled Analysis	74/291	101/292	0.66	0.48; 0.89	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pain (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	22/64	21/62	0.90	0.48; 1.70	0.691
ASC4START	31/138	41/141	0.70	0.44; 1.13	0.146
Pooled Analysis	53/202	62/203	0.77	0.53; 1.13	0.159
Germany					
ASC4FIRST	2/19	2/15	4.23	0.24; 74.30	0.619
ASC4START	12/72	8/53	1.09	0.42; 2.86	0.952
Pooled Analysis	14/91	10/68	1.29	0.52; 3.22	0.804
Others					
ASC4FIRST	32/114	50/116	0.44	0.28; 0.70	<0.001
ASC4START	33/74	31/90	1.26	0.77; 2.07	0.426
Pooled Analysis	65/188	81/206	0.71	0.50; 0.99	0.027




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pain (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	11/41	13/42	0.75	0.32; 1.76	0.339
Pooled Analysis	11/41	13/42	0.75	0.32; 1.76	0.339
Imatinib					
ASC4FIRST	31/101	43/102	0.54	0.34; 0.87	0.006
Pooled Analysis	31/101	43/102	0.54	0.34; 0.87	0.006
Nilotinib					
ASC4FIRST	14/55	17/49	0.58	0.28; 1.20	0.123
ASC4START	76/284	80/284	0.93	0.68; 1.28	0.544
Pooled Analysis	90/339	97/333	0.87	0.65; 1.16	0.241




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pain (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	19/40	20/46	0.91	0.48; 1.71	0.730
Pooled Analysis	42/128	61/132	0.59	0.39; 0.87	0.006
Asian/Others					
ASC4FIRST	24/91	41/90	0.44	0.26; 0.74	0.001
Others					
ASC4START	3/17	2/21	2.05	0.20; 21.07	0.435
Pooled Analysis	4/20	2/25	2.05	0.20; 21.07	0.435
White					
ASC4FIRST	32/106	32/103	0.81	0.49; 1.36	0.180
ASC4START	54/227	58/217	0.87	0.60; 1.27	0.358
Pooled Analysis	86/333	90/320	0.86	0.64; 1.17	0.125




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pain (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	22/68	37/75	0.54	0.31; 0.93	0.019
ASC4START	37/107	36/126	1.27	0.79; 2.04	0.544
Pooled Analysis	59/175	73/201	0.87	0.61; 1.25	0.259
Male					
ASC4FIRST	34/129	36/118	0.73	0.45; 1.19	0.131
ASC4START	39/177	44/158	0.76	0.50; 1.18	0.202
Pooled Analysis	73/306	80/276	0.75	0.54; 1.04	0.050




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Physical functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	22/153	33/150	0.55	0.32; 0.94	0.029
ASC4START	44/237	47/247	0.95	0.63; 1.44	0.822
Pooled Analysis	66/390	80/397	0.77	0.56; 1.07	0.130
65 - < 75 years					
ASC4FIRST	7/34	7/29	0.66	0.21; 2.08	0.389
ASC4START	3/38	6/24	0.28	0.07; 1.13	0.056
Pooled Analysis	10/72	13/53	0.46	0.19; 1.11	0.059
>= 75 years					
ASC4FIRST	4/10	4/14	0.82	0.17; 3.83	0.869
ASC4START	2/9	0/13	3.29	0.09; 121.85	0.199
Pooled Analysis	6/19	4/27	1.42	0.35; 5.80	0.635




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Physical functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	1/20	0.94	0.05; 16.78	0.859
ASC4START	7/38	3/37	1.56	0.40; 6.09	0.370
Pooled Analysis	8/61	4/57	1.42	0.42; 4.81	0.455
Intermediate					
ASC4FIRST	15/54	17/53	0.49	0.24; 1.01	0.051
ASC4START	15/75	10/75	1.71	0.76; 3.83	0.349
Pooled Analysis	30/129	27/128	0.83	0.49; 1.42	0.429
Low					
ASC4FIRST	17/120	26/120	0.61	0.33; 1.14	0.107
ASC4START	27/171	40/172	0.65	0.40; 1.07	0.092
Pooled Analysis	44/291	66/292	0.64	0.43; 0.94	0.020




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Physical functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	13/64	15/62	0.68	0.31; 1.49	0.313
ASC4START	21/138	28/141	0.79	0.44; 1.40	0.376
Pooled Analysis	34/202	43/203	0.75	0.47; 1.19	0.191
Germany					
ASC4FIRST	3/19	1/15	22.27	0.14; >1000	0.919
ASC4START	7/72	7/53	0.46	0.15; 1.43	0.189
Pooled Analysis	10/91	8/68	0.52	0.18; 1.53	0.210
Others					
ASC4FIRST	17/114	28/116	0.49	0.27; 0.91	0.021
ASC4START	21/74	18/90	1.35	0.71; 2.57	0.336
Pooled Analysis	38/188	46/206	0.79	0.51; 1.23	0.297




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Physical functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	7/41	12/42	0.41	0.15; 1.14	0.103
Pooled Analysis	7/41	12/42	0.41	0.15; 1.14	0.103
Imatinib					
ASC4FIRST	17/101	24/102	0.50	0.27; 0.95	0.035
Pooled Analysis	17/101	24/102	0.50	0.27; 0.95	0.035
Nilotinib					
ASC4FIRST	9/55	8/49	0.91	0.35; 2.40	0.836
ASC4START	49/284	53/284	0.90	0.61; 1.32	0.538
Pooled Analysis	58/339	61/333	0.89	0.62; 1.28	0.517




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Physical functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	16/40	14/46	1.12	0.53; 2.35	0.713
Pooled Analysis	32/128	37/132	0.73	0.45; 1.20	0.230
Asian/Others					
ASC4FIRST	17/91	23/90	0.55	0.29; 1.06	0.072
Others					
ASC4START	2/17	1/21	4.39	0.11; 182.44	0.180
Pooled Analysis	3/20	1/25	4.39	0.11; 182.44	0.180
White					
ASC4FIRST	16/106	21/103	0.53	0.26; 1.05	0.049
ASC4START	31/227	38/217	0.76	0.47; 1.22	0.216
Pooled Analysis	47/333	59/320	0.67	0.45; 1.00	0.032




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Physical functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	13/68	21/75	0.64	0.31; 1.29	0.206
ASC4START	25/107	29/126	1.03	0.60; 1.77	0.946
Pooled Analysis	38/175	50/201	0.85	0.56; 1.31	0.402
Male					
ASC4FIRST	20/129	23/118	0.61	0.33; 1.14	0.103
ASC4START	24/177	24/158	0.87	0.49; 1.53	0.619
Pooled Analysis	44/306	47/276	0.74	0.49; 1.13	0.143




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Role functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	32/153	45/150	0.52	0.33; 0.82	0.004
ASC4START	61/237	55/247	1.21	0.83; 1.75	0.241
Pooled Analysis	93/390	100/397	0.86	0.65; 1.15	0.362
65 - < 75 years					
ASC4FIRST	10/34	10/29	0.63	0.21; 1.87	0.195
ASC4START	3/38	5/24	0.37	0.08; 1.63	0.092
Pooled Analysis	13/72	15/53	0.52	0.21; 1.26	0.043
>= 75 years					
ASC4FIRST	3/10	6/14	0.08	0.01; 0.88	0.021
ASC4START	2/9	2/13	14.16	0.12; >1000	0.541
Pooled Analysis	5/19	8/27	0.36	0.08; 1.56	0.110




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Role functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	1/20	1.32	0.12; 14.98	0.589
ASC4START	5/38	4/37	0.82	0.22; 3.06	0.888
Pooled Analysis	8/61	5/57	0.89	0.28; 2.83	0.861
Intermediate					
ASC4FIRST	18/54	20/53	0.50	0.26; 0.97	0.028
ASC4START	17/75	19/75	1.07	0.55; 2.11	0.936
Pooled Analysis	35/129	39/128	0.72	0.45; 1.17	0.136
Low					
ASC4FIRST	24/120	40/120	0.48	0.28; 0.80	0.003
ASC4START	44/171	39/172	1.17	0.76; 1.80	0.441
Pooled Analysis	68/291	79/292	0.79	0.57; 1.10	0.167




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Role functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	20/64	22/62	0.66	0.34; 1.27	0.153
ASC4START	33/138	34/141	1.04	0.64; 1.69	0.810
Pooled Analysis	53/202	56/203	0.88	0.59; 1.30	0.513
Germany					
ASC4FIRST	3/19	2/15	0.21	0.01; 3.67	0.608
ASC4START	12/72	9/53	0.44	0.16; 1.19	0.279
Pooled Analysis	15/91	11/68	0.58	0.24; 1.36	0.231
Others					
ASC4FIRST	22/114	37/116	0.41	0.24; 0.71	0.001
ASC4START	21/74	19/90	1.41	0.75; 2.66	0.287
Pooled Analysis	43/188	56/206	0.68	0.45; 1.02	0.069




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Role functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	7/41	15/42	0.41	0.16; 1.06	0.024
Pooled Analysis	7/41	15/42	0.41	0.16; 1.06	0.024
Imatinib					
ASC4FIRST	22/101	35/102	0.38	0.22; 0.67	<0.001
Pooled Analysis	22/101	35/102	0.38	0.22; 0.67	<0.001
Nilotinib					
ASC4FIRST	16/55	11/49	0.99	0.45; 2.17	0.989
ASC4START	66/284	62/284	1.11	0.78; 1.57	0.530
Pooled Analysis	82/339	73/333	1.08	0.78; 1.49	0.563




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Role functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	12/40	15/46	0.93	0.43; 2.03	0.875
Pooled Analysis	33/128	44/132	0.66	0.41; 1.04	0.083
Asian/Others					
ASC4FIRST	23/91	29/90	0.58	0.33; 1.02	0.064
Others					
ASC4START	2/17	2/21	1.00	0.14; 7.24	0.964
Pooled Analysis	4/20	2/25	1.00	0.14; 7.24	0.964
White					
ASC4FIRST	22/106	32/103	0.45	0.25; 0.81	0.003
ASC4START	52/227	45/217	1.14	0.76; 1.71	0.508
Pooled Analysis	74/333	77/320	0.83	0.60; 1.15	0.223




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Role functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	18/68	26/75	0.52	0.28; 0.97	0.026
ASC4START	30/107	31/126	1.25	0.75; 2.08	0.507
Pooled Analysis	48/175	57/201	0.87	0.59; 1.30	0.360
Male					
ASC4FIRST	27/129	35/118	0.51	0.30; 0.85	0.007
ASC4START	36/177	31/158	1.09	0.67; 1.79	0.592
Pooled Analysis	63/306	66/276	0.75	0.53; 1.07	0.139




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	37/153	51/150	0.54	0.35; 0.83	0.004
ASC4START	52/237	61/247	0.79	0.54; 1.15	0.300
Pooled Analysis	89/390	112/397	0.67	0.51; 0.89	0.007
65 - < 75 years					
ASC4FIRST	7/34	8/29	0.58	0.17; 1.98	0.276
ASC4START	5/38	5/24	0.46	0.12; 1.73	0.292
Pooled Analysis	12/72	13/53	0.52	0.21; 1.27	0.130
>= 75 years					
ASC4FIRST	3/10	4/14	2.48	0.28; 22.11	0.907
ASC4START	1/9	1/13	1.55	0.00; 874.00	0.739
Pooled Analysis	4/19	5/27	2.46	0.32; 19.15	0.799




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	5/23	3/20	0.93	0.21; 4.14	0.809
ASC4START	7/38	6/37	0.84	0.28; 2.51	0.691
Pooled Analysis	12/61	9/57	0.85	0.35; 2.04	0.871
Intermediate					
ASC4FIRST	18/54	17/53	0.79	0.40; 1.54	0.440
ASC4START	16/75	18/75	0.84	0.43; 1.65	0.629
Pooled Analysis	34/129	35/128	0.81	0.50; 1.31	0.375
Low					
ASC4FIRST	24/120	43/120	0.45	0.27; 0.75	0.001
ASC4START	35/171	43/172	0.73	0.46; 1.14	0.204
Pooled Analysis	59/291	86/292	0.59	0.42; 0.83	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	16/64	21/62	0.71	0.36; 1.42	0.328
ASC4START	30/138	40/141	0.70	0.43; 1.14	0.189
Pooled Analysis	46/202	61/203	0.71	0.48; 1.05	0.102
Germany					
ASC4FIRST	3/19	1/15	0.74	0.03; 19.38	0.450
ASC4START	5/72	7/53	0.21	0.05; 0.82	0.022
Pooled Analysis	8/91	8/68	0.24	0.07; 0.80	0.016
Others					
ASC4FIRST	28/114	41/116	0.58	0.35; 0.95	0.019
ASC4START	23/74	20/90	1.29	0.70; 2.36	0.413
Pooled Analysis	51/188	61/206	0.79	0.54; 1.16	0.180




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	4/41	13/42	0.29	0.09; 0.94	0.009
Pooled Analysis	4/41	13/42	0.29	0.09; 0.94	0.009
Imatinib					
ASC4FIRST	26/101	35/102	0.58	0.34; 0.97	0.027
Pooled Analysis	26/101	35/102	0.58	0.34; 0.97	0.027
Nilotinib					
ASC4FIRST	17/55	15/49	0.81	0.39; 1.66	0.538
ASC4START	58/284	67/284	0.76	0.53; 1.09	0.167
Pooled Analysis	75/339	82/333	0.77	0.56; 1.06	0.130




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	15/40	15/46	0.92	0.45; 1.90	0.804
Pooled Analysis	40/128	48/132	0.78	0.51; 1.20	0.231
Asian/Others					
ASC4FIRST	26/91	33/90	0.72	0.43; 1.21	0.193
Others					
ASC4START	2/17	1/21	5.53	0.11; 274.09	0.180
Pooled Analysis	3/20	1/25	5.53	0.11; 274.09	0.180
White					
ASC4FIRST	21/106	30/103	0.53	0.30; 0.94	0.015
ASC4START	41/227	51/217	0.67	0.44; 1.01	0.085
Pooled Analysis	62/333	81/320	0.62	0.44; 1.87	0.005




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.1.1: Forest-Plot for EORTC QLQ-C30: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Social functioning (MID=10)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	18/68	27/75	0.61	0.33; 1.12	0.079
ASC4START	23/107	30/126	0.81	0.47; 1.40	0.272
Pooled Analysis	41/175	57/201	0.71	0.47; 1.07	0.046
Male					
ASC4FIRST	29/129	36/118	0.60	0.36; 0.99	0.026
ASC4START	35/177	37/158	0.78	0.49; 1.26	0.415
Pooled Analysis	64/306	73/276	0.69	0.49; 0.97	0.034



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-7.2 EORTC QLQ-CML24: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Body Image Problems (MID=15)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.545)								
Low	66/291 (22.7)	22.2 [22.1; N.E.]	67/292 (22.9)	N.E. [22.1; N.E.]	0.98	[0.70; 1.38]	0.954	0.161
Intermediate	36/129 (27.9)	24.7 [11.1; N.E.]	36/128 (28.1)	11.1 [5.4; N.E.]	0.83	[0.51; 1.33]	0.292	0.385
High	15/61 (24.6)	N.E. [11.1; N.E.]	9/57 (15.8)	N.E. [5.6; N.E.]	1.22	[0.52; 2.87]	0.751	0.248
Sex								
(Interaction test: p = 0.959)								
Female	48/175	22.2 [5.6; N.E.]	55/201	11.6 [5.6; N.E.]	1.03	[0.69; 1.55]	0.573	0.468

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(27.4)		(27.4)					
Male	69/306	24.7 [22.1; N.E.]	57/276	N.E. [22.1; N.E.]	0.97	[0.68; 1.39]	0.945	0.484
	(22.5)		(20.7)					
Race								
(Interaction test: p = 0.685)								
Asian	38/128	N.E. [N.E.; N.E.]	42/132	N.E. [5.6; N.E.]	0.80	[0.51; 1.25]	0.336	0.267
	(29.7)		(31.8)					
White	76/333	22.2 [11.1; 24.7]	67/320	22.1 [11.1; N.E.]	1.03	[0.73; 1.44]	0.898	0.716
	(22.8)		(20.9)					
Others	3/20	N.E. [1.8; N.E.]	3/25	11.1 [5.6; N.E.]	5.72	[0.14; 242.57]	0.134	N.E.
	(15.0)		(12.0)					
Age groups								
(Interaction test: p = 0.966)								
18 - < 65 years	96/390	22.2 [22.0; N.E.]	96/397	22.1 [11.6; N.E.]	0.96	[0.72; 1.28]	0.730	0.393
	(24.6)		(24.2)					
65 - < 75 years	14/72	24.7 [11.0; N.E.]	11/53	N.E. [4.2; N.E.]	0.86	[0.35; 2.12]	0.691	0.080

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(19.4)		(20.8)					
>= 75 years	7/19	2.8 [1.0; N.E.]	5/27	11.1 [1.9; N.E.]	1.69	[0.32; 8.80]	0.355	0.996
	(36.8)		(18.5)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.531)								
Imatinib	27/101	22.2 [22.0; N.E.]	29/102	22.1 [5.7; N.E.]	0.68	[0.40; 1.17]	0.244	N.E.
	(26.7)		(28.4)					
Nilotinib	82/339	22.5 [11.1; N.E.]	74/333	N.E. [11.6; N.E.]	1.06	[0.77; 1.46]	0.843	0.615
	(24.2)		(22.2)					
Dasatinib	8/41	N.E. [N.E.; N.E.]	9/42	N.E. [1.9; N.E.]	0.83	[0.30; 2.28]	0.595	N.E.
	(19.5)		(21.4)					
Geographic region								
(Interaction test: p = 0.718)								
Europe excluding Germany	52/202	22.1 [11.1; N.E.]	49/203	16.6 [11.1; N.E.]	1.00	[0.67; 1.50]	0.828	0.587

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(25.7)		(24.1)					
Germany	12/91	22.5 [11.1; N.E.]	8/68	N.E. [5.6; N.E.]	0.73	[0.26; 2.06]	0.730	0.994
	(13.2)		(11.8)					
Others	53/188	24.7 [N.E.; N.E.]	55/206	N.E. [22.1; N.E.]	0.86	[0.59; 1.27]	0.559	0.130
	(28.2)		(26.7)					
Impact on Daily Life (MID=15)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.504)								
Low	44/291	N.E. [N.E.; N.E.]	63/292	N.E. [22.1; N.E.]	0.69	[0.47; 1.02]	0.072	0.168
	(15.1)		(21.6)					
Intermediate	18/129	N.E. [N.E.; N.E.]	30/128	N.E. [11.0; N.E.]	0.50	[0.28; 0.90]	0.009	0.827
	(14.0)		(23.4)					
High	8/61	N.E. [N.E.; N.E.]	5/57	N.E. [N.E.; N.E.]	0.64	[0.20; 2.09]	0.909	0.713
	(13.1)		(8.8)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.276)								
Female	27/175 (15.4)	N.E. [N.E.; N.E.]	53/201 (26.4)	11.8 [11.1; N.E.]	0.55	[0.34; 0.89]	0.003	0.204
Male	43/306 (14.1)	N.E. [N.E.; N.E.]	45/276 (16.3)	N.E. [N.E.; N.E.]	0.77	[0.51; 1.18]	0.364	0.770
Race								
(Interaction test: p = 0.390)								
Asian	25/128 (19.5)	N.E. [N.E.; N.E.]	32/132 (24.2)	N.E. [N.E.; N.E.]	0.76	[0.45; 1.30]	0.292	0.072
White	41/333 (12.3)	N.E. [N.E.; N.E.]	62/320 (19.4)	N.E. [11.8; N.E.]	0.56	[0.37; 0.83]	0.004	0.616
Others	4/20 (20.0)	N.E. [1.0; N.E.]	4/25 (16.0)	11.1 [2.8; N.E.]	0.81	[0.11; 6.00]	0.765	N.E.
Age groups								
(Interaction test: p = 0.678)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	60/390 (15.4)	N.E. [N.E.; N.E.]	84/397 (21.2)	N.E. [22.1; N.E.]	0.65	[0.46; 0.91]	0.018	0.534
65 - < 75 years	7/72 (9.7)	N.E. [N.E.; N.E.]	7/53 (13.2)	N.E. [N.E.; N.E.]	0.60	[0.19; 1.90]	0.327	0.608
>= 75 years	3/19 (15.8)	N.E. [1.8; N.E.]	7/27 (25.9)	2.8 [1.0; N.E.]	0.28	[0.07; 1.17]	0.064	0.996
Pre-randomization selection of TKI								
(Interaction test: p = 0.159)								
Imatinib	13/101 (12.9)	N.E. [N.E.; N.E.]	25/102 (24.5)	N.E. [11.1; N.E.]	0.45	[0.23; 0.90]	0.011	N.E.
Nilotinib	56/339 (16.5)	N.E. [N.E.; N.E.]	66/333 (19.8)	N.E. [16.6; N.E.]	0.73	[0.51; 1.05]	0.134	0.774
Dasatinib	1/41 (2.4)	N.E. [N.E.; N.E.]	7/42 (16.7)	N.E. [N.E.; N.E.]	0.12	[0.01; 1.04]	0.024	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.506)								
Europe excluding Germany	34/202 (16.8)	N.E. [N.E.; N.E.]	54/203 (26.6)	11.8 [11.1; N.E.]	0.58	[0.38; 0.90]	0.012	0.981
Germany	4/91 (4.4)	N.E. [N.E.; N.E.]	4/68 (5.9)	N.E. [N.E.; N.E.]	0.89	[0.18; 4.29]	0.892	0.996
Others	32/188 (17.0)	N.E. [N.E.; N.E.]	40/206 (19.4)	N.E. [N.E.; N.E.]	0.80	[0.50; 1.28]	0.344	0.038
Impact on Worry/Mood (MID=15)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.567)								
Low	41/291 (14.1)	N.E. [22.2; N.E.]	49/292 (16.8)	N.E. [22.1; N.E.]	0.78	[0.51; 1.18]	0.241	0.114
Intermediate	24/129	N.E. [22.1; N.E.]	16/128	N.E. [22.1; N.E.]	1.18	[0.62; 2.24]	0.545	0.430

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(18.6)		(12.5)					
High	5/61	N.E. [N.E.; N.E.]	4/57	N.E. [N.E.; N.E.]	0.78	[0.21; 2.94]	0.834	0.933
	(8.2)		(7.0)					
Sex								
(Interaction test: p = 0.160)								
Female	32/175	22.2 [22.2; N.E.]	30/201	N.E. [N.E.; N.E.]	1.27	[0.76; 2.11]	0.590	0.087
	(18.3)		(14.9)					
Male	38/306	N.E. [N.E.; N.E.]	39/276	N.E. [22.1; N.E.]	0.75	[0.48; 1.19]	0.314	0.677
	(12.4)		(14.1)					
Race								
(Interaction test: p = 0.339)								
Asian	32/128	N.E. [N.E.; N.E.]	30/132	N.E. [22.1; N.E.]	0.94	[0.57; 1.57]	0.962	0.092
	(25.0)		(22.7)					
White	34/333	N.E. [22.2; N.E.]	38/320	N.E. [22.1; N.E.]	0.83	[0.52; 1.32]	0.363	0.460
	(10.2)		(11.9)					
Others	4/20	11.0 [2.8; N.E.]	1/25	N.E. [5.6; N.E.]	6.16	[0.18; 208.31]	0.121	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(20.0)		(4.0)					
Age groups								
(Interaction test: p = 0.522)								
18 - < 65 years	63/390	N.E. [22.2; N.E.]	61/397	N.E. [N.E.; N.E.]	0.93	[0.65; 1.33]	0.833	0.099
	(16.2)		(15.4)					
65 - < 75 years	6/72	N.E. [N.E.; N.E.]	5/53	N.E. [22.1; N.E.]	0.64	[0.13; 3.07]	0.466	0.683
	(8.3)		(9.4)					
>= 75 years	1/19	N.E. [N.E.; N.E.]	3/27	N.E. [5.4; N.E.]	0.32	[0.03; 4.02]	0.187	N.E.
	(5.3)		(11.1)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.091)								
Imatinib	14/101	N.E. [22.2; N.E.]	25/102	22.1 [22.0; N.E.]	0.44	[0.23; 0.86]	0.010	N.E.
	(13.9)		(24.5)					
Nilotinib	48/339	N.E. [N.E.; N.E.]	36/333	N.E. [N.E.; N.E.]	1.08	[0.70; 1.68]	0.514	0.350
	(14.2)		(10.8)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	8/41 (19.5)	N.E. [11.1; N.E.]	8/42 (19.0)	N.E. [11.0; N.E.]	1.10	[0.41; 2.95]	0.855	N.E.
Geographic region (Interaction test: p = 0.855)								
Europe excluding Germany	26/202 (12.9)	N.E. [22.2; N.E.]	27/203 (13.3)	N.E. [N.E.; N.E.]	0.98	[0.57; 1.69]	0.918	0.272
Germany	4/91 (4.4)	N.E. [N.E.; N.E.]	4/68 (5.9)	N.E. [N.E.; N.E.]	0.35	[0.07; 1.69]	0.239	0.996
Others	40/188 (21.3)	N.E. [N.E.; N.E.]	38/206 (18.4)	N.E. [22.1; N.E.]	0.88	[0.56; 1.39]	0.770	0.023
Symptom Burden (MID=15)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.265)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Low	18/291 (6.2)	N.E. [N.E.; N.E.]	53/292 (18.2)	25.7 [22.1; N.E.]	0.32	[0.19; 0.55]	<0.001	0.532
Intermediate	8/129 (6.2)	N.E. [N.E.; N.E.]	17/128 (13.3)	22.3 [22.1; N.E.]	0.33	[0.14; 0.78]	0.007	0.343
High	5/61 (8.2)	N.E. [22.1; N.E.]	3/57 (5.3)	N.E. [11.2; N.E.]	0.97	[0.22; 4.22]	0.775	0.762
Sex								
(Interaction test: p = 0.263)								
Female	12/175 (6.9)	N.E. [N.E.; N.E.]	40/201 (19.9)	N.E. [11.6; N.E.]	0.28	[0.15; 0.54]	<0.001	0.219
Male	19/306 (6.2)	N.E. [N.E.; N.E.]	33/276 (12.0)	25.7 [22.3; N.E.]	0.43	[0.24; 0.78]	0.004	0.594
Race								
(Interaction test: p = 0.928)								
Asian	11/128 (8.6)	N.E. [N.E.; N.E.]	33/132 (25.0)	25.7 [22.1; N.E.]	0.33	[0.16; 0.66]	<0.001	0.329

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
White	17/333 (5.1)	N.E. [N.E.; N.E.]	40/320 (12.5)	N.E. [22.1; N.E.]	0.36	[0.20; 0.63]	<0.001	0.985
Others	3/20 (15.0)	N.E. [0.9; N.E.]	0/25	N.E. [N.E.; N.E.]	3.51	[0.05; 263.62]	0.187	N.E.
Age groups (Interaction test: p = 0.996)								
18 - < 65 years	29/390 (7.4)	N.E. [N.E.; N.E.]	61/397 (15.4)	25.7 [N.E.; N.E.]	0.42	[0.27; 0.66]	<0.001	0.253
65 - < 75 years	0/72	N.E. [N.E.; N.E.]	7/53 (13.2)	N.E. [22.1; N.E.]	0.05	[0.00; 1.07]	0.003	1.000
>= 75 years	2/19 (10.5)	N.E. [22.1; N.E.]	5/27 (18.5)	22.3 [2.6; N.E.]	0.29	[0.04; 2.35]	0.176	N.E.
Pre-randomization selection of TKI (Interaction test: p = 0.202)								
Imatinib	7/101	N.E. [N.E.; N.E.]	26/102	22.1 [11.1; N.E.]	0.20	[0.09; 0.46]	<0.001	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(6.9)		(25.5)					
Nilotinib	18/339	N.E. [N.E.; N.E.]	38/333	N.E. [22.3; N.E.]	0.45	[0.25; 0.79]	0.005	0.707
	(5.3)		(11.4)					
Dasatinib	6/41	N.E. [22.1; N.E.]	9/42	25.7 [5.7; N.E.]	0.64	[0.21; 1.95]	0.443	N.E.
	(14.6)		(21.4)					
Geographic region								
(Interaction test: p = 0.947)								
Europe excluding Germany	15/202	N.E. [N.E.; N.E.]	31/203	N.E. [N.E.; N.E.]	0.37	[0.19; 0.72]	0.002	0.742
	(7.4)		(15.3)					
Germany	1/91	N.E. [N.E.; N.E.]	2/68	N.E. [N.E.; N.E.]	0.05	[0.00; 4.16]	0.201	N.E.
	(1.1)		(2.9)					
Others	15/188	N.E. [N.E.; N.E.]	40/206	22.3 [22.1; N.E.]	0.34	[0.19; 0.63]	<0.001	0.107
	(8.0)		(19.4)					
Satisfaction with Care and Information (MID=15)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.377)								
Low	64/291 (22.0)	N.E. [N.E.; N.E.]	51/292 (17.5)	N.E. [N.E.; N.E.]	1.20	[0.83; 1.74]	0.109	0.960
Intermediate	39/129 (30.2)	11.2 [6.1; N.E.]	25/128 (19.5)	N.E. [N.E.; N.E.]	1.06	[0.62; 1.79]	0.259	0.891
High	17/61 (27.9)	N.E. [2.8; N.E.]	7/57 (12.3)	N.E. [N.E.; N.E.]	1.61	[0.65; 3.96]	0.192	0.750
Sex								
(Interaction test: p = 0.549)								
Female	46/175 (26.3)	13.1 [11.0; N.E.]	31/201 (15.4)	N.E. [N.E.; N.E.]	1.24	[0.77; 2.00]	0.054	0.605
Male	74/306 (24.2)	N.E. [11.2; N.E.]	52/276 (18.8)	N.E. [N.E.; N.E.]	1.12	[0.77; 1.61]	0.217	0.621

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.750)								
Asian	67/128 (52.3)	5.4 [1.9; 11.0]	40/132 (30.3)	N.E. [N.E.; N.E.]	1.20	[0.80; 1.81]	0.009	0.706
White	51/333 (15.3)	N.E. [N.E.; N.E.]	39/320 (12.2)	N.E. [N.E.; N.E.]	1.25	[0.81; 1.92]	0.475	0.783
Others	2/20 (10.0)	N.E. [1.0; N.E.]	4/25 (16.0)	N.E. [2.8; N.E.]	0.25	[0.02; 2.81]	0.328	N.E.
Age groups								
(Interaction test: p = 0.010)								
18 - < 65 years	104/390 (26.7)	N.E. [11.1; N.E.]	68/397 (17.1)	N.E. [N.E.; N.E.]	1.35	[0.99; 1.85]	0.003	0.917
65 - < 75 years	13/72 (18.1)	N.E. [13.1; N.E.]	12/53 (22.6)	N.E. [2.8; N.E.]	0.47	[0.19; 1.17]	0.290	0.634
>= 75 years	3/19 (15.8)	N.E. [1.8; N.E.]	3/27 (11.1)	N.E. [1.0; N.E.]	1.35	[0.10; 19.02]	0.855	1.000

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.040)								
Imatinib	30/101 (29.7)	N.E. [5.4; N.E.]	24/102 (23.5)	N.E. [11.1; N.E.]	0.98	[0.56; 1.71]	0.495	N.E.
Nilotinib	79/339 (23.3)	N.E. [11.2; N.E.]	50/333 (15.0)	N.E. [N.E.; N.E.]	1.43	[1.00; 2.05]	0.025	0.147
Dasatinib	11/41 (26.8)	N.E. [1.9; N.E.]	9/42 (21.4)	N.E. [2.7; N.E.]	0.59	[0.21; 1.68]	0.687	N.E.
Geographic region								
(Interaction test: p = 0.668)								
Europe excluding Germany	35/202 (17.3)	N.E. [13.1; N.E.]	31/203 (15.3)	N.E. [N.E.; N.E.]	0.94	[0.56; 1.57]	0.818	0.512
Germany	7/91 (7.7)	N.E. [N.E.; N.E.]	2/68 (2.9)	N.E. [N.E.; N.E.]	2.39	[0.48; 11.95]	0.338	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	78/188 (41.5)	6.0 [2.8; 11.1]	50/206 (24.3)	N.E. [N.E.; N.E.]	1.29	[0.89; 1.86]	0.009	0.390
Satisfaction with Social Life (MID=15)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.335)								
Low	75/291 (25.8)	N.E. [11.1; N.E.]	70/292 (24.0)	25.7 [22.1; N.E.]	1.19	[0.86; 1.65]	0.387	0.146
Intermediate	40/129 (31.0)	11.1 [5.6; N.E.]	35/128 (27.3)	11.3 [2.9; N.E.]	1.01	[0.63; 1.62]	0.955	0.190
High	21/61 (34.4)	11.1 [1.9; N.E.]	8/57 (14.0)	N.E. [N.E.; N.E.]	1.29	[0.55; 3.00]	0.100	0.331
Sex (Interaction test: p = 0.810)								
Female	53/175	11.1 [5.6; N.E.]	45/201	N.E. [11.1; N.E.]	1.17	[0.78; 1.77]	0.128	0.418

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(30.3)		(22.4)					
Male	83/306	N.E. [11.1; N.E.]	68/276	25.7 [16.6; N.E.]	1.13	[0.81; 1.57]	0.685	0.374
	(27.1)		(24.6)					
Race								
(Interaction test: p = 0.877)								
Asian	50/128	22.1 [5.6; N.E.]	43/132	25.7 [5.6; N.E.]	1.16	[0.75; 1.78]	0.398	0.710
	(39.1)		(32.6)					
White	82/333	N.E. [11.0; N.E.]	66/320	22.1 [11.2; N.E.]	1.16	[0.83; 1.62]	0.333	0.243
	(24.6)		(20.6)					
Others	4/20	11.1 [0.9; N.E.]	4/25	5.6 [1.0; N.E.]	0.86	[0.15; 4.82]	0.613	N.E.
	(20.0)		(16.0)					
Age groups								
(Interaction test: p = 0.702)								
18 - < 65 years	114/390	21.9 [11.0; N.E.]	101/397	25.7 [11.2; N.E.]	1.19	[0.91; 1.57]	0.225	0.275
	(29.2)		(25.4)					
65 - < 75 years	19/72	11.1 [5.6; N.E.]	10/53	N.E. [5.6; N.E.]	0.95	[0.41; 2.17]	0.950	0.154


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(26.4)		(18.9)					
>= 75 years	3/19	N.E. [1.0; N.E.]	2/27	N.E. [1.0; N.E.]	1.80	[0.22; 14.69]	0.982	0.683
	(15.8)		(7.4)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.725)								
Imatinib	27/101	N.E. [11.0; N.E.]	22/102	N.E. [11.1; N.E.]	1.17	[0.64; 2.14]	0.584	N.E.
	(26.7)		(21.6)					
Nilotinib	97/339	11.1 [6.1; N.E.]	83/333	22.1 [10.9; N.E.]	1.18	[0.87; 1.58]	0.360	0.441
	(28.6)		(24.9)					
Dasatinib	12/41	N.E. [2.6; N.E.]	8/42	25.7 [N.E.; N.E.]	0.77	[0.27; 2.20]	0.316	N.E.
	(29.3)		(19.0)					
Geographic region								
(Interaction test: p = 0.208)								
Europe excluding Germany	60/202	11.1 [5.6; N.E.]	51/203	22.1 [11.0; N.E.]	1.37	[0.93; 2.03]	0.409	0.514

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(29.7)		(25.1)					
Germany	11/91	N.E. [6.1; N.E.]	9/68	16.6 [1.9; N.E.]	0.54	[0.18; 1.64]	0.701	0.995
	(12.1)		(13.2)					
Others	65/188	22.1 [8.3; N.E.]	53/206	25.7 [N.E.; N.E.]	1.11	[0.76; 1.62]	0.339	0.735
	(34.6)		(25.7)					

MID: Minimally important difference
N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
In this sensitivity analysis a missing assessment before randomization is substituted by the last assessment before or on the day of treatment start, if such an assessment is available.
If there are not at least 10 patients in every subgroup or not more than 10 events per subgroup per treatment arm, no subgroup analyses were performed for the corresponding attribute.
If there are not more than 10 events per subgroup per treatment arm, no Cox PH hazard analysis is carried out.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline PRO score.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates. P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT) and Pre-Randomization selection TKI (IRT).
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2 EORTC QLQ-CML24: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Satisfaction with Care and Information (MID=15): Age groups: 18 - < 65 years




Pts at Risk (censored)

Asciminib	390 (0)	119 (182)	34 (252)	34 (252)	1 (285)	0 (286)	0 (286)
Investigator Selected TKI	397 (0)	131 (203)	51 (278)	42 (287)	4 (325)	1 (328)	0 (329)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2 EORTC QLQ-CML24: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Satisfaction with Care and Information (MID=15): Age groups: 65 - < 75 years




Pts at Risk (censored)

Asciminib	72 (0)	25 (37)	12 (48)	11 (48)	2 (57)	0 (59)	0 (59)
Investigator Selected TKI	53 (0)	12 (29)	6 (35)	6 (35)	1 (40)	0 (41)	0 (41)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2 EORTC QLQ-CML24: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Satisfaction with Care and Information (MID=15): Age groups: >= 75 years




Pts at Risk (censored)

Asciminib	19 (0)	5 (11)	2 (14)	2 (14)	0 (16)	0 (16)	0 (16)
Investigator Selected TKI	27 (0)	5 (19)	3 (21)	2 (22)	0 (24)	0 (24)	0 (24)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2 EORTC QLQ-CML24: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Satisfaction with Care and Information (MID=15): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	101 (0)	33 (43)	21 (50)	21 (50)	2 (69)	0 (71)	0 (71)
Investigator Selected TKI	102 (0)	29 (50)	15 (63)	13 (65)	0 (78)	0 (78)	0 (78)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2 EORTC QLQ-CML24: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Satisfaction with Care and Information (MID=15): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	103 (170)	18 (243)	17 (243)	0 (260)	0 (260)	0 (260)
Investigator Selected TKI	333 (0)	106 (181)	34 (249)	27 (256)	3 (280)	0 (283)	0 (283)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2 EORTC QLQ-CML24: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Satisfaction with Care and Information (MID=15): Pre-randomization selection of TKI: Dasatinib



Pts at Risk (censored)


Asciminib	41 (0)	13 (17)	9 (21)	9 (21)	1 (29)	0 (30)	0 (30)
Investigator Selected TKI	42 (0)	13 (20)	11 (22)	10 (23)	2 (31)	1 (32)	0 (33)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Body Image Problems (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	40/153	41/150	0.84	0.54; 1.31	0.284
ASC4START	56/237	55/247	1.07	0.74; 1.57	0.644
Pooled Analysis	96/390	96/397	0.96	0.72; 1.28	0.730
65 - < 75 years					
ASC4FIRST	8/34	8/29	0.42	0.12; 1.44	0.372
ASC4START	6/38	3/24	2.43	0.53; 11.23	0.644
Pooled Analysis	14/72	11/53	0.86	0.35; 2.12	0.691
>= 75 years					
ASC4FIRST	4/10	4/14	1.06	0.18; 6.08	0.559
ASC4START	3/9	1/13	1.45	0.12; 17.57	0.455
Pooled Analysis	7/19	5/27	1.69	0.32; 8.80	0.355




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Body Image Problems (MID=15)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	6/23	3/20	2.51	0.56; 11.20	0.499
ASC4START	9/38	6/37	0.82	0.29; 2.36	0.890
Pooled Analysis	15/61	9/57	1.22	0.52; 2.87	0.751
Intermediate					
ASC4FIRST	17/54	15/53	0.64	0.31; 1.30	0.292
ASC4START	19/75	21/75	0.97	0.51; 1.81	0.628
Pooled Analysis	36/129	36/128	0.83	0.51; 1.33	0.292
Low					
ASC4FIRST	29/120	35/120	0.76	0.46; 1.25	0.255
ASC4START	37/171	32/172	1.25	0.78; 2.01	0.311
Pooled Analysis	66/291	67/292	0.98	0.70; 1.38	0.954



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Body Image Problems (MID=15)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Body Image Problems (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	8/41	9/42	0.83	0.30; 2.28	0.595
Pooled Analysis	8/41	9/42	0.83	0.30; 2.28	0.595
Imatinib					
ASC4FIRST	27/101	29/102	0.68	0.40; 1.17	0.244
Pooled Analysis	27/101	29/102	0.68	0.40; 1.17	0.244
Nilotinib					
ASC4FIRST	17/55	15/49	0.90	0.44; 1.85	0.662
ASC4START	65/284	59/284	1.11	0.78; 1.58	0.662
Pooled Analysis	82/339	74/333	1.06	0.77; 1.46	0.843




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Body Image Problems (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	15/40	13/46	1.17	0.55; 2.48	0.659
Pooled Analysis	38/128	42/132	0.80	0.51; 1.25	0.336
Asian/Others					
ASC4FIRST	24/91	29/90	0.67	0.38; 1.16	0.140
Others					
ASC4START	2/17	3/21	5.72	0.14; 242.57	0.134
Pooled Analysis	3/20	3/25	5.72	0.14; 242.57	0.134
White					
ASC4FIRST	28/106	24/103	0.94	0.53; 1.67	0.740
ASC4START	48/227	43/217	1.08	0.71; 1.64	0.932
Pooled Analysis	76/333	67/320	1.03	0.73; 1.44	0.898




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Body Image Problems (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	17/68	24/75	0.86	0.44; 1.68	0.205
ASC4START	31/107	31/126	1.16	0.69; 1.95	0.768
Pooled Analysis	48/175	55/201	1.03	0.69; 1.55	0.573
Male					
ASC4FIRST	35/129	29/118	0.84	0.51; 1.40	0.628
ASC4START	34/177	28/158	1.10	0.67; 1.83	0.702
Pooled Analysis	69/306	57/276	0.97	0.68; 1.39	0.945




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Daily Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	21/153	32/150	0.57	0.32; 0.99	0.035
ASC4START	39/237	52/247	0.70	0.46; 1.07	0.174
Pooled Analysis	60/390	84/397	0.65	0.46; 0.91	0.018
65 - < 75 years					
ASC4FIRST	3/34	3/29	0.77	0.11; 5.15	0.717
ASC4START	4/38	4/24	0.31	0.06; 1.77	0.325
Pooled Analysis	7/72	7/53	0.60	0.19; 1.90	0.327
>= 75 years					
ASC4FIRST	2/10	7/14	0.20	0.04; 0.98	0.027
ASC4START	1/9	0/13	27.00	0.00; >1000	0.480
Pooled Analysis	3/19	7/27	0.28	0.07; 1.17	0.064




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Daily Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	1/20	0.97	0.08; 11.89	0.635
ASC4START	5/38	4/37	0.56	0.14; 2.18	0.651
Pooled Analysis	8/61	5/57	0.64	0.20; 2.09	0.909
Intermediate					
ASC4FIRST	10/54	14/53	0.54	0.24; 1.22	0.079
ASC4START	8/75	16/75	0.46	0.20; 1.08	0.056
Pooled Analysis	18/129	30/128	0.50	0.28; 0.90	0.009
Low					
ASC4FIRST	13/120	27/120	0.47	0.24; 0.92	0.020
ASC4START	31/171	36/172	0.84	0.52; 1.36	0.640
Pooled Analysis	44/291	63/292	0.69	0.47; 1.02	0.072




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Daily Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	12/64	18/62	0.59	0.27; 1.27	0.105
ASC4START	22/138	36/141	0.58	0.34; 0.99	0.051
Pooled Analysis	34/202	54/203	0.58	0.38; 0.90	0.012
Germany					
ASC4FIRST	1/19	1/15	1.89	0.01; 311.12	0.317
ASC4START	3/72	3/53	0.50	0.09; 2.76	0.556
Pooled Analysis	4/91	4/68	0.89	0.18; 4.29	0.892
Others					
ASC4FIRST	13/114	23/116	0.48	0.24; 0.95	0.028
ASC4START	19/74	17/90	1.31	0.68; 2.54	0.381
Pooled Analysis	32/188	40/206	0.80	0.50; 1.28	0.344




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Daily Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	1/41	7/42	0.12	0.01; 1.04	0.024
Pooled Analysis	1/41	7/42	0.12	0.01; 1.04	0.024
Imatinib					
ASC4FIRST	13/101	25/102	0.45	0.23; 0.90	0.011
Pooled Analysis	13/101	25/102	0.45	0.23; 0.90	0.011
Nilotinib					
ASC4FIRST	12/55	10/49	0.83	0.35; 1.95	0.687
ASC4START	44/284	56/284	0.71	0.48; 1.06	0.144
Pooled Analysis	56/339	66/333	0.73	0.51; 1.05	0.134




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Daily Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	12/40	10/46	1.38	0.59; 3.22	0.405
Pooled Analysis	25/128	32/132	0.76	0.45; 1.30	0.292
Asian/Others					
ASC4FIRST	15/91	22/90	0.57	0.29; 1.10	0.080
Others					
ASC4START	2/17	4/21	0.81	0.11; 6.00	0.765
Pooled Analysis	4/20	4/25	0.81	0.11; 6.00	0.765
White					
ASC4FIRST	11/106	20/103	0.47	0.22; 1.01	0.032
ASC4START	30/227	42/217	0.60	0.37; 0.96	0.045
Pooled Analysis	41/333	62/320	0.56	0.37; 0.83	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Daily Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	7/68	21/75	0.34	0.14; 0.81	0.003
ASC4START	20/107	32/126	0.69	0.39; 1.21	0.118
Pooled Analysis	27/175	53/201	0.55	0.34; 0.89	0.003
Male					
ASC4FIRST	19/129	21/118	0.73	0.39; 1.37	0.346
ASC4START	24/177	24/158	0.80	0.45; 1.42	0.711
Pooled Analysis	43/306	45/276	0.77	0.51; 1.18	0.364




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Worry/Mood (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	33/153	38/150	0.72	0.45; 1.15	0.176
ASC4START	30/237	23/247	1.28	0.73; 2.22	0.221
Pooled Analysis	63/390	61/397	0.93	0.65; 1.33	0.833
65 - < 75 years					
ASC4FIRST	4/34	4/29	0.45	0.05; 4.30	0.505
ASC4START	2/38	1/24	0.93	0.08; 10.28	0.757
Pooled Analysis	6/72	5/53	0.64	0.13; 3.07	0.466
>= 75 years					
ASC4FIRST	1/10	3/14	0.32	0.03; 4.02	0.187
ASC4START	0/9	0/13	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	1/19	3/27	0.32	0.03; 4.02	0.187




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Worry/Mood (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	2/20	0.73	0.10; 5.30	0.803
ASC4START	3/38	2/37	0.79	0.13; 4.86	0.956
Pooled Analysis	5/61	4/57	0.78	0.21; 2.94	0.834
Intermediate					
ASC4FIRST	13/54	9/53	0.93	0.39; 2.20	0.900
ASC4START	11/75	7/75	1.50	0.58; 3.89	0.305
Pooled Analysis	24/129	16/128	1.18	0.62; 2.24	0.545
Low					
ASC4FIRST	23/120	34/120	0.60	0.35; 1.02	0.050
ASC4START	18/171	15/172	1.20	0.60; 2.39	0.533
Pooled Analysis	41/291	49/292	0.78	0.51; 1.18	0.241




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Worry/Mood (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	11/64	15/62	0.70	0.31; 1.55	0.315
ASC4START	15/138	12/141	1.29	0.60; 2.78	0.412
Pooled Analysis	26/202	27/203	0.98	0.57; 1.69	0.918
Germany					
ASC4FIRST	2/19	0/15	4.43	0.10; 200.65	0.225
ASC4START	2/72	4/53	0.08	0.01; 0.83	0.026
Pooled Analysis	4/91	4/68	0.35	0.07; 1.69	0.239
Others					
ASC4FIRST	25/114	30/116	0.63	0.37; 1.08	0.119
ASC4START	15/74	8/90	2.04	0.85; 4.90	0.063
Pooled Analysis	40/188	38/206	0.88	0.56; 1.39	0.770




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Worry/Mood (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	8/41	8/42	1.10	0.41; 2.95	0.855
Pooled Analysis	8/41	8/42	1.10	0.41; 2.95	0.855
Imatinib					
ASC4FIRST	14/101	25/102	0.44	0.23; 0.86	0.010
Pooled Analysis	14/101	25/102	0.44	0.23; 0.86	0.010
Nilotinib					
ASC4FIRST	16/55	12/49	0.80	0.37; 1.74	0.702
ASC4START	32/284	24/284	1.23	0.72; 2.10	0.295
Pooled Analysis	48/339	36/333	1.08	0.70; 1.68	0.514




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Worry/Mood (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	10/40	5/46	1.98	0.66; 5.94	0.129
Pooled Analysis	32/128	30/132	0.94	0.57; 1.57	0.962
Asian/Others					
ASC4FIRST	23/91	25/90	0.75	0.42; 1.34	0.408
Others					
ASC4START	3/17	1/21	6.16	0.18; 208.31	0.121
Pooled Analysis	4/20	1/25	6.16	0.18; 208.31	0.121
White					
ASC4FIRST	15/106	20/103	0.67	0.34; 1.33	0.185
ASC4START	19/227	18/217	0.96	0.50; 1.84	0.994
Pooled Analysis	34/333	38/320	0.83	0.52; 1.32	0.363




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Impact on Worry/Mood (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	16/68	22/75	0.81	0.42; 1.58	0.418
ASC4START	16/107	8/126	2.24	0.95; 5.27	0.061
Pooled Analysis	32/175	30/201	1.27	0.76; 2.11	0.590
Male					
ASC4FIRST	22/129	23/118	0.70	0.38; 1.26	0.267
ASC4START	16/177	16/158	0.84	0.42; 1.70	0.801
Pooled Analysis	38/306	39/276	0.75	0.48; 1.19	0.314




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Care and Information (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	57/153	34/150	1.28	0.82; 2.00	0.012
ASC4START	47/237	34/247	1.39	0.89; 2.17	0.107
Pooled Analysis	104/390	68/397	1.35	0.99; 1.85	0.003
65 - < 75 years					
ASC4FIRST	8/34	7/29	0.40	0.11; 1.50	0.615
ASC4START	5/38	5/24	0.61	0.17; 2.18	0.299
Pooled Analysis	13/72	12/53	0.47	0.19; 1.17	0.290
>= 75 years					
ASC4FIRST	2/10	2/14	3.26	0.11; 96.91	0.471
ASC4START	1/9	1/13	0.71	0.03; 17.62	0.515
Pooled Analysis	3/19	3/27	1.35	0.10; 19.02	0.855




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Care and Information (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	7/23	3/20	1.26	0.29; 5.56	0.330
ASC4START	10/38	4/37	1.76	0.55; 5.64	0.378
Pooled Analysis	17/61	7/57	1.61	0.65; 3.96	0.192
Intermediate					
ASC4FIRST	21/54	10/53	0.99	0.43; 2.26	0.149
ASC4START	18/75	15/75	1.09	0.54; 2.18	0.861
Pooled Analysis	39/129	25/128	1.06	0.62; 1.79	0.259
Low					
ASC4FIRST	39/120	30/120	1.19	0.74; 1.93	0.166
ASC4START	25/171	21/172	1.21	0.68; 2.16	0.403
Pooled Analysis	64/291	51/292	1.20	0.83; 1.74	0.109




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Care and Information (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	15/64	9/62	1.22	0.47; 3.16	0.502
ASC4START	20/138	22/141	0.83	0.45; 1.54	0.435
Pooled Analysis	35/202	31/203	0.94	0.56; 1.57	0.818
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	7/72	2/53	2.39	0.48; 11.95	0.338
Pooled Analysis	7/91	2/68	2.39	0.48; 11.95	0.338
Others					
ASC4FIRST	52/114	34/116	1.11	0.70; 1.74	0.074
ASC4START	26/74	16/90	1.71	0.91; 3.23	0.044
Pooled Analysis	78/188	50/206	1.29	0.89; 1.86	0.009




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Care and Information (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	11/41	9/42	0.59	0.21; 1.68	0.687
Pooled Analysis	11/41	9/42	0.59	0.21; 1.68	0.687
Imatinib					
ASC4FIRST	30/101	24/102	0.98	0.56; 1.71	0.495
Pooled Analysis	30/101	24/102	0.98	0.56; 1.71	0.495
Nilotinib					
ASC4FIRST	26/55	10/49	2.25	1.06; 4.76	0.010
ASC4START	53/284	40/284	1.22	0.81; 1.84	0.302
Pooled Analysis	79/339	50/333	1.43	1.00; 2.05	0.025




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Care and Information (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	18/40	10/46	1.52	0.68; 3.40	0.087
Pooled Analysis	67/128	40/132	1.20	0.80; 1.81	0.009
Asian/Others					
ASC4FIRST	49/91	30/90	1.11	0.69; 1.78	0.066
Others					
ASC4START	2/17	4/21	0.25	0.02; 2.81	0.328
Pooled Analysis	2/20	4/25	0.25	0.02; 2.81	0.328
White					
ASC4FIRST	18/106	13/103	1.43	0.66; 3.09	0.550
ASC4START	33/227	26/217	1.18	0.70; 1.99	0.653
Pooled Analysis	51/333	39/320	1.25	0.81; 1.92	0.475




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Care and Information (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	20/68	11/75	1.43	0.61; 3.38	0.045
ASC4START	26/107	20/126	1.18	0.65; 2.13	0.394
Pooled Analysis	46/175	31/201	1.24	0.77; 2.00	0.054
Male					
ASC4FIRST	47/129	32/118	1.01	0.62; 1.64	0.282
ASC4START	27/177	20/158	1.22	0.68; 2.18	0.528
Pooled Analysis	74/306	52/276	1.12	0.77; 1.61	0.217




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Social Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	43/153	33/150	1.57	0.96; 2.57	0.272
ASC4START	71/237	68/247	1.08	0.77; 1.51	0.485
Pooled Analysis	114/390	101/397	1.19	0.91; 1.57	0.225
65 - < 75 years					
ASC4FIRST	11/34	6/29	0.55	0.16; 1.93	0.975
ASC4START	8/38	4/24	2.56	0.62; 10.55	0.954
Pooled Analysis	19/72	10/53	0.95	0.41; 2.17	0.950
>= 75 years					
ASC4FIRST	1/10	1/14	1.79	0.07; 46.86	0.866
ASC4START	2/9	1/13	1.62	0.14; 18.31	0.861
Pooled Analysis	3/19	2/27	1.80	0.22; 14.69	0.982




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Social Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	10/23	4/20	0.82	0.22; 3.01	0.196
ASC4START	11/38	4/37	1.83	0.58; 5.75	0.298
Pooled Analysis	21/61	8/57	1.29	0.55; 3.00	0.100
Intermediate					
ASC4FIRST	14/54	10/53	0.59	0.25; 1.41	0.896
ASC4START	26/75	25/75	1.22	0.69; 2.14	0.874
Pooled Analysis	40/129	35/128	1.01	0.63; 1.62	0.955
Low					
ASC4FIRST	31/120	26/120	1.68	0.98; 2.88	0.292
ASC4START	44/171	44/172	0.98	0.65; 1.49	0.796
Pooled Analysis	75/291	70/292	1.19	0.86; 1.65	0.387




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Social Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	19/64	11/62	1.79	0.75; 4.27	0.270
ASC4START	41/138	40/141	1.26	0.80; 1.96	0.756
Pooled Analysis	60/202	51/203	1.37	0.93; 2.03	0.409
Germany					
ASC4FIRST	1/19	0/15	1.00	0.00; 493.67	0.414
ASC4START	10/72	9/53	0.54	0.18; 1.66	0.535
Pooled Analysis	11/91	9/68	0.54	0.18; 1.64	0.701
Others					
ASC4FIRST	35/114	29/116	1.05	0.62; 1.77	0.842
ASC4START	30/74	24/90	1.21	0.70; 2.09	0.230
Pooled Analysis	65/188	53/206	1.11	0.76; 1.62	0.339




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Social Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	12/41	8/42	0.77	0.27; 2.20	0.316
Pooled Analysis	12/41	8/42	0.77	0.27; 2.20	0.316
Imatinib					
ASC4FIRST	27/101	22/102	1.17	0.64; 2.14	0.584
Pooled Analysis	27/101	22/102	1.17	0.64; 2.14	0.584
Nilotinib					
ASC4FIRST	16/55	10/49	1.75	0.75; 4.05	0.360
ASC4START	81/284	73/284	1.12	0.81; 1.54	0.541
Pooled Analysis	97/339	83/333	1.18	0.87; 1.58	0.360




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Social Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	20/40	15/46	1.38	0.69; 2.78	0.173
Pooled Analysis	50/128	43/132	1.16	0.75; 1.78	0.398
Asian/Others					
ASC4FIRST	30/91	28/90	1.11	0.63; 1.94	0.919
Others					
ASC4START	4/17	4/21	0.86	0.15; 4.82	0.613
Pooled Analysis	4/20	4/25	0.86	0.15; 4.82	0.613
White					
ASC4FIRST	25/106	12/103	1.68	0.79; 3.57	0.026
ASC4START	57/227	54/217	1.04	0.71; 1.52	0.873
Pooled Analysis	82/333	66/320	1.16	0.83; 1.62	0.333




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Satisfaction with Social Life (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	18/68	16/75	0.89	0.43; 1.85	0.523
ASC4START	35/107	29/126	1.33	0.80; 2.20	0.157
Pooled Analysis	53/175	45/201	1.17	0.78; 1.77	0.128
Male					
ASC4FIRST	37/129	24/118	1.38	0.79; 2.40	0.315
ASC4START	46/177	44/158	1.00	0.65; 1.51	0.773
Pooled Analysis	83/306	68/276	1.13	0.81; 1.57	0.685




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	16/153	38/150	0.34	0.19; 0.62	<0.001
ASC4START	13/237	23/247	0.57	0.28; 1.13	0.127
Pooled Analysis	29/390	61/397	0.42	0.27; 0.66	<0.001
65 - < 75 years					
ASC4FIRST	0/34	4/29	0.16	0.01; 4.07	0.066
ASC4START	0/38	3/24	0.00	0.00; 6.70	0.018
Pooled Analysis	0/72	7/53	0.05	0.00; 1.07	0.003
>= 75 years					
ASC4FIRST	2/10	5/14	0.29	0.04; 2.35	0.176
ASC4START	0/9	0/13	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	2/19	5/27	0.29	0.04; 2.35	0.176




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	2/20	0.97	0.14; 6.48	0.895
ASC4START	2/38	1/37	1.22	0.11; 13.97	0.768
Pooled Analysis	5/61	3/57	0.97	0.22; 4.22	0.775
Intermediate					
ASC4FIRST	4/54	10/53	0.22	0.07; 0.73	0.007
ASC4START	4/75	7/75	0.53	0.15; 1.81	0.285
Pooled Analysis	8/129	17/128	0.33	0.14; 0.78	0.007
Low					
ASC4FIRST	11/120	35/120	0.28	0.14; 0.56	<0.001
ASC4START	7/171	18/172	0.40	0.17; 0.97	0.037
Pooled Analysis	18/291	53/292	0.32	0.19; 0.55	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	9/64	17/62	0.34	0.14; 0.84	0.012
ASC4START	6/138	14/141	0.42	0.16; 1.12	0.076
Pooled Analysis	15/202	31/203	0.37	0.19; 0.72	0.002
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	1/72	2/53	0.05	0.00; 4.16	0.201
Pooled Analysis	1/91	2/68	0.05	0.00; 4.16	0.201
Others					
ASC4FIRST	9/114	30/116	0.25	0.12; 0.53	<0.001
ASC4START	6/74	10/90	0.67	0.24; 1.91	0.501
Pooled Analysis	15/188	40/206	0.34	0.19; 0.63	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	6/41	9/42	0.64	0.21; 1.95	0.443
Pooled Analysis	6/41	9/42	0.64	0.21; 1.95	0.443
Imatinib					
ASC4FIRST	7/101	26/102	0.20	0.09; 0.46	<0.001
Pooled Analysis	7/101	26/102	0.20	0.09; 0.46	<0.001
Nilotinib					
ASC4FIRST	5/55	12/49	0.38	0.13; 1.11	0.064
ASC4START	13/284	26/284	0.48	0.24; 0.93	0.031
Pooled Analysis	18/339	38/333	0.45	0.25; 0.79	0.005




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	4/40	9/46	0.54	0.16; 1.80	0.314
Pooled Analysis	11/128	33/132	0.33	0.16; 0.66	<0.001
Asian/Others					
ASC4FIRST	8/91	24/90	0.30	0.13; 0.68	0.002
Others					
ASC4START	2/17	0/21	3.51	0.05; 263.62	0.187
Pooled Analysis	3/20	0/25	3.51	0.05; 263.62	0.187
White					
ASC4FIRST	10/106	23/103	0.37	0.17; 0.78	0.003
ASC4START	7/227	17/217	0.36	0.15; 0.88	0.020
Pooled Analysis	17/333	40/320	0.36	0.20; 0.63	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.2.1: Forest-Plot for EORTC QLQ-CML24: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Symptom Burden (MID=15)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	5/68	23/75	0.19	0.07; 0.49	<0.001
ASC4START	7/107	17/126	0.43	0.18; 1.05	0.050
Pooled Analysis	12/175	40/201	0.28	0.15; 0.54	<0.001
Male					
ASC4FIRST	13/129	24/118	0.39	0.19; 0.79	0.007
ASC4START	6/177	9/158	0.54	0.19; 1.54	0.291
Pooled Analysis	19/306	33/276	0.43	0.24; 0.78	0.004



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-7.3 FACIT GP5: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
V4 (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.799)								
Low	138/291 (47.4)	1.8 [1.0; 3.1]	164/292 (56.2)	0.7 [0.5; 1.0]	0.67	[0.53; 0.84]	0.004	0.145
Intermediate	56/129 (43.4)	5.4 [1.7; N.E.]	66/128 (51.6)	1.0 [0.5; 2.6]	0.57	[0.40; 0.82]	0.009	0.190
High	26/61 (42.6)	1.9 [1.0; N.E.]	29/57 (50.9)	0.8 [0.4; 2.1]	0.58	[0.34; 1.00]	0.064	0.873
Sex								
(Interaction test: p = 0.814)								
Female	82/175	1.0 [0.7; 2.3]	115/201	0.5 [0.5; 1.0]	0.67	[0.50; 0.89]	0.007	0.708

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(46.9)		(57.2)					
Male	138/306	3.1 [1.9; 9.3]	144/276	1.0 [0.7; 1.9]	0.65	[0.51; 0.82]	0.004	0.058
	(45.1)		(52.2)					
Race								
(Interaction test: p = 0.859)								
Asian	56/128	11.0 [2.0; N.E.]	83/132	1.4 [0.5; 2.8]	0.56	[0.39; 0.80]	<0.001	0.048
	(43.8)		(62.9)					
White	155/333	1.7 [1.0; 2.7]	165/320	0.7 [0.5; 1.0]	0.64	[0.51; 0.80]	0.002	0.781
	(46.5)		(51.6)					
Others	9/20	2.1 [0.5; N.E.]	11/25	1.0 [0.4; 7.4]	0.47	[0.16; 1.34]	0.154	N.E.
	(45.0)		(44.0)					
Age groups								
(Interaction test: p = 0.576)								
18 - < 65 years	180/390	2.3 [1.6; 4.4]	209/397	0.9 [0.5; 1.4]	0.65	[0.54; 0.80]	<0.001	0.098
	(46.2)		(52.6)					
65 - < 75 years	33/72	1.2 [0.5; 5.4]	31/53	0.9 [0.5; 2.1]	0.59	[0.34; 1.04]	0.346	0.615

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(45.8)		(58.5)					
>= 75 years	7/19	5.0 [0.3; N.E.]	19/27	0.5 [0.3; 0.8]	0.44	[0.13; 1.47]	0.035	0.359
	(36.8)		(70.4)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.993)								
Imatinib	40/101	1.6 [1.0; 14.8]	58/102	0.9 [0.5; 1.4]	0.61	[0.41; 0.92]	0.029	N.E.
	(39.6)		(56.9)					
Nilotinib	160/339	2.1 [1.6; 5.4]	180/333	0.8 [0.5; 1.1]	0.65	[0.52; 0.81]	<0.001	0.013
	(47.2)		(54.1)					
Dasatinib	20/41	1.9 [0.5; N.E.]	21/42	1.4 [0.3; 6.5]	0.49	[0.25; 0.97]	0.157	N.E.
	(48.8)		(50.0)					
Geographic region								
(Interaction test: p = 0.058)								
Europe excluding Germany	96/202	1.7 [1.0; 4.2]	114/203	0.6 [0.5; 1.0]	0.62	[0.47; 0.82]	0.002	0.518


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(47.5)		(56.2)					
Germany	35/91	1.9 [0.8; 7.4]	34/68	0.4 [0.3; 0.5]	0.33	[0.19; 0.57]	<0.001	0.379
	(38.5)		(50.0)					
Others	89/188	2.8 [1.7; 14.8]	111/206	2.1 [1.0; 2.9]	0.72	[0.54; 0.96]	0.088	0.003
	(47.3)		(53.9)					

MID: Minimally important difference
N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
In this sensitivity analysis a missing assessment before randomization is substituted by the last assessment before or on the day of treatment start, if such an assessment is available.
If there are not at least 10 patients in every subgroup or not more than 10 events per subgroup per treatment arm, no subgroup analyses were performed for the corresponding attribute.
If there are not more than 10 events per subgroup per treatment arm, no Cox PH hazard analysis is carried out.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline PRO score.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates. P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT) and Pre-Randomization selection TKI (IRT).
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	58/153	76/150	0.50	0.35; 0.71	0.002
ASC4START	122/237	133/247	0.74	0.58; 0.95	0.046
Pooled Analysis	180/390	209/397	0.65	0.54; 0.80	<0.001
65 - < 75 years					
ASC4FIRST	13/34	19/29	0.48	0.21; 1.11	0.259
ASC4START	20/38	12/24	0.70	0.32; 1.52	0.831
Pooled Analysis	33/72	31/53	0.59	0.34; 1.04	0.346
>= 75 years					
ASC4FIRST	5/10	9/14	0.29	0.06; 1.49	0.053
ASC4START	2/9	10/13	0.80	0.13; 5.02	0.333
Pooled Analysis	7/19	19/27	0.44	0.13; 1.47	0.035




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	7/23	6/20	0.63	0.20; 2.02	0.415
ASC4START	19/38	23/37	0.57	0.31; 1.05	0.097
Pooled Analysis	26/61	29/57	0.58	0.34; 1.00	0.064
Intermediate					
ASC4FIRST	22/54	32/53	0.40	0.23; 0.71	0.009
ASC4START	34/75	34/75	0.71	0.44; 1.14	0.224
Pooled Analysis	56/129	66/128	0.57	0.40; 0.82	0.009
Low					
ASC4FIRST	47/120	66/120	0.52	0.36; 0.77	0.007
ASC4START	91/171	98/172	0.76	0.57; 1.02	0.111
Pooled Analysis	138/291	164/292	0.67	0.53; 0.84	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	25/64	34/62	0.52	0.30; 0.88	0.025
ASC4START	71/138	80/141	0.66	0.48; 0.91	0.019
Pooled Analysis	96/202	114/203	0.62	0.47; 0.82	0.002
Germany					
ASC4FIRST	3/19	3/15	0.75	0.08; 7.35	1.000
ASC4START	32/72	31/53	0.31	0.17; 0.55	<0.001
Pooled Analysis	35/91	34/68	0.33	0.19; 0.57	<0.001
Others					
ASC4FIRST	48/114	67/116	0.49	0.33; 0.71	0.002
ASC4START	41/74	44/90	1.19	0.77; 1.84	0.374
Pooled Analysis	89/188	111/206	0.72	0.54; 0.96	0.088




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	20/41	21/42	0.49	0.25; 0.97	0.157
Pooled Analysis	20/41	21/42	0.49	0.25; 0.97	0.157
Imatinib					
ASC4FIRST	40/101	58/102	0.61	0.41; 0.92	0.029
Pooled Analysis	40/101	58/102	0.61	0.41; 0.92	0.029
Nilotinib					
ASC4FIRST	16/55	25/49	0.28	0.14; 0.54	0.002
ASC4START	144/284	155/284	0.72	0.57; 0.90	0.014
Pooled Analysis	160/339	180/333	0.65	0.52; 0.81	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	20/40	27/46	0.94	0.51; 1.75	0.573
Pooled Analysis	56/128	83/132	0.56	0.39; 0.80	<0.001
Asian/Others					
ASC4FIRST	38/91	56/90	0.46	0.30; 0.70	<0.001
Others					
ASC4START	7/17	11/21	0.47	0.16; 1.34	0.154
Pooled Analysis	9/20	11/25	0.47	0.16; 1.34	0.154
White					
ASC4FIRST	38/106	48/103	0.55	0.35; 0.86	0.143
ASC4START	117/227	117/217	0.66	0.51; 0.86	0.007
Pooled Analysis	155/333	165/320	0.64	0.51; 0.80	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.3.1: Forest-Plot for FACT-ITEM GP5: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

V4 (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	26/68	41/75	0.62	0.37; 1.03	0.038
ASC4START	56/107	74/126	0.70	0.49; 0.99	0.065
Pooled Analysis	82/175	115/201	0.67	0.50; 0.89	0.007
Male					
ASC4FIRST	50/129	63/118	0.46	0.31; 0.68	0.005
ASC4START	88/177	81/158	0.78	0.57; 1.05	0.146
Pooled Analysis	138/306	144/276	0.65	0.51; 0.82	0.004



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-7.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Headache - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.069)								
Low	136/291 (46.7)	3.3 [2.1; 4.9]	167/292 (57.2)	1.5 [0.8; 2.8]	0.63	[0.50; 0.79]	0.003	0.979
Intermediate	64/129 (49.6)	2.6 [1.6; 4.4]	55/128 (43.0)	2.8 [1.2; 6.5]	1.05	[0.73; 1.51]	0.896	0.348
High	30/61 (49.2)	4.4 [1.9; 11.1]	30/57 (52.6)	1.0 [0.5; 3.4]	0.59	[0.34; 1.01]	0.034	0.809
Sex								
(Interaction test: p = 0.692)								
Female	89/175	2.6 [1.2; 4.2]	113/201	1.2 [0.6; 2.1]	0.74	[0.55; 0.98]	0.045	0.764

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(50.9)		(56.2)					
Male	141/306	3.8 [2.6; 5.6]	139/276	2.2 [1.5; 4.2]	0.72	[0.56; 0.91]	0.031	0.663
	(46.1)		(50.4)					
Race								
(Interaction test: p = 0.082)								
Asian	63/128	4.2 [1.8; 19.4]	81/132	2.1 [1.2; 4.2]	0.66	[0.47; 0.93]	0.036	0.288
	(49.2)		(61.4)					
White	159/333	3.2 [2.1; 4.2]	158/320	1.8 [1.0; 2.8]	0.80	[0.64; 1.00]	0.109	0.822
	(47.7)		(49.4)					
Others	8/20	5.6 [0.4; N.E.]	13/25	0.5 [0.3; 1.4]	0.28	[0.09; 0.91]	0.028	N.E.
	(40.0)		(52.0)					
Age groups								
(Interaction test: p = 0.561)								
18 - < 65 years	191/390	3.5 [2.2; 4.6]	207/397	1.9 [1.2; 2.8]	0.72	[0.59; 0.88]	0.019	0.666
	(49.0)		(52.1)					
65 - < 75 years	31/72	3.8 [1.9; 14.8]	31/53	1.1 [0.5; 3.0]	0.59	[0.34; 1.02]	0.040	0.866

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(43.1)		(58.5)					
>= 75 years	8/19	1.3 [0.3; N.E.]	14/27	1.7 [0.7; 3.1]	3.56	[1.02; 12.40]	0.176	0.110
	(42.1)		(51.9)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.292)								
Imatinib	42/101	3.0 [1.4; 10.2]	48/102	3.0 [1.2; 5.6]	0.95	[0.63; 1.44]	0.913	N.E.
	(41.6)		(47.1)					
Nilotinib	172/339	3.3 [2.1; 4.4]	185/333	1.5 [0.8; 2.3]	0.68	[0.55; 0.84]	0.003	0.887
	(50.7)		(55.6)					
Dasatinib	16/41	6.4 [1.9; N.E.]	19/42	2.1 [0.3; 18.5]	0.50	[0.24; 1.06]	0.067	N.E.
	(39.0)		(45.2)					
Geographic region								
(Interaction test: p = 0.249)								
Europe excluding Germany	103/202	3.5 [2.1; 5.5]	100/203	2.2 [1.0; 5.4]	0.84	[0.63; 1.11]	0.410	0.551

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(51.0)		(49.3)					
Germany	35/91	3.8 [1.9; 5.1]	32/68	0.6 [0.3; 2.8]	0.44	[0.25; 0.76]	0.009	0.515
	(38.5)		(47.1)					
Others	92/188	2.8 [1.9; 5.6]	120/206	1.9 [1.0; 2.8]	0.68	[0.52; 0.90]	0.015	0.688
	(48.9)		(58.3)					
Rash - Presence/Absence (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.117)								
Low	123/291	7.4 [4.7; 12.0]	135/292	3.4 [1.9; 6.5]	0.72	[0.56; 0.92]	0.054	0.660
	(42.3)		(46.2)					
Intermediate	52/129	8.4 [4.2; N.E.]	58/128	2.9 [1.9; 5.7]	0.66	[0.45; 0.97]	0.015	0.099
	(40.3)		(45.3)					
High	16/61	N.E. [11.2; N.E.]	24/57	3.9 [1.0; N.E.]	0.40	[0.21; 0.76]	0.003	0.487
	(26.2)		(42.1)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.699)								
Female	80/175 (45.7)	5.1 [3.1; 11.1]	98/201 (48.8)	2.3 [1.4; 5.1]	0.64	[0.47; 0.87]	0.078	0.794
Male	111/306 (36.3)	13.8 [7.6; N.E.]	119/276 (43.1)	4.2 [2.4; 12.9]	0.70	[0.54; 0.91]	0.003	0.474
Race								
(Interaction test: p = 0.686)								
Asian	58/128 (45.3)	10.2 [4.7; N.E.]	74/132 (56.1)	2.9 [1.4; 9.2]	0.57	[0.40; 0.81]	0.010	0.060
White	128/333 (38.4)	8.4 [5.1; 14.8]	134/320 (41.9)	3.3 [2.0; 6.1]	0.70	[0.55; 0.89]	0.007	0.873
Others	5/20 (25.0)	N.E. [0.5; N.E.]	9/25 (36.0)	3.4 [0.6; N.E.]	0.75	[0.21; 2.60]	0.478	N.E.
Age groups								
(Interaction test: p = 0.898)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	160/390 (41.0)	10.2 [5.4; 13.8]	179/397 (45.1)	3.4 [2.3; 5.6]	0.68	[0.54; 0.84]	0.002	0.832
65 - < 75 years	25/72 (34.7)	16.6 [4.4; N.E.]	25/53 (47.2)	3.4 [1.6; 25.8]	0.64	[0.35; 1.18]	0.207	0.913
>= 75 years	6/19 (31.6)	7.6 [1.2; N.E.]	13/27 (48.1)	1.7 [0.7; 6.3]	0.31	[0.08; 1.19]	0.034	0.345
Pre-randomization selection of TKI								
(Interaction test: p = 0.616)								
Imatinib	35/101 (34.7)	10.2 [5.1; N.E.]	43/102 (42.2)	5.6 [2.5; 17.6]	0.76	[0.48; 1.19]	0.266	N.E.
Nilotinib	138/339 (40.7)	10.2 [5.6; 19.3]	152/333 (45.6)	2.9 [1.7; 5.6]	0.63	[0.50; 0.80]	<0.001	0.924
Dasatinib	18/41 (43.9)	10.2 [1.9; N.E.]	22/42 (52.4)	1.6 [1.2; 6.1]	0.71	[0.36; 1.39]	0.209	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.937)								
Europe excluding Germany	85/202 (42.1)	8.3 [4.5; 16.7]	87/203 (42.9)	3.3 [1.9; 7.4]	0.69	[0.51; 0.94]	0.048	0.930
Germany	26/91 (28.6)	13.0 [2.3; N.E.]	28/68 (41.2)	2.0 [1.4; 8.8]	0.67	[0.38; 1.20]	0.037	0.946
Others	80/188 (42.6)	10.2 [5.6; N.E.]	102/206 (49.5)	4.2 [1.9; 8.4]	0.61	[0.45; 0.83]	0.010	0.219
Diarrhea - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.724)								
Low	132/291 (45.4)	2.4 [1.6; 5.2]	158/292 (54.1)	2.1 [1.2; 2.9]	0.84	[0.67; 1.06]	0.090	0.673
Intermediate	57/129	5.1 [2.3; 17.5]	58/128	2.3 [1.4; 4.9]	0.73	[0.50; 1.06]	0.065	0.064

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(44.2)		(45.3)					
High	27/61	4.0 [1.0; 20.3]	24/57	2.5 [1.4; N.E.]	0.96	[0.55; 1.69]	0.869	0.451
	(44.3)		(42.1)					
Sex								
(Interaction test: p = 0.774)								
Female	75/175	5.1 [2.2; 15.7]	102/201	2.1 [1.2; 2.8]	0.78	[0.57; 1.06]	0.051	0.557
	(42.9)		(50.7)					
Male	141/306	2.8 [1.9; 5.2]	138/276	2.6 [1.4; 3.3]	0.86	[0.68; 1.09]	0.189	0.124
	(46.1)		(50.0)					
Race								
(Interaction test: p = 0.766)								
Asian	67/128	5.2 [2.2; 13.7]	74/132	2.3 [1.5; 5.6]	0.89	[0.63; 1.25]	0.408	0.143
	(52.3)		(56.1)					
White	140/333	2.6 [1.7; 5.1]	158/320	2.1 [1.2; 2.8]	0.79	[0.63; 1.00]	0.033	0.339
	(42.0)		(49.4)					
Others	9/20	13.8 [0.5; 20.3]	8/25	3.2 [0.5; N.E.]	1.01	[0.32; 3.23]	0.936	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(45.0)		(32.0)					
Age groups								
(Interaction test: p = 0.672)								
18 - < 65 years	174/390	3.7 [2.1; 6.7]	197/397	2.6 [1.9; 3.3]	0.86	[0.70; 1.05]	0.059	0.527
	(44.6)		(49.6)					
65 - < 75 years	33/72	3.0 [1.7; 17.5]	28/53	1.6 [0.7; 3.2]	0.78	[0.45; 1.32]	0.380	0.031
	(45.8)		(52.8)					
>= 75 years	9/19	1.9 [0.5; N.E.]	15/27	0.8 [0.5; 1.9]	0.49	[0.17; 1.46]	0.247	0.537
	(47.4)		(55.6)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.038)								
Imatinib	39/101	5.1 [1.0; 17.5]	62/102	0.8 [0.5; 1.4]	0.53	[0.35; 0.80]	0.001	N.E.
	(38.6)		(60.8)					
Nilotinib	155/339	4.0 [2.3; 7.4]	156/333	2.8 [2.1; 4.6]	0.94	[0.75; 1.17]	0.405	0.846
	(45.7)		(46.8)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	22/41 (53.7)	1.2 [0.4; 13.7]	22/42 (52.4)	1.9 [0.5; 11.1]	1.01	[0.55; 1.87]	0.956	N.E.
Geographic region (Interaction test: p = 0.470)								
Europe excluding Germany	102/202 (50.5)	1.7 [1.0; 2.9]	107/203 (52.7)	1.4 [1.0; 2.6]	0.83	[0.63; 1.10]	0.210	0.026
Germany	23/91 (25.3)	N.E. [4.6; N.E.]	25/68 (36.8)	3.3 [0.9; 17.5]	0.64	[0.35; 1.18]	0.115	0.308
Others	91/188 (48.4)	5.1 [2.2; 13.7]	108/206 (52.4)	2.6 [1.9; 4.9]	0.89	[0.67; 1.19]	0.252	0.072
Vomiting - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.678)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Low	40/291 (13.7)	N.E. [N.E.; N.E.]	79/292 (27.1)	N.E. [N.E.; N.E.]	0.45	[0.31; 0.66]	<0.001	0.670
Intermediate	25/129 (19.4)	N.E. [N.E.; N.E.]	36/128 (28.1)	N.E. [5.6; N.E.]	0.49	[0.29; 0.83]	0.010	0.200
High	6/61 (9.8)	N.E. [N.E.; N.E.]	13/57 (22.8)	N.E. [6.5; N.E.]	0.37	[0.14; 0.99]	0.038	0.732
Sex								
(Interaction test: p = 0.346)								
Female	29/175 (16.6)	N.E. [N.E.; N.E.]	66/201 (32.8)	N.E. [5.6; N.E.]	0.40	[0.26; 0.63]	<0.001	0.759
Male	42/306 (13.7)	N.E. [N.E.; N.E.]	62/276 (22.5)	N.E. [N.E.; N.E.]	0.54	[0.37; 0.80]	0.002	0.404
Race								
(Interaction test: p = 0.322)								
Asian	25/128 (19.5)	N.E. [N.E.; N.E.]	52/132 (39.4)	N.E. [5.4; N.E.]	0.39	[0.24; 0.64]	<0.001	0.586

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
White	44/333 (13.2)	N.E. [N.E.; N.E.]	68/320 (21.3)	N.E. [N.E.; N.E.]	0.55	[0.37; 0.81]	0.002	0.768
Others	2/20 (10.0)	N.E. [N.E.; N.E.]	8/25 (32.0)	15.7 [1.2; N.E.]	0.17	[0.02; 1.47]	0.073	N.E.
Age groups (Interaction test: p = 0.869)								
18 - < 65 years	56/390 (14.4)	N.E. [N.E.; N.E.]	105/397 (26.4)	N.E. [N.E.; N.E.]	0.46	[0.33; 0.64]	<0.001	0.798
65 - < 75 years	11/72 (15.3)	N.E. [N.E.; N.E.]	13/53 (24.5)	N.E. [4.6; N.E.]	0.47	[0.19; 1.16]	0.096	0.245
>= 75 years	4/19 (21.1)	22.1 [3.3; N.E.]	10/27 (37.0)	5.4 [1.4; N.E.]	0.26	[0.07; 1.06]	0.045	0.351
Pre-randomization selection of TKI (Interaction test: p = 0.428)								
Imatinib	13/101	N.E. [N.E.; N.E.]	36/102	7.2 [3.1; N.E.]	0.32	[0.17; 0.62]	<0.001	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(12.9)		(35.3)					
Nilotinib	51/339	N.E. [N.E.; N.E.]	79/333	N.E. [N.E.; N.E.]	0.52	[0.36; 0.74]	<0.001	0.551
	(15.0)		(23.7)					
Dasatinib	7/41	N.E. [N.E.; N.E.]	13/42	N.E. [3.0; N.E.]	0.47	[0.18; 1.22]	0.115	N.E.
	(17.1)		(31.0)					
Geographic region								
(Interaction test: p = 0.351)								
Europe excluding Germany	30/202	N.E. [N.E.; N.E.]	42/203	N.E. [N.E.; N.E.]	0.62	[0.38; 1.00]	0.047	0.553
	(14.9)		(20.7)					
Germany	7/91	N.E. [N.E.; N.E.]	11/68	N.E. [N.E.; N.E.]	0.43	[0.16; 1.17]	0.090	0.323
	(7.7)		(16.2)					
Others	34/188	N.E. [N.E.; N.E.]	75/206	22.1 [5.6; N.E.]	0.37	[0.24; 0.56]	<0.001	0.753
	(18.1)		(36.4)					
Nausea - Frequency (MID=1)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.591)								
Low	102/291 (35.1)	25.8 [6.5; N.E.]	141/292 (48.3)	2.3 [1.2; 3.8]	0.61	[0.47; 0.79]	<0.001	0.113
Intermediate	38/129 (29.5)	25.8 [15.7; N.E.]	60/128 (46.9)	2.8 [1.5; 4.9]	0.41	[0.27; 0.63]	<0.001	0.464
High	18/61 (29.5)	N.E. [3.5; N.E.]	23/57 (40.4)	4.9 [2.1; N.E.]	0.68	[0.37; 1.27]	0.214	0.640
Sex								
(Interaction test: p = 0.394)								
Female	66/175 (37.7)	13.8 [3.3; N.E.]	108/201 (53.7)	1.2 [0.6; 1.9]	0.54	[0.40; 0.74]	<0.001	0.494
Male	92/306 (30.1)	N.E. [25.8; N.E.]	116/276 (42.0)	5.3 [3.3; 12.0]	0.61	[0.46; 0.81]	<0.001	0.063

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.162)								
Asian	43/128 (33.6)	N.E. [18.4; N.E.]	75/132 (56.8)	2.8 [1.6; 4.9]	0.44	[0.30; 0.65]	<0.001	0.109
White	108/333 (32.4)	22.1 [8.3; N.E.]	143/320 (44.7)	2.4 [1.4; 4.5]	0.61	[0.47; 0.78]	<0.001	0.428
Others	7/20 (35.0)	N.E. [0.5; N.E.]	6/25 (24.0)	18.4 [0.3; N.E.]	0.72	[0.18; 2.87]	0.797	N.E.
Age groups								
(Interaction test: p = 0.735)								
18 - < 65 years	131/390 (33.6)	25.8 [13.8; N.E.]	181/397 (45.6)	3.5 [2.1; 5.6]	0.59	[0.47; 0.74]	<0.001	0.078
65 - < 75 years	21/72 (29.2)	N.E. [7.4; N.E.]	29/53 (54.7)	1.9 [1.0; 3.9]	0.38	[0.20; 0.73]	0.003	0.292
>= 75 years	6/19 (31.6)	22.1 [0.6; N.E.]	14/27 (51.9)	1.0 [0.5; 2.8]	0.36	[0.09; 1.42]	0.085	0.794

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.007)								
Imatinib	26/101 (25.7)	N.E. [5.3; N.E.]	64/102 (62.7)	0.9 [0.5; 1.4]	0.30	[0.19; 0.48]	<0.001	N.E.
Nilotinib	116/339 (34.2)	25.8 [11.1; N.E.]	139/333 (41.7)	5.6 [3.5; 12.0]	0.68	[0.53; 0.87]	0.002	0.910
Dasatinib	16/41 (39.0)	18.4 [0.7; N.E.]	21/42 (50.0)	1.9 [0.5; 21.2]	0.65	[0.32; 1.31]	0.213	N.E.
Geographic region								
(Interaction test: p = 0.955)								
Europe excluding Germany	67/202 (33.2)	N.E. [9.3; N.E.]	94/203 (46.3)	2.1 [1.2; 4.6]	0.58	[0.42; 0.80]	<0.001	0.671
Germany	26/91 (28.6)	7.4 [2.6; N.E.]	28/68 (41.2)	4.0 [0.8; 11.0]	0.68	[0.38; 1.21]	0.194	0.128

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	65/188 (34.6)	N.E. [11.1; N.E.]	102/206 (49.5)	3.3 [1.9; 5.4]	0.55	[0.40; 0.76]	<0.001	0.035
Edema - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.913)								
Low	86/291 (29.6)	N.E. [18.5; N.E.]	126/292 (43.2)	7.4 [4.2; 12.0]	0.59	[0.44; 0.77]	<0.001	0.070
Intermediate	42/129 (32.6)	22.1 [11.1; N.E.]	50/128 (39.1)	5.6 [3.3; 22.1]	0.61	[0.40; 0.92]	0.018	0.031
High	17/61 (27.9)	N.E. [9.3; N.E.]	17/57 (29.8)	N.E. [1.7; N.E.]	0.77	[0.39; 1.54]	0.462	0.018
Sex (Interaction test: p = 0.767)								
Female	67/175	11.1 [4.9; N.E.]	99/201	3.0 [1.6; 4.5]	0.62	[0.45; 0.86]	0.003	0.002

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(38.3)		(49.3)					
Male	78/306	N.E. [N.E.; N.E.]	94/276	14.8 [11.1; N.E.]	0.64	[0.47; 0.86]	0.004	0.088
	(25.5)		(34.1)					
Race								
(Interaction test: p = 0.135)								
Asian	47/128	N.E. [8.4; N.E.]	78/132	2.1 [1.4; 4.6]	0.49	[0.34; 0.71]	<0.001	0.110
	(36.7)		(59.1)					
White	92/333	24.9 [22.1; N.E.]	108/320	12.0 [7.4; N.E.]	0.68	[0.52; 0.91]	0.007	0.005
	(27.6)		(33.8)					
Others	6/20	N.E. [0.5; N.E.]	7/25	15.7 [1.5; N.E.]	0.96	[0.26; 3.46]	0.957	N.E.
	(30.0)		(28.0)					
Age groups								
(Interaction test: p = 0.712)								
18 - < 65 years	117/390	N.E. [22.1; N.E.]	160/397	11.1 [5.2; 13.8]	0.61	[0.48; 0.78]	<0.001	0.003
	(30.0)		(40.3)					
65 - < 75 years	22/72	N.E. [4.9; N.E.]	24/53	3.9 [1.0; N.E.]	0.49	[0.26; 0.94]	0.046	0.031

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(30.6)		(45.3)					
>= 75 years	6/19	22.1 [0.6; N.E.]	9/27	N.E. [1.1; N.E.]	0.92	[0.26; 3.24]	0.883	0.421
	(31.6)		(33.3)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.012)								
Imatinib	29/101	24.9 [12.0; N.E.]	59/102	1.4 [1.0; 2.2]	0.32	[0.20; 0.51]	<0.001	N.E.
	(28.7)		(57.8)					
Nilotinib	105/339	N.E. [22.1; N.E.]	118/333	13.9 [11.1; N.E.]	0.79	[0.61; 1.03]	0.069	0.230
	(31.0)		(35.4)					
Dasatinib	11/41	N.E. [11.0; N.E.]	16/42	2.1 [0.6; N.E.]	0.48	[0.21; 1.09]	0.089	N.E.
	(26.8)		(38.1)					
Geographic region								
(Interaction test: p = 0.530)								
Europe excluding Germany	56/202	N.E. [19.4; N.E.]	74/203	12.0 [5.6; 24.9]	0.60	[0.42; 0.85]	0.004	0.003

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(27.7)		(36.5)					
Germany	22/91	22.1 [4.2; N.E.]	19/68	13.9 [4.4; N.E.]	0.89	[0.46; 1.69]	0.675	0.195
	(24.2)		(27.9)					
Others	67/188	24.9 [11.1; N.E.]	100/206	3.3 [2.1; 10.2]	0.59	[0.43; 0.81]	0.001	0.030
	(35.6)		(48.5)					
Muscle Pain - Frequency (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.622)								
Low	141/291	1.2 [0.7; 2.0]	177/292	0.8 [0.6; 1.2]	0.74	[0.59; 0.92]	0.008	0.476
	(48.5)		(60.6)					
Intermediate	65/129	1.4 [1.0; 2.8]	64/128	1.2 [0.7; 2.8]	0.90	[0.64; 1.27]	0.438	0.423
	(50.4)		(50.0)					
High	26/61	2.2 [0.7; N.E.]	30/57	1.2 [0.7; 2.4]	0.74	[0.43; 1.26]	0.232	0.557
	(42.6)		(52.6)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.620)								
Female	90/175 (51.4)	0.8 [0.5; 1.4]	124/201 (61.7)	0.8 [0.6; 1.2]	0.83	[0.63; 1.10]	0.097	0.637
Male	142/306 (46.4)	1.9 [1.1; 4.4]	147/276 (53.3)	1.2 [0.7; 2.0]	0.77	[0.61; 0.97]	0.030	0.245
Race								
(Interaction test: p = 0.089)								
Asian	66/128 (51.6)	2.3 [1.0; 10.2]	98/132 (74.2)	0.7 [0.5; 1.0]	0.59	[0.43; 0.82]	<0.001	0.917
White	156/333 (46.8)	1.2 [0.8; 1.9]	164/320 (51.3)	1.1 [0.7; 1.7]	0.87	[0.70; 1.08]	0.175	0.815
Others	10/20 (50.0)	2.2 [0.3; N.E.]	9/25 (36.0)	2.3 [0.4; N.E.]	1.01	[0.33; 3.05]	0.614	N.E.
Age groups								
(Interaction test: p = 0.865)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	186/390 (47.7)	1.4 [1.0; 2.3]	221/397 (55.7)	1.0 [0.7; 1.4]	0.77	[0.64; 0.94]	0.010	0.327
65 - < 75 years	36/72 (50.0)	1.0 [0.6; 3.3]	34/53 (64.2)	1.2 [0.5; 2.1]	0.67	[0.39; 1.13]	0.141	0.615
>= 75 years	10/19 (52.6)	1.1 [0.5; 2.1]	16/27 (59.3)	1.0 [0.3; 1.7]	1.03	[0.38; 2.80]	0.989	0.070
Pre-randomization selection of TKI								
(Interaction test: p = 0.833)								
Imatinib	41/101 (40.6)	1.0 [0.5; 4.2]	62/102 (60.8)	0.8 [0.5; 1.3]	0.68	[0.46; 1.02]	0.062	N.E.
Nilotinib	171/339 (50.4)	1.2 [1.0; 2.0]	189/333 (56.8)	1.1 [0.7; 1.6]	0.80	[0.65; 0.99]	0.026	0.510
Dasatinib	20/41 (48.8)	1.9 [0.5; 10.2]	20/42 (47.6)	1.0 [0.5; 4.6]	0.70	[0.36; 1.37]	0.298	N.E.
Geographic region								


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.789)								
Europe excluding Germany	96/202 (47.5)	1.5 [1.0; 3.0]	106/203 (52.2)	1.2 [0.7; 1.9]	0.84	[0.63; 1.10]	0.174	0.625
Germany	35/91 (38.5)	0.8 [0.5; 2.2]	31/68 (45.6)	0.6 [0.5; 1.7]	0.81	[0.48; 1.36]	0.395	0.987
Others	101/188 (53.7)	1.4 [0.8; 3.8]	134/206 (65.0)	1.0 [0.7; 1.4]	0.70	[0.54; 0.91]	0.007	0.501

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				

MID: Minimally important difference
N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
In this sensitivity analysis a missing assessment before randomization is substituted by the last assessment before or on the day of treatment start, if such an assessment is available.
If there are not at least 10 patients in every subgroup or not more than 10 events per subgroup per treatment arm, no subgroup analyses were performed for the corresponding attribute.
If there are not more than 10 events per subgroup per treatment arm, no Cox PH hazard analysis is carried out.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline PRO score.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates. P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT) and Pre-Randomization selection TKI (IRT).
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Diarrhea - Frequency (MID=1): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	101 (0)	24 (42)	22 (43)	19 (44)	12 (50)	2 (60)	0 (62)
Investigator Selected TKI	102 (0)	12 (32)	7 (35)	6 (35)	2 (38)	1 (39)	0 (40)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Diarrhea - Frequency (MID=1): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	104 (94)	67 (123)	34 (151)	11 (173)	2 (182)	0 (184)
Investigator Selected TKI	333 (0)	93 (100)	56 (129)	32 (148)	13 (165)	2 (175)	0 (177)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Diarrhea - Frequency (MID=1): Pre-randomization selection of TKI: Dasatinib




Pts at Risk (censored)

Asciminib	41 (0)	10 (11)	8 (13)	5 (15)	2 (17)	1 (18)	0 (19)
Investigator Selected TKI	42 (0)	9 (15)	6 (17)	4 (18)	3 (18)	1 (19)	0 (20)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Nausea - Frequency (MID=1): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	101 (0)	36 (42)	29 (47)	27 (48)	12 (63)	3 (72)	0 (75)
Investigator Selected TKI	102 (0)	10 (29)	7 (31)	6 (32)	3 (35)	0 (38)	0 (38)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Nausea - Frequency (MID=1): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	146 (92)	83 (145)	44 (182)	22 (203)	3 (220)	0 (223)
Investigator Selected TKI	333 (0)	103 (108)	63 (137)	34 (163)	10 (185)	3 (191)	0 (194)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Nausea - Frequency (MID=1): Pre-randomization selection of TKI: Dasatinib




Pts at Risk (censored)

Asciminib	41 (0)	14 (12)	12 (14)	9 (17)	6 (19)	2 (23)	0 (25)
Investigator Selected TKI	42 (0)	10 (15)	8 (17)	8 (17)	3 (19)	2 (19)	0 (21)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Frequency (MID=1): Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Frequency (MID=1): Pre-randomization selection of TKI: Nilotinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4 PRO-CTCAE - Frequency: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Edema - Frequency (MID=1): Pre-randomization selection of TKI: Dasatinib




Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	67/153	77/150	0.79	0.56; 1.10	0.121
ASC4START	107/237	120/247	0.89	0.69; 1.16	0.234
Pooled Analysis	174/390	197/397	0.86	0.70; 1.05	0.059
65 - < 75 years					
ASC4FIRST	12/34	19/29	0.42	0.18; 0.94	0.031
ASC4START	21/38	9/24	1.42	0.64; 3.17	0.365
Pooled Analysis	33/72	28/53	0.78	0.45; 1.32	0.380
>= 75 years					
ASC4FIRST	5/10	7/14	0.26	0.04; 1.66	0.237
ASC4START	4/9	8/13	0.69	0.18; 2.71	0.615
Pooled Analysis	9/19	15/27	0.49	0.17; 1.46	0.247




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	10/23	8/20	0.73	0.27; 1.94	0.540
ASC4START	17/38	16/37	1.12	0.57; 2.23	0.820
Pooled Analysis	27/61	24/57	0.96	0.55; 1.69	0.869
Intermediate					
ASC4FIRST	23/54	30/53	0.50	0.28; 0.88	0.006
ASC4START	34/75	28/75	1.00	0.61; 1.65	0.959
Pooled Analysis	57/129	58/128	0.73	0.50; 1.06	0.065
Low					
ASC4FIRST	51/120	65/120	0.78	0.54; 1.13	0.239
ASC4START	81/171	93/172	0.87	0.64; 1.17	0.220
Pooled Analysis	132/291	158/292	0.84	0.67; 1.06	0.090




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	32/64	37/62	0.48	0.28; 0.81	0.040
ASC4START	70/138	70/141	1.02	0.73; 1.42	0.877
Pooled Analysis	102/202	107/203	0.83	0.63; 1.10	0.210
Germany					
ASC4FIRST	2/19	4/15	1.76	0.14; 22.29	0.549
ASC4START	21/72	21/53	0.60	0.32; 1.12	0.072
Pooled Analysis	23/91	25/68	0.64	0.35; 1.18	0.115
Others					
ASC4FIRST	50/114	62/116	0.71	0.49; 1.04	0.045
ASC4START	41/74	46/90	1.17	0.76; 1.81	0.592
Pooled Analysis	91/188	108/206	0.89	0.67; 1.19	0.252




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	22/41	22/42	1.01	0.55; 1.87	0.956
Pooled Analysis	22/41	22/42	1.01	0.55; 1.87	0.956
Imatinib					
ASC4FIRST	39/101	62/102	0.53	0.35; 0.80	0.001
Pooled Analysis	39/101	62/102	0.53	0.35; 0.80	0.001
Nilotinib					
ASC4FIRST	23/55	19/49	0.96	0.51; 1.82	0.920
ASC4START	132/284	137/284	0.93	0.73; 1.18	0.352
Pooled Analysis	155/339	156/333	0.94	0.75; 1.17	0.405




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	24/40	25/46	1.17	0.65; 2.09	0.570
Pooled Analysis	67/128	74/132	0.89	0.63; 1.25	0.408
Asian/Others					
ASC4FIRST	46/91	49/90	0.76	0.50; 1.14	0.174
Others					
ASC4START	6/17	8/21	1.01	0.32; 3.23	0.936
Pooled Analysis	9/20	8/25	1.01	0.32; 3.23	0.936
White					
ASC4FIRST	38/106	54/103	0.65	0.42; 1.00	0.088
ASC4START	102/227	104/217	0.85	0.65; 1.12	0.151
Pooled Analysis	140/333	158/320	0.79	0.63; 1.00	0.033




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Diarrhea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	28/68	41/75	0.73	0.43; 1.22	0.068
ASC4START	47/107	61/126	0.83	0.56; 1.22	0.283
Pooled Analysis	75/175	102/201	0.78	0.57; 1.06	0.051
Male					
ASC4FIRST	56/129	62/118	0.67	0.46; 0.98	0.101
ASC4START	85/177	76/158	1.00	0.73; 1.37	0.724
Pooled Analysis	141/306	138/276	0.86	0.68; 1.09	0.189




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	40/153	71/150	0.38	0.25; 0.56	<0.001
ASC4START	77/237	89/247	0.82	0.60; 1.11	0.180
Pooled Analysis	117/390	160/397	0.61	0.48; 0.78	<0.001
65 - < 75 years					
ASC4FIRST	9/34	18/29	0.23	0.08; 0.62	0.003
ASC4START	13/38	6/24	1.10	0.41; 2.95	0.782
Pooled Analysis	22/72	24/53	0.49	0.26; 0.94	0.046
>= 75 years					
ASC4FIRST	5/10	6/14	1.86	0.32; 10.76	0.713
ASC4START	1/9	3/13	0.44	0.04; 4.43	0.472
Pooled Analysis	6/19	9/27	0.92	0.26; 3.24	0.883




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	8/20	0.08	0.01; 0.50	0.005
ASC4START	14/38	9/37	1.30	0.56; 3.01	0.366
Pooled Analysis	17/61	17/57	0.77	0.39; 1.54	0.462
Intermediate					
ASC4FIRST	19/54	30/53	0.39	0.21; 0.70	0.001
ASC4START	23/75	20/75	0.98	0.54; 1.79	0.917
Pooled Analysis	42/129	50/128	0.61	0.40; 0.92	0.018
Low					
ASC4FIRST	32/120	57/120	0.43	0.28; 0.67	<0.001
ASC4START	54/171	69/172	0.73	0.51; 1.04	0.069
Pooled Analysis	86/291	126/292	0.59	0.44; 0.77	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	14/64	31/62	0.25	0.13; 0.49	<0.001
ASC4START	42/138	43/141	0.88	0.58; 1.36	0.535
Pooled Analysis	56/202	74/203	0.60	0.42; 0.85	0.004
Germany					
ASC4FIRST	3/19	3/15	8.35	0.27; 261.60	0.303
ASC4START	19/72	16/53	0.76	0.39; 1.50	0.425
Pooled Analysis	22/91	19/68	0.89	0.46; 1.69	0.675
Others					
ASC4FIRST	37/114	61/116	0.44	0.29; 0.67	<0.001
ASC4START	30/74	39/90	0.89	0.55; 1.46	0.674
Pooled Analysis	67/188	100/206	0.59	0.43; 0.81	0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	11/41	16/42	0.48	0.21; 1.09	0.089
Pooled Analysis	11/41	16/42	0.48	0.21; 1.09	0.089
Imatinib					
ASC4FIRST	29/101	59/102	0.32	0.20; 0.51	<0.001
Pooled Analysis	29/101	59/102	0.32	0.20; 0.51	<0.001
Nilotinib					
ASC4FIRST	14/55	20/49	0.53	0.27; 1.07	0.066
ASC4START	91/284	98/284	0.85	0.64; 1.13	0.226
Pooled Analysis	105/339	118/333	0.79	0.61; 1.03	0.069




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	17/40	25/46	0.74	0.40; 1.38	0.303
Pooled Analysis	47/128	78/132	0.49	0.34; 0.71	<0.001
Asian/Others					
ASC4FIRST	31/91	53/90	0.41	0.26; 0.64	<0.001
Others					
ASC4START	5/17	7/21	0.96	0.26; 3.46	0.957
Pooled Analysis	6/20	7/25	0.96	0.26; 3.46	0.957
White					
ASC4FIRST	23/106	42/103	0.35	0.20; 0.60	<0.001
ASC4START	69/227	66/217	0.90	0.64; 1.26	0.501
Pooled Analysis	92/333	108/320	0.68	0.52; 0.91	0.007




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	20/68	45/75	0.30	0.17; 0.53	<0.001
ASC4START	47/107	54/126	0.93	0.62; 1.37	0.648
Pooled Analysis	67/175	99/201	0.62	0.45; 0.86	0.003
Male					
ASC4FIRST	34/129	50/118	0.48	0.31; 0.75	0.001
ASC4START	44/177	44/158	0.82	0.54; 1.25	0.354
Pooled Analysis	78/306	94/276	0.64	0.47; 0.86	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	70/153	69/150	0.75	0.53; 1.07	0.501
ASC4START	121/237	138/247	0.70	0.55; 0.90	0.017
Pooled Analysis	191/390	207/397	0.72	0.59; 0.88	0.019
65 - < 75 years					
ASC4FIRST	13/34	17/29	0.61	0.27; 1.40	0.186
ASC4START	18/38	14/24	0.56	0.27; 1.18	0.114
Pooled Analysis	31/72	31/53	0.59	0.34; 1.02	0.040
>= 75 years					
ASC4FIRST	3/10	6/14	1.31	0.26; 6.68	0.872
ASC4START	5/9	8/13	12.84	1.39; 118.50	0.039
Pooled Analysis	8/19	14/27	3.56	1.02; 12.40	0.176




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	10/23	8/20	0.54	0.18; 1.63	0.175
ASC4START	20/38	22/37	0.61	0.33; 1.13	0.096
Pooled Analysis	30/61	30/57	0.59	0.34; 1.01	0.034
Intermediate					
ASC4FIRST	27/54	22/53	1.32	0.74; 2.33	0.453
ASC4START	37/75	33/75	0.91	0.57; 1.45	0.645
Pooled Analysis	64/129	55/128	1.05	0.73; 1.51	0.896
Low					
ASC4FIRST	49/120	62/120	0.62	0.42; 0.92	0.118
ASC4START	87/171	105/172	0.63	0.48; 0.84	0.009
Pooled Analysis	136/291	167/292	0.63	0.50; 0.79	0.003




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	30/64	26/62	0.94	0.54; 1.64	0.877
ASC4START	73/138	74/141	0.80	0.58; 1.11	0.293
Pooled Analysis	103/202	100/203	0.84	0.63; 1.11	0.410
Germany					
ASC4FIRST	2/19	5/15	0.53	0.07; 3.98	0.647
ASC4START	33/72	27/53	0.41	0.23; 0.73	0.009
Pooled Analysis	35/91	32/68	0.44	0.25; 0.76	0.009
Others					
ASC4FIRST	54/114	61/116	0.73	0.50; 1.07	0.233
ASC4START	38/74	59/90	0.64	0.43; 0.97	0.022
Pooled Analysis	92/188	120/206	0.68	0.52; 0.90	0.015




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	16/41	19/42	0.50	0.24; 1.06	0.067
Pooled Analysis	16/41	19/42	0.50	0.24; 1.06	0.067
Imatinib					
ASC4FIRST	42/101	48/102	0.95	0.63; 1.44	0.913
Pooled Analysis	42/101	48/102	0.95	0.63; 1.44	0.913
Nilotinib					
ASC4FIRST	28/55	25/49	0.60	0.33; 1.08	0.489
ASC4START	144/284	160/284	0.69	0.55; 0.86	0.004
Pooled Analysis	172/339	185/333	0.68	0.55; 0.84	0.003




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	20/40	35/46	0.52	0.30; 0.91	0.020
Pooled Analysis	63/128	81/132	0.66	0.47; 0.93	0.036
Asian/Others					
ASC4FIRST	46/91	46/90	0.80	0.52; 1.21	0.502
Others					
ASC4START	5/17	13/21	0.28	0.09; 0.91	0.028
Pooled Analysis	8/20	13/25	0.28	0.09; 0.91	0.028
White					
ASC4FIRST	40/106	46/103	0.83	0.53; 1.29	0.503
ASC4START	119/227	112/217	0.79	0.61; 1.02	0.143
Pooled Analysis	159/333	158/320	0.80	0.64; 1.00	0.109




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	32/68	38/75	0.78	0.48; 1.29	0.553
ASC4START	57/107	75/126	0.71	0.50; 1.01	0.042
Pooled Analysis	89/175	113/201	0.74	0.55; 0.98	0.045
Male					
ASC4FIRST	54/129	54/118	0.76	0.51; 1.12	0.348
ASC4START	87/177	85/158	0.69	0.51; 0.94	0.045
Pooled Analysis	141/306	139/276	0.72	0.56; 0.91	0.031




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	67/153	84/150	0.68	0.49; 0.94	0.026
ASC4START	119/237	137/247	0.83	0.65; 1.07	0.126
Pooled Analysis	186/390	221/397	0.77	0.64; 0.94	0.010
65 - < 75 years					
ASC4FIRST	14/34	19/29	0.74	0.35; 1.58	0.462
ASC4START	22/38	15/24	0.57	0.27; 1.18	0.175
Pooled Analysis	36/72	34/53	0.67	0.39; 1.13	0.141
>= 75 years					
ASC4FIRST	5/10	7/14	6.37	0.90; 44.93	0.274
ASC4START	5/9	9/13	0.41	0.09; 1.88	0.286
Pooled Analysis	10/19	16/27	1.03	0.38; 2.80	0.989




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	10/23	8/20	0.92	0.36; 2.38	0.888
ASC4START	16/38	22/37	0.67	0.35; 1.28	0.178
Pooled Analysis	26/61	30/57	0.74	0.43; 1.26	0.232
Intermediate					
ASC4FIRST	24/54	26/53	0.75	0.43; 1.32	0.422
ASC4START	41/75	38/75	1.01	0.64; 1.57	0.723
Pooled Analysis	65/129	64/128	0.90	0.64; 1.27	0.438
Low					
ASC4FIRST	52/120	76/120	0.67	0.46; 0.95	0.019
ASC4START	89/171	101/172	0.79	0.59; 1.05	0.125
Pooled Analysis	141/291	177/292	0.74	0.59; 0.92	0.008




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	26/64	34/62	0.78	0.46; 1.32	0.193
ASC4START	70/138	72/141	0.87	0.63; 1.21	0.433
Pooled Analysis	96/202	106/203	0.84	0.63; 1.10	0.174
Germany					
ASC4FIRST	2/19	3/15	20.22	0.22; >1000	0.090
ASC4START	33/72	28/53	0.74	0.43; 1.25	0.232
Pooled Analysis	35/91	31/68	0.81	0.48; 1.36	0.395
Others					
ASC4FIRST	58/114	73/116	0.65	0.45; 0.93	0.026
ASC4START	43/74	61/90	0.78	0.52; 1.16	0.115
Pooled Analysis	101/188	134/206	0.70	0.54; 0.91	0.007




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	20/41	20/42	0.70	0.36; 1.37	0.298
Pooled Analysis	20/41	20/42	0.70	0.36; 1.37	0.298
Imatinib					
ASC4FIRST	41/101	62/102	0.68	0.46; 1.02	0.062
Pooled Analysis	41/101	62/102	0.68	0.46; 1.02	0.062
Nilotinib					
ASC4FIRST	25/55	28/49	0.67	0.38; 1.17	0.173
ASC4START	146/284	161/284	0.82	0.66; 1.03	0.063
Pooled Analysis	171/339	189/333	0.80	0.65; 0.99	0.026




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	21/40	37/46	0.60	0.35; 1.05	0.030
Pooled Analysis	66/128	98/132	0.59	0.43; 0.82	<0.001
Asian/Others					
ASC4FIRST	47/91	61/90	0.60	0.40; 0.88	0.010
Others					
ASC4START	8/17	9/21	1.01	0.33; 3.05	0.614
Pooled Analysis	10/20	9/25	1.01	0.33; 3.05	0.614
White					
ASC4FIRST	39/106	49/103	0.91	0.59; 1.40	0.585
ASC4START	117/227	115/217	0.85	0.66; 1.10	0.209
Pooled Analysis	156/333	164/320	0.87	0.70; 1.08	0.175




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	29/68	46/75	0.93	0.57; 1.50	0.476
ASC4START	61/107	78/126	0.79	0.56; 1.12	0.126
Pooled Analysis	90/175	124/201	0.83	0.63; 1.10	0.097
Male					
ASC4FIRST	57/129	64/118	0.65	0.45; 0.94	0.028
ASC4START	85/177	83/158	0.86	0.64; 1.17	0.315
Pooled Analysis	142/306	147/276	0.77	0.61; 0.97	0.030




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	50/153	79/150	0.46	0.32; 0.67	<0.001
ASC4START	81/237	102/247	0.70	0.52; 0.94	0.018
Pooled Analysis	131/390	181/397	0.59	0.47; 0.74	<0.001
65 - < 75 years					
ASC4FIRST	7/34	18/29	0.21	0.06; 0.70	0.005
ASC4START	14/38	11/24	0.50	0.21; 1.19	0.178
Pooled Analysis	21/72	29/53	0.38	0.20; 0.73	0.003
>= 75 years					
ASC4FIRST	4/10	8/14	0.41	0.07; 2.43	0.238
ASC4START	2/9	6/13	0.32	0.03; 2.91	0.208
Pooled Analysis	6/19	14/27	0.36	0.09; 1.42	0.085




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	5/23	8/20	0.54	0.17; 1.71	0.205
ASC4START	13/38	15/37	0.75	0.36; 1.59	0.519
Pooled Analysis	18/61	23/57	0.68	0.37; 1.27	0.214
Intermediate					
ASC4FIRST	16/54	30/53	0.34	0.18; 0.64	<0.001
ASC4START	22/75	30/75	0.48	0.27; 0.85	0.007
Pooled Analysis	38/129	60/128	0.41	0.27; 0.63	<0.001
Low					
ASC4FIRST	40/120	67/120	0.48	0.32; 0.72	<0.001
ASC4START	62/171	74/172	0.73	0.52; 1.03	0.083
Pooled Analysis	102/291	141/292	0.61	0.47; 0.79	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	20/64	34/62	0.53	0.29; 0.94	0.013
ASC4START	47/138	60/141	0.61	0.41; 0.89	0.008
Pooled Analysis	67/202	94/203	0.58	0.42; 0.80	<0.001
Germany					
ASC4FIRST	2/19	4/15	2.88	0.24; 34.58	0.225
ASC4START	24/72	24/53	0.60	0.34; 1.09	0.113
Pooled Analysis	26/91	28/68	0.68	0.38; 1.21	0.194
Others					
ASC4FIRST	39/114	67/116	0.43	0.29; 0.64	<0.001
ASC4START	26/74	35/90	0.86	0.51; 1.44	0.536
Pooled Analysis	65/188	102/206	0.55	0.40; 0.76	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	16/41	21/42	0.65	0.32; 1.31	0.213
Pooled Analysis	16/41	21/42	0.65	0.32; 1.31	0.213
Imatinib					
ASC4FIRST	26/101	64/102	0.30	0.19; 0.48	<0.001
Pooled Analysis	26/101	64/102	0.30	0.19; 0.48	<0.001
Nilotinib					
ASC4FIRST	19/55	20/49	0.67	0.35; 1.26	0.370
ASC4START	97/284	119/284	0.67	0.51; 0.88	0.004
Pooled Analysis	116/339	139/333	0.68	0.53; 0.87	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	14/40	22/46	0.70	0.36; 1.38	0.276
Pooled Analysis	43/128	75/132	0.44	0.30; 0.65	<0.001
Asian/Others					
ASC4FIRST	31/91	53/90	0.38	0.24; 0.61	<0.001
Others					
ASC4START	5/17	6/21	0.72	0.18; 2.87	0.797
Pooled Analysis	7/20	6/25	0.72	0.18; 2.87	0.797
White					
ASC4FIRST	30/106	52/103	0.51	0.32; 0.81	0.002
ASC4START	78/227	91/217	0.65	0.48; 0.88	0.004
Pooled Analysis	108/333	143/320	0.61	0.47; 0.78	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	22/68	46/75	0.45	0.26; 0.76	0.001
ASC4START	44/107	62/126	0.59	0.40; 0.87	0.010
Pooled Analysis	66/175	108/201	0.54	0.40; 0.74	<0.001
Male					
ASC4FIRST	39/129	59/118	0.46	0.31; 0.70	<0.001
ASC4START	53/177	57/158	0.78	0.54; 1.14	0.147
Pooled Analysis	92/306	116/276	0.61	0.46; 0.81	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Rash - Presence/Absence (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	61/153	67/150	0.70	0.49; 0.99	0.050
ASC4START	99/237	112/247	0.66	0.50; 0.87	0.013
Pooled Analysis	160/390	179/397	0.68	0.54; 0.84	0.002
65 - < 75 years					
ASC4FIRST	11/34	16/29	0.62	0.26; 1.47	0.220
ASC4START	14/38	9/24	0.66	0.28; 1.58	0.584
Pooled Analysis	25/72	25/53	0.64	0.35; 1.18	0.207
>= 75 years					
ASC4FIRST	4/10	6/14	0.60	0.10; 3.75	0.405
ASC4START	2/9	7/13	0.15	0.02; 1.35	0.032
Pooled Analysis	6/19	13/27	0.31	0.08; 1.19	0.034




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Rash - Presence/Absence (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	6/20	0.25	0.06; 1.10	0.049
ASC4START	13/38	18/37	0.45	0.22; 0.92	0.020
Pooled Analysis	16/61	24/57	0.40	0.21; 0.76	0.003
Intermediate					
ASC4FIRST	23/54	23/53	0.97	0.54; 1.74	0.583
ASC4START	29/75	35/75	0.51	0.31; 0.83	0.006
Pooled Analysis	52/129	58/128	0.66	0.45; 0.97	0.015
Low					
ASC4FIRST	50/120	60/120	0.67	0.46; 0.98	0.075
ASC4START	73/171	75/172	0.75	0.54; 1.04	0.313
Pooled Analysis	123/291	135/292	0.72	0.56; 0.92	0.054




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Rash - Presence/Absence (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	25/64	26/62	0.71	0.39; 1.28	0.315
ASC4START	60/138	61/141	0.68	0.48; 0.98	0.089
Pooled Analysis	85/202	87/203	0.69	0.51; 0.94	0.048
Germany					
ASC4FIRST	2/19	5/15	0.62	0.05; 7.00	0.170
ASC4START	24/72	23/53	0.67	0.37; 1.22	0.078
Pooled Analysis	26/91	28/68	0.67	0.38; 1.20	0.037
Others					
ASC4FIRST	49/114	58/116	0.71	0.48; 1.05	0.086
ASC4START	31/74	44/90	0.48	0.29; 0.79	0.052
Pooled Analysis	80/188	102/206	0.61	0.45; 0.83	0.010




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Rash - Presence/Absence (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	18/41	22/42	0.71	0.36; 1.39	0.209
Pooled Analysis	18/41	22/42	0.71	0.36; 1.39	0.209
Imatinib					
ASC4FIRST	35/101	43/102	0.76	0.48; 1.19	0.266
Pooled Analysis	35/101	43/102	0.76	0.48; 1.19	0.266
Nilotinib					
ASC4FIRST	23/55	24/49	0.62	0.34; 1.10	0.135
ASC4START	115/284	128/284	0.63	0.49; 0.82	0.003
Pooled Analysis	138/339	152/333	0.63	0.50; 0.80	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Rash - Presence/Absence (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	14/40	26/46	0.32	0.16; 0.65	0.009
Pooled Analysis	58/128	74/132	0.57	0.40; 0.81	0.010
Asian/Others					
ASC4FIRST	45/91	48/90	0.71	0.47; 1.07	0.178
Others					
ASC4START	4/17	9/21	0.75	0.21; 2.60	0.478
Pooled Analysis	5/20	9/25	0.75	0.21; 2.60	0.478
White					
ASC4FIRST	31/106	41/103	0.67	0.41; 1.10	0.054
ASC4START	97/227	93/217	0.71	0.53; 0.94	0.047
Pooled Analysis	128/333	134/320	0.70	0.55; 0.89	0.007




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Rash - Presence/Absence (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	26/68	35/75	0.60	0.35; 1.04	0.263
ASC4START	54/107	63/126	0.66	0.45; 0.95	0.171
Pooled Analysis	80/175	98/201	0.64	0.47; 0.87	0.078
Male					
ASC4FIRST	50/129	54/118	0.78	0.52; 1.15	0.081
ASC4START	61/177	65/158	0.64	0.45; 0.91	0.014
Pooled Analysis	111/306	119/276	0.70	0.54; 0.91	0.003




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	24/153	44/150	0.49	0.29; 0.80	0.004
ASC4START	32/237	61/247	0.45	0.29; 0.69	<0.001
Pooled Analysis	56/390	105/397	0.46	0.33; 0.64	<0.001
65 - < 75 years					
ASC4FIRST	4/34	9/29	0.24	0.05; 1.14	0.053
ASC4START	7/38	4/24	0.79	0.22; 2.78	0.717
Pooled Analysis	11/72	13/53	0.47	0.19; 1.16	0.096
>= 75 years					
ASC4FIRST	3/10	8/14	0.19	0.04; 0.96	0.027
ASC4START	1/9	2/13	0.87	0.05; 13.95	0.919
Pooled Analysis	4/19	10/27	0.26	0.07; 1.06	0.045




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	5/20	0.26	0.05; 1.38	0.147
ASC4START	4/38	8/37	0.39	0.11; 1.37	0.133
Pooled Analysis	6/61	13/57	0.37	0.14; 0.99	0.038
Intermediate					
ASC4FIRST	11/54	22/53	0.36	0.17; 0.75	0.006
ASC4START	14/75	14/75	0.70	0.33; 1.48	0.424
Pooled Analysis	25/129	36/128	0.49	0.29; 0.83	0.010
Low					
ASC4FIRST	18/120	34/120	0.50	0.28; 0.89	0.015
ASC4START	22/171	45/172	0.42	0.25; 0.70	<0.001
Pooled Analysis	40/291	79/292	0.45	0.31; 0.66	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	9/64	16/62	0.52	0.22; 1.22	0.103
ASC4START	21/138	26/141	0.68	0.38; 1.22	0.200
Pooled Analysis	30/202	42/203	0.62	0.38; 1.00	0.047
Germany					
ASC4FIRST	2/19	3/15	1.28	0.11; 14.56	0.841
ASC4START	5/72	8/53	0.33	0.11; 1.03	0.046
Pooled Analysis	7/91	11/68	0.43	0.16; 1.17	0.090
Others					
ASC4FIRST	20/114	42/116	0.39	0.23; 0.67	<0.001
ASC4START	14/74	33/90	0.34	0.17; 0.68	0.001
Pooled Analysis	34/188	75/206	0.37	0.24; 0.56	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	7/41	13/42	0.47	0.18; 1.22	0.115
Pooled Analysis	7/41	13/42	0.47	0.18; 1.22	0.115
Imatinib					
ASC4FIRST	13/101	36/102	0.32	0.17; 0.62	<0.001
Pooled Analysis	13/101	36/102	0.32	0.17; 0.62	<0.001
Nilotinib					
ASC4FIRST	11/55	12/49	0.63	0.28; 1.45	0.307
ASC4START	40/284	67/284	0.49	0.33; 0.73	<0.001
Pooled Analysis	51/339	79/333	0.52	0.36; 0.74	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	8/40	17/46	0.48	0.20; 1.12	0.079
Pooled Analysis	25/128	52/132	0.39	0.24; 0.64	<0.001
Asian/Others					
ASC4FIRST	18/91	35/90	0.37	0.21; 0.67	<0.001
Others					
ASC4START	1/17	8/21	0.17	0.02; 1.47	0.073
Pooled Analysis	2/20	8/25	0.17	0.02; 1.47	0.073
White					
ASC4FIRST	13/106	26/103	0.46	0.23; 0.93	0.045
ASC4START	31/227	42/217	0.57	0.36; 0.91	0.017
Pooled Analysis	44/333	68/320	0.55	0.37; 0.81	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.4.1: Forest-Plot for PRO-CTCAE - Frequency: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Frequency (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	12/68	27/75	0.43	0.21; 0.87	0.019
ASC4START	17/107	39/126	0.39	0.22; 0.69	<0.001
Pooled Analysis	29/175	66/201	0.40	0.26; 0.63	<0.001
Male					
ASC4FIRST	19/129	34/118	0.45	0.26; 0.80	0.006
ASC4START	23/177	28/158	0.64	0.37; 1.12	0.114
Pooled Analysis	42/306	62/276	0.54	0.37; 0.80	0.002



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-7.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Fatigue - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.655)								
Low	137/291 (47.1)	2.1 [1.2; 5.1]	156/292 (53.4)	1.2 [1.0; 2.3]	0.81	[0.64; 1.02]	0.176	0.128
Intermediate	60/129 (46.5)	7.4 [2.1; 18.5]	60/128 (46.9)	2.8 [0.8; 6.0]	0.75	[0.52; 1.08]	0.100	0.375
High	21/61 (34.4)	N.E. [2.2; N.E.]	23/57 (40.4)	11.0 [0.5; N.E.]	0.53	[0.29; 0.98]	0.187	0.981
Sex								
(Interaction test: p = 0.172)								
Female	79/175	2.2 [1.0; 13.8]	113/201	1.1 [0.7; 2.3]	0.68	[0.50; 0.92]	0.022	0.160

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(45.1)		(56.2)					
Male	139/306	3.9 [2.2; 10.2]	126/276	2.6 [1.1; 5.6]	0.87	[0.68; 1.11]	0.403	0.919
	(45.4)		(45.7)					
Race								
(Interaction test: p = 0.167)								
Asian	66/128	3.8 [1.1; 21.2]	75/132	2.1 [0.9; 5.6]	0.82	[0.58; 1.15]	0.306	0.958
	(51.6)		(56.8)					
White	144/333	4.9 [2.0; 11.1]	160/320	1.1 [0.9; 2.3]	0.70	[0.55; 0.88]	0.005	0.245
	(43.2)		(50.0)					
Others	8/20	2.8 [0.3; N.E.]	4/25	N.E. [11.0; N.E.]	1.78	[0.33; 9.65]	0.066	N.E.
	(40.0)		(16.0)					
Age groups								
(Interaction test: p = 0.388)								
18 - < 65 years	182/390	3.0 [1.9; 9.0]	192/397	2.3 [1.1; 3.8]	0.83	[0.67; 1.01]	0.263	0.712
	(46.7)		(48.4)					
65 - < 75 years	27/72	15.7 [1.6; N.E.]	33/53	0.7 [0.5; 2.1]	0.62	[0.35; 1.08]	0.033	0.440

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(37.5)		(62.3)					
>= 75 years	9/19	8.3 [0.5; N.E.]	14/27	0.5 [0.3; 6.0]	0.75	[0.25; 2.29]	0.330	0.705
	(47.4)		(51.9)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.363)								
Imatinib	41/101	1.0 [0.5; 8.4]	50/102	1.4 [0.5; 4.2]	0.91	[0.60; 1.38]	0.608	N.E.
	(40.6)		(49.0)					
Nilotinib	158/339	4.0 [2.1; 11.1]	165/333	2.2 [1.0; 3.5]	0.77	[0.62; 0.96]	0.077	0.235
	(46.6)		(49.5)					
Dasatinib	19/41	8.4 [1.0; 26.7]	24/42	0.5 [0.3; 2.3]	0.46	[0.23; 0.89]	0.017	N.E.
	(46.3)		(57.1)					
Geographic region								
(Interaction test: p = 0.735)								
Europe excluding Germany	93/202	2.7 [1.4; 11.1]	102/203	1.1 [0.8; 2.8]	0.77	[0.58; 1.02]	0.129	0.864

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(46.0)		(50.2)					
Germany	37/91	2.3 [0.8; 11.1]	30/68	1.0 [0.5; 3.1]	0.63	[0.37; 1.07]	0.322	0.475
	(40.7)		(44.1)					
Others	88/188	4.5 [2.1; 22.1]	107/206	2.3 [1.2; 5.6]	0.82	[0.61; 1.09]	0.219	0.392
	(46.8)		(51.9)					
Headache - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.462)								
Low	140/291	2.8 [1.9; 4.2]	160/292	1.8 [1.0; 3.0]	0.74	[0.59; 0.94]	0.096	0.333
	(48.1)		(54.8)					
Intermediate	59/129	2.8 [1.9; 10.8]	54/128	2.3 [1.1; 8.3]	0.95	[0.66; 1.38]	0.645	0.232
	(45.7)		(42.2)					
High	28/61	4.4 [2.1; N.E.]	29/57	1.7 [0.5; 3.7]	0.66	[0.39; 1.12]	0.068	0.770
	(45.9)		(50.9)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.385)								
Female	90/175 (51.4)	1.9 [1.2; 3.0]	108/201 (53.7)	1.2 [0.8; 2.1]	0.88	[0.66; 1.17]	0.429	0.626
Male	137/306 (44.8)	3.7 [2.6; 9.0]	135/276 (48.9)	2.3 [1.5; 4.4]	0.74	[0.58; 0.94]	0.048	0.732
Race								
(Interaction test: p = 0.274)								
Asian	63/128 (49.2)	4.2 [1.8; 19.4]	80/132 (60.6)	1.9 [1.0; 4.2]	0.69	[0.50; 0.97]	0.046	0.283
White	157/333 (47.1)	2.6 [2.1; 3.7]	152/320 (47.5)	1.9 [1.1; 3.3]	0.86	[0.68; 1.08]	0.360	0.776
Others	7/20 (35.0)	13.8 [0.5; N.E.]	11/25 (44.0)	2.2 [0.4; 15.7]	0.48	[0.13; 1.78]	0.254	N.E.
Age groups								
(Interaction test: p = 0.355)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	191/390 (49.0)	2.8 [2.1; 4.2]	203/397 (51.1)	1.9 [1.2; 3.3]	0.79	[0.65; 0.97]	0.116	0.845
65 - < 75 years	28/72 (38.9)	4.2 [1.9; N.E.]	28/53 (52.8)	1.7 [0.6; 7.4]	0.66	[0.36; 1.19]	0.113	0.934
>= 75 years	8/19 (42.1)	1.3 [0.3; N.E.]	12/27 (44.4)	1.7 [0.7; N.E.]	14.30	[1.72; 118.91]	0.060	0.997
Pre-randomization selection of TKI								
(Interaction test: p = 0.837)								
Imatinib	37/101 (36.6)	3.0 [1.8; N.E.]	48/102 (47.1)	2.0 [1.0; 5.6]	0.85	[0.56; 1.32]	0.340	N.E.
Nilotinib	172/339 (50.7)	2.8 [2.1; 4.2]	179/333 (53.8)	1.8 [1.1; 3.0]	0.76	[0.61; 0.94]	0.051	0.513
Dasatinib	18/41 (43.9)	5.1 [1.6; N.E.]	16/42 (38.1)	2.1 [0.5; N.E.]	0.76	[0.36; 1.58]	0.517	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.746)								
Europe excluding Germany	97/202 (48.0)	2.8 [2.1; 5.4]	98/203 (48.3)	1.9 [1.0; 5.6]	0.82	[0.62; 1.09]	0.307	0.807
Germany	41/91 (45.1)	2.3 [1.6; 3.9]	28/68 (41.2)	1.4 [0.5; 4.6]	0.84	[0.48; 1.45]	0.968	0.092
Others	89/188 (47.3)	3.2 [2.0; 11.0]	117/206 (56.8)	1.9 [1.2; 3.3]	0.73	[0.55; 0.96]	0.034	0.909
Vomiting - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.959)								
Low	36/291 (12.4)	N.E. [N.E.; N.E.]	75/292 (25.7)	N.E. [N.E.; N.E.]	0.43	[0.29; 0.64]	<0.001	0.955
Intermediate	19/129	N.E. [N.E.; N.E.]	33/128	N.E. [10.0; N.E.]	0.42	[0.24; 0.74]	0.002	0.054

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(14.7)		(25.8)					
High	6/61	N.E. [N.E.; N.E.]	12/57	N.E. [13.8; N.E.]	0.42	[0.16; 1.13]	0.073	0.607
	(9.8)		(21.1)					
Sex								
(Interaction test: p = 0.543)								
Female	25/175	N.E. [N.E.; N.E.]	60/201	N.E. [13.0; N.E.]	0.39	[0.24; 0.63]	<0.001	0.812
	(14.3)		(29.9)					
Male	36/306	N.E. [N.E.; N.E.]	60/276	N.E. [N.E.; N.E.]	0.48	[0.32; 0.73]	<0.001	0.197
	(11.8)		(21.7)					
Race								
(Interaction test: p = 0.706)								
Asian	21/128	N.E. [N.E.; N.E.]	46/132	N.E. [13.0; N.E.]	0.39	[0.23; 0.66]	<0.001	0.212
	(16.4)		(34.8)					
White	38/333	N.E. [N.E.; N.E.]	67/320	N.E. [N.E.; N.E.]	0.46	[0.31; 0.69]	<0.001	0.366
	(11.4)		(20.9)					
Others	2/20	N.E. [N.E.; N.E.]	7/25	18.4 [1.2; N.E.]	0.18	[0.02; 1.54]	0.083	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(10.0)		(28.0)					
Age groups								
(Interaction test: p = 0.778)								
18 - < 65 years	49/390	N.E. [N.E.; N.E.]	98/397	N.E. [N.E.; N.E.]	0.44	[0.31; 0.62]	<0.001	0.935
	(12.6)		(24.7)					
65 - < 75 years	9/72	N.E. [N.E.; N.E.]	12/53	N.E. [N.E.; N.E.]	0.56	[0.23; 1.37]	0.199	0.135
	(12.5)		(22.6)					
>= 75 years	3/19	N.E. [7.4; N.E.]	10/27	5.4 [1.4; N.E.]	0.19	[0.04; 0.93]	0.024	0.227
	(15.8)		(37.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.117)								
Imatinib	11/101	N.E. [N.E.; N.E.]	34/102	N.E. [3.5; N.E.]	0.29	[0.15; 0.58]	<0.001	N.E.
	(10.9)		(33.3)					
Nilotinib	47/339	N.E. [N.E.; N.E.]	73/333	N.E. [N.E.; N.E.]	0.52	[0.36; 0.75]	<0.001	0.609
	(13.9)		(21.9)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	3/41 (7.3)	N.E. [N.E.; N.E.]	13/42 (31.0)	N.E. [3.0; N.E.]	0.16	[0.05; 0.60]	0.002	N.E.
Geographic region (Interaction test: p = 0.422)								
Europe excluding Germany	27/202 (13.4)	N.E. [N.E.; N.E.]	41/203 (20.2)	N.E. [N.E.; N.E.]	0.56	[0.34; 0.92]	0.019	0.608
Germany	5/91 (5.5)	N.E. [N.E.; N.E.]	10/68 (14.7)	N.E. [N.E.; N.E.]	0.33	[0.11; 1.03]	0.046	0.994
Others	29/188 (15.4)	N.E. [N.E.; N.E.]	69/206 (33.5)	N.E. [13.0; N.E.]	0.34	[0.22; 0.54]	<0.001	0.697
Nausea - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.560)								
Low	95/291	N.E. [11.1; N.E.]	141/292	2.9 [1.6; 4.2]	0.58	[0.44; 0.75]	<0.001	0.101

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(32.6)		(48.3)					
Intermediate	35/129	N.E. [22.1; N.E.]	58/128	4.0 [1.6; 8.3]	0.39	[0.26; 0.60]	<0.001	0.300
	(27.1)		(45.3)					
High	18/61	N.E. [3.5; N.E.]	24/57	4.5 [1.9; N.E.]	0.65	[0.35; 1.21]	0.153	0.608
	(29.5)		(42.1)					
Sex								
(Interaction test: p = 0.832)								
Female	62/175	18.4 [4.2; N.E.]	103/201	1.8 [1.0; 3.3]	0.56	[0.41; 0.77]	<0.001	0.499
	(35.4)		(51.2)					
Male	86/306	N.E. [N.E.; N.E.]	120/276	4.6 [3.3; 11.1]	0.54	[0.41; 0.72]	<0.001	0.051
	(28.1)		(43.5)					
Race								
(Interaction test: p = 0.196)								
Asian	40/128	N.E. [25.8; N.E.]	74/132	2.9 [1.8; 5.6]	0.43	[0.29; 0.63]	<0.001	0.164
	(31.3)		(56.1)					
White	101/333	N.E. [11.0; N.E.]	142/320	3.3 [1.7; 5.3]	0.57	[0.44; 0.74]	<0.001	0.229

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(30.3)		(44.4)					
Others	7/20	8.3 [0.5; N.E.]	7/25	18.4 [0.3; N.E.]	0.75	[0.21; 2.71]	0.981	N.E.
	(35.0)		(28.0)					
Age groups								
(Interaction test: p = 0.798)								
18 - < 65 years	122/390	N.E. [18.4; N.E.]	183/397	3.5 [2.3; 5.5]	0.55	[0.43; 0.69]	<0.001	0.121
	(31.3)		(46.1)					
65 - < 75 years	18/72	N.E. [8.4; N.E.]	27/53	2.6 [1.3; 10.2]	0.41	[0.22; 0.79]	0.005	0.052
	(25.0)		(50.9)					
>= 75 years	8/19	3.3 [0.6; N.E.]	13/27	1.1 [0.5; 2.8]	0.33	[0.08; 1.42]	0.151	0.955
	(42.1)		(48.1)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.005)								
Imatinib	25/101	N.E. [11.1; N.E.]	63/102	1.0 [0.5; 1.4]	0.28	[0.18; 0.46]	<0.001	N.E.
	(24.8)		(61.8)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Nilotinib	109/339 (32.2)	N.E. [22.1; N.E.]	139/333 (41.7)	6.5 [3.8; 12.0]	0.66	[0.51; 0.85]	<0.001	0.766
Dasatinib	14/41 (34.1)	N.E. [1.2; N.E.]	21/42 (50.0)	1.9 [0.5; 21.2]	0.46	[0.22; 0.98]	0.033	N.E.
Geographic region (Interaction test: p = 0.818)								
Europe excluding Germany	64/202 (31.7)	N.E. [13.8; N.E.]	96/203 (47.3)	2.3 [1.4; 4.6]	0.52	[0.38; 0.73]	<0.001	0.705
Germany	24/91 (26.4)	N.E. [2.6; N.E.]	27/68 (39.7)	6.5 [1.2; 11.1]	0.70	[0.39; 1.26]	0.264	0.642
Others	60/188 (31.9)	N.E. [18.4; N.E.]	100/206 (48.5)	3.5 [2.1; 5.5]	0.52	[0.37; 0.71]	<0.001	0.031
Edema - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.861)								
Low	75/291 (25.8)	N.E. [N.E.; N.E.]	110/292 (37.7)	12.0 [6.5; N.E.]	0.59	[0.44; 0.80]	<0.001	0.095
Intermediate	35/129 (27.1)	N.E. [22.1; N.E.]	47/128 (36.7)	9.2 [3.7; N.E.]	0.53	[0.34; 0.82]	0.004	0.072
High	13/61 (21.3)	N.E. [16.6; N.E.]	16/57 (28.1)	N.E. [2.8; N.E.]	0.55	[0.26; 1.17]	0.156	0.073
Sex								
(Interaction test: p = 0.620)								
Female	58/175 (33.1)	24.9 [7.4; N.E.]	92/201 (45.8)	4.2 [2.2; 10.2]	0.59	[0.42; 0.83]	0.002	0.001
Male	65/306 (21.2)	N.E. [N.E.; N.E.]	81/276 (29.3)	N.E. [14.8; N.E.]	0.62	[0.44; 0.86]	0.004	0.338
Race								
(Interaction test: p = 0.364)								
Asian	41/128	N.E. [19.4; N.E.]	69/132	3.9 [1.7; 14.8]	0.47	[0.31; 0.69]	<0.001	0.452

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(32.0)		(52.3)					
White	77/333	N.E. [24.9; N.E.]	98/320	16.6 [11.1; N.E.]	0.63	[0.47; 0.86]	0.002	0.004
	(23.1)		(30.6)					
Others	5/20	N.E. [2.8; N.E.]	6/25	N.E. [1.5; N.E.]	0.65	[0.17; 2.49]	0.585	N.E.
	(25.0)		(24.0)					
Age groups								
(Interaction test: p = 0.254)								
18 - < 65 years	102/390	N.E. [N.E.; N.E.]	137/397	14.8 [9.2; N.E.]	0.63	[0.49; 0.82]	<0.001	0.013
	(26.2)		(34.5)					
65 - < 75 years	16/72	N.E. [22.1; N.E.]	25/53	4.2 [1.0; 22.1]	0.39	[0.19; 0.77]	0.006	0.056
	(22.2)		(47.2)					
>= 75 years	5/19	N.E. [0.6; N.E.]	11/27	3.7 [1.2; N.E.]	0.57	[0.17; 1.96]	0.378	0.995
	(26.3)		(40.7)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.003)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Imatinib	20/101 (19.8)	N.E. [24.9; N.E.]	54/102 (52.9)	1.7 [1.0; 4.2]	0.23	[0.14; 0.40]	<0.001	N.E.
Nilotinib	92/339 (27.1)	N.E. [N.E.; N.E.]	105/333 (31.5)	N.E. [12.9; N.E.]	0.76	[0.57; 1.01]	0.053	0.782
Dasatinib	11/41 (26.8)	N.E. [6.7; N.E.]	14/42 (33.3)	22.1 [1.4; N.E.]	0.62	[0.27; 1.41]	0.333	N.E.
Geographic region (Interaction test: p = 0.589)								
Europe excluding Germany	43/202 (21.3)	N.E. [N.E.; N.E.]	66/203 (32.5)	13.8 [7.4; N.E.]	0.51	[0.35; 0.76]	<0.001	0.002
Germany	20/91 (22.0)	22.1 [6.7; N.E.]	19/68 (27.9)	12.9 [4.0; N.E.]	0.81	[0.42; 1.56]	0.544	0.331
Others	60/188 (31.9)	N.E. [19.4; N.E.]	88/206 (42.7)	5.6 [2.3; N.E.]	0.57	[0.41; 0.81]	0.001	0.159

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Muscle Pain - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.723)								
Low	133/291 (45.7)	2.1 [1.2; 5.6]	180/292 (61.6)	0.8 [0.6; 1.2]	0.64	[0.51; 0.80]	<0.001	0.260
Intermediate	60/129 (46.5)	1.9 [1.2; 6.5]	66/128 (51.6)	1.4 [0.7; 2.8]	0.76	[0.53; 1.08]	0.073	0.225
High	23/61 (37.7)	10.2 [0.8; N.E.]	27/57 (47.4)	1.4 [0.7; 2.8]	0.69	[0.39; 1.22]	0.149	0.561
Sex								
(Interaction test: p = 0.651)								
Female	85/175 (48.6)	1.1 [0.6; 2.1]	127/201 (63.2)	1.0 [0.7; 1.2]	0.69	[0.52; 0.92]	0.003	0.624
Male	131/306	4.4 [1.9; 12.0]	146/276	1.1 [0.6; 2.6]	0.66	[0.52; 0.84]	<0.001	0.073

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(42.8)		(52.9)					
Race								
(Interaction test: p = 0.347)								
Asian	61/128	6.2 [1.4; N.E.]	94/132	1.0 [0.5; 1.4]	0.56	[0.40; 0.78]	<0.001	0.564
	(47.7)		(71.2)					
White	145/333	1.7 [1.0; 4.4]	166/320	1.1 [0.7; 1.7]	0.74	[0.59; 0.92]	0.004	0.602
	(43.5)		(51.9)					
Others	10/20	2.2 [0.3; N.E.]	13/25	2.2 [0.4; 5.5]	0.64	[0.22; 1.88]	0.289	N.E.
	(50.0)		(52.0)					
Age groups								
(Interaction test: p = 0.826)								
18 - < 65 years	174/390	2.7 [1.4; 7.4]	223/397	1.0 [0.7; 1.4]	0.67	[0.55; 0.82]	<0.001	0.142
	(44.6)		(56.2)					
65 - < 75 years	32/72	1.4 [0.8; 13.9]	33/53	1.4 [0.5; 2.6]	0.62	[0.36; 1.06]	0.072	0.397
	(44.4)		(62.3)					
>= 75 years	10/19	1.1 [0.5; N.E.]	17/27	1.0 [0.3; 1.7]	1.03	[0.39; 2.76]	0.970	0.432

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(52.6)		(63.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.493)								
Imatinib	37/101	2.3 [0.7; 24.9]	63/102	0.6 [0.5; 1.0]	0.53	[0.35; 0.80]	<0.001	N.E.
	(36.6)		(61.8)					
Nilotinib	162/339	2.2 [1.2; 5.2]	188/333	1.2 [0.8; 1.9]	0.72	[0.58; 0.89]	0.001	0.532
	(47.8)		(56.5)					
Dasatinib	17/41	4.2 [0.4; N.E.]	22/42	1.4 [0.3; 4.6]	0.55	[0.28; 1.11]	0.054	N.E.
	(41.5)		(52.4)					
Geographic region								
(Interaction test: p = 0.899)								
Europe excluding Germany	90/202	2.1 [1.2; 13.9]	108/203	1.2 [0.7; 1.9]	0.69	[0.52; 0.91]	0.007	0.266
	(44.6)		(53.2)					
Germany	34/91	0.8 [0.5; 6.5]	33/68	0.8 [0.4; 1.7]	0.70	[0.41; 1.18]	0.122	0.986

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(37.4)		(48.5)					
Others	92/188	3.3 [1.2; 9.2]	132/206	1.0 [0.6; 1.9]	0.63	[0.48; 0.82]	<0.001	0.242
	(48.9)		(64.1)					
Pruritus - Severity (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.243)								
Low	137/291	3.8 [2.6; 5.6]	167/292	1.6 [1.1; 2.4]	0.68	[0.54; 0.86]	0.001	0.592
	(47.1)		(57.2)					
Intermediate	57/129	4.1 [2.6; 22.1]	59/128	3.0 [1.9; 5.6]	0.75	[0.52; 1.10]	0.159	0.191
	(44.2)		(46.1)					
High	23/61	11.1 [2.8; N.E.]	31/57	2.0 [1.0; 2.6]	0.44	[0.25; 0.76]	0.003	0.162
	(37.7)		(54.4)					
Sex								
(Interaction test: p = 0.889)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Female	81/175 (46.3)	3.3 [2.0; 5.6]	116/201 (57.7)	1.7 [1.0; 2.3]	0.66	[0.49; 0.88]	0.003	0.011
Male	136/306 (44.4)	4.7 [3.2; 7.6]	141/276 (51.1)	2.2 [1.6; 3.1]	0.67	[0.52; 0.85]	0.004	0.931
Race								
(Interaction test: p = 0.669)								
Asian	55/128 (43.0)	8.3 [2.8; N.E.]	78/132 (59.1)	2.8 [1.4; 5.6]	0.61	[0.43; 0.86]	0.008	0.050
White	152/333 (45.6)	3.7 [2.6; 4.6]	166/320 (51.9)	1.9 [1.2; 2.4]	0.69	[0.55; 0.87]	0.002	0.310
Others	10/20 (50.0)	3.3 [0.3; N.E.]	13/25 (52.0)	1.1 [0.5; 2.1]	0.62	[0.22; 1.70]	0.297	N.E.
Age groups								
(Interaction test: p = 0.885)								
18 - < 65 years	177/390 (45.4)	4.4 [3.0; 7.4]	208/397 (52.4)	2.1 [1.4; 2.8]	0.67	[0.55; 0.82]	<0.001	0.517

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
65 - < 75 years	31/72 (43.1)	3.5 [1.6; 24.0]	31/53 (58.5)	2.4 [1.1; 3.1]	0.78	[0.44; 1.36]	0.387	0.031
>= 75 years	9/19 (47.4)	2.2 [0.7; 3.8]	18/27 (66.7)	2.1 [0.5; 2.3]	0.68	[0.27; 1.71]	0.468	0.018
Pre-randomization selection of TKI (Interaction test: p = 0.016)								
Imatinib	39/101 (38.6)	3.8 [1.6; 10.2]	44/102 (43.1)	3.7 [2.8; 16.7]	1.28	[0.82; 1.99]	0.541	N.E.
Nilotinib	158/339 (46.6)	4.2 [2.9; 7.2]	192/333 (57.7)	1.6 [1.1; 2.1]	0.58	[0.47; 0.72]	<0.001	0.557
Dasatinib	20/41 (48.8)	3.7 [0.7; 13.6]	21/42 (50.0)	1.5 [0.5; 6.4]	0.64	[0.33; 1.25]	0.196	N.E.
Geographic region (Interaction test: p = 0.553)								


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Europe excluding Germany	98/202 (48.5)	3.7 [2.1; 4.7]	107/203 (52.7)	2.1 [1.2; 3.1]	0.73	[0.55; 0.97]	0.041	0.042
Germany	33/91 (36.3)	3.5 [1.4; 19.4]	34/68 (50.0)	1.2 [0.6; 2.1]	0.51	[0.30; 0.86]	0.005	0.675
Others	86/188 (45.7)	5.8 [3.2; 22.1]	116/206 (56.3)	2.4 [1.5; 3.1]	0.66	[0.50; 0.88]	0.004	0.533

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				

MID: Minimally important difference
N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
In this sensitivity analysis a missing assessment before randomization is substituted by the last assessment before or on the day of treatment start, if such an assessment is available.
If there are not at least 10 patients in every subgroup or not more than 10 events per subgroup per treatment arm, no subgroup analyses were performed for the corresponding attribute.
If there are not more than 10 events per subgroup per treatment arm, no Cox PH hazard analysis is carried out.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline PRO score.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates. P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT) and Pre-Randomization selection TKI (IRT).
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Nausea - Severity (MID=1): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	101 (0)	37 (42)	33 (45)	30 (46)	14 (62)	3 (73)	0 (76)
Investigator Selected TKI	102 (0)	11 (29)	7 (32)	6 (33)	3 (36)	0 (39)	0 (39)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Nausea - Severity (MID=1): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	153 (93)	84 (150)	43 (189)	24 (207)	3 (227)	0 (230)
Investigator Selected TKI	333 (0)	109 (104)	64 (137)	35 (163)	9 (186)	3 (191)	0 (194)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Nausea - Severity (MID=1): Pre-randomization selection of TKI: Dasatinib




Pts at Risk (censored)

Asciminib	41 (0)	14 (14)	12 (16)	8 (20)	5 (22)	1 (26)	0 (27)
Investigator Selected TKI	42 (0)	10 (15)	8 (17)	7 (17)	3 (19)	2 (19)	0 (21)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Severity (MID=1): Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Edema - Severity (MID=1): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	166 (95)	99 (152)	52 (196)	22 (225)	3 (244)	0 (247)
Investigator Selected TKI	333 (0)	130 (114)	76 (157)	35 (194)	12 (216)	2 (226)	0 (228)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Severity (MID=1): Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)


Pruritus - Severity (MID=1): Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)


Pruritus - Severity (MID=1): Pre-randomization selection of TKI: Nilotinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5 PRO-CTCAE - Severity: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Pruritus - Severity (MID=1): Pre-randomization selection of TKI: Dasatinib



Pts at Risk (censored)


Asciminib	41 (0)	11 (12)	9 (13)	7 (14)	5 (16)	2 (19)	0 (21)
Investigator Selected TKI	42 (0)	9 (15)	7 (16)	5 (16)	2 (19)	0 (21)	0 (21)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	35/153	60/150	0.41	0.27; 0.63	<0.001
ASC4START	67/237	77/247	0.82	0.59; 1.13	0.223
Pooled Analysis	102/390	137/397	0.63	0.49; 0.82	<0.001
65 - < 75 years					
ASC4FIRST	5/34	18/29	0.16	0.04; 0.56	0.001
ASC4START	11/38	7/24	0.75	0.28; 1.96	0.569
Pooled Analysis	16/72	25/53	0.39	0.19; 0.77	0.006
>= 75 years					
ASC4FIRST	5/10	6/14	1.51	0.32; 7.17	0.625
ASC4START	0/9	5/13	0.11	0.00; 2.69	0.045
Pooled Analysis	5/19	11/27	0.57	0.17; 1.96	0.378




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	6/20	0.09	0.01; 0.85	0.007
ASC4START	11/38	10/37	0.84	0.35; 2.00	0.913
Pooled Analysis	13/61	16/57	0.55	0.26; 1.17	0.156
Intermediate					
ASC4FIRST	14/54	26/53	0.34	0.17; 0.66	0.001
ASC4START	21/75	21/75	0.79	0.43; 1.44	0.375
Pooled Analysis	35/129	47/128	0.53	0.34; 0.82	0.004
Low					
ASC4FIRST	29/120	52/120	0.44	0.28; 0.70	<0.001
ASC4START	46/171	58/172	0.73	0.50; 1.08	0.130
Pooled Analysis	75/291	110/292	0.59	0.44; 0.80	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	8/64	27/62	0.17	0.07; 0.41	<0.001
ASC4START	35/138	39/141	0.77	0.48; 1.22	0.275
Pooled Analysis	43/202	66/203	0.51	0.35; 0.76	<0.001
Germany					
ASC4FIRST	2/19	3/15	2.56	0.23; 29.12	0.433
ASC4START	18/72	16/53	0.73	0.37; 1.45	0.384
Pooled Analysis	20/91	19/68	0.81	0.42; 1.56	0.544
Others					
ASC4FIRST	35/114	54/116	0.46	0.30; 0.72	<0.001
ASC4START	25/74	34/90	0.76	0.45; 1.29	0.357
Pooled Analysis	60/188	88/206	0.57	0.41; 0.81	0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	11/41	14/42	0.62	0.27; 1.41	0.333
Pooled Analysis	11/41	14/42	0.62	0.27; 1.41	0.333
Imatinib					
ASC4FIRST	20/101	54/102	0.23	0.14; 0.40	<0.001
Pooled Analysis	20/101	54/102	0.23	0.14; 0.40	<0.001
Nilotinib					
ASC4FIRST	14/55	16/49	0.69	0.34; 1.43	0.317
ASC4START	78/284	89/284	0.77	0.57; 1.05	0.093
Pooled Analysis	92/339	105/333	0.76	0.57; 1.01	0.053




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	13/40	22/46	0.59	0.30; 1.17	0.130
Pooled Analysis	41/128	69/132	0.47	0.31; 0.69	<0.001
Asian/Others					
ASC4FIRST	29/91	47/90	0.43	0.27; 0.70	<0.001
Others					
ASC4START	4/17	6/21	0.65	0.17; 2.49	0.585
Pooled Analysis	5/20	6/25	0.65	0.17; 2.49	0.585
White					
ASC4FIRST	16/106	37/103	0.30	0.16; 0.55	<0.001
ASC4START	61/227	61/217	0.84	0.59; 1.19	0.312
Pooled Analysis	77/333	98/320	0.63	0.47; 0.86	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	14/68	41/75	0.26	0.14; 0.49	<0.001
ASC4START	44/107	51/126	0.90	0.60; 1.35	0.604
Pooled Analysis	58/175	92/201	0.59	0.42; 0.83	0.002
Male					
ASC4FIRST	31/129	43/118	0.52	0.33; 0.84	0.007
ASC4START	34/177	38/158	0.72	0.46; 1.15	0.152
Pooled Analysis	65/306	81/276	0.62	0.44; 0.86	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	66/153	69/150	0.80	0.56; 1.13	0.389
ASC4START	116/237	123/247	0.85	0.65; 1.09	0.449
Pooled Analysis	182/390	192/397	0.83	0.67; 1.01	0.263
65 - < 75 years					
ASC4FIRST	10/34	21/29	0.48	0.21; 1.12	0.016
ASC4START	17/38	12/24	0.76	0.35; 1.66	0.585
Pooled Analysis	27/72	33/53	0.62	0.35; 1.08	0.033
>= 75 years					
ASC4FIRST	5/10	8/14	1.39	0.26; 7.45	0.343
ASC4START	4/9	6/13	0.61	0.12; 3.02	0.686
Pooled Analysis	9/19	14/27	0.75	0.25; 2.29	0.330




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	6/23	8/20	0.53	0.17; 1.65	0.214
ASC4START	15/38	15/37	0.53	0.25; 1.11	0.444
Pooled Analysis	21/61	23/57	0.53	0.29; 0.98	0.187
Intermediate					
ASC4FIRST	27/54	27/53	0.89	0.51; 1.53	0.738
ASC4START	33/75	33/75	0.64	0.39; 1.05	0.056
Pooled Analysis	60/129	60/128	0.75	0.52; 1.08	0.100
Low					
ASC4FIRST	48/120	63/120	0.65	0.44; 0.95	0.039
ASC4START	89/171	93/172	0.93	0.69; 1.24	0.901
Pooled Analysis	137/291	156/292	0.81	0.64; 1.02	0.176




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	28/64	31/62	0.81	0.47; 1.37	0.552
ASC4START	65/138	71/141	0.75	0.54; 1.06	0.154
Pooled Analysis	93/202	102/203	0.77	0.58; 1.02	0.129
Germany					
ASC4FIRST	3/19	6/15	0.36	0.03; 3.99	0.433
ASC4START	34/72	24/53	0.65	0.38; 1.13	0.408
Pooled Analysis	37/91	30/68	0.63	0.37; 1.07	0.322
Others					
ASC4FIRST	50/114	61/116	0.73	0.50; 1.07	0.113
ASC4START	38/74	46/90	0.95	0.61; 1.47	0.956
Pooled Analysis	88/188	107/206	0.82	0.61; 1.09	0.219




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	19/41	24/42	0.46	0.23; 0.89	0.017
Pooled Analysis	19/41	24/42	0.46	0.23; 0.89	0.017
Imatinib					
ASC4FIRST	41/101	50/102	0.91	0.60; 1.38	0.608
Pooled Analysis	41/101	50/102	0.91	0.60; 1.38	0.608
Nilotinib					
ASC4FIRST	21/55	24/49	0.55	0.30; 1.01	0.105
ASC4START	137/284	141/284	0.81	0.64; 1.03	0.206
Pooled Analysis	158/339	165/333	0.77	0.62; 1.96	0.077




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	22/40	27/46	0.77	0.42; 1.39	0.830
Pooled Analysis	66/128	75/132	0.82	0.58; 1.15	0.306
Asian/Others					
ASC4FIRST	46/91	48/90	0.82	0.54; 1.25	0.304
Others					
ASC4START	6/17	4/21	1.78	0.33; 9.65	0.066
Pooled Analysis	8/20	4/25	1.78	0.33; 9.65	0.066
White					
ASC4FIRST	35/106	50/103	0.55	0.35; 0.87	0.026
ASC4START	109/227	110/217	0.76	0.58; 0.99	0.051
Pooled Analysis	144/333	160/320	0.70	0.55; 0.88	0.005




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	22/68	44/75	0.50	0.29; 0.85	0.007
ASC4START	57/107	69/126	0.79	0.55; 1.14	0.373
Pooled Analysis	79/175	113/201	0.68	0.50; 0.92	0.022
Male					
ASC4FIRST	59/129	54/118	0.86	0.59; 1.26	0.692
ASC4START	80/177	72/158	0.87	0.63; 1.20	0.447
Pooled Analysis	139/306	126/276	0.87	0.68; 1.11	0.403




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	70/153	72/150	0.76	0.54; 1.07	0.363
ASC4START	121/237	131/247	0.81	0.63; 1.04	0.199
Pooled Analysis	191/390	203/397	0.79	0.65; 0.97	0.116
65 - < 75 years					
ASC4FIRST	10/34	15/29	0.62	0.24; 1.61	0.124
ASC4START	18/38	13/24	0.67	0.30; 1.47	0.461
Pooled Analysis	28/72	28/53	0.66	0.36; 1.19	0.113
>= 75 years					
ASC4FIRST	3/10	4/14	3.91	0.40; 38.29	0.561
ASC4START	5/9	8/13	19.45	0.92; 409.25	0.045
Pooled Analysis	8/19	12/27	14.30	1.72; 118.91	0.060




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	9/23	7/20	0.82	0.29; 2.34	0.376
ASC4START	19/38	22/37	0.62	0.33; 1.16	0.110
Pooled Analysis	28/61	29/57	0.66	0.39; 1.12	0.068
Intermediate					
ASC4FIRST	26/54	21/53	1.26	0.71; 2.26	0.583
ASC4START	33/75	33/75	0.79	0.48; 1.28	0.286
Pooled Analysis	59/129	54/128	0.95	0.66; 1.38	0.645
Low					
ASC4FIRST	48/120	63/120	0.63	0.43; 0.93	0.084
ASC4START	92/171	97/172	0.81	0.61; 1.09	0.434
Pooled Analysis	140/291	160/292	0.74	0.59; 0.94	0.096




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	28/64	29/62	0.86	0.50; 1.48	0.528
ASC4START	69/138	69/141	0.80	0.57; 1.12	0.418
Pooled Analysis	97/202	98/203	0.82	0.62; 1.09	0.307
Germany					
ASC4FIRST	4/19	4/15	9.25	0.38; 223.93	0.086
ASC4START	37/72	24/53	0.70	0.40; 1.24	0.615
Pooled Analysis	41/91	28/68	0.84	0.48; 1.45	0.968
Others					
ASC4FIRST	51/114	58/116	0.71	0.48; 1.04	0.224
ASC4START	38/74	59/90	0.71	0.47; 1.06	0.074
Pooled Analysis	89/188	117/206	0.73	0.55; 0.96	0.034




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	18/41	16/42	0.76	0.36; 1.58	0.517
Pooled Analysis	18/41	16/42	0.76	0.36; 1.58	0.517
Imatinib					
ASC4FIRST	37/101	48/102	0.85	0.56; 1.32	0.340
Pooled Analysis	37/101	48/102	0.85	0.56; 1.32	0.340
Nilotinib					
ASC4FIRST	28/55	27/49	0.62	0.35; 1.11	0.338
ASC4START	144/284	152/284	0.78	0.62; 0.98	0.087
Pooled Analysis	172/339	179/333	0.76	0.61; 0.94	0.051




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	20/40	35/46	0.54	0.31; 0.95	0.025
Pooled Analysis	63/128	80/132	0.69	0.50; 0.97	0.046
Asian/Others					
ASC4FIRST	46/91	45/90	0.81	0.53; 1.24	0.572
Others					
ASC4START	4/17	11/21	0.48	0.13; 1.78	0.254
Pooled Analysis	7/20	11/25	0.48	0.13; 1.78	0.254
White					
ASC4FIRST	37/106	46/103	0.81	0.51; 1.28	0.280
ASC4START	120/227	106/217	0.88	0.68; 1.14	0.668
Pooled Analysis	157/333	152/320	0.86	0.68; 1.08	0.360




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	31/68	36/75	0.97	0.60; 1.60	0.998
ASC4START	59/107	72/126	0.83	0.59; 1.18	0.335
Pooled Analysis	90/175	108/201	0.88	0.66; 1.17	0.429
Male					
ASC4FIRST	52/129	55/118	0.68	0.46; 1.01	0.121
ASC4START	85/177	80/158	0.77	0.57; 1.05	0.196
Pooled Analysis	137/306	135/276	0.74	0.58; 0.94	0.048




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	62/153	85/150	0.54	0.39; 0.76	<0.001
ASC4START	112/237	138/247	0.74	0.58; 0.96	0.012
Pooled Analysis	174/390	223/397	0.67	0.55; 0.82	<0.001
65 - < 75 years					
ASC4FIRST	12/34	18/29	0.77	0.35; 1.69	0.506
ASC4START	20/38	15/24	0.49	0.23; 1.03	0.059
Pooled Analysis	32/72	33/53	0.62	0.36; 1.06	0.072
>= 75 years					
ASC4FIRST	5/10	8/14	1.70	0.30; 9.62	1.000
ASC4START	5/9	9/13	0.70	0.17; 2.93	0.958
Pooled Analysis	10/19	17/27	1.03	0.39; 2.76	0.970




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	9/23	7/20	0.90	0.33; 2.46	0.830
ASC4START	14/38	20/37	0.62	0.31; 1.24	0.112
Pooled Analysis	23/61	27/57	0.69	0.39; 1.22	0.149
Intermediate					
ASC4FIRST	23/54	29/53	0.58	0.34; 1.02	0.066
ASC4START	37/75	37/75	0.94	0.59; 1.49	0.419
Pooled Analysis	60/129	66/128	0.76	0.53; 1.08	0.073
Low					
ASC4FIRST	47/120	75/120	0.55	0.37; 0.79	<0.001
ASC4START	86/171	105/172	0.70	0.53; 0.94	0.015
Pooled Analysis	133/291	180/292	0.64	0.51; 0.80	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	25/64	36/62	0.52	0.31; 0.90	0.009
ASC4START	65/138	72/141	0.76	0.54; 1.07	0.119
Pooled Analysis	90/202	108/203	0.69	0.52; 0.91	0.007
Germany					
ASC4FIRST	2/19	3/15	11.70	0.13; >1000	0.090
ASC4START	32/72	30/53	0.63	0.37; 1.08	0.056
Pooled Analysis	34/91	33/68	0.70	0.41; 1.18	0.122
Others					
ASC4FIRST	52/114	72/116	0.54	0.38; 0.78	0.001
ASC4START	40/74	60/90	0.75	0.50; 1.12	0.075
Pooled Analysis	92/188	132/206	0.63	0.48; 0.82	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	17/41	22/42	0.55	0.28; 1.11	0.054
Pooled Analysis	17/41	22/42	0.55	0.28; 1.11	0.054
Imatinib					
ASC4FIRST	37/101	63/102	0.53	0.35; 0.80	<0.001
Pooled Analysis	37/101	63/102	0.53	0.35; 0.80	<0.001
Nilotinib					
ASC4FIRST	25/55	26/49	0.60	0.34; 1.07	0.129
ASC4START	137/284	162/284	0.74	0.59; 0.93	0.004
Pooled Analysis	162/339	188/333	0.72	0.58; 0.89	0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	19/40	34/46	0.64	0.36; 1.14	0.054
Pooled Analysis	61/128	94/132	0.56	0.40; 0.78	<0.001
Asian/Others					
ASC4FIRST	44/91	60/90	0.54	0.36; 0.80	0.001
Others					
ASC4START	8/17	13/21	0.64	0.22; 1.88	0.289
Pooled Analysis	10/20	13/25	0.64	0.22; 1.88	0.289
White					
ASC4FIRST	35/106	51/103	0.67	0.43; 1.04	0.048
ASC4START	110/227	115/217	0.76	0.59; 0.99	0.028
Pooled Analysis	145/333	166/320	0.74	0.59; 0.92	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	28/68	48/75	0.74	0.46; 1.20	0.116
ASC4START	57/107	79/126	0.66	0.47; 0.94	0.011
Pooled Analysis	85/175	127/201	0.69	0.52; 0.92	0.003
Male					
ASC4FIRST	51/129	63/118	0.50	0.34; 0.73	<0.001
ASC4START	80/177	83/158	0.79	0.58; 1.07	0.087
Pooled Analysis	131/306	146/276	0.66	0.52; 0.84	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	48/153	79/150	0.44	0.30; 0.63	<0.001
ASC4START	74/237	104/247	0.64	0.47; 0.86	0.002
Pooled Analysis	122/390	183/397	0.55	0.43; 0.69	<0.001
65 - < 75 years					
ASC4FIRST	5/34	18/29	0.19	0.06; 0.66	<0.001
ASC4START	13/38	9/24	0.80	0.32; 1.99	0.623
Pooled Analysis	18/72	27/53	0.41	0.22; 0.79	0.005
>= 75 years					
ASC4FIRST	5/10	8/14	0.34	0.06; 2.06	0.238
ASC4START	3/9	5/13	0.27	0.02; 3.82	0.407
Pooled Analysis	8/19	13/27	0.33	0.08; 1.42	0.151




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	6/23	9/20	0.53	0.18; 1.52	0.203
ASC4START	12/38	15/37	0.74	0.34; 1.58	0.403
Pooled Analysis	18/61	24/57	0.65	0.35; 1.21	0.153
Intermediate					
ASC4FIRST	14/54	29/53	0.31	0.16; 0.60	<0.001
ASC4START	21/75	29/75	0.45	0.25; 0.82	0.010
Pooled Analysis	35/129	58/128	0.39	0.26; 0.60	<0.001
Low					
ASC4FIRST	38/120	67/120	0.45	0.30; 0.67	<0.001
ASC4START	57/171	74/172	0.70	0.49; 0.99	0.042
Pooled Analysis	95/291	141/292	0.58	0.44; 0.75	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	21/64	35/62	0.50	0.28; 0.89	0.007
ASC4START	43/138	61/141	0.54	0.36; 0.81	0.002
Pooled Analysis	64/202	96/203	0.52	0.38; 0.73	<0.001
Germany					
ASC4FIRST	1/19	4/15	2.23	0.08; 59.29	0.808
ASC4START	23/72	23/53	0.67	0.37; 1.22	0.233
Pooled Analysis	24/91	27/68	0.70	0.39; 1.26	0.264
Others					
ASC4FIRST	36/114	66/116	0.40	0.26; 0.60	<0.001
ASC4START	24/74	34/90	0.83	0.49; 1.41	0.428
Pooled Analysis	60/188	100/206	0.52	0.37; 0.71	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	14/41	21/42	0.46	0.22; 0.98	0.033
Pooled Analysis	14/41	21/42	0.46	0.22; 0.98	0.033
Imatinib					
ASC4FIRST	25/101	63/102	0.28	0.18; 0.46	<0.001
Pooled Analysis	25/101	63/102	0.28	0.18; 0.46	<0.001
Nilotinib					
ASC4FIRST	19/55	21/49	0.71	0.38; 1.34	0.309
ASC4START	90/284	118/284	0.65	0.49; 0.85	0.001
Pooled Analysis	109/339	139/333	0.66	0.51; 0.85	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	12/40	21/46	0.65	0.32; 1.33	0.212
Pooled Analysis	40/128	74/132	0.43	0.29; 0.63	<0.001
Asian/Others					
ASC4FIRST	30/91	53/90	0.38	0.24; 0.61	<0.001
Others					
ASC4START	5/17	7/21	0.75	0.21; 2.71	0.981
Pooled Analysis	7/20	7/25	0.75	0.21; 2.71	0.981
White					
ASC4FIRST	28/106	52/103	0.45	0.28; 0.73	<0.001
ASC4START	73/227	90/217	0.63	0.46; 0.86	0.003
Pooled Analysis	101/333	142/320	0.57	0.44; 0.74	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Nausea - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	23/68	45/75	0.48	0.28; 0.81	0.003
ASC4START	39/107	58/126	0.61	0.40; 0.92	0.021
Pooled Analysis	62/175	103/201	0.56	0.41; 0.77	<0.001
Male					
ASC4FIRST	35/129	60/118	0.40	0.26; 0.61	<0.001
ASC4START	51/177	60/158	0.70	0.48; 1.01	0.041
Pooled Analysis	86/306	120/276	0.54	0.41; 0.72	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pruritus - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	62/153	68/150	0.74	0.52; 1.06	0.144
ASC4START	115/237	140/247	0.64	0.50; 0.82	<0.001
Pooled Analysis	177/390	208/397	0.67	0.55; 0.82	<0.001
65 - < 75 years					
ASC4FIRST	13/34	16/29	1.71	0.75; 3.87	0.294
ASC4START	18/38	15/24	0.46	0.22; 0.96	0.027
Pooled Analysis	31/72	31/53	0.78	0.44; 1.36	0.387
>= 75 years					
ASC4FIRST	6/10	8/14	2.32	0.60; 9.03	0.209
ASC4START	3/9	10/13	0.18	0.03; 0.93	0.027
Pooled Analysis	9/19	18/27	0.68	0.27; 1.71	0.468




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pruritus - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	9/23	6/20	0.78	0.25; 2.40	0.951
ASC4START	14/38	25/37	0.34	0.17; 0.66	<0.001
Pooled Analysis	23/61	31/57	0.44	0.25; 0.76	0.003
Intermediate					
ASC4FIRST	22/54	24/53	1.06	0.58; 1.96	0.909
ASC4START	35/75	35/75	0.63	0.39; 1.01	0.086
Pooled Analysis	57/129	59/128	0.75	0.52; 1.10	0.159
Low					
ASC4FIRST	50/120	62/120	0.74	0.51; 1.09	0.166
ASC4START	87/171	105/172	0.65	0.49; 0.87	0.003
Pooled Analysis	137/291	167/292	0.68	0.54; 0.86	0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pruritus - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	29/64	27/62	1.18	0.68; 2.04	0.427
ASC4START	69/138	80/141	0.62	0.44; 0.85	0.004
Pooled Analysis	98/202	107/203	0.73	0.55; 0.97	0.041
Germany					
ASC4FIRST	2/19	5/15	0.31	0.03; 3.17	0.303
ASC4START	31/72	29/53	0.52	0.30; 0.89	0.009
Pooled Analysis	33/91	34/68	0.51	0.30; 0.86	0.005
Others					
ASC4FIRST	50/114	60/116	0.72	0.49; 1.06	0.080
ASC4START	36/74	56/90	0.60	0.39; 0.92	0.020
Pooled Analysis	86/188	116/206	0.66	0.50; 0.88	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pruritus - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	20/41	21/42	0.64	0.33; 1.25	0.196
Pooled Analysis	20/41	21/42	0.64	0.33; 1.25	0.196
Imatinib					
ASC4FIRST	39/101	44/102	1.28	0.82; 1.99	0.541
Pooled Analysis	39/101	44/102	1.28	0.82; 1.99	0.541
Nilotinib					
ASC4FIRST	22/55	27/49	0.49	0.27; 0.87	0.032
ASC4START	136/284	165/284	0.60	0.47; 0.75	<0.001
Pooled Analysis	158/339	192/333	0.58	0.47; 0.72	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pruritus - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	13/40	30/46	0.35	0.18; 0.69	0.003
Pooled Analysis	55/128	78/132	0.61	0.43; 0.86	0.008
Asian/Others					
ASC4FIRST	43/91	48/90	0.78	0.51; 1.19	0.269
Others					
ASC4START	9/17	13/21	0.62	0.22; 1.70	0.297
Pooled Analysis	10/20	13/25	0.62	0.22; 1.70	0.297
White					
ASC4FIRST	38/106	44/103	0.84	0.53; 1.34	0.553
ASC4START	114/227	122/217	0.65	0.50; 0.84	<0.001
Pooled Analysis	152/333	166/320	0.69	0.55; 0.87	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Pruritus - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	28/68	38/75	1.20	0.72; 1.99	0.759
ASC4START	53/107	78/126	0.51	0.36; 0.73	<0.001
Pooled Analysis	81/175	116/201	0.66	0.49; 0.88	0.003
Male					
ASC4FIRST	53/129	54/118	0.65	0.43; 0.98	0.103
ASC4START	83/177	87/158	0.68	0.50; 0.92	0.019
Pooled Analysis	136/306	141/276	0.67	0.52; 0.85	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	20/153	41/150	0.43	0.25; 0.74	0.002
ASC4START	29/237	57/247	0.44	0.28; 0.69	<0.001
Pooled Analysis	49/390	98/397	0.44	0.31; 0.62	<0.001
65 - < 75 years					
ASC4FIRST	2/34	9/29	0.24	0.05; 1.14	0.053
ASC4START	7/38	3/24	1.18	0.30; 4.66	0.824
Pooled Analysis	9/72	12/53	0.56	0.23; 1.37	0.199
>= 75 years					
ASC4FIRST	2/10	8/14	0.10	0.01; 0.85	0.011
ASC4START	1/9	2/13	0.87	0.05; 13.95	0.919
Pooled Analysis	3/19	10/27	0.19	0.04; 0.93	0.024




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	5/20	0.26	0.05; 1.38	0.147
ASC4START	4/38	7/37	0.47	0.13; 1.70	0.254
Pooled Analysis	6/61	12/57	0.42	0.16; 1.13	0.073
Intermediate					
ASC4FIRST	7/54	21/53	0.24	0.10; 0.57	<0.001
ASC4START	12/75	12/75	0.70	0.31; 1.59	0.463
Pooled Analysis	19/129	33/128	0.42	0.24; 0.74	0.002
Low					
ASC4FIRST	15/120	32/120	0.43	0.23; 0.79	0.007
ASC4START	21/171	43/172	0.43	0.25; 0.72	0.001
Pooled Analysis	36/291	75/292	0.43	0.29; 0.64	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	8/64	15/62	0.47	0.19; 1.18	0.083
ASC4START	19/138	26/141	0.61	0.33; 1.10	0.096
Pooled Analysis	27/202	41/203	0.56	0.34; 0.92	0.019
Germany					
ASC4FIRST	0/19	3/15	0.33	0.00; 30.79	0.317
ASC4START	5/72	7/53	0.36	0.11; 1.16	0.076
Pooled Analysis	5/91	10/68	0.33	0.11; 1.03	0.046
Others					
ASC4FIRST	16/114	40/116	0.32	0.18; 0.57	<0.001
ASC4START	13/74	29/90	0.38	0.19; 0.78	0.006
Pooled Analysis	29/188	69/206	0.34	0.22; 0.54	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	3/41	13/42	0.16	0.05; 0.60	0.002
Pooled Analysis	3/41	13/42	0.16	0.05; 0.60	0.002
Imatinib					
ASC4FIRST	11/101	34/102	0.29	0.15; 0.58	<0.001
Pooled Analysis	11/101	34/102	0.29	0.15; 0.58	<0.001
Nilotinib					
ASC4FIRST	10/55	11/49	0.62	0.26; 1.49	0.312
ASC4START	37/284	62/284	0.50	0.33; 0.75	<0.001
Pooled Analysis	47/339	73/333	0.52	0.36; 0.75	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	7/40	13/46	0.66	0.26; 1.72	0.392
Pooled Analysis	21/128	46/132	0.39	0.23; 0.66	<0.001
Asian/Others					
ASC4FIRST	15/91	33/90	0.33	0.18; 0.62	<0.001
Others					
ASC4START	1/17	7/21	0.18	0.02; 1.54	0.083
Pooled Analysis	2/20	7/25	0.18	0.02; 1.54	0.083
White					
ASC4FIRST	9/106	25/103	0.30	0.14; 0.68	0.005
ASC4START	29/227	42/217	0.53	0.33; 0.86	0.007
Pooled Analysis	38/333	67/320	0.46	0.31; 0.69	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.5.1: Forest-Plot for PRO-CTCAE - Severity: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Vomiting - Severity (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	10/68	26/75	0.37	0.17; 0.77	0.006
ASC4START	15/107	34/126	0.41	0.22; 0.76	0.003
Pooled Analysis	25/175	60/201	0.39	0.24; 0.63	<0.001
Male					
ASC4FIRST	14/129	32/118	0.35	0.19; 0.66	<0.001
ASC4START	22/177	28/158	0.62	0.35; 1.08	0.086
Pooled Analysis	36/306	60/276	0.48	0.32; 0.73	<0.001



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 3-7.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline (Full Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Fatigue - Interference (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.551)								
Low	138/291 (47.4)	2.7 [1.7; 5.2]	158/292 (54.1)	1.1 [0.7; 2.1]	0.76	[0.61; 0.96]	0.034	0.006
Intermediate	61/129 (47.3)	4.4 [1.7; 11.1]	65/128 (50.8)	1.0 [0.5; 3.0]	0.74	[0.52; 1.06]	0.075	0.277
High	18/61 (29.5)	N.E. [8.3; N.E.]	22/57 (38.6)	2.1 [0.7; N.E.]	0.49	[0.26; 0.94]	0.064	0.240
Sex								
(Interaction test: p = 0.820)								
Female	82/175	3.0 [1.4; 5.8]	111/201	1.1 [0.7; 2.1]	0.74	[0.55; 0.99]	0.042	0.018

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(46.9)		(55.2)					
Male	135/306	4.5 [2.6; 11.1]	134/276	1.4 [0.7; 2.6]	0.77	[0.60; 0.98]	0.036	0.060
	(44.1)		(48.6)					
Race								
(Interaction test: p = 0.478)								
Asian	62/128	4.4 [1.9; 23.1]	83/132	1.1 [0.6; 2.6]	0.65	[0.46; 0.91]	0.024	0.490
	(48.4)		(62.9)					
White	147/333	3.7 [2.2; 8.3]	154/320	1.1 [0.7; 2.1]	0.78	[0.62; 0.98]	0.019	0.002
	(44.1)		(48.1)					
Others	8/20	2.8 [1.1; N.E.]	8/25	16.5 [0.4; N.E.]	0.79	[0.26; 2.40]	0.773	N.E.
	(40.0)		(32.0)					
Age groups								
(Interaction test: p = 0.834)								
18 - < 65 years	183/390	3.7 [2.6; 8.3]	201/397	1.3 [1.0; 2.6]	0.75	[0.61; 0.92]	0.022	0.006
	(46.9)		(50.6)					
65 - < 75 years	27/72	5.6 [1.0; N.E.]	29/53	1.0 [0.5; 1.7]	0.63	[0.35; 1.16]	0.112	0.257

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(37.5)		(54.7)					
>= 75 years	7/19	11.9 [0.5; N.E.]	15/27	1.0 [0.3; 3.1]	1.01	[0.34; 3.05]	0.144	0.147
	(36.8)		(55.6)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.141)								
Imatinib	41/101	3.3 [0.7; 18.4]	58/102	0.6 [0.5; 1.4]	0.63	[0.42; 0.94]	0.013	N.E.
	(40.6)		(56.9)					
Nilotinib	163/339	3.6 [2.4; 7.4]	166/333	1.9 [1.0; 3.0]	0.81	[0.65; 1.00]	0.116	0.004
	(48.1)		(49.8)					
Dasatinib	13/41	N.E. [1.2; N.E.]	21/42	0.5 [0.3; 1.4]	0.42	[0.21; 0.87]	0.014	N.E.
	(31.7)		(50.0)					
Geographic region								
(Interaction test: p = 0.170)								
Europe excluding Germany	97/202	2.9 [1.4; 8.3]	100/203	1.3 [0.7; 2.8]	0.87	[0.65; 1.15]	0.244	0.118

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(48.0)		(49.3)					
Germany	38/91	2.4 [1.2; 9.0]	29/68	0.8 [0.4; 2.8]	0.60	[0.35; 1.03]	0.279	0.622
	(41.8)		(42.6)					
Others	82/188	7.4 [3.0; N.E.]	116/206	1.4 [0.7; 2.6]	0.63	[0.47; 0.84]	0.003	0.060
	(43.6)		(56.3)					
Headache - Interference (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.191)								
Low	121/291	7.4 [3.7; 17.5]	148/292	2.8 [1.9; 4.7]	0.67	[0.53; 0.86]	0.004	0.826
	(41.6)		(50.7)					
Intermediate	48/129	16.6 [4.4; N.E.]	42/128	20.3 [4.2; N.E.]	1.00	[0.66; 1.52]	0.966	0.489
	(37.2)		(32.8)					
High	25/61	11.1 [3.5; 22.1]	21/57	11.1 [1.7; N.E.]	0.99	[0.55; 1.79]	0.967	0.548
	(41.0)		(36.8)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.580)								
Female	82/175 (46.9)	3.8 [2.3; 11.2]	96/201 (47.8)	2.6 [1.9; 4.6]	0.85	[0.63; 1.15]	0.405	0.565
Male	112/306 (36.6)	18.4 [9.0; N.E.]	115/276 (41.7)	8.3 [3.5; 13.9]	0.76	[0.58; 0.99]	0.050	0.921
Race								
(Interaction test: p = 0.486)								
Asian	53/128 (41.4)	23.0 [4.2; N.E.]	67/132 (50.8)	4.4 [2.3; 19.4]	0.74	[0.52; 1.07]	0.128	0.503
White	136/333 (40.8)	6.5 [3.9; 15.7]	135/320 (42.2)	4.2 [2.6; 11.1]	0.83	[0.65; 1.06]	0.167	0.939
Others	5/20 (25.0)	N.E. [0.4; N.E.]	9/25 (36.0)	3.7 [0.4; N.E.]	0.50	[0.15; 1.67]	0.305	N.E.
Age groups								
(Interaction test: p = 0.684)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	162/390 (41.5)	10.2 [4.6; 18.4]	183/397 (46.1)	3.5 [2.3; 5.6]	0.74	[0.60; 0.92]	0.013	0.947
65 - < 75 years	26/72 (36.1)	16.6 [2.7; N.E.]	18/53 (34.0)	12.9 [2.8; N.E.]	0.89	[0.46; 1.75]	0.713	0.768
>= 75 years	6/19 (31.6)	19.4 [0.5; N.E.]	10/27 (37.0)	10.3 [1.2; N.E.]	0.64	[0.19; 2.17]	0.381	0.400
Pre-randomization selection of TKI								
(Interaction test: p = 0.521)								
Imatinib	34/101 (33.7)	18.4 [3.5; N.E.]	40/102 (39.2)	6.6 [2.6; N.E.]	0.83	[0.52; 1.31]	0.422	N.E.
Nilotinib	148/339 (43.7)	6.5 [4.2; 12.9]	153/333 (45.9)	3.7 [2.3; 8.3]	0.78	[0.62; 0.98]	0.060	0.594
Dasatinib	12/41 (29.3)	N.E. [1.9; N.E.]	18/42 (42.9)	3.3 [0.5; 18.5]	0.64	[0.30; 1.33]	0.251	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.268)								
Europe excluding Germany	89/202 (44.1)	5.3 [3.3; 16.6]	84/203 (41.4)	5.2 [2.8; 14.8]	0.92	[0.67; 1.24]	0.754	0.159
Germany	33/91 (36.3)	4.7 [3.3; 10.3]	27/68 (39.7)	4.6 [1.2; 13.9]	0.62	[0.36; 1.07]	0.149	0.972
Others	72/188 (38.3)	23.0 [5.6; N.E.]	100/206 (48.5)	3.5 [2.3; 8.3]	0.65	[0.48; 0.88]	0.007	0.754
Edema - Interference (MID=1)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.736)								
Low	53/291 (18.2)	N.E. [N.E.; N.E.]	87/292 (29.8)	27.6 [18.5; N.E.]	0.53	[0.37; 0.75]	<0.001	0.174
Intermediate	32/129	N.E. [22.1; N.E.]	36/128	N.E. [7.5; N.E.]	0.65	[0.40; 1.06]	0.098	0.311

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(24.8)		(28.1)					
High	8/61	N.E. [N.E.; N.E.]	12/57	N.E. [12.9; N.E.]	0.40	[0.16; 1.02]	0.081	0.486
	(13.1)		(21.1)					
Sex								
(Interaction test: p = 0.211)								
Female	37/175	N.E. [N.E.; N.E.]	70/201	18.5 [5.8; N.E.]	0.51	[0.34; 0.77]	0.001	0.023
	(21.1)		(34.8)					
Male	56/306	N.E. [N.E.; N.E.]	65/276	N.E. [27.6; N.E.]	0.64	[0.44; 0.93]	0.023	0.592
	(18.3)		(23.6)					
Race								
(Interaction test: p = 0.496)								
Asian	33/128	N.E. [N.E.; N.E.]	54/132	N.E. [4.9; N.E.]	0.51	[0.33; 0.80]	0.003	0.735
	(25.8)		(40.9)					
White	55/333	N.E. [N.E.; N.E.]	76/320	27.6 [22.1; N.E.]	0.56	[0.39; 0.80]	0.002	0.037
	(16.5)		(23.8)					
Others	5/20	N.E. [2.8; N.E.]	5/25	N.E. [1.5; N.E.]	1.04	[0.24; 4.41]	0.865	N.E.

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(25.0)		(20.0)					
Age groups								
(Interaction test: p = 0.471)								
18 - < 65 years	76/390	N.E. [N.E.; N.E.]	106/397	N.E. [27.6; N.E.]	0.62	[0.46; 0.84]	0.002	0.073
	(19.5)		(26.7)					
65 - < 75 years	12/72	N.E. [N.E.; N.E.]	18/53	11.2 [2.1; N.E.]	0.38	[0.17; 0.86]	0.016	0.378
	(16.7)		(34.0)					
>= 75 years	5/19	22.1 [2.3; N.E.]	11/27	3.1 [1.1; N.E.]	0.34	[0.09; 1.29]	0.094	0.995
	(26.3)		(40.7)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.008)								
Imatinib	15/101	N.E. [N.E.; N.E.]	43/102	4.9 [1.9; 13.8]	0.24	[0.13; 0.45]	<0.001	N.E.
	(14.9)		(42.2)					
Nilotinib	67/339	N.E. [N.E.; N.E.]	83/333	27.6 [27.6; N.E.]	0.68	[0.49; 0.93]	0.020	0.558
	(19.8)		(24.9)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	11/41 (26.8)	N.E. [6.7; N.E.]	9/42 (21.4)	N.E. [4.2; N.E.]	1.03	[0.40; 2.64]	0.990	N.E.
Geographic region (Interaction test: p = 0.303)								
Europe excluding Germany	32/202 (15.8)	N.E. [N.E.; N.E.]	51/203 (25.1)	27.6 [18.5; N.E.]	0.44	[0.27; 0.70]	0.001	0.009
Germany	15/91 (16.5)	N.E. [N.E.; N.E.]	12/68 (17.6)	N.E. [12.9; N.E.]	0.97	[0.43; 2.20]	0.991	0.989
Others	46/188 (24.5)	N.E. [N.E.; N.E.]	72/206 (35.0)	27.6 [10.2; N.E.]	0.57	[0.39; 0.83]	0.003	0.713
Muscle Pain - Interference (MID=1)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.047)								

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Low	116/291 (39.9)	7.4 [3.3; 22.1]	153/292 (52.4)	1.3 [1.0; 2.1]	0.65	[0.51; 0.83]	<0.001	0.356
Intermediate	62/129 (48.1)	1.9 [1.0; 3.8]	54/128 (42.2)	3.7 [1.6; 13.9]	1.14	[0.79; 1.64]	0.547	0.285
High	20/61 (32.8)	N.E. [2.1; N.E.]	22/57 (38.6)	2.8 [1.3; N.E.]	0.75	[0.41; 1.38]	0.340	0.707
Sex								
(Interaction test: p = 0.177)								
Female	82/175 (46.9)	1.4 [1.0; 3.7]	102/201 (50.7)	1.6 [1.0; 2.6]	0.92	[0.69; 1.24]	0.488	0.709
Male	116/306 (37.9)	15.6 [4.4; N.E.]	127/276 (46.0)	3.3 [1.4; 6.5]	0.71	[0.55; 0.91]	0.008	0.288
Race								
(Interaction test: p = 0.368)								
Asian	63/128 (49.2)	4.6 [1.4; 24.9]	73/132 (55.3)	2.1 [0.8; 6.5]	0.83	[0.59; 1.17]	0.322	0.664

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
White	126/333 (37.8)	4.9 [2.8; 22.1]	148/320 (46.3)	1.7 [1.2; 2.8]	0.73	[0.57; 0.92]	0.005	0.239
Others	9/20 (45.0)	3.3 [0.3; N.E.]	8/25 (32.0)	5.5 [0.4; N.E.]	1.81	[0.51; 6.45]	0.614	N.E.
Age groups (Interaction test: p = 0.930)								
18 - < 65 years	159/390 (40.8)	5.2 [3.3; 22.1]	187/397 (47.1)	1.9 [1.1; 3.7]	0.75	[0.60; 0.93]	0.008	0.171
65 - < 75 years	30/72 (41.7)	4.4 [1.2; N.E.]	27/53 (50.9)	2.8 [1.3; 4.4]	0.66	[0.37; 1.17]	0.268	0.405
>= 75 years	9/19 (47.4)	1.8 [0.5; N.E.]	15/27 (55.6)	1.4 [0.5; 4.2]	0.69	[0.24; 1.96]	0.458	0.284
Pre-randomization selection of TKI (Interaction test: p = 0.164)								
Imatinib	32/101	19.4 [1.5; N.E.]	54/102	1.0 [0.5; 3.5]	0.53	[0.34; 0.82]	0.003	N.E.


	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(31.7)		(52.9)					
Nilotinib	150/339	3.8 [2.4; 8.3]	160/333	1.9 [1.2; 3.3]	0.81	[0.65; 1.02]	0.070	0.518
	(44.2)		(48.0)					
Dasatinib	16/41	3.4 [0.7; N.E.]	15/42	13.8 [0.5; N.E.]	1.04	[0.50; 2.15]	0.919	N.E.
	(39.0)		(35.7)					
Geographic region								
(Interaction test: p = 0.495)								
Europe excluding Germany	77/202	14.8 [2.6; N.E.]	96/203	1.7 [1.2; 3.7]	0.68	[0.50; 0.92]	0.010	0.146
	(38.1)		(47.3)					
Germany	33/91	3.1 [0.6; 11.1]	31/68	0.9 [0.5; 1.7]	0.76	[0.44; 1.31]	0.315	0.986
	(36.3)		(45.6)					
Others	88/188	3.8 [2.1; 19.4]	102/206	3.2 [1.6; 6.5]	0.87	[0.66; 1.17]	0.414	0.345
	(46.8)		(49.5)					

	Treatment groups				Comparison			
	Asciminib (N=481)		Investigator Selected TKI (N=477)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				

MID: Minimally important difference
N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
In this sensitivity analysis a missing assessment before randomization is substituted by the last assessment before or on the day of treatment start, if such an assessment is available.
If there are not at least 10 patients in every subgroup or not more than 10 events per subgroup per treatment arm, no subgroup analyses were performed for the corresponding attribute.
If there are not more than 10 events per subgroup per treatment arm, no Cox PH hazard analysis is carried out.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariates treatment arm and baseline PRO score.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates. P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT) and Pre-Randomization selection TKI (IRT).
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Interference (MID=1): Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Interference (MID=1): Pre-randomization selection of TKI: Nilotinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)


Edema - Interference (MID=1): Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Muscle Pain - Interference (MID=1): Stratification factor: ELTS based on randomization data from IRT: Low




Pts at Risk (censored)

Asciminib	291 (0)	99 (89)	69 (113)	45 (133)	23 (153)	7 (168)	0 (175)
Investigator Selected TKI	292 (0)	72 (78)	44 (100)	27 (114)	15 (124)	3 (136)	0 (139)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Muscle Pain - Interference (MID=1): Stratification factor: ELTS based on randomization data from IRT: Intermediate




Pts at Risk (censored)

Asciminib	129 (0)	35 (34)	23 (45)	15 (52)	6 (61)	0 (67)	0 (67)
Investigator Selected TKI	128 (0)	36 (43)	20 (56)	10 (64)	5 (69)	1 (73)	0 (74)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6 PRO-CTCAE - Interference: Time to first deterioration analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START - Sensitivity analysis with alternative definition of baseline: Kaplan-Meier plot by subgroups (Full Analysis Set)

Muscle Pain - Interference (MID=1): Stratification factor: ELTS based on randomization data from IRT: High



Pts at Risk (censored)


Asciminib	61 (0)	24 (18)	16 (25)	10 (31)	6 (35)	2 (39)	0 (41)
Investigator Selected TKI	57 (0)	12 (23)	7 (28)	5 (30)	3 (32)	0 (35)	0 (35)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	27/153	47/150	0.43	0.26; 0.70	<0.001
ASC4START	49/237	59/247	0.78	0.53; 1.14	0.200
Pooled Analysis	76/390	106/397	0.62	0.46; 0.84	0.002
65 - < 75 years					
ASC4FIRST	5/34	12/29	0.25	0.07; 0.93	0.027
ASC4START	7/38	6/24	0.54	0.18; 1.64	0.255
Pooled Analysis	12/72	18/53	0.38	0.17; 0.86	0.016
>= 75 years					
ASC4FIRST	4/10	6/14	0.66	0.15; 3.02	0.595
ASC4START	1/9	5/13	0.13	0.01; 2.75	0.045
Pooled Analysis	5/19	11/27	0.34	0.09; 1.29	0.094




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	3/20	0.19	0.02; 1.87	0.118
ASC4START	6/38	9/37	0.48	0.17; 1.38	0.243
Pooled Analysis	8/61	12/57	0.40	0.16; 1.02	0.081
Intermediate					
ASC4FIRST	14/54	20/53	0.52	0.25; 1.07	0.048
ASC4START	18/75	16/75	0.85	0.43; 1.69	0.698
Pooled Analysis	32/129	36/128	0.65	0.40; 1.06	0.098
Low					
ASC4FIRST	20/120	42/120	0.38	0.22; 0.66	<0.001
ASC4START	33/171	45/172	0.67	0.43; 1.06	0.096
Pooled Analysis	53/291	87/292	0.53	0.37; 0.75	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	7/64	23/62	0.15	0.06; 0.38	<0.001
ASC4START	25/138	28/141	0.73	0.42; 1.28	0.350
Pooled Analysis	32/202	51/203	0.44	0.27; 0.70	0.001
Germany					
ASC4FIRST	3/19	2/15	8.33	0.24; 289.29	0.072
ASC4START	12/72	10/53	0.72	0.31; 1.70	0.496
Pooled Analysis	15/91	12/68	0.97	0.43; 2.20	0.991
Others					
ASC4FIRST	26/114	40/116	0.53	0.32; 0.89	0.015
ASC4START	20/74	32/90	0.61	0.34; 1.08	0.096
Pooled Analysis	46/188	72/206	0.57	0.39; 0.83	0.003




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	11/41	9/42	1.03	0.40; 2.64	0.990
Pooled Analysis	11/41	9/42	1.03	0.40; 2.64	0.990
Imatinib					
ASC4FIRST	15/101	43/102	0.24	0.13; 0.45	<0.001
Pooled Analysis	15/101	43/102	0.24	0.13; 0.45	<0.001
Nilotinib					
ASC4FIRST	10/55	13/49	0.54	0.23; 1.23	0.137
ASC4START	57/284	70/284	0.71	0.50; 1.01	0.056
Pooled Analysis	67/339	83/333	0.68	0.49; 0.93	0.020




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	12/40	20/46	0.58	0.28; 1.19	0.121
Pooled Analysis	33/128	54/132	0.51	0.33; 0.80	0.003
Asian/Others					
ASC4FIRST	22/91	34/90	0.53	0.31; 0.93	0.014
Others					
ASC4START	4/17	5/21	1.04	0.24; 4.41	0.865
Pooled Analysis	5/20	5/25	1.04	0.24; 4.41	0.865
White					
ASC4FIRST	14/106	31/103	0.29	0.14; 0.58	<0.001
ASC4START	41/227	45/217	0.74	0.48; 1.13	0.174
Pooled Analysis	55/333	76/320	0.56	0.39; 0.80	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Edema - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	8/68	30/75	0.24	0.11; 0.54	<0.001
ASC4START	29/107	40/126	0.72	0.44; 1.17	0.183
Pooled Analysis	37/175	70/201	0.51	0.34; 0.77	0.001
Male					
ASC4FIRST	28/129	35/118	0.58	0.34; 0.97	0.039
ASC4START	28/177	30/158	0.73	0.44; 1.23	0.251
Pooled Analysis	56/306	65/276	0.64	0.44; 0.93	0.023




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	59/153	80/150	0.52	0.37; 0.74	<0.001
ASC4START	124/237	121/247	0.93	0.72; 1.19	0.801
Pooled Analysis	183/390	201/397	0.75	0.61; 0.92	0.022
65 - < 75 years					
ASC4FIRST	9/34	19/29	0.41	0.15; 1.09	0.014
ASC4START	18/38	10/24	0.86	0.37; 2.01	0.853
Pooled Analysis	27/72	29/53	0.63	0.35; 1.16	0.112
>= 75 years					
ASC4FIRST	5/10	8/14	3.91	0.60; 25.63	0.731
ASC4START	2/9	7/13	0.43	0.08; 2.30	0.076
Pooled Analysis	7/19	15/27	1.01	0.34; 3.05	0.144




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	4/23	8/20	0.25	0.06; 0.96	0.020
ASC4START	14/38	14/37	0.61	0.29; 1.31	0.448
Pooled Analysis	18/61	22/57	0.49	0.26; 0.94	0.064
Intermediate					
ASC4FIRST	24/54	29/53	0.59	0.34; 1.02	0.064
ASC4START	37/75	36/75	0.88	0.56; 1.39	0.431
Pooled Analysis	61/129	65/128	0.74	0.52; 1.06	0.075
Low					
ASC4FIRST	45/120	70/120	0.50	0.34; 0.73	<0.001
ASC4START	93/171	88/172	0.98	0.73; 1.31	0.863
Pooled Analysis	138/291	158/292	0.76	0.61; 0.96	0.034




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	27/64	34/62	0.59	0.35; 1.01	0.023
ASC4START	70/138	66/141	1.00	0.71; 1.41	0.963
Pooled Analysis	97/202	100/203	0.87	0.65; 1.15	0.244
Germany					
ASC4FIRST	2/19	5/15	0.32	0.03; 3.31	0.317
ASC4START	36/72	24/53	0.62	0.35; 1.07	0.382
Pooled Analysis	38/91	29/68	0.60	0.35; 1.03	0.279
Others					
ASC4FIRST	44/114	68/116	0.50	0.34; 0.73	<0.001
ASC4START	38/74	48/90	0.87	0.56; 1.34	0.519
Pooled Analysis	82/188	116/206	0.63	0.47; 0.84	0.003




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	13/41	21/42	0.42	0.21; 0.87	0.014
Pooled Analysis	13/41	21/42	0.42	0.21; 0.87	0.014
Imatinib					
ASC4FIRST	41/101	58/102	0.63	0.42; 0.94	0.013
Pooled Analysis	41/101	58/102	0.63	0.42; 0.94	0.013
Nilotinib					
ASC4FIRST	19/55	28/49	0.36	0.20; 0.67	0.002
ASC4START	144/284	138/284	0.92	0.72; 1.16	0.618
Pooled Analysis	163/339	166/333	0.81	0.65; 1.00	0.116




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	22/40	31/46	0.75	0.43; 1.32	0.398
Pooled Analysis	62/128	83/132	0.65	0.46; 0.91	0.024
Asian/Others					
ASC4FIRST	41/91	52/90	0.61	0.40; 0.92	0.029
Others					
ASC4START	7/17	8/21	0.79	0.26; 2.40	0.773
Pooled Analysis	8/20	8/25	0.79	0.26; 2.40	0.773
White					
ASC4FIRST	32/106	55/103	0.41	0.26; 0.66	<0.001
ASC4START	115/227	99/217	0.97	0.74; 1.27	0.848
Pooled Analysis	147/333	154/320	0.78	0.62; 0.98	0.019




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Fatigue - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	22/68	44/75	0.43	0.25; 0.74	<0.001
ASC4START	60/107	67/126	0.94	0.66; 1.34	0.899
Pooled Analysis	82/175	111/201	0.74	0.55; 0.99	0.042
Male					
ASC4FIRST	51/129	63/118	0.59	0.40; 0.85	0.005
ASC4START	84/177	71/158	0.94	0.68; 1.29	0.702
Pooled Analysis	135/306	134/276	0.77	0.60; 0.98	0.036




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	57/153	64/150	0.75	0.52; 1.08	0.152
ASC4START	105/237	119/247	0.75	0.57; 0.97	0.043
Pooled Analysis	162/390	183/397	0.74	0.60; 0.92	0.013
65 - < 75 years					
ASC4FIRST	10/34	11/29	0.81	0.30; 2.18	0.408
ASC4START	16/38	7/24	0.99	0.38; 2.59	0.779
Pooled Analysis	26/72	18/53	0.89	0.46; 1.75	0.713
>= 75 years					
ASC4FIRST	3/10	3/14	1.28	0.18; 9.24	0.977
ASC4START	3/9	7/13	0.42	0.08; 2.16	0.289
Pooled Analysis	6/19	10/27	0.64	0.19; 2.17	0.381




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	8/23	5/20	1.27	0.40; 3.98	0.632
ASC4START	17/38	16/37	0.89	0.45; 1.77	0.739
Pooled Analysis	25/61	21/57	0.99	0.55; 1.79	0.967
Intermediate					
ASC4FIRST	20/54	21/53	0.86	0.46; 1.61	0.556
ASC4START	28/75	21/75	1.15	0.65; 2.02	0.637
Pooled Analysis	48/129	42/128	1.00	0.66; 1.52	0.966
Low					
ASC4FIRST	42/120	52/120	0.72	0.47; 1.09	0.153
ASC4START	79/171	96/172	0.66	0.49; 0.89	0.012
Pooled Analysis	121/291	148/292	0.67	0.53; 0.86	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	27/64	22/62	1.33	0.73; 2.40	0.300
ASC4START	62/138	62/141	0.80	0.56; 1.14	0.322
Pooled Analysis	89/202	84/203	0.92	0.67; 1.24	0.754
Germany					
ASC4FIRST	2/19	4/15	0.59	0.09; 3.94	0.647
ASC4START	31/72	23/53	0.62	0.35; 1.10	0.171
Pooled Analysis	33/91	27/68	0.62	0.36; 1.07	0.149
Others					
ASC4FIRST	41/114	52/116	0.62	0.41; 0.94	0.032
ASC4START	31/74	48/90	0.69	0.44; 1.08	0.101
Pooled Analysis	72/188	100/206	0.65	0.48; 0.88	0.007




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	12/41	18/42	0.64	0.30; 1.33	0.251
Pooled Analysis	12/41	18/42	0.64	0.30; 1.33	0.251
Imatinib					
ASC4FIRST	34/101	40/102	0.83	0.52; 1.31	0.422
Pooled Analysis	34/101	40/102	0.83	0.52; 1.31	0.422
Nilotinib					
ASC4FIRST	24/55	20/49	0.91	0.49; 1.69	0.923
ASC4START	124/284	133/284	0.76	0.60; 0.98	0.047
Pooled Analysis	148/339	153/333	0.78	0.62; 0.98	0.060




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	18/40	30/46	0.65	0.36; 1.17	0.125
Pooled Analysis	53/128	67/132	0.74	0.52; 1.07	0.128
Asian/Others					
ASC4FIRST	36/91	37/90	0.80	0.50; 1.28	0.483
Others					
ASC4START	4/17	9/21	0.50	0.15; 1.67	0.305
Pooled Analysis	5/20	9/25	0.50	0.15; 1.67	0.305
White					
ASC4FIRST	34/106	41/103	0.84	0.53; 1.34	0.464
ASC4START	102/227	94/217	0.82	0.62; 1.09	0.242
Pooled Analysis	136/333	135/320	0.83	0.65; 1.06	0.167




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Headache - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	26/68	31/75	1.06	0.61; 1.85	0.862
ASC4START	56/107	65/126	0.80	0.56; 1.14	0.269
Pooled Analysis	82/175	96/201	0.85	0.63; 1.15	0.405
Male					
ASC4FIRST	44/129	47/118	0.74	0.48; 1.12	0.184
ASC4START	68/177	68/158	0.78	0.55; 1.09	0.147
Pooled Analysis	112/306	115/276	0.76	0.58; 0.99	0.050




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	55/153	72/150	0.61	0.43; 0.87	0.009
ASC4START	104/237	115/247	0.84	0.64; 1.09	0.181
Pooled Analysis	159/390	187/397	0.75	0.60; 0.93	0.008
65 - < 75 years					
ASC4FIRST	11/34	13/29	0.86	0.35; 2.08	0.646
ASC4START	19/38	14/24	0.52	0.25; 1.10	0.282
Pooled Analysis	30/72	27/53	0.66	0.37; 1.17	0.268
>= 75 years					
ASC4FIRST	4/10	7/14	1.16	0.28; 4.72	0.921
ASC4START	5/9	8/13	0.35	0.07; 1.91	0.222
Pooled Analysis	9/19	15/27	0.69	0.24; 1.96	0.458




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	5/23	4/20	0.94	0.25; 3.58	0.941
ASC4START	15/38	18/37	0.71	0.35; 1.41	0.300
Pooled Analysis	20/61	22/57	0.75	0.41; 1.38	0.340
Intermediate					
ASC4FIRST	23/54	24/53	0.88	0.49; 1.58	0.754
ASC4START	39/75	30/75	1.32	0.81; 2.13	0.303
Pooled Analysis	62/129	54/128	1.14	0.79; 1.64	0.547
Low					
ASC4FIRST	42/120	64/120	0.56	0.38; 0.83	0.003
ASC4START	74/171	89/172	0.71	0.52; 0.97	0.033
Pooled Analysis	116/291	153/292	0.65	0.51; 0.83	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	21/64	34/62	0.48	0.27; 0.84	0.007
ASC4START	56/138	62/141	0.79	0.55; 1.13	0.197
Pooled Analysis	77/202	96/203	0.68	0.50; 0.92	0.010
Germany					
ASC4FIRST	2/19	3/15	15.06	0.19; >1000	0.090
ASC4START	31/72	28/53	0.69	0.40; 1.20	0.173
Pooled Analysis	33/91	31/68	0.76	0.44; 1.31	0.315
Others					
ASC4FIRST	47/114	55/116	0.76	0.52; 1.13	0.246
ASC4START	41/74	47/90	1.01	0.66; 1.54	0.964
Pooled Analysis	88/188	102/206	0.87	0.66; 1.17	0.414




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	16/41	15/42	1.04	0.50; 2.15	0.919
Pooled Analysis	16/41	15/42	1.04	0.50; 2.15	0.919
Imatinib					
ASC4FIRST	32/101	54/102	0.53	0.34; 0.82	0.003
Pooled Analysis	32/101	54/102	0.53	0.34; 0.82	0.003
Nilotinib					
ASC4FIRST	22/55	23/49	0.66	0.36; 1.21	0.267
ASC4START	128/284	137/284	0.84	0.66; 1.07	0.131
Pooled Analysis	150/339	160/333	0.81	0.65; 1.02	0.070




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	24/40	30/46	0.90	0.52; 1.55	0.713
Pooled Analysis	63/128	73/132	0.83	0.59; 1.17	0.322
Asian/Others					
ASC4FIRST	40/91	43/90	0.77	0.50; 1.20	0.351
Others					
ASC4START	8/17	8/21	1.81	0.51; 6.45	0.614
Pooled Analysis	9/20	8/25	1.81	0.51; 6.45	0.614
White					
ASC4FIRST	30/106	49/103	0.57	0.36; 0.90	0.012
ASC4START	96/227	99/217	0.79	0.60; 1.05	0.089
Pooled Analysis	126/333	148/320	0.73	0.57; 0.92	0.005




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 3-7.6.1: Forest-Plot for PRO-CTCAE - Interference: time to first deterioration - Subgroup analysis - Sensitivity analysis with alternative definition of baseline - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Full Analysis Set)

Muscle Pain - Interference (MID=1)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	24/68	36/75	0.84	0.49; 1.43	0.471
ASC4START	58/107	66/126	0.96	0.67; 1.37	0.723
Pooled Analysis	82/175	102/201	0.92	0.69; 1.24	0.488
Male					
ASC4FIRST	46/129	56/118	0.60	0.40; 0.89	0.014
ASC4START	70/177	71/158	0.79	0.57; 1.10	0.163
Pooled Analysis	116/306	127/276	0.71	0.55; 0.91	0.008



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


4. Safety

Table 4-1.1 Any AE: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	480	472	0.74	0.346
Number of patients with events, n (%)	436 (90.8)	443 (93.9)	[0.65; 0.85]	
			<0.001	
Percentiles (months) [95% CI]				
25th	0.1 [0.1; 0.2]	0.1 [0.1; 0.1]		
Median	0.5 [0.5; 0.8]	0.4 [0.3; 0.5]		
75th	2.5 [1.5; 3.0]	1.0 [0.9; 1.2]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.1 Any AE - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.1.1: Forest-Plot for Any AE: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.2 Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Blood and lymphatic system disorders				
N*	480	472	0.86	0.082
Number of patients with events, n (%)	128 (26.7)	141 (29.9)	[0.68; 1.09]	
			0.221	
Percentiles (months) [95% CI]				
25th	8.2 [1.4; N.E.]	2.8 [1.4; 8.9]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Cardiac disorders				
N*	480	472	0.61	0.480
Number of patients with events, n (%)	23 (4.8)	34 (7.2)	[0.36; 1.04]	
			0.065	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [32.6; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [32.6; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Ear and labyrinth disorders				
N*	480	472	0.61	0.030
Number of patients with events, n (%)	14 (2.9)	21 (4.4)	[0.31; 1.20]	
			0.146	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Endocrine disorders				
N*	480	472	1.87	0.664
Number of patients with events, n (%)	12 (2.5)	6 (1.3)	[0.70; 4.98]	
			0.206	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Eye disorders				
N*	480	472	0.67	0.120
Number of patients with events, n (%)	57 (11.9)	75 (15.9)	[0.47; 0.95]	
			0.023	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Gastrointestinal disorders				
N*	480	472	0.82	0.245
Number of patients with events, n (%)	188 (39.2)	204 (43.2)	[0.67; 1.00]	
			0.053	
Percentiles (months) [95% CI]				
25th	3.3 [1.9; 5.4]	1.4 [0.6; 1.9]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [19.9; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
General disorders and administration site conditions				
N*	480	472	0.79	0.208
Number of patients with events, n (%)	143 (29.8)	163 (34.5)	[0.63; 0.99]	
			0.041	
Percentiles (months) [95% CI]				
25th	10.8 [5.6; 16.6]	4.2 [2.3; 6.8]		
Median	N.E. [N.E.; N.E.]	N.E. [31.0; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hepatobiliary disorders				
N*	480	472	0.67	0.016
Number of patients with events, n (%)	26 (5.4)	34 (7.2)	[0.40; 1.13]	
			0.130	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Infections and infestations				
N*	480	472	0.95	0.067
Number of patients with events, n (%)	213 (44.4)	202 (42.8)	[0.78; 1.15]	
			0.591	
Percentiles (months) [95% CI]				
25th	5.9 [4.3; 7.3]	5.4 [3.8; 6.7]		
Median	24.9 [18.1; N.E.]	22.6 [16.6; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Injury, poisoning and procedural complications				
N*	480	472	1.52	0.199
Number of patients with events, n (%)	39 (8.1)	24 (5.1)	[0.91; 2.53]	
			0.103	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Investigations				
N*	480	472	0.74	0.599
Number of patients with events, n (%)	190 (39.6)	225 (47.7)	[0.61; 0.90]	
			0.002	
Percentiles (months) [95% CI]				
25th	2.3 [1.2; 5.5]	1.0 [1.0; 1.4]		
Median	N.E. [N.E.; N.E.]	24.8 [11.1; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Metabolism and nutrition disorders				
N*	480	472	0.81	0.479
Number of patients with events, n (%)	94 (19.6)	102 (21.6)	[0.61; 1.07]	
			0.139	
Percentiles (months) [95% CI]				
25th	30.2 [22.0; N.E.]	25.8 [13.8; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Musculoskeletal and connective tissue disorders				
N*	480	472	0.91	0.029
Number of patients with events, n (%)	178 (37.1)	179 (37.9)	[0.74; 1.12]	
			0.396	
Percentiles (months) [95% CI]				
25th	5.4 [2.4; 8.3]	2.8 [1.4; 4.2]		
Median	N.E. [N.E.; N.E.]	31.0 [30.4; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [31.0; N.E.]		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)				
N*	480	472	0.64	0.163
Number of patients with events, n (%)	16 (3.3)	22 (4.7)	[0.34; 1.22]	
			0.174	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Nervous system disorders				
N*	480	472	0.92	0.672
Number of patients with events, n (%)	121 (25.2)	117 (24.8)	[0.72; 1.19]	
			0.552	
Percentiles (months) [95% CI]				
25th	16.6 [11.2; 31.8]	15.3 [8.2; 28.8]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Psychiatric disorders				
N*	480	472	1.51	0.292
Number of patients with events, n (%)	46 (9.6)	29 (6.1)	[0.95; 2.41]	
			0.080	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Renal and urinary disorders				
N*	480	472	0.56	0.833
Number of patients with events, n (%)	16 (3.3)	26 (5.5)	[0.30; 1.05]	
			0.065	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [31.2; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Reproductive system and breast disorders				
N*	480	472	0.94	0.763
Number of patients with events, n (%)	35 (7.3)	33 (7.0)	[0.59; 1.52]	
			0.814	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [29.6; N.E.]		


	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Respiratory, thoracic and mediastinal disorders				
N*	480	472	0.81	0.207
Number of patients with events, n (%)	75 (15.6)	83 (17.6)	[0.59; 1.10]	
			0.178	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	29.2 [22.1; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [31.0; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Skin and subcutaneous tissue disorders				
N*	480	472	0.64	0.055
Number of patients with events, n (%)	165 (34.4)	210 (44.5)	[0.52; 0.78]	
			<0.001	
Percentiles (months) [95% CI]				
25th	5.6 [4.0; 7.8]	1.0 [0.7; 1.7]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [15.8; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Vascular disorders				
N*	480	472	1.44	0.650
Number of patients with events, n (%)	71 (14.8)	46 (9.7)	[0.99; 2.09]	
			0.052	
Percentiles (months) [95% CI]				
25th	32.4 [27.6; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
SOC: System Organ Class
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT),Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Blood and lymphatic system disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Cardiac disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Ear and labyrinth disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Endocrine disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Eye disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Gastrointestinal disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


General disorders and administration site conditions



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hepatobiliary disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Infections and infestations



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Injury, poisoning and procedural complications



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Investigations



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Metabolism and nutrition disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Musculoskeletal and connective tissue disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Neoplasms benign, malignant and unspecified (incl cysts and polyps)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Nervous system disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Psychiatric disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Renal and urinary disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Reproductive system and breast disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Respiratory, thoracic and mediastinal disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Skin and subcutaneous tissue disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2 Any AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Vascular disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Blood and lymphatic system disorders



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Cardiac disorders



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ear and labyrinth disorders




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Endocrine disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	5/196	3/190	1.47	0.35; 6.17	0.597
ASC4START	7/284	3/282	2.27	0.59; 8.79	0.221
Pooled Analysis	12/480	6/472	1.87	0.70; 4.98	0.206




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Eye disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	Hazard Ratio and 95% CL	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**				
ASC4FIRST	31/196	49/190		0.53	0.34; 0.84	0.006
ASC4START	26/284	26/282		0.94	0.54; 1.61	0.817
Pooled Analysis	57/480	75/472		0.67	0.47; 0.95	0.023




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal disorders


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	90/196	102/190	0.73	0.55; 0.97	0.029
ASC4START	98/284	102/282	0.92	0.70; 1.22	0.564
Pooled Analysis	188/480	204/472	0.82	0.67; 1.00	0.053



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

General disorders and administration site conditions




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatobiliary disorders


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	15/196	8/190	1.56	0.65; 3.70	0.312
ASC4START	11/284	26/282	0.39	0.19; 0.79	0.007
Pooled Analysis	26/480	34/472	0.67	0.40; 1.13	0.130



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Infections and infestations




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Injury, poisoning and procedural complications


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	20/196	16/190	1.15	0.59; 2.21	0.687
ASC4START	19/284	8/282	2.29	1.00; 5.23	0.043
Pooled Analysis	39/480	24/472	1.52	0.91; 2.53	0.103



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Metabolism and nutrition disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	Hazard Ratio and 95% CL	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**				
ASC4FIRST	56/196	52/190		0.89	0.61; 1.30	0.536
ASC4START	38/284	50/282		0.72	0.47; 1.10	0.129
Pooled Analysis	94/480	102/472		0.81	0.61; 1.07	0.139




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Musculoskeletal and connective tissue disorders


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	75/196	88/190	0.71	0.52; 0.96	0.028
ASC4START	103/284	91/282	1.13	0.85; 1.50	0.399
Pooled Analysis	178/480	179/472	0.91	0.74; 1.12	0.396



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Neoplasms benign, malignant and unspecified (incl cysts and polyps)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Nervous system disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	55/196	53/190	0.87	0.59; 1.27	0.478
ASC4START	66/284	64/282	0.97	0.69; 1.37	0.870
Pooled Analysis	121/480	117/472	0.92	0.72; 1.19	0.552




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Psychiatric disorders


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	22/196	17/190	1.19	0.63; 2.25	0.588
ASC4START	24/284	12/282	1.97	0.99; 3.95	0.050
Pooled Analysis	46/480	29/472	1.51	0.95; 2.41	0.080



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Renal and urinary disorders




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Reproductive system and breast disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	19/196	16/190	1.01	0.52; 1.98	0.966
ASC4START	16/284	17/282	0.88	0.44; 1.73	0.705
Pooled Analysis	35/480	33/472	0.94	0.59; 1.52	0.814




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Respiratory, thoracic and mediastinal disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	35/196	44/190	0.66	0.42; 1.03	0.064
ASC4START	40/284	39/282	0.98	0.63; 1.53	0.947
Pooled Analysis	75/480	83/472	0.81	0.59; 1.10	0.178




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Skin and subcutaneous tissue disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	77/196	78/190	0.81	0.59; 1.11	0.184
ASC4START	88/284	132/282	0.54	0.41; 0.70	<0.001
Pooled Analysis	165/480	210/472	0.64	0.52; 0.78	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Vascular disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	31/196	17/190	1.61	0.89; 2.91	0.116
ASC4START	40/284	29/282	1.35	0.83; 2.17	0.222
Pooled Analysis	71/480	46/472	1.44	0.99; 2.09	0.052



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.3 Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Abdominal distension				
N*	480	472	0.08	0.994
Number of patients with events, n (%)	1 (0.2)	12 (2.5)	[0.01; 0.59]	
			0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Abdominal pain				
N*	480	472	1.15	0.289
Number of patients with events, n (%)	40 (8.3)	32 (6.8)	[0.72; 1.83]	
			0.554	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Abdominal pain upper				
N*	480	472	1.38	0.770
Number of patients with events, n (%)	23 (4.8)	16 (3.4)	[0.73; 2.61]	
			0.319	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Alanine aminotransferase increased				
N*	480	472	0.44	0.129
Number of patients with events, n (%)	32 (6.7)	65 (13.8)	[0.28; 0.67]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Alopecia				
N*	480	472	0.30	0.855
Number of patients with events, n (%)	14 (2.9)	43 (9.1)	[0.17; 0.55]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Amylase increased				
N*	480	472	0.73	0.257
Number of patients with events, n (%)	20 (4.2)	26 (5.5)	[0.40; 1.30]	
			0.279	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Anaemia				
N*	480	472	0.63	0.026
Number of patients with events, n (%)	49 (10.2)	71 (15.0)	[0.44; 0.91]	
			0.013	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Anxiety				
N*	480	472	1.50	0.663
Number of patients with events, n (%)	13 (2.7)	8 (1.7)	[0.62; 3.63]	
			0.364	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Arthralgia				
N*	480	472	0.88	0.115
Number of patients with events, n (%)	48 (10.0)	51 (10.8)	[0.59; 1.30]	
			0.519	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Aspartate aminotransferase increased				
N*	480	472	0.37	0.366
Number of patients with events, n (%)	19 (4.0)	46 (9.7)	[0.22; 0.63]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Asthenia				
N*	480	472	0.88	0.558
Number of patients with events, n (%)	29 (6.0)	32 (6.8)	[0.53; 1.46]	
			0.626	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Back pain				
N*	480	472	0.96	0.004
Number of patients with events, n (%)	35 (7.3)	34 (7.2)	[0.60; 1.53]	
			0.855	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [30.4; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Blood alkaline phosphatase increased				
N*	480	472	0.63	0.939
Number of patients with events, n (%)	17 (3.5)	26 (5.5)	[0.34; 1.17]	
			0.138	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Blood bilirubin increased				
N*	480	472	0.24	0.033
Number of patients with events, n (%)	14 (2.9)	52 (11.0)	[0.13; 0.44]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Blood cholesterol increased				
N*	480	472	0.76	0.111
Number of patients with events, n (%)	13 (2.7)	16 (3.4)	[0.36; 1.58]	
			0.460	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Blood creatine phosphokinase increased				
N*	480	472	0.70	0.506
Number of patients with events, n (%)	16 (3.3)	21 (4.4)	[0.37; 1.35]	
			0.288	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Blood creatinine increased				
N*	480	472	0.42	0.933
Number of patients with events, n (%)	7 (1.5)	15 (3.2)	[0.17; 1.02]	
			0.048	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Bone pain				
N*	480	472	3.14	0.249
Number of patients with events, n (%)	16 (3.3)	5 (1.1)	[1.15; 8.58]	
			0.018	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Bronchitis				
N*	480	472	0.67	0.166
Number of patients with events, n (%)	12 (2.5)	16 (3.4)	[0.32; 1.43]	
			0.299	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Chest pain				
N*	480	472	0.51	0.151
Number of patients with events, n (%)	7 (1.5)	13 (2.8)	[0.20; 1.28]	
			0.145	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Constipation				
N*	480	472	0.75	0.075
Number of patients with events, n (%)	30 (6.3)	37 (7.8)	[0.46; 1.21]	
			0.234	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Cough				
N*	480	472	0.88	0.066
Number of patients with events, n (%)	31 (6.5)	32 (6.8)	[0.54; 1.45]	
			0.623	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
COVID-19				
N*	480	472	0.96	0.429
Number of patients with events, n (%)	60 (12.5)	56 (11.9)	[0.66; 1.38]	
			0.816	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [30.3; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Decreased appetite				
N*	480	472	0.81	0.420
Number of patients with events, n (%)	12 (2.5)	14 (3.0)	[0.37; 1.74]	
			0.583	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Depression				
N*	480	472	1.43	0.606
Number of patients with events, n (%)	11 (2.3)	7 (1.5)	[0.55; 3.69]	
			0.458	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Diarrhoea				
N*	480	472	0.83	0.046
Number of patients with events, n (%)	65 (13.5)	72 (15.3)	[0.59; 1.16]	
			0.272	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [29.4; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Dizziness				
N*	480	472	0.70	0.428
Number of patients with events, n (%)	18 (3.8)	24 (5.1)	[0.38; 1.30]	
			0.260	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Dry eye				
N*	480	472	1.05	0.216
Number of patients with events, n (%)	21 (4.4)	19 (4.0)	[0.56; 1.95]	
			0.888	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Dry skin				
N*	480	472	0.86	0.290
Number of patients with events, n (%)	22 (4.6)	24 (5.1)	[0.48; 1.53]	
			0.607	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Dyspepsia				
N*	480	472	0.64	0.746
Number of patients with events, n (%)	13 (2.7)	18 (3.8)	[0.31; 1.32]	
			0.223	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Dyspnoea				
N*	480	472	1.12	0.019
Number of patients with events, n (%)	14 (2.9)	12 (2.5)	[0.52; 2.44]	
			0.765	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [31.0; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Eczema				
N*	480	472	0.52	0.857
Number of patients with events, n (%)	7 (1.5)	12 (2.5)	[0.20; 1.32]	
			0.161	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Face oedema				
N*	480	472	0.05	N.E.
Number of patients with events, n (%)	0	10 (2.1)	[0.00; 0.92]	
			0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Fatigue				
N*	480	472	0.84	0.891
Number of patients with events, n (%)	62 (12.9)	68 (14.4)	[0.59; 1.19]	
			0.320	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [29.4; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Folliculitis				
N*	480	472	0.58	0.240
Number of patients with events, n (%)	6 (1.3)	10 (2.1)	[0.21; 1.58]	
			0.278	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Gamma-glutamyltransferase increased				
N*	480	472	0.75	0.112
Number of patients with events, n (%)	27 (5.6)	33 (7.0)	[0.45; 1.25]	
			0.274	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Gastroenteritis				
N*	480	472	0.72	0.302
Number of patients with events, n (%)	11 (2.3)	14 (3.0)	[0.33; 1.59]	
			0.415	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Gastrooesophageal reflux disease				
N*	480	472	1.08	0.671
Number of patients with events, n (%)	13 (2.7)	11 (2.3)	[0.48; 2.41]	
			0.854	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Headache				
N*	480	472	0.91	0.728
Number of patients with events, n (%)	71 (14.8)	71 (15.0)	[0.66; 1.27]	
			0.606	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hyperbilirubinaemia				
N*	480	472	0.31	0.203
Number of patients with events, n (%)	4 (0.8)	12 (2.5)	[0.10; 0.96]	
			0.032	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hypercholesterolaemia				
N*	480	472	0.49	0.078
Number of patients with events, n (%)	13 (2.7)	23 (4.9)	[0.25; 0.98]	
			0.040	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hyperlipidaemia				
N*	480	472	1.01	0.335
Number of patients with events, n (%)	14 (2.9)	12 (2.5)	[0.46; 2.19]	
			0.986	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hypertension				
N*	480	472	2.13	0.428
Number of patients with events, n (%)	46 (9.6)	20 (4.2)	[1.26; 3.61]	
			0.004	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hypertriglyceridaemia				
N*	480	472	2.00	0.244
Number of patients with events, n (%)	19 (4.0)	9 (1.9)	[0.91; 4.43]	
			0.079	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hyperuricaemia				
N*	480	472	1.36	0.487
Number of patients with events, n (%)	15 (3.1)	10 (2.1)	[0.61; 3.02]	
			0.456	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hypocalcaemia				
N*	480	472	0.65	0.990
Number of patients with events, n (%)	7 (1.5)	10 (2.1)	[0.25; 1.72]	
			0.387	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hypokalaemia				
N*	480	472	0.25	0.211
Number of patients with events, n (%)	3 (0.6)	10 (2.1)	[0.07; 0.93]	
			0.026	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hypophosphataemia				
N*	480	472	0.17	0.168
Number of patients with events, n (%)	3 (0.6)	16 (3.4)	[0.05; 0.59]	
			0.002	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Influenza				
N*	480	472	1.00	0.852
Number of patients with events, n (%)	14 (2.9)	13 (2.8)	[0.47; 2.13]	
			0.996	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Influenza like illness				
N*	480	472	0.88	0.045
Number of patients with events, n (%)	15 (3.1)	15 (3.2)	[0.43; 1.81]	
			0.732	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Insomnia				
N*	480	472	1.26	0.620
Number of patients with events, n (%)	16 (3.3)	12 (2.5)	[0.59; 2.66]	
			0.546	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Leukopenia				
N*	480	472	0.96	0.267
Number of patients with events, n (%)	23 (4.8)	23 (4.9)	[0.54; 1.72]	
			0.898	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Lipase increased				
N*	480	472	0.94	0.608
Number of patients with events, n (%)	57 (11.9)	57 (12.1)	[0.65; 1.35]	
			0.722	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [30.4; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Low density lipoprotein increased				
N*	480	472	0.76	0.042
Number of patients with events, n (%)	9 (1.9)	11 (2.3)	[0.32; 1.84]	
			0.544	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Lymphocyte count decreased				
N*	480	472	0.68	0.780
Number of patients with events, n (%)	11 (2.3)	16 (3.4)	[0.31; 1.46]	
			0.314	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Muscle spasms				
N*	480	472	0.39	0.066
Number of patients with events, n (%)	16 (3.3)	37 (7.8)	[0.22; 0.70]	
			0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Myalgia				
N*	480	472	1.05	0.197
Number of patients with events, n (%)	66 (13.8)	59 (12.5)	[0.73; 1.49]	
			0.800	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [31.0; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Nasopharyngitis				
N*	480	472	1.21	0.557
Number of patients with events, n (%)	29 (6.0)	23 (4.9)	[0.70; 2.09]	
			0.495	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Nausea				
N*	480	472	0.86	0.004
Number of patients with events, n (%)	51 (10.6)	55 (11.7)	[0.59; 1.26]	
			0.449	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Neutropenia				
N*	480	472	0.82	0.098
Number of patients with events, n (%)	49 (10.2)	57 (12.1)	[0.56; 1.21]	
			0.314	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Neutrophil count decreased				
N*	480	472	0.82	0.705
Number of patients with events, n (%)	38 (7.9)	44 (9.3)	[0.53; 1.27]	
			0.382	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Night sweats				
N*	480	472	2.06	0.073
Number of patients with events, n (%)	11 (2.3)	5 (1.1)	[0.71; 5.92]	
			0.172	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Oedema peripheral				
N*	480	472	0.37	0.380
Number of patients with events, n (%)	8 (1.7)	20 (4.2)	[0.16; 0.84]	
			0.014	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Pain in extremity				
N*	480	472	0.94	0.545
Number of patients with events, n (%)	20 (4.2)	19 (4.0)	[0.50; 1.77]	
			0.853	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Paraesthesia				
N*	480	472	1.74	0.450
Number of patients with events, n (%)	11 (2.3)	6 (1.3)	[0.64; 4.71]	
			0.269	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Periorbital oedema				
N*	480	472	0.16	N.E.
Number of patients with events, n (%)	2 (0.4)	12 (2.5)	[0.04; 0.71]	
			0.006	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Platelet count decreased				
N*	480	472	1.08	0.058
Number of patients with events, n (%)	42 (8.8)	37 (7.8)	[0.69; 1.68]	
			0.739	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Pleural effusion				
N*	480	472	0.03	1.000
Number of patients with events, n (%)	0	13 (2.8)	[0.00; 0.55]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Pneumonia				
N*	480	472	0.63	0.434
Number of patients with events, n (%)	8 (1.7)	10 (2.1)	[0.25; 1.64]	
			0.343	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Pruritus				
N*	480	472	1.00	0.027
Number of patients with events, n (%)	41 (8.5)	38 (8.1)	[0.64; 1.55]	
			0.992	
Percentiles (months) [95% CI]				
25th	N.E. [32.6; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Pyrexia				
N*	480	472	0.74	0.533
Number of patients with events, n (%)	18 (3.8)	22 (4.7)	[0.40; 1.38]	
			0.342	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [31.0; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Rash				
N*	480	472	0.70	0.372
Number of patients with events, n (%)	62 (12.9)	79 (16.7)	[0.50; 0.98]	
			0.038	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Rash maculo-papular				
N*	480	472	0.37	0.211
Number of patients with events, n (%)	6 (1.3)	15 (3.2)	[0.14; 0.95]	
			0.031	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Respiratory tract infection				
N*	480	472	1.89	0.680
Number of patients with events, n (%)	10 (2.1)	5 (1.1)	[0.64; 5.52]	
			0.239	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Rhinorrhoea				
N*	480	472	0.70	0.204
Number of patients with events, n (%)	10 (2.1)	13 (2.8)	[0.31; 1.59]	
			0.390	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Thrombocytopenia				
N*	480	472	0.99	0.322
Number of patients with events, n (%)	72 (15.0)	71 (15.0)	[0.71; 1.37]	
			0.944	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Upper respiratory tract infection				
N*	480	472	0.82	0.234
Number of patients with events, n (%)	30 (6.3)	33 (7.0)	[0.50; 1.34]	
			0.430	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [30.4; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Urinary tract infection				
N*	480	472	0.88	0.261
Number of patients with events, n (%)	10 (2.1)	10 (2.1)	[0.36; 2.12]	
			0.775	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Vertigo				
N*	480	472	0.68	0.020
Number of patients with events, n (%)	8 (1.7)	11 (2.3)	[0.28; 1.70]	
			0.414	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Vitamin D deficiency				
N*	480	472	2.24	0.100
Number of patients with events, n (%)	12 (2.5)	5 (1.1)	[0.79; 6.36]	
			0.120	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Vomiting				
N*	480	472	0.78	0.450
Number of patients with events, n (%)	28 (5.8)	34 (7.2)	[0.47; 1.29]	
			0.332	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Weight increased				
N*	480	472	1.40	0.253
Number of patients with events, n (%)	19 (4.0)	12 (2.5)	[0.68; 2.90]	
			0.359	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
White blood cell count decreased				
N*	480	472	0.80	0.290
Number of patients with events, n (%)	28 (5.8)	34 (7.2)	[0.48; 1.32]	
			0.378	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
PT: Preferred Term
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Abdominal distension



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Abdominal pain



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Abdominal pain upper



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Alanine aminotransferase increased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Alopecia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Amylase increased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Anaemia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Anxiety



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Arthralgia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Aspartate aminotransferase increased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Asthenia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Back pain



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Blood alkaline phosphatase increased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Blood bilirubin increased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Blood cholesterol increased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Blood creatine phosphokinase increased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Blood creatinine increased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Bone pain



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Bronchitis



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Chest pain



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Constipation



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Cough



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


COVID-19



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Decreased appetite



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Depression



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Diarrhoea



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Dizziness



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Dry eye



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Dry skin



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Dyspepsia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Dyspnoea



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Eczema



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Face oedema



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Fatigue



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Folliculitis



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Gamma-glutamyltransferase increased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Gastroenteritis



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Gastrooesophageal reflux disease



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Headache



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hyperbilirubinaemia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hypercholesterolaemia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hyperlipidaemia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hypertension



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hypertriglyceridaemia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hyperuricaemia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hypocalcaemia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hypokalaemia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hypophosphataemia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Influenza



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Influenza like illness



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Insomnia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Leukopenia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Lipase increased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Low density lipoprotein increased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Lymphocyte count decreased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Muscle spasms



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Myalgia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Nasopharyngitis



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Nausea



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Neutropenia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Neutrophil count decreased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Night sweats



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Oedema peripheral



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Pain in extremity



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Paraesthesia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Periorbital oedema



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Platelet count decreased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Pleural effusion



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Pneumonia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Pruritus



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Pyrexia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Rash



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Rash maculo-papular



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Respiratory tract infection



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Rhinorrhoea



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Thrombocytopenia



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Upper respiratory tract infection



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Urinary tract infection



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Vertigo



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Vitamin D deficiency



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Vomiting



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Weight increased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3 Any AE by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


White blood cell count decreased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Abdominal distension




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Abdominal pain


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	Hazard Ratio and 95% CL	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**				
ASC4FIRST	22/196	13/190		1.50	0.76; 2.99	0.242
ASC4START	18/284	19/282		0.90	0.47; 1.72	0.757
Pooled Analysis	40/480	32/472		1.15	0.72; 1.83	0.554



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Abdominal pain upper



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alanine aminotransferase increased




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alopecia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	4/196	13/190	0.28	0.09; 0.85	0.017
ASC4START	10/284	30/282	0.31	0.15; 0.64	<0.001
Pooled Analysis	14/480	43/472	0.30	0.17; 0.55	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Amylase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	Hazard Ratio and 95% CL	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**				
ASC4FIRST	11/196	10/190		1.05	0.44; 2.47	0.917
ASC4START	9/284	16/282		0.53	0.23; 1.19	0.118
Pooled Analysis	20/480	26/472		0.73	0.40; 1.30	0.279




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Anaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	25/196	49/190	0.45	0.28; 0.73	<0.001
ASC4START	24/284	22/282	1.06	0.59; 1.88	0.860
Pooled Analysis	49/480	71/472	0.63	0.44; 0.91	0.013




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Anxiety

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	4/196	3/190	1.14	0.25; 5.13	0.863
ASC4START	9/284	5/282	1.72	0.58; 5.15	0.323
Pooled Analysis	13/480	8/472	1.50	0.62; 3.63	0.364




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arthralgia


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	26/196	19/190	1.25	0.69; 2.26	0.461
ASC4START	22/284	32/282	0.65	0.38; 1.13	0.122
Pooled Analysis	48/480	51/472	0.88	0.59; 1.30	0.519



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Aspartate aminotransferase increased




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Asthenia


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	Hazard Ratio and 95% CL	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**				
ASC4FIRST	8/196	11/190		0.70	0.28; 1.75	0.448
ASC4START	21/284	21/282		0.98	0.53; 1.79	0.939
Pooled Analysis	29/480	32/472		0.88	0.53; 1.46	0.626



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Back pain



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Blood alkaline phosphatase increased



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Blood bilirubin increased



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood cholesterol increased




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood creatine phosphokinase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	11/196	12/190	0.84	0.37; 1.89	0.666
ASC4START	5/284	9/282	0.53	0.18; 1.57	0.241
Pooled Analysis	16/480	21/472	0.70	0.37; 1.35	0.288




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood creatinine increased


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	4/196	8/190	0.43	0.13; 1.43	0.157
ASC4START	3/284	7/282	0.40	0.10; 1.54	0.168
Pooled Analysis	7/480	15/472	0.42	0.17; 1.02	0.048



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Bone pain



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Bronchitis




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

COVID-19

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	41/196	41/190	0.87	0.56; 1.34	0.532
ASC4START	19/284	15/282	1.20	0.61; 2.37	0.591
Pooled Analysis	60/480	56/472	0.96	0.66; 1.38	0.816




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Chest pain

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	2/196	8/190	0.23	0.05; 1.08	0.042
ASC4START	5/284	5/282	0.98	0.28; 3.40	0.978
Pooled Analysis	7/480	13/472	0.51	0.20; 1.28	0.145




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Constipation


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	20/196	16/190	1.12	0.58; 2.17	0.731
ASC4START	10/284	21/282	0.45	0.21; 0.96	0.034
Pooled Analysis	30/480	37/472	0.75	0.46; 1.21	0.234



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Cough




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Decreased appetite


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	6/196	9/190	0.61	0.22; 1.72	0.345
ASC4START	6/284	5/282	1.17	0.36; 3.83	0.798
Pooled Analysis	12/480	14/472	0.81	0.37; 1.74	0.583



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Depression



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Diarrhoea




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Dizziness

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	9/196	9/190	0.93	0.37; 2.36	0.887
ASC4START	9/284	15/282	0.57	0.25; 1.29	0.172
Pooled Analysis	18/480	24/472	0.70	0.38; 1.30	0.260




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Dry eye

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	14/196	9/190	1.48	0.64; 3.42	0.358
ASC4START	7/284	10/282	0.66	0.25; 1.73	0.394
Pooled Analysis	21/480	19/472	1.05	0.56; 1.95	0.888




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Dry skin


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	11/196	8/190	1.25	0.50; 3.12	0.629
ASC4START	11/284	16/282	0.66	0.31; 1.42	0.282
Pooled Analysis	22/480	24/472	0.86	0.48; 1.53	0.607



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Dyspepsia




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Dyspnoea


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	2/196	7/190	0.25	0.05; 1.22	0.065
ASC4START	12/284	5/282	2.42	0.85; 6.86	0.087
Pooled Analysis	14/480	12/472	1.12	0.52; 2.44	0.765



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Eczema




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Face oedema

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	0/196	10/190	0.05	0.00; 0.92	0.001
ASC4START	0/284	0/282	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/480	10/472	0.05	0.00; 0.92	0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Fatigue


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	30/196	33/190	0.82	0.50; 1.35	0.430
ASC4START	32/284	35/282	0.86	0.53; 1.39	0.535
Pooled Analysis	62/480	68/472	0.84	0.59; 1.19	0.320



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Folliculitis



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gamma-glutamyltransferase increased




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastroenteritis

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	3/196	6/190	0.40	0.10; 1.62	0.185
ASC4START	8/284	8/282	0.98	0.37; 2.62	0.975
Pooled Analysis	11/480	14/472	0.72	0.33; 1.59	0.415




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrooesophageal reflux disease

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	6/196	4/190	1.33	0.37; 4.74	0.658
ASC4START	7/284	7/282	0.93	0.33; 2.66	0.895
Pooled Analysis	13/480	11/472	1.08	0.48; 2.41	0.854




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Headache

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	33/196	30/190	0.98	0.59; 1.61	0.939
ASC4START	38/284	41/282	0.87	0.56; 1.35	0.533
Pooled Analysis	71/480	71/472	0.91	0.66; 1.27	0.606




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hyperbilirubinaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	2/196	2/190	0.93	0.13; 6.59	0.940
ASC4START	2/284	10/282	0.19	0.04; 0.85	0.015
Pooled Analysis	4/480	12/472	0.31	0.10; 0.96	0.032




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypercholesterolaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	9/196	8/190	0.94	0.35; 2.47	0.892
ASC4START	4/284	15/282	0.25	0.08; 0.75	0.008
Pooled Analysis	13/480	23/472	0.49	0.25; 0.98	0.040




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hyperlipidaemia


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	11/196	7/190	1.31	0.51; 3.40	0.576
ASC4START	3/284	5/282	0.56	0.13; 2.35	0.424
Pooled Analysis	14/480	12/472	1.01	0.46; 2.19	0.986



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypertension




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypertriglyceridaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	11/196	3/190	3.44	0.96; 12.32	0.044
ASC4START	8/284	6/282	1.28	0.45; 3.70	0.644
Pooled Analysis	19/480	9/472	2.00	0.91; 4.43	0.079




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hyperuricaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	12/196	9/190	1.19	0.50; 2.84	0.687
ASC4START	3/284	1/282	2.82	0.29; 27.16	0.347
Pooled Analysis	15/480	10/472	1.36	0.61; 3.02	0.456




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypocalcaemia


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	6/196	10/190	0.56	0.20; 1.54	0.252
ASC4START	1/284	0/282	3.01	0.03; 276.93	0.316
Pooled Analysis	7/480	10/472	0.65	0.25; 1.72	0.387



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypokalaemia




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypophosphataemia


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	1/196	12/190	0.07	0.01; 0.58	0.001
ASC4START	2/284	4/282	0.48	0.09; 2.65	0.392
Pooled Analysis	3/480	16/472	0.17	0.05; 0.59	0.002



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Influenza



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Influenza like illness



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Insomnia




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Leukopenia


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	17/196	20/190	0.82	0.43; 1.56	0.537
ASC4START	6/284	3/282	1.94	0.49; 7.77	0.338
Pooled Analysis	23/480	23/472	0.96	0.54; 1.72	0.898



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Lipase increased



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Low density lipoprotein increased




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Lymphocyte count decreased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	10/196	15/190	0.66	0.29; 1.46	0.297
ASC4START	1/284	1/282	0.99	0.06; 15.82	0.994
Pooled Analysis	11/480	16/472	0.68	0.31; 1.46	0.314




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Muscle spasms

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	6/196	23/190	0.22	0.09; 0.55	<0.001
ASC4START	10/284	14/282	0.69	0.31; 1.56	0.370
Pooled Analysis	16/480	37/472	0.39	0.22; 0.70	0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myalgia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	31/196	33/190	0.83	0.51; 1.36	0.470
ASC4START	35/284	26/282	1.33	0.80; 2.20	0.273
Pooled Analysis	66/480	59/472	1.05	0.73; 1.49	0.800




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Nasopharyngitis

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	14/196	13/190	1.03	0.49; 2.20	0.932
ASC4START	15/284	10/282	1.44	0.65; 3.20	0.371
Pooled Analysis	29/480	23/472	1.21	0.70; 2.09	0.495




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Nausea

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	19/196	34/190	0.48	0.27; 0.85	0.010
ASC4START	32/284	21/282	1.52	0.88; 2.63	0.134
Pooled Analysis	51/480	55/472	0.86	0.59; 1.26	0.449




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Neutropenia


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	21/196	33/190	0.59	0.34; 1.03	0.060
ASC4START	28/284	24/282	1.14	0.66; 1.97	0.632
Pooled Analysis	49/480	57/472	0.82	0.56; 1.21	0.314



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Neutrophil count decreased



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Night sweats




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Oedema peripheral

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	3/196	11/190	0.25	0.07; 0.89	0.020
ASC4START	5/284	9/282	0.52	0.18; 1.57	0.240
Pooled Analysis	8/480	20/472	0.37	0.16; 0.84	0.014




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Pain in extremity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	10/196	11/190	0.78	0.33; 1.86	0.583
ASC4START	10/284	8/282	1.16	0.46; 2.95	0.752
Pooled Analysis	20/480	19/472	0.94	0.50; 1.77	0.853




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Paraesthesia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	2/196	2/190	0.90	0.13; 6.40	0.915
ASC4START	9/284	4/282	2.17	0.67; 7.05	0.186
Pooled Analysis	11/480	6/472	1.74	0.64; 4.71	0.269




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Periorbital oedema

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	2/196	12/190	0.16	0.04; 0.71	0.006
ASC4START	0/284	0/282	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	2/480	12/472	0.16	0.04; 0.71	0.006




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Platelet count decreased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	29/196	32/190	0.85	0.51; 1.40	0.515
ASC4START	13/284	5/282	2.58	0.92; 7.23	0.062
Pooled Analysis	42/480	37/472	1.08	0.69; 1.68	0.739




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Pleural effusion

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	0/196	9/190	0.04	0.00; 0.80	<0.001
ASC4START	0/284	4/282	0.10	0.00; 2.61	0.035
Pooled Analysis	0/480	13/472	0.03	0.00; 0.55	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Pneumonia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	4/196	6/190	0.45	0.12; 1.66	0.217
ASC4START	4/284	4/282	0.95	0.24; 3.82	0.948
Pooled Analysis	8/480	10/472	0.63	0.25; 1.64	0.343




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Pruritus

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	19/196	8/190	2.13	0.93; 4.89	0.067
ASC4START	22/284	30/282	0.69	0.40; 1.20	0.187
Pooled Analysis	41/480	38/472	1.00	0.64; 1.55	0.992




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Pyrexia


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	12/196	12/190	0.87	0.39; 1.94	0.734
ASC4START	6/284	10/282	0.58	0.21; 1.59	0.280
Pooled Analysis	18/480	22/472	0.74	0.40; 1.38	0.342



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash maculo-papular


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	3/196	3/190	0.87	0.17; 4.32	0.863
ASC4START	3/284	12/282	0.24	0.07; 0.83	0.015
Pooled Analysis	6/480	15/472	0.37	0.14; 0.95	0.031



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Respiratory tract infection




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rhinorrhoea

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	3/196	7/190	0.36	0.09; 1.40	0.125
ASC4START	7/284	6/282	1.12	0.37; 3.32	0.844
Pooled Analysis	10/480	13/472	0.70	0.31; 1.59	0.390




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Thrombocytopenia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	26/196	31/190	0.81	0.48; 1.36	0.418
ASC4START	46/284	40/282	1.13	0.74; 1.73	0.569
Pooled Analysis	72/480	71/472	0.99	0.71; 1.37	0.944




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Upper respiratory tract infection


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	17/196	23/190	0.65	0.35; 1.22	0.176
ASC4START	13/284	10/282	1.22	0.54; 2.78	0.635
Pooled Analysis	30/480	33/472	0.82	0.50; 1.34	0.430



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Urinary tract infection



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Vertigo



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Vitamin D deficiency



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Vomiting



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Weight increased



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

White blood cell count decreased




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.4 AE with grade >=3: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	480	472	0.76	0.446
Number of patients with events, n (%)	189 (39.4)	215 (45.6)	[0.62; 0.92]	
			0.006	
Percentiles (months) [95% CI]				
25th	4.9 [2.8; 10.1]	2.0 [1.4; 2.8]		
Median	N.E. [31.3; N.E.]	25.8 [16.6; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.4 AE with grade >=3 - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.4.1: Forest-Plot for AE with grade >=3: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.5 AE with grade>=3 by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Blood and lymphatic system disorders				
N*	480	472	0.77	0.022
Number of patients with events, n (%)	55 (11.5)	66 (14.0)	[0.54; 1.11]	
			0.159	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Cardiac disorders				
N*	480	472	0.31	0.992
Number of patients with events, n (%)	4 (0.8)	11 (2.3)	[0.10; 0.98]	
			0.036	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Gastrointestinal disorders				
N*	480	472	0.50	0.906
Number of patients with events, n (%)	7 (1.5)	13 (2.8)	[0.20; 1.25]	
			0.129	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Infections and infestations				
N*	480	472	0.97	0.061
Number of patients with events, n (%)	20 (4.2)	18 (3.8)	[0.51; 1.83]	
			0.921	
Percentiles (months) [95% CI]				
25th	N.E. [31.3; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Investigations				
N*	480	472	0.61	0.031
Number of patients with events, n (%)	60 (12.5)	90 (19.1)	[0.44; 0.85]	
			0.003	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [25.3; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Metabolism and nutrition disorders				
N*	480	472	0.60	0.262
Number of patients with events, n (%)	8 (1.7)	11 (2.3)	[0.24; 1.51]	
			0.277	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Musculoskeletal and connective tissue disorders				
N*	480	472	2.38	0.616
Number of patients with events, n (%)	17 (3.5)	6 (1.3)	[0.93; 6.08]	
			0.061	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Vascular disorders				
N*	480	472	2.05	0.421
Number of patients with events, n (%)	30 (6.3)	13 (2.8)	[1.07; 3.94]	
			0.028	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
SOC: System Organ Class
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT),Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5 AE with grade>=3 by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)

Blood and lymphatic system disorders




Pts at Risk (censored)

Asciminib	480 (0)	408 (18)	377 (49)	268 (158)	164 (262)	41 (385)	0 (425)
Investigator Selected TKI	472 (0)	365 (46)	318 (91)	210 (197)	112 (294)	17 (389)	0 (406)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5 AE with grade>=3 by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Cardiac disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5 AE with grade>=3 by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)

Gastrointestinal disorders




Pts at Risk (censored)

Asciminib	480 (0)	448 (28)	406 (67)	289 (184)	178 (295)	41 (432)	0 (473)
Investigator Selected TKI	472 (0)	417 (48)	357 (106)	237 (223)	137 (323)	23 (436)	0 (459)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5 AE with grade>=3 by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)

Infections and infestations




Pts at Risk (censored)

Asciminib	480 (0)	442 (28)	403 (66)	284 (180)	173 (289)	41 (420)	0 (460)
Investigator Selected TKI	472 (0)	417 (50)	354 (107)	237 (223)	132 (324)	21 (433)	0 (454)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5 AE with grade>=3 by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Investigations



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5 AE with grade>=3 by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Metabolism and nutrition disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5 AE with grade>=3 by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Musculoskeletal and connective tissue disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5 AE with grade>=3 by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)

Vascular disorders



Pts at Risk (censored)


Asciminib	480 (0)	439 (29)	393 (67)	276 (178)	172 (279)	40 (410)	0 (450)
Investigator Selected TKI	472 (0)	414 (52)	351 (112)	239 (223)	136 (326)	23 (436)	0 (459)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood and lymphatic system disorders


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	20/196	36/190	0.48	0.28; 0.84	0.008
ASC4START	35/284	30/282	1.14	0.70; 1.86	0.594
Pooled Analysis	55/480	66/472	0.77	0.54; 1.11	0.159



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Cardiac disorders




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal disorders


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	3/196	5/190	0.53	0.13; 2.23	0.379
ASC4START	4/284	8/282	0.47	0.14; 1.58	0.214
Pooled Analysis	7/480	13/472	0.50	0.20; 1.25	0.129



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Infections and infestations



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Metabolism and nutrition disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	6/196	5/190	0.95	0.28; 3.15	0.929
ASC4START	2/284	6/282	0.30	0.06; 1.49	0.119
Pooled Analysis	8/480	11/472	0.60	0.24; 1.51	0.277




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Musculoskeletal and connective tissue disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	10/196	4/190	1.96	0.61; 6.34	0.252
ASC4START	7/284	2/282	3.24	0.67; 15.61	0.121
Pooled Analysis	17/480	6/472	2.38	0.93; 6.08	0.061




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Vascular disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	13/196	7/190	1.55	0.61; 3.91	0.354
ASC4START	17/284	6/282	2.65	1.04; 6.72	0.033
Pooled Analysis	30/480	13/472	2.05	1.07; 3.94	0.028



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.6 AE with grade>=3 by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Alanine aminotransferase increased				
N*	480	472	0.50	0.842
Number of patients with events, n (%)	10 (2.1)	19 (4.0)	[0.23; 1.07]	
			0.069	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Anaemia				
N*	480	472	0.85	0.006
Number of patients with events, n (%)	15 (3.1)	16 (3.4)	[0.42; 1.72]	
			0.644	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hypertension				
N*	480	472	1.79	0.281
Number of patients with events, n (%)	24 (5.0)	12 (2.5)	[0.89; 3.59]	
			0.097	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Lipase increased				
N*	480	472	0.55	0.368
Number of patients with events, n (%)	9 (1.9)	15 (3.2)	[0.24; 1.26]	
			0.154	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Neutropenia				
N*	480	472	0.70	0.039
Number of patients with events, n (%)	28 (5.8)	38 (8.1)	[0.43; 1.14]	
			0.148	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Neutrophil count decreased				
N*	480	472	0.80	0.770
Number of patients with events, n (%)	15 (3.1)	18 (3.8)	[0.40; 1.58]	
			0.513	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Platelet count decreased				
N*	480	472	1.19	0.392
Number of patients with events, n (%)	13 (2.7)	10 (2.1)	[0.52; 2.73]	
			0.674	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Thrombocytopenia				
N*	480	472	1.28	0.952
Number of patients with events, n (%)	41 (8.5)	31 (6.6)	[0.80; 2.04]	
			0.305	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
PT: Preferred Term
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6 AE with grade>=3 by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)

Alanine aminotransferase increased




Pts at Risk (censored)

Asciminib	480 (0)	448 (27)	407 (66)	288 (182)	178 (292)	42 (428)	0 (470)
Investigator Selected TKI	472 (0)	407 (48)	347 (107)	231 (222)	130 (323)	23 (430)	0 (453)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6 AE with grade>=3 by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)

Anaemia




Pts at Risk (censored)

Asciminib	480 (0)	440 (27)	404 (62)	288 (178)	178 (288)	43 (423)	0 (465)
Investigator Selected TKI	472 (0)	408 (51)	350 (108)	230 (227)	130 (327)	20 (436)	0 (456)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6 AE with grade>=3 by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)

Hypertension




Pts at Risk (censored)

Asciminib	480 (0)	440 (30)	396 (68)	277 (181)	173 (283)	41 (415)	0 (456)
Investigator Selected TKI	472 (0)	415 (52)	352 (112)	239 (224)	136 (327)	23 (437)	0 (460)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6 AE with grade>=3 by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Lipase increased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6 AE with grade>=3 by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)

Neutropenia




Pts at Risk (censored)

Asciminib	480 (0)	430 (22)	397 (55)	284 (168)	173 (279)	43 (409)	0 (452)
Investigator Selected TKI	472 (0)	389 (48)	337 (98)	228 (206)	127 (307)	22 (412)	0 (434)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6 AE with grade>=3 by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)

Neutrophil count decreased




Pts at Risk (censored)

Asciminib	480 (0)	438 (27)	399 (66)	283 (182)	173 (292)	40 (425)	0 (465)
Investigator Selected TKI	472 (0)	407 (50)	347 (108)	229 (225)	128 (326)	21 (433)	0 (454)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6 AE with grade>=3 by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Platelet count decreased



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6 AE with grade>=3 by PT - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)

Thrombocytopenia




Pts at Risk (censored)

Asciminib	480 (0)	419 (20)	386 (53)	274 (165)	169 (270)	42 (397)	0 (439)
Investigator Selected TKI	472 (0)	395 (48)	343 (98)	230 (211)	128 (313)	22 (419)	0 (441)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6.1: Forest-Plot for AE with grade>=3 by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alanine aminotransferase increased




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6.1: Forest-Plot for AE with grade>=3 by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Anaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	4/196	12/190	0.28	0.09; 0.87	0.019
ASC4START	11/284	4/282	2.66	0.85; 8.37	0.081
Pooled Analysis	15/480	16/472	0.85	0.42; 1.72	0.644




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6.1: Forest-Plot for AE with grade>=3 by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypertension

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	10/196	7/190	1.20	0.45; 3.20	0.710
ASC4START	14/284	5/282	2.62	0.94; 7.28	0.055
Pooled Analysis	24/480	12/472	1.79	0.89; 3.59	0.097




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6.1: Forest-Plot for AE with grade>=3 by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Lipase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	6/196	7/190	0.78	0.26; 2.32	0.651
ASC4START	3/284	8/282	0.35	0.09; 1.33	0.107
Pooled Analysis	9/480	15/472	0.55	0.24; 1.26	0.154




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6.1: Forest-Plot for AE with grade>=3 by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Neutropenia


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	9/196	21/190	0.38	0.17; 0.83	0.012
ASC4START	19/284	17/282	1.12	0.58; 2.15	0.743
Pooled Analysis	28/480	38/472	0.70	0.43; 1.14	0.148



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6.1: Forest-Plot for AE with grade>=3 by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Neutrophil count decreased




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6.1: Forest-Plot for AE with grade>=3 by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Platelet count decreased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	10/196	9/190	1.01	0.41; 2.48	0.989
ASC4START	3/284	1/282	2.92	0.30; 28.07	0.331
Pooled Analysis	13/480	10/472	1.19	0.52; 2.73	0.674




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.6.1: Forest-Plot for AE with grade>=3 by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Thrombocytopenia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	15/196	11/190	1.30	0.60; 2.84	0.505
ASC4START	26/284	20/282	1.26	0.70; 2.26	0.434
Pooled Analysis	41/480	31/472	1.28	0.80; 2.04	0.305




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.7 Serious AE: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	480	472	0.88	0.167
Number of patients with events, n (%)	76 (15.8)	77 (16.3)	[0.64; 1.21]	
			0.430	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [24.6; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.7 Serious AE - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.7.1: Forest-Plot for Serious AE: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.8 Serious AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Cardiac disorders				
N*	480	472	0.40	0.992
Number of patients with events, n (%)	5 (1.0)	11 (2.3)	[0.14; 1.14]	
			0.076	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Gastrointestinal disorders				
N*	480	472	0.84	0.587
Number of patients with events, n (%)	11 (2.3)	12 (2.5)	[0.37; 1.91]	
			0.685	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Infections and infestations				
N*	480	472	0.69	0.006
Number of patients with events, n (%)	16 (3.3)	20 (4.2)	[0.36; 1.33]	
			0.263	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
SOC: System Organ Class
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT),Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.8 Serious AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Cardiac disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.8 Serious AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Gastrointestinal disorders



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.8 Serious AE by SOC - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)

Infections and infestations




Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.8.1: Forest-Plot for Serious AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Cardiac disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	0/196	4/190	0.08	0.00; 2.16	0.020
ASC4START	5/284	7/282	0.66	0.21; 2.07	0.471
Pooled Analysis	5/480	11/472	0.40	0.14; 1.14	0.076




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.8.1: Forest-Plot for Serious AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	6/196	5/190	1.07	0.33; 3.51	0.911
ASC4START	5/284	7/282	0.68	0.21; 2.14	0.504
Pooled Analysis	11/480	12/472	0.84	0.37; 1.91	0.685




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.8.1: Forest-Plot for Serious AE by SOC: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Infections and infestations

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	5/196	15/190	0.26	0.09; 0.72	0.006
ASC4START	11/284	5/282	2.09	0.73; 6.01	0.162
Pooled Analysis	16/480	20/472	0.69	0.36; 1.33	0.263



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.9 Serious AE by PT: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

No analyses were performed, because there are not enough patients with an event.

.....
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.10 AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Acute pancreatitis (clinical events)				
N*	480	472	0.33	0.182
Number of patients with events, n (%)	3 (0.6)	9 (1.9)	[0.09; 1.20]	
			0.077	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Acute pancreatitis (including isolated pancreatic enzyme elevations)				
N*	480	472	0.80	0.875
Number of patients with events, n (%)	62 (12.9)	72 (15.3)	[0.57; 1.12]	
			0.196	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [30.4; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Arterial-occlusive events (AOE)				
N*	480	472	0.79	0.327
Number of patients with events, n (%)	11 (2.3)	12 (2.5)	[0.35; 1.79]	
			0.570	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Cardiac failure				
N*	480	472	0.30	0.996
Number of patients with events, n (%)	1 (0.2)	3 (0.6)	[0.03; 2.87]	
			0.267	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Edema and fluid retention				
N*	480	472	0.38	0.255
Number of patients with events, n (%)	19 (4.0)	45 (9.5)	[0.22; 0.65]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Gastrointestinal toxicity				
N*	480	472	0.92	0.091
Number of patients with events, n (%)	162 (33.8)	164 (34.7)	[0.74; 1.14]	
			0.452	
Percentiles (months) [95% CI]				
25th	5.3 [2.3; 10.7]	2.9 [1.7; 5.6]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hemorrhage				
N*	480	472	0.69	0.403
Number of patients with events, n (%)	30 (6.3)	39 (8.3)	[0.43; 1.11]	
			0.121	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hepatotoxicity (clinical events)				
N*	480	472	0.71	0.141
Number of patients with events, n (%)	14 (2.9)	18 (3.8)	[0.35; 1.43]	
			0.339	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hepatotoxicity (including laboratory terms)				
N*	480	472	0.47	0.021
Number of patients with events, n (%)	75 (15.6)	137 (29.0)	[0.35; 0.62]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [30.5; N.E.]	8.3 [5.1; 13.8]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hypersensitivity				
N*	480	472	0.51	0.657
Number of patients with events, n (%)	102 (21.3)	162 (34.3)	[0.40; 0.65]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [15.9; N.E.]	2.3 [1.4; 5.6]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Ischemic heart and CNS conditions				
N*	480	472	0.76	0.371
Number of patients with events, n (%)	26 (5.4)	31 (6.6)	[0.45; 1.28]	
			0.302	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Myelosuppression (Erythropenia)				
N*	480	472	0.63	0.030
Number of patients with events, n (%)	51 (10.6)	74 (15.7)	[0.44; 0.90]	
			0.011	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Myelosuppression (Leukopenia)				
N*	480	472	0.94	0.127
Number of patients with events, n (%)	107 (22.3)	111 (23.5)	[0.72; 1.22]	
			0.644	
Percentiles (months) [95% CI]				
25th	N.E. [2.8; N.E.]	N.E. [2.8; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Myelosuppression (Thrombocytopenia)				
N*	480	472	1.04	0.123
Number of patients with events, n (%)	113 (23.5)	107 (22.7)	[0.80; 1.35]	
			0.772	
Percentiles (months) [95% CI]				
25th	N.E. [2.0; N.E.]	N.E. [2.4; N.E.]		


	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Phototoxicity				
N*	480	472	1.18	0.816
Number of patients with events, n (%)	5 (1.0)	4 (0.8)	[0.32; 4.39]	
			0.809	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
QTc prolongation				
N*	480	472	0.81	0.967
Number of patients with events, n (%)	9 (1.9)	10 (2.1)	[0.33; 2.00]	
			0.653	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Reproductive toxicity				
N*	480	472	0.61	0.245
Number of patients with events, n (%)	4 (0.8)	6 (1.3)	[0.17; 2.18]	
			0.446	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Acute pancreatitis (clinical events)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Acute pancreatitis (including isolated pancreatic enzyme elevations)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Arterial-occlusive events (AOE)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Cardiac failure



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Edema and fluid retention



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Gastrointestinal toxicity



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hemorrhage



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hepatotoxicity (clinical events)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hepatotoxicity (including laboratory terms)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hypersensitivity



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Ischemic heart and CNS conditions



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Myelosuppression (Erythropenia)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Myelosuppression (Leukopenia)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Myelosuppression (Thrombocytopenia)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Phototoxicity



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


QTc prolongation



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10 AESI all grades - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Reproductive toxicity



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Acute pancreatitis (clinical events)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arterial-occlusive events (AOE)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	4/196	2/190	1.64	0.30; 8.99	0.567
ASC4START	7/284	10/282	0.61	0.23; 1.61	0.318
Pooled Analysis	11/480	12/472	0.79	0.35; 1.79	0.570



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Cardiac failure



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	77/196	87/190	0.76	0.56; 1.04	0.085
ASC4START	85/284	77/282	1.11	0.81; 1.51	0.510
Pooled Analysis	162/480	164/472	0.92	0.74; 1.14	0.452




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	13/196	20/190	0.55	0.27; 1.12	0.094
ASC4START	17/284	19/282	0.83	0.43; 1.61	0.586
Pooled Analysis	30/480	39/472	0.69	0.43; 1.11	0.121




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	7/196	4/190	1.50	0.44; 5.15	0.516
ASC4START	7/284	14/282	0.48	0.19; 1.18	0.100
Pooled Analysis	14/480	18/472	0.71	0.35; 1.43	0.339




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	40/196	51/190	0.68	0.45; 1.03	0.069
ASC4START	35/284	86/282	0.35	0.23; 0.51	<0.001
Pooled Analysis	75/480	137/472	0.47	0.35; 0.62	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	52/196	83/190	0.48	0.34; 0.68	<0.001
ASC4START	50/284	79/282	0.54	0.38; 0.77	<0.001
Pooled Analysis	102/480	162/472	0.51	0.40; 0.65	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	15/196	14/190	0.96	0.46; 1.99	0.914
ASC4START	11/284	17/282	0.59	0.28; 1.27	0.174
Pooled Analysis	26/480	31/472	0.76	0.45; 1.28	0.302



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Myelosuppression (Erythropenia)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	55/196	62/190	0.85	0.59; 1.23	0.402
ASC4START	58/284	45/282	1.30	0.88; 1.91	0.192
Pooled Analysis	113/480	107/472	1.04	0.80; 1.35	0.772



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Phototoxicity




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

QTc prolongation

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	4/196	4/190	0.83	0.21; 3.33	0.798
ASC4START	5/284	6/282	0.80	0.24; 2.62	0.709
Pooled Analysis	9/480	10/472	0.81	0.33; 2.00	0.653




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.10.1: Forest-Plot for AESI all grades: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Reproductive toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	3/196	2/190	1.31	0.22; 7.90	0.767
ASC4START	1/284	4/282	0.24	0.03; 2.18	0.171
Pooled Analysis	4/480	6/472	0.61	0.17; 2.18	0.446



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.11 Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Acute pancreatitis (clinical events)				
N*	480	472	0.08	1.000
Number of patients with events, n (%)	0	5 (1.1)	[0.00; 2.02]	
			0.021	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Acute pancreatitis (including isolated pancreatic enzyme elevations)				
N*	480	472	0.82	0.882
Number of patients with events, n (%)	57 (11.9)	65 (13.8)	[0.57; 1.17]	
			0.269	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [30.4; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Arterial-occlusive events (AOE)				
N*	480	472	0.75	0.547
Number of patients with events, n (%)	7 (1.5)	8 (1.7)	[0.27; 2.06]	
			0.570	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Cardiac failure				
N*	284	282	0.28	N.E.
Number of patients with events, n (%)	0	1 (0.4)	[0.00; 26.00]	
			0.277	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Edema and fluid retention				
N*	480	472	0.39	0.307
Number of patients with events, n (%)	19 (4.0)	44 (9.3)	[0.23; 0.67]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Gastrointestinal toxicity				
N*	480	472	0.91	0.103
Number of patients with events, n (%)	161 (33.5)	164 (34.7)	[0.73; 1.14]	
			0.418	
Percentiles (months) [95% CI]				
25th	5.3 [2.3; 10.7]	2.9 [1.7; 5.6]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hemorrhage				
N*	480	472	0.70	0.632
Number of patients with events, n (%)	29 (6.0)	37 (7.8)	[0.43; 1.14]	
			0.150	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hepatotoxicity (clinical events)				
N*	480	472	0.56	0.106
Number of patients with events, n (%)	10 (2.1)	16 (3.4)	[0.26; 1.25]	
			0.152	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hepatotoxicity (including laboratory terms)				
N*	480	472	0.48	0.020
Number of patients with events, n (%)	73 (15.2)	130 (27.5)	[0.36; 0.65]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [30.5; N.E.]	9.2 [5.5; 18.5]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hypersensitivity				
N*	480	472	0.50	0.657
Number of patients with events, n (%)	100 (20.8)	162 (34.3)	[0.39; 0.64]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [16.1; N.E.]	2.6 [1.4; 5.6]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Ischemic heart and CNS conditions				
N*	480	472	0.68	0.534
Number of patients with events, n (%)	18 (3.8)	24 (5.1)	[0.37; 1.25]	
			0.211	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Myelosuppression (Erythropenia)				
N*	480	472	0.58	0.126
Number of patients with events, n (%)	44 (9.2)	70 (14.8)	[0.40; 0.84]	
			0.004	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Myelosuppression (Leukopenia)				
N*	480	472	0.91	0.225
Number of patients with events, n (%)	88 (18.3)	95 (20.1)	[0.68; 1.22]	
			0.542	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [24.8; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Myelosuppression (Thrombocytopenia)				
N*	480	472	0.99	0.112
Number of patients with events, n (%)	103 (21.5)	101 (21.4)	[0.75; 1.30]	
			0.958	
Percentiles (months) [95% CI]				
25th	N.E. [11.1; N.E.]	N.E. [4.0; N.E.]		


	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Phototoxicity				
N*	480	472	1.18	0.816
Number of patients with events, n (%)	5 (1.0)	4 (0.8)	[0.32; 4.39]	
			0.809	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
QTc prolongation				
N*	480	472	0.79	0.665
Number of patients with events, n (%)	6 (1.3)	7 (1.5)	[0.26; 2.35]	
			0.672	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Reproductive toxicity				
N*	480	472	0.46	0.399
Number of patients with events, n (%)	3 (0.6)	6 (1.3)	[0.11; 1.85]	
			0.264	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Acute pancreatitis (clinical events)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Acute pancreatitis (including isolated pancreatic enzyme elevations)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Arterial-occlusive events (AOE)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Cardiac failure



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Edema and fluid retention



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Gastrointestinal toxicity



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hemorrhage



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hepatotoxicity (clinical events)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hepatotoxicity (including laboratory terms)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hypersensitivity



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Ischemic heart and CNS conditions



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Myelosuppression (Erythropenia)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Myelosuppression (Leukopenia)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Myelosuppression (Thrombocytopenia)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Phototoxicity



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


QTc prolongation



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11 Grade 1/2 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)

Reproductive toxicity




Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	0/196	2/190	0.17	0.00; 7.22	0.129
ASC4START	0/284	3/282	0.14	0.00; 4.28	0.080
Pooled Analysis	0/480	5/472	0.08	0.00; 2.02	0.021




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	26/196	30/190	0.79	0.47; 1.35	0.392
ASC4START	31/284	35/282	0.84	0.52; 1.36	0.474
Pooled Analysis	57/480	65/472	0.82	0.57; 1.17	0.269




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arterial-occlusive events (AOE)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	3/196	2/190	1.17	0.19; 7.02	0.865
ASC4START	4/284	6/282	0.59	0.17; 2.11	0.416
Pooled Analysis	7/480	8/472	0.75	0.27; 2.06	0.570




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Cardiac failure


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	0/196	0/190	N.E.	N.E.; N.E.	N.E.
ASC4START	0/284	1/282	0.28	0.00; 26.00	0.277
Pooled Analysis	0/480	1/472	0.28	0.00; 26.00	0.277



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	77/196	87/190	0.76	0.56; 1.04	0.085
ASC4START	84/284	77/282	1.10	0.80; 1.49	0.560
Pooled Analysis	161/480	164/472	0.91	0.73; 1.14	0.418




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	13/196	18/190	0.62	0.30; 1.26	0.182
ASC4START	16/284	19/282	0.78	0.40; 1.52	0.471
Pooled Analysis	29/480	37/472	0.70	0.43; 1.14	0.150




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	6/196	4/190	1.28	0.36; 4.55	0.703
ASC4START	4/284	12/282	0.31	0.10; 0.97	0.034
Pooled Analysis	10/480	16/472	0.56	0.26; 1.25	0.152




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	39/196	48/190	0.71	0.46; 1.08	0.114
ASC4START	34/284	82/282	0.35	0.24; 0.53	<0.001
Pooled Analysis	73/480	130/472	0.48	0.36; 0.65	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	51/196	83/190	0.47	0.33; 0.67	<0.001
ASC4START	49/284	79/282	0.53	0.37; 0.76	<0.001
Pooled Analysis	100/480	162/472	0.50	0.39; 0.64	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	11/196	12/190	0.81	0.36; 1.83	0.609
ASC4START	7/284	12/282	0.54	0.21; 1.38	0.195
Pooled Analysis	18/480	24/472	0.68	0.37; 1.25	0.211




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	24/196	47/190	0.46	0.28; 0.75	0.001
ASC4START	20/284	23/282	0.84	0.46; 1.52	0.555
Pooled Analysis	44/480	70/472	0.58	0.40; 0.84	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	56/196	69/190	0.81	0.57; 1.15	0.232
ASC4START	32/284	26/282	1.19	0.71; 2.00	0.508
Pooled Analysis	88/480	95/472	0.91	0.68; 1.22	0.542




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	50/196	59/190	0.80	0.55; 1.17	0.256
ASC4START	53/284	42/282	1.26	0.84; 1.89	0.261
Pooled Analysis	103/480	101/472	0.99	0.75; 1.30	0.958




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Phototoxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	3/196	2/190	1.36	0.23; 8.15	0.738
ASC4START	2/284	2/282	0.99	0.14; 7.02	0.991
Pooled Analysis	5/480	4/472	1.18	0.32; 4.39	0.809




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

QTc prolongation

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	2/196	3/190	0.58	0.10; 3.47	0.549
ASC4START	4/284	4/282	0.95	0.24; 3.81	0.946
Pooled Analysis	6/480	7/472	0.79	0.26; 2.35	0.672




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Reproductive toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	2/196	2/190	0.87	0.12; 6.22	0.887
ASC4START	1/284	4/282	0.24	0.03; 2.18	0.171
Pooled Analysis	3/480	6/472	0.46	0.11; 1.85	0.264



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.12 Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Acute pancreatitis (clinical events)				
N*	480	472	0.58	0.215
Number of patients with events, n (%)	3 (0.6)	5 (1.1)	[0.14; 2.45]	
			0.457	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Acute pancreatitis (including isolated pancreatic enzyme elevations)				
N*	480	472	0.44	0.210
Number of patients with events, n (%)	11 (2.3)	23 (4.9)	[0.22; 0.91]	
			0.023	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Arterial-occlusive events (AOE)				
N*	480	472	0.63	0.741
Number of patients with events, n (%)	5 (1.0)	7 (1.5)	[0.20; 2.00]	
			0.434	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Cardiac failure				
N*	480	472	0.30	0.996
Number of patients with events, n (%)	1 (0.2)	3 (0.6)	[0.03; 2.87]	
			0.267	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Edema and fluid retention				
N*	196	190	0.09	N.E.
Number of patients with events, n (%)	0	3 (1.6)	[0.00; 2.92]	
			0.034	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Gastrointestinal toxicity				
N*	480	472	0.35	0.840
Number of patients with events, n (%)	2 (0.4)	5 (1.1)	[0.07; 1.82]	
			0.193	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hemorrhage				
N*	480	472	0.23	0.996
Number of patients with events, n (%)	1 (0.2)	4 (0.8)	[0.03; 2.07]	
			0.152	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hepatotoxicity (clinical events)				
N*	480	472	0.98	0.985
Number of patients with events, n (%)	4 (0.8)	4 (0.8)	[0.24; 3.91]	
			0.975	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hepatotoxicity (including laboratory terms)				
N*	480	472	0.31	0.393
Number of patients with events, n (%)	13 (2.7)	39 (8.3)	[0.16; 0.58]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hypersensitivity				
N*	480	472	0.24	0.745
Number of patients with events, n (%)	2 (0.4)	8 (1.7)	[0.05; 1.14]	
			0.052	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Ischemic heart and CNS conditions				
N*	480	472	1.00	0.265
Number of patients with events, n (%)	11 (2.3)	10 (2.1)	[0.42; 2.35]	
			0.992	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Myelosuppression (Erythropenia)				
N*	480	472	0.91	0.004
Number of patients with events, n (%)	16 (3.3)	16 (3.4)	[0.45; 1.82]	
			0.782	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Myelosuppression (Leukopenia)				
N*	480	472	0.77	0.098
Number of patients with events, n (%)	49 (10.2)	60 (12.7)	[0.53; 1.12]	
			0.168	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Myelosuppression (Thrombocytopenia)				
N*	480	472	1.27	0.726
Number of patients with events, n (%)	54 (11.3)	41 (8.7)	[0.85; 1.91]	
			0.244	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
QTc prolongation				
N*	480	472	1.45	0.554
Number of patients with events, n (%)	5 (1.0)	3 (0.6)	[0.35; 6.12]	
			0.608	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Reproductive toxicity				
N*	480	472	4.60	1.000
Number of patients with events, n (%)	2 (0.4)	0	[0.11; 189.8]	
			0.175	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Acute pancreatitis (clinical events)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Acute pancreatitis (including isolated pancreatic enzyme elevations)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Arterial-occlusive events (AOE)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Cardiac failure



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Edema and fluid retention



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Gastrointestinal toxicity



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hemorrhage



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hepatotoxicity (clinical events)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hepatotoxicity (including laboratory terms)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hypersensitivity



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Ischemic heart and CNS conditions



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Myelosuppression (Erythropenia)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Myelosuppression (Leukopenia)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Myelosuppression (Thrombocytopenia)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


QTc prolongation



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12 Grade >=3 AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)

Reproductive toxicity




Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	2/196	1/190	1.92	0.17; 21.25	0.587
ASC4START	1/284	4/282	0.25	0.03; 2.20	0.174
Pooled Analysis	3/480	5/472	0.58	0.14; 2.45	0.457




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	7/196	9/190	0.70	0.26; 1.89	0.484
ASC4START	4/284	14/282	0.27	0.09; 0.82	0.014
Pooled Analysis	11/480	23/472	0.44	0.22; 0.91	0.023



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arterial-occlusive events (AOE)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Cardiac failure

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	0/196	2/190	0.18	0.00; 7.26	0.132
ASC4START	1/284	1/282	0.91	0.06; 14.59	0.949
Pooled Analysis	1/480	3/472	0.30	0.03; 2.87	0.267




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	0/196	3/190	0.09	0.00; 2.92	0.034
ASC4START	0/284	0/282	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/480	3/472	0.09	0.00; 2.92	0.034




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	1/196	2/190	0.42	0.04; 4.69	0.471
ASC4START	1/284	3/282	0.30	0.03; 2.91	0.272
Pooled Analysis	2/480	5/472	0.35	0.07; 1.82	0.193




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	0/196	3/190	0.13	0.00; 3.89	0.066
ASC4START	1/284	1/282	0.98	0.06; 15.63	0.987
Pooled Analysis	1/480	4/472	0.23	0.03; 2.07	0.152




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	1/196	1/190	0.96	0.06; 15.29	0.975
ASC4START	3/284	3/282	0.99	0.20; 4.88	0.986
Pooled Analysis	4/480	4/472	0.98	0.24; 3.91	0.975




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	5/196	10/190	0.46	0.16; 1.34	0.142
ASC4START	8/284	29/282	0.26	0.12; 0.56	<0.001
Pooled Analysis	13/480	39/472	0.31	0.16; 0.58	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	1/196	5/190	0.19	0.02; 1.65	0.094
ASC4START	1/284	3/282	0.32	0.03; 3.12	0.305
Pooled Analysis	2/480	8/472	0.24	0.05; 1.14	0.052



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	4/196	12/190	0.28	0.09; 0.87	0.019
ASC4START	12/284	4/282	2.91	0.94; 9.03	0.053
Pooled Analysis	16/480	16/472	0.91	0.45; 1.82	0.782



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	25/196	20/190	1.18	0.65; 2.12	0.581
ASC4START	29/284	21/282	1.36	0.78; 2.39	0.279
Pooled Analysis	54/480	41/472	1.27	0.85; 1.91	0.244




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

QTc prolongation


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	3/196	1/190	2.38	0.25; 23.13	0.441
ASC4START	2/284	2/282	0.96	0.14; 6.83	0.968
Pooled Analysis	5/480	3/472	1.45	0.35; 6.12	0.608



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Reproductive toxicity



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.13 Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Acute pancreatitis (clinical events)				
N*	480	472	0.42	0.131
Number of patients with events, n (%)	3 (0.6)	7 (1.5)	[0.11; 1.62]	
			0.191	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Acute pancreatitis (including isolated pancreatic enzyme elevations)				
N*	480	472	0.48	0.185
Number of patients with events, n (%)	4 (0.8)	8 (1.7)	[0.15; 1.60]	
			0.224	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Arterial-occlusive events (AOE)				
N*	480	472	1.28	0.833
Number of patients with events, n (%)	7 (1.5)	5 (1.1)	[0.41; 4.03]	
			0.675	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Cardiac failure				
N*	480	472	0.30	0.996
Number of patients with events, n (%)	1 (0.2)	3 (0.6)	[0.03; 2.87]	
			0.267	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Edema and fluid retention				
N*	196	190	0.09	N.E.
Number of patients with events, n (%)	0	3 (1.6)	[0.00; 2.92]	
			0.034	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Gastrointestinal toxicity				
N*	480	472	1.36	0.724
Number of patients with events, n (%)	3 (0.6)	2 (0.4)	[0.23; 8.17]	
			0.734	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hemorrhage				
N*	480	472	0.57	0.810
Number of patients with events, n (%)	2 (0.4)	3 (0.6)	[0.10; 3.46]	
			0.540	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hepatotoxicity (clinical events)				
N*	480	472	0.98	0.994
Number of patients with events, n (%)	3 (0.6)	3 (0.6)	[0.20; 4.84]	
			0.977	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Hepatotoxicity (including laboratory terms)				
N*	480	472	0.59	0.994
Number of patients with events, n (%)	3 (0.6)	5 (1.1)	[0.14; 2.47]	
			0.465	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Ischemic heart and CNS conditions				
N*	480	472	1.07	0.899
Number of patients with events, n (%)	7 (1.5)	6 (1.3)	[0.36; 3.19]	
			0.901	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Myelosuppression (Erythropenia)				
N*	196	190	0.28	N.E.
Number of patients with events, n (%)	0	1 (0.5)	[0.00; 25.64]	
			0.273	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Myelosuppression (Leukopenia)				
N*	480	472	6.60	1.000
Number of patients with events, n (%)	3 (0.6)	0	[0.22; 202.4]	
			0.093	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Myelosuppression (Thrombocytopenia)				
N*	480	472	0.54	0.917
Number of patients with events, n (%)	4 (0.8)	7 (1.5)	[0.16; 1.85]	
			0.320	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
QTc prolongation				
N*	480	472	0.48	0.996
Number of patients with events, n (%)	1 (0.2)	2 (0.4)	[0.04; 5.25]	
			0.535	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Reproductive toxicity				
N*	480	472	4.60	1.000
Number of patients with events, n (%)	2 (0.4)	0	[0.11; 189.8]	
			0.175	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Acute pancreatitis (clinical events)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Acute pancreatitis (including isolated pancreatic enzyme elevations)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Arterial-occlusive events (AOE)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Cardiac failure



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Edema and fluid retention



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Gastrointestinal toxicity



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hemorrhage



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hepatotoxicity (clinical events)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Hepatotoxicity (including laboratory terms)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Ischemic heart and CNS conditions



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Myelosuppression (Erythropenia)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Myelosuppression (Leukopenia)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Myelosuppression (Thrombocytopenia)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


QTc prolongation



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13 Serious AESI - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)


Reproductive toxicity



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (clinical events)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	2/196	1/190	1.92	0.17; 21.25	0.587
ASC4START	2/284	7/282	0.28	0.06; 1.33	0.086
Pooled Analysis	4/480	8/472	0.48	0.15; 1.60	0.224



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Arterial-occlusive events (AOE)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Cardiac failure




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	0/196	3/190	0.09	0.00; 2.92	0.034
ASC4START	0/284	0/282	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/480	3/472	0.09	0.00; 2.92	0.034




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	1/196	1/190	0.93	0.06; 14.83	0.957
ASC4START	2/284	1/282	1.79	0.16; 19.82	0.629
Pooled Analysis	3/480	2/472	1.36	0.23; 8.17	0.734




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	1/196	1/190	0.75	0.05; 12.01	0.836
ASC4START	1/284	2/282	0.48	0.04; 5.25	0.535
Pooled Analysis	2/480	3/472	0.57	0.10; 3.46	0.540




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	1/196	0/190	2.74	0.03; 253.1	0.339
ASC4START	2/284	3/282	0.66	0.11; 3.95	0.646
Pooled Analysis	3/480	3/472	0.98	0.20; 4.84	0.977




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	1/196	0/190	2.74	0.03; 253.1	0.339
ASC4START	2/284	5/282	0.40	0.08; 2.05	0.253
Pooled Analysis	3/480	5/472	0.59	0.14; 2.47	0.465




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	2/196	2/190	0.96	0.14; 6.85	0.971
ASC4START	5/284	4/282	1.12	0.30; 4.19	0.862
Pooled Analysis	7/480	6/472	1.07	0.36; 3.19	0.901



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Myelosuppression (Erythropenia)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	1/196	2/190	0.48	0.04; 5.35	0.546
ASC4START	3/284	5/282	0.56	0.13; 2.36	0.425
Pooled Analysis	4/480	7/472	0.54	0.16; 1.85	0.320




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

QTc prolongation


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Main Analysis	**n/N**	**n/N**			
ASC4FIRST	0/196	1/190	0.31	0.00; 28.22	0.296
ASC4START	1/284	1/282	0.97	0.06; 15.51	0.983
Pooled Analysis	1/480	2/472	0.48	0.04; 5.25	0.535



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.13.1: Forest-Plot for Serious AESI: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Reproductive toxicity




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.14 AE leading to discontinuation of treatment: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	480	472	0.43	0.494
Number of patients with events, n (%)	33 (6.9)	69 (14.6)	[0.29; 0.66]	
			<0.001	
Percentiles (months) [95% CI]				
25th	N.E. [32.4; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.14 AE leading to discontinuation of treatment - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.14.1: Forest-Plot for AE leading to discontinuation of treatment: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.15 Severe AE leading to discontinuation of treatment: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	480	472	0.54	0.883
Number of patients with events, n (%)	24 (5.0)	41 (8.7)	[0.33; 0.90]	
			0.016	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		


HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.15 Severe AE leading to discontinuation of treatment - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)



Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.15.1: Forest-Plot for Severe AE leading to discontinuation of treatment: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-1.16 SAE leading to discontinuation of treatment: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups		Comparison	
	Asciminib (N = 480)	**Investigator Selected TKI (N = 472)**	**HR [95% CI] p-value**	**Test for Heterogeneity p-value**
N*	480	472	0.73	0.679
Number of patients with events, n (%)	17 (3.5)	22 (4.7)	[0.39; 1.37]	
			0.324	
Percentiles (months) [95% CI]				
25th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
Median	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		
75th	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]		

HR: Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients with event
IPD: Individual Patient Data
.....
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study and covariate treatment arm.
P-Values are from a stratified logrank test with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and Study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.16 SAE leading to discontinuation of treatment - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot (Safety Analysis Set)




Pts at Risk (censored)

Asciminib	480 (0)	450 (21)	411 (57)	291 (173)	180 (283)	43 (420)	0 (463)
Investigator Selected TKI	472 (0)	418 (41)	360 (93)	241 (209)	138 (312)	24 (426)	0 (450)

Note: o = Censored observations
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-1.16.1: Forest-Plot for SAE leading to discontinuation of treatment: time to first occurrence - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.1 Time to first any AE: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.479)								
Low	265/290 (91.4)	0.5 [0.5; 0.7]	280/291 (96.2)	0.4 [0.3; 0.5]	0.70	[0.59; 0.83]	<0.001	0.436
Intermediate	114/129 (88.4)	0.6 [0.4; 0.9]	112/125 (89.6)	0.5 [0.3; 0.5]	0.86	[0.66; 1.12]	0.298	0.696
High	57/61 (93.4)	1.0 [0.6; 1.1]	51/56 (91.1)	0.5 [0.3; 0.5]	0.73	[0.49; 1.07]	0.121	0.660
Sex								
(Interaction test: p = 0.639)								
Female	162/174 (93.1)	0.5 [0.3; 0.5]	191/198 (96.5)	0.4 [0.3; 0.5]	0.77	[0.62; 0.95]	0.020	0.933

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Male	274/306 (89.5)	0.8 [0.5; 0.9]	252/274 (92.0)	0.5 [0.3; 0.5]	0.74	[0.62; 0.88]	<0.001	0.214
Race								
(Interaction test: p = 0.022)								
Asian	118/128 (92.2)	0.9 [0.6; 1.0]	126/130 (96.9)	0.3 [0.2; 0.5]	0.52	[0.40; 0.68]	<0.001	0.981
White	300/332 (90.4)	0.5 [0.5; 0.7]	292/317 (92.1)	0.5 [0.3; 0.5]	0.85	[0.73; 1.01]	0.066	0.958
Others	18/20 (90.0)	0.4 [0.1; 1.0]	25/25 (100.0)	0.3 [0.1; 0.5]	0.66	[0.33; 1.32]	0.249	0.958
Age groups								
(Interaction test: p = 0.982)								
18 - < 65 years	352/389 (90.5)	0.6 [0.5; 0.9]	368/394 (93.4)	0.4 [0.3; 0.5]	0.74	[0.64; 0.86]	<0.001	0.280
65 - < 75 years	66/72 (91.7)	0.6 [0.3; 0.9]	50/53 (94.3)	0.5 [0.1; 0.5]	0.74	[0.49; 1.10]	0.150	0.774


	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
>= 75 years	18/19 (94.7)	0.5 [0.1; 1.0]	25/25 (100.0)	0.3 [0.1; 0.5]	0.81	[0.41; 1.58]	0.601	0.877
Pre-randomization selection of TKI								
(Interaction test: p = 0.499)								
Imatinib	97/100 (97.0)	0.5 [0.3; 0.6]	96/100 (96.0)	0.3 [0.2; 0.5]	0.83	[0.62; 1.10]	0.209	N.E.
Nilotinib	300/339 (88.5)	0.7 [0.5; 0.9]	305/330 (92.4)	0.5 [0.4; 0.5]	0.73	[0.62; 0.86]	<0.001	0.044
Dasatinib	39/41 (95.1)	0.5 [0.2; 0.9]	42/42 (100.0)	0.2 [0.1; 0.5]	0.60	[0.37; 0.95]	0.032	N.E.
Geographic region								
(Interaction test: p = 0.218)								
Europe excluding Germany	177/201 (88.1)	0.6 [0.5; 1.0]	184/201 (91.5)	0.5 [0.3; 0.6]	0.77	[0.63; 0.96]	0.020	0.348

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Germany	81/91 (89.0)	0.6 [0.4; 1.0]	61/68 (89.7)	0.5 [0.3; 0.7]	0.90	[0.63; 1.28]	0.610	0.067
Others	178/188 (94.7)	0.5 [0.5; 0.8]	198/203 (97.5)	0.3 [0.2; 0.4]	0.65	[0.52; 0.80]	<0.001	0.465

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.1 Time to first any AE: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Race: Asian




Pts at Risk (censored)

Asciminib	128 (0)	17 (1)	11 (2)	8 (4)	3 (7)	1 (9)	0 (10)
Investigator Selected TKI	130 (0)	6 (1)	4 (1)	3 (1)	0 (4)	0 (4)	0 (4)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.1 Time to first any AE: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Race: White



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.1 Time to first any AE: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Race: Others



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.1.1: Forest-Plot for Any AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	144/152	145/148	0.67	0.53; 0.85	<0.001
ASC4START	208/237	223/246	0.79	0.66; 0.96	0.019
Pooled Analysis	352/389	368/394	0.74	0.64; 0.86	<0.001
65 - < 75 years					
ASC4FIRST	34/34	28/29	0.78	0.44; 1.38	0.403
ASC4START	32/38	22/24	0.70	0.40; 1.22	0.228
Pooled Analysis	66/72	50/53	0.74	0.49; 1.10	0.150
>= 75 years					
ASC4FIRST	9/10	13/13	0.85	0.33; 2.23	0.849
ASC4START	9/9	12/12	0.76	0.30; 1.97	0.592
Pooled Analysis	18/19	25/25	0.81	0.41; 1.58	0.601



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.1.1: Forest-Plot for Any AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	22/23	18/19	0.65	0.34; 1.24	0.202
ASC4START	35/38	33/37	0.78	0.48; 1.26	0.319
Pooled Analysis	57/61	51/56	0.73	0.49; 1.07	0.121
Intermediate					
ASC4FIRST	50/54	50/52	0.81	0.54; 1.21	0.328
ASC4START	64/75	62/73	0.90	0.63; 1.28	0.595
Pooled Analysis	114/129	112/125	0.86	0.66; 1.12	0.298
Low					
ASC4FIRST	115/119	118/119	0.65	0.50; 0.84	<0.001
ASC4START	150/171	162/172	0.74	0.59; 0.93	0.009
Pooled Analysis	265/290	280/291	0.70	0.59; 0.83	<0.001



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.1.1: Forest-Plot for Any AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	59/63	60/61	0.66	0.45; 0.98	0.035
ASC4START	118/138	124/140	0.83	0.64; 1.07	0.160
Pooled Analysis	177/201	184/201	0.77	0.63; 0.96	0.020
Germany					
ASC4FIRST	19/19	13/15	1.84	0.78; 4.32	0.126
ASC4START	62/72	48/53	0.77	0.52; 1.13	0.196
Pooled Analysis	81/91	61/68	0.90	0.63; 1.28	0.610
Others					
ASC4FIRST	109/114	113/114	0.60	0.46; 0.80	<0.001
ASC4START	69/74	85/89	0.71	0.51; 0.99	0.039
Pooled Analysis	178/188	198/203	0.65	0.52; 0.80	<0.001



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.1.1: Forest-Plot for Any AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	39/41	42/42	0.60	0.37; 0.95	0.032
Pooled Analysis	39/41	42/42	0.60	0.37; 0.95	0.032
Imatinib					
ASC4FIRST	97/100	96/100	0.83	0.62; 1.10	0.209
Pooled Analysis	97/100	96/100	0.83	0.62; 1.10	0.209
Nilotinib					
ASC4FIRST	51/55	48/48	0.49	0.33; 0.75	<0.001
ASC4START	249/284	257/282	0.78	0.66; 0.93	0.007
Pooled Analysis	300/339	305/330	0.73	0.62; 0.86	<0.001



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.1.1: Forest-Plot for Any AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	35/40	42/45	0.52	0.32; 0.84	0.006
Pooled Analysis	118/128	126/130	0.52	0.40; 0.68	<0.001
Asian/Others					
ASC4FIRST	85/91	88/89	0.52	0.38; 0.72	<0.001
Others					
ASC4START	16/17	21/21	0.66	0.32; 1.37	0.298
Pooled Analysis	18/20	25/25	0.66	0.33; 1.32	0.249
White					
ASC4FIRST	102/105	98/101	0.86	0.65; 1.14	0.305
ASC4START	198/227	194/216	0.85	0.70; 1.04	0.127
Pooled Analysis	300/332	292/317	0.85	0.73; 1.01	0.066



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.1.1: Forest-Plot for Any AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	65/67	72/74	0.78	0.55; 1.11	0.164
ASC4START	97/107	119/124	0.76	0.58; 1.00	0.062
Pooled Analysis	162/174	191/198	0.77	0.62; 0.95	0.020
Male					
ASC4FIRST	122/129	114/116	0.65	0.49; 0.85	0.002
ASC4START	152/177	138/158	0.81	0.64; 1.02	0.082
Pooled Analysis	274/306	252/274	0.74	0.62; 0.88	<0.001



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.2 Time to first any AE by SOC: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Eye disorders								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.610)								
Low	34/290 (11.7)	N.E. [N.E.; N.E.]	50/291 (17.2)	N.E. [N.E.; N.E.]	0.63	[0.40; 0.97]	0.034	0.922
Intermediate	17/129 (13.2)	N.E. [N.E.; N.E.]	21/125 (16.8)	N.E. [N.E.; N.E.]	0.66	[0.35; 1.26]	0.206	0.014
High	6/61 (9.8)	N.E. [N.E.; N.E.]	4/56 (7.1)	N.E. [N.E.; N.E.]	1.26	[0.35; 4.46]	0.724	0.852
Sex								
(Interaction test: p = 0.366)								
Female	31/174	N.E. [N.E.; N.E.]	39/198	N.E. [N.E.; N.E.]	0.80	[0.50; 1.29]	0.363	0.203

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(17.8)		(19.7)					
Male	26/306	N.E. [N.E.; N.E.]	36/274	N.E. [N.E.; N.E.]	0.57	[0.34; 0.94]	0.027	0.356
	(8.5)		(13.1)					
Race								
(Interaction test: p = 0.408)								
Asian	13/128	N.E. [N.E.; N.E.]	24/130	N.E. [N.E.; N.E.]	0.47	[0.24; 0.94]	0.028	0.360
	(10.2)		(18.5)					
White	42/332	N.E. [N.E.; N.E.]	47/317	N.E. [N.E.; N.E.]	0.80	[0.52; 1.21]	0.286	0.062
	(12.7)		(14.8)					
Others	2/20	N.E. [N.E.; N.E.]	4/25	N.E. [N.E.; N.E.]	0.28	[0.03; 2.59]	0.234	0.997
	(10.0)		(16.0)					
Age groups								
(Interaction test: p = 0.088)								
18 - < 65 years	46/389	N.E. [N.E.; N.E.]	54/394	N.E. [N.E.; N.E.]	0.81	[0.54; 1.20]	0.284	0.472
	(11.8)		(13.7)					
65 - < 75 years	10/72	N.E. [N.E.; N.E.]	15/53	N.E. [21.9; N.E.]	0.43	[0.18; 1.02]	0.050	0.143

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(13.9)		(28.3)					
>= 75 years	1/19	N.E. [N.E.; N.E.]	6/25	N.E. [N.E.; N.E.]	0.14	[0.02; 1.16]	0.034	0.997
	(5.3)		(24.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.002)								
Imatinib	11/100	N.E. [N.E.; N.E.]	34/100	N.E. [N.E.; N.E.]	0.25	[0.13; 0.50]	<0.001	N.E.
	(11.0)		(34.0)					
Nilotinib	38/339	N.E. [N.E.; N.E.]	34/330	N.E. [N.E.; N.E.]	1.01	[0.64; 1.61]	0.964	0.607
	(11.2)		(10.3)					
Dasatinib	8/41	N.E. [N.E.; N.E.]	7/42	N.E. [N.E.; N.E.]	1.14	[0.41; 3.18]	0.809	N.E.
	(19.5)		(16.7)					
Geographic region								
(Interaction test: p = 0.153)								
Europe excluding Germany	17/201	N.E. [N.E.; N.E.]	31/201	N.E. [N.E.; N.E.]	0.47	[0.26; 0.86]	0.012	0.040

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(8.5)		(15.4)					
Germany	11/91	N.E. [N.E.; N.E.]	5/68	N.E. [N.E.; N.E.]	1.73	[0.59; 5.07]	0.310	0.923
	(12.1)		(7.4)					
Others	29/188	N.E. [N.E.; N.E.]	39/203	N.E. [N.E.; N.E.]	0.71	[0.44; 1.16]	0.170	0.918
	(15.4)		(19.2)					
General disorders and administration site conditions								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.128)								
Low	96/290	N.E. [N.E.; N.E.]	115/291	31.0 [31.0; N.E.]	0.76	[0.58; 1.00]	0.052	0.605
	(33.1)		(39.5)					
Intermediate	30/129	N.E. [N.E.; N.E.]	39/125	N.E. [N.E.; N.E.]	0.67	[0.42; 1.08]	0.101	0.180
	(23.3)		(31.2)					
High	17/61	N.E. [N.E.; N.E.]	9/56	N.E. [N.E.; N.E.]	1.62	[0.72; 3.65]	0.235	0.308

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(27.9)		(16.1)					
Sex								
(Interaction test: p = 0.166)								
Female	73/174	N.E. [19.4; N.E.]	82/198	31.0 [19.0; N.E.]	0.96	[0.70; 1.33]	0.832	0.923
	(42.0)		(41.4)					
Male	70/306	N.E. [N.E.; N.E.]	81/274	N.E. [N.E.; N.E.]	0.70	[0.51; 0.96]	0.029	0.084
	(22.9)		(29.6)					
Race								
(Interaction test: p = 0.372)								
Asian	28/128	N.E. [N.E.; N.E.]	42/130	31.0 [31.0; N.E.]	0.60	[0.37; 0.98]	0.037	0.097
	(21.9)		(32.3)					
White	110/332	N.E. [N.E.; N.E.]	115/317	N.E. [N.E.; N.E.]	0.84	[0.65; 1.10]	0.212	0.908
	(33.1)		(36.3)					
Others	5/20	N.E. [11.1; N.E.]	6/25	N.E. [N.E.; N.E.]	1.08	[0.27; 4.38]	0.917	0.994
	(25.0)		(24.0)					
Age groups								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.556)								
18 - < 65 years	117/389 (30.1)	N.E. [N.E.; N.E.]	131/394 (33.2)	N.E. [31.0; N.E.]	0.83	[0.65; 1.07]	0.144	0.314
65 - < 75 years	18/72 (25.0)	N.E. [N.E.; N.E.]	19/53 (35.8)	N.E. [4.2; N.E.]	0.61	[0.31; 1.17]	0.134	0.248
>= 75 years	8/19 (42.1)	N.E. [0.4; N.E.]	13/25 (52.0)	13.5 [1.6; N.E.]	0.68	[0.25; 1.90]	0.450	0.651
Pre-randomization selection of TKI								
(Interaction test: p = 0.125)								
Imatinib	30/100 (30.0)	N.E. [N.E.; N.E.]	46/100 (46.0)	24.3 [5.6; N.E.]	0.55	[0.34; 0.87]	0.010	N.E.
Nilotinib	95/339 (28.0)	N.E. [N.E.; N.E.]	94/330 (28.5)	N.E. [N.E.; N.E.]	0.93	[0.70; 1.23]	0.601	0.813
Dasatinib	18/41 (43.9)	N.E. [8.3; N.E.]	23/42 (54.8)	18.0 [5.6; N.E.]	0.70	[0.37; 1.32]	0.266	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Geographic region								
(Interaction test: p = 0.316)								
Europe excluding Germany	52/201 (25.9)	N.E. [N.E.; N.E.]	67/201 (33.3)	N.E. [N.E.; N.E.]	0.70	[0.49; 1.01]	0.060	0.929
Germany	34/91 (37.4)	N.E. [19.9; N.E.]	21/68 (30.9)	N.E. [N.E.; N.E.]	1.10	[0.63; 1.92]	0.722	0.621
Others	57/188 (30.3)	N.E. [N.E.; N.E.]	75/203 (36.9)	31.0 [31.0; N.E.]	0.74	[0.53; 1.05]	0.095	0.197
Investigations								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.304)								
Low	111/290 (38.3)	N.E. [N.E.; N.E.]	141/291 (48.5)	24.8 [8.4; N.E.]	0.70	[0.54; 0.90]	0.004	0.752
Intermediate	55/129	N.E. [11.4; N.E.]	55/125	N.E. [8.3; N.E.]	0.93	[0.64; 1.35]	0.708	0.275

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(42.6)		(44.0)					
High	24/61	N.E. [11.1; N.E.]	29/56	13.8 [1.0; N.E.]	0.60	[0.35; 1.03]	0.064	0.634
	(39.3)		(51.8)					
Sex								
(Interaction test: p = 0.164)								
Female	59/174	N.E. [N.E.; N.E.]	94/198	24.8 [8.3; N.E.]	0.60	[0.43; 0.83]	0.002	0.044
	(33.9)		(47.5)					
Male	131/306	N.E. [19.4; N.E.]	131/274	22.1 [8.4; N.E.]	0.82	[0.64; 1.04]	0.108	0.263
	(42.8)		(47.8)					
Race								
(Interaction test: p = 0.800)								
Asian	69/128	13.7 [4.3; N.E.]	77/130	2.6 [1.3; 11.1]	0.80	[0.58; 1.11]	0.190	0.763
	(53.9)		(59.2)					
White	114/332	N.E. [N.E.; N.E.]	136/317	N.E. [16.6; N.E.]	0.74	[0.58; 0.96]	0.021	0.474
	(34.3)		(42.9)					
Others	7/20	N.E. [1.2; N.E.]	12/25	N.E. [0.5; N.E.]	0.77	[0.29; 2.07]	0.617	0.995

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(35.0)		(48.0)					
Age groups								
(Interaction test: p = 0.211)								
18 - < 65 years	157/389	N.E. [N.E.; N.E.]	182/394	N.E. [11.1; N.E.]	0.79	[0.64; 0.98]	0.034	0.918
	(40.4)		(46.2)					
65 - < 75 years	27/72	N.E. [13.8; N.E.]	26/53	8.5 [2.8; N.E.]	0.63	[0.36; 1.12]	0.114	0.187
	(37.5)		(49.1)					
>= 75 years	6/19	N.E. [1.5; N.E.]	17/25	2.8 [1.0; 22.1]	0.46	[0.18; 1.20]	0.105	0.313
	(31.6)		(68.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.331)								
Imatinib	47/100	N.E. [5.7; N.E.]	46/100	N.E. [3.6; N.E.]	0.98	[0.65; 1.48]	0.936	N.E.
	(47.0)		(46.0)					
Nilotinib	126/339	N.E. [N.E.; N.E.]	155/330	24.8 [11.1; N.E.]	0.68	[0.54; 0.86]	0.001	0.587
	(37.2)		(47.0)					

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	17/41 (41.5)	N.E. [11.0; N.E.]	24/42 (57.1)	5.7 [1.9; N.E.]	0.59	[0.31; 1.12]	0.102	N.E.
Geographic region (Interaction test: p = 0.603)								
Europe excluding Germany	60/201 (29.9)	N.E. [N.E.; N.E.]	69/201 (34.3)	N.E. [24.8; N.E.]	0.82	[0.58; 1.16]	0.267	0.753
Germany	35/91 (38.5)	N.E. [16.6; N.E.]	37/68 (54.4)	5.6 [2.8; N.E.]	0.62	[0.39; 1.00]	0.049	0.956
Others	95/188 (50.5)	16.6 [8.3; N.E.]	119/203 (58.6)	3.7 [1.5; 8.5]	0.75	[0.57; 0.99]	0.040	0.544
Skin and subcutaneous tissue disorders								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.445)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Low	109/290 (37.6)	N.E. [N.E.; N.E.]	138/291 (47.4)	24.8 [8.9; N.E.]	0.66	[0.52; 0.85]	0.001	0.172
Intermediate	42/129 (32.6)	N.E. [24.7; N.E.]	49/125 (39.2)	N.E. [18.0; N.E.]	0.65	[0.43; 0.99]	0.042	0.364
High	14/61 (23.0)	N.E. [N.E.; N.E.]	23/56 (41.1)	N.E. [4.1; N.E.]	0.45	[0.23; 0.87]	0.015	0.375
Sex								
(Interaction test: p = 0.391)								
Female	71/174 (40.8)	N.E. [19.4; N.E.]	105/198 (53.0)	8.3 [2.8; N.E.]	0.58	[0.43; 0.79]	<0.001	0.328
Male	94/306 (30.7)	N.E. [N.E.; N.E.]	105/274 (38.3)	N.E. [N.E.; N.E.]	0.71	[0.54; 0.94]	0.016	0.084
Race								
(Interaction test: p = 0.847)								
Asian	41/128 (32.0)	N.E. [N.E.; N.E.]	51/130 (39.2)	N.E. [16.5; N.E.]	0.66	[0.43; 1.00]	0.050	0.108

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
White	116/332 (34.9)	N.E. [N.E.; N.E.]	146/317 (46.1)	N.E. [11.1; N.E.]	0.62	[0.48; 0.79]	<0.001	0.101
Others	8/20 (40.0)	N.E. [1.0; N.E.]	13/25 (52.0)	11.1 [1.2; N.E.]	1.21	[0.46; 3.17]	0.703	0.994
Age groups (Interaction test: p = 0.626)								
18 - < 65 years	133/389 (34.2)	N.E. [N.E.; N.E.]	173/394 (43.9)	N.E. [14.8; N.E.]	0.65	[0.52; 0.82]	<0.001	0.056
65 - < 75 years	25/72 (34.7)	N.E. [20.7; N.E.]	23/53 (43.4)	18.4 [11.3; N.E.]	0.60	[0.33; 1.10]	0.097	0.357
>= 75 years	7/19 (36.8)	N.E. [8.6; N.E.]	14/25 (56.0)	4.4 [1.0; N.E.]	0.47	[0.17; 1.29]	0.140	0.447
Pre-randomization selection of TKI (Interaction test: p = 0.007)								
Imatinib	40/100	N.E. [19.2; N.E.]	32/100	N.E. [N.E.; N.E.]	1.14	[0.71; 1.82]	0.574	N.E.


	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(40.0)		(32.0)					
Nilotinib	106/339	N.E. [N.E.; N.E.]	155/330	N.E. [8.5; N.E.]	0.53	[0.41; 0.68]	<0.001	0.838
	(31.3)		(47.0)					
Dasatinib	19/41	N.E. [5.1; N.E.]	23/42	9.8 [1.0; N.E.]	0.79	[0.43; 1.47]	0.466	N.E.
	(46.3)		(54.8)					
Geographic region								
(Interaction test: p = 0.310)								
Europe excluding Germany	57/201	N.E. [N.E.; N.E.]	91/201	24.8 [11.1; N.E.]	0.53	[0.38; 0.74]	<0.001	0.037
	(28.4)		(45.3)					
Germany	37/91	N.E. [15.9; N.E.]	31/68	N.E. [1.8; N.E.]	0.79	[0.49; 1.29]	0.344	0.457
	(40.7)		(45.6)					
Others	71/188	N.E. [24.7; N.E.]	88/203	N.E. [9.8; N.E.]	0.69	[0.50; 0.94]	0.019	0.610
	(37.8)		(43.3)					

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
SOC: System Organ Class
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Results on AEs differentiated by SOC or PT are only reported if the given result is statistically significant for the total population.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data and Stratification factor: ELTS based on data collected in the eCRF only the stratification variable Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variable ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2 Time to first any AE by SOC: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Eye disorders: Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	100 (0)	84 (7)	79 (12)	75 (15)	54 (35)	12 (77)	0 (89)
Investigator Selected TKI	100 (0)	60 (12)	46 (22)	36 (32)	27 (39)	2 (64)	0 (66)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2 Time to first any AE by SOC: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Eye disorders: Pre-randomization selection of TKI: Nilotinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2 Time to first any AE by SOC: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Eye disorders: Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2 Time to first any AE by SOC: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Skin and subcutaneous tissue disorders: Pre-randomization selection of TKI: Imatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2 Time to first any AE by SOC: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Skin and subcutaneous tissue disorders: Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	240 (16)	203 (36)	113 (121)	62 (171)	8 (225)	0 (233)
Investigator Selected TKI	330 (0)	166 (28)	130 (50)	77 (99)	34 (141)	1 (174)	0 (175)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2 Time to first any AE by SOC: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Skin and subcutaneous tissue disorders: Pre-randomization selection of TKI: Dasatinib




Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Eye disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	24/152	31/148	0.71	0.41; 1.21	0.201
ASC4START	22/237	23/246	0.95	0.53; 1.70	0.853
Pooled Analysis	46/389	54/394	0.81	0.54; 1.20	0.284
65 - < 75 years					
ASC4FIRST	6/34	13/29	0.28	0.09; 0.82	0.015
ASC4START	4/38	2/24	1.28	0.23; 7.13	0.781
Pooled Analysis	10/72	15/53	0.43	0.18; 1.02	0.050
>= 75 years					
ASC4FIRST	1/10	5/13	0.16	0.02; 1.40	0.060
ASC4START	0/9	1/12	0.33	0.00; 30.79	0.317
Pooled Analysis	1/19	6/25	0.14	0.02; 1.16	0.034




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Eye disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	2/19	1.11	0.19; 6.67	0.908
ASC4START	3/38	2/37	1.41	0.24; 8.46	0.703
Pooled Analysis	6/61	4/56	1.26	0.35; 4.46	0.724
Intermediate					
ASC4FIRST	7/54	16/52	0.32	0.13; 0.79	0.009
ASC4START	10/75	5/73	1.86	0.64; 5.44	0.249
Pooled Analysis	17/129	21/125	0.66	0.35; 1.26	0.206
Low					
ASC4FIRST	21/119	31/119	0.62	0.35; 1.07	0.084
ASC4START	13/171	19/172	0.64	0.32; 1.30	0.217
Pooled Analysis	34/290	50/291	0.63	0.40; 0.97	0.034




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Eye disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	7/63	21/61	0.26	0.11; 0.62	0.001
ASC4START	10/138	10/140	0.95	0.39; 2.28	0.906
Pooled Analysis	17/201	31/201	0.47	0.26; 0.86	0.012
Germany					
ASC4FIRST	3/19	1/15	1.91	0.20; 18.59	0.570
ASC4START	8/72	4/53	1.68	0.50; 5.70	0.398
Pooled Analysis	11/91	5/68	1.73	0.59; 5.07	0.310
Others					
ASC4FIRST	21/114	27/114	0.70	0.39; 1.25	0.226
ASC4START	8/74	12/89	0.74	0.30; 1.82	0.513
Pooled Analysis	29/188	39/203	0.71	0.44; 1.16	0.170




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Eye disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	8/41	7/42	1.14	0.41; 3.18	0.809
Pooled Analysis	8/41	7/42	1.14	0.41; 3.18	0.809
Imatinib					
ASC4FIRST	11/100	34/100	0.25	0.13; 0.50	<0.001
Pooled Analysis	11/100	34/100	0.25	0.13; 0.50	<0.001
Nilotinib					
ASC4FIRST	12/55	8/48	1.23	0.50; 3.03	0.645
ASC4START	26/284	26/282	0.94	0.54; 1.61	0.817
Pooled Analysis	38/339	34/330	1.01	0.64; 1.61	0.964




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Eye disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	1/40	5/45	0.19	0.02; 1.62	0.090
Pooled Analysis	13/128	24/130	0.47	0.24; 0.94	0.028
Asian/Others					
ASC4FIRST	13/91	20/89	0.58	0.29; 1.19	0.135
Others					
ASC4START	1/17	3/21	0.34	0.03; 3.30	0.327
Pooled Analysis	2/20	4/25	0.28	0.03; 2.59	0.234
White					
ASC4FIRST	18/105	29/101	0.54	0.30; 0.98	0.038
ASC4START	24/227	18/216	1.21	0.66; 2.23	0.538
Pooled Analysis	42/332	47/317	0.80	0.52; 1.21	0.286




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Eye disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	16/67	25/74	0.61	0.32; 1.16	0.129
ASC4START	15/107	14/124	1.15	0.55; 2.38	0.711
Pooled Analysis	31/174	39/198	0.80	0.50; 1.29	0.363
Male					
ASC4FIRST	15/129	24/116	0.47	0.24; 0.90	0.021
ASC4START	11/177	12/158	0.77	0.34; 1.74	0.527
Pooled Analysis	26/306	36/274	0.57	0.34; 0.94	0.027




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

General disorders and administration site conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	53/152	63/148	0.72	0.50; 1.04	0.082
ASC4START	64/237	68/246	0.94	0.67; 1.32	0.707
Pooled Analysis	117/389	131/394	0.83	0.65; 1.07	0.144
65 - < 75 years					
ASC4FIRST	8/34	14/29	0.43	0.18; 1.05	0.058
ASC4START	10/38	5/24	0.99	0.33; 2.91	0.980
Pooled Analysis	18/72	19/53	0.61	0.31; 1.17	0.134
>= 75 years					
ASC4FIRST	6/10	7/13	0.84	0.22; 3.16	0.768
ASC4START	2/9	6/12	0.51	0.10; 2.67	0.420
Pooled Analysis	8/19	13/25	0.68	0.25; 1.90	0.450




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

General disorders and administration site conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	9/23	6/19	1.13	0.40; 3.19	0.812
ASC4START	8/38	3/37	2.71	0.72; 10.23	0.125
Pooled Analysis	17/61	9/56	1.62	0.72; 3.65	0.235
Intermediate					
ASC4FIRST	12/54	21/52	0.47	0.23; 0.96	0.035
ASC4START	18/75	18/73	0.92	0.48; 1.76	0.793
Pooled Analysis	30/129	39/125	0.67	0.42; 1.08	0.101
Low					
ASC4FIRST	46/119	57/119	0.71	0.48; 1.05	0.084
ASC4START	50/171	58/172	0.82	0.56; 1.20	0.302
Pooled Analysis	96/290	115/291	0.76	0.58; 1.00	0.052




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

General disorders and administration site conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	20/63	25/61	0.69	0.38; 1.26	0.226
ASC4START	32/138	42/140	0.71	0.45; 1.13	0.150
Pooled Analysis	52/201	67/201	0.70	0.49; 1.01	0.060
Germany					
ASC4FIRST	8/19	6/15	0.86	0.28; 2.63	0.796
ASC4START	26/72	15/53	1.19	0.63; 2.27	0.581
Pooled Analysis	34/91	21/68	1.10	0.63; 1.92	0.722
Others					
ASC4FIRST	39/114	53/114	0.64	0.42; 0.97	0.036
ASC4START	18/74	22/89	1.06	0.56; 1.98	0.871
Pooled Analysis	57/188	75/203	0.74	0.53; 1.05	0.095




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

General disorders and administration site conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	18/41	23/42	0.70	0.37; 1.32	0.266
Pooled Analysis	18/41	23/42	0.70	0.37; 1.32	0.266
Imatinib					
ASC4FIRST	30/100	46/100	0.55	0.34; 0.87	0.010
Pooled Analysis	30/100	46/100	0.55	0.34; 0.87	0.010
Nilotinib					
ASC4FIRST	19/55	15/48	1.00	0.51; 1.97	0.998
ASC4START	76/284	79/282	0.91	0.66; 1.25	0.563
Pooled Analysis	95/339	94/330	0.93	0.70; 1.23	0.601




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

General disorders and administration site conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	8/40	8/45	1.26	0.47; 3.38	0.649
Pooled Analysis	28/128	42/130	0.60	0.37; 0.98	0.037
Asian/Others					
ASC4FIRST	21/91	36/89	0.49	0.29; 0.85	0.009
Others					
ASC4START	4/17	4/21	1.32	0.30; 5.86	0.715
Pooled Analysis	5/20	6/25	1.08	0.27; 4.38	0.917
White					
ASC4FIRST	46/105	48/101	0.83	0.55; 1.25	0.374
ASC4START	64/227	67/216	0.86	0.61; 1.21	0.378
Pooled Analysis	110/332	115/317	0.84	0.65; 1.10	0.212




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

General disorders and administration site conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	33/67	35/74	0.95	0.58; 1.54	0.833
ASC4START	40/107	47/124	0.98	0.64; 1.49	0.922
Pooled Analysis	73/174	82/198	0.96	0.70; 1.33	0.832
Male					
ASC4FIRST	34/129	49/116	0.53	0.34; 0.84	0.005
ASC4START	36/177	32/158	0.95	0.59; 1.53	0.841
Pooled Analysis	70/306	81/274	0.70	0.51; 0.96	0.029




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	74/152	82/148	0.80	0.59; 1.10	0.173
ASC4START	83/237	100/246	0.79	0.59; 1.05	0.104
Pooled Analysis	157/389	182/394	0.79	0.64; 0.98	0.034
65 - < 75 years					
ASC4FIRST	16/34	14/29	0.88	0.42; 1.86	0.733
ASC4START	11/38	12/24	0.41	0.17; 0.97	0.040
Pooled Analysis	27/72	26/53	0.63	0.36; 1.12	0.114
>= 75 years					
ASC4FIRST	4/10	8/13	0.73	0.21; 2.62	0.633
ASC4START	2/9	9/12	0.26	0.06; 1.24	0.065
Pooled Analysis	6/19	17/25	0.46	0.18; 1.20	0.105




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	12/23	11/19	0.69	0.30; 1.59	0.394
ASC4START	12/38	18/37	0.53	0.26; 1.10	0.088
Pooled Analysis	24/61	29/56	0.60	0.35; 1.03	0.064
Intermediate					
ASC4FIRST	29/54	25/52	1.15	0.67; 1.96	0.598
ASC4START	26/75	30/73	0.75	0.45; 1.28	0.299
Pooled Analysis	55/129	55/125	0.93	0.64; 1.35	0.708
Low					
ASC4FIRST	53/119	68/119	0.67	0.47; 0.96	0.027
ASC4START	58/171	73/172	0.73	0.51; 1.03	0.066
Pooled Analysis	111/290	141/291	0.70	0.54; 0.90	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	20/63	21/61	0.89	0.47; 1.68	0.723
ASC4START	40/138	48/140	0.79	0.52; 1.20	0.272
Pooled Analysis	60/201	69/201	0.82	0.58; 1.16	0.267
Germany					
ASC4FIRST	8/19	9/15	0.64	0.23; 1.81	0.359
ASC4START	27/72	28/53	0.62	0.36; 1.06	0.082
Pooled Analysis	35/91	37/68	0.62	0.39; 1.00	0.049
Others					
ASC4FIRST	66/114	74/114	0.80	0.57; 1.12	0.193
ASC4START	29/74	45/89	0.67	0.42; 1.07	0.091
Pooled Analysis	95/188	119/203	0.75	0.57; 0.99	0.040




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	17/41	24/42	0.59	0.31; 1.12	0.102
Pooled Analysis	17/41	24/42	0.59	0.31; 1.12	0.102
Imatinib					
ASC4FIRST	47/100	46/100	0.98	0.65; 1.48	0.936
Pooled Analysis	47/100	46/100	0.98	0.65; 1.48	0.936
Nilotinib					
ASC4FIRST	30/55	34/48	0.60	0.37; 0.99	0.041
ASC4START	96/284	121/282	0.70	0.54; 0.92	0.010
Pooled Analysis	126/339	155/330	0.68	0.54; 0.86	0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	16/40	21/45	0.73	0.38; 1.42	0.360
Pooled Analysis	69/128	77/130	0.80	0.58; 1.11	0.190
Asian/Others					
ASC4FIRST	53/91	59/89	0.78	0.53; 1.13	0.189
Others					
ASC4START	7/17	9/21	0.83	0.30; 2.28	0.733
Pooled Analysis	7/20	12/25	0.77	0.29; 2.07	0.617
White					
ASC4FIRST	41/105	45/101	0.85	0.55; 1.31	0.446
ASC4START	73/227	91/216	0.70	0.51; 0.95	0.022
Pooled Analysis	114/332	136/317	0.74	0.58; 0.96	0.021




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	30/67	36/74	0.88	0.54; 1.45	0.630
ASC4START	29/107	58/124	0.44	0.28; 0.70	<0.001
Pooled Analysis	59/174	94/198	0.60	0.43; 0.83	0.002
Male					
ASC4FIRST	64/129	68/116	0.71	0.50; 1.00	0.054
ASC4START	67/177	63/158	0.94	0.66; 1.32	0.715
Pooled Analysis	131/306	131/274	0.82	0.64; 1.04	0.108




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Skin and subcutaneous tissue disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	62/152	61/148	0.85	0.60; 1.21	0.379
ASC4START	71/237	112/246	0.54	0.40; 0.73	<0.001
Pooled Analysis	133/389	173/394	0.65	0.52; 0.82	<0.001
65 - < 75 years					
ASC4FIRST	10/34	10/29	0.85	0.33; 2.15	0.729
ASC4START	15/38	13/24	0.48	0.23; 1.03	0.056
Pooled Analysis	25/72	23/53	0.60	0.33; 1.10	0.097
>= 75 years					
ASC4FIRST	5/10	7/13	0.67	0.17; 2.63	0.567
ASC4START	2/9	7/12	0.30	0.06; 1.49	0.123
Pooled Analysis	7/19	14/25	0.47	0.17; 1.29	0.140




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Skin and subcutaneous tissue disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	5/23	5/19	0.72	0.21; 2.51	0.609
ASC4START	9/38	18/37	0.37	0.17; 0.82	0.011
Pooled Analysis	14/61	23/56	0.45	0.23; 0.87	0.015
Intermediate					
ASC4FIRST	18/54	16/52	0.84	0.42; 1.65	0.607
ASC4START	24/75	33/73	0.56	0.33; 0.95	0.030
Pooled Analysis	42/129	49/125	0.65	0.43; 0.99	0.042
Low					
ASC4FIRST	54/119	57/119	0.80	0.55; 1.17	0.258
ASC4START	55/171	81/172	0.56	0.40; 0.80	<0.001
Pooled Analysis	109/290	138/291	0.66	0.52; 0.85	0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Skin and subcutaneous tissue disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	23/63	24/61	0.90	0.50; 1.61	0.719
ASC4START	34/138	67/140	0.42	0.27; 0.63	<0.001
Pooled Analysis	57/201	91/201	0.53	0.38; 0.74	<0.001
Germany					
ASC4FIRST	9/19	7/15	1.13	0.39; 3.21	0.825
ASC4START	28/72	24/53	0.72	0.41; 1.25	0.230
Pooled Analysis	37/91	31/68	0.79	0.49; 1.29	0.344
Others					
ASC4FIRST	45/114	47/114	0.73	0.49; 1.11	0.143
ASC4START	26/74	41/89	0.62	0.38; 1.02	0.058
Pooled Analysis	71/188	88/203	0.69	0.50; 0.94	0.019




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Skin and subcutaneous tissue disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	19/41	23/42	0.79	0.43; 1.47	0.466
Pooled Analysis	19/41	23/42	0.79	0.43; 1.47	0.466
Imatinib					
ASC4FIRST	40/100	32/100	1.14	0.71; 1.82	0.574
Pooled Analysis	40/100	32/100	1.14	0.71; 1.82	0.574
Nilotinib					
ASC4FIRST	18/55	23/48	0.50	0.27; 0.93	0.026
ASC4START	88/284	132/282	0.54	0.41; 0.70	<0.001
Pooled Analysis	106/339	155/330	0.53	0.41; 0.68	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Skin and subcutaneous tissue disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	10/40	21/45	0.40	0.18; 0.85	0.015
Pooled Analysis	41/128	51/130	0.66	0.43; 1.00	0.050
Asian/Others					
ASC4FIRST	32/91	34/89	0.78	0.48; 1.27	0.316
Others					
ASC4START	7/17	9/21	1.03	0.38; 2.80	0.960
Pooled Analysis	8/20	13/25	1.21	0.46; 3.17	0.703
White					
ASC4FIRST	45/105	44/101	0.82	0.54; 1.26	0.369
ASC4START	71/227	102/216	0.53	0.39; 0.72	<0.001
Pooled Analysis	116/332	146/317	0.62	0.48; 0.79	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.2.1: Forest-Plot for Any AE by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Skin and subcutaneous tissue disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	28/67	35/74	0.72	0.43; 1.20	0.208
ASC4START	43/107	70/124	0.52	0.36; 0.76	<0.001
Pooled Analysis	71/174	105/198	0.58	0.43; 0.79	<0.001
Male					
ASC4FIRST	49/129	43/116	0.93	0.61; 1.40	0.730
ASC4START	45/177	62/158	0.56	0.38; 0.83	0.003
Pooled Analysis	94/306	105/274	0.71	0.54; 0.94	0.016



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.3 Time to first any AE by PT: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Abdominal distension								
Age groups								
(Interaction test: p = 1.000)								
18 - < 65 years	1/389 (0.3)	N.E. [N.E.; N.E.]	10/394 (2.5)	N.E. [N.E.; N.E.]	0.10	[0.01; 0.74]	0.005	0.992
65 - < 75 years	0/72	N.E. [N.E.; N.E.]	0/53	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
>= 75 years	0/19	N.E. [N.E.; N.E.]	2/25 (8.0)	N.E. [N.E.; N.E.]	0.39	[0.00; 38.92]	0.371	N.E.
Geographic region								
(Interaction test: p = 1.000)								
Europe excluding Germany	0/201	N.E. [N.E.; N.E.]	1/201 (0.5)	N.E. [N.E.; N.E.]	0.35	[0.00; 31.98]	0.326	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Germany	0/91	N.E. [N.E.; N.E.]	0/68	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Others	1/188 (0.5)	N.E. [N.E.; N.E.]	11/203 (5.4)	N.E. [N.E.; N.E.]	0.10	[0.01; 0.79]	0.007	0.994
Alanine aminotransferase increased								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.615)								
Low	22/290 (7.6)	N.E. [N.E.; N.E.]	43/291 (14.8)	N.E. [N.E.; N.E.]	0.47	[0.28; 0.79]	0.004	0.749
Intermediate	5/129 (3.9)	N.E. [N.E.; N.E.]	15/125 (12.0)	N.E. [N.E.; N.E.]	0.27	[0.10; 0.75]	0.007	0.071
High	5/61 (8.2)	N.E. [N.E.; N.E.]	7/56 (12.5)	N.E. [N.E.; N.E.]	0.56	[0.18; 1.78]	0.323	0.296
Sex								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.991)								
Female	11/174 (6.3)	N.E. [N.E.; N.E.]	27/198 (13.6)	N.E. [N.E.; N.E.]	0.41	[0.20; 0.83]	0.011	0.591
Male	21/306 (6.9)	N.E. [N.E.; N.E.]	38/274 (13.9)	N.E. [N.E.; N.E.]	0.42	[0.24; 0.72]	0.001	0.266
Race								
(Interaction test: p = 0.532)								
Asian	13/128 (10.2)	N.E. [N.E.; N.E.]	19/130 (14.6)	N.E. [N.E.; N.E.]	0.64	[0.31; 1.30]	0.213	0.968
White	19/332 (5.7)	N.E. [N.E.; N.E.]	42/317 (13.2)	N.E. [N.E.; N.E.]	0.38	[0.22; 0.65]	<0.001	0.398
Others	0/20	N.E. [N.E.; N.E.]	4/25 (16.0)	N.E. [N.E.; N.E.]	0.14	[0.00; 3.90]	0.080	N.E.
Age groups								
(Interaction test: p = 0.951)								
18 - < 65 years	28/389	N.E. [N.E.; N.E.]	59/394	N.E. [N.E.; N.E.]	0.44	[0.28; 0.69]	<0.001	0.156

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(7.2)		(15.0)					
65 - < 75 years	4/72	N.E. [N.E.; N.E.]	4/53	N.E. [N.E.; N.E.]	0.43	[0.10; 1.90]	0.272	0.171
	(5.6)		(7.5)					
>= 75 years	0/19	N.E. [N.E.; N.E.]	2/25	N.E. [N.E.; N.E.]	0.53	[0.01; 51.67]	0.439	N.E.
			(8.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.077)								
Imatinib	9/100	N.E. [N.E.; N.E.]	7/100	N.E. [N.E.; N.E.]	1.22	[0.45; 3.28]	0.697	N.E.
	(9.0)		(7.0)					
Nilotinib	19/339	N.E. [N.E.; N.E.]	52/330	N.E. [N.E.; N.E.]	0.31	[0.19; 0.53]	<0.001	0.823
	(5.6)		(15.8)					
Dasatinib	4/41	N.E. [N.E.; N.E.]	6/42	N.E. [N.E.; N.E.]	0.51	[0.14; 1.90]	0.311	N.E.
	(9.8)		(14.3)					
Geographic region								
(Interaction test: p = 0.874)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Europe excluding Germany	11/201 (5.5)	N.E. [N.E.; N.E.]	22/201 (10.9)	N.E. [N.E.; N.E.]	0.43	[0.20; 0.90]	0.021	0.168
Germany	7/91 (7.7)	N.E. [N.E.; N.E.]	13/68 (19.1)	N.E. [N.E.; N.E.]	0.33	[0.13; 0.85]	0.016	0.650
Others	14/188 (7.4)	N.E. [N.E.; N.E.]	30/203 (14.8)	N.E. [N.E.; N.E.]	0.45	[0.24; 0.85]	0.012	0.246
Alopecia								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.572)								
Low	8/290 (2.8)	N.E. [N.E.; N.E.]	30/291 (10.3)	N.E. [N.E.; N.E.]	0.25	[0.12; 0.55]	<0.001	0.393
Intermediate	5/129 (3.9)	N.E. [N.E.; N.E.]	9/125 (7.2)	N.E. [N.E.; N.E.]	0.48	[0.16; 1.45]	0.187	0.171
High	1/61	N.E. [N.E.; N.E.]	4/56	N.E. [N.E.; N.E.]	0.23	[0.03; 2.07]	0.152	0.996

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(1.6)		(7.1)					
Sex								
(Interaction test: p = 0.124)								
Female	7/174 (4.0)	N.E. [N.E.; N.E.]	33/198 (16.7)	N.E. [N.E.; N.E.]	0.21	[0.09; 0.48]	<0.001	0.921
Male	7/306 (2.3)	N.E. [N.E.; N.E.]	10/274 (3.6)	N.E. [N.E.; N.E.]	0.58	[0.22; 1.53]	0.262	0.300
Race								
(Interaction test: p = 0.781)								
Asian	1/128 (0.8)	N.E. [N.E.; N.E.]	6/130 (4.6)	N.E. [N.E.; N.E.]	0.15	[0.02; 1.29]	0.049	0.995
White	13/332 (3.9)	N.E. [N.E.; N.E.]	35/317 (11.0)	N.E. [N.E.; N.E.]	0.34	[0.18; 0.64]	<0.001	0.511
Others	0/20	N.E. [N.E.; N.E.]	2/25 (8.0)	N.E. [N.E.; N.E.]	0.28	[0.00; 26.04]	0.277	N.E.
Age groups								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.854)								
18 - < 65 years	12/389 (3.1)	N.E. [N.E.; N.E.]	37/394 (9.4)	N.E. [N.E.; N.E.]	0.32	[0.17; 0.61]	<0.001	0.727
65 - < 75 years	2/72 (2.8)	N.E. [N.E.; N.E.]	2/53 (3.8)	N.E. [N.E.; N.E.]	0.55	[0.07; 4.13]	0.558	0.967
>= 75 years	0/19	N.E. [N.E.; N.E.]	4/25 (16.0)	N.E. [N.E.; N.E.]	0.13	[0.00; 3.46]	0.066	1.000
Pre-randomization selection of TKI								
(Interaction test: p = 0.624)								
Imatinib	3/100 (3.0)	N.E. [N.E.; N.E.]	5/100 (5.0)	N.E. [N.E.; N.E.]	0.56	[0.13; 2.36]	0.422	N.E.
Nilotinib	10/339 (2.9)	N.E. [N.E.; N.E.]	33/330 (10.0)	N.E. [N.E.; N.E.]	0.28	[0.14; 0.58]	<0.001	0.985
Dasatinib	1/41 (2.4)	N.E. [N.E.; N.E.]	5/42 (11.9)	N.E. [N.E.; N.E.]	0.22	[0.03; 1.91]	0.133	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Geographic region								
(Interaction test: p = 0.056)								
Europe excluding Germany	5/201 (2.5)	N.E. [N.E.; N.E.]	25/201 (12.4)	N.E. [N.E.; N.E.]	0.19	[0.07; 0.51]	<0.001	0.055
Germany	7/91 (7.7)	N.E. [N.E.; N.E.]	5/68 (7.4)	N.E. [N.E.; N.E.]	1.01	[0.32; 3.20]	0.993	0.734
Others	2/188 (1.1)	N.E. [N.E.; N.E.]	13/203 (6.4)	N.E. [N.E.; N.E.]	0.15	[0.03; 0.67]	0.004	0.994
Anaemia								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.312)								
Low	27/290 (9.3)	N.E. [N.E.; N.E.]	40/291 (13.7)	N.E. [N.E.; N.E.]	0.65	[0.40; 1.06]	0.083	0.146
Intermediate	16/129	N.E. [N.E.; N.E.]	18/125	N.E. [N.E.; N.E.]	0.83	[0.42; 1.62]	0.582	0.582

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(12.4)		(14.4)					
High	6/61	N.E. [N.E.; N.E.]	13/56	N.E. [22.9; N.E.]	0.34	[0.13; 0.89]	0.022	0.023
	(9.8)		(23.2)					
Sex								
(Interaction test: p = 0.938)								
Female	23/174	N.E. [N.E.; N.E.]	38/198	N.E. [N.E.; N.E.]	0.68	[0.40; 1.14]	0.138	0.002
	(13.2)		(19.2)					
Male	26/306	N.E. [N.E.; N.E.]	33/274	N.E. [N.E.; N.E.]	0.68	[0.41; 1.15]	0.152	0.752
	(8.5)		(12.0)					
Race								
(Interaction test: p = 0.550)								
Asian	23/128	N.E. [N.E.; N.E.]	31/130	N.E. [N.E.; N.E.]	0.68	[0.39; 1.17]	0.167	0.718
	(18.0)		(23.8)					
White	22/332	N.E. [N.E.; N.E.]	36/317	N.E. [N.E.; N.E.]	0.55	[0.32; 0.95]	0.029	0.010
	(6.6)		(11.4)					
Others	4/20	N.E. [13.8; N.E.]	4/25	N.E. [N.E.; N.E.]	1.98	[0.42; 9.32]	0.384	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(20.0)		(16.0)					
Age groups								
(Interaction test: p = 0.553)								
18 - < 65 years	42/389	N.E. [N.E.; N.E.]	56/394	N.E. [N.E.; N.E.]	0.71	[0.47; 1.05]	0.088	0.074
	(10.8)		(14.2)					
65 - < 75 years	5/72	N.E. [N.E.; N.E.]	8/53	N.E. [N.E.; N.E.]	0.61	[0.20; 1.89]	0.384	0.435
	(6.9)		(15.1)					
>= 75 years	2/19	29.1 [N.E.; N.E.]	7/25	N.E. [5.6; N.E.]	0.22	[0.03; 1.85]	0.124	N.E.
	(10.5)		(28.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.002)								
Imatinib	11/100	N.E. [N.E.; N.E.]	26/100	N.E. [N.E.; N.E.]	0.40	[0.20; 0.81]	0.009	N.E.
	(11.0)		(26.0)					
Nilotinib	35/339	N.E. [N.E.; N.E.]	29/330	N.E. [N.E.; N.E.]	1.12	[0.69; 1.84]	0.644	0.683
	(10.3)		(8.8)					

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	3/41 (7.3)	N.E. [N.E.; N.E.]	16/42 (38.1)	N.E. [5.6; N.E.]	0.11	[0.03; 0.40]	<0.001	N.E.
Geographic region (Interaction test: p = 0.471)								
Europe excluding Germany	13/201 (6.5)	N.E. [N.E.; N.E.]	20/201 (10.0)	N.E. [N.E.; N.E.]	0.64	[0.31; 1.30]	0.208	0.004
Germany	3/91 (3.3)	N.E. [N.E.; N.E.]	7/68 (10.3)	N.E. [N.E.; N.E.]	0.35	[0.09; 1.43]	0.128	0.590
Others	33/188 (17.6)	N.E. [N.E.; N.E.]	44/203 (21.7)	N.E. [N.E.; N.E.]	0.76	[0.48; 1.19]	0.234	0.359
Aspartate aminotransferase increased								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.341)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Low	11/290 (3.8)	N.E. [N.E.; N.E.]	35/291 (12.0)	N.E. [N.E.; N.E.]	0.29	[0.15; 0.57]	<0.001	0.062
Intermediate	4/129 (3.1)	N.E. [N.E.; N.E.]	7/125 (5.6)	N.E. [N.E.; N.E.]	0.49	[0.14; 1.67]	0.243	0.179
High	4/61 (6.6)	N.E. [N.E.; N.E.]	4/56 (7.1)	N.E. [N.E.; N.E.]	0.82	[0.20; 3.29]	0.777	0.833
Sex								
(Interaction test: p = 0.412)								
Female	6/174 (3.4)	N.E. [N.E.; N.E.]	23/198 (11.6)	N.E. [N.E.; N.E.]	0.26	[0.11; 0.64]	0.002	0.530
Male	13/306 (4.2)	N.E. [N.E.; N.E.]	23/274 (8.4)	N.E. [N.E.; N.E.]	0.43	[0.22; 0.86]	0.014	0.166
Race								
(Interaction test: p = 0.530)								
Asian	4/128 (3.1)	N.E. [N.E.; N.E.]	16/130 (12.3)	N.E. [N.E.; N.E.]	0.25	[0.08; 0.75]	0.008	0.799

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
White	14/332 (4.2)	N.E. [N.E.; N.E.]	26/317 (8.2)	N.E. [N.E.; N.E.]	0.48	[0.25; 0.93]	0.025	0.884
Others	1/20 (5.0)	N.E. [N.E.; N.E.]	4/25 (16.0)	N.E. [N.E.; N.E.]	0.35	[0.04; 3.47]	0.349	N.E.
Age groups								
(Interaction test: p = 0.950)								
18 - < 65 years	15/389 (3.9)	N.E. [N.E.; N.E.]	41/394 (10.4)	N.E. [N.E.; N.E.]	0.34	[0.19; 0.62]	<0.001	0.233
65 - < 75 years	4/72 (5.6)	N.E. [N.E.; N.E.]	5/53 (9.4)	N.E. [N.E.; N.E.]	0.39	[0.10; 1.61]	0.182	0.254
>= 75 years	0/19	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Pre-randomization selection of TKI								
(Interaction test: p = 0.828)								
Imatinib	2/100	N.E. [N.E.; N.E.]	7/100	N.E. [N.E.; N.E.]	0.26	[0.05; 1.23]	0.066	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(2.0)		(7.0)					
Nilotinib	15/339	N.E. [N.E.; N.E.]	34/330	N.E. [N.E.; N.E.]	0.40	[0.22; 0.73]	0.002	0.416
	(4.4)		(10.3)					
Dasatinib	2/41	N.E. [N.E.; N.E.]	5/42	N.E. [N.E.; N.E.]	0.37	[0.07; 2.04]	0.239	N.E.
	(4.9)		(11.9)					
Geographic region								
(Interaction test: p = 0.506)								
Europe excluding Germany	7/201	N.E. [N.E.; N.E.]	12/201	N.E. [N.E.; N.E.]	0.53	[0.20; 1.37]	0.180	0.517
	(3.5)		(6.0)					
Germany	6/91	N.E. [N.E.; N.E.]	10/68	N.E. [N.E.; N.E.]	0.35	[0.13; 0.96]	0.034	0.669
	(6.6)		(14.7)					
Others	6/188	N.E. [N.E.; N.E.]	24/203	N.E. [N.E.; N.E.]	0.25	[0.10; 0.62]	0.001	0.735
	(3.2)		(11.8)					
Blood bilirubin increased								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.845)								
Low	9/290 (3.1)	N.E. [N.E.; N.E.]	35/291 (12.0)	N.E. [N.E.; N.E.]	0.24	[0.11; 0.49]	<0.001	0.072
Intermediate	3/129 (2.3)	N.E. [N.E.; N.E.]	8/125 (6.4)	N.E. [N.E.; N.E.]	0.33	[0.09; 1.26]	0.088	0.399
High	2/61 (3.3)	N.E. [N.E.; N.E.]	9/56 (16.1)	N.E. [N.E.; N.E.]	0.19	[0.04; 0.89]	0.018	0.507
Sex								
(Interaction test: p = 0.928)								
Female	4/174 (2.3)	N.E. [N.E.; N.E.]	19/198 (9.6)	N.E. [N.E.; N.E.]	0.22	[0.08; 0.66]	0.003	0.584
Male	10/306 (3.3)	N.E. [N.E.; N.E.]	33/274 (12.0)	N.E. [N.E.; N.E.]	0.24	[0.12; 0.49]	<0.001	0.054

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.620)								
Asian	7/128 (5.5)	N.E. [N.E.; N.E.]	19/130 (14.6)	N.E. [N.E.; N.E.]	0.36	[0.15; 0.86]	0.017	0.990
White	7/332 (2.1)	N.E. [N.E.; N.E.]	30/317 (9.5)	N.E. [N.E.; N.E.]	0.20	[0.09; 0.46]	<0.001	0.331
Others	0/20	N.E. [N.E.; N.E.]	3/25 (12.0)	N.E. [N.E.; N.E.]	0.16	[0.00; 5.17]	0.105	N.E.
Age groups								
(Interaction test: p = 0.752)								
18 - < 65 years	13/389 (3.3)	N.E. [N.E.; N.E.]	45/394 (11.4)	N.E. [N.E.; N.E.]	0.27	[0.14; 0.50]	<0.001	0.025
65 - < 75 years	0/72	N.E. [N.E.; N.E.]	5/53 (9.4)	N.E. [N.E.; N.E.]	0.06	[0.00; 1.49]	0.007	1.000
>= 75 years	1/19 (5.3)	N.E. [N.E.; N.E.]	2/25 (8.0)	N.E. [N.E.; N.E.]	0.54	[0.05; 5.95]	0.589	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.192)								
Imatinib	2/100 (2.0)	N.E. [N.E.; N.E.]	2/100 (2.0)	N.E. [N.E.; N.E.]	0.91	[0.13; 6.51]	0.929	N.E.
Nilotinib	11/339 (3.2)	N.E. [N.E.; N.E.]	49/330 (14.8)	N.E. [N.E.; N.E.]	0.20	[0.10; 0.38]	<0.001	0.149
Dasatinib	1/41 (2.4)	N.E. [N.E.; N.E.]	1/42 (2.4)	N.E. [N.E.; N.E.]	1.18	[0.07; 18.92]	0.905	N.E.
Geographic region								
(Interaction test: p = 0.206)								
Europe excluding Germany	5/201 (2.5)	N.E. [N.E.; N.E.]	15/201 (7.5)	N.E. [N.E.; N.E.]	0.30	[0.11; 0.83]	0.015	0.930
Germany	1/91 (1.1)	N.E. [N.E.; N.E.]	13/68 (19.1)	N.E. [N.E.; N.E.]	0.05	[0.01; 0.36]	<0.001	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	8/188 (4.3)	N.E. [N.E.; N.E.]	24/203 (11.8)	N.E. [N.E.; N.E.]	0.35	[0.16; 0.77]	0.007	0.113
Blood creatinine increased								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.582)								
Low	5/290 (1.7)	N.E. [N.E.; N.E.]	8/291 (2.7)	N.E. [N.E.; N.E.]	0.59	[0.19; 1.81]	0.350	0.688
Intermediate	1/129 (0.8)	N.E. [N.E.; N.E.]	5/125 (4.0)	N.E. [N.E.; N.E.]	0.17	[0.02; 1.44]	0.063	0.995
High	1/61 (1.6)	N.E. [N.E.; N.E.]	2/56 (3.6)	N.E. [N.E.; N.E.]	0.39	[0.04; 4.36]	0.432	0.996
Sex (Interaction test: p = 0.272)								
Female	1/174	N.E. [N.E.; N.E.]	7/198	N.E. [N.E.; N.E.]	0.16	[0.02; 1.27]	0.047	0.995

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(0.6)		(3.5)					
Male	6/306	N.E. [N.E.; N.E.]	8/274	N.E. [N.E.; N.E.]	0.59	[0.20; 1.73]	0.331	0.522
	(2.0)		(2.9)					
Race								
(Interaction test: p = 1.000)								
Asian	0/128	N.E. [N.E.; N.E.]	8/130	N.E. [N.E.; N.E.]	0.05	[0.00; 1.06]	0.003	1.000
			(6.2)					
White	6/332	N.E. [N.E.; N.E.]	7/317	N.E. [N.E.; N.E.]	0.70	[0.23; 2.10]	0.524	0.261
	(1.8)		(2.2)					
Others	1/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	2.64	[0.03; 255.27]	0.358	N.E.
	(5.0)							
Age groups								
(Interaction test: p = 0.496)								
18 - < 65 years	6/389	N.E. [N.E.; N.E.]	8/394	N.E. [N.E.; N.E.]	0.70	[0.24; 2.02]	0.509	0.770
	(1.5)		(2.0)					
65 - < 75 years	1/72	N.E. [N.E.; N.E.]	4/53	N.E. [N.E.; N.E.]	0.17	[0.02; 1.51]	0.069	0.997

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(1.4)		(7.5)					
>= 75 years	0/19	N.E. [N.E.; N.E.]	3/25 (12.0)	N.E. [N.E.; N.E.]	0.27	[0.01; 11.48]	0.229	1.000
Pre-randomization selection of TKI								
(Interaction test: p = 0.811)								
Imatinib	2/100 (2.0)	N.E. [N.E.; N.E.]	5/100 (5.0)	N.E. [N.E.; N.E.]	0.35	[0.07; 1.79]	0.185	N.E.
Nilotinib	4/339 (1.2)	N.E. [N.E.; N.E.]	9/330 (2.7)	N.E. [N.E.; N.E.]	0.39	[0.12; 1.28]	0.108	0.968
Dasatinib	1/41 (2.4)	N.E. [N.E.; N.E.]	1/42 (2.4)	N.E. [N.E.; N.E.]	0.33	[0.02; 5.27]	0.407	N.E.
Geographic region								
(Interaction test: p = 0.123)								
Europe excluding Germany	4/201	N.E. [N.E.; N.E.]	2/201	N.E. [N.E.; N.E.]	1.59	[0.28; 9.12]	0.602	0.995

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(2.0)		(1.0)					
Germany	1/91	N.E. [N.E.; N.E.]	1/68	N.E. [N.E.; N.E.]	0.17	[0.00; 15.37]	0.157	N.E.
	(1.1)		(1.5)					
Others	2/188	N.E. [N.E.; N.E.]	12/203	N.E. [N.E.; N.E.]	0.17	[0.04; 0.76]	0.008	0.744
	(1.1)		(5.9)					
Bone pain								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 1.000)								
Low	9/290	N.E. [N.E.; N.E.]	3/291	N.E. [N.E.; N.E.]	3.00	[0.81; 11.10]	0.083	0.321
	(3.1)		(1.0)					
Intermediate	7/129	N.E. [N.E.; N.E.]	0/125	N.E. [N.E.; N.E.]	14.60	[0.68; 311.76]	0.009	1.000
	(5.4)							
High	0/61	N.E. [N.E.; N.E.]	2/56	N.E. [N.E.; N.E.]	0.18	[0.00; 7.43]	0.136	1.000
			(3.6)					

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.242)								
Female	10/174 (5.7)	N.E. [N.E.; N.E.]	2/198 (1.0)	N.E. [N.E.; N.E.]	5.87	[1.28; 26.93]	0.010	0.824
Male	6/306 (2.0)	N.E. [N.E.; N.E.]	3/274 (1.1)	N.E. [N.E.; N.E.]	1.68	[0.42; 6.77]	0.459	0.134
Race								
(Interaction test: p = 0.456)								
Asian	2/128 (1.6)	N.E. [N.E.; N.E.]	2/130 (1.5)	N.E. [N.E.; N.E.]	1.17	[0.16; 8.30]	0.877	0.927
White	14/332 (4.2)	N.E. [N.E.; N.E.]	3/317 (0.9)	N.E. [N.E.; N.E.]	4.62	[1.32; 16.15]	0.008	0.252
Others	0/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Age groups								
(Interaction test: p = 1.000)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	14/389 (3.6)	N.E. [N.E.; N.E.]	5/394 (1.3)	N.E. [N.E.; N.E.]	2.83	[1.02; 7.85]	0.037	0.193
65 - < 75 years	2/72 (2.8)	N.E. [N.E.; N.E.]	0/53	N.E. [N.E.; N.E.]	3.65	[0.09; 152.20]	0.228	1.000
>= 75 years	0/19	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Pre-randomization selection of TKI								
(Interaction test: p = 0.829)								
Imatinib	2/100 (2.0)	N.E. [N.E.; N.E.]	1/100 (1.0)	N.E. [N.E.; N.E.]	2.06	[0.19; 22.67]	0.548	N.E.
Nilotinib	12/339 (3.5)	N.E. [N.E.; N.E.]	3/330 (0.9)	N.E. [N.E.; N.E.]	4.04	[1.14; 14.35]	0.019	0.326
Dasatinib	2/41 (4.9)	N.E. [N.E.; N.E.]	1/42 (2.4)	N.E. [N.E.; N.E.]	2.40	[0.22; 26.49]	0.461	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.947)								
Europe excluding Germany	4/201 (2.0)	N.E. [N.E.; N.E.]	2/201 (1.0)	N.E. [N.E.; N.E.]	2.13	[0.39; 11.61]	0.373	0.993
Germany	4/91 (4.4)	N.E. [N.E.; N.E.]	0/68	N.E. [N.E.; N.E.]	8.18	[0.31; 218.57]	0.058	1.000
Others	8/188 (4.3)	N.E. [N.E.; N.E.]	3/203 (1.5)	N.E. [N.E.; N.E.]	2.95	[0.78; 11.18]	0.095	0.513
Face oedema								
Pre-randomization selection of TKI								
(Interaction test: p = 1.000)								
Imatinib	0/100	N.E. [N.E.; N.E.]	10/100 (10.0)	N.E. [N.E.; N.E.]	0.05	[0.00; 0.92]	0.001	N.E.
Nilotinib	0/339	N.E. [N.E.; N.E.]	0/330	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	0/41	N.E. [N.E.; N.E.]	0/42	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Hyperbilirubinaemia								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.834)								
Low	3/290 (1.0)	N.E. [N.E.; N.E.]	8/291 (2.7)	N.E. [N.E.; N.E.]	0.35	[0.09; 1.33]	0.108	0.102
Intermediate	0/129	N.E. [N.E.; N.E.]	3/125 (2.4)	N.E. [N.E.; N.E.]	0.13	[0.00; 3.90]	0.066	N.E.
High	1/61 (1.6)	N.E. [N.E.; N.E.]	1/56 (1.8)	N.E. [N.E.; N.E.]	0.91	[0.06; 14.62]	0.949	0.998
Age groups								
(Interaction test: p = 1.000)								
18 - < 65 years	4/389	N.E. [N.E.; N.E.]	10/394	N.E. [N.E.; N.E.]	0.39	[0.12; 1.23]	0.096	0.142

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(1.0)		(2.5)					
65 - < 75 years	0/72	N.E. [N.E.; N.E.]	1/53	N.E. [N.E.; N.E.]	0.17	[0.00; 15.37]	0.157	N.E.
			(1.9)					
>= 75 years	0/19	N.E. [N.E.; N.E.]	1/25	N.E. [N.E.; N.E.]	0.39	[0.00; 37.18]	0.361	N.E.
			(4.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 1.000)								
Imatinib	0/100	N.E. [N.E.; N.E.]	0/100	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Nilotinib	4/339	N.E. [N.E.; N.E.]	12/330	N.E. [N.E.; N.E.]	0.31	[0.10; 0.96]	0.032	0.203
	(1.2)		(3.6)					
Dasatinib	0/41	N.E. [N.E.; N.E.]	0/42	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Hypercholesterolaemia								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.723)								
Low	9/290 (3.1)	N.E. [N.E.; N.E.]	19/291 (6.5)	N.E. [N.E.; N.E.]	0.46	[0.21; 1.01]	0.046	0.055
Intermediate	3/129 (2.3)	N.E. [N.E.; N.E.]	3/125 (2.4)	N.E. [N.E.; N.E.]	0.79	[0.16; 3.94]	0.773	0.994
High	1/61 (1.6)	N.E. [N.E.; N.E.]	1/56 (1.8)	N.E. [N.E.; N.E.]	0.31	[0.02; 6.26]	0.432	N.E.
Sex								
(Interaction test: p = 0.729)								
Female	7/174 (4.0)	N.E. [N.E.; N.E.]	15/198 (7.6)	N.E. [N.E.; N.E.]	0.48	[0.19; 1.17]	0.099	0.019
Male	6/306 (2.0)	N.E. [N.E.; N.E.]	8/274 (2.9)	N.E. [N.E.; N.E.]	0.51	[0.16; 1.59]	0.237	0.524

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.969)								
Asian	4/128 (3.1)	N.E. [N.E.; N.E.]	7/130 (5.4)	N.E. [N.E.; N.E.]	0.62	[0.18; 2.11]	0.435	0.994
White	9/332 (2.7)	N.E. [N.E.; N.E.]	16/317 (5.0)	N.E. [N.E.; N.E.]	0.47	[0.20; 1.08]	0.069	0.056
Others	0/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Age groups								
(Interaction test: p = 0.930)								
18 - < 65 years	10/389 (2.6)	N.E. [N.E.; N.E.]	22/394 (5.6)	N.E. [N.E.; N.E.]	0.41	[0.19; 0.88]	0.018	0.229
65 - < 75 years	2/72 (2.8)	N.E. [N.E.; N.E.]	0/53	N.E. [N.E.; N.E.]	5.90	[0.14; 243.62]	0.125	N.E.
>= 75 years	1/19 (5.3)	N.E. [22.1; N.E.]	1/25 (4.0)	N.E. [N.E.; N.E.]	0.71	[0.04; 11.79]	0.808	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.151)								
Imatinib	5/100 (5.0)	N.E. [N.E.; N.E.]	2/100 (2.0)	N.E. [N.E.; N.E.]	1.94	[0.36; 10.42]	0.434	N.E.
Nilotinib	8/339 (2.4)	N.E. [N.E.; N.E.]	20/330 (6.1)	N.E. [N.E.; N.E.]	0.36	[0.16; 0.81]	0.010	0.278
Dasatinib	0/41	N.E. [N.E.; N.E.]	1/42 (2.4)	N.E. [N.E.; N.E.]	0.39	[0.00; 38.92]	0.371	N.E.
Geographic region								
(Interaction test: p = 0.975)								
Europe excluding Germany	7/201 (3.5)	N.E. [N.E.; N.E.]	12/201 (6.0)	N.E. [N.E.; N.E.]	0.48	[0.18; 1.27]	0.130	0.019
Germany	0/91	N.E. [N.E.; N.E.]	1/68 (1.5)	N.E. [N.E.; N.E.]	0.17	[0.00; 16.29]	0.168	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	6/188 (3.2)	N.E. [N.E.; N.E.]	10/203 (4.9)	N.E. [N.E.; N.E.]	0.64	[0.23; 1.75]	0.378	0.773
Hypertension								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.757)								
Low	27/290 (9.3)	N.E. [N.E.; N.E.]	12/291 (4.1)	N.E. [N.E.; N.E.]	2.15	[1.09; 4.24]	0.024	0.750
Intermediate	14/129 (10.9)	N.E. [N.E.; N.E.]	5/125 (4.0)	N.E. [N.E.; N.E.]	2.62	[0.94; 7.28]	0.055	0.050
High	5/61 (8.2)	N.E. [N.E.; N.E.]	3/56 (5.4)	N.E. [N.E.; N.E.]	1.28	[0.29; 5.54]	0.743	0.851
Sex (Interaction test: p = 0.901)								
Female	13/174	N.E. [N.E.; N.E.]	7/198	N.E. [N.E.; N.E.]	2.13	[0.84; 5.37]	0.103	0.458

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(7.5)		(3.5)					
Male	33/306 (10.8)	N.E. [N.E.; N.E.]	13/274 (4.7)	N.E. [N.E.; N.E.]	2.14	[1.12; 4.08]	0.018	0.798
Race								
(Interaction test: p = 0.785)								
Asian	5/128 (3.9)	N.E. [N.E.; N.E.]	4/130 (3.1)	N.E. [N.E.; N.E.]	1.21	[0.32; 4.55]	0.773	0.435
White	38/332 (11.4)	N.E. [N.E.; N.E.]	16/317 (5.0)	N.E. [N.E.; N.E.]	2.06	[1.14; 3.70]	0.014	0.334
Others	3/20 (15.0)	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	8.80	[0.27; 290.82]	0.060	1.000
Age groups								
(Interaction test: p = 0.535)								
18 - < 65 years	31/389 (8.0)	N.E. [N.E.; N.E.]	13/394 (3.3)	N.E. [N.E.; N.E.]	2.24	[1.17; 4.28]	0.013	0.351
65 - < 75 years	10/72	N.E. [N.E.; N.E.]	5/53	N.E. [26.5; N.E.]	1.65	[0.51; 5.35]	0.403	0.870

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(13.9)		(9.4)					
>= 75 years	5/19	N.E. [8.3; N.E.]	2/25	N.E. [24.9; N.E.]	2.55	[0.49; 13.32]	0.250	0.639
	(26.3)		(8.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.676)								
Imatinib	14/100	N.E. [N.E.; N.E.]	5/100	N.E. [N.E.; N.E.]	2.55	[0.91; 7.13]	0.065	N.E.
	(14.0)		(5.0)					
Nilotinib	29/339	N.E. [N.E.; N.E.]	12/330	N.E. [N.E.; N.E.]	2.27	[1.16; 4.46]	0.014	0.257
	(8.6)		(3.6)					
Dasatinib	3/41	N.E. [N.E.; N.E.]	3/42	N.E. [N.E.; N.E.]	1.09	[0.21; 5.62]	0.915	N.E.
	(7.3)		(7.1)					
Geographic region								
(Interaction test: p = 0.779)								
Europe excluding Germany	21/201	N.E. [N.E.; N.E.]	8/201	N.E. [N.E.; N.E.]	2.41	[1.07; 5.46]	0.029	0.578

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(10.4)		(4.0)					
Germany	9/91	N.E. [N.E.; N.E.]	5/68	N.E. [N.E.; N.E.]	1.71	[0.51; 5.72]	0.383	0.453
	(9.9)		(7.4)					
Others	16/188	N.E. [N.E.; N.E.]	7/203	N.E. [N.E.; N.E.]	2.29	[0.93; 5.65]	0.063	0.280
	(8.5)		(3.4)					
Hypokalaemia								
Age groups								
(Interaction test: p = 1.000)								
18 - < 65 years	3/389	N.E. [N.E.; N.E.]	7/394	N.E. [N.E.; N.E.]	0.40	[0.10; 1.55]	0.169	0.253
	(0.8)		(1.8)					
65 - < 75 years	0/72	N.E. [N.E.; N.E.]	3/53	N.E. [N.E.; N.E.]	0.10	[0.00; 3.33]	0.047	1.000
			(5.7)					
>= 75 years	0/19	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Hypophosphataemia								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.894)								
Low	2/290 (0.7)	N.E. [N.E.; N.E.]	13/291 (4.5)	N.E. [N.E.; N.E.]	0.14	[0.03; 0.63]	0.003	0.570
Intermediate	1/129 (0.8)	N.E. [N.E.; N.E.]	3/125 (2.4)	N.E. [N.E.; N.E.]	0.30	[0.03; 2.84]	0.262	0.996
High	0/61	N.E. [N.E.; N.E.]	0/56	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Sex								
(Interaction test: p = 0.204)								
Female	2/174 (1.1)	N.E. [N.E.; N.E.]	5/198 (2.5)	N.E. [N.E.; N.E.]	0.44	[0.08; 2.25]	0.308	0.881
Male	1/306 (0.3)	N.E. [N.E.; N.E.]	11/274 (4.0)	N.E. [N.E.; N.E.]	0.07	[0.01; 0.58]	0.001	0.992

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 1.000)								
Asian	0/128	N.E. [N.E.; N.E.]	6/130 (4.6)	N.E. [N.E.; N.E.]	0.06	[0.00; 1.41]	0.007	N.E.
White	3/332 (0.9)	N.E. [N.E.; N.E.]	10/317 (3.2)	N.E. [N.E.; N.E.]	0.29	[0.08; 1.07]	0.050	0.462
Others	0/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Age groups								
(Interaction test: p = 1.000)								
18 - < 65 years	3/389 (0.8)	N.E. [N.E.; N.E.]	13/394 (3.3)	N.E. [N.E.; N.E.]	0.22	[0.06; 0.76]	0.009	0.231
65 - < 75 years	0/72	N.E. [N.E.; N.E.]	2/53 (3.8)	N.E. [N.E.; N.E.]	0.14	[0.00; 5.61]	0.086	N.E.
>= 75 years	0/19	N.E. [N.E.; N.E.]	1/25 (4.0)	N.E. [N.E.; N.E.]	0.33	[0.00; 30.79]	0.317	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.712)								
Imatinib	1/100 (1.0)	N.E. [N.E.; N.E.]	9/100 (9.0)	N.E. [N.E.; N.E.]	0.10	[0.01; 0.78]	0.007	N.E.
Nilotinib	2/339 (0.6)	N.E. [N.E.; N.E.]	6/330 (1.8)	N.E. [N.E.; N.E.]	0.30	[0.06; 1.49]	0.118	0.995
Dasatinib	0/41	N.E. [N.E.; N.E.]	1/42 (2.4)	N.E. [N.E.; N.E.]	0.36	[0.00; 33.17]	0.335	N.E.
Geographic region								
(Interaction test: p = 1.000)								
Europe excluding Germany	0/201	N.E. [N.E.; N.E.]	4/201 (2.0)	N.E. [N.E.; N.E.]	0.11	[0.00; 2.94]	0.045	1.000
Germany	0/91	N.E. [N.E.; N.E.]	3/68 (4.4)	N.E. [N.E.; N.E.]	0.09	[0.00; 2.66]	0.026	1.000

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	3/188 (1.6)	N.E. [N.E.; N.E.]	9/203 (4.4)	N.E. [N.E.; N.E.]	0.33	[0.09; 1.21]	0.078	0.142
Muscle spasms								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.914)								
Low	13/290 (4.5)	N.E. [N.E.; N.E.]	29/291 (10.0)	N.E. [N.E.; N.E.]	0.42	[0.22; 0.81]	0.007	0.051
Intermediate	2/129 (1.6)	N.E. [N.E.; N.E.]	6/125 (4.8)	N.E. [N.E.; N.E.]	0.26	[0.05; 1.31]	0.081	0.587
High	1/61 (1.6)	N.E. [N.E.; N.E.]	2/56 (3.6)	N.E. [N.E.; N.E.]	0.40	[0.04; 4.40]	0.435	0.998
Sex (Interaction test: p = 0.914)								
Female	7/174	N.E. [N.E.; N.E.]	18/198	N.E. [N.E.; N.E.]	0.40	[0.17; 0.95]	0.033	0.099

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(4.0)		(9.1)					
Male	9/306	N.E. [N.E.; N.E.]	19/274	N.E. [N.E.; N.E.]	0.39	[0.18; 0.86]	0.016	0.300
	(2.9)		(6.9)					
Race								
(Interaction test: p = 0.800)								
Asian	0/128	N.E. [N.E.; N.E.]	5/130	N.E. [N.E.; N.E.]	0.07	[0.00; 1.79]	0.014	1.000
			(3.8)					
White	15/332	N.E. [N.E.; N.E.]	31/317	N.E. [N.E.; N.E.]	0.42	[0.23; 0.79]	0.005	0.117
	(4.5)		(9.8)					
Others	1/20	N.E. [N.E.; N.E.]	1/25	N.E. [N.E.; N.E.]	1.35	[0.08; 22.82]	0.833	0.998
	(5.0)		(4.0)					
Age groups								
(Interaction test: p = 0.377)								
18 - < 65 years	13/389	N.E. [N.E.; N.E.]	28/394	N.E. [N.E.; N.E.]	0.44	[0.23; 0.86]	0.013	0.135
	(3.3)		(7.1)					
65 - < 75 years	2/72	N.E. [N.E.; N.E.]	8/53	N.E. [N.E.; N.E.]	0.15	[0.03; 0.73]	0.007	0.995

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(2.8)		(15.1)					
>= 75 years	1/19	N.E. [N.E.; N.E.]	1/25	N.E. [N.E.; N.E.]	0.76	[0.04; 13.00]	0.852	N.E.
	(5.3)		(4.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.160)								
Imatinib	4/100	N.E. [N.E.; N.E.]	19/100	N.E. [N.E.; N.E.]	0.17	[0.06; 0.52]	<0.001	N.E.
	(4.0)		(19.0)					
Nilotinib	11/339	N.E. [N.E.; N.E.]	16/330	N.E. [N.E.; N.E.]	0.64	[0.30; 1.39]	0.259	0.625
	(3.2)		(4.8)					
Dasatinib	1/41	N.E. [N.E.; N.E.]	2/42	N.E. [N.E.; N.E.]	0.55	[0.05; 6.09]	0.622	N.E.
	(2.4)		(4.8)					
Geographic region								
(Interaction test: p = 0.726)								
Europe excluding Germany	8/201	N.E. [N.E.; N.E.]	23/201	N.E. [N.E.; N.E.]	0.33	[0.15; 0.74]	0.005	0.028

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(4.0)		(11.4)					
Germany	3/91	N.E. [N.E.; N.E.]	3/68	N.E. [N.E.; N.E.]	0.48	[0.09; 2.47]	0.376	0.996
	(3.3)		(4.4)					
Others	5/188	N.E. [N.E.; N.E.]	11/203	N.E. [N.E.; N.E.]	0.45	[0.15; 1.30]	0.128	0.642
	(2.7)		(5.4)					
Oedema peripheral								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.583)								
Low	6/290	N.E. [N.E.; N.E.]	10/291	N.E. [N.E.; N.E.]	0.58	[0.21; 1.61]	0.293	0.207
	(2.1)		(3.4)					
Intermediate	2/129	N.E. [N.E.; N.E.]	8/125	N.E. [N.E.; N.E.]	0.22	[0.05; 1.03]	0.035	0.993
	(1.6)		(6.4)					
High	0/61	N.E. [N.E.; N.E.]	2/56	N.E. [N.E.; N.E.]	0.16	[0.00; 6.73]	0.117	N.E.
			(3.6)					

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.314)								
Female	4/174 (2.3)	N.E. [N.E.; N.E.]	15/198 (7.6)	N.E. [N.E.; N.E.]	0.30	[0.10; 0.90]	0.023	0.993
Male	4/306 (1.3)	N.E. [N.E.; N.E.]	5/274 (1.8)	N.E. [N.E.; N.E.]	0.69	[0.18; 2.57]	0.577	0.302
Race								
(Interaction test: p = 0.403)								
Asian	1/128 (0.8)	N.E. [N.E.; N.E.]	7/130 (5.4)	N.E. [N.E.; N.E.]	0.13	[0.02; 1.07]	0.026	0.995
White	7/332 (2.1)	N.E. [N.E.; N.E.]	10/317 (3.2)	N.E. [N.E.; N.E.]	0.62	[0.24; 1.64]	0.334	0.559
Others	0/20	N.E. [N.E.; N.E.]	3/25 (12.0)	N.E. [N.E.; N.E.]	0.44	[0.01; 18.43]	0.343	1.000
Age groups								
(Interaction test: p = 0.563)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	6/389 (1.5)	N.E. [N.E.; N.E.]	12/394 (3.0)	N.E. [N.E.; N.E.]	0.49	[0.19; 1.32]	0.150	0.430
65 - < 75 years	1/72 (1.4)	N.E. [N.E.; N.E.]	4/53 (7.5)	N.E. [N.E.; N.E.]	0.21	[0.02; 1.89]	0.125	N.E.
>= 75 years	1/19 (5.3)	N.E. [N.E.; N.E.]	4/25 (16.0)	N.E. [N.E.; N.E.]	0.29	[0.03; 2.82]	0.255	0.998
Pre-randomization selection of TKI								
(Interaction test: p = 0.459)								
Imatinib	1/100 (1.0)	N.E. [N.E.; N.E.]	7/100 (7.0)	N.E. [N.E.; N.E.]	0.13	[0.02; 1.05]	0.024	N.E.
Nilotinib	6/339 (1.8)	N.E. [N.E.; N.E.]	10/330 (3.0)	N.E. [N.E.; N.E.]	0.56	[0.20; 1.53]	0.250	0.773
Dasatinib	1/41 (2.4)	N.E. [N.E.; N.E.]	3/42 (7.1)	N.E. [N.E.; N.E.]	0.27	[0.03; 2.72]	0.235	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.281)								
Europe excluding Germany	0/201	N.E. [N.E.; N.E.]	4/201 (2.0)	N.E. [N.E.; N.E.]	0.12	[0.00; 3.19]	0.056	1.000
Germany	4/91 (4.4)	N.E. [N.E.; N.E.]	2/68 (2.9)	N.E. [N.E.; N.E.]	1.42	[0.25; 7.96]	0.687	N.E.
Others	4/188 (2.1)	N.E. [N.E.; N.E.]	14/203 (6.9)	N.E. [N.E.; N.E.]	0.27	[0.09; 0.83]	0.015	0.803
Periorbital oedema								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.780)								
Low	1/290 (0.3)	N.E. [N.E.; N.E.]	9/291 (3.1)	N.E. [N.E.; N.E.]	0.11	[0.01; 0.85]	0.010	N.E.
Intermediate	1/129 (0.8)	N.E. [N.E.; N.E.]	3/125 (2.4)	N.E. [N.E.; N.E.]	0.31	[0.03; 3.01]	0.287	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
High	0/61	N.E. [N.E.; N.E.]	0/56	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Race								
(Interaction test: p = 1.000)								
Asian	0/128	N.E. [N.E.; N.E.]	4/130 (3.1)	N.E. [N.E.; N.E.]	0.10	[0.00; 2.50]	0.031	N.E.
White	2/332 (0.6)	N.E. [N.E.; N.E.]	8/317 (2.5)	N.E. [N.E.; N.E.]	0.27	[0.06; 1.28]	0.077	N.E.
Others	0/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Pre-randomization selection of TKI								
(Interaction test: p = 1.000)								
Imatinib	0/100	N.E. [N.E.; N.E.]	11/100 (11.0)	N.E. [N.E.; N.E.]	0.04	[0.00; 0.82]	<0.001	N.E.
Nilotinib	0/339	N.E. [N.E.; N.E.]	0/330	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	2/41 (4.9)	N.E. [N.E.; N.E.]	1/42 (2.4)	N.E. [N.E.; N.E.]	2.21	[0.20; 24.44]	0.506	N.E.
Rash								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.298)								
Low	42/290 (14.5)	N.E. [N.E.; N.E.]	54/291 (18.6)	N.E. [N.E.; N.E.]	0.72	[0.48; 1.08]	0.113	0.313
Intermediate	16/129 (12.4)	N.E. [N.E.; N.E.]	15/125 (12.0)	N.E. [N.E.; N.E.]	0.90	[0.44; 1.82]	0.764	0.899
High	4/61 (6.6)	N.E. [N.E.; N.E.]	10/56 (17.9)	N.E. [N.E.; N.E.]	0.33	[0.10; 1.06]	0.049	0.765
Sex (Interaction test: p = 0.007)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Female	21/174 (12.1)	N.E. [N.E.; N.E.]	47/198 (23.7)	N.E. [N.E.; N.E.]	0.44	[0.26; 0.73]	0.001	0.895
Male	41/306 (13.4)	N.E. [N.E.; N.E.]	32/274 (11.7)	N.E. [N.E.; N.E.]	1.13	[0.71; 1.79]	0.612	0.311
Race (Interaction test: p = 0.955)								
Asian	18/128 (14.1)	N.E. [N.E.; N.E.]	23/130 (17.7)	N.E. [N.E.; N.E.]	0.73	[0.39; 1.37]	0.331	0.166
White	42/332 (12.7)	N.E. [N.E.; N.E.]	52/317 (16.4)	N.E. [N.E.; N.E.]	0.69	[0.46; 1.04]	0.079	0.970
Others	2/20 (10.0)	N.E. [N.E.; N.E.]	4/25 (16.0)	N.E. [N.E.; N.E.]	0.88	[0.14; 5.44]	0.889	0.996
Age groups (Interaction test: p = 0.092)								
18 - < 65 years	56/389 (14.4)	N.E. [N.E.; N.E.]	66/394 (16.8)	N.E. [N.E.; N.E.]	0.79	[0.55; 1.13]	0.201	0.299

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
65 - < 75 years	3/72 (4.2)	N.E. [N.E.; N.E.]	10/53 (18.9)	N.E. [N.E.; N.E.]	0.18	[0.05; 0.69]	0.006	0.703
>= 75 years	3/19 (15.8)	N.E. [24.8; N.E.]	3/25 (12.0)	N.E. [N.E.; N.E.]	1.62	[0.27; 9.71]	0.595	0.997
Pre-randomization selection of TKI								
(Interaction test: p = 0.611)								
Imatinib	9/100 (9.0)	N.E. [N.E.; N.E.]	11/100 (11.0)	N.E. [N.E.; N.E.]	0.75	[0.31; 1.81]	0.514	N.E.
Nilotinib	45/339 (13.3)	N.E. [N.E.; N.E.]	60/330 (18.2)	N.E. [N.E.; N.E.]	0.64	[0.44; 0.95]	0.026	0.689
Dasatinib	8/41 (19.5)	N.E. [N.E.; N.E.]	8/42 (19.0)	N.E. [N.E.; N.E.]	1.07	[0.40; 2.89]	0.884	N.E.
Geographic region								
(Interaction test: p = 0.953)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Europe excluding Germany	22/201 (10.9)	N.E. [N.E.; N.E.]	29/201 (14.4)	N.E. [N.E.; N.E.]	0.71	[0.41; 1.25]	0.239	0.481
Germany	16/91 (17.6)	N.E. [N.E.; N.E.]	17/68 (25.0)	N.E. [N.E.; N.E.]	0.67	[0.33; 1.35]	0.260	0.785
Others	24/188 (12.8)	N.E. [N.E.; N.E.]	33/203 (16.3)	N.E. [N.E.; N.E.]	0.72	[0.42; 1.22]	0.219	0.263
Rash maculo-papular								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.993)								
Low	3/290 (1.0)	N.E. [N.E.; N.E.]	8/291 (2.7)	N.E. [N.E.; N.E.]	0.37	[0.10; 1.38]	0.121	0.795
Intermediate	2/129 (1.6)	N.E. [N.E.; N.E.]	5/125 (4.0)	N.E. [N.E.; N.E.]	0.36	[0.07; 1.84]	0.198	0.993
High	1/61	N.E. [N.E.; N.E.]	2/56	N.E. [N.E.; N.E.]	0.40	[0.04; 4.43]	0.438	0.996

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(1.6)		(3.6)					
Sex								
(Interaction test: p = 0.269)								
Female	1/174	N.E. [N.E.; N.E.]	8/198	N.E. [N.E.; N.E.]	0.14	[0.02; 1.10]	0.028	0.993
	(0.6)		(4.0)					
Male	5/306	N.E. [N.E.; N.E.]	7/274	N.E. [N.E.; N.E.]	0.50	[0.16; 1.63]	0.246	0.969
	(1.6)		(2.6)					
Race								
(Interaction test: p = 0.666)								
Asian	1/128	N.E. [N.E.; N.E.]	6/130	N.E. [N.E.; N.E.]	0.18	[0.02; 1.51]	0.076	0.996
	(0.8)		(4.6)					
White	4/332	N.E. [N.E.; N.E.]	7/317	N.E. [N.E.; N.E.]	0.48	[0.14; 1.68]	0.242	0.081
	(1.2)		(2.2)					
Others	1/20	N.E. [N.E.; N.E.]	2/25	N.E. [N.E.; N.E.]	1.52	[0.09; 26.48]	0.773	N.E.
	(5.0)		(8.0)					
Age groups								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.499)								
18 - < 65 years	4/389 (1.0)	N.E. [N.E.; N.E.]	14/394 (3.6)	N.E. [N.E.; N.E.]	0.27	[0.09; 0.83]	0.014	0.360
65 - < 75 years	1/72 (1.4)	N.E. [N.E.; N.E.]	0/53	N.E. [N.E.; N.E.]	1.45	[0.02; 139.78]	0.495	N.E.
>= 75 years	1/19 (5.3)	N.E. [N.E.; N.E.]	1/25 (4.0)	N.E. [N.E.; N.E.]	1.12	[0.07; 17.96]	0.937	0.999
Pre-randomization selection of TKI								
(Interaction test: p = 1.000)								
Imatinib	1/100 (1.0)	N.E. [N.E.; N.E.]	0/100	N.E. [N.E.; N.E.]	3.04	[0.03; 280.00]	0.313	N.E.
Nilotinib	3/339 (0.9)	N.E. [N.E.; N.E.]	15/330 (4.5)	N.E. [N.E.; N.E.]	0.19	[0.05; 0.65]	0.003	0.991
Dasatinib	2/41 (4.9)	N.E. [N.E.; N.E.]	0/42	N.E. [N.E.; N.E.]	3.51	[0.07; 178.31]	0.254	N.E.


	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Geographic region								
(Interaction test: p = 0.970)								
Europe excluding Germany	1/201 (0.5)	N.E. [N.E.; N.E.]	3/201 (1.5)	N.E. [N.E.; N.E.]	0.34	[0.03; 3.25]	0.324	0.996
Germany	0/91	N.E. [N.E.; N.E.]	0/68	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Others	5/188 (2.7)	N.E. [N.E.; N.E.]	12/203 (5.9)	N.E. [N.E.; N.E.]	0.43	[0.15; 1.23]	0.106	0.607

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
PT: Preferred Term
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Results on AEs differentiated by SOC or PT are only reported if the given result is statistically significant for the total population.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data and Stratification factor: ELTS based on data collected in the eCRF only the stratification variable Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variable ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3 Time to first any AE by PT: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Anaemia: Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	100 (0)	83 (7)	79 (11)	76 (14)	55 (34)	11 (78)	0 (89)
Investigator Selected TKI	100 (0)	64 (11)	55 (20)	42 (32)	27 (47)	2 (72)	0 (74)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3 Time to first any AE by PT: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Anaemia: Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	289 (17)	262 (43)	156 (148)	77 (227)	11 (293)	0 (304)
Investigator Selected TKI	330 (0)	270 (36)	228 (76)	133 (169)	61 (240)	7 (294)	0 (301)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3 Time to first any AE by PT: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Anaemia: Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3 Time to first any AE by PT: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Rash: Sex: Female



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3 Time to first any AE by PT: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Rash: Sex: Male



Pts at Risk (censored)


Asciminib	306 (0)	260 (15)	233 (38)	157 (112)	99 (167)	21 (244)	0 (265)
Investigator Selected TKI	274 (0)	217 (32)	184 (59)	129 (113)	73 (169)	12 (230)	0 (242)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Abdominal distension

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	1/152	5/148	0.18	0.02; 1.58	0.082
ASC4START	0/237	5/246	0.09	0.00; 2.15	0.025
Pooled Analysis	1/389	10/394	0.10	0.01; 0.74	0.005
65 - < 75 years					
ASC4FIRST	0/34	0/29	N.E.	N.E.; N.E.	N.E.
ASC4START	0/38	0/24	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/72	0/53	N.E.	N.E.; N.E.	N.E.
>= 75 years					
ASC4FIRST	0/10	0/13	N.E.	N.E.; N.E.	N.E.
ASC4START	0/9	2/12	0.39	0.00; 38.92	0.371
Pooled Analysis	0/19	2/25	0.39	0.00; 38.92	0.371




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Abdominal distension

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	0/63	1/61	0.35	0.00; 31.98	0.326
ASC4START	0/138	0/140	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/201	1/201	0.35	0.00; 31.98	0.326
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	0/72	0/53	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/91	0/68	N.E.	N.E.; N.E.	N.E.
Others					
ASC4FIRST	1/114	4/114	0.23	0.03; 2.04	0.147
ASC4START	0/74	7/89	0.09	0.00; 1.88	0.021
Pooled Analysis	1/188	11/203	0.10	0.01; 0.79	0.007




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alanine aminotransferase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	15/152	21/148	0.64	0.33; 1.24	0.179
ASC4START	13/237	38/246	0.33	0.17; 0.62	<0.001
Pooled Analysis	28/389	59/394	0.44	0.28; 0.69	<0.001
65 - < 75 years					
ASC4FIRST	2/34	1/29	1.71	0.14; 20.65	0.671
ASC4START	2/38	3/24	0.19	0.03; 1.27	0.067
Pooled Analysis	4/72	4/53	0.43	0.10; 1.90	0.272
>= 75 years					
ASC4FIRST	0/10	1/13	N.E.	N.E.; N.E.	N.E.
ASC4START	0/9	1/12	0.53	0.01; 51.67	0.439
Pooled Analysis	0/19	2/25	0.53	0.01; 51.67	0.439




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alanine aminotransferase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	4/23	3/19	0.95	0.21; 4.25	0.943
ASC4START	1/38	4/37	0.23	0.03; 2.05	0.151
Pooled Analysis	5/61	7/56	0.56	0.18; 1.78	0.323
Intermediate					
ASC4FIRST	4/54	4/52	0.76	0.19; 3.08	0.704
ASC4START	1/75	11/73	0.08	0.01; 0.61	0.002
Pooled Analysis	5/129	15/125	0.27	0.10; 0.75	0.007
Low					
ASC4FIRST	9/119	16/119	0.53	0.23; 1.19	0.117
ASC4START	13/171	27/172	0.44	0.23; 0.86	0.013
Pooled Analysis	22/290	43/291	0.47	0.28; 0.79	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alanine aminotransferase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	4/63	2/61	1.35	0.22; 8.28	0.742
ASC4START	7/138	20/140	0.33	0.14; 0.78	0.008
Pooled Analysis	11/201	22/201	0.43	0.20; 0.90	0.021
Germany					
ASC4FIRST	1/19	2/15	0.61	0.04; 9.93	0.728
ASC4START	6/72	11/53	0.31	0.11; 0.84	0.015
Pooled Analysis	7/91	13/68	0.33	0.13; 0.85	0.016
Others					
ASC4FIRST	12/114	19/114	0.57	0.27; 1.17	0.120
ASC4START	2/74	11/89	0.21	0.05; 0.95	0.026
Pooled Analysis	14/188	30/203	0.45	0.24; 0.85	0.012




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alanine aminotransferase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	4/41	6/42	0.51	0.14; 1.90	0.311
Pooled Analysis	4/41	6/42	0.51	0.14; 1.90	0.311
Imatinib					
ASC4FIRST	9/100	7/100	1.22	0.45; 3.28	0.697
Pooled Analysis	9/100	7/100	1.22	0.45; 3.28	0.697
Nilotinib					
ASC4FIRST	4/55	10/48	0.28	0.09; 0.90	0.023
ASC4START	15/284	42/282	0.32	0.18; 0.58	<0.001
Pooled Analysis	19/339	52/330	0.31	0.19; 0.53	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alanine aminotransferase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	2/40	4/45	0.62	0.11; 3.38	0.574
Pooled Analysis	13/128	19/130	0.64	0.31; 1.30	0.213
Asian/Others					
ASC4FIRST	11/91	15/89	0.66	0.30; 1.45	0.301
Others					
ASC4START	0/17	4/21	0.14	0.00; 3.90	0.080
Pooled Analysis	0/20	4/25	0.14	0.00; 3.90	0.080
White					
ASC4FIRST	6/105	8/101	0.57	0.19; 1.70	0.308
ASC4START	13/227	34/216	0.33	0.17; 0.63	<0.001
Pooled Analysis	19/332	42/317	0.38	0.22; 0.65	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alanine aminotransferase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	4/67	7/74	0.55	0.15; 1.97	0.354
ASC4START	7/107	20/124	0.36	0.15; 0.85	0.015
Pooled Analysis	11/174	27/198	0.41	0.20; 0.83	0.011
Male					
ASC4FIRST	13/129	16/116	0.57	0.27; 1.20	0.131
ASC4START	8/177	22/158	0.30	0.13; 0.68	0.002
Pooled Analysis	21/306	38/274	0.42	0.24; 0.72	0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alopecia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	3/152	11/148	0.26	0.07; 0.94	0.027
ASC4START	9/237	26/246	0.34	0.16; 0.73	0.004
Pooled Analysis	12/389	37/394	0.32	0.17; 0.61	<0.001
65 - < 75 years					
ASC4FIRST	1/34	1/29	0.58	0.03; 10.72	0.710
ASC4START	1/38	1/24	0.53	0.03; 8.49	0.649
Pooled Analysis	2/72	2/53	0.55	0.07; 4.13	0.558
>= 75 years					
ASC4FIRST	0/10	1/13	0.33	0.00; 30.79	0.317
ASC4START	0/9	3/12	0.18	0.01; 5.51	0.123
Pooled Analysis	0/19	4/25	0.13	0.00; 3.46	0.066




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alopecia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	0/23	1/19	0.28	0.00; 26.04	0.277
ASC4START	1/38	3/37	0.31	0.03; 3.03	0.290
Pooled Analysis	1/61	4/56	0.23	0.03; 2.07	0.152
Intermediate					
ASC4FIRST	1/54	5/52	0.16	0.02; 1.35	0.054
ASC4START	4/75	4/73	0.94	0.23; 3.75	0.928
Pooled Analysis	5/129	9/125	0.48	0.16; 1.45	0.187
Low					
ASC4FIRST	3/119	7/119	0.42	0.11; 1.63	0.198
ASC4START	5/171	23/172	0.20	0.08; 0.54	<0.001
Pooled Analysis	8/290	30/291	0.25	0.12; 0.55	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alopecia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	3/63	5/61	0.68	0.16; 2.89	0.604
ASC4START	2/138	20/140	0.09	0.02; 0.40	<0.001
Pooled Analysis	5/201	25/201	0.19	0.07; 0.51	<0.001
Germany					
ASC4FIRST	1/19	1/15	0.65	0.04; 10.56	0.757
ASC4START	6/72	4/53	1.10	0.31; 3.94	0.883
Pooled Analysis	7/91	5/68	1.01	0.32; 3.20	0.993
Others					
ASC4FIRST	0/114	7/114	0.05	0.00; 1.09	0.003
ASC4START	2/74	6/89	0.42	0.08; 2.08	0.271
Pooled Analysis	2/188	13/203	0.15	0.03; 0.67	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alopecia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	1/41	5/42	0.22	0.03; 1.91	0.133
Pooled Analysis	1/41	5/42	0.22	0.03; 1.91	0.133
Imatinib					
ASC4FIRST	3/100	5/100	0.56	0.13; 2.36	0.422
Pooled Analysis	3/100	5/100	0.56	0.13; 2.36	0.422
Nilotinib					
ASC4FIRST	0/55	3/48	0.13	0.00; 4.00	0.069
ASC4START	10/284	30/282	0.31	0.15; 0.64	<0.001
Pooled Analysis	10/339	33/330	0.28	0.14; 0.58	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alopecia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	1/40	2/45	0.65	0.06; 7.18	0.724
Pooled Analysis	1/128	6/130	0.15	0.02; 1.29	0.049
Asian/Others					
ASC4FIRST	0/91	5/89	0.07	0.00; 1.73	0.013
Others					
ASC4START	0/17	1/21	0.28	0.00; 26.04	0.277
Pooled Analysis	0/20	2/25	0.28	0.00; 26.04	0.277
White					
ASC4FIRST	4/105	8/101	0.48	0.14; 1.64	0.234
ASC4START	9/227	27/216	0.30	0.14; 0.64	<0.001
Pooled Analysis	13/332	35/317	0.34	0.18; 0.64	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Alopecia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	2/67	8/74	0.23	0.05; 1.10	0.045
ASC4START	5/107	25/124	0.21	0.08; 0.54	<0.001
Pooled Analysis	7/174	33/198	0.21	0.09; 0.48	<0.001
Male					
ASC4FIRST	2/129	5/116	0.29	0.06; 1.55	0.127
ASC4START	5/177	5/158	0.88	0.25; 3.04	0.841
Pooled Analysis	7/306	10/274	0.58	0.22; 1.53	0.262




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Anaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	20/152	35/148	0.51	0.29; 0.88	0.014
ASC4START	22/237	21/246	1.06	0.58; 1.93	0.847
Pooled Analysis	42/389	56/394	0.71	0.47; 1.05	0.088
65 - < 75 years					
ASC4FIRST	3/34	7/29	0.46	0.12; 1.81	0.254
ASC4START	2/38	1/24	1.41	0.12; 15.84	0.782
Pooled Analysis	5/72	8/53	0.61	0.20; 1.89	0.384
>= 75 years					
ASC4FIRST	2/10	7/13	0.22	0.03; 1.85	0.124
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	2/19	7/25	0.22	0.03; 1.85	0.124




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Anaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	9/19	0.07	0.01; 0.52	<0.001
ASC4START	5/38	4/37	1.13	0.30; 4.22	0.858
Pooled Analysis	6/61	13/56	0.34	0.13; 0.89	0.022
Intermediate					
ASC4FIRST	10/54	13/52	0.72	0.32; 1.66	0.443
ASC4START	6/75	5/73	1.09	0.33; 3.56	0.890
Pooled Analysis	16/129	18/125	0.83	0.42; 1.62	0.582
Low					
ASC4FIRST	14/119	27/119	0.48	0.25; 0.92	0.024
ASC4START	13/171	13/172	1.02	0.47; 2.20	0.968
Pooled Analysis	27/290	40/291	0.65	0.40; 1.06	0.083




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Anaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	3/63	15/61	0.18	0.05; 0.64	0.003
ASC4START	10/138	5/140	2.06	0.70; 6.03	0.182
Pooled Analysis	13/201	20/201	0.64	0.31; 1.30	0.208
Germany					
ASC4FIRST	1/19	4/15	0.22	0.02; 2.16	0.157
ASC4START	2/72	3/53	0.50	0.08; 3.01	0.437
Pooled Analysis	3/91	7/68	0.35	0.09; 1.43	0.128
Others					
ASC4FIRST	21/114	30/114	0.65	0.37; 1.14	0.135
ASC4START	12/74	14/89	1.02	0.47; 2.21	0.963
Pooled Analysis	33/188	44/203	0.76	0.48; 1.19	0.234




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Anaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	3/41	16/42	0.11	0.03; 0.40	<0.001
Pooled Analysis	3/41	16/42	0.11	0.03; 0.40	<0.001
Imatinib					
ASC4FIRST	11/100	26/100	0.40	0.20; 0.81	0.009
Pooled Analysis	11/100	26/100	0.40	0.20; 0.81	0.009
Nilotinib					
ASC4FIRST	11/55	7/48	1.33	0.51; 3.46	0.553
ASC4START	24/284	22/282	1.06	0.59; 1.88	0.860
Pooled Analysis	35/339	29/330	1.12	0.69; 1.84	0.644




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Anaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	4/40	5/45	0.85	0.23; 3.17	0.822
Pooled Analysis	23/128	31/130	0.68	0.39; 1.17	0.167
Asian/Others					
ASC4FIRST	19/91	27/89	0.64	0.35; 1.15	0.134
Others					
ASC4START	4/17	3/21	1.98	0.42; 9.32	0.384
Pooled Analysis	4/20	4/25	1.98	0.42; 9.32	0.384
White					
ASC4FIRST	6/105	22/101	0.23	0.09; 0.58	<0.001
ASC4START	16/227	14/216	1.08	0.53; 2.21	0.844
Pooled Analysis	22/332	36/317	0.55	0.32; 0.95	0.029




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Anaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	7/67	27/74	0.28	0.12; 0.65	0.002
ASC4START	16/107	11/124	1.65	0.77; 3.57	0.199
Pooled Analysis	23/174	38/198	0.68	0.40; 1.14	0.138
Male					
ASC4FIRST	18/129	22/116	0.73	0.39; 1.36	0.322
ASC4START	8/177	11/158	0.61	0.24; 1.51	0.277
Pooled Analysis	26/306	33/274	0.68	0.41; 1.15	0.152




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Aspartate aminotransferase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	4/152	17/148	0.20	0.07; 0.61	0.002
ASC4START	11/237	24/246	0.45	0.22; 0.92	0.025
Pooled Analysis	15/389	41/394	0.34	0.19; 0.62	<0.001
65 - < 75 years					
ASC4FIRST	2/34	2/29	0.95	0.13; 6.97	0.959
ASC4START	2/38	3/24	0.19	0.03; 1.27	0.060
Pooled Analysis	4/72	5/53	0.39	0.10; 1.61	0.182
>= 75 years					
ASC4FIRST	0/10	0/13	N.E.	N.E.; N.E.	N.E.
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/19	0/25	N.E.	N.E.; N.E.	N.E.




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Aspartate aminotransferase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	2/19	0.70	0.10; 5.03	0.725
ASC4START	2/38	2/37	0.95	0.13; 6.74	0.958
Pooled Analysis	4/61	4/56	0.82	0.20; 3.29	0.777
Intermediate					
ASC4FIRST	3/54	2/52	1.22	0.20; 7.30	0.830
ASC4START	1/75	5/73	0.18	0.02; 1.53	0.076
Pooled Analysis	4/129	7/125	0.49	0.14; 1.67	0.243
Low					
ASC4FIRST	1/119	15/119	0.06	0.01; 0.45	<0.001
ASC4START	10/171	20/172	0.47	0.22; 1.01	0.047
Pooled Analysis	11/290	35/291	0.29	0.15; 0.57	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Aspartate aminotransferase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	1/63	2/61	0.23	0.02; 3.35	0.262
ASC4START	6/138	10/140	0.60	0.22; 1.65	0.317
Pooled Analysis	7/201	12/201	0.53	0.20; 1.37	0.180
Germany					
ASC4FIRST	1/19	1/15	0.61	0.04; 9.93	0.728
ASC4START	5/72	9/53	0.32	0.11; 0.96	0.032
Pooled Analysis	6/91	10/68	0.35	0.13; 0.96	0.034
Others					
ASC4FIRST	4/114	16/114	0.23	0.08; 0.68	0.004
ASC4START	2/74	8/89	0.31	0.07; 1.49	0.125
Pooled Analysis	6/188	24/203	0.25	0.10; 0.62	0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Aspartate aminotransferase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	2/41	5/42	0.37	0.07; 2.04	0.239
Pooled Analysis	2/41	5/42	0.37	0.07; 2.04	0.239
Imatinib					
ASC4FIRST	2/100	7/100	0.26	0.05; 1.23	0.066
Pooled Analysis	2/100	7/100	0.26	0.05; 1.23	0.066
Nilotinib					
ASC4FIRST	2/55	7/48	0.22	0.05; 1.07	0.041
ASC4START	13/284	27/282	0.45	0.23; 0.87	0.015
Pooled Analysis	15/339	34/330	0.40	0.22; 0.73	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Aspartate aminotransferase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	1/40	4/45	0.32	0.04; 2.87	0.282
Pooled Analysis	4/128	16/130	0.25	0.08; 0.75	0.008
Asian/Others					
ASC4FIRST	3/91	13/89	0.22	0.06; 0.77	0.010
Others					
ASC4START	1/17	3/21	0.35	0.04; 3.47	0.349
Pooled Analysis	1/20	4/25	0.35	0.04; 3.47	0.349
White					
ASC4FIRST	3/105	6/101	0.44	0.11; 1.82	0.246
ASC4START	11/227	20/216	0.49	0.24; 1.03	0.056
Pooled Analysis	14/332	26/317	0.48	0.25; 0.93	0.025




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Aspartate aminotransferase increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	1/67	6/74	0.15	0.02; 1.21	0.039
ASC4START	5/107	17/124	0.31	0.11; 0.84	0.015
Pooled Analysis	6/174	23/198	0.26	0.11; 0.64	0.002
Male					
ASC4FIRST	5/129	13/116	0.25	0.09; 0.73	0.007
ASC4START	8/177	10/158	0.69	0.27; 1.75	0.431
Pooled Analysis	13/306	23/274	0.43	0.22; 0.86	0.014




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood bilirubin increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	8/152	11/148	0.63	0.25; 1.58	0.322
ASC4START	5/237	34/246	0.14	0.06; 0.36	<0.001
Pooled Analysis	13/389	45/394	0.27	0.14; 0.50	<0.001
65 - < 75 years					
ASC4FIRST	0/34	2/29	0.23	0.01; 9.61	0.187
ASC4START	0/38	3/24	0.07	0.00; 2.30	0.016
Pooled Analysis	0/72	5/53	0.06	0.00; 1.49	0.007
>= 75 years					
ASC4FIRST	0/10	0/13	N.E.	N.E.; N.E.	N.E.
ASC4START	1/9	2/12	0.54	0.05; 5.95	0.589
Pooled Analysis	1/19	2/25	0.54	0.05; 5.95	0.589




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood bilirubin increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	2/19	0.38	0.03; 4.23	0.414
ASC4START	1/38	7/37	0.13	0.02; 1.05	0.023
Pooled Analysis	2/61	9/56	0.19	0.04; 0.89	0.018
Intermediate					
ASC4FIRST	2/54	3/52	0.59	0.10; 3.55	0.562
ASC4START	1/75	5/73	0.18	0.02; 1.52	0.075
Pooled Analysis	3/129	8/125	0.33	0.09; 1.26	0.088
Low					
ASC4FIRST	5/119	8/119	0.56	0.18; 1.71	0.302
ASC4START	4/171	27/172	0.14	0.05; 0.39	<0.001
Pooled Analysis	9/290	35/291	0.24	0.11; 0.49	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood bilirubin increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	1/63	2/61	0.27	0.02; 3.19	0.271
ASC4START	4/138	13/140	0.31	0.10; 0.94	0.028
Pooled Analysis	5/201	15/201	0.30	0.11; 0.83	0.015
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	1/72	13/53	0.05	0.01; 0.36	<0.001
Pooled Analysis	1/91	13/68	0.05	0.01; 0.36	<0.001
Others					
ASC4FIRST	7/114	11/114	0.58	0.23; 1.51	0.261
ASC4START	1/74	13/89	0.10	0.01; 0.73	0.005
Pooled Analysis	8/188	24/203	0.35	0.16; 0.77	0.007




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood bilirubin increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	1/41	1/42	1.18	0.07; 18.92	0.905
Pooled Analysis	1/41	1/42	1.18	0.07; 18.92	0.905
Imatinib					
ASC4FIRST	2/100	2/100	0.91	0.13; 6.51	0.929
Pooled Analysis	2/100	2/100	0.91	0.13; 6.51	0.929
Nilotinib					
ASC4FIRST	5/55	10/48	0.39	0.13; 1.15	0.077
ASC4START	6/284	39/282	0.14	0.06; 0.33	<0.001
Pooled Analysis	11/339	49/330	0.20	0.10; 0.38	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood bilirubin increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	7/45	0.08	0.00; 1.61	0.013
Pooled Analysis	7/128	19/130	0.36	0.15; 0.86	0.017
Asian/Others					
ASC4FIRST	7/91	12/89	0.54	0.21; 1.39	0.196
Others					
ASC4START	0/17	3/21	0.16	0.00; 5.17	0.105
Pooled Analysis	0/20	3/25	0.16	0.00; 5.17	0.105
White					
ASC4FIRST	1/105	1/101	0.76	0.05; 12.20	0.847
ASC4START	6/227	29/216	0.18	0.07; 0.43	<0.001
Pooled Analysis	7/332	30/317	0.20	0.09; 0.46	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood bilirubin increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	1/67	3/74	0.40	0.04; 3.94	0.418
ASC4START	3/107	16/124	0.19	0.06; 0.67	0.004
Pooled Analysis	4/174	19/198	0.22	0.08; 0.66	0.003
Male					
ASC4FIRST	7/129	10/116	0.51	0.19; 1.34	0.164
ASC4START	3/177	23/158	0.11	0.03; 0.37	<0.001
Pooled Analysis	10/306	33/274	0.24	0.12; 0.49	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood creatinine increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	3/152	3/148	0.84	0.17; 4.17	0.830
ASC4START	3/237	5/246	0.61	0.15; 2.55	0.493
Pooled Analysis	6/389	8/394	0.70	0.24; 2.02	0.509
65 - < 75 years					
ASC4FIRST	1/34	3/29	0.25	0.03; 2.40	0.189
ASC4START	0/38	1/24	0.16	0.00; 14.35	0.143
Pooled Analysis	1/72	4/53	0.17	0.02; 1.51	0.069
>= 75 years					
ASC4FIRST	0/10	2/13	0.37	0.00; 36.17	0.355
ASC4START	0/9	1/12	0.53	0.01; 51.67	0.439
Pooled Analysis	0/19	3/25	0.27	0.01; 11.48	0.229




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood creatinine increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	1/19	0.77	0.05; 12.36	0.853
ASC4START	0/38	1/37	0.28	0.00; 25.64	0.273
Pooled Analysis	1/61	2/56	0.39	0.04; 4.36	0.432
Intermediate					
ASC4FIRST	1/54	3/52	0.28	0.03; 2.68	0.235
ASC4START	0/75	2/73	0.17	0.00; 6.99	0.125
Pooled Analysis	1/129	5/125	0.17	0.02; 1.44	0.063
Low					
ASC4FIRST	2/119	4/119	0.46	0.08; 2.50	0.355
ASC4START	3/171	4/172	0.73	0.16; 3.25	0.677
Pooled Analysis	5/290	8/291	0.59	0.19; 1.81	0.350




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood creatinine increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	2/63	0/61	2.62	0.05; 150.76	0.329
ASC4START	2/138	2/140	1.02	0.14; 7.28	0.980
Pooled Analysis	4/201	2/201	1.59	0.28; 9.12	0.602
Germany					
ASC4FIRST	1/19	1/15	0.17	0.00; 15.37	0.157
ASC4START	0/72	0/53	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	1/91	1/68	0.17	0.00; 15.37	0.157
Others					
ASC4FIRST	1/114	7/114	0.13	0.02; 1.10	0.028
ASC4START	1/74	5/89	0.22	0.03; 1.94	0.138
Pooled Analysis	2/188	12/203	0.17	0.04; 0.76	0.008




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood creatinine increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	1/41	1/42	0.33	0.02; 5.27	0.407
Pooled Analysis	1/41	1/42	0.33	0.02; 5.27	0.407
Imatinib					
ASC4FIRST	2/100	5/100	0.35	0.07; 1.79	0.185
Pooled Analysis	2/100	5/100	0.35	0.07; 1.79	0.185
Nilotinib					
ASC4FIRST	1/55	2/48	0.38	0.03; 4.16	0.408
ASC4START	3/284	7/282	0.40	0.10; 1.54	0.168
Pooled Analysis	4/339	9/330	0.39	0.12; 1.28	0.108




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood creatinine increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	2/45	0.19	0.00; 8.57	0.159
Pooled Analysis	0/128	8/130	0.05	0.00; 1.06	0.003
Asian/Others					
ASC4FIRST	0/91	6/89	0.07	0.00; 1.50	0.009
Others					
ASC4START	1/17	0/21	2.64	0.03; 255.27	0.358
Pooled Analysis	1/20	0/25	2.64	0.03; 255.27	0.358
White					
ASC4FIRST	4/105	2/101	1.44	0.26; 8.00	0.675
ASC4START	2/227	5/216	0.37	0.07; 1.91	0.216
Pooled Analysis	6/332	7/317	0.70	0.23; 2.10	0.524




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Blood creatinine increased

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	1/67	3/74	0.38	0.04; 3.74	0.389
ASC4START	0/107	4/124	0.12	0.00; 3.10	0.052
Pooled Analysis	1/174	7/198	0.16	0.02; 1.27	0.047
Male					
ASC4FIRST	3/129	5/116	0.43	0.10; 1.86	0.246
ASC4START	3/177	3/158	0.88	0.18; 4.35	0.873
Pooled Analysis	6/306	8/274	0.59	0.20; 1.73	0.331




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Bone pain

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	4/152	3/148	1.26	0.28; 5.66	0.759
ASC4START	10/237	2/246	5.22	1.14; 23.83	0.017
Pooled Analysis	14/389	5/394	2.83	1.02; 7.85	0.037
65 - < 75 years					
ASC4FIRST	1/34	0/29	2.60	0.03; 250.43	0.361
ASC4START	1/38	0/24	1.96	0.02; 191.12	0.429
Pooled Analysis	2/72	0/53	3.65	0.09; 152.20	0.228
>= 75 years					
ASC4FIRST	0/10	0/13	N.E.	N.E.; N.E.	N.E.
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/19	0/25	N.E.	N.E.; N.E.	N.E.




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Bone pain

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	0/23	1/19	0.29	0.00; 26.38	0.280
ASC4START	0/38	1/37	0.32	0.00; 29.17	0.304
Pooled Analysis	0/61	2/56	0.18	0.00; 7.43	0.136
Intermediate					
ASC4FIRST	2/54	0/52	4.79	0.12; 197.61	0.166
ASC4START	5/75	0/73	10.78	0.45; 257.21	0.027
Pooled Analysis	7/129	0/125	14.60	0.68; 311.76	0.009
Low					
ASC4FIRST	3/119	2/119	1.49	0.25; 8.90	0.662
ASC4START	6/171	1/172	6.05	0.73; 50.20	0.057
Pooled Analysis	9/290	3/291	3.00	0.81; 11.10	0.083




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Bone pain

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	0/63	1/61	0.36	0.00; 35.30	0.349
ASC4START	4/138	1/140	4.20	0.47; 37.56	0.163
Pooled Analysis	4/201	2/201	2.13	0.39; 11.61	0.373
Germany					
ASC4FIRST	1/19	0/15	2.60	0.03; 250.43	0.361
ASC4START	3/72	0/53	6.54	0.21; 206.13	0.097
Pooled Analysis	4/91	0/68	8.18	0.31; 218.57	0.058
Others					
ASC4FIRST	4/114	2/114	1.99	0.36; 10.87	0.419
ASC4START	4/74	1/89	5.02	0.56; 45.29	0.111
Pooled Analysis	8/188	3/203	2.95	0.78; 11.18	0.095




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Bone pain

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	2/41	1/42	2.40	0.22; 26.49	0.461
Pooled Analysis	2/41	1/42	2.40	0.22; 26.49	0.461
Imatinib					
ASC4FIRST	2/100	1/100	2.06	0.19; 22.67	0.548
Pooled Analysis	2/100	1/100	2.06	0.19; 22.67	0.548
Nilotinib					
ASC4FIRST	1/55	1/48	1.11	0.07; 18.27	0.944
ASC4START	11/284	2/282	5.46	1.21; 24.61	0.013
Pooled Analysis	12/339	3/330	4.04	1.14; 14.35	0.019




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Bone pain

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	1/40	1/45	1.28	0.08; 20.46	0.861
Pooled Analysis	2/128	2/130	1.17	0.16; 8.30	0.877
Asian/Others					
ASC4FIRST	1/91	1/89	1.13	0.07; 18.08	0.931
Others					
ASC4START	0/17	0/21	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/20	0/25	N.E.	N.E.; N.E.	N.E.
White					
ASC4FIRST	4/105	2/101	2.02	0.36; 11.30	0.413
ASC4START	10/227	1/216	9.69	1.24; 75.71	0.008
Pooled Analysis	14/332	3/317	4.62	1.32; 16.15	0.008




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Bone pain

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	4/67	1/74	4.86	0.53; 44.08	0.122
ASC4START	6/107	1/124	6.87	0.83; 57.13	0.038
Pooled Analysis	10/174	2/198	5.87	1.28; 26.93	0.010
Male					
ASC4FIRST	1/129	2/116	0.37	0.03; 4.20	0.403
ASC4START	5/177	1/158	4.39	0.51; 37.60	0.139
Pooled Analysis	6/306	3/274	1.68	0.42; 6.77	0.459




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Face oedema

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	0/41	0/42	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/41	0/42	N.E.	N.E.; N.E.	N.E.
Imatinib					
ASC4FIRST	0/100	10/100	0.05	0.00; 0.92	0.001
Pooled Analysis	0/100	10/100	0.05	0.00; 0.92	0.001
Nilotinib					
ASC4FIRST	0/55	0/48	N.E.	N.E.; N.E.	N.E.
ASC4START	0/284	0/282	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/339	0/330	N.E.	N.E.; N.E.	N.E.




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hyperbilirubinaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	2/152	1/148	1.84	0.17; 20.26	0.614
ASC4START	2/237	9/246	0.22	0.05; 1.01	0.032
Pooled Analysis	4/389	10/394	0.39	0.12; 1.23	0.096
65 - < 75 years					
ASC4FIRST	0/34	1/29	0.17	0.00; 15.37	0.157
ASC4START	0/38	0/24	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/72	1/53	0.17	0.00; 15.37	0.157
>= 75 years					
ASC4FIRST	0/10	0/13	N.E.	N.E.; N.E.	N.E.
ASC4START	0/9	1/12	0.39	0.00; 37.18	0.361
Pooled Analysis	0/19	1/25	0.39	0.00; 37.18	0.361




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hyperbilirubinaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	0/23	1/19	0.29	0.00; 26.38	0.280
ASC4START	1/38	0/37	2.91	0.03; 268.67	0.324
Pooled Analysis	1/61	1/56	0.91	0.06; 14.62	0.949
Intermediate					
ASC4FIRST	0/54	0/52	N.E.	N.E.; N.E.	N.E.
ASC4START	0/75	3/73	0.13	0.00; 3.90	0.066
Pooled Analysis	0/129	3/125	0.13	0.00; 3.90	0.066
Low					
ASC4FIRST	2/119	1/119	1.91	0.17; 21.02	0.592
ASC4START	1/171	7/172	0.13	0.02; 1.09	0.027
Pooled Analysis	3/290	8/291	0.35	0.09; 1.33	0.108




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hyperbilirubinaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	0/41	0/42	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/41	0/42	N.E.	N.E.; N.E.	N.E.
Imatinib					
ASC4FIRST	0/100	0/100	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/100	0/100	N.E.	N.E.; N.E.	N.E.
Nilotinib					
ASC4FIRST	2/55	2/48	0.94	0.13; 6.77	0.948
ASC4START	2/284	10/282	0.19	0.04; 0.85	0.015
Pooled Analysis	4/339	12/330	0.31	0.10; 0.96	0.032




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypercholesterolaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	6/152	7/148	0.69	0.23; 2.10	0.516
ASC4START	4/237	15/246	0.27	0.09; 0.80	0.012
Pooled Analysis	10/389	22/394	0.41	0.19; 0.88	0.018
65 - < 75 years					
ASC4FIRST	2/34	0/29	5.90	0.14; 243.62	0.125
ASC4START	0/38	0/24	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	2/72	0/53	5.90	0.14; 243.62	0.125
>= 75 years					
ASC4FIRST	1/10	1/13	0.71	0.04; 11.79	0.808
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	1/19	1/25	0.71	0.04; 11.79	0.808




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypercholesterolaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	1/19	0.31	0.02; 6.26	0.432
ASC4START	0/38	0/37	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	1/61	1/56	0.31	0.02; 6.26	0.432
Intermediate					
ASC4FIRST	1/54	0/52	1.49	0.02; 144.25	0.489
ASC4START	2/75	3/73	0.58	0.10; 3.46	0.546
Pooled Analysis	3/129	3/125	0.79	0.16; 3.94	0.773
Low					
ASC4FIRST	7/119	7/119	0.96	0.34; 2.75	0.944
ASC4START	2/171	12/172	0.16	0.04; 0.72	0.006
Pooled Analysis	9/290	19/291	0.46	0.21; 1.01	0.046




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypercholesterolaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	5/63	1/61	4.19	0.46; 38.03	0.167
ASC4START	2/138	11/140	0.17	0.04; 0.77	0.009
Pooled Analysis	7/201	12/201	0.48	0.18; 1.27	0.130
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	0/72	1/53	0.17	0.00; 16.29	0.168
Pooled Analysis	0/91	1/68	0.17	0.00; 16.29	0.168
Others					
ASC4FIRST	4/114	7/114	0.58	0.17; 1.97	0.372
ASC4START	2/74	3/89	0.79	0.13; 4.80	0.801
Pooled Analysis	6/188	10/203	0.64	0.23; 1.75	0.378




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypercholesterolaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	0/41	1/42	0.39	0.00; 38.92	0.371
Pooled Analysis	0/41	1/42	0.39	0.00; 38.92	0.371
Imatinib					
ASC4FIRST	5/100	2/100	1.94	0.36; 10.42	0.434
Pooled Analysis	5/100	2/100	1.94	0.36; 10.42	0.434
Nilotinib					
ASC4FIRST	4/55	5/48	0.65	0.17; 2.41	0.512
ASC4START	4/284	15/282	0.25	0.08; 0.75	0.008
Pooled Analysis	8/339	20/330	0.36	0.16; 0.81	0.010




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypercholesterolaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	1/45	0.46	0.00; 44.32	0.403
Pooled Analysis	4/128	7/130	0.62	0.18; 2.11	0.435
Asian/Others					
ASC4FIRST	4/91	6/89	0.74	0.21; 2.64	0.646
Others					
ASC4START	0/17	0/21	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/20	0/25	N.E.	N.E.; N.E.	N.E.
White					
ASC4FIRST	5/105	2/101	1.87	0.35; 10.15	0.460
ASC4START	4/227	14/216	0.26	0.09; 0.79	0.011
Pooled Analysis	9/332	16/317	0.47	0.20; 1.08	0.069




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypercholesterolaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	5/67	2/74	2.37	0.45; 12.36	0.292
ASC4START	2/107	13/124	0.16	0.04; 0.73	0.007
Pooled Analysis	7/174	15/198	0.48	0.19; 1.17	0.099
Male					
ASC4FIRST	4/129	6/116	0.39	0.10; 1.62	0.183
ASC4START	2/177	2/158	0.87	0.12; 6.16	0.887
Pooled Analysis	6/306	8/274	0.51	0.16; 1.59	0.237




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypertension

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	13/152	7/148	1.61	0.64; 4.05	0.311
ASC4START	18/237	6/246	2.99	1.19; 7.55	0.015
Pooled Analysis	31/389	13/394	2.24	1.17; 4.28	0.013
65 - < 75 years					
ASC4FIRST	4/34	2/29	1.82	0.33; 10.12	0.486
ASC4START	6/38	3/24	1.50	0.30; 7.48	0.620
Pooled Analysis	10/72	5/53	1.65	0.51; 5.35	0.403
>= 75 years					
ASC4FIRST	2/10	1/13	1.62	0.14; 18.31	0.695
ASC4START	3/9	1/12	3.58	0.37; 34.48	0.239
Pooled Analysis	5/19	2/25	2.55	0.49; 13.32	0.250




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypertension

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	1/19	1.04	0.08; 13.20	0.973
ASC4START	3/38	2/37	1.41	0.24; 8.43	0.707
Pooled Analysis	5/61	3/56	1.28	0.29; 5.54	0.743
Intermediate					
ASC4FIRST	2/54	3/52	0.56	0.09; 3.38	0.522
ASC4START	12/75	2/73	5.80	1.30; 25.92	0.009
Pooled Analysis	14/129	5/125	2.62	0.94; 7.28	0.055
Low					
ASC4FIRST	15/119	6/119	2.38	0.92; 6.15	0.064
ASC4START	12/171	6/172	1.91	0.72; 5.09	0.188
Pooled Analysis	27/290	12/291	2.15	1.09; 4.24	0.024




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypertension

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	7/63	2/61	3.48	0.72; 16.79	0.097
ASC4START	14/138	6/140	2.07	0.79; 5.39	0.130
Pooled Analysis	21/201	8/201	2.41	1.07; 5.46	0.029
Germany					
ASC4FIRST	3/19	3/15	0.99	0.16; 5.98	0.994
ASC4START	6/72	2/53	2.54	0.48; 13.41	0.259
Pooled Analysis	9/91	5/68	1.71	0.51; 5.72	0.383
Others					
ASC4FIRST	9/114	5/114	1.52	0.50; 4.67	0.459
ASC4START	7/74	2/89	4.42	0.91; 21.38	0.044
Pooled Analysis	16/188	7/203	2.29	0.93; 5.65	0.063




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypertension

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	3/41	3/42	1.09	0.21; 5.62	0.915
Pooled Analysis	3/41	3/42	1.09	0.21; 5.62	0.915
Imatinib					
ASC4FIRST	14/100	5/100	2.55	0.91; 7.13	0.065
Pooled Analysis	14/100	5/100	2.55	0.91; 7.13	0.065
Nilotinib					
ASC4FIRST	2/55	2/48	0.75	0.10; 5.59	0.780
ASC4START	27/284	10/282	2.58	1.25; 5.34	0.008
Pooled Analysis	29/339	12/330	2.27	1.16; 4.46	0.014




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypertension

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	1/40	2/45	0.56	0.05; 6.23	0.630
Pooled Analysis	5/128	4/130	1.21	0.32; 4.55	0.773
Asian/Others					
ASC4FIRST	5/91	2/89	2.31	0.45; 11.94	0.304
Others					
ASC4START	2/17	0/21	4.33	0.11; 178.67	0.188
Pooled Analysis	3/20	0/25	8.80	0.27; 290.82	0.060
White					
ASC4FIRST	14/105	8/101	1.47	0.61; 3.55	0.389
ASC4START	24/227	8/216	2.64	1.19; 5.89	0.013
Pooled Analysis	38/332	16/317	2.06	1.14; 3.70	0.014




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypertension

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	5/67	4/74	1.46	0.38; 5.55	0.580
ASC4START	8/107	3/124	2.97	0.79; 11.22	0.091
Pooled Analysis	13/174	7/198	2.13	0.84; 5.37	0.103
Male					
ASC4FIRST	14/129	6/116	1.94	0.73; 5.13	0.174
ASC4START	19/177	7/158	2.30	0.97; 5.48	0.053
Pooled Analysis	33/306	13/274	2.14	1.12; 4.08	0.018




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypokalaemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	1/152	5/148	0.18	0.02; 1.54	0.078
ASC4START	2/237	2/246	0.98	0.14; 6.96	0.983
Pooled Analysis	3/389	7/394	0.40	0.10; 1.55	0.169
65 - < 75 years					
ASC4FIRST	0/34	2/29	0.13	0.00; 5.54	0.083
ASC4START	0/38	1/24	0.33	0.00; 30.79	0.317
Pooled Analysis	0/72	3/53	0.10	0.00; 3.33	0.047
>= 75 years					
ASC4FIRST	0/10	0/13	N.E.	N.E.; N.E.	N.E.
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/19	0/25	N.E.	N.E.; N.E.	N.E.




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypophosphataemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	1/152	9/148	0.10	0.01; 0.79	0.007
ASC4START	2/237	4/246	0.51	0.09; 2.78	0.427
Pooled Analysis	3/389	13/394	0.22	0.06; 0.76	0.009
65 - < 75 years					
ASC4FIRST	0/34	2/29	0.14	0.00; 5.61	0.086
ASC4START	0/38	0/24	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/72	2/53	0.14	0.00; 5.61	0.086
>= 75 years					
ASC4FIRST	0/10	1/13	0.33	0.00; 30.79	0.317
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/19	1/25	0.33	0.00; 30.79	0.317




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypophosphataemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	0/23	0/19	N.E.	N.E.; N.E.	N.E.
ASC4START	0/38	0/37	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/61	0/56	N.E.	N.E.; N.E.	N.E.
Intermediate					
ASC4FIRST	0/54	3/52	0.12	0.00; 3.76	0.062
ASC4START	1/75	0/73	2.91	0.03; 268.58	0.324
Pooled Analysis	1/129	3/125	0.30	0.03; 2.84	0.262
Low					
ASC4FIRST	1/119	9/119	0.10	0.01; 0.80	0.007
ASC4START	1/171	4/172	0.24	0.03; 2.17	0.168
Pooled Analysis	2/290	13/291	0.14	0.03; 0.63	0.003




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypophosphataemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	0/63	3/61	0.14	0.00; 4.35	0.080
ASC4START	0/138	1/140	0.35	0.00; 32.68	0.332
Pooled Analysis	0/201	4/201	0.11	0.00; 2.94	0.045
Germany					
ASC4FIRST	0/19	2/15	0.12	0.00; 5.04	0.070
ASC4START	0/72	1/53	0.20	0.00; 18.59	0.198
Pooled Analysis	0/91	3/68	0.09	0.00; 2.66	0.026
Others					
ASC4FIRST	1/114	7/114	0.13	0.02; 1.06	0.025
ASC4START	2/74	2/89	1.13	0.16; 8.03	0.905
Pooled Analysis	3/188	9/203	0.33	0.09; 1.21	0.078




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypophosphataemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	0/41	1/42	0.36	0.00; 33.17	0.335
Pooled Analysis	0/41	1/42	0.36	0.00; 33.17	0.335
Imatinib					
ASC4FIRST	1/100	9/100	0.10	0.01; 0.78	0.007
Pooled Analysis	1/100	9/100	0.10	0.01; 0.78	0.007
Nilotinib					
ASC4FIRST	0/55	2/48	0.15	0.00; 6.00	0.097
ASC4START	2/284	4/282	0.48	0.09; 2.65	0.392
Pooled Analysis	2/339	6/330	0.30	0.06; 1.49	0.118




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypophosphataemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	0/45	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/128	6/130	0.06	0.00; 1.41	0.007
Asian/Others					
ASC4FIRST	0/91	6/89	0.06	0.00; 1.47	0.008
Others					
ASC4START	0/17	0/21	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/20	0/25	N.E.	N.E.; N.E.	N.E.
White					
ASC4FIRST	1/105	6/101	0.17	0.02; 1.42	0.064
ASC4START	2/227	4/216	0.47	0.09; 2.57	0.373
Pooled Analysis	3/332	10/317	0.29	0.08; 1.07	0.050




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypophosphataemia

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	1/67	2/74	0.50	0.05; 5.51	0.564
ASC4START	1/107	3/124	0.39	0.04; 3.74	0.396
Pooled Analysis	2/174	5/198	0.44	0.08; 2.25	0.308
Male					
ASC4FIRST	0/129	10/116	0.04	0.00; 0.77	<0.001
ASC4START	1/177	1/158	0.86	0.05; 13.76	0.915
Pooled Analysis	1/306	11/274	0.07	0.01; 0.58	0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Muscle spasms

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	5/152	17/148	0.27	0.10; 0.72	0.005
ASC4START	8/237	11/246	0.74	0.30; 1.85	0.525
Pooled Analysis	13/389	28/394	0.44	0.23; 0.86	0.013
65 - < 75 years					
ASC4FIRST	0/34	5/29	0.08	0.00; 1.88	0.016
ASC4START	2/38	3/24	0.30	0.05; 1.84	0.170
Pooled Analysis	2/72	8/53	0.15	0.03; 0.73	0.007
>= 75 years					
ASC4FIRST	1/10	1/13	0.76	0.04; 13.00	0.852
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	1/19	1/25	0.76	0.04; 13.00	0.852




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Muscle spasms

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	1/19	0.72	0.04; 11.54	0.816
ASC4START	0/38	1/37	0.33	0.00; 29.98	0.311
Pooled Analysis	1/61	2/56	0.40	0.04; 4.40	0.435
Intermediate					
ASC4FIRST	1/54	4/52	0.18	0.02; 1.65	0.090
ASC4START	1/75	2/73	0.45	0.04; 4.95	0.501
Pooled Analysis	2/129	6/125	0.26	0.05; 1.31	0.081
Low					
ASC4FIRST	4/119	18/119	0.20	0.07; 0.59	0.001
ASC4START	9/171	11/172	0.80	0.33; 1.93	0.620
Pooled Analysis	13/290	29/291	0.42	0.22; 0.81	0.007




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Muscle spasms

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	2/63	16/61	0.11	0.03; 0.49	<0.001
ASC4START	6/138	7/140	0.88	0.29; 2.62	0.817
Pooled Analysis	8/201	23/201	0.33	0.15; 0.74	0.005
Germany					
ASC4FIRST	1/19	0/15	1.57	0.02; 152.79	0.480
ASC4START	2/72	3/53	0.31	0.05; 1.96	0.195
Pooled Analysis	3/91	3/68	0.48	0.09; 2.47	0.376
Others					
ASC4FIRST	3/114	7/114	0.37	0.10; 1.44	0.135
ASC4START	2/74	4/89	0.62	0.11; 3.41	0.579
Pooled Analysis	5/188	11/203	0.45	0.15; 1.30	0.128




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Muscle spasms

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	1/41	2/42	0.55	0.05; 6.09	0.622
Pooled Analysis	1/41	2/42	0.55	0.05; 6.09	0.622
Imatinib					
ASC4FIRST	4/100	19/100	0.17	0.06; 0.52	<0.001
Pooled Analysis	4/100	19/100	0.17	0.06; 0.52	<0.001
Nilotinib					
ASC4FIRST	1/55	2/48	0.37	0.03; 4.05	0.394
ASC4START	10/284	14/282	0.69	0.31; 1.56	0.370
Pooled Analysis	11/339	16/330	0.64	0.30; 1.39	0.259




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Muscle spasms

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	2/45	0.26	0.01; 10.54	0.211
Pooled Analysis	0/128	5/130	0.07	0.00; 1.79	0.014
Asian/Others					
ASC4FIRST	0/91	4/89	0.07	0.00; 2.02	0.016
Others					
ASC4START	1/17	0/21	2.75	0.03; 253.84	0.338
Pooled Analysis	1/20	1/25	1.35	0.08; 22.82	0.833
White					
ASC4FIRST	6/105	19/101	0.26	0.10; 0.65	0.002
ASC4START	9/227	12/216	0.71	0.30; 1.68	0.433
Pooled Analysis	15/332	31/317	0.42	0.23; 0.79	0.005




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Muscle spasms

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	2/67	11/74	0.17	0.04; 0.76	0.008
ASC4START	5/107	7/124	0.82	0.26; 2.59	0.740
Pooled Analysis	7/174	18/198	0.40	0.17; 0.95	0.033
Male					
ASC4FIRST	4/129	12/116	0.26	0.08; 0.82	0.013
ASC4START	5/177	7/158	0.62	0.20; 1.94	0.405
Pooled Analysis	9/306	19/274	0.39	0.18; 0.86	0.016




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Oedema peripheral

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	1/152	4/148	0.23	0.03; 2.10	0.157
ASC4START	5/237	8/246	0.63	0.21; 1.93	0.415
Pooled Analysis	6/389	12/394	0.49	0.19; 1.32	0.150
65 - < 75 years					
ASC4FIRST	1/34	4/29	0.21	0.02; 1.89	0.125
ASC4START	0/38	0/24	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	1/72	4/53	0.21	0.02; 1.89	0.125
>= 75 years					
ASC4FIRST	1/10	3/13	0.39	0.03; 4.44	0.433
ASC4START	0/9	1/12	0.39	0.00; 37.18	0.361
Pooled Analysis	1/19	4/25	0.29	0.03; 2.82	0.255




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Oedema peripheral

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	0/23	2/19	0.16	0.00; 6.73	0.117
ASC4START	0/38	0/37	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/61	2/56	0.16	0.00; 6.73	0.117
Intermediate					
ASC4FIRST	2/54	4/52	0.44	0.08; 2.39	0.325
ASC4START	0/75	4/73	0.10	0.00; 2.59	0.034
Pooled Analysis	2/129	8/125	0.22	0.05; 1.03	0.035
Low					
ASC4FIRST	1/119	5/119	0.20	0.02; 1.68	0.098
ASC4START	5/171	5/172	0.97	0.28; 3.35	0.960
Pooled Analysis	6/290	10/291	0.58	0.21; 1.61	0.293




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Oedema peripheral

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	0/63	2/61	0.24	0.01; 9.75	0.194
ASC4START	0/138	2/140	0.20	0.00; 8.39	0.161
Pooled Analysis	0/201	4/201	0.12	0.00; 3.19	0.056
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	4/72	2/53	1.42	0.25; 7.96	0.687
Pooled Analysis	4/91	2/68	1.42	0.25; 7.96	0.687
Others					
ASC4FIRST	3/114	9/114	0.30	0.08; 1.11	0.057
ASC4START	1/74	5/89	0.22	0.03; 1.87	0.127
Pooled Analysis	4/188	14/203	0.27	0.09; 0.83	0.015




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Oedema peripheral

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	1/41	3/42	0.27	0.03; 2.72	0.235
Pooled Analysis	1/41	3/42	0.27	0.03; 2.72	0.235
Imatinib					
ASC4FIRST	1/100	7/100	0.13	0.02; 1.05	0.024
Pooled Analysis	1/100	7/100	0.13	0.02; 1.05	0.024
Nilotinib					
ASC4FIRST	1/55	1/48	0.81	0.05; 13.00	0.884
ASC4START	5/284	9/282	0.52	0.18; 1.57	0.240
Pooled Analysis	6/339	10/330	0.56	0.20; 1.53	0.250




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Oedema peripheral

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	2/45	0.24	0.01; 10.02	0.200
Pooled Analysis	1/128	7/130	0.13	0.02; 1.07	0.026
Asian/Others					
ASC4FIRST	1/91	7/89	0.12	0.02; 1.02	0.022
Others					
ASC4START	0/17	1/21	0.80	0.01; 77.50	0.527
Pooled Analysis	0/20	3/25	0.44	0.01; 18.43	0.343
White					
ASC4FIRST	2/105	4/101	0.41	0.07; 2.29	0.297
ASC4START	5/227	6/216	0.77	0.23; 2.52	0.664
Pooled Analysis	7/332	10/317	0.62	0.24; 1.64	0.334




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Oedema peripheral

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	0/67	9/74	0.06	0.00; 1.15	0.004
ASC4START	4/107	6/124	0.75	0.21; 2.68	0.662
Pooled Analysis	4/174	15/198	0.30	0.10; 0.90	0.023
Male					
ASC4FIRST	3/129	2/116	1.30	0.22; 7.84	0.772
ASC4START	1/177	3/158	0.28	0.03; 2.74	0.246
Pooled Analysis	4/306	5/274	0.69	0.18; 2.57	0.577




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Periorbital oedema

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	0/23	0/19	N.E.	N.E.; N.E.	N.E.
ASC4START	0/38	0/37	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/61	0/56	N.E.	N.E.; N.E.	N.E.
Intermediate					
ASC4FIRST	1/54	3/52	0.31	0.03; 3.01	0.287
ASC4START	0/75	0/73	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	1/129	3/125	0.31	0.03; 3.01	0.287
Low					
ASC4FIRST	1/119	9/119	0.11	0.01; 0.85	0.010
ASC4START	0/171	0/172	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	1/290	9/291	0.11	0.01; 0.85	0.010




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Periorbital oedema

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	2/41	1/42	2.21	0.20; 24.44	0.506
Pooled Analysis	2/41	1/42	2.21	0.20; 24.44	0.506
Imatinib					
ASC4FIRST	0/100	11/100	0.04	0.00; 0.82	<0.001
Pooled Analysis	0/100	11/100	0.04	0.00; 0.82	<0.001
Nilotinib					
ASC4FIRST	0/55	0/48	N.E.	N.E.; N.E.	N.E.
ASC4START	0/284	0/282	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/339	0/330	N.E.	N.E.; N.E.	N.E.




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Periorbital oedema

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	0/45	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/128	4/130	0.10	0.00; 2.50	0.031
Asian/Others					
ASC4FIRST	0/91	4/89	0.10	0.00; 2.61	0.034
Others					
ASC4START	0/17	0/21	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/20	0/25	N.E.	N.E.; N.E.	N.E.
White					
ASC4FIRST	2/105	8/101	0.27	0.06; 1.28	0.077
ASC4START	0/227	0/216	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	2/332	8/317	0.27	0.06; 1.28	0.077




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	26/152	24/148	0.99	0.57; 1.73	0.981
ASC4START	30/237	42/246	0.68	0.42; 1.08	0.100
Pooled Analysis	56/389	66/394	0.79	0.55; 1.13	0.201
65 - < 75 years					
ASC4FIRST	1/34	4/29	0.27	0.03; 2.60	0.229
ASC4START	2/38	6/24	0.16	0.03; 0.78	0.010
Pooled Analysis	3/72	10/53	0.18	0.05; 0.69	0.006
>= 75 years					
ASC4FIRST	2/10	3/13	1.04	0.15; 7.39	0.969
ASC4START	1/9	0/12	3.71	0.04; 338.14	0.264
Pooled Analysis	3/19	3/25	1.62	0.27; 9.71	0.595




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	3/19	0.25	0.03; 2.39	0.191
ASC4START	3/38	7/37	0.37	0.10; 1.43	0.134
Pooled Analysis	4/61	10/56	0.33	0.10; 1.06	0.049
Intermediate					
ASC4FIRST	6/54	5/52	0.95	0.29; 3.15	0.939
ASC4START	10/75	10/73	0.87	0.36; 2.09	0.751
Pooled Analysis	16/129	15/125	0.90	0.44; 1.82	0.764
Low					
ASC4FIRST	22/119	23/119	0.90	0.50; 1.61	0.721
ASC4START	20/171	31/172	0.59	0.34; 1.04	0.065
Pooled Analysis	42/290	54/291	0.72	0.48; 1.08	0.113




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	10/63	10/61	0.92	0.37; 2.29	0.864
ASC4START	12/138	19/140	0.61	0.30; 1.25	0.174
Pooled Analysis	22/201	29/201	0.71	0.41; 1.25	0.239
Germany					
ASC4FIRST	3/19	5/15	0.56	0.12; 2.50	0.438
ASC4START	13/72	12/53	0.70	0.32; 1.56	0.390
Pooled Analysis	16/91	17/68	0.67	0.33; 1.35	0.260
Others					
ASC4FIRST	16/114	16/114	0.93	0.47; 1.87	0.844
ASC4START	8/74	17/89	0.50	0.21; 1.16	0.101
Pooled Analysis	24/188	33/203	0.72	0.42; 1.22	0.219




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	8/41	8/42	1.07	0.40; 2.89	0.884
Pooled Analysis	8/41	8/42	1.07	0.40; 2.89	0.884
Imatinib					
ASC4FIRST	9/100	11/100	0.75	0.31; 1.81	0.514
Pooled Analysis	9/100	11/100	0.75	0.31; 1.81	0.514
Nilotinib					
ASC4FIRST	12/55	12/48	0.74	0.33; 1.66	0.469
ASC4START	33/284	48/282	0.62	0.40; 0.96	0.032
Pooled Analysis	45/339	60/330	0.64	0.44; 0.95	0.026




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	4/40	10/45	0.38	0.12; 1.21	0.089
Pooled Analysis	18/128	23/130	0.73	0.39; 1.37	0.331
Asian/Others					
ASC4FIRST	15/91	14/89	1.02	0.49; 2.13	0.961
Others					
ASC4START	1/17	3/21	0.39	0.04; 3.85	0.403
Pooled Analysis	2/20	4/25	0.88	0.14; 5.44	0.889
White					
ASC4FIRST	14/105	17/101	0.69	0.34; 1.40	0.301
ASC4START	28/227	35/216	0.70	0.42; 1.15	0.155
Pooled Analysis	42/332	52/317	0.69	0.46; 1.04	0.079




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	7/67	17/74	0.42	0.17; 1.02	0.049
ASC4START	14/107	30/124	0.45	0.24; 0.85	0.011
Pooled Analysis	21/174	47/198	0.44	0.26; 0.73	0.001
Male					
ASC4FIRST	22/129	14/116	1.44	0.74; 2.83	0.282
ASC4START	19/177	18/158	0.89	0.47; 1.70	0.729
Pooled Analysis	41/306	32/274	1.13	0.71; 1.79	0.612




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash maculo-papular

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	2/152	3/148	0.55	0.09; 3.31	0.507
ASC4START	2/237	11/246	0.18	0.04; 0.83	0.013
Pooled Analysis	4/389	14/394	0.27	0.09; 0.83	0.014
65 - < 75 years					
ASC4FIRST	0/34	0/29	N.E.	N.E.; N.E.	N.E.
ASC4START	1/38	0/24	1.45	0.02; 139.78	0.495
Pooled Analysis	1/72	0/53	1.45	0.02; 139.78	0.495
>= 75 years					
ASC4FIRST	1/10	0/13	2.99	0.03; 275.43	0.317
ASC4START	0/9	1/12	0.39	0.00; 38.92	0.371
Pooled Analysis	1/19	1/25	1.12	0.07; 17.96	0.937




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash maculo-papular

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	1/19	0.73	0.04; 11.72	0.821
ASC4START	0/38	1/37	0.33	0.00; 29.98	0.311
Pooled Analysis	1/61	2/56	0.40	0.04; 4.43	0.438
Intermediate					
ASC4FIRST	1/54	0/52	2.75	0.03; 253.84	0.338
ASC4START	1/75	5/73	0.18	0.02; 1.52	0.075
Pooled Analysis	2/129	5/125	0.36	0.07; 1.84	0.198
Low					
ASC4FIRST	1/119	2/119	0.48	0.04; 5.29	0.539
ASC4START	2/171	6/172	0.33	0.07; 1.62	0.149
Pooled Analysis	3/290	8/291	0.37	0.10; 1.38	0.121




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash maculo-papular

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	1/63	0/61	3.54	0.04; 323.96	0.275
ASC4START	0/138	3/140	0.14	0.00; 4.20	0.077
Pooled Analysis	1/201	3/201	0.34	0.03; 3.25	0.324
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	0/72	0/53	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/91	0/68	N.E.	N.E.; N.E.	N.E.
Others					
ASC4FIRST	2/114	3/114	0.64	0.11; 3.83	0.621
ASC4START	3/74	9/89	0.36	0.10; 1.33	0.108
Pooled Analysis	5/188	12/203	0.43	0.15; 1.23	0.106




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash maculo-papular

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	2/41	0/42	3.51	0.07; 178.31	0.254
Pooled Analysis	2/41	0/42	3.51	0.07; 178.31	0.254
Imatinib					
ASC4FIRST	1/100	0/100	3.04	0.03; 280.00	0.313
Pooled Analysis	1/100	0/100	3.04	0.03; 280.00	0.313
Nilotinib					
ASC4FIRST	0/55	3/48	0.13	0.00; 4.16	0.074
ASC4START	3/284	12/282	0.24	0.07; 0.83	0.015
Pooled Analysis	3/339	15/330	0.19	0.05; 0.65	0.003




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash maculo-papular

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	1/40	5/45	0.22	0.03; 1.88	0.128
Pooled Analysis	1/128	6/130	0.18	0.02; 1.51	0.076
Asian/Others					
ASC4FIRST	0/91	2/89	0.23	0.01; 9.30	0.183
Others					
ASC4START	1/17	1/21	1.52	0.09; 26.48	0.773
Pooled Analysis	1/20	2/25	1.52	0.09; 26.48	0.773
White					
ASC4FIRST	3/105	1/101	2.53	0.24; 26.31	0.423
ASC4START	1/227	6/216	0.15	0.02; 1.26	0.044
Pooled Analysis	4/332	7/317	0.48	0.14; 1.68	0.242




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.3.1: Forest-Plot for Any AE by PT: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Rash maculo-papular

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	1/67	1/74	1.07	0.07; 17.18	0.960
ASC4START	0/107	7/124	0.07	0.00; 1.57	0.012
Pooled Analysis	1/174	8/198	0.14	0.02; 1.10	0.028
Male					
ASC4FIRST	2/129	2/116	0.49	0.06; 3.78	0.485
ASC4START	3/177	5/158	0.51	0.12; 2.15	0.352
Pooled Analysis	5/306	7/274	0.50	0.16; 1.63	0.246



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.4 Time to first AE with grade >=3: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.291)								
Low	96/290 (33.1)	N.E. [31.3; N.E.]	124/291 (42.6)	N.E. [24.0; N.E.]	0.70	[0.53; 0.91]	0.008	0.436
Intermediate	56/129 (43.4)	N.E. [17.1; N.E.]	63/125 (50.4)	16.5 [5.7; N.E.]	0.73	[0.51; 1.05]	0.087	0.362
High	37/61 (60.7)	11.2 [2.8; 23.1]	28/56 (50.0)	11.2 [2.8; N.E.]	1.10	[0.67; 1.82]	0.698	0.152
Sex								
(Interaction test: p = 0.928)								
Female	74/174 (42.5)	N.E. [17.3; N.E.]	97/198 (49.0)	18.8 [8.3; N.E.]	0.78	[0.57; 1.05]	0.104	0.178

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Male	115/306 (37.6)	N.E. [31.3; N.E.]	118/274 (43.1)	26.4 [22.2; N.E.]	0.75	[0.58; 0.97]	0.030	0.043
Race								
(Interaction test: p = 0.479)								
Asian	52/128 (40.6)	31.3 [20.1; N.E.]	68/130 (52.3)	13.8 [4.4; N.E.]	0.63	[0.44; 0.92]	0.014	0.710
White	126/332 (38.0)	N.E. [27.6; N.E.]	134/317 (42.3)	26.4 [21.7; N.E.]	0.80	[0.63; 1.03]	0.084	0.571
Others	11/20 (55.0)	10.2 [2.8; N.E.]	13/25 (52.0)	12.4 [2.1; N.E.]	1.34	[0.56; 3.22]	0.490	0.994
Age groups								
(Interaction test: p = 0.860)								
18 - < 65 years	146/389 (37.5)	N.E. [31.3; N.E.]	173/394 (43.9)	N.E. [21.7; N.E.]	0.76	[0.61; 0.95]	0.016	0.324
65 - < 75 years	33/72 (45.8)	27.6 [16.3; N.E.]	28/53 (52.8)	11.1 [2.8; N.E.]	0.77	[0.45; 1.32]	0.364	0.235


	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
>= 75 years	10/19 (52.6)	10.8 [2.8; N.E.]	14/25 (56.0)	16.6 [2.5; N.E.]	0.89	[0.37; 2.12]	0.792	0.278
Pre-randomization selection of TKI								
(Interaction test: p = 0.575)								
Imatinib	48/100 (48.0)	N.E. [13.8; N.E.]	49/100 (49.0)	18.8 [8.3; N.E.]	0.87	[0.58; 1.30]	0.505	N.E.
Nilotinib	123/339 (36.3)	31.3 [27.6; N.E.]	142/330 (43.0)	26.4 [22.2; N.E.]	0.76	[0.59; 0.96]	0.024	0.199
Dasatinib	18/41 (43.9)	N.E. [13.8; N.E.]	24/42 (57.1)	7.0 [2.3; N.E.]	0.52	[0.27; 0.99]	0.042	N.E.
Geographic region								
(Interaction test: p = 0.354)								
Europe excluding Germany	72/201 (35.8)	N.E. [N.E.; N.E.]	87/201 (43.3)	N.E. [14.1; N.E.]	0.77	[0.56; 1.05]	0.096	0.208

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Germany	27/91 (29.7)	N.E. [26.2; N.E.]	31/68 (45.6)	24.0 [4.9; N.E.]	0.58	[0.34; 0.99]	0.046	0.668
Others	90/188 (47.9)	27.6 [14.3; N.E.]	97/203 (47.8)	25.3 [8.3; N.E.]	0.87	[0.65; 1.16]	0.341	0.730

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.4.1: Forest-Plot for AE with grade >=3: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	61/152	76/148	0.67	0.48; 0.94	0.020
ASC4START	85/237	97/246	0.84	0.63; 1.12	0.240
Pooled Analysis	146/389	173/394	0.76	0.61; 0.95	0.016
65 - < 75 years					
ASC4FIRST	22/34	16/29	0.99	0.50; 1.96	0.989
ASC4START	11/38	12/24	0.51	0.22; 1.21	0.127
Pooled Analysis	33/72	28/53	0.77	0.45; 1.32	0.364
>= 75 years					
ASC4FIRST	4/10	9/13	0.53	0.15; 1.92	0.328
ASC4START	6/9	5/12	1.41	0.42; 4.66	0.567
Pooled Analysis	10/19	14/25	0.89	0.37; 2.12	0.792



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.4.1: Forest-Plot for AE with grade >=3: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	13/23	11/19	0.68	0.29; 1.55	0.344
ASC4START	24/38	17/37	1.44	0.77; 2.69	0.246
Pooled Analysis	37/61	28/56	1.10	0.67; 1.82	0.698
Intermediate					
ASC4FIRST	31/54	30/52	0.86	0.52; 1.42	0.567
ASC4START	25/75	33/73	0.61	0.36; 1.03	0.063
Pooled Analysis	56/129	63/125	0.73	0.51; 1.05	0.087
Low					
ASC4FIRST	43/119	60/119	0.62	0.42; 0.92	0.017
ASC4START	53/171	64/172	0.77	0.53; 1.11	0.162
Pooled Analysis	96/290	124/291	0.70	0.53; 1.91	0.008



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 4-2.4.1: Forest-Plot for AE with grade >=3: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	25/63	36/61	0.59	0.35; 0.99	0.043
ASC4START	47/138	51/140	0.90	0.60; 1.33	0.587
Pooled Analysis	72/201	87/201	0.77	0.56; 1.05	0.096
Germany					
ASC4FIRST	6/19	9/15	0.47	0.16; 1.43	0.187
ASC4START	21/72	22/53	0.62	0.34; 1.14	0.120
Pooled Analysis	27/91	31/68	0.58	0.34; 0.99	0.046
Others					
ASC4FIRST	56/114	56/114	0.83	0.57; 1.21	0.333
ASC4START	34/74	41/89	0.92	0.58; 1.46	0.747
Pooled Analysis	90/188	97/203	0.87	0.65; 1.16	0.341




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.4.1: Forest-Plot for AE with grade >=3: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 4-2.4.1: Forest-Plot for AE with grade >=3: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.4.1: Forest-Plot for AE with grade >=3: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	36/67	40/74	0.98	0.62; 1.56	0.945
ASC4START	38/107	57/124	0.64	0.43; 0.97	0.035
Pooled Analysis	74/174	97/198	0.78	0.57; 1.05	0.104
Male					
ASC4FIRST	51/129	61/116	0.56	0.38; 0.82	0.003
ASC4START	64/177	57/158	0.96	0.67; 1.38	0.852
Pooled Analysis	115/306	118/274	0.75	0.58; 0.97	0.030



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.5 Time to first AE with grade >=3 by SOC: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Cardiac disorders								
Race								
(Interaction test: p = 1.000)								
Asian	0/128	N.E. [N.E.; N.E.]	3/130 (2.3)	N.E. [N.E.; N.E.]	0.12	[0.00; 3.76]	0.060	1.000
White	4/332 (1.2)	N.E. [N.E.; N.E.]	8/317 (2.5)	N.E. [N.E.; N.E.]	0.43	[0.13; 1.44]	0.159	0.993
Others	0/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Pre-randomization selection of TKI								
(Interaction test: p = 1.000)								
Imatinib	0/100	N.E. [N.E.; N.E.]	1/100 (1.0)	N.E. [N.E.; N.E.]	0.16	[0.00; 14.70]	0.148	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Nilotinib	4/339 (1.2)	N.E. [N.E.; N.E.]	7/330 (2.1)	N.E. [N.E.; N.E.]	0.52	[0.15; 1.77]	0.287	N.E.
Dasatinib	0/41	N.E. [N.E.; N.E.]	3/42 (7.1)	N.E. [N.E.; N.E.]	0.10	[0.00; 3.41]	0.049	N.E.
Investigations								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.894)								
Low	33/290 (11.4)	N.E. [N.E.; N.E.]	53/291 (18.2)	N.E. [N.E.; N.E.]	0.60	[0.39; 0.93]	0.020	0.096
Intermediate	16/129 (12.4)	N.E. [30.4; N.E.]	21/125 (16.8)	N.E. [N.E.; N.E.]	0.69	[0.36; 1.32]	0.257	0.117
High	11/61 (18.0)	N.E. [N.E.; N.E.]	16/56 (28.6)	N.E. [N.E.; N.E.]	0.56	[0.26; 1.20]	0.131	0.797
Sex								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.868)								
Female	25/174 (14.4)	N.E. [N.E.; N.E.]	43/198 (21.7)	N.E. [N.E.; N.E.]	0.62	[0.38; 1.02]	0.055	0.001
Male	35/306 (11.4)	N.E. [N.E.; N.E.]	47/274 (17.2)	N.E. [N.E.; N.E.]	0.60	[0.38; 0.93]	0.021	0.892
Race								
(Interaction test: p = 0.228)								
Asian	27/128 (21.1)	N.E. [N.E.; N.E.]	31/130 (23.8)	N.E. [N.E.; N.E.]	0.86	[0.51; 1.45]	0.565	0.642
White	32/332 (9.6)	N.E. [N.E.; N.E.]	54/317 (17.0)	N.E. [N.E.; N.E.]	0.53	[0.34; 0.82]	0.004	0.087
Others	1/20 (5.0)	N.E. [N.E.; N.E.]	5/25 (20.0)	N.E. [N.E.; N.E.]	0.36	[0.04; 3.30]	0.344	N.E.
Age groups								
(Interaction test: p = 0.271)								
18 - < 65 years	50/389	N.E. [N.E.; N.E.]	68/394	N.E. [N.E.; N.E.]	0.70	[0.48; 1.00]	0.050	0.092

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(12.9)		(17.3)					
65 - < 75 years	9/72	N.E. [30.4; N.E.]	12/53	N.E. [25.3; N.E.]	0.41	[0.16; 1.08]	0.067	0.260
	(12.5)		(22.6)					
>= 75 years	1/19	N.E. [N.E.; N.E.]	10/25	N.E. [7.3; N.E.]	0.13	[0.02; 1.07]	0.026	0.997
	(5.3)		(40.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.058)								
Imatinib	20/100	N.E. [30.4; N.E.]	19/100	N.E. [N.E.; N.E.]	1.01	[0.54; 1.90]	0.971	N.E.
	(20.0)		(19.0)					
Nilotinib	32/339	N.E. [N.E.; N.E.]	64/330	N.E. [N.E.; N.E.]	0.44	[0.29; 0.68]	<0.001	0.505
	(9.4)		(19.4)					
Dasatinib	8/41	N.E. [N.E.; N.E.]	7/42	N.E. [N.E.; N.E.]	0.98	[0.34; 2.77]	0.966	N.E.
	(19.5)		(16.7)					
Geographic region								
(Interaction test: p = 0.111)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Europe excluding Germany	21/201 (10.4)	N.E. [N.E.; N.E.]	32/201 (15.9)	N.E. [N.E.; N.E.]	0.60	[0.34; 1.05]	0.071	0.908
Germany	4/91 (4.4)	N.E. [N.E.; N.E.]	13/68 (19.1)	N.E. [N.E.; N.E.]	0.21	[0.07; 0.65]	0.003	0.021
Others	35/188 (18.6)	N.E. [N.E.; N.E.]	45/203 (22.2)	N.E. [N.E.; N.E.]	0.80	[0.52; 1.25]	0.326	0.306
Vascular disorders								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.995)								
Low	15/290 (5.2)	N.E. [N.E.; N.E.]	7/291 (2.4)	N.E. [N.E.; N.E.]	1.98	[0.81; 4.87]	0.127	0.932
Intermediate	10/129 (7.8)	N.E. [N.E.; N.E.]	4/125 (3.2)	N.E. [N.E.; N.E.]	2.26	[0.71; 7.22]	0.156	0.110
High	5/61	N.E. [N.E.; N.E.]	2/56	N.E. [N.E.; N.E.]	1.86	[0.35; 9.91]	0.462	0.999

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(8.2)		(3.6)					
Sex								
(Interaction test: p = 0.681)								
Female	11/174 (6.3)	N.E. [N.E.; N.E.]	5/198 (2.5)	N.E. [N.E.; N.E.]	2.74	[0.92; 8.16]	0.060	0.825
Male	19/306 (6.2)	N.E. [N.E.; N.E.]	8/274 (2.9)	N.E. [N.E.; N.E.]	1.83	[0.79; 4.21]	0.153	0.590
Race								
(Interaction test: p = 0.829)								
Asian	2/128 (1.6)	N.E. [N.E.; N.E.]	2/130 (1.5)	N.E. [N.E.; N.E.]	0.97	[0.13; 7.11]	0.978	N.E.
White	25/332 (7.5)	N.E. [N.E.; N.E.]	11/317 (3.5)	N.E. [N.E.; N.E.]	1.86	[0.91; 3.79]	0.084	0.620
Others	3/20 (15.0)	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	8.80	[0.27; 290.82]	0.060	1.000
Age groups								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.126)								
18 - < 65 years	16/389 (4.1)	N.E. [N.E.; N.E.]	8/394 (2.0)	N.E. [N.E.; N.E.]	1.76	[0.75; 4.14]	0.188	0.588
65 - < 75 years	7/72 (9.7)	N.E. [N.E.; N.E.]	4/53 (7.5)	N.E. [26.4; N.E.]	1.97	[0.50; 7.77]	0.325	0.829
>= 75 years	7/19 (36.8)	N.E. [5.6; N.E.]	1/25 (4.0)	N.E. [24.9; N.E.]	8.42	[1.02; 69.50]	0.019	0.996
Pre-randomization selection of TKI								
(Interaction test: p = 0.340)								
Imatinib	8/100 (8.0)	N.E. [N.E.; N.E.]	2/100 (2.0)	N.E. [N.E.; N.E.]	3.40	[0.71; 16.26]	0.104	N.E.
Nilotinib	20/339 (5.9)	N.E. [N.E.; N.E.]	8/330 (2.4)	N.E. [N.E.; N.E.]	2.29	[1.01; 5.21]	0.042	0.457
Dasatinib	2/41 (4.9)	N.E. [N.E.; N.E.]	3/42 (7.1)	N.E. [N.E.; N.E.]	0.65	[0.10; 4.12]	0.647	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Geographic region								
(Interaction test: p = 0.194)								
Europe excluding Germany	16/201	N.E. [N.E.; N.E.]	5/201	N.E. [N.E.; N.E.]	3.03	[1.11; 8.29]	0.023	0.777
	(8.0)		(2.5)					
Germany	4/91	N.E. [N.E.; N.E.]	5/68	N.E. [N.E.; N.E.]	0.81	[0.19; 3.39]	0.770	0.336
	(4.4)		(7.4)					
Others	10/188	N.E. [N.E.; N.E.]	3/203	N.E. [N.E.; N.E.]	2.97	[0.80; 11.03]	0.088	0.995
	(5.3)		(1.5)					


	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
SOC: System Organ Class
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Results on AEs differentiated by SOC or PT are only reported if the given result is statistically significant for the total population.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data and Stratification factor: ELTS based on data collected in the eCRF only the stratification variable Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variable ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Cardiac disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	0/41	3/42	0.10	0.00; 3.41	0.049
Pooled Analysis	0/41	3/42	0.10	0.00; 3.41	0.049
Imatinib					
ASC4FIRST	0/100	1/100	0.16	0.00; 14.70	0.148
Pooled Analysis	0/100	1/100	0.16	0.00; 14.70	0.148
Nilotinib					
ASC4FIRST	0/55	0/48	N.E.	N.E.; N.E.	N.E.
ASC4START	4/284	7/282	0.52	0.15; 1.77	0.287
Pooled Analysis	4/339	7/330	0.52	0.15; 1.77	0.287




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Cardiac disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	2/45	0.19	0.00; 8.57	0.159
Pooled Analysis	0/128	3/130	0.12	0.00; 3.76	0.060
Asian/Others					
ASC4FIRST	0/91	1/89	0.20	0.00; 18.10	0.192
Others					
ASC4START	0/17	0/21	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/20	0/25	N.E.	N.E.; N.E.	N.E.
White					
ASC4FIRST	0/105	3/101	0.10	0.00; 3.33	0.046
ASC4START	4/227	5/216	0.72	0.19; 2.67	0.617
Pooled Analysis	4/332	8/317	0.43	0.13; 1.44	0.159




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	32/152	32/148	0.93	0.57; 1.52	0.755
ASC4START	18/237	36/246	0.49	0.28; 0.86	0.011
Pooled Analysis	50/389	68/394	0.70	0.48; 1.00	0.050
65 - < 75 years					
ASC4FIRST	6/34	5/29	0.73	0.19; 2.79	0.646
ASC4START	3/38	7/24	0.24	0.06; 0.97	0.035
Pooled Analysis	9/72	12/53	0.41	0.16; 1.08	0.067
>= 75 years					
ASC4FIRST	1/10	5/13	0.33	0.03; 3.18	0.313
ASC4START	0/9	5/12	0.10	0.00; 2.48	0.037
Pooled Analysis	1/19	10/25	0.13	0.02; 1.07	0.026




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	6/23	7/19	0.62	0.21; 1.84	0.381
ASC4START	5/38	9/37	0.50	0.17; 1.50	0.210
Pooled Analysis	11/61	16/56	0.56	0.26; 1.20	0.131
Intermediate					
ASC4FIRST	11/54	9/52	1.11	0.46; 2.68	0.814
ASC4START	5/75	12/73	0.37	0.13; 1.06	0.054
Pooled Analysis	16/129	21/125	0.69	0.36; 1.32	0.257
Low					
ASC4FIRST	22/119	26/119	0.83	0.47; 1.47	0.513
ASC4START	11/171	27/172	0.39	0.19; 0.78	0.006
Pooled Analysis	33/290	53/291	0.60	0.39; 0.93	0.020




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	9/63	12/61	0.63	0.26; 1.53	0.299
ASC4START	12/138	20/140	0.58	0.29; 1.20	0.139
Pooled Analysis	21/201	32/201	0.60	0.34; 1.05	0.071
Germany					
ASC4FIRST	3/19	2/15	2.02	0.21; 19.75	0.539
ASC4START	1/72	11/53	0.05	0.01; 0.42	<0.001
Pooled Analysis	4/91	13/68	0.21	0.07; 0.65	0.003
Others					
ASC4FIRST	27/114	28/114	0.94	0.55; 1.59	0.798
ASC4START	8/74	17/89	0.56	0.24; 1.30	0.167
Pooled Analysis	35/188	45/203	0.80	0.52; 1.25	0.326




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	8/41	7/42	0.98	0.34; 2.77	0.966
Pooled Analysis	8/41	7/42	0.98	0.34; 2.77	0.966
Imatinib					
ASC4FIRST	20/100	19/100	1.01	0.54; 1.90	0.971
Pooled Analysis	20/100	19/100	1.01	0.54; 1.90	0.971
Nilotinib					
ASC4FIRST	11/55	16/48	0.55	0.26; 1.20	0.127
ASC4START	21/284	48/282	0.40	0.24; 0.68	<0.001
Pooled Analysis	32/339	64/330	0.44	0.29; 0.68	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	6/40	9/45	0.70	0.25; 1.97	0.491
Pooled Analysis	27/128	31/130	0.86	0.51; 1.45	0.565
Asian/Others					
ASC4FIRST	21/91	22/89	0.92	0.50; 1.68	0.772
Others					
ASC4START	1/17	5/21	0.36	0.04; 3.30	0.344
Pooled Analysis	1/20	5/25	0.36	0.04; 3.30	0.344
White					
ASC4FIRST	18/105	20/101	0.80	0.42; 1.54	0.508
ASC4START	14/227	34/216	0.37	0.20; 0.68	0.001
Pooled Analysis	32/332	54/317	0.53	0.34; 0.82	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Investigations

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	19/67	16/74	1.39	0.71; 2.73	0.342
ASC4START	6/107	27/124	0.22	0.09; 0.53	<0.001
Pooled Analysis	25/174	43/198	0.62	0.38; 1.02	0.055
Male					
ASC4FIRST	20/129	26/116	0.58	0.32; 1.05	0.069
ASC4START	15/177	21/158	0.62	0.32; 1.20	0.151
Pooled Analysis	35/306	47/274	0.60	0.38; 0.93	0.021




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Vascular disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	7/152	4/148	1.36	0.39; 4.71	0.625
ASC4START	9/237	4/246	2.18	0.67; 7.10	0.182
Pooled Analysis	16/389	8/394	1.76	0.75; 4.14	0.188
65 - < 75 years					
ASC4FIRST	4/34	2/29	2.19	0.40; 12.05	0.354
ASC4START	3/38	2/24	1.61	0.17; 15.44	0.679
Pooled Analysis	7/72	4/53	1.97	0.50; 7.77	0.325
>= 75 years					
ASC4FIRST	2/10	1/13	1.52	0.13; 17.09	0.734
ASC4START	5/9	0/12	16.42	0.68; 396.25	0.007
Pooled Analysis	7/19	1/25	8.42	1.02; 69.50	0.019




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Vascular disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	1/19	1.86	0.18; 19.25	0.597
ASC4START	2/38	1/37	1.85	0.17; 20.46	0.608
Pooled Analysis	5/61	2/56	1.86	0.35; 9.91	0.462
Intermediate					
ASC4FIRST	1/54	2/52	0.41	0.04; 4.53	0.450
ASC4START	9/75	2/73	4.17	0.90; 19.32	0.047
Pooled Analysis	10/129	4/125	2.26	0.71; 7.22	0.156
Low					
ASC4FIRST	9/119	4/119	2.05	0.63; 6.67	0.222
ASC4START	6/171	3/172	1.89	0.47; 7.58	0.358
Pooled Analysis	15/290	7/291	1.98	0.81; 4.87	0.127




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Vascular disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	4/63	1/61	4.00	0.45; 35.82	0.180
ASC4START	12/138	4/140	2.80	0.90; 8.68	0.063
Pooled Analysis	16/201	5/201	3.03	1.11; 8.29	0.023
Germany					
ASC4FIRST	1/19	3/15	0.32	0.03; 3.61	0.335
ASC4START	3/72	2/53	1.45	0.22; 9.54	0.696
Pooled Analysis	4/91	5/68	0.81	0.19; 3.39	0.770
Others					
ASC4FIRST	8/114	3/114	2.17	0.56; 8.45	0.250
ASC4START	2/74	0/89	6.46	0.16; 266.14	0.108
Pooled Analysis	10/188	3/203	2.97	0.80; 11.03	0.088




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Vascular disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	2/41	3/42	0.65	0.10; 4.12	0.647
Pooled Analysis	2/41	3/42	0.65	0.10; 4.12	0.647
Imatinib					
ASC4FIRST	8/100	2/100	3.40	0.71; 16.26	0.104
Pooled Analysis	8/100	2/100	3.40	0.71; 16.26	0.104
Nilotinib					
ASC4FIRST	3/55	2/48	1.22	0.20; 7.55	0.833
ASC4START	17/284	6/282	2.65	1.04; 6.72	0.033
Pooled Analysis	20/339	8/330	2.29	1.01; 5.21	0.042




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Vascular disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	0/45	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	2/128	2/130	0.97	0.13; 7.11	0.978
Asian/Others					
ASC4FIRST	3/91	2/89	1.36	0.22; 8.23	0.737
Others					
ASC4START	2/17	0/21	4.33	0.11; 178.67	0.188
Pooled Analysis	3/20	0/25	8.80	0.27; 290.82	0.060
White					
ASC4FIRST	10/105	5/101	1.50	0.50; 4.46	0.463
ASC4START	15/227	6/216	2.16	0.84; 5.57	0.102
Pooled Analysis	25/332	11/317	1.86	0.91; 3.79	0.084




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.5.1: Forest-Plot for AE with grade>=3 by SOC: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Vascular disorders

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	5/67	3/74	2.43	0.54; 11.00	0.236
ASC4START	6/107	2/124	3.12	0.63; 15.47	0.142
Pooled Analysis	11/174	5/198	2.74	0.92; 8.16	0.060
Male					
ASC4FIRST	8/129	4/116	1.41	0.41; 4.87	0.590
ASC4START	11/177	4/158	2.24	0.71; 7.04	0.157
Pooled Analysis	19/306	8/274	1.83	0.79; 4.21	0.153



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.6 Time to first AE with grade >=3 by PT: Time to event analysis by subgroups (Safety Analysis Set)

No subgroup analyses by PTs were performed, because there are either not enough patients with an event or there was no significant difference between asciminib and investigator selected TKI in the overall population.

.....
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.7 Time to first serious AE: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.897)								
Low	44/290 (15.2)	N.E. [N.E.; N.E.]	46/291 (15.8)	N.E. [N.E.; N.E.]	0.90	[0.60; 1.37]	0.630	0.180
Intermediate	21/129 (16.3)	N.E. [N.E.; N.E.]	22/125 (17.6)	N.E. [N.E.; N.E.]	0.79	[0.43; 1.44]	0.443	0.788
High	11/61 (18.0)	N.E. [N.E.; N.E.]	9/56 (16.1)	N.E. [N.E.; N.E.]	0.99	[0.40; 2.43]	0.974	0.664
Sex								
(Interaction test: p = 0.106)								
Female	34/174 (19.5)	N.E. [N.E.; N.E.]	30/198 (15.2)	N.E. [N.E.; N.E.]	1.27	[0.77; 2.08]	0.352	0.645

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Male	42/306 (13.7)	N.E. [N.E.; N.E.]	47/274 (17.2)	N.E. [N.E.; N.E.]	0.72	[0.47; 1.09]	0.117	0.091
Race								
(Interaction test: p = 0.020)								
Asian	14/128 (10.9)	N.E. [N.E.; N.E.]	29/130 (22.3)	N.E. [N.E.; N.E.]	0.42	[0.22; 0.80]	0.007	0.535
White	56/332 (16.9)	N.E. [N.E.; N.E.]	44/317 (13.9)	N.E. [N.E.; N.E.]	1.11	[0.75; 1.66]	0.593	0.798
Others	6/20 (30.0)	N.E. [12.6; N.E.]	4/25 (16.0)	N.E. [N.E.; N.E.]	4.34	[0.86; 22.04]	0.055	0.997
Age groups								
(Interaction test: p = 0.346)								
18 - < 65 years	53/389 (13.6)	N.E. [N.E.; N.E.]	65/394 (16.5)	N.E. [N.E.; N.E.]	0.78	[0.55; 1.13]	0.190	0.121
65 - < 75 years	16/72 (22.2)	N.E. [N.E.; N.E.]	6/53 (11.3)	N.E. [N.E.; N.E.]	1.91	[0.73; 5.04]	0.183	0.510


	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
>= 75 years	7/19 (36.8)	N.E. [12.5; N.E.]	6/25 (24.0)	N.E. [18.8; N.E.]	1.45	[0.45; 4.67]	0.528	0.695
Pre-randomization selection of TKI								
(Interaction test: p = 0.387)								
Imatinib	18/100 (18.0)	N.E. [N.E.; N.E.]	16/100 (16.0)	N.E. [29.1; N.E.]	0.89	[0.45; 1.77]	0.748	N.E.
Nilotinib	53/339 (15.6)	N.E. [N.E.; N.E.]	50/330 (15.2)	N.E. [N.E.; N.E.]	0.97	[0.66; 1.42]	0.858	0.218
Dasatinib	5/41 (12.2)	N.E. [N.E.; N.E.]	11/42 (26.2)	N.E. [N.E.; N.E.]	0.40	[0.14; 1.18]	0.086	N.E.
Geographic region								
(Interaction test: p = 0.331)								
Europe excluding Germany	26/201 (12.9)	N.E. [N.E.; N.E.]	28/201 (13.9)	N.E. [N.E.; N.E.]	0.80	[0.47; 1.39]	0.432	0.310

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Germany	18/91 (19.8)	N.E. [N.E.; N.E.]	8/68 (11.8)	N.E. [N.E.; N.E.]	1.51	[0.65; 3.50]	0.332	0.874
Others	32/188 (17.0)	N.E. [N.E.; N.E.]	41/203 (20.2)	N.E. [N.E.; N.E.]	0.78	[0.48; 1.24]	0.291	0.370

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.7 Time to first serious AE: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Race: Asian



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.7 Time to first serious AE: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Race: White



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.7 Time to first serious AE: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Race: Others



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.7.1: Forest-Plot for Serious AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	16/152	27/148	0.53	0.28; 0.99	0.042
ASC4START	37/237	38/246	0.97	0.62; 1.53	0.913
Pooled Analysis	53/389	65/394	0.78	0.55; 1.13	0.190
65 - < 75 years					
ASC4FIRST	10/34	5/29	1.55	0.50; 4.78	0.444
ASC4START	6/38	1/24	3.48	0.42; 29.08	0.221
Pooled Analysis	16/72	6/53	1.91	0.73; 5.04	0.183
>= 75 years					
ASC4FIRST	3/10	3/13	1.10	0.18; 6.67	0.921
ASC4START	4/9	3/12	1.75	0.39; 7.92	0.459
Pooled Analysis	7/19	6/25	1.45	0.45; 4.67	0.528



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.7.1: Forest-Plot for Serious AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	2/19	0.68	0.10; 4.52	0.686
ASC4START	8/38	7/37	1.09	0.40; 3.02	0.865
Pooled Analysis	11/61	9/56	0.99	0.40; 2.43	0.974
Intermediate					
ASC4FIRST	11/54	12/52	0.73	0.32; 1.67	0.456
ASC4START	10/75	10/73	0.86	0.36; 2.08	0.743
Pooled Analysis	21/129	22/125	0.79	0.43; 1.44	0.443
Low					
ASC4FIRST	15/119	21/119	0.64	0.33; 1.23	0.177
ASC4START	29/171	25/172	1.14	0.67; 1.94	0.633
Pooled Analysis	44/290	46/291	0.90	0.60; 1.37	0.630



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.7.1: Forest-Plot for Serious AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	7/63	10/61	0.52	0.19; 1.44	0.199
ASC4START	19/138	18/140	0.97	0.51; 1.85	0.921
Pooled Analysis	26/201	28/201	0.80	0.47; 1.39	0.432
Germany					
ASC4FIRST	4/19	2/15	1.34	0.24; 7.39	0.738
ASC4START	14/72	6/53	1.57	0.60; 4.12	0.356
Pooled Analysis	18/91	8/68	1.51	0.65; 3.50	0.332
Others					
ASC4FIRST	18/114	23/114	0.64	0.34; 1.21	0.165
ASC4START	14/74	18/89	0.99	0.49; 2.01	0.979
Pooled Analysis	32/188	41/203	0.78	0.48; 1.24	0.291



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.7.1: Forest-Plot for Serious AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	5/41	11/42	0.40	0.14; 1.18	0.086
Pooled Analysis	5/41	11/42	0.40	0.14; 1.18	0.086
Imatinib					
ASC4FIRST	18/100	16/100	0.89	0.45; 1.77	0.748
Pooled Analysis	18/100	16/100	0.89	0.45; 1.77	0.748
Nilotinib					
ASC4FIRST	6/55	8/48	0.52	0.18; 1.50	0.218
ASC4START	47/284	42/282	1.06	0.70; 1.61	0.773
Pooled Analysis	53/339	50/330	0.97	0.66; 1.42	0.858



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.7.1: Forest-Plot for Serious AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	5/40	10/45	0.56	0.19; 1.64	0.281
Pooled Analysis	14/128	29/130	0.42	0.22; 0.80	0.007
Asian/Others					
ASC4FIRST	10/91	20/89	0.39	0.18; 0.84	0.014
Others					
ASC4START	5/17	3/21	3.41	0.64; 18.10	0.128
Pooled Analysis	6/20	4/25	4.34	0.86; 22.04	0.055
White					
ASC4FIRST	19/105	15/101	1.03	0.52; 2.07	0.924
ASC4START	37/227	29/216	1.16	0.71; 1.88	0.559
Pooled Analysis	56/332	44/317	1.11	0.75; 1.66	0.593



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.7.1: Forest-Plot for Serious AE: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	13/67	10/74	1.49	0.64; 3.47	0.358
ASC4START	21/107	20/124	1.16	0.63; 2.15	0.631
Pooled Analysis	34/174	30/198	1.27	0.77; 2.08	0.352
Male					
ASC4FIRST	16/129	25/116	0.47	0.25; 0.90	0.020
ASC4START	26/177	22/158	1.00	0.56; 1.76	0.990
Pooled Analysis	42/306	47/274	0.72	0.47; 1.09	0.117



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.8 Time to first serious AE by SOC: Time to event analysis by subgroups (Safety Analysis Set)

No subgroup analyses by SOCs were performed, because there are either not enough patients with an event or there was no significant difference between asciminib and investigator selected TKI in the overall population.

.....
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.9 Time to first serious AE by PT: Time to event analysis by subgroups (Safety Analysis Set)

No subgroup analyses by PTs were performed, because there are not enough patients with an event.

.....
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Acute pancreatitis (clinical events)								
Race								
(Interaction test: p = 1.000)								
Asian	0/128	N.E. [N.E.; N.E.]	1/130 (0.8)	N.E. [N.E.; N.E.]	0.28	[0.00; 25.64]	0.273	N.E.
White	3/332 (0.9)	N.E. [N.E.; N.E.]	8/317 (2.5)	N.E. [N.E.; N.E.]	0.38	[0.10; 1.45]	0.144	0.159
Others	0/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Acute pancreatitis (including isolated pancreatic enzyme elevations)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.769)								
Low	40/290 (13.8)	N.E. [N.E.; N.E.]	48/291 (16.5)	N.E. [N.E.; N.E.]	0.80	[0.53; 1.22]	0.300	0.940
Intermediate	14/129 (10.9)	N.E. [N.E.; N.E.]	18/125 (14.4)	N.E. [N.E.; N.E.]	0.70	[0.35; 1.41]	0.313	0.411
High	8/61 (13.1)	N.E. [N.E.; N.E.]	6/56 (10.7)	N.E. [N.E.; N.E.]	1.07	[0.37; 3.12]	0.893	0.436
Sex								
(Interaction test: p = 0.736)								
Female	21/174 (12.1)	N.E. [N.E.; N.E.]	30/198 (15.2)	N.E. [N.E.; N.E.]	0.72	[0.41; 1.26]	0.249	0.053
Male	41/306 (13.4)	N.E. [N.E.; N.E.]	42/274 (15.3)	N.E. [30.4; N.E.]	0.82	[0.53; 1.26]	0.356	0.136

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.890)								
Asian	21/128 (16.4)	N.E. [N.E.; N.E.]	22/130 (16.9)	N.E. [N.E.; N.E.]	0.98	[0.54; 1.80]	0.943	0.302
White	39/332 (11.7)	N.E. [N.E.; N.E.]	47/317 (14.8)	N.E. [30.4; N.E.]	0.77	[0.50; 1.18]	0.224	0.519
Others	2/20 (10.0)	N.E. [N.E.; N.E.]	3/25 (12.0)	N.E. [16.6; N.E.]	0.93	[0.15; 5.84]	0.941	N.E.
Age groups								
(Interaction test: p = 0.349)								
18 - < 65 years	51/389 (13.1)	N.E. [N.E.; N.E.]	57/394 (14.5)	N.E. [N.E.; N.E.]	0.87	[0.60; 1.27]	0.468	0.734
65 - < 75 years	10/72 (13.9)	N.E. [N.E.; N.E.]	9/53 (17.0)	N.E. [N.E.; N.E.]	0.90	[0.36; 2.25]	0.817	0.217
>= 75 years	1/19 (5.3)	N.E. [N.E.; N.E.]	6/25 (24.0)	N.E. [13.8; N.E.]	0.19	[0.02; 1.54]	0.081	0.997

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.281)								
Imatinib	21/100 (21.0)	N.E. [N.E.; N.E.]	16/100 (16.0)	N.E. [N.E.; N.E.]	1.29	[0.67; 2.47]	0.445	N.E.
Nilotinib	38/339 (11.2)	N.E. [N.E.; N.E.]	52/330 (15.8)	N.E. [30.4; N.E.]	0.63	[0.42; 0.97]	0.032	0.048
Dasatinib	3/41 (7.3)	N.E. [N.E.; N.E.]	4/42 (9.5)	N.E. [N.E.; N.E.]	0.73	[0.16; 3.36]	0.681	N.E.
Geographic region								
(Interaction test: p = 0.852)								
Europe excluding Germany	22/201 (10.9)	N.E. [N.E.; N.E.]	26/201 (12.9)	N.E. [N.E.; N.E.]	0.81	[0.46; 1.45]	0.485	0.545
Germany	12/91 (13.2)	N.E. [N.E.; N.E.]	8/68 (11.8)	N.E. [N.E.; N.E.]	0.82	[0.33; 2.07]	0.679	0.325

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	28/188 (14.9)	N.E. [N.E.; N.E.]	38/203 (18.7)	N.E. [30.4; N.E.]	0.75	[0.46; 1.23]	0.251	0.781
Arterial-occlusive events (AOE)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.769)								
Low	5/290 (1.7)	N.E. [N.E.; N.E.]	4/291 (1.4)	N.E. [N.E.; N.E.]	1.13	[0.30; 4.22]	0.855	0.684
Intermediate	5/129 (3.9)	N.E. [N.E.; N.E.]	7/125 (5.6)	N.E. [N.E.; N.E.]	0.59	[0.19; 1.87]	0.367	0.353
High	1/61 (1.6)	N.E. [N.E.; N.E.]	1/56 (1.8)	N.E. [N.E.; N.E.]	0.86	[0.05; 13.79]	0.916	N.E.
Sex (Interaction test: p = 0.206)								
Female	2/174	N.E. [N.E.; N.E.]	6/198	N.E. [N.E.; N.E.]	0.37	[0.07; 1.83]	0.204	0.286

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(1.1)		(3.0)					
Male	9/306	N.E. [N.E.; N.E.]	6/274	N.E. [N.E.; N.E.]	1.13	[0.40; 3.20]	0.812	0.561
	(2.9)		(2.2)					
Race								
(Interaction test: p = 0.995)								
Asian	3/128	N.E. [N.E.; N.E.]	4/130	N.E. [N.E.; N.E.]	0.66	[0.14; 3.14]	0.602	0.982
	(2.3)		(3.1)					
White	7/332	N.E. [N.E.; N.E.]	8/317	N.E. [N.E.; N.E.]	0.72	[0.26; 2.00]	0.529	0.991
	(2.1)		(2.5)					
Others	1/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	2.48	[0.03; 245.03]	0.378	N.E.
	(5.0)							
Age groups								
(Interaction test: p = 0.830)								
18 - < 65 years	5/389	N.E. [N.E.; N.E.]	7/394	N.E. [N.E.; N.E.]	0.66	[0.21; 2.09]	0.477	0.402
	(1.3)		(1.8)					
65 - < 75 years	3/72	N.E. [N.E.; N.E.]	2/53	N.E. [26.4; N.E.]	1.38	[0.14; 13.33]	0.781	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(4.2)		(3.8)					
>= 75 years	3/19	N.E. [N.E.; N.E.]	3/25	N.E. [N.E.; N.E.]	0.97	[0.19; 4.97]	0.973	0.675
	(15.8)		(12.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.921)								
Imatinib	2/100	N.E. [N.E.; N.E.]	0/100	N.E. [N.E.; N.E.]	4.26	[0.10; 180.00]	0.195	N.E.
	(2.0)							
Nilotinib	8/339	N.E. [N.E.; N.E.]	11/330	N.E. [N.E.; N.E.]	0.61	[0.24; 1.52]	0.284	0.967
	(2.4)		(3.3)					
Dasatinib	1/41	N.E. [N.E.; N.E.]	1/42	N.E. [N.E.; N.E.]	1.04	[0.06; 16.60]	0.979	N.E.
	(2.4)		(2.4)					
Geographic region								
(Interaction test: p = 0.901)								
Europe excluding Germany	4/201	N.E. [N.E.; N.E.]	5/201	N.E. [N.E.; N.E.]	0.69	[0.18; 2.59]	0.579	0.994

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(2.0)		(2.5)					
Germany	2/91	N.E. [N.E.; N.E.]	2/68	N.E. [N.E.; N.E.]	0.96	[0.13; 7.24]	0.967	N.E.
	(2.2)		(2.9)					
Others	5/188	N.E. [N.E.; N.E.]	5/203	N.E. [N.E.; N.E.]	0.97	[0.28; 3.41]	0.961	0.760
	(2.7)		(2.5)					
Edema and fluid retention								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.219)								
Low	14/290	N.E. [N.E.; N.E.]	24/291	N.E. [N.E.; N.E.]	0.55	[0.29; 1.07]	0.073	0.227
	(4.8)		(8.2)					
Intermediate	4/129	N.E. [N.E.; N.E.]	14/125	N.E. [N.E.; N.E.]	0.25	[0.08; 0.76]	0.008	0.712
	(3.1)		(11.2)					
High	1/61	N.E. [N.E.; N.E.]	7/56	N.E. [29.2; N.E.]	0.10	[0.01; 0.85]	0.010	0.995
	(1.6)		(12.5)					

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.343)								
Female	8/174 (4.6)	N.E. [N.E.; N.E.]	27/198 (13.6)	N.E. [N.E.; N.E.]	0.32	[0.14; 0.70]	0.003	0.046
Male	11/306 (3.6)	N.E. [N.E.; N.E.]	18/274 (6.6)	N.E. [N.E.; N.E.]	0.49	[0.23; 1.03]	0.056	0.850
Race								
(Interaction test: p = 0.154)								
Asian	3/128 (2.3)	N.E. [N.E.; N.E.]	17/130 (13.1)	N.E. [N.E.; N.E.]	0.16	[0.05; 0.57]	0.001	0.992
White	16/332 (4.8)	N.E. [N.E.; N.E.]	24/317 (7.6)	N.E. [N.E.; N.E.]	0.61	[0.32; 1.16]	0.132	0.294
Others	0/20	N.E. [N.E.; N.E.]	4/25 (16.0)	N.E. [N.E.; N.E.]	0.20	[0.01; 6.89]	0.158	1.000
Age groups								
(Interaction test: p = 0.404)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	15/389 (3.9)	N.E. [N.E.; N.E.]	30/394 (7.6)	N.E. [N.E.; N.E.]	0.47	[0.25; 0.88]	0.016	0.376
65 - < 75 years	2/72 (2.8)	N.E. [N.E.; N.E.]	7/53 (13.2)	N.E. [N.E.; N.E.]	0.19	[0.04; 1.00]	0.033	0.996
>= 75 years	2/19 (10.5)	N.E. [N.E.; N.E.]	8/25 (32.0)	N.E. [3.9; N.E.]	0.27	[0.06; 1.34]	0.088	0.996
Pre-randomization selection of TKI								
(Interaction test: p = 0.197)								
Imatinib	3/100 (3.0)	N.E. [N.E.; N.E.]	15/100 (15.0)	N.E. [N.E.; N.E.]	0.18	[0.05; 0.61]	0.002	N.E.
Nilotinib	13/339 (3.8)	N.E. [N.E.; N.E.]	21/330 (6.4)	N.E. [N.E.; N.E.]	0.58	[0.29; 1.16]	0.119	0.595
Dasatinib	3/41 (7.3)	N.E. [N.E.; N.E.]	9/42 (21.4)	N.E. [N.E.; N.E.]	0.30	[0.08; 1.14]	0.063	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.045)								
Europe excluding Germany	1/201 (0.5)	N.E. [N.E.; N.E.]	13/201 (6.5)	N.E. [N.E.; N.E.]	0.08	[0.01; 0.59]	0.001	0.993
Germany	8/91 (8.8)	N.E. [N.E.; N.E.]	5/68 (7.4)	N.E. [N.E.; N.E.]	1.02	[0.33; 3.18]	0.967	0.994
Others	10/188 (5.3)	N.E. [N.E.; N.E.]	27/203 (13.3)	N.E. [N.E.; N.E.]	0.35	[0.17; 0.73]	0.004	0.876
Gastrointestinal toxicity								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.380)								
Low	99/290 (34.1)	N.E. [N.E.; N.E.]	109/291 (37.5)	N.E. [N.E.; N.E.]	0.85	[0.65; 1.11]	0.238	0.058
Intermediate	42/129 (32.6)	N.E. [N.E.; N.E.]	41/125 (32.8)	N.E. [N.E.; N.E.]	0.95	[0.62; 1.46]	0.810	0.399

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
High	21/61 (34.4)	N.E. [16.6; N.E.]	14/56 (25.0)	N.E. [N.E.; N.E.]	1.38	[0.70; 2.73]	0.342	0.473
Sex								
(Interaction test: p = 0.434)								
Female	63/174 (36.2)	N.E. [N.E.; N.E.]	80/198 (40.4)	N.E. [N.E.; N.E.]	0.88	[0.63; 1.24]	0.481	0.400
Male	99/306 (32.4)	N.E. [N.E.; N.E.]	84/274 (30.7)	N.E. [N.E.; N.E.]	0.99	[0.74; 1.33]	0.961	0.194
Race								
(Interaction test: p = 0.524)								
Asian	38/128 (29.7)	N.E. [N.E.; N.E.]	44/130 (33.8)	N.E. [N.E.; N.E.]	0.80	[0.52; 1.24]	0.316	0.502
White	118/332 (35.5)	N.E. [N.E.; N.E.]	109/317 (34.4)	N.E. [N.E.; N.E.]	0.99	[0.76; 1.29]	0.966	0.083
Others	6/20 (30.0)	N.E. [10.2; N.E.]	11/25 (44.0)	N.E. [0.5; N.E.]	0.77	[0.24; 2.42]	0.616	0.381

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Age groups								
(Interaction test: p = 0.518)								
18 - < 65 years	130/389 (33.4)	N.E. [N.E.; N.E.]	133/394 (33.8)	N.E. [N.E.; N.E.]	0.94	[0.74; 1.20]	0.620	0.081
65 - < 75 years	22/72 (30.6)	N.E. [N.E.; N.E.]	14/53 (26.4)	N.E. [N.E.; N.E.]	1.10	[0.55; 2.18]	0.793	0.673
>= 75 years	10/19 (52.6)	18.9 [0.4; N.E.]	17/25 (68.0)	1.3 [0.2; 12.7]	0.71	[0.31; 1.65]	0.437	0.711
Pre-randomization selection of TKI								
(Interaction test: p = 0.163)								
Imatinib	34/100 (34.0)	N.E. [N.E.; N.E.]	43/100 (43.0)	N.E. [5.4; N.E.]	0.64	[0.41; 1.00]	0.053	N.E.
Nilotinib	106/339 (31.3)	N.E. [N.E.; N.E.]	98/330 (29.7)	N.E. [N.E.; N.E.]	1.02	[0.78; 1.35]	0.859	0.264
Dasatinib	22/41	8.7 [1.0; N.E.]	23/42	9.8 [2.9; N.E.]	1.05	[0.58; 1.92]	0.874	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(53.7)		(54.8)					
Geographic region								
(Interaction test: p = 0.132)								
Europe excluding Germany	62/201	N.E. [N.E.; N.E.]	65/201	N.E. [N.E.; N.E.]	0.88	[0.62; 1.25]	0.480	0.033
	(30.8)		(32.3)					
Germany	32/91	N.E. [19.4; N.E.]	17/68	N.E. [N.E.; N.E.]	1.72	[0.92; 3.20]	0.084	0.149
	(35.2)		(25.0)					
Others	68/188	N.E. [N.E.; N.E.]	82/203	N.E. [19.3; N.E.]	0.81	[0.58; 1.12]	0.193	0.901
	(36.2)		(40.4)					
Hemorrhage								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.653)								
Low	16/290	N.E. [N.E.; N.E.]	24/291	N.E. [N.E.; N.E.]	0.63	[0.34; 1.19]	0.152	0.478
	(5.5)		(8.2)					

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Intermediate	11/129 (8.5)	N.E. [N.E.; N.E.]	10/125 (8.0)	N.E. [N.E.; N.E.]	0.89	[0.37; 2.09]	0.782	0.358
High	3/61 (4.9)	N.E. [N.E.; N.E.]	5/56 (8.9)	N.E. [N.E.; N.E.]	0.53	[0.13; 2.20]	0.372	N.E.
Sex								
(Interaction test: p = 0.026)								
Female	21/174 (12.1)	N.E. [N.E.; N.E.]	19/198 (9.6)	N.E. [N.E.; N.E.]	1.14	[0.61; 2.13]	0.671	0.135
Male	9/306 (2.9)	N.E. [N.E.; N.E.]	20/274 (7.3)	N.E. [N.E.; N.E.]	0.35	[0.16; 0.77]	0.006	0.910
Race								
(Interaction test: p = 0.272)								
Asian	5/128 (3.9)	N.E. [N.E.; N.E.]	11/130 (8.5)	N.E. [N.E.; N.E.]	0.39	[0.13; 1.15]	0.079	0.730
White	22/332 (6.6)	N.E. [N.E.; N.E.]	26/317 (8.2)	N.E. [N.E.; N.E.]	0.76	[0.43; 1.34]	0.333	0.735

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	3/20 (15.0)	N.E. [N.E.; N.E.]	2/25 (8.0)	N.E. [N.E.; N.E.]	5.09	[0.48; 54.08]	0.144	N.E.
Age groups (Interaction test: p = 0.512)								
18 - < 65 years	23/389 (5.9)	N.E. [N.E.; N.E.]	30/394 (7.6)	N.E. [N.E.; N.E.]	0.71	[0.41; 1.23]	0.221	0.958
65 - < 75 years	5/72 (6.9)	N.E. [N.E.; N.E.]	9/53 (17.0)	N.E. [N.E.; N.E.]	0.37	[0.12; 1.12]	0.069	0.114
>= 75 years	2/19 (10.5)	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	2.92	[0.07; 121.64]	0.281	N.E.
Pre-randomization selection of TKI (Interaction test: p = 0.315)								
Imatinib	6/100 (6.0)	N.E. [N.E.; N.E.]	10/100 (10.0)	N.E. [N.E.; N.E.]	0.52	[0.19; 1.43]	0.198	N.E.
Nilotinib	22/339	N.E. [N.E.; N.E.]	22/330	N.E. [N.E.; N.E.]	0.91	[0.50; 1.64]	0.750	0.550

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(6.5)		(6.7)					
Dasatinib	2/41	N.E. [N.E.; N.E.]	7/42	N.E. [N.E.; N.E.]	0.27	[0.06; 1.34]	0.087	N.E.
	(4.9)		(16.7)					
Geographic region								
(Interaction test: p = 0.348)								
Europe excluding Germany	8/201	N.E. [N.E.; N.E.]	17/201	N.E. [N.E.; N.E.]	0.42	[0.18; 0.98]	0.040	0.308
	(4.0)		(8.5)					
Germany	5/91	N.E. [N.E.; N.E.]	4/68	N.E. [N.E.; N.E.]	0.95	[0.25; 3.59]	0.941	0.880
	(5.5)		(5.9)					
Others	17/188	N.E. [N.E.; N.E.]	18/203	N.E. [N.E.; N.E.]	0.95	[0.48; 1.85]	0.870	0.521
	(9.0)		(8.9)					
Hepatotoxicity (clinical events)								
Stratification factor: ELTS based on randomization data from IRT								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 1.000)								
Low	10/290 (3.4)	N.E. [N.E.; N.E.]	12/291 (4.1)	N.E. [N.E.; N.E.]	0.80	[0.34; 1.85]	0.596	0.492
Intermediate	4/129 (3.1)	N.E. [N.E.; N.E.]	0/125	N.E. [N.E.; N.E.]	6.81	[0.26; 180.38]	0.083	1.000
High	0/61	N.E. [N.E.; N.E.]	6/56 (10.7)	N.E. [N.E.; N.E.]	0.07	[0.00; 1.54]	0.010	1.000
Sex								
(Interaction test: p = 0.080)								
Female	2/174 (1.1)	N.E. [N.E.; N.E.]	9/198 (4.5)	N.E. [N.E.; N.E.]	0.23	[0.05; 1.09]	0.044	0.995
Male	12/306 (3.9)	N.E. [N.E.; N.E.]	9/274 (3.3)	N.E. [N.E.; N.E.]	1.09	[0.46; 2.60]	0.845	0.153
Race								
(Interaction test: p = 0.892)								
Asian	7/128	N.E. [N.E.; N.E.]	11/130	N.E. [N.E.; N.E.]	0.63	[0.24; 1.66]	0.352	0.160

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(5.5)		(8.5)					
White	7/332	N.E. [N.E.; N.E.]	7/317	N.E. [N.E.; N.E.]	0.92	[0.32; 2.62]	0.872	0.511
	(2.1)		(2.2)					
Others	0/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Age groups								
(Interaction test: p = 0.980)								
18 - < 65 years	12/389	N.E. [N.E.; N.E.]	15/394	N.E. [N.E.; N.E.]	0.78	[0.36; 1.66]	0.515	0.133
	(3.1)		(3.8)					
65 - < 75 years	2/72	N.E. [N.E.; N.E.]	2/53	N.E. [N.E.; N.E.]	0.72	[0.10; 5.39]	0.751	0.931
	(2.8)		(3.8)					
>= 75 years	0/19	N.E. [N.E.; N.E.]	1/25	N.E. [N.E.; N.E.]	0.53	[0.01; 51.67]	0.439	N.E.
			(4.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.384)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Imatinib	3/100 (3.0)	N.E. [N.E.; N.E.]	1/100 (1.0)	N.E. [N.E.; N.E.]	2.46	[0.25; 23.90]	0.424	N.E.
Nilotinib	9/339 (2.7)	N.E. [N.E.; N.E.]	17/330 (5.2)	N.E. [N.E.; N.E.]	0.49	[0.22; 1.10]	0.079	0.868
Dasatinib	2/41 (4.9)	N.E. [N.E.; N.E.]	0/42	N.E. [N.E.; N.E.]	5.50	[0.13; 227.65]	0.138	N.E.
Geographic region (Interaction test: p = 0.840)								
Europe excluding Germany	7/201 (3.5)	N.E. [N.E.; N.E.]	6/201 (3.0)	N.E. [N.E.; N.E.]	1.14	[0.38; 3.40]	0.818	0.615
Germany	0/91	N.E. [N.E.; N.E.]	1/68 (1.5)	N.E. [N.E.; N.E.]	0.24	[0.00; 21.52]	0.232	N.E.
Others	7/188 (3.7)	N.E. [N.E.; N.E.]	11/203 (5.4)	N.E. [N.E.; N.E.]	0.68	[0.26; 1.78]	0.432	0.199

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Hepatotoxicity (including laboratory terms)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.999)								
Low	47/290 (16.2)	N.E. [N.E.; N.E.]	88/291 (30.2)	N.E. [N.E.; N.E.]	0.47	[0.33; 0.67]	<0.001	0.292
Intermediate	16/129 (12.4)	N.E. [30.5; N.E.]	29/125 (23.2)	N.E. [N.E.; N.E.]	0.46	[0.25; 0.85]	0.011	0.023
High	12/61 (19.7)	N.E. [N.E.; N.E.]	20/56 (35.7)	N.E. [11.3; N.E.]	0.48	[0.23; 0.98]	0.042	0.307
Sex								
(Interaction test: p = 0.969)								
Female	29/174 (16.7)	N.E. [N.E.; N.E.]	60/198 (30.3)	N.E. [N.E.; N.E.]	0.46	[0.29; 0.72]	<0.001	0.430
Male	46/306	N.E. [N.E.; N.E.]	77/274	N.E. [N.E.; N.E.]	0.46	[0.32; 0.66]	<0.001	0.048

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(15.0)		(28.1)					
Race								
(Interaction test: p = 0.285)								
Asian	34/128	N.E. [30.5; N.E.]	53/130	N.E. [13.8; N.E.]	0.56	[0.36; 0.87]	0.009	0.621
	(26.6)		(40.8)					
White	40/332	N.E. [N.E.; N.E.]	75/317	N.E. [N.E.; N.E.]	0.44	[0.30; 0.65]	<0.001	0.043
	(12.0)		(23.7)					
Others	1/20	N.E. [N.E.; N.E.]	9/25	N.E. [11.0; N.E.]	0.13	[0.02; 1.03]	0.023	N.E.
	(5.0)		(36.0)					
Age groups								
(Interaction test: p = 0.449)								
18 - < 65 years	62/389	N.E. [N.E.; N.E.]	116/394	N.E. [N.E.; N.E.]	0.48	[0.35; 0.66]	<0.001	0.040
	(15.9)		(29.4)					
65 - < 75 years	12/72	N.E. [N.E.; N.E.]	13/53	N.E. [N.E.; N.E.]	0.58	[0.26; 1.30]	0.191	0.182
	(16.7)		(24.5)					
>= 75 years	1/19	N.E. [N.E.; N.E.]	8/25	N.E. [11.3; N.E.]	0.14	[0.02; 1.17]	0.030	0.997

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(5.3)		(32.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.024)								
Imatinib	21/100	N.E. [30.5; N.E.]	21/100	N.E. [N.E.; N.E.]	0.93	[0.51; 1.71]	0.824	N.E.
	(21.0)		(21.0)					
Nilotinib	46/339	N.E. [N.E.; N.E.]	105/330	N.E. [N.E.; N.E.]	0.36	[0.26; 0.51]	<0.001	0.628
	(13.6)		(31.8)					
Dasatinib	8/41	N.E. [N.E.; N.E.]	11/42	N.E. [N.E.; N.E.]	0.61	[0.24; 1.55]	0.295	N.E.
	(19.5)		(26.2)					
Geographic region								
(Interaction test: p = 0.289)								
Europe excluding Germany	24/201	N.E. [N.E.; N.E.]	36/201	N.E. [N.E.; N.E.]	0.57	[0.34; 0.97]	0.036	0.180
	(11.9)		(17.9)					
Germany	12/91	N.E. [N.E.; N.E.]	24/68	N.E. [N.E.; N.E.]	0.31	[0.15; 0.62]	<0.001	0.598

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(13.2)		(35.3)					
Others	39/188	N.E. [N.E.; N.E.]	77/203	N.E. [N.E.; N.E.]	0.47	[0.32; 0.70]	<0.001	0.062
	(20.7)		(37.9)					
Hypersensitivity								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.296)								
Low	64/290	N.E. [N.E.; N.E.]	109/291	N.E. [N.E.; N.E.]	0.49	[0.36; 0.66]	<0.001	0.555
	(22.1)		(37.5)					
Intermediate	31/129	N.E. [N.E.; N.E.]	37/125	N.E. [N.E.; N.E.]	0.66	[0.41; 1.06]	0.084	0.856
	(24.0)		(29.6)					
High	7/61	N.E. [N.E.; N.E.]	16/56	N.E. [24.9; N.E.]	0.33	[0.13; 0.80]	0.010	0.768
	(11.5)		(28.6)					
Sex								
(Interaction test: p = 0.007)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Female	36/174 (20.7)	N.E. [N.E.; N.E.]	86/198 (43.4)	N.E. [10.8; N.E.]	0.35	[0.24; 0.52]	<0.001	0.624
Male	66/306 (21.6)	N.E. [N.E.; N.E.]	76/274 (27.7)	N.E. [N.E.; N.E.]	0.69	[0.50; 0.96]	0.028	0.660
Race								
(Interaction test: p = 0.562)								
Asian	35/128 (27.3)	N.E. [N.E.; N.E.]	54/130 (41.5)	N.E. [14.8; N.E.]	0.50	[0.32; 0.77]	0.001	0.208
White	61/332 (18.4)	N.E. [N.E.; N.E.]	100/317 (31.5)	N.E. [N.E.; N.E.]	0.49	[0.36; 0.68]	<0.001	0.290
Others	6/20 (30.0)	N.E. [3.5; N.E.]	8/25 (32.0)	N.E. [1.7; N.E.]	1.46	[0.46; 4.64]	0.519	0.981
Age groups								
(Interaction test: p = 0.028)								
18 - < 65 years	89/389 (22.9)	N.E. [N.E.; N.E.]	129/394 (32.7)	N.E. [N.E.; N.E.]	0.60	[0.45; 0.78]	<0.001	0.607

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
65 - < 75 years	10/72 (13.9)	N.E. [N.E.; N.E.]	23/53 (43.4)	N.E. [2.8; N.E.]	0.24	[0.11; 0.51]	<0.001	0.315
>= 75 years	3/19 (15.8)	N.E. [N.E.; N.E.]	10/25 (40.0)	N.E. [1.0; N.E.]	0.32	[0.08; 1.21]	0.078	0.329
Pre-randomization selection of TKI								
(Interaction test: p = 0.584)								
Imatinib	23/100 (23.0)	N.E. [N.E.; N.E.]	43/100 (43.0)	N.E. [5.6; N.E.]	0.41	[0.24; 0.68]	<0.001	N.E.
Nilotinib	68/339 (20.1)	N.E. [N.E.; N.E.]	100/330 (30.3)	N.E. [N.E.; N.E.]	0.54	[0.40; 0.74]	<0.001	0.995
Dasatinib	11/41 (26.8)	N.E. [N.E.; N.E.]	19/42 (45.2)	N.E. [9.8; N.E.]	0.56	[0.26; 1.20]	0.134	N.E.
Geographic region								
(Interaction test: p = 0.532)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Europe excluding Germany	30/201 (14.9)	N.E. [N.E.; N.E.]	60/201 (29.9)	N.E. [N.E.; N.E.]	0.42	[0.27; 0.66]	<0.001	0.348
Germany	17/91 (18.7)	N.E. [N.E.; N.E.]	20/68 (29.4)	N.E. [N.E.; N.E.]	0.59	[0.30; 1.14]	0.115	0.932
Others	55/188 (29.3)	N.E. [N.E.; N.E.]	82/203 (40.4)	N.E. [16.7; N.E.]	0.58	[0.41; 0.81]	0.002	0.777
Ischemic heart and CNS conditions								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.272)								
Low	9/290 (3.1)	N.E. [N.E.; N.E.]	18/291 (6.2)	N.E. [N.E.; N.E.]	0.47	[0.21; 1.04]	0.056	0.526
Intermediate	14/129 (10.9)	N.E. [N.E.; N.E.]	11/125 (8.8)	N.E. [N.E.; N.E.]	1.12	[0.51; 2.48]	0.771	0.081

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
High	3/61 (4.9)	N.E. [N.E.; N.E.]	2/56 (3.6)	N.E. [N.E.; N.E.]	1.33	[0.22; 7.95]	0.755	0.996
Sex								
(Interaction test: p = 0.175)								
Female	4/174 (2.3)	N.E. [N.E.; N.E.]	11/198 (5.6)	N.E. [N.E.; N.E.]	0.38	[0.12; 1.20]	0.086	0.349
Male	22/306 (7.2)	N.E. [N.E.; N.E.]	20/274 (7.3)	N.E. [N.E.; N.E.]	0.91	[0.49; 1.67]	0.755	0.582
Race								
(Interaction test: p = 0.678)								
Asian	10/128 (7.8)	N.E. [N.E.; N.E.]	11/130 (8.5)	N.E. [N.E.; N.E.]	0.77	[0.32; 1.85]	0.562	0.700
White	14/332 (4.2)	N.E. [N.E.; N.E.]	19/317 (6.0)	N.E. [N.E.; N.E.]	0.67	[0.33; 1.34]	0.253	0.227
Others	2/20 (10.0)	N.E. [N.E.; N.E.]	1/25 (4.0)	N.E. [N.E.; N.E.]	2.31	[0.20; 26.79]	0.491	0.998

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Age groups								
(Interaction test: p = 0.815)								
18 - < 65 years	18/389 (4.6)	N.E. [N.E.; N.E.]	24/394 (6.1)	N.E. [N.E.; N.E.]	0.72	[0.39; 1.32]	0.285	0.379
65 - < 75 years	4/72 (5.6)	N.E. [N.E.; N.E.]	2/53 (3.8)	N.E. [N.E.; N.E.]	1.11	[0.20; 6.15]	0.908	0.740
>= 75 years	4/19 (21.1)	N.E. [N.E.; N.E.]	5/25 (20.0)	N.E. [N.E.; N.E.]	0.76	[0.20; 2.88]	0.689	0.448
Pre-randomization selection of TKI								
(Interaction test: p = 0.881)								
Imatinib	7/100 (7.0)	N.E. [N.E.; N.E.]	7/100 (7.0)	N.E. [N.E.; N.E.]	0.91	[0.32; 2.59]	0.855	N.E.
Nilotinib	15/339 (4.4)	N.E. [N.E.; N.E.]	19/330 (5.8)	N.E. [N.E.; N.E.]	0.68	[0.35; 1.35]	0.272	0.391
Dasatinib	4/41	N.E. [N.E.; N.E.]	5/42	N.E. [N.E.; N.E.]	0.83	[0.22; 3.16]	0.780	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(9.8)		(11.9)					
Geographic region								
(Interaction test: p = 0.271)								
Europe excluding Germany	10/201	N.E. [N.E.; N.E.]	6/201	N.E. [N.E.; N.E.]	1.49	[0.53; 4.15]	0.445	0.196
	(5.0)		(3.0)					
Germany	4/91	N.E. [N.E.; N.E.]	6/68	N.E. [N.E.; N.E.]	0.54	[0.15; 1.94]	0.325	0.981
	(4.4)		(8.8)					
Others	12/188	N.E. [N.E.; N.E.]	19/203	N.E. [N.E.; N.E.]	0.61	[0.29; 1.25]	0.173	0.603
	(6.4)		(9.4)					
Myelosuppression (Erythropenia)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.262)								
Low	27/290	N.E. [N.E.; N.E.]	42/291	N.E. [N.E.; N.E.]	0.62	[0.38; 1.01]	0.051	0.233

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(9.3)		(14.4)					
Intermediate	18/129	N.E. [N.E.; N.E.]	19/125	N.E. [N.E.; N.E.]	0.89	[0.46; 1.69]	0.716	0.439
	(14.0)		(15.2)					
High	6/61	N.E. [N.E.; N.E.]	13/56	N.E. [22.9; N.E.]	0.34	[0.13; 0.89]	0.022	0.023
	(9.8)		(23.2)					
Sex								
(Interaction test: p = 0.734)								
Female	23/174	N.E. [N.E.; N.E.]	40/198	N.E. [N.E.; N.E.]	0.64	[0.38; 1.08]	0.090	0.005
	(13.2)		(20.2)					
Male	28/306	N.E. [N.E.; N.E.]	34/274	N.E. [N.E.; N.E.]	0.72	[0.43; 1.19]	0.198	0.954
	(9.2)		(12.4)					
Race								
(Interaction test: p = 0.877)								
Asian	23/128	N.E. [N.E.; N.E.]	31/130	N.E. [N.E.; N.E.]	0.68	[0.39; 1.17]	0.167	0.718
	(18.0)		(23.8)					
White	24/332	N.E. [N.E.; N.E.]	37/317	N.E. [N.E.; N.E.]	0.59	[0.35; 0.99]	0.045	0.007

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(7.2)		(11.7)					
Others	4/20	N.E. [13.8; N.E.]	6/25	N.E. [N.E.; N.E.]	1.09	[0.28; 4.21]	0.910	N.E.
	(20.0)		(24.0)					
Age groups								
(Interaction test: p = 0.549)								
18 - < 65 years	44/389	N.E. [N.E.; N.E.]	59/394	N.E. [N.E.; N.E.]	0.71	[0.48; 1.04]	0.080	0.083
	(11.3)		(15.0)					
65 - < 75 years	5/72	N.E. [N.E.; N.E.]	8/53	N.E. [N.E.; N.E.]	0.61	[0.20; 1.89]	0.384	0.435
	(6.9)		(15.1)					
>= 75 years	2/19	29.1 [N.E.; N.E.]	7/25	N.E. [5.6; N.E.]	0.22	[0.03; 1.85]	0.124	N.E.
	(10.5)		(28.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.002)								
Imatinib	11/100	N.E. [N.E.; N.E.]	26/100	N.E. [N.E.; N.E.]	0.40	[0.20; 0.81]	0.009	N.E.
	(11.0)		(26.0)					

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Nilotinib	37/339 (10.9)	N.E. [N.E.; N.E.]	32/330 (9.7)	N.E. [N.E.; N.E.]	1.08	[0.67; 1.74]	0.749	0.620
Dasatinib	3/41 (7.3)	N.E. [N.E.; N.E.]	16/42 (38.1)	N.E. [5.6; N.E.]	0.11	[0.03; 0.40]	<0.001	N.E.
Geographic region (Interaction test: p = 0.478)								
Europe excluding Germany	15/201 (7.5)	N.E. [N.E.; N.E.]	23/201 (11.4)	N.E. [N.E.; N.E.]	0.64	[0.33; 1.24]	0.184	0.007
Germany	3/91 (3.3)	N.E. [N.E.; N.E.]	7/68 (10.3)	N.E. [N.E.; N.E.]	0.35	[0.09; 1.43]	0.128	0.590
Others	33/188 (17.6)	N.E. [N.E.; N.E.]	44/203 (21.7)	N.E. [N.E.; N.E.]	0.76	[0.48; 1.19]	0.234	0.359
Myelosuppression (Leukopenia)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.579)								
Low	63/290 (21.7)	N.E. [N.E.; N.E.]	68/291 (23.4)	N.E. [N.E.; N.E.]	0.93	[0.66; 1.30]	0.662	0.274
Intermediate	30/129 (23.3)	N.E. [N.E.; N.E.]	27/125 (21.6)	N.E. [N.E.; N.E.]	1.09	[0.65; 1.83]	0.745	0.531
High	14/61 (23.0)	N.E. [N.E.; N.E.]	16/56 (28.6)	N.E. [N.E.; N.E.]	0.75	[0.37; 1.55]	0.434	0.094
Sex								
(Interaction test: p = 0.921)								
Female	41/174 (23.6)	N.E. [N.E.; N.E.]	49/198 (24.7)	N.E. [N.E.; N.E.]	0.91	[0.59; 1.38]	0.629	0.255
Male	66/306 (21.6)	N.E. [N.E.; N.E.]	62/274 (22.6)	N.E. [N.E.; N.E.]	0.98	[0.69; 1.38]	0.902	0.375

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.741)								
Asian	45/128 (35.2)	N.E. [N.E.; N.E.]	48/130 (36.9)	N.E. [N.E.; N.E.]	0.87	[0.58; 1.32]	0.516	0.760
White	53/332 (16.0)	N.E. [N.E.; N.E.]	55/317 (17.4)	N.E. [N.E.; N.E.]	0.95	[0.65; 1.39]	0.773	0.144
Others	9/20 (45.0)	N.E. [2.8; N.E.]	8/25 (32.0)	N.E. [5.6; N.E.]	2.22	[0.77; 6.38]	0.104	N.E.
Age groups								
(Interaction test: p = 0.311)								
18 - < 65 years	90/389 (23.1)	N.E. [N.E.; N.E.]	89/394 (22.6)	N.E. [N.E.; N.E.]	1.02	[0.76; 1.36]	0.899	0.156
65 - < 75 years	12/72 (16.7)	N.E. [N.E.; N.E.]	16/53 (30.2)	N.E. [N.E.; N.E.]	0.48	[0.21; 1.09]	0.062	0.968
>= 75 years	5/19 (26.3)	N.E. [2.3; N.E.]	6/25 (24.0)	N.E. [N.E.; N.E.]	1.26	[0.34; 4.71]	0.732	0.996

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.084)								
Imatinib	31/100 (31.0)	N.E. [N.E.; N.E.]	38/100 (38.0)	N.E. [N.E.; N.E.]	0.80	[0.50; 1.28]	0.343	N.E.
Nilotinib	66/339 (19.5)	N.E. [N.E.; N.E.]	52/330 (15.8)	N.E. [N.E.; N.E.]	1.21	[0.84; 1.74]	0.298	0.855
Dasatinib	10/41 (24.4)	N.E. [N.E.; N.E.]	21/42 (50.0)	24.8 [2.7; N.E.]	0.49	[0.23; 1.07]	0.068	N.E.
Geographic region								
(Interaction test: p = 0.319)								
Europe excluding Germany	30/201 (14.9)	N.E. [N.E.; N.E.]	24/201 (11.9)	N.E. [N.E.; N.E.]	1.35	[0.79; 2.32]	0.276	0.202
Germany	15/91 (16.5)	N.E. [N.E.; N.E.]	15/68 (22.1)	N.E. [N.E.; N.E.]	0.83	[0.39; 1.76]	0.633	0.932

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	62/188 (33.0)	N.E. [N.E.; N.E.]	72/203 (35.5)	N.E. [N.E.; N.E.]	0.89	[0.63; 1.25]	0.518	0.194
Myelosuppression (Thrombocytopenia)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.890)								
Low	52/290 (17.9)	N.E. [N.E.; N.E.]	54/291 (18.6)	N.E. [N.E.; N.E.]	0.97	[0.66; 1.41]	0.860	0.626
Intermediate	37/129 (28.7)	N.E. [N.E.; N.E.]	33/125 (26.4)	N.E. [N.E.; N.E.]	1.14	[0.71; 1.83]	0.542	0.461
High	24/61 (39.3)	N.E. [2.8; N.E.]	20/56 (35.7)	N.E. [2.8; N.E.]	1.05	[0.58; 1.91]	0.872	0.060
Sex (Interaction test: p = 0.127)								
Female	40/174	N.E. [N.E.; N.E.]	34/198	N.E. [N.E.; N.E.]	1.34	[0.84; 2.12]	0.217	0.690

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(23.0)		(17.2)					
Male	73/306	N.E. [N.E.; N.E.]	73/274	N.E. [N.E.; N.E.]	0.89	[0.64; 1.23]	0.496	0.134
	(23.9)		(26.6)					
Race								
(Interaction test: p = 0.978)								
Asian	46/128	N.E. [N.E.; N.E.]	45/130	N.E. [N.E.; N.E.]	1.06	[0.70; 1.61]	0.805	0.960
	(35.9)		(34.6)					
White	62/332	N.E. [N.E.; N.E.]	57/317	N.E. [N.E.; N.E.]	1.03	[0.72; 1.48]	0.873	0.036
	(18.7)		(18.0)					
Others	5/20	N.E. [1.2; N.E.]	5/25	N.E. [N.E.; N.E.]	2.00	[0.51; 7.79]	0.275	N.E.
	(25.0)		(20.0)					
Age groups								
(Interaction test: p = 0.469)								
18 - < 65 years	97/389	N.E. [N.E.; N.E.]	90/394	N.E. [N.E.; N.E.]	1.11	[0.83; 1.47]	0.480	0.241
	(24.9)		(22.8)					
65 - < 75 years	12/72	N.E. [N.E.; N.E.]	13/53	N.E. [N.E.; N.E.]	0.70	[0.31; 1.56]	0.394	0.897

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(16.7)		(24.5)					
>= 75 years	4/19	N.E. [N.E.; N.E.]	4/25	N.E. [N.E.; N.E.]	2.33	[0.43; 12.74]	0.316	0.996
	(21.1)		(16.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.300)								
Imatinib	26/100	N.E. [N.E.; N.E.]	29/100	N.E. [N.E.; N.E.]	0.90	[0.53; 1.53]	0.702	N.E.
	(26.0)		(29.0)					
Nilotinib	76/339	N.E. [N.E.; N.E.]	62/330	N.E. [N.E.; N.E.]	1.20	[0.86; 1.68]	0.284	0.458
	(22.4)		(18.8)					
Dasatinib	11/41	N.E. [N.E.; N.E.]	16/42	N.E. [2.3; N.E.]	0.61	[0.28; 1.35]	0.231	N.E.
	(26.8)		(38.1)					
Geographic region								
(Interaction test: p = 0.157)								
Europe excluding Germany	30/201	N.E. [N.E.; N.E.]	21/201	N.E. [N.E.; N.E.]	1.41	[0.80; 2.48]	0.224	0.172

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(14.9)		(10.4)					
Germany	17/91	N.E. [N.E.; N.E.]	21/68	N.E. [N.E.; N.E.]	0.59	[0.31; 1.13]	0.115	0.041
	(18.7)		(30.9)					
Others	66/188	N.E. [N.E.; N.E.]	65/203	N.E. [N.E.; N.E.]	1.13	[0.80; 1.60]	0.484	0.678
	(35.1)		(32.0)					
QTc prolongation								
Sex								
(Interaction test: p = 0.856)								
Female	2/174	N.E. [N.E.; N.E.]	3/198	N.E. [N.E.; N.E.]	0.72	[0.12; 4.34]	0.723	N.E.
	(1.1)		(1.5)					
Male	7/306	N.E. [N.E.; N.E.]	7/274	N.E. [N.E.; N.E.]	0.68	[0.23; 1.97]	0.477	0.695
	(2.3)		(2.6)					
Race								
(Interaction test: p = 0.980)								
Asian	1/128	N.E. [N.E.; N.E.]	1/130	N.E. [N.E.; N.E.]	1.26	[0.08; 20.93]	0.871	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(0.8)		(0.8)					
White	8/332	N.E. [N.E.; N.E.]	8/317	N.E. [N.E.; N.E.]	0.83	[0.31; 2.26]	0.722	0.776
	(2.4)		(2.5)					
Others	0/20	N.E. [N.E.; N.E.]	1/25	N.E. [N.E.; N.E.]	0.64	[0.01; 62.05]	0.480	N.E.
			(4.0)					
Age groups								
(Interaction test: p = 0.898)								
18 - < 65 years	5/389	N.E. [N.E.; N.E.]	6/394	N.E. [N.E.; N.E.]	0.81	[0.25; 2.65]	0.729	0.785
	(1.3)		(1.5)					
65 - < 75 years	4/72	N.E. [N.E.; N.E.]	3/53	N.E. [N.E.; N.E.]	0.57	[0.11; 2.89]	0.496	0.996
	(5.6)		(5.7)					
>= 75 years	0/19	N.E. [N.E.; N.E.]	1/25	N.E. [N.E.; N.E.]	0.39	[0.00; 37.18]	0.361	N.E.
			(4.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.771)								


	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Imatinib	1/100 (1.0)	N.E. [N.E.; N.E.]	0/100	N.E. [N.E.; N.E.]	3.09	[0.03; 283.80]	0.310	N.E.
Nilotinib	7/339 (2.1)	N.E. [N.E.; N.E.]	8/330 (2.4)	N.E. [N.E.; N.E.]	0.86	[0.31; 2.39]	0.777	0.800
Dasatinib	1/41 (2.4)	N.E. [N.E.; N.E.]	2/42 (4.8)	N.E. [N.E.; N.E.]	0.30	[0.02; 3.82]	0.340	N.E.
Geographic region (Interaction test: p = 0.586)								
Europe excluding Germany	3/201 (1.5)	N.E. [N.E.; N.E.]	4/201 (2.0)	N.E. [N.E.; N.E.]	0.63	[0.13; 3.07]	0.561	0.918
Germany	0/91	N.E. [N.E.; N.E.]	2/68 (2.9)	N.E. [N.E.; N.E.]	0.11	[0.00; 4.80]	0.063	1.000
Others	6/188 (3.2)	N.E. [N.E.; N.E.]	4/203 (2.0)	N.E. [N.E.; N.E.]	1.84	[0.52; 6.57]	0.339	0.973

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Edema and fluid retention: Geographic region: Europe excluding Germany




Pts at Risk (censored)

Asciminib	201 (0)	192 (8)	174 (26)	117 (83)	67 (133)	11 (189)	0 (200)
Investigator Selected TKI	201 (0)	172 (21)	149 (43)	81 (109)	42 (147)	4 (184)	0 (188)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Edema and fluid retention: Geographic region: Germany




Pts at Risk (censored)

Asciminib	91 (0)	82 (6)	77 (10)	52 (33)	26 (57)	8 (75)	0 (83)
Investigator Selected TKI	68 (0)	60 (6)	54 (12)	34 (29)	20 (43)	3 (60)	0 (63)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Edema and fluid retention: Geographic region: Others




Pts at Risk (censored)

Asciminib	188 (0)	164 (16)	147 (32)	111 (68)	80 (99)	21 (158)	0 (178)
Investigator Selected TKI	203 (0)	161 (20)	140 (41)	108 (71)	66 (111)	13 (163)	0 (176)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Hemorrhage: Sex: Female




Pts at Risk (censored)

Asciminib	174 (0)	153 (10)	133 (24)	92 (62)	52 (102)	17 (136)	0 (153)
Investigator Selected TKI	198 (0)	173 (18)	141 (44)	84 (95)	50 (129)	8 (171)	0 (179)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Hemorrhage: Sex: Male



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Hepatotoxicity (including laboratory terms): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	100 (0)	83 (4)	75 (8)	69 (11)	51 (29)	11 (69)	0 (79)
Investigator Selected TKI	100 (0)	72 (11)	62 (19)	50 (31)	31 (48)	4 (75)	0 (79)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Hepatotoxicity (including laboratory terms): Pre-randomization selection of TKI: Nilotinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Hepatotoxicity (including laboratory terms): Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Hypersensitivity: Sex: Female




Pts at Risk (censored)

Asciminib	174 (0)	137 (12)	117 (24)	78 (61)	44 (94)	14 (124)	0 (138)
Investigator Selected TKI	198 (0)	104 (17)	79 (37)	46 (67)	28 (85)	4 (108)	0 (112)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Hypersensitivity: Sex: Male




Pts at Risk (censored)

Asciminib	306 (0)	246 (15)	213 (36)	141 (103)	87 (154)	18 (222)	0 (240)
Investigator Selected TKI	274 (0)	185 (28)	153 (49)	100 (98)	54 (144)	5 (193)	0 (198)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Hypersensitivity: Age groups: 18 - < 65 years




Pts at Risk (censored)

Asciminib	389 (0)	307 (21)	261 (50)	167 (138)	101 (200)	24 (276)	0 (300)
Investigator Selected TKI	394 (0)	254 (33)	204 (68)	126 (140)	72 (194)	8 (257)	0 (265)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Hypersensitivity: Age groups: 65 - < 75 years



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Hypersensitivity: Age groups: >= 75 years



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Myelosuppression (Erythropenia): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	100 (0)	83 (7)	79 (11)	76 (14)	55 (34)	11 (78)	0 (89)
Investigator Selected TKI	100 (0)	64 (11)	55 (20)	42 (32)	27 (47)	2 (72)	0 (74)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Myelosuppression (Erythropenia): Pre-randomization selection of TKI: Nilotinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10 Time to first AESI all grades: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Myelosuppression (Erythropenia): Pre-randomization selection of TKI: Dasatinib




Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	1/45	0.28	0.00; 25.64	0.273
Pooled Analysis	0/128	1/130	0.28	0.00; 25.64	0.273
Asian/Others					
ASC4FIRST	0/91	0/89	N.E.	N.E.; N.E.	N.E.
Others					
ASC4START	0/17	0/21	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/20	0/25	N.E.	N.E.; N.E.	N.E.
White					
ASC4FIRST	2/105	2/101	1.23	0.17; 8.80	0.834
ASC4START	1/227	6/216	0.15	0.02; 1.29	0.047
Pooled Analysis	3/332	8/317	0.38	0.10; 1.45	0.144




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	20/152	23/148	0.80	0.44; 1.47	0.469
ASC4START	31/237	34/246	0.92	0.56; 1.49	0.728
Pooled Analysis	51/389	57/394	0.87	0.60; 1.27	0.468
65 - < 75 years					
ASC4FIRST	8/34	6/29	1.27	0.43; 3.70	0.663
ASC4START	2/38	3/24	0.34	0.06; 2.06	0.218
Pooled Analysis	10/72	9/53	0.90	0.36; 2.25	0.817
>= 75 years					
ASC4FIRST	1/10	3/13	0.35	0.04; 3.33	0.336
ASC4START	0/9	3/12	0.18	0.01; 5.39	0.119
Pooled Analysis	1/19	6/25	0.19	0.02; 1.54	0.081




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	3/19	0.66	0.13; 3.30	0.606
ASC4START	5/38	3/37	1.55	0.37; 6.49	0.545
Pooled Analysis	8/61	6/56	1.07	0.37; 3.12	0.893
Intermediate					
ASC4FIRST	9/54	9/52	0.90	0.36; 2.28	0.833
ASC4START	5/75	9/73	0.50	0.17; 1.48	0.199
Pooled Analysis	14/129	18/125	0.70	0.35; 1.41	0.313
Low					
ASC4FIRST	17/119	20/119	0.82	0.43; 1.56	0.538
ASC4START	23/171	28/172	0.79	0.46; 1.37	0.402
Pooled Analysis	40/290	48/291	0.80	0.53; 1.22	0.300




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	8/63	8/61	1.06	0.38; 2.95	0.913
ASC4START	14/138	18/140	0.72	0.36; 1.45	0.359
Pooled Analysis	22/201	26/201	0.81	0.46; 1.45	0.485
Germany					
ASC4FIRST	2/19	2/15	0.27	0.02; 3.04	0.259
ASC4START	10/72	6/53	1.02	0.37; 2.85	0.970
Pooled Analysis	12/91	8/68	0.82	0.33; 2.07	0.679
Others					
ASC4FIRST	19/114	22/114	0.79	0.43; 1.47	0.456
ASC4START	9/74	16/89	0.68	0.30; 1.56	0.362
Pooled Analysis	28/188	38/203	0.75	0.46; 1.23	0.251




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	3/41	4/42	0.73	0.16; 3.36	0.681
Pooled Analysis	3/41	4/42	0.73	0.16; 3.36	0.681
Imatinib					
ASC4FIRST	21/100	16/100	1.29	0.67; 2.47	0.445
Pooled Analysis	21/100	16/100	1.29	0.67; 2.47	0.445
Nilotinib					
ASC4FIRST	5/55	12/48	0.24	0.08; 0.70	0.005
ASC4START	33/284	40/282	0.78	0.49; 1.24	0.289
Pooled Analysis	38/339	52/330	0.63	0.42; 0.97	0.032




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	7/40	6/45	1.59	0.53; 4.76	0.406
Pooled Analysis	21/128	22/130	0.98	0.54; 1.80	0.943
Asian/Others					
ASC4FIRST	14/91	16/89	0.82	0.40; 1.70	0.587
Others					
ASC4START	2/17	3/21	0.93	0.15; 5.84	0.941
Pooled Analysis	2/20	3/25	0.93	0.15; 5.84	0.941
White					
ASC4FIRST	15/105	16/101	0.93	0.45; 1.91	0.838
ASC4START	24/227	31/216	0.69	0.41; 1.18	0.173
Pooled Analysis	39/332	47/317	0.77	0.50; 1.18	0.224




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	13/67	10/74	1.32	0.58; 3.01	0.505
ASC4START	8/107	20/124	0.42	0.18; 0.95	0.031
Pooled Analysis	21/174	30/198	0.72	0.41; 1.26	0.249
Male					
ASC4FIRST	16/129	22/116	0.56	0.29; 1.09	0.082
ASC4START	25/177	20/158	1.10	0.61; 1.98	0.747
Pooled Analysis	41/306	42/274	0.82	0.53; 1.26	0.356




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arterial-occlusive events (AOE)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	2/152	1/148	1.60	0.14; 17.93	0.699
ASC4START	3/237	6/246	0.49	0.12; 1.95	0.299
Pooled Analysis	5/389	7/394	0.66	0.21; 2.09	0.477
65 - < 75 years					
ASC4FIRST	0/34	0/29	N.E.	N.E.; N.E.	N.E.
ASC4START	3/38	2/24	1.38	0.14; 13.33	0.781
Pooled Analysis	3/72	2/53	1.38	0.14; 13.33	0.781
>= 75 years					
ASC4FIRST	2/10	1/13	1.41	0.12; 15.84	0.782
ASC4START	1/9	2/12	0.68	0.06; 7.50	0.748
Pooled Analysis	3/19	3/25	0.97	0.19; 4.97	0.973




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arterial-occlusive events (AOE)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	0/23	0/19	N.E.	N.E.; N.E.	N.E.
ASC4START	1/38	1/37	0.86	0.05; 13.79	0.916
Pooled Analysis	1/61	1/56	0.86	0.05; 13.79	0.916
Intermediate					
ASC4FIRST	2/54	1/52	1.57	0.14; 17.44	0.709
ASC4START	3/75	6/73	0.42	0.11; 1.69	0.210
Pooled Analysis	5/129	7/125	0.59	0.19; 1.87	0.367
Low					
ASC4FIRST	2/119	1/119	1.70	0.15; 18.96	0.662
ASC4START	3/171	3/172	0.93	0.19; 4.63	0.933
Pooled Analysis	5/290	4/291	1.13	0.30; 4.22	0.855




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arterial-occlusive events (AOE)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	2/63	0/61	5.10	0.12; 211.57	0.154
ASC4START	2/138	5/140	0.33	0.06; 1.70	0.161
Pooled Analysis	4/201	5/201	0.69	0.18; 2.59	0.579
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	2/72	2/53	0.96	0.13; 7.24	0.967
Pooled Analysis	2/91	2/68	0.96	0.13; 7.24	0.967
Others					
ASC4FIRST	2/114	2/114	0.76	0.11; 5.47	0.789
ASC4START	3/74	3/89	1.14	0.22; 5.77	0.875
Pooled Analysis	5/188	5/203	0.97	0.28; 3.41	0.961




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arterial-occlusive events (AOE)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	1/41	1/42	1.04	0.06; 16.60	0.979
Pooled Analysis	1/41	1/42	1.04	0.06; 16.60	0.979
Imatinib					
ASC4FIRST	2/100	0/100	4.26	0.10; 180.00	0.195
Pooled Analysis	2/100	0/100	4.26	0.10; 180.00	0.195
Nilotinib					
ASC4FIRST	1/55	1/48	0.58	0.04; 9.35	0.695
ASC4START	7/284	10/282	0.61	0.23; 1.61	0.318
Pooled Analysis	8/339	11/330	0.61	0.24; 1.52	0.284




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arterial-occlusive events (AOE)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	1/40	2/45	0.68	0.06; 8.26	0.760
Pooled Analysis	3/128	4/130	0.66	0.14; 3.14	0.602
Asian/Others					
ASC4FIRST	2/91	2/89	0.64	0.09; 4.70	0.662
Others					
ASC4START	1/17	0/21	2.48	0.03; 245.03	0.378
Pooled Analysis	1/20	0/25	2.48	0.03; 245.03	0.378
White					
ASC4FIRST	2/105	0/101	4.84	0.12; 200.94	0.165
ASC4START	5/227	8/216	0.50	0.16; 1.54	0.220
Pooled Analysis	7/332	8/317	0.72	0.26; 2.00	0.529




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arterial-occlusive events (AOE)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	1/67	1/74	1.41	0.08; 23.57	0.808
ASC4START	1/107	5/124	0.21	0.02; 1.77	0.111
Pooled Analysis	2/174	6/198	0.37	0.07; 1.83	0.204
Male					
ASC4FIRST	3/129	1/116	2.02	0.21; 19.56	0.535
ASC4START	6/177	5/158	0.95	0.29; 3.11	0.927
Pooled Analysis	9/306	6/274	1.13	0.40; 3.20	0.812




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	6/152	15/148	0.35	0.13; 0.90	0.022
ASC4START	9/237	15/246	0.61	0.27; 1.40	0.243
Pooled Analysis	15/389	30/394	0.47	0.25; 0.88	0.016
65 - < 75 years					
ASC4FIRST	1/34	7/29	0.12	0.01; 1.00	0.021
ASC4START	1/38	0/24	0.52	0.01; 45.81	0.670
Pooled Analysis	2/72	7/53	0.19	0.04; 1.00	0.033
>= 75 years					
ASC4FIRST	2/10	5/13	0.43	0.08; 2.37	0.317
ASC4START	0/9	3/12	0.18	0.01; 5.51	0.123
Pooled Analysis	2/19	8/25	0.27	0.06; 1.34	0.088




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	5/19	0.14	0.02; 1.19	0.034
ASC4START	0/38	2/37	0.18	0.00; 7.31	0.133
Pooled Analysis	1/61	7/56	0.10	0.01; 0.85	0.010
Intermediate					
ASC4FIRST	3/54	9/52	0.29	0.08; 1.06	0.047
ASC4START	1/75	5/73	0.18	0.02; 1.53	0.076
Pooled Analysis	4/129	14/125	0.25	0.08; 0.76	0.008
Low					
ASC4FIRST	5/119	13/119	0.35	0.12; 0.98	0.036
ASC4START	9/171	11/172	0.80	0.33; 1.94	0.627
Pooled Analysis	14/290	24/291	0.55	0.29; 1.07	0.073




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	1/63	9/61	0.11	0.01; 0.87	0.011
ASC4START	0/138	4/140	0.12	0.00; 3.09	0.052
Pooled Analysis	1/201	13/201	0.08	0.01; 0.59	0.001
Germany					
ASC4FIRST	1/19	0/15	2.11	0.02; 207.43	0.414
ASC4START	7/72	5/53	0.89	0.28; 2.85	0.844
Pooled Analysis	8/91	5/68	1.02	0.33; 3.18	0.967
Others					
ASC4FIRST	7/114	18/114	0.34	0.14; 0.82	0.011
ASC4START	3/74	9/89	0.39	0.10; 1.43	0.140
Pooled Analysis	10/188	27/203	0.35	0.17; 0.73	0.004




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	3/41	9/42	0.30	0.08; 1.14	0.063
Pooled Analysis	3/41	9/42	0.30	0.08; 1.14	0.063
Imatinib					
ASC4FIRST	3/100	15/100	0.18	0.05; 0.61	0.002
Pooled Analysis	3/100	15/100	0.18	0.05; 0.61	0.002
Nilotinib					
ASC4FIRST	3/55	3/48	0.86	0.17; 4.33	0.856
ASC4START	10/284	18/282	0.53	0.24; 1.15	0.103
Pooled Analysis	13/339	21/330	0.58	0.29; 1.16	0.119




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	5/45	0.09	0.00; 2.31	0.030
Pooled Analysis	3/128	17/130	0.16	0.05; 0.57	0.001
Asian/Others					
ASC4FIRST	3/91	14/89	0.19	0.05; 0.66	0.004
Others					
ASC4START	0/17	2/21	0.25	0.01; 11.81	0.219
Pooled Analysis	0/20	4/25	0.20	0.01; 6.89	0.158
White					
ASC4FIRST	6/105	13/101	0.42	0.16; 1.12	0.074
ASC4START	10/227	11/216	0.84	0.36; 1.98	0.695
Pooled Analysis	16/332	24/317	0.61	0.32; 1.16	0.132




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	1/67	15/74	0.07	0.01; 0.51	<0.001
ASC4START	7/107	12/124	0.65	0.26; 1.65	0.362
Pooled Analysis	8/174	27/198	0.32	0.14; 0.70	0.003
Male					
ASC4FIRST	8/129	12/116	0.51	0.21; 1.26	0.138
ASC4START	3/177	6/158	0.43	0.11; 1.74	0.224
Pooled Analysis	11/306	18/274	0.49	0.23; 1.03	0.056




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	59/152	68/148	0.75	0.53; 1.07	0.109
ASC4START	71/237	65/246	1.16	0.83; 1.62	0.396
Pooled Analysis	130/389	133/394	0.94	0.74; 1.20	0.620
65 - < 75 years					
ASC4FIRST	11/34	9/29	0.96	0.39; 2.40	0.935
ASC4START	11/38	5/24	1.30	0.45; 3.81	0.625
Pooled Analysis	22/72	14/53	1.10	0.55; 2.18	0.793
>= 75 years					
ASC4FIRST	7/10	10/13	0.81	0.28; 2.35	0.710
ASC4START	3/9	7/12	0.58	0.14; 2.34	0.439
Pooled Analysis	10/19	17/25	0.71	0.31; 1.65	0.437




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	12/23	6/19	1.79	0.67; 4.79	0.243
ASC4START	9/38	8/37	1.08	0.42; 2.80	0.868
Pooled Analysis	21/61	14/56	1.38	0.70; 2.73	0.342
Intermediate					
ASC4FIRST	21/54	23/52	0.80	0.44; 1.44	0.451
ASC4START	21/75	18/73	1.15	0.62; 2.17	0.656
Pooled Analysis	42/129	41/125	0.95	0.62; 1.46	0.810
Low					
ASC4FIRST	44/119	58/119	0.65	0.44; 0.96	0.029
ASC4START	55/171	51/172	1.10	0.75; 1.61	0.632
Pooled Analysis	99/290	109/291	0.85	0.65; 1.11	0.238




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	22/63	31/61	0.55	0.32; 0.96	0.036
ASC4START	40/138	34/140	1.21	0.76; 1.91	0.414
Pooled Analysis	62/201	65/201	0.88	0.62; 1.25	0.480
Germany					
ASC4FIRST	8/19	4/15	4.67	0.98; 22.18	0.033
ASC4START	24/72	13/53	1.34	0.68; 2.64	0.407
Pooled Analysis	32/91	17/68	1.72	0.92; 3.20	0.084
Others					
ASC4FIRST	47/114	52/114	0.79	0.53; 1.18	0.259
ASC4START	21/74	30/89	0.83	0.47; 1.45	0.509
Pooled Analysis	68/188	82/203	0.81	0.58; 1.12	0.193




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	22/41	23/42	1.05	0.58; 1.92	0.874
Pooled Analysis	22/41	23/42	1.05	0.58; 1.92	0.874
Imatinib					
ASC4FIRST	34/100	43/100	0.64	0.41; 1.00	0.053
Pooled Analysis	34/100	43/100	0.64	0.41; 1.00	0.053
Nilotinib					
ASC4FIRST	21/55	21/48	0.75	0.41; 1.38	0.358
ASC4START	85/284	77/282	1.11	0.81; 1.51	0.510
Pooled Analysis	106/339	98/330	1.02	0.78; 1.35	0.859




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	12/40	14/45	1.00	0.46; 2.17	0.994
Pooled Analysis	38/128	44/130	0.80	0.52; 1.24	0.316
Asian/Others					
ASC4FIRST	28/91	33/89	0.73	0.44; 1.21	0.215
Others					
ASC4START	4/17	8/21	0.63	0.18; 2.19	0.466
Pooled Analysis	6/20	11/25	0.77	0.24; 2.42	0.616
White					
ASC4FIRST	49/105	54/101	0.77	0.52; 1.14	0.185
ASC4START	69/227	55/216	1.22	0.86; 1.74	0.263
Pooled Analysis	118/332	109/317	0.99	0.76; 1.29	0.966




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	29/67	41/74	0.76	0.46; 1.24	0.277
ASC4START	34/107	39/124	1.01	0.64; 1.60	0.960
Pooled Analysis	63/174	80/198	0.88	0.63; 1.24	0.481
Male					
ASC4FIRST	48/129	46/116	0.82	0.55; 1.23	0.344
ASC4START	51/177	38/158	1.21	0.79; 1.84	0.375
Pooled Analysis	99/306	84/274	0.99	0.74; 1.33	0.961




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	10/152	13/148	0.70	0.31; 1.60	0.398
ASC4START	13/237	17/246	0.72	0.35; 1.49	0.376
Pooled Analysis	23/389	30/394	0.71	0.41; 1.23	0.221
65 - < 75 years					
ASC4FIRST	1/34	7/29	0.11	0.01; 0.94	0.017
ASC4START	4/38	2/24	1.01	0.18; 5.52	0.992
Pooled Analysis	5/72	9/53	0.37	0.12; 1.12	0.069
>= 75 years					
ASC4FIRST	2/10	0/13	2.92	0.07; 121.64	0.281
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	2/19	0/25	2.92	0.07; 121.64	0.281




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	0/23	0/19	N.E.	N.E.; N.E.	N.E.
ASC4START	3/38	5/37	0.53	0.13; 2.20	0.372
Pooled Analysis	3/61	5/56	0.53	0.13; 2.20	0.372
Intermediate					
ASC4FIRST	6/54	7/52	0.64	0.21; 1.93	0.426
ASC4START	5/75	3/73	1.50	0.36; 6.27	0.578
Pooled Analysis	11/129	10/125	0.89	0.37; 2.09	0.782
Low					
ASC4FIRST	7/119	13/119	0.50	0.20; 1.25	0.132
ASC4START	9/171	11/172	0.79	0.33; 1.91	0.605
Pooled Analysis	16/290	24/291	0.63	0.34; 1.19	0.152




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	2/63	8/61	0.23	0.05; 1.07	0.041
ASC4START	6/138	9/140	0.60	0.21; 1.69	0.327
Pooled Analysis	8/201	17/201	0.42	0.18; 0.98	0.040
Germany					
ASC4FIRST	1/19	1/15	0.79	0.05; 12.65	0.868
ASC4START	4/72	3/53	1.01	0.22; 4.57	0.995
Pooled Analysis	5/91	4/68	0.95	0.25; 3.59	0.941
Others					
ASC4FIRST	10/114	11/114	0.79	0.34; 1.87	0.596
ASC4START	7/74	7/89	1.24	0.43; 3.60	0.690
Pooled Analysis	17/188	18/203	0.95	0.48; 1.85	0.870




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	2/41	7/42	0.27	0.06; 1.34	0.087
Pooled Analysis	2/41	7/42	0.27	0.06; 1.34	0.087
Imatinib					
ASC4FIRST	6/100	10/100	0.52	0.19; 1.43	0.198
Pooled Analysis	6/100	10/100	0.52	0.19; 1.43	0.198
Nilotinib					
ASC4FIRST	5/55	3/48	1.35	0.32; 5.65	0.682
ASC4START	17/284	19/282	0.83	0.43; 1.61	0.586
Pooled Analysis	22/339	22/330	0.91	0.50; 1.64	0.750




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	1/40	4/45	0.28	0.03; 2.55	0.231
Pooled Analysis	5/128	11/130	0.39	0.13; 1.15	0.079
Asian/Others					
ASC4FIRST	4/91	8/89	0.40	0.12; 1.36	0.129
Others					
ASC4START	3/17	1/21	5.09	0.48; 54.08	0.144
Pooled Analysis	3/20	2/25	5.09	0.48; 54.08	0.144
White					
ASC4FIRST	9/105	12/101	0.67	0.28; 1.61	0.373
ASC4START	13/227	14/216	0.82	0.39; 1.75	0.613
Pooled Analysis	22/332	26/317	0.76	0.43; 1.34	0.333




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	9/67	12/74	0.73	0.31; 1.72	0.465
ASC4START	12/107	7/124	1.91	0.75; 4.86	0.166
Pooled Analysis	21/174	19/198	1.14	0.61; 2.13	0.671
Male					
ASC4FIRST	4/129	8/116	0.37	0.11; 1.23	0.092
ASC4START	5/177	12/158	0.34	0.12; 0.96	0.032
Pooled Analysis	9/306	20/274	0.35	0.16; 0.77	0.006




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	6/152	3/148	1.84	0.46; 7.38	0.382
ASC4START	6/237	12/246	0.50	0.19; 1.33	0.158
Pooled Analysis	12/389	15/394	0.78	0.36; 1.66	0.515
65 - < 75 years					
ASC4FIRST	1/34	1/29	0.79	0.05; 13.60	0.871
ASC4START	1/38	1/24	0.66	0.04; 11.22	0.773
Pooled Analysis	2/72	2/53	0.72	0.10; 5.39	0.751
>= 75 years					
ASC4FIRST	0/10	0/13	N.E.	N.E.; N.E.	N.E.
ASC4START	0/9	1/12	0.53	0.01; 51.67	0.439
Pooled Analysis	0/19	1/25	0.53	0.01; 51.67	0.439



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	2/63	1/61	1.96	0.17; 22.08	0.579
ASC4START	5/138	5/140	0.98	0.28; 3.38	0.968
Pooled Analysis	7/201	6/201	1.14	0.38; 3.40	0.818
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	0/72	1/53	0.24	0.00; 21.52	0.232
Pooled Analysis	0/91	1/68	0.24	0.00; 21.52	0.232
Others					
ASC4FIRST	5/114	3/114	1.36	0.32; 5.80	0.673
ASC4START	2/74	8/89	0.34	0.07; 1.60	0.153
Pooled Analysis	7/188	11/203	0.68	0.26; 1.78	0.432




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	2/41	0/42	5.50	0.13; 227.65	0.138
Pooled Analysis	2/41	0/42	5.50	0.13; 227.65	0.138
Imatinib					
ASC4FIRST	3/100	1/100	2.46	0.25; 23.90	0.424
Pooled Analysis	3/100	1/100	2.46	0.25; 23.90	0.424
Nilotinib					
ASC4FIRST	2/55	3/48	0.56	0.09; 3.43	0.528
ASC4START	7/284	14/282	0.48	0.19; 1.18	0.100
Pooled Analysis	9/339	17/330	0.49	0.22; 1.10	0.079




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	2/40	8/45	0.30	0.06; 1.41	0.106
Pooled Analysis	7/128	11/130	0.63	0.24; 1.66	0.352
Asian/Others					
ASC4FIRST	5/91	3/89	1.36	0.32; 5.91	0.676
Others					
ASC4START	0/17	0/21	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/20	0/25	N.E.	N.E.; N.E.	N.E.
White					
ASC4FIRST	2/105	1/101	1.88	0.17; 21.00	0.603
ASC4START	5/227	6/216	0.76	0.23; 2.50	0.651
Pooled Analysis	7/332	7/317	0.92	0.32; 2.62	0.872




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	0/67	2/74	0.21	0.01; 8.63	0.167
ASC4START	2/107	7/124	0.30	0.06; 1.46	0.115
Pooled Analysis	2/174	9/198	0.23	0.05; 1.09	0.044
Male					
ASC4FIRST	7/129	2/116	2.61	0.54; 12.66	0.216
ASC4START	5/177	7/158	0.63	0.20; 1.99	0.426
Pooled Analysis	12/306	9/274	1.09	0.46; 2.60	0.845




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	33/152	43/148	0.69	0.44; 1.09	0.116
ASC4START	29/237	73/246	0.36	0.23; 0.55	<0.001
Pooled Analysis	62/389	116/394	0.48	0.35; 0.66	<0.001
65 - < 75 years					
ASC4FIRST	7/34	6/29	0.97	0.32; 2.92	0.956
ASC4START	5/38	7/24	0.32	0.10; 1.06	0.056
Pooled Analysis	12/72	13/53	0.58	0.26; 1.30	0.191
>= 75 years					
ASC4FIRST	0/10	2/13	0.33	0.00; 30.79	0.317
ASC4START	1/9	6/12	0.17	0.02; 1.40	0.052
Pooled Analysis	1/19	8/25	0.14	0.02; 1.17	0.030




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	6/23	6/19	0.76	0.25; 2.37	0.649
ASC4START	6/38	14/37	0.35	0.14; 0.92	0.026
Pooled Analysis	12/61	20/56	0.48	0.23; 0.98	0.042
Intermediate					
ASC4FIRST	11/54	10/52	0.96	0.41; 2.27	0.935
ASC4START	5/75	19/73	0.21	0.08; 0.57	<0.001
Pooled Analysis	16/129	29/125	0.46	0.25; 0.85	0.011
Low					
ASC4FIRST	23/119	35/119	0.58	0.34; 0.99	0.043
ASC4START	24/171	53/172	0.40	0.24; 0.64	<0.001
Pooled Analysis	47/290	88/291	0.47	0.33; 0.67	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	8/63	5/61	1.17	0.36; 3.75	0.796
ASC4START	16/138	31/140	0.47	0.26; 0.87	0.014
Pooled Analysis	24/201	36/201	0.57	0.34; 0.97	0.036
Germany					
ASC4FIRST	2/19	4/15	0.48	0.08; 2.93	0.421
ASC4START	10/72	20/53	0.29	0.13; 0.62	<0.001
Pooled Analysis	12/91	24/68	0.31	0.15; 0.62	<0.001
Others					
ASC4FIRST	30/114	42/114	0.62	0.39; 0.99	0.048
ASC4START	9/74	35/89	0.27	0.13; 0.56	<0.001
Pooled Analysis	39/188	77/203	0.47	0.32; 0.70	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	8/41	11/42	0.61	0.24; 1.55	0.295
Pooled Analysis	8/41	11/42	0.61	0.24; 1.55	0.295
Imatinib					
ASC4FIRST	21/100	21/100	0.93	0.51; 1.71	0.824
Pooled Analysis	21/100	21/100	0.93	0.51; 1.71	0.824
Nilotinib					
ASC4FIRST	11/55	19/48	0.43	0.20; 0.90	0.023
ASC4START	35/284	86/282	0.35	0.23; 0.51	<0.001
Pooled Analysis	46/339	105/330	0.36	0.26; 0.51	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	8/40	17/45	0.47	0.20; 1.09	0.070
Pooled Analysis	34/128	53/130	0.56	0.36; 0.87	0.009
Asian/Others					
ASC4FIRST	26/91	37/89	0.60	0.36; 1.00	0.051
Others					
ASC4START	1/17	8/21	0.13	0.02; 1.03	0.023
Pooled Analysis	1/20	9/25	0.13	0.02; 1.03	0.023
White					
ASC4FIRST	14/105	14/101	0.88	0.41; 1.87	0.739
ASC4START	26/227	61/216	0.35	0.22; 0.56	<0.001
Pooled Analysis	40/332	75/317	0.44	0.30; 0.65	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	11/67	18/74	0.59	0.28; 1.28	0.179
ASC4START	18/107	42/124	0.41	0.23; 0.71	<0.001
Pooled Analysis	29/174	60/198	0.46	0.29; 0.72	<0.001
Male					
ASC4FIRST	29/129	33/116	0.66	0.40; 1.10	0.111
ASC4START	17/177	44/158	0.31	0.18; 0.54	<0.001
Pooled Analysis	46/306	77/274	0.46	0.32; 0.66	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	45/152	58/148	0.64	0.43; 0.95	0.026
ASC4START	44/237	71/246	0.56	0.38; 0.81	0.002
Pooled Analysis	89/389	129/394	0.60	0.45; 0.78	<0.001
65 - < 75 years					
ASC4FIRST	5/34	17/29	0.17	0.06; 0.48	<0.001
ASC4START	5/38	6/24	0.38	0.12; 1.27	0.104
Pooled Analysis	10/72	23/53	0.24	0.11; 0.51	<0.001
>= 75 years					
ASC4FIRST	2/10	8/13	0.23	0.05; 1.11	0.046
ASC4START	1/9	2/12	1.12	0.07; 17.96	0.937
Pooled Analysis	3/19	10/25	0.32	0.08; 1.21	0.078




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	5/19	0.39	0.09; 1.64	0.181
ASC4START	4/38	11/37	0.29	0.09; 0.92	0.026
Pooled Analysis	7/61	16/56	0.33	0.13; 0.80	0.010
Intermediate					
ASC4FIRST	15/54	18/52	0.63	0.31; 1.25	0.182
ASC4START	16/75	19/73	0.69	0.35; 1.34	0.264
Pooled Analysis	31/129	37/125	0.66	0.41; 1.06	0.084
Low					
ASC4FIRST	34/119	60/119	0.45	0.29; 0.68	<0.001
ASC4START	30/171	49/172	0.54	0.34; 0.85	0.007
Pooled Analysis	64/290	109/291	0.49	0.36; 0.66	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	13/63	30/61	0.34	0.17; 0.66	<0.001
ASC4START	17/138	30/140	0.52	0.28; 0.94	0.027
Pooled Analysis	30/201	60/201	0.42	0.27; 0.66	<0.001
Germany					
ASC4FIRST	3/19	5/15	0.56	0.12; 2.50	0.438
ASC4START	14/72	15/53	0.60	0.29; 1.25	0.169
Pooled Analysis	17/91	20/68	0.59	0.30; 1.14	0.115
Others					
ASC4FIRST	36/114	48/114	0.60	0.39; 0.93	0.020
ASC4START	19/74	34/89	0.54	0.31; 0.95	0.032
Pooled Analysis	55/188	82/203	0.58	0.41; 0.81	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	11/41	19/42	0.56	0.26; 1.20	0.134
Pooled Analysis	11/41	19/42	0.56	0.26; 1.20	0.134
Imatinib					
ASC4FIRST	23/100	43/100	0.41	0.24; 0.68	<0.001
Pooled Analysis	23/100	43/100	0.41	0.24; 0.68	<0.001
Nilotinib					
ASC4FIRST	18/55	21/48	0.54	0.29; 1.02	0.055
ASC4START	50/284	79/282	0.54	0.38; 0.77	<0.001
Pooled Analysis	68/339	100/330	0.54	0.40; 0.74	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	6/40	17/45	0.30	0.12; 0.76	0.008
Pooled Analysis	35/128	54/130	0.50	0.32; 0.77	0.001
Asian/Others					
ASC4FIRST	30/91	40/89	0.57	0.35; 0.92	0.019
Others					
ASC4START	5/17	5/21	1.47	0.41; 5.22	0.550
Pooled Analysis	6/20	8/25	1.46	0.46; 4.64	0.519
White					
ASC4FIRST	22/105	43/101	0.40	0.23; 0.67	<0.001
ASC4START	39/227	57/216	0.57	0.38; 0.85	0.006
Pooled Analysis	61/332	100/317	0.49	0.36; 0.68	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	16/67	40/74	0.32	0.18; 0.57	<0.001
ASC4START	20/107	46/124	0.39	0.23; 0.66	<0.001
Pooled Analysis	36/174	86/198	0.35	0.24; 0.52	<0.001
Male					
ASC4FIRST	36/129	43/116	0.65	0.41; 1.01	0.054
ASC4START	30/177	33/158	0.75	0.46; 1.23	0.254
Pooled Analysis	66/306	76/274	0.69	0.50; 0.96	0.028




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	11/152	11/148	0.93	0.40; 2.15	0.866
ASC4START	7/237	13/246	0.53	0.21; 1.33	0.171
Pooled Analysis	18/389	24/394	0.72	0.39; 1.32	0.285
65 - < 75 years					
ASC4FIRST	1/34	1/29	0.76	0.05; 12.29	0.847
ASC4START	3/38	1/24	1.40	0.14; 13.54	0.772
Pooled Analysis	4/72	2/53	1.11	0.20; 6.15	0.908
>= 75 years					
ASC4FIRST	3/10	2/13	1.21	0.20; 7.36	0.833
ASC4START	1/9	3/12	0.40	0.04; 3.81	0.406
Pooled Analysis	4/19	5/25	0.76	0.20; 2.88	0.689




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	0/19	2.68	0.03; 259.50	0.355
ASC4START	2/38	2/37	0.89	0.13; 6.34	0.909
Pooled Analysis	3/61	2/56	1.33	0.22; 7.95	0.755
Intermediate					
ASC4FIRST	10/54	4/52	2.23	0.70; 7.13	0.162
ASC4START	4/75	7/73	0.50	0.15; 1.70	0.255
Pooled Analysis	14/129	11/125	1.12	0.51; 2.48	0.771
Low					
ASC4FIRST	4/119	10/119	0.36	0.11; 1.15	0.071
ASC4START	5/171	8/172	0.61	0.20; 1.85	0.375
Pooled Analysis	9/290	18/291	0.47	0.21; 1.04	0.056




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	5/63	1/61	4.61	0.53; 40.24	0.130
ASC4START	5/138	5/140	0.88	0.25; 3.09	0.847
Pooled Analysis	10/201	6/201	1.49	0.53; 4.15	0.445
Germany					
ASC4FIRST	2/19	3/15	0.55	0.09; 3.29	0.485
ASC4START	2/72	3/53	0.53	0.08; 3.30	0.489
Pooled Analysis	4/91	6/68	0.54	0.15; 1.94	0.325
Others					
ASC4FIRST	8/114	10/114	0.71	0.28; 1.80	0.470
ASC4START	4/74	9/89	0.48	0.15; 1.56	0.210
Pooled Analysis	12/188	19/203	0.61	0.29; 1.25	0.173




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	4/41	5/42	0.83	0.22; 3.16	0.780
Pooled Analysis	4/41	5/42	0.83	0.22; 3.16	0.780
Imatinib					
ASC4FIRST	7/100	7/100	0.91	0.32; 2.59	0.855
Pooled Analysis	7/100	7/100	0.91	0.32; 2.59	0.855
Nilotinib					
ASC4FIRST	4/55	2/48	1.34	0.24; 7.40	0.733
ASC4START	11/284	17/282	0.59	0.28; 1.27	0.174
Pooled Analysis	15/339	19/330	0.68	0.35; 1.35	0.272




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	2/40	4/45	0.58	0.10; 3.28	0.531
Pooled Analysis	10/128	11/130	0.77	0.32; 1.85	0.562
Asian/Others					
ASC4FIRST	8/91	8/89	0.75	0.28; 2.01	0.563
Others					
ASC4START	2/17	0/21	4.25	0.10; 175.93	0.193
Pooled Analysis	2/20	1/25	2.31	0.20; 26.79	0.491
White					
ASC4FIRST	7/105	6/101	1.14	0.38; 3.48	0.813
ASC4START	7/227	13/216	0.47	0.19; 1.18	0.100
Pooled Analysis	14/332	19/317	0.67	0.33; 1.34	0.253




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	3/67	5/74	0.61	0.14; 2.59	0.500
ASC4START	1/107	6/124	0.18	0.02; 1.49	0.074
Pooled Analysis	4/174	11/198	0.38	0.12; 1.20	0.086
Male					
ASC4FIRST	12/129	9/116	1.08	0.45; 2.57	0.863
ASC4START	10/177	11/158	0.77	0.33; 1.81	0.541
Pooled Analysis	22/306	20/274	0.91	0.49; 1.67	0.755




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	20/152	35/148	0.51	0.29; 0.88	0.014
ASC4START	24/237	24/246	1.02	0.58; 1.80	0.952
Pooled Analysis	44/389	59/394	0.71	0.48; 1.04	0.080
65 - < 75 years					
ASC4FIRST	3/34	7/29	0.46	0.12; 1.81	0.254
ASC4START	2/38	1/24	1.41	0.12; 15.84	0.782
Pooled Analysis	5/72	8/53	0.61	0.20; 1.89	0.384
>= 75 years					
ASC4FIRST	2/10	7/13	0.22	0.03; 1.85	0.124
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	2/19	7/25	0.22	0.03; 1.85	0.124




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	9/19	0.07	0.01; 0.52	<0.001
ASC4START	5/38	4/37	1.13	0.30; 4.22	0.858
Pooled Analysis	6/61	13/56	0.34	0.13; 0.89	0.022
Intermediate					
ASC4FIRST	10/54	13/52	0.72	0.32; 1.66	0.443
ASC4START	8/75	6/73	1.23	0.43; 3.55	0.698
Pooled Analysis	18/129	19/125	0.89	0.46; 1.69	0.716
Low					
ASC4FIRST	14/119	27/119	0.48	0.25; 0.92	0.024
ASC4START	13/171	15/172	0.88	0.42; 1.85	0.730
Pooled Analysis	27/290	42/291	0.62	0.38; 1.01	0.051




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	3/63	15/61	0.18	0.05; 0.64	0.003
ASC4START	12/138	8/140	1.54	0.63; 3.77	0.347
Pooled Analysis	15/201	23/201	0.64	0.33; 1.24	0.184
Germany					
ASC4FIRST	1/19	4/15	0.22	0.02; 2.16	0.157
ASC4START	2/72	3/53	0.50	0.08; 3.01	0.437
Pooled Analysis	3/91	7/68	0.35	0.09; 1.43	0.128
Others					
ASC4FIRST	21/114	30/114	0.65	0.37; 1.14	0.135
ASC4START	12/74	14/89	1.02	0.47; 2.21	0.963
Pooled Analysis	33/188	44/203	0.76	0.48; 1.19	0.234




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	3/41	16/42	0.11	0.03; 0.40	<0.001
Pooled Analysis	3/41	16/42	0.11	0.03; 0.40	<0.001
Imatinib					
ASC4FIRST	11/100	26/100	0.40	0.20; 0.81	0.009
Pooled Analysis	11/100	26/100	0.40	0.20; 0.81	0.009
Nilotinib					
ASC4FIRST	11/55	7/48	1.33	0.51; 3.46	0.553
ASC4START	26/284	25/282	1.01	0.58; 1.75	0.982
Pooled Analysis	37/339	32/330	1.08	0.67; 1.74	0.749




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	4/40	5/45	0.85	0.23; 3.17	0.822
Pooled Analysis	23/128	31/130	0.68	0.39; 1.17	0.167
Asian/Others					
ASC4FIRST	19/91	27/89	0.64	0.35; 1.15	0.134
Others					
ASC4START	4/17	5/21	1.09	0.28; 4.21	0.910
Pooled Analysis	4/20	6/25	1.09	0.28; 4.21	0.910
White					
ASC4FIRST	6/105	22/101	0.23	0.09; 0.58	<0.001
ASC4START	18/227	15/216	1.13	0.57; 2.25	0.723
Pooled Analysis	24/332	37/317	0.59	0.35; 0.99	0.045




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	7/67	27/74	0.28	0.12; 0.65	0.002
ASC4START	16/107	13/124	1.40	0.67; 2.92	0.373
Pooled Analysis	23/174	40/198	0.64	0.38; 1.08	0.090
Male					
ASC4FIRST	18/129	22/116	0.73	0.39; 1.36	0.322
ASC4START	10/177	12/158	0.70	0.30; 1.63	0.408
Pooled Analysis	28/306	34/274	0.72	0.43; 1.19	0.198




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	49/152	57/148	0.85	0.58; 1.25	0.409
ASC4START	41/237	32/246	1.32	0.83; 2.09	0.236
Pooled Analysis	90/389	89/394	1.02	0.76; 1.36	0.899
65 - < 75 years					
ASC4FIRST	10/34	13/29	0.47	0.19; 1.19	0.092
ASC4START	2/38	3/24	0.49	0.08; 2.96	0.424
Pooled Analysis	12/72	16/53	0.48	0.21; 1.09	0.062
>= 75 years					
ASC4FIRST	4/10	6/13	0.98	0.24; 3.93	0.976
ASC4START	1/9	0/12	3.71	0.04; 338.14	0.264
Pooled Analysis	5/19	6/25	1.26	0.34; 4.71	0.732




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	7/19	0.29	0.08; 1.14	0.062
ASC4START	11/38	9/37	1.17	0.49; 2.83	0.727
Pooled Analysis	14/61	16/56	0.75	0.37; 1.55	0.434
Intermediate					
ASC4FIRST	22/54	22/52	0.99	0.55; 1.80	0.988
ASC4START	8/75	5/73	1.49	0.49; 4.55	0.482
Pooled Analysis	30/129	27/125	1.09	0.65; 1.83	0.745
Low					
ASC4FIRST	38/119	47/119	0.80	0.52; 1.23	0.307
ASC4START	25/171	21/172	1.20	0.67; 2.15	0.520
Pooled Analysis	63/290	68/291	0.93	0.66; 1.30	0.662




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	14/63	16/61	0.99	0.48; 2.04	0.963
ASC4START	16/138	8/140	2.05	0.87; 4.79	0.093
Pooled Analysis	30/201	24/201	1.35	0.79; 2.32	0.276
Germany					
ASC4FIRST	7/19	8/15	0.86	0.29; 2.59	0.793
ASC4START	8/72	7/53	0.81	0.29; 2.24	0.685
Pooled Analysis	15/91	15/68	0.83	0.39; 1.76	0.633
Others					
ASC4FIRST	42/114	52/114	0.77	0.51; 1.16	0.208
ASC4START	20/74	20/89	1.26	0.68; 2.36	0.437
Pooled Analysis	62/188	72/203	0.89	0.63; 1.25	0.518




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	10/41	21/42	0.49	0.23; 1.07	0.068
Pooled Analysis	10/41	21/42	0.49	0.23; 1.07	0.068
Imatinib					
ASC4FIRST	31/100	38/100	0.80	0.50; 1.28	0.343
Pooled Analysis	31/100	38/100	0.80	0.50; 1.28	0.343
Nilotinib					
ASC4FIRST	22/55	17/48	1.15	0.61; 2.17	0.652
ASC4START	44/284	35/282	1.24	0.79; 1.93	0.341
Pooled Analysis	66/339	52/330	1.21	0.84; 1.74	0.298




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	5/40	7/45	0.74	0.23; 2.35	0.609
Pooled Analysis	45/128	48/130	0.87	0.58; 1.32	0.516
Asian/Others					
ASC4FIRST	40/91	43/89	0.87	0.56; 1.34	0.516
Others					
ASC4START	9/17	6/21	2.22	0.77; 6.38	0.104
Pooled Analysis	9/20	8/25	2.22	0.77; 6.38	0.104
White					
ASC4FIRST	23/105	33/101	0.71	0.41; 1.23	0.211
ASC4START	30/227	22/216	1.27	0.73; 2.20	0.394
Pooled Analysis	53/332	55/317	0.95	0.65; 1.39	0.773




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	25/67	35/74	0.76	0.45; 1.28	0.289
ASC4START	16/107	14/124	1.27	0.62; 2.60	0.519
Pooled Analysis	41/174	49/198	0.91	0.59; 1.38	0.629
Male					
ASC4FIRST	38/129	41/116	0.86	0.55; 1.34	0.513
ASC4START	28/177	21/158	1.19	0.68; 2.10	0.531
Pooled Analysis	66/306	62/274	0.98	0.69; 1.38	0.902




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	44/152	48/148	0.93	0.61; 1.40	0.733
ASC4START	53/237	42/246	1.31	0.87; 1.96	0.188
Pooled Analysis	97/389	90/394	1.11	0.83; 1.47	0.480
65 - < 75 years					
ASC4FIRST	9/34	10/29	0.68	0.26; 1.72	0.428
ASC4START	3/38	3/24	0.76	0.15; 3.81	0.742
Pooled Analysis	12/72	13/53	0.70	0.31; 1.56	0.394
>= 75 years					
ASC4FIRST	2/10	4/13	1.13	0.16; 8.06	0.903
ASC4START	2/9	0/12	6.13	0.15; 252.58	0.118
Pooled Analysis	4/19	4/25	2.33	0.43; 12.74	0.316




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	7/23	10/19	0.51	0.19; 1.34	0.156
ASC4START	17/38	10/37	1.67	0.77; 3.66	0.193
Pooled Analysis	24/61	20/56	1.05	0.58; 1.91	0.872
Intermediate					
ASC4FIRST	21/54	22/52	0.99	0.54; 1.81	0.971
ASC4START	16/75	11/73	1.43	0.66; 3.08	0.354
Pooled Analysis	37/129	33/125	1.14	0.71; 1.83	0.542
Low					
ASC4FIRST	27/119	30/119	0.89	0.53; 1.49	0.644
ASC4START	25/171	24/172	1.07	0.61; 1.88	0.813
Pooled Analysis	52/290	54/291	0.97	0.66; 1.41	0.860




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	10/63	11/61	0.88	0.37; 2.12	0.786
ASC4START	20/138	10/140	1.98	0.93; 4.24	0.073
Pooled Analysis	30/201	21/201	1.41	0.80; 2.48	0.224
Germany					
ASC4FIRST	2/19	9/15	0.15	0.03; 0.71	0.007
ASC4START	15/72	12/53	0.91	0.42; 1.95	0.826
Pooled Analysis	17/91	21/68	0.59	0.31; 1.13	0.115
Others					
ASC4FIRST	43/114	42/114	1.07	0.70; 1.65	0.750
ASC4START	23/74	23/89	1.25	0.70; 2.24	0.453
Pooled Analysis	66/188	65/203	1.13	0.80; 1.60	0.484




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	11/41	16/42	0.61	0.28; 1.35	0.231
Pooled Analysis	11/41	16/42	0.61	0.28; 1.35	0.231
Imatinib					
ASC4FIRST	26/100	29/100	0.90	0.53; 1.53	0.702
Pooled Analysis	26/100	29/100	0.90	0.53; 1.53	0.702
Nilotinib					
ASC4FIRST	18/55	17/48	0.97	0.50; 1.88	0.903
ASC4START	58/284	45/282	1.30	0.88; 1.91	0.192
Pooled Analysis	76/339	62/330	1.20	0.86; 1.68	0.284




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	8/40	8/45	1.04	0.39; 2.77	0.943
Pooled Analysis	46/128	45/130	1.06	0.70; 1.61	0.805
Asian/Others					
ASC4FIRST	38/91	37/89	1.05	0.66; 1.66	0.879
Others					
ASC4START	5/17	5/21	2.00	0.51; 7.79	0.275
Pooled Analysis	5/20	5/25	2.00	0.51; 7.79	0.275
White					
ASC4FIRST	17/105	25/101	0.60	0.32; 1.12	0.109
ASC4START	45/227	32/216	1.37	0.87; 2.15	0.173
Pooled Analysis	62/332	57/317	1.03	0.72; 1.48	0.873




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	21/67	20/74	1.23	0.66; 2.29	0.511
ASC4START	19/107	14/124	1.48	0.74; 2.97	0.266
Pooled Analysis	40/174	34/198	1.34	0.84; 2.12	0.217
Male					
ASC4FIRST	34/129	42/116	0.70	0.44; 1.10	0.122
ASC4START	39/177	31/158	1.15	0.72; 1.85	0.549
Pooled Analysis	73/306	73/274	0.89	0.64; 1.23	0.496




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

QTc prolongation

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	3/152	3/148	0.94	0.19; 4.67	0.946
ASC4START	2/237	3/246	0.67	0.11; 4.02	0.661
Pooled Analysis	5/389	6/394	0.81	0.25; 2.65	0.729
65 - < 75 years					
ASC4FIRST	1/34	1/29	0.17	0.00; 15.37	0.157
ASC4START	3/38	2/24	0.89	0.15; 5.45	0.903
Pooled Analysis	4/72	3/53	0.57	0.11; 2.89	0.496
>= 75 years					
ASC4FIRST	0/10	0/13	N.E.	N.E.; N.E.	N.E.
ASC4START	0/9	1/12	0.39	0.00; 37.18	0.361
Pooled Analysis	0/19	1/25	0.39	0.00; 37.18	0.361




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

QTc prolongation

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	1/63	1/61	0.53	0.02; 15.97	0.718
ASC4START	2/138	3/140	0.65	0.11; 3.92	0.640
Pooled Analysis	3/201	4/201	0.63	0.13; 3.07	0.561
Germany					
ASC4FIRST	0/19	1/15	0.25	0.00; 23.06	0.248
ASC4START	0/72	1/53	0.15	0.00; 13.98	0.138
Pooled Analysis	0/91	2/68	0.11	0.00; 4.80	0.063
Others					
ASC4FIRST	3/114	2/114	1.80	0.30; 10.87	0.514
ASC4START	3/74	2/89	1.88	0.31; 11.38	0.484
Pooled Analysis	6/188	4/203	1.84	0.52; 6.57	0.339




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

QTc prolongation

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	1/41	2/42	0.30	0.02; 3.82	0.340
Pooled Analysis	1/41	2/42	0.30	0.02; 3.82	0.340
Imatinib					
ASC4FIRST	1/100	0/100	3.09	0.03; 283.80	0.310
Pooled Analysis	1/100	0/100	3.09	0.03; 283.80	0.310
Nilotinib					
ASC4FIRST	2/55	2/48	1.08	0.15; 7.74	0.943
ASC4START	5/284	6/282	0.80	0.24; 2.62	0.709
Pooled Analysis	7/339	8/330	0.86	0.31; 2.39	0.777




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

QTc prolongation

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	0/45	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	1/128	1/130	1.26	0.08; 20.93	0.871
Asian/Others					
ASC4FIRST	1/91	1/89	1.16	0.07; 18.74	0.918
Others					
ASC4START	0/17	1/21	0.64	0.01; 62.05	0.480
Pooled Analysis	0/20	1/25	0.64	0.01; 62.05	0.480
White					
ASC4FIRST	3/105	3/101	0.68	0.13; 3.67	0.663
ASC4START	5/227	5/216	0.92	0.27; 3.19	0.900
Pooled Analysis	8/332	8/317	0.83	0.31; 2.26	0.722




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.10.1: Forest-Plot for AESI all grades: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

QTc prolongation

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	0/67	0/74	N.E.	N.E.; N.E.	N.E.
ASC4START	2/107	3/124	0.72	0.12; 4.34	0.723
Pooled Analysis	2/174	3/198	0.72	0.12; 4.34	0.723
Male					
ASC4FIRST	4/129	4/116	0.56	0.14; 2.32	0.425
ASC4START	3/177	3/158	0.86	0.17; 4.27	0.855
Pooled Analysis	7/306	7/274	0.68	0.23; 1.97	0.477



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Acute pancreatitis (including isolated pancreatic enzyme elevations)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.819)								
Low	39/290 (13.4)	N.E. [N.E.; N.E.]	44/291 (15.1)	N.E. [N.E.; N.E.]	0.85	[0.55; 1.31]	0.470	0.808
Intermediate	12/129 (9.3)	N.E. [N.E.; N.E.]	16/125 (12.8)	N.E. [N.E.; N.E.]	0.67	[0.32; 1.41]	0.289	0.927
High	6/61 (9.8)	N.E. [N.E.; N.E.]	5/56 (8.9)	N.E. [N.E.; N.E.]	1.00	[0.30; 3.28]	0.998	0.292
Sex (Interaction test: p = 0.591)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Female	20/174 (11.5)	N.E. [N.E.; N.E.]	23/198 (11.6)	N.E. [N.E.; N.E.]	0.90	[0.49; 1.64]	0.732	0.121
Male	37/306 (12.1)	N.E. [N.E.; N.E.]	42/274 (15.3)	N.E. [30.4; N.E.]	0.74	[0.48; 1.16]	0.187	0.136
Race (Interaction test: p = 0.930)								
Asian	19/128 (14.8)	N.E. [N.E.; N.E.]	21/130 (16.2)	N.E. [N.E.; N.E.]	0.92	[0.49; 1.73]	0.787	0.433
White	36/332 (10.8)	N.E. [N.E.; N.E.]	42/317 (13.2)	N.E. [30.4; N.E.]	0.78	[0.50; 1.23]	0.287	0.863
Others	2/20 (10.0)	N.E. [N.E.; N.E.]	2/25 (8.0)	N.E. [16.6; N.E.]	1.37	[0.18; 10.39]	0.762	N.E.
Age groups (Interaction test: p = 0.768)								
18 - < 65 years	48/389 (12.3)	N.E. [N.E.; N.E.]	50/394 (12.7)	N.E. [N.E.; N.E.]	0.94	[0.63; 1.40]	0.774	0.681

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
65 - < 75 years	9/72 (12.5)	N.E. [N.E.; N.E.]	9/53 (17.0)	N.E. [25.7; N.E.]	0.78	[0.30; 2.00]	0.602	0.285
>= 75 years	0/19	N.E. [N.E.; N.E.]	6/25 (24.0)	N.E. [13.8; N.E.]	0.07	[0.00; 1.70]	0.014	1.000
Pre-randomization selection of TKI								
(Interaction test: p = 0.380)								
Imatinib	19/100 (19.0)	N.E. [N.E.; N.E.]	15/100 (15.0)	N.E. [N.E.; N.E.]	1.26	[0.64; 2.48]	0.499	N.E.
Nilotinib	36/339 (10.6)	N.E. [N.E.; N.E.]	46/330 (13.9)	N.E. [30.4; N.E.]	0.68	[0.44; 1.06]	0.082	0.057
Dasatinib	2/41 (4.9)	N.E. [N.E.; N.E.]	4/42 (9.5)	N.E. [N.E.; N.E.]	0.46	[0.08; 2.65]	0.377	N.E.
Geographic region								
(Interaction test: p = 0.558)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Europe excluding Germany	21/201 (10.4)	N.E. [N.E.; N.E.]	22/201 (10.9)	N.E. [N.E.; N.E.]	0.92	[0.50; 1.69]	0.778	0.554
Germany	12/91 (13.2)	N.E. [N.E.; N.E.]	7/68 (10.3)	N.E. [N.E.; N.E.]	0.92	[0.35; 2.39]	0.858	0.277
Others	24/188 (12.8)	N.E. [N.E.; N.E.]	36/203 (17.7)	N.E. [30.4; N.E.]	0.68	[0.40; 1.14]	0.138	0.833
Arterial-occlusive events (AOE)								
Sex								
(Interaction test: p = 0.993)								
Female	0/174	N.E. [N.E.; N.E.]	4/198 (2.0)	N.E. [N.E.; N.E.]	0.13	[0.00; 3.59]	0.070	1.000
Male	7/306 (2.3)	N.E. [N.E.; N.E.]	4/274 (1.5)	N.E. [N.E.; N.E.]	1.35	[0.39; 4.63]	0.630	0.666
Pre-randomization selection of TKI								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.920)								
Imatinib	1/100 (1.0)	N.E. [N.E.; N.E.]	0/100	N.E. [N.E.; N.E.]	2.11	[0.02; 207.43]	0.414	N.E.
Nilotinib	5/339 (1.5)	N.E. [N.E.; N.E.]	7/330 (2.1)	N.E. [N.E.; N.E.]	0.59	[0.19; 1.87]	0.367	0.984
Dasatinib	1/41 (2.4)	N.E. [N.E.; N.E.]	1/42 (2.4)	N.E. [N.E.; N.E.]	1.04	[0.06; 16.60]	0.979	N.E.
Edema and fluid retention								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.260)								
Low	14/290 (4.8)	N.E. [N.E.; N.E.]	24/291 (8.2)	N.E. [N.E.; N.E.]	0.55	[0.29; 1.07]	0.073	0.227
Intermediate	4/129 (3.1)	N.E. [N.E.; N.E.]	14/125 (11.2)	N.E. [N.E.; N.E.]	0.25	[0.08; 0.76]	0.008	0.712

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
High	1/61 (1.6)	N.E. [N.E.; N.E.]	6/56 (10.7)	N.E. [N.E.; N.E.]	0.14	[0.02; 1.12]	0.028	0.995
Sex								
(Interaction test: p = 0.278)								
Female	8/174 (4.6)	N.E. [N.E.; N.E.]	27/198 (13.6)	N.E. [N.E.; N.E.]	0.32	[0.14; 0.70]	0.003	0.046
Male	11/306 (3.6)	N.E. [N.E.; N.E.]	17/274 (6.2)	N.E. [N.E.; N.E.]	0.54	[0.25; 1.15]	0.103	0.716
Race								
(Interaction test: p = 0.173)								
Asian	3/128 (2.3)	N.E. [N.E.; N.E.]	16/130 (12.3)	N.E. [N.E.; N.E.]	0.17	[0.05; 0.60]	0.002	0.992
White	16/332 (4.8)	N.E. [N.E.; N.E.]	24/317 (7.6)	N.E. [N.E.; N.E.]	0.61	[0.32; 1.16]	0.132	0.294
Others	0/20	N.E. [N.E.; N.E.]	4/25 (16.0)	N.E. [N.E.; N.E.]	0.20	[0.01; 6.89]	0.158	1.000

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Age groups								
(Interaction test: p = 0.394)								
18 - < 65 years	15/389 (3.9)	N.E. [N.E.; N.E.]	29/394 (7.4)	N.E. [N.E.; N.E.]	0.50	[0.27; 0.93]	0.026	0.467
65 - < 75 years	2/72 (2.8)	N.E. [N.E.; N.E.]	7/53 (13.2)	N.E. [N.E.; N.E.]	0.19	[0.04; 1.00]	0.033	0.996
>= 75 years	2/19 (10.5)	N.E. [N.E.; N.E.]	8/25 (32.0)	N.E. [3.9; N.E.]	0.27	[0.06; 1.34]	0.088	0.996
Pre-randomization selection of TKI								
(Interaction test: p = 0.207)								
Imatinib	3/100 (3.0)	N.E. [N.E.; N.E.]	15/100 (15.0)	N.E. [N.E.; N.E.]	0.18	[0.05; 0.61]	0.002	N.E.
Nilotinib	13/339 (3.8)	N.E. [N.E.; N.E.]	21/330 (6.4)	N.E. [N.E.; N.E.]	0.58	[0.29; 1.16]	0.119	0.595
Dasatinib	3/41	N.E. [N.E.; N.E.]	8/42	N.E. [N.E.; N.E.]	0.36	[0.09; 1.40]	0.127	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(7.3)		(19.0)					
Geographic region								
(Interaction test: p = 0.050)								
Europe excluding Germany	1/201	N.E. [N.E.; N.E.]	13/201	N.E. [N.E.; N.E.]	0.08	[0.01; 0.59]	0.001	0.993
	(0.5)		(6.5)					
Germany	8/91	N.E. [N.E.; N.E.]	5/68	N.E. [N.E.; N.E.]	1.02	[0.33; 3.18]	0.967	0.994
	(8.8)		(7.4)					
Others	10/188	N.E. [N.E.; N.E.]	26/203	N.E. [N.E.; N.E.]	0.37	[0.18; 0.77]	0.006	0.945
	(5.3)		(12.8)					
Gastrointestinal toxicity								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.461)								
Low	99/290	N.E. [N.E.; N.E.]	109/291	N.E. [N.E.; N.E.]	0.85	[0.65; 1.11]	0.238	0.058
	(34.1)		(37.5)					

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Intermediate	42/129 (32.6)	N.E. [N.E.; N.E.]	41/125 (32.8)	N.E. [N.E.; N.E.]	0.95	[0.62; 1.46]	0.810	0.399
High	20/61 (32.8)	N.E. [16.6; N.E.]	14/56 (25.0)	N.E. [N.E.; N.E.]	1.32	[0.66; 2.61]	0.429	0.380
Sex								
(Interaction test: p = 0.463)								
Female	63/174 (36.2)	N.E. [N.E.; N.E.]	80/198 (40.4)	N.E. [N.E.; N.E.]	0.88	[0.63; 1.24]	0.481	0.400
Male	98/306 (32.0)	N.E. [N.E.; N.E.]	84/274 (30.7)	N.E. [N.E.; N.E.]	0.98	[0.73; 1.32]	0.903	0.220
Race								
(Interaction test: p = 0.378)								
Asian	38/128 (29.7)	N.E. [N.E.; N.E.]	44/130 (33.8)	N.E. [N.E.; N.E.]	0.80	[0.52; 1.24]	0.316	0.502
White	118/332 (35.5)	N.E. [N.E.; N.E.]	109/317 (34.4)	N.E. [N.E.; N.E.]	0.99	[0.76; 1.29]	0.966	0.083

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	5/20 (25.0)	N.E. [10.2; N.E.]	11/25 (44.0)	N.E. [0.5; N.E.]	0.57	[0.17; 1.95]	0.326	0.271
Age groups (Interaction test: p = 0.513)								
18 - < 65 years	129/389 (33.2)	N.E. [N.E.; N.E.]	133/394 (33.8)	N.E. [N.E.; N.E.]	0.93	[0.73; 1.19]	0.578	0.091
65 - < 75 years	22/72 (30.6)	N.E. [N.E.; N.E.]	14/53 (26.4)	N.E. [N.E.; N.E.]	1.10	[0.55; 2.18]	0.793	0.673
>= 75 years	10/19 (52.6)	18.9 [0.4; N.E.]	17/25 (68.0)	1.3 [0.2; 12.7]	0.71	[0.31; 1.65]	0.437	0.711
Pre-randomization selection of TKI (Interaction test: p = 0.171)								
Imatinib	34/100 (34.0)	N.E. [N.E.; N.E.]	43/100 (43.0)	N.E. [5.4; N.E.]	0.64	[0.41; 1.00]	0.053	N.E.
Nilotinib	105/339	N.E. [N.E.; N.E.]	98/330	N.E. [N.E.; N.E.]	1.02	[0.77; 1.34]	0.914	0.279

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(31.0)		(29.7)					
Dasatinib	22/41	8.7 [1.0; N.E.]	23/42	9.8 [2.9; N.E.]	1.05	[0.58; 1.92]	0.874	N.E.
	(53.7)		(54.8)					
Geographic region								
(Interaction test: p = 0.127)								
Europe excluding Germany	61/201	N.E. [N.E.; N.E.]	65/201	N.E. [N.E.; N.E.]	0.87	[0.61; 1.23]	0.436	0.038
	(30.3)		(32.3)					
Germany	32/91	N.E. [19.4; N.E.]	17/68	N.E. [N.E.; N.E.]	1.72	[0.92; 3.20]	0.084	0.149
	(35.2)		(25.0)					
Others	68/188	N.E. [N.E.; N.E.]	82/203	N.E. [19.3; N.E.]	0.81	[0.58; 1.12]	0.193	0.901
	(36.2)		(40.4)					
Hemorrhage								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.495)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Low	16/290 (5.5)	N.E. [N.E.; N.E.]	22/291 (7.6)	N.E. [N.E.; N.E.]	0.69	[0.36; 1.32]	0.264	0.672
Intermediate	11/129 (8.5)	N.E. [N.E.; N.E.]	10/125 (8.0)	N.E. [N.E.; N.E.]	0.89	[0.37; 2.09]	0.782	0.358
High	2/61 (3.3)	N.E. [N.E.; N.E.]	5/56 (8.9)	N.E. [N.E.; N.E.]	0.35	[0.07; 1.79]	0.186	N.E.
Sex								
(Interaction test: p = 0.017)								
Female	21/174 (12.1)	N.E. [N.E.; N.E.]	18/198 (9.1)	N.E. [N.E.; N.E.]	1.21	[0.64; 2.28]	0.552	0.179
Male	8/306 (2.6)	N.E. [N.E.; N.E.]	19/274 (6.9)	N.E. [N.E.; N.E.]	0.32	[0.14; 0.74]	0.005	0.594
Race								
(Interaction test: p = 0.270)								
Asian	5/128 (3.9)	N.E. [N.E.; N.E.]	11/130 (8.5)	N.E. [N.E.; N.E.]	0.39	[0.13; 1.15]	0.078	0.726

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
White	21/332 (6.3)	N.E. [N.E.; N.E.]	24/317 (7.6)	N.E. [N.E.; N.E.]	0.79	[0.44; 1.42]	0.428	0.891
Others	3/20 (15.0)	N.E. [N.E.; N.E.]	2/25 (8.0)	N.E. [N.E.; N.E.]	5.09	[0.48; 54.08]	0.144	N.E.
Age groups (Interaction test: p = 0.631)								
18 - < 65 years	22/389 (5.7)	N.E. [N.E.; N.E.]	29/394 (7.4)	N.E. [N.E.; N.E.]	0.71	[0.41; 1.23]	0.218	0.815
65 - < 75 years	5/72 (6.9)	N.E. [N.E.; N.E.]	8/53 (15.1)	N.E. [N.E.; N.E.]	0.41	[0.13; 1.28]	0.113	0.143
>= 75 years	2/19 (10.5)	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	2.92	[0.07; 121.64]	0.281	N.E.
Pre-randomization selection of TKI (Interaction test: p = 0.356)								
Imatinib	6/100	N.E. [N.E.; N.E.]	9/100	N.E. [N.E.; N.E.]	0.58	[0.21; 1.64]	0.299	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(6.0)		(9.0)					
Nilotinib	21/339	N.E. [N.E.; N.E.]	21/330	N.E. [N.E.; N.E.]	0.91	[0.50; 1.67]	0.757	0.294
	(6.2)		(6.4)					
Dasatinib	2/41	N.E. [N.E.; N.E.]	7/42	N.E. [N.E.; N.E.]	0.27	[0.06; 1.34]	0.087	N.E.
	(4.9)		(16.7)					
Geographic region								
(Interaction test: p = 0.491)								
Europe excluding Germany	8/201	N.E. [N.E.; N.E.]	15/201	N.E. [N.E.; N.E.]	0.48	[0.20; 1.14]	0.091	0.493
	(4.0)		(7.5)					
Germany	4/91	N.E. [N.E.; N.E.]	4/68	N.E. [N.E.; N.E.]	0.76	[0.19; 3.08]	0.699	0.976
	(4.4)		(5.9)					
Others	17/188	N.E. [N.E.; N.E.]	18/203	N.E. [N.E.; N.E.]	0.95	[0.48; 1.85]	0.871	0.520
	(9.0)		(8.9)					
Hepatotoxicity (clinical events)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 1.000)								
Low	6/290 (2.1)	N.E. [N.E.; N.E.]	12/291 (4.1)	N.E. [N.E.; N.E.]	0.48	[0.18; 1.27]	0.128	0.316
Intermediate	4/129 (3.1)	N.E. [N.E.; N.E.]	0/125	N.E. [N.E.; N.E.]	6.81	[0.26; 180.38]	0.083	1.000
High	0/61	N.E. [N.E.; N.E.]	4/56 (7.1)	N.E. [N.E.; N.E.]	0.10	[0.00; 2.57]	0.033	1.000
Sex								
(Interaction test: p = 0.057)								
Female	1/174 (0.6)	N.E. [N.E.; N.E.]	9/198 (4.5)	N.E. [N.E.; N.E.]	0.11	[0.01; 0.91]	0.013	0.995
Male	9/306 (2.9)	N.E. [N.E.; N.E.]	7/274 (2.6)	N.E. [N.E.; N.E.]	1.02	[0.38; 2.75]	0.969	0.191

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.999)								
Asian	6/128 (4.7)	N.E. [N.E.; N.E.]	10/130 (7.7)	N.E. [N.E.; N.E.]	0.57	[0.20; 1.61]	0.287	0.104
White	4/332 (1.2)	N.E. [N.E.; N.E.]	6/317 (1.9)	N.E. [N.E.; N.E.]	0.63	[0.18; 2.25]	0.478	0.665
Others	0/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Age groups								
(Interaction test: p = 0.829)								
18 - < 65 years	9/389 (2.3)	N.E. [N.E.; N.E.]	13/394 (3.3)	N.E. [N.E.; N.E.]	0.67	[0.29; 1.57]	0.351	0.061
65 - < 75 years	1/72 (1.4)	N.E. [N.E.; N.E.]	2/53 (3.8)	N.E. [N.E.; N.E.]	0.29	[0.03; 3.35]	0.297	0.998
>= 75 years	0/19	N.E. [N.E.; N.E.]	1/25 (4.0)	N.E. [N.E.; N.E.]	0.53	[0.01; 51.67]	0.439	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.290)								
Imatinib	3/100 (3.0)	N.E. [N.E.; N.E.]	1/100 (1.0)	N.E. [N.E.; N.E.]	2.46	[0.25; 23.90]	0.424	N.E.
Nilotinib	6/339 (1.8)	N.E. [N.E.; N.E.]	15/330 (4.5)	N.E. [N.E.; N.E.]	0.37	[0.14; 0.95]	0.031	0.590
Dasatinib	1/41 (2.4)	N.E. [N.E.; N.E.]	0/42	N.E. [N.E.; N.E.]	2.99	[0.03; 275.43]	0.317	N.E.
Geographic region								
(Interaction test: p = 0.999)								
Europe excluding Germany	4/201 (2.0)	N.E. [N.E.; N.E.]	6/201 (3.0)	N.E. [N.E.; N.E.]	0.66	[0.19; 2.36]	0.522	0.645
Germany	0/91	N.E. [N.E.; N.E.]	0/68	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	6/188 (3.2)	N.E. [N.E.; N.E.]	10/203 (4.9)	N.E. [N.E.; N.E.]	0.61	[0.22; 1.72]	0.348	0.128
Hepatotoxicity (including laboratory terms)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.886)								
Low	45/290 (15.5)	N.E. [N.E.; N.E.]	86/291 (29.6)	N.E. [N.E.; N.E.]	0.46	[0.32; 0.66]	<0.001	0.216
Intermediate	16/129 (12.4)	N.E. [30.5; N.E.]	27/125 (21.6)	N.E. [N.E.; N.E.]	0.50	[0.27; 0.93]	0.027	0.039
High	12/61 (19.7)	N.E. [N.E.; N.E.]	17/56 (30.4)	N.E. [N.E.; N.E.]	0.58	[0.27; 1.21]	0.144	0.332
Sex (Interaction test: p = 0.847)								
Female	28/174	N.E. [N.E.; N.E.]	55/198	N.E. [N.E.; N.E.]	0.48	[0.31; 0.77]	0.002	0.484

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(16.1)		(27.8)					
Male	45/306	N.E. [N.E.; N.E.]	75/274	N.E. [N.E.; N.E.]	0.46	[0.32; 0.67]	<0.001	0.041
	(14.7)		(27.4)					
Race								
(Interaction test: p = 0.412)								
Asian	33/128	N.E. [30.5; N.E.]	53/130	N.E. [13.8; N.E.]	0.54	[0.35; 0.84]	0.005	0.425
	(25.8)		(40.8)					
White	39/332	N.E. [N.E.; N.E.]	69/317	N.E. [N.E.; N.E.]	0.48	[0.32; 0.71]	<0.001	0.025
	(11.7)		(21.8)					
Others	1/20	N.E. [N.E.; N.E.]	8/25	N.E. [11.0; N.E.]	0.13	[0.02; 1.07]	0.026	N.E.
	(5.0)		(32.0)					
Age groups								
(Interaction test: p = 0.735)								
18 - < 65 years	61/389	N.E. [N.E.; N.E.]	113/394	N.E. [N.E.; N.E.]	0.49	[0.36; 0.67]	<0.001	0.023
	(15.7)		(28.7)					
65 - < 75 years	11/72	N.E. [N.E.; N.E.]	12/53	N.E. [N.E.; N.E.]	0.57	[0.24; 1.33]	0.200	0.342

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(15.3)		(22.6)					
>= 75 years	1/19	N.E. [N.E.; N.E.]	5/25	N.E. [N.E.; N.E.]	0.23	[0.03; 1.95]	0.130	0.996
	(5.3)		(20.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.019)								
Imatinib	21/100	N.E. [30.5; N.E.]	20/100	N.E. [N.E.; N.E.]	0.98	[0.53; 1.81]	0.951	N.E.
	(21.0)		(20.0)					
Nilotinib	45/339	N.E. [N.E.; N.E.]	101/330	N.E. [N.E.; N.E.]	0.37	[0.26; 0.53]	<0.001	0.666
	(13.3)		(30.6)					
Dasatinib	7/41	N.E. [N.E.; N.E.]	9/42	N.E. [N.E.; N.E.]	0.68	[0.25; 1.86]	0.448	N.E.
	(17.1)		(21.4)					
Geographic region								
(Interaction test: p = 0.558)								
Europe excluding Germany	23/201	N.E. [N.E.; N.E.]	35/201	N.E. [N.E.; N.E.]	0.56	[0.33; 0.96]	0.033	0.184

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(11.4)		(17.4)					
Germany	12/91	N.E. [N.E.; N.E.]	20/68	N.E. [N.E.; N.E.]	0.36	[0.17; 0.74]	0.004	0.720
	(13.2)		(29.4)					
Others	38/188	N.E. [N.E.; N.E.]	75/203	N.E. [N.E.; N.E.]	0.47	[0.32; 0.69]	<0.001	0.034
	(20.2)		(36.9)					
Hypersensitivity								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.343)								
Low	63/290	N.E. [N.E.; N.E.]	109/291	N.E. [N.E.; N.E.]	0.48	[0.35; 0.65]	<0.001	0.631
	(21.7)		(37.5)					
Intermediate	30/129	N.E. [N.E.; N.E.]	37/125	N.E. [N.E.; N.E.]	0.63	[0.39; 1.03]	0.063	0.736
	(23.3)		(29.6)					
High	7/61	N.E. [N.E.; N.E.]	16/56	N.E. [24.9; N.E.]	0.33	[0.13; 0.80]	0.010	0.768
	(11.5)		(28.6)					

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.011)								
Female	36/174 (20.7)	N.E. [N.E.; N.E.]	86/198 (43.4)	N.E. [10.8; N.E.]	0.35	[0.24; 0.52]	<0.001	0.624
Male	64/306 (20.9)	N.E. [N.E.; N.E.]	76/274 (27.7)	N.E. [N.E.; N.E.]	0.67	[0.48; 0.94]	0.018	0.671
Race								
(Interaction test: p = 0.533)								
Asian	34/128 (26.6)	N.E. [N.E.; N.E.]	54/130 (41.5)	N.E. [14.8; N.E.]	0.49	[0.31; 0.75]	<0.001	0.235
White	60/332 (18.1)	N.E. [N.E.; N.E.]	100/317 (31.5)	N.E. [N.E.; N.E.]	0.48	[0.35; 0.67]	<0.001	0.333
Others	6/20 (30.0)	N.E. [3.5; N.E.]	8/25 (32.0)	N.E. [1.7; N.E.]	1.46	[0.46; 4.64]	0.519	0.981
Age groups								
(Interaction test: p = 0.036)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	87/389 (22.4)	N.E. [N.E.; N.E.]	129/394 (32.7)	N.E. [N.E.; N.E.]	0.58	[0.44; 0.76]	<0.001	0.617
65 - < 75 years	10/72 (13.9)	N.E. [N.E.; N.E.]	23/53 (43.4)	N.E. [2.8; N.E.]	0.24	[0.11; 0.51]	<0.001	0.315
>= 75 years	3/19 (15.8)	N.E. [N.E.; N.E.]	10/25 (40.0)	N.E. [1.0; N.E.]	0.32	[0.08; 1.21]	0.078	0.329
Pre-randomization selection of TKI								
(Interaction test: p = 0.634)								
Imatinib	23/100 (23.0)	N.E. [N.E.; N.E.]	43/100 (43.0)	N.E. [5.6; N.E.]	0.41	[0.24; 0.68]	<0.001	N.E.
Nilotinib	66/339 (19.5)	N.E. [N.E.; N.E.]	100/330 (30.3)	N.E. [N.E.; N.E.]	0.52	[0.38; 0.72]	<0.001	0.926
Dasatinib	11/41 (26.8)	N.E. [N.E.; N.E.]	19/42 (45.2)	N.E. [9.8; N.E.]	0.56	[0.26; 1.21]	0.136	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.604)								
Europe excluding Germany	30/201 (14.9)	N.E. [N.E.; N.E.]	60/201 (29.9)	N.E. [N.E.; N.E.]	0.42	[0.27; 0.66]	<0.001	0.348
Germany	17/91 (18.7)	N.E. [N.E.; N.E.]	20/68 (29.4)	N.E. [N.E.; N.E.]	0.60	[0.31; 1.16]	0.124	0.966
Others	53/188 (28.2)	N.E. [N.E.; N.E.]	82/203 (40.4)	N.E. [16.7; N.E.]	0.55	[0.39; 0.78]	<0.001	0.731
Ischemic heart and CNS conditions								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.382)								
Low	7/290 (2.4)	N.E. [N.E.; N.E.]	15/291 (5.2)	N.E. [N.E.; N.E.]	0.43	[0.18; 1.07]	0.061	0.569
Intermediate	10/129	N.E. [N.E.; N.E.]	8/125	N.E. [N.E.; N.E.]	1.09	[0.43; 2.75]	0.861	0.183

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(7.8)		(6.4)					
High	1/61	N.E. [N.E.; N.E.]	1/56	N.E. [N.E.; N.E.]	0.94	[0.06; 15.05]	0.966	N.E.
	(1.6)		(1.8)					
Sex								
(Interaction test: p = 0.054)								
Female	1/174	N.E. [N.E.; N.E.]	9/198	N.E. [N.E.; N.E.]	0.12	[0.01; 0.92]	0.014	0.995
	(0.6)		(4.5)					
Male	17/306	N.E. [N.E.; N.E.]	15/274	N.E. [N.E.; N.E.]	0.94	[0.47; 1.89]	0.870	0.518
	(5.6)		(5.5)					
Race								
(Interaction test: p = 0.996)								
Asian	7/128	N.E. [N.E.; N.E.]	10/130	N.E. [N.E.; N.E.]	0.58	[0.22; 1.54]	0.266	0.666
	(5.5)		(7.7)					
White	9/332	N.E. [N.E.; N.E.]	14/317	N.E. [N.E.; N.E.]	0.61	[0.26; 1.43]	0.249	0.263
	(2.7)		(4.4)					
Others	2/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	4.25	[0.10; 175.93]	0.193	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(10.0)							
Age groups								
(Interaction test: p = 0.833)								
18 - < 65 years	13/389 (3.3)	N.E. [N.E.; N.E.]	19/394 (4.8)	N.E. [N.E.; N.E.]	0.65	[0.32; 1.32]	0.227	0.806
65 - < 75 years	2/72 (2.8)	N.E. [N.E.; N.E.]	2/53 (3.8)	N.E. [N.E.; N.E.]	0.59	[0.08; 4.27]	0.596	0.799
>= 75 years	3/19 (15.8)	N.E. [N.E.; N.E.]	3/25 (12.0)	N.E. [N.E.; N.E.]	1.09	[0.22; 5.48]	0.920	0.996
Pre-randomization selection of TKI								
(Interaction test: p = 0.891)								
Imatinib	5/100 (5.0)	N.E. [N.E.; N.E.]	6/100 (6.0)	N.E. [N.E.; N.E.]	0.73	[0.22; 2.39]	0.599	N.E.
Nilotinib	10/339 (2.9)	N.E. [N.E.; N.E.]	14/330 (4.2)	N.E. [N.E.; N.E.]	0.62	[0.28; 1.41]	0.250	0.544

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	3/41 (7.3)	N.E. [N.E.; N.E.]	4/42 (9.5)	N.E. [N.E.; N.E.]	0.90	[0.20; 4.04]	0.891	N.E.
Geographic region (Interaction test: p = 0.205)								
Europe excluding Germany	7/201 (3.5)	N.E. [N.E.; N.E.]	4/201 (2.0)	N.E. [N.E.; N.E.]	1.74	[0.51; 5.98]	0.371	0.516
Germany	3/91 (3.3)	N.E. [N.E.; N.E.]	6/68 (8.8)	N.E. [N.E.; N.E.]	0.44	[0.11; 1.76]	0.219	0.706
Others	8/188 (4.3)	N.E. [N.E.; N.E.]	14/203 (6.9)	N.E. [N.E.; N.E.]	0.54	[0.22; 1.29]	0.156	0.521
Myelosuppression (Erythropenia)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.120)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Low	23/290 (7.9)	N.E. [N.E.; N.E.]	41/291 (14.1)	N.E. [N.E.; N.E.]	0.54	[0.32; 0.90]	0.016	0.384
Intermediate	17/129 (13.2)	N.E. [N.E.; N.E.]	17/125 (13.6)	N.E. [N.E.; N.E.]	0.94	[0.48; 1.84]	0.853	0.503
High	4/61 (6.6)	N.E. [N.E.; N.E.]	12/56 (21.4)	N.E. [22.9; N.E.]	0.25	[0.08; 0.77]	0.009	0.101
Sex								
(Interaction test: p = 0.373)								
Female	19/174 (10.9)	N.E. [N.E.; N.E.]	40/198 (20.2)	N.E. [N.E.; N.E.]	0.53	[0.31; 0.92]	0.022	0.026
Male	25/306 (8.2)	N.E. [N.E.; N.E.]	30/274 (10.9)	N.E. [N.E.; N.E.]	0.73	[0.43; 1.25]	0.254	0.825
Race								
(Interaction test: p = 0.672)								
Asian	22/128 (17.2)	N.E. [N.E.; N.E.]	29/130 (22.3)	N.E. [N.E.; N.E.]	0.70	[0.40; 1.22]	0.211	0.857

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
White	19/332 (5.7)	N.E. [N.E.; N.E.]	35/317 (11.0)	N.E. [N.E.; N.E.]	0.49	[0.28; 0.86]	0.011	0.014
Others	3/20 (15.0)	N.E. [N.E.; N.E.]	6/25 (24.0)	N.E. [N.E.; N.E.]	0.82	[0.19; 3.57]	0.790	N.E.
Age groups (Interaction test: p = 0.676)								
18 - < 65 years	37/389 (9.5)	N.E. [N.E.; N.E.]	55/394 (14.0)	N.E. [N.E.; N.E.]	0.64	[0.42; 0.96]	0.032	0.272
65 - < 75 years	5/72 (6.9)	N.E. [N.E.; N.E.]	8/53 (15.1)	N.E. [N.E.; N.E.]	0.60	[0.19; 1.86]	0.371	0.428
>= 75 years	2/19 (10.5)	29.1 [N.E.; N.E.]	7/25 (28.0)	N.E. [5.6; N.E.]	0.22	[0.03; 1.85]	0.124	N.E.
Pre-randomization selection of TKI (Interaction test: p = 0.015)								
Imatinib	11/100	N.E. [N.E.; N.E.]	25/100	N.E. [N.E.; N.E.]	0.42	[0.20; 0.85]	0.013	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(11.0)		(25.0)					
Nilotinib	30/339	N.E. [N.E.; N.E.]	30/330	N.E. [N.E.; N.E.]	0.92	[0.56; 1.53]	0.759	0.534
	(8.8)		(9.1)					
Dasatinib	3/41	N.E. [N.E.; N.E.]	15/42	N.E. [13.8; N.E.]	0.15	[0.04; 0.52]	<0.001	N.E.
	(7.3)		(35.7)					
Geographic region								
(Interaction test: p = 0.249)								
Europe excluding Germany	10/201	N.E. [N.E.; N.E.]	22/201	N.E. [N.E.; N.E.]	0.44	[0.21; 0.94]	0.030	0.013
	(5.0)		(10.9)					
Germany	3/91	N.E. [N.E.; N.E.]	7/68	N.E. [N.E.; N.E.]	0.35	[0.09; 1.43]	0.128	0.590
	(3.3)		(10.3)					
Others	31/188	N.E. [N.E.; N.E.]	41/203	N.E. [N.E.; N.E.]	0.77	[0.48; 1.23]	0.281	0.641
	(16.5)		(20.2)					
Myelosuppression (Leukopenia)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.169)								
Low	53/290 (18.3)	N.E. [N.E.; N.E.]	58/291 (19.9)	N.E. [N.E.; N.E.]	0.92	[0.64; 1.34]	0.668	0.249
Intermediate	27/129 (20.9)	N.E. [N.E.; N.E.]	23/125 (18.4)	N.E. [N.E.; N.E.]	1.18	[0.68; 2.07]	0.544	0.399
High	8/61 (13.1)	N.E. [N.E.; N.E.]	14/56 (25.0)	N.E. [N.E.; N.E.]	0.47	[0.20; 1.13]	0.087	0.299
Sex								
(Interaction test: p = 0.674)								
Female	35/174 (20.1)	N.E. [N.E.; N.E.]	40/198 (20.2)	N.E. [N.E.; N.E.]	0.97	[0.62; 1.54]	0.915	0.164
Male	53/306 (17.3)	N.E. [N.E.; N.E.]	55/274 (20.1)	N.E. [N.E.; N.E.]	0.89	[0.61; 1.29]	0.533	0.716

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.775)								
Asian	40/128 (31.3)	N.E. [N.E.; N.E.]	46/130 (35.4)	N.E. [N.E.; N.E.]	0.81	[0.53; 1.24]	0.340	0.988
White	41/332 (12.3)	N.E. [N.E.; N.E.]	41/317 (12.9)	N.E. [N.E.; N.E.]	1.03	[0.66; 1.60]	0.904	0.359
Others	7/20 (35.0)	N.E. [2.8; N.E.]	8/25 (32.0)	N.E. [5.6; N.E.]	1.92	[0.62; 5.93]	0.218	N.E.
Age groups								
(Interaction test: p = 0.536)								
18 - < 65 years	74/389 (19.0)	N.E. [N.E.; N.E.]	76/394 (19.3)	N.E. [N.E.; N.E.]	0.98	[0.71; 1.36]	0.935	0.259
65 - < 75 years	10/72 (13.9)	N.E. [N.E.; N.E.]	13/53 (24.5)	N.E. [N.E.; N.E.]	0.56	[0.23; 1.36]	0.173	0.719
>= 75 years	4/19 (21.1)	N.E. [N.E.; N.E.]	6/25 (24.0)	N.E. [N.E.; N.E.]	1.07	[0.27; 4.29]	0.921	0.996

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.063)								
Imatinib	29/100 (29.0)	N.E. [N.E.; N.E.]	34/100 (34.0)	N.E. [N.E.; N.E.]	0.88	[0.54; 1.45]	0.604	N.E.
Nilotinib	51/339 (15.0)	N.E. [N.E.; N.E.]	40/330 (12.1)	N.E. [N.E.; N.E.]	1.19	[0.78; 1.80]	0.406	0.994
Dasatinib	8/41 (19.5)	N.E. [N.E.; N.E.]	21/42 (50.0)	24.8 [3.5; N.E.]	0.40	[0.17; 0.92]	0.025	N.E.
Geographic region								
(Interaction test: p = 0.299)								
Europe excluding Germany	21/201 (10.4)	N.E. [N.E.; N.E.]	16/201 (8.0)	N.E. [N.E.; N.E.]	1.48	[0.77; 2.85]	0.240	0.624
Germany	14/91 (15.4)	N.E. [N.E.; N.E.]	14/68 (20.6)	N.E. [N.E.; N.E.]	0.78	[0.37; 1.67]	0.526	0.811

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	53/188 (28.2)	N.E. [N.E.; N.E.]	65/203 (32.0)	N.E. [N.E.; N.E.]	0.85	[0.59; 1.22]	0.376	0.077
Myelosuppression (Thrombocytopenia)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.677)								
Low	48/290 (16.6)	N.E. [N.E.; N.E.]	53/291 (18.2)	N.E. [N.E.; N.E.]	0.90	[0.61; 1.33]	0.587	0.546
Intermediate	34/129 (26.4)	N.E. [N.E.; N.E.]	29/125 (23.2)	N.E. [N.E.; N.E.]	1.19	[0.73; 1.95]	0.465	0.475
High	21/61 (34.4)	N.E. [N.E.; N.E.]	19/56 (33.9)	N.E. [N.E.; N.E.]	0.95	[0.51; 1.77]	0.871	0.044
Sex (Interaction test: p = 0.218)								
Female	36/174	N.E. [N.E.; N.E.]	33/198	N.E. [N.E.; N.E.]	1.18	[0.73; 1.91]	0.489	0.552

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(20.7)		(16.7)					
Male	67/306	N.E. [N.E.; N.E.]	68/274	N.E. [N.E.; N.E.]	0.87	[0.62; 1.22]	0.423	0.140
	(21.9)		(24.8)					
Race								
(Interaction test: p = 0.892)								
Asian	44/128	N.E. [N.E.; N.E.]	43/130	N.E. [N.E.; N.E.]	1.05	[0.69; 1.62]	0.843	0.879
	(34.4)		(33.1)					
White	54/332	N.E. [N.E.; N.E.]	53/317	N.E. [N.E.; N.E.]	0.94	[0.64; 1.38]	0.754	0.014
	(16.3)		(16.7)					
Others	5/20	N.E. [1.9; N.E.]	5/25	N.E. [N.E.; N.E.]	2.00	[0.51; 7.79]	0.311	N.E.
	(25.0)		(20.0)					
Age groups								
(Interaction test: p = 0.379)								
18 - < 65 years	88/389	N.E. [N.E.; N.E.]	84/394	N.E. [N.E.; N.E.]	1.07	[0.79; 1.44]	0.660	0.268
	(22.6)		(21.3)					
65 - < 75 years	11/72	N.E. [N.E.; N.E.]	13/53	N.E. [N.E.; N.E.]	0.61	[0.27; 1.40]	0.251	0.764

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(15.3)		(24.5)					
>= 75 years	4/19	N.E. [N.E.; N.E.]	4/25	N.E. [N.E.; N.E.]	2.33	[0.43; 12.74]	0.316	0.996
	(21.1)		(16.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.167)								
Imatinib	24/100	N.E. [N.E.; N.E.]	29/100	N.E. [N.E.; N.E.]	0.80	[0.47; 1.38]	0.434	N.E.
	(24.0)		(29.0)					
Nilotinib	70/339	N.E. [N.E.; N.E.]	57/330	N.E. [N.E.; N.E.]	1.21	[0.85; 1.71]	0.293	0.681
	(20.6)		(17.3)					
Dasatinib	9/41	N.E. [N.E.; N.E.]	15/42	N.E. [4.0; N.E.]	0.54	[0.23; 1.26]	0.148	N.E.
	(22.0)		(35.7)					
Geographic region								
(Interaction test: p = 0.338)								
Europe excluding Germany	24/201	N.E. [N.E.; N.E.]	19/201	N.E. [N.E.; N.E.]	1.24	[0.67; 2.28]	0.488	0.182


	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(11.9)		(9.5)					
Germany	17/91	N.E. [N.E.; N.E.]	20/68	N.E. [N.E.; N.E.]	0.63	[0.32; 1.21]	0.180	0.066
	(18.7)		(29.4)					
Others	62/188	N.E. [N.E.; N.E.]	62/203	N.E. [N.E.; N.E.]	1.09	[0.77; 1.55]	0.637	0.501
	(33.0)		(30.5)					
QTc prolongation								
Race								
(Interaction test: p = 0.999)								
Asian	1/128	N.E. [N.E.; N.E.]	1/130	N.E. [N.E.; N.E.]	1.26	[0.08; 20.93]	0.871	N.E.
	(0.8)		(0.8)					
White	5/332	N.E. [N.E.; N.E.]	5/317	N.E. [N.E.; N.E.]	0.96	[0.27; 3.39]	0.964	0.549
	(1.5)		(1.6)					
Others	0/20	N.E. [N.E.; N.E.]	1/25	N.E. [N.E.; N.E.]	0.64	[0.01; 62.05]	0.480	N.E.
			(4.0)					
Pre-randomization selection of TKI								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 1.000)								
Imatinib	1/100 (1.0)	N.E. [N.E.; N.E.]	0/100	N.E. [N.E.; N.E.]	3.09	[0.03; 283.80]	0.310	N.E.
Nilotinib	5/339 (1.5)	N.E. [N.E.; N.E.]	5/330 (1.5)	N.E. [N.E.; N.E.]	1.02	[0.29; 3.53]	0.978	0.836
Dasatinib	0/41	N.E. [N.E.; N.E.]	2/42 (4.8)	N.E. [N.E.; N.E.]	0.22	[0.01; 8.88]	0.165	N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Hemorrhage: Sex: Female




Pts at Risk (censored)

Asciminib	174 (0)	153 (10)	133 (24)	92 (62)	52 (102)	17 (136)	0 (153)
Investigator Selected TKI	198 (0)	173 (18)	141 (44)	85 (95)	51 (129)	9 (171)	0 (180)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Hemorrhage: Sex: Male




Pts at Risk (censored)

Asciminib	306 (0)	284 (18)	258 (42)	182 (118)	115 (183)	22 (276)	0 (298)
Investigator Selected TKI	274 (0)	234 (31)	197 (62)	135 (121)	76 (180)	12 (243)	0 (255)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Hepatotoxicity (including laboratory terms): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	100 (0)	83 (4)	75 (8)	69 (11)	51 (29)	11 (69)	0 (79)
Investigator Selected TKI	100 (0)	72 (12)	62 (20)	50 (32)	31 (49)	4 (76)	0 (80)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Hepatotoxicity (including laboratory terms): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	289 (18)	252 (46)	152 (143)	74 (220)	11 (283)	0 (294)
Investigator Selected TKI	330 (0)	226 (23)	176 (55)	105 (124)	44 (185)	5 (224)	0 (229)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Hepatotoxicity (including laboratory terms): Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Hypersensitivity: Sex: Female




Pts at Risk (censored)

Asciminib	174 (0)	137 (12)	117 (24)	78 (61)	44 (94)	14 (124)	0 (138)
Investigator Selected TKI	198 (0)	104 (17)	79 (37)	47 (67)	28 (85)	4 (108)	0 (112)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Hypersensitivity: Sex: Male



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Hypersensitivity: Age groups: 18 - < 65 years




Pts at Risk (censored)

Asciminib	389 (0)	308 (22)	262 (51)	168 (139)	102 (201)	24 (278)	0 (302)
Investigator Selected TKI	394 (0)	254 (33)	204 (68)	126 (140)	72 (194)	8 (257)	0 (265)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Hypersensitivity: Age groups: 65 - < 75 years



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Hypersensitivity: Age groups: >= 75 years



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Myelosuppression (Erythropenia): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	100 (0)	83 (7)	79 (11)	76 (14)	55 (34)	11 (78)	0 (89)
Investigator Selected TKI	100 (0)	65 (11)	55 (21)	42 (33)	27 (48)	2 (73)	0 (75)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Myelosuppression (Erythropenia): Pre-randomization selection of TKI: Nilotinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11 Time to first grade 1/2 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Myelosuppression (Erythropenia): Pre-randomization selection of TKI: Dasatinib




Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	19/152	21/148	0.85	0.46; 1.59	0.616
ASC4START	29/237	29/246	1.01	0.60; 1.69	0.967
Pooled Analysis	48/389	50/394	0.94	0.63; 1.40	0.774
65 - < 75 years					
ASC4FIRST	7/34	6/29	1.07	0.36; 3.22	0.903
ASC4START	2/38	3/24	0.34	0.06; 2.06	0.218
Pooled Analysis	9/72	9/53	0.78	0.30; 2.00	0.602
>= 75 years					
ASC4FIRST	0/10	3/13	0.11	0.00; 3.60	0.055
ASC4START	0/9	3/12	0.18	0.01; 5.39	0.119
Pooled Analysis	0/19	6/25	0.07	0.00; 1.70	0.014




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	3/19	0.49	0.08; 2.93	0.419
ASC4START	4/38	2/37	1.84	0.34; 10.05	0.475
Pooled Analysis	6/61	5/56	1.00	0.30; 3.28	0.998
Intermediate					
ASC4FIRST	7/54	9/52	0.69	0.26; 1.86	0.459
ASC4START	5/75	7/73	0.64	0.20; 2.02	0.444
Pooled Analysis	12/129	16/125	0.67	0.32; 1.41	0.289
Low					
ASC4FIRST	17/119	18/119	0.91	0.47; 1.77	0.778
ASC4START	22/171	26/172	0.82	0.46; 1.44	0.478
Pooled Analysis	39/290	44/291	0.85	0.55; 1.31	0.470




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	8/63	7/61	1.19	0.41; 3.45	0.746
ASC4START	13/138	15/140	0.81	0.38; 1.70	0.568
Pooled Analysis	21/201	22/201	0.92	0.50; 1.69	0.778
Germany					
ASC4FIRST	2/19	2/15	0.27	0.02; 3.04	0.259
ASC4START	10/72	5/53	1.19	0.40; 3.52	0.756
Pooled Analysis	12/91	7/68	0.92	0.35; 2.39	0.858
Others					
ASC4FIRST	16/114	21/114	0.71	0.37; 1.36	0.294
ASC4START	8/74	15/89	0.63	0.27; 1.49	0.287
Pooled Analysis	24/188	36/203	0.68	0.40; 1.14	0.138




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	2/41	4/42	0.46	0.08; 2.65	0.377
Pooled Analysis	2/41	4/42	0.46	0.08; 2.65	0.377
Imatinib					
ASC4FIRST	19/100	15/100	1.26	0.64; 2.48	0.499
Pooled Analysis	19/100	15/100	1.26	0.64; 2.48	0.499
Nilotinib					
ASC4FIRST	5/55	11/48	0.26	0.09; 0.78	0.010
ASC4START	31/284	35/282	0.84	0.52; 1.36	0.474
Pooled Analysis	36/339	46/330	0.68	0.44; 1.06	0.082




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	6/40	6/45	1.35	0.43; 4.21	0.609
Pooled Analysis	19/128	21/130	0.92	0.49; 1.73	0.787
Asian/Others					
ASC4FIRST	13/91	15/89	0.81	0.38; 1.71	0.567
Others					
ASC4START	2/17	2/21	1.37	0.18; 10.39	0.762
Pooled Analysis	2/20	2/25	1.37	0.18; 10.39	0.762
White					
ASC4FIRST	13/105	15/101	0.83	0.39; 1.77	0.623
ASC4START	23/227	27/216	0.76	0.44; 1.33	0.338
Pooled Analysis	36/332	42/317	0.78	0.50; 1.23	0.287




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	12/67	8/74	1.51	0.62; 3.70	0.357
ASC4START	8/107	15/124	0.56	0.24; 1.33	0.187
Pooled Analysis	20/174	23/198	0.90	0.49; 1.64	0.732
Male					
ASC4FIRST	14/129	22/116	0.51	0.26; 1.00	0.046
ASC4START	23/177	20/158	1.01	0.55; 1.84	0.981
Pooled Analysis	37/306	42/274	0.74	0.48; 1.16	0.187




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arterial-occlusive events (AOE)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	1/41	1/42	1.04	0.06; 16.60	0.979
Pooled Analysis	1/41	1/42	1.04	0.06; 16.60	0.979
Imatinib					
ASC4FIRST	1/100	0/100	2.11	0.02; 207.43	0.414
Pooled Analysis	1/100	0/100	2.11	0.02; 207.43	0.414
Nilotinib					
ASC4FIRST	1/55	1/48	0.58	0.04; 9.35	0.695
ASC4START	4/284	6/282	0.59	0.17; 2.11	0.416
Pooled Analysis	5/339	7/330	0.59	0.19; 1.87	0.367




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arterial-occlusive events (AOE)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	0/67	1/74	0.64	0.01; 62.05	0.480
ASC4START	0/107	3/124	0.15	0.00; 4.69	0.094
Pooled Analysis	0/174	4/198	0.13	0.00; 3.59	0.070
Male					
ASC4FIRST	3/129	1/116	2.02	0.21; 19.56	0.535
ASC4START	4/177	3/158	1.11	0.25; 4.97	0.890
Pooled Analysis	7/306	4/274	1.35	0.39; 4.63	0.630




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	6/152	14/148	0.38	0.15; 1.00	0.042
ASC4START	9/237	15/246	0.61	0.27; 1.40	0.243
Pooled Analysis	15/389	29/394	0.50	0.27; 0.93	0.026
65 - < 75 years					
ASC4FIRST	1/34	7/29	0.12	0.01; 1.00	0.021
ASC4START	1/38	0/24	0.52	0.01; 45.81	0.670
Pooled Analysis	2/72	7/53	0.19	0.04; 1.00	0.033
>= 75 years					
ASC4FIRST	2/10	5/13	0.43	0.08; 2.37	0.317
ASC4START	0/9	3/12	0.18	0.01; 5.51	0.123
Pooled Analysis	2/19	8/25	0.27	0.06; 1.34	0.088




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	4/19	0.20	0.02; 1.76	0.101
ASC4START	0/38	2/37	0.18	0.00; 7.31	0.133
Pooled Analysis	1/61	6/56	0.14	0.02; 1.12	0.028
Intermediate					
ASC4FIRST	3/54	9/52	0.29	0.08; 1.06	0.047
ASC4START	1/75	5/73	0.18	0.02; 1.53	0.076
Pooled Analysis	4/129	14/125	0.25	0.08; 0.76	0.008
Low					
ASC4FIRST	5/119	13/119	0.35	0.12; 0.98	0.036
ASC4START	9/171	11/172	0.80	0.33; 1.94	0.627
Pooled Analysis	14/290	24/291	0.55	0.29; 1.07	0.073




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	1/63	9/61	0.11	0.01; 0.87	0.011
ASC4START	0/138	4/140	0.12	0.00; 3.09	0.052
Pooled Analysis	1/201	13/201	0.08	0.01; 0.59	0.001
Germany					
ASC4FIRST	1/19	0/15	2.11	0.02; 207.43	0.414
ASC4START	7/72	5/53	0.89	0.28; 2.85	0.844
Pooled Analysis	8/91	5/68	1.02	0.33; 3.18	0.967
Others					
ASC4FIRST	7/114	17/114	0.36	0.15; 0.88	0.020
ASC4START	3/74	9/89	0.39	0.10; 1.43	0.140
Pooled Analysis	10/188	26/203	0.37	0.18; 0.77	0.006




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	3/41	8/42	0.36	0.09; 1.40	0.127
Pooled Analysis	3/41	8/42	0.36	0.09; 1.40	0.127
Imatinib					
ASC4FIRST	3/100	15/100	0.18	0.05; 0.61	0.002
Pooled Analysis	3/100	15/100	0.18	0.05; 0.61	0.002
Nilotinib					
ASC4FIRST	3/55	3/48	0.86	0.17; 4.33	0.856
ASC4START	10/284	18/282	0.53	0.24; 1.15	0.103
Pooled Analysis	13/339	21/330	0.58	0.29; 1.16	0.119




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	5/45	0.09	0.00; 2.31	0.030
Pooled Analysis	3/128	16/130	0.17	0.05; 0.60	0.002
Asian/Others					
ASC4FIRST	3/91	13/89	0.21	0.06; 0.74	0.007
Others					
ASC4START	0/17	2/21	0.25	0.01; 11.81	0.219
Pooled Analysis	0/20	4/25	0.20	0.01; 6.89	0.158
White					
ASC4FIRST	6/105	13/101	0.42	0.16; 1.12	0.074
ASC4START	10/227	11/216	0.84	0.36; 1.98	0.695
Pooled Analysis	16/332	24/317	0.61	0.32; 1.16	0.132




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Edema and fluid retention

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	1/67	15/74	0.07	0.01; 0.51	<0.001
ASC4START	7/107	12/124	0.65	0.26; 1.65	0.362
Pooled Analysis	8/174	27/198	0.32	0.14; 0.70	0.003
Male					
ASC4FIRST	8/129	11/116	0.59	0.24; 1.48	0.255
ASC4START	3/177	6/158	0.43	0.11; 1.74	0.224
Pooled Analysis	11/306	17/274	0.54	0.25; 1.15	0.103




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	59/152	68/148	0.75	0.53; 1.07	0.109
ASC4START	70/237	65/246	1.14	0.81; 1.60	0.443
Pooled Analysis	129/389	133/394	0.93	0.73; 1.19	0.578
65 - < 75 years					
ASC4FIRST	11/34	9/29	0.96	0.39; 2.40	0.935
ASC4START	11/38	5/24	1.30	0.45; 3.81	0.625
Pooled Analysis	22/72	14/53	1.10	0.55; 2.18	0.793
>= 75 years					
ASC4FIRST	7/10	10/13	0.81	0.28; 2.35	0.710
ASC4START	3/9	7/12	0.58	0.14; 2.34	0.439
Pooled Analysis	10/19	17/25	0.71	0.31; 1.65	0.437




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	12/23	6/19	1.79	0.67; 4.79	0.243
ASC4START	8/38	8/37	0.96	0.36; 2.55	0.936
Pooled Analysis	20/61	14/56	1.32	0.66; 2.61	0.429
Intermediate					
ASC4FIRST	21/54	23/52	0.80	0.44; 1.44	0.451
ASC4START	21/75	18/73	1.15	0.62; 2.17	0.656
Pooled Analysis	42/129	41/125	0.95	0.62; 1.46	0.810
Low					
ASC4FIRST	44/119	58/119	0.65	0.44; 0.96	0.029
ASC4START	55/171	51/172	1.10	0.75; 1.61	0.632
Pooled Analysis	99/290	109/291	0.85	0.65; 1.11	0.238




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	22/63	31/61	0.55	0.32; 0.96	0.036
ASC4START	39/138	34/140	1.19	0.75; 1.88	0.465
Pooled Analysis	61/201	65/201	0.87	0.61; 1.23	0.436
Germany					
ASC4FIRST	8/19	4/15	4.67	0.98; 22.18	0.033
ASC4START	24/72	13/53	1.34	0.68; 2.64	0.407
Pooled Analysis	32/91	17/68	1.72	0.92; 3.20	0.084
Others					
ASC4FIRST	47/114	52/114	0.79	0.53; 1.18	0.259
ASC4START	21/74	30/89	0.83	0.47; 1.45	0.509
Pooled Analysis	68/188	82/203	0.81	0.58; 1.12	0.193




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	22/41	23/42	1.05	0.58; 1.92	0.874
Pooled Analysis	22/41	23/42	1.05	0.58; 1.92	0.874
Imatinib					
ASC4FIRST	34/100	43/100	0.64	0.41; 1.00	0.053
Pooled Analysis	34/100	43/100	0.64	0.41; 1.00	0.053
Nilotinib					
ASC4FIRST	21/55	21/48	0.75	0.41; 1.38	0.358
ASC4START	84/284	77/282	1.10	0.80; 1.49	0.560
Pooled Analysis	105/339	98/330	1.02	0.77; 1.34	0.914




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	12/40	14/45	1.00	0.46; 2.17	0.994
Pooled Analysis	38/128	44/130	0.80	0.52; 1.24	0.316
Asian/Others					
ASC4FIRST	28/91	33/89	0.73	0.44; 1.21	0.215
Others					
ASC4START	3/17	8/21	0.43	0.11; 1.69	0.215
Pooled Analysis	5/20	11/25	0.57	0.17; 1.95	0.326
White					
ASC4FIRST	49/105	54/101	0.77	0.52; 1.14	0.185
ASC4START	69/227	55/216	1.22	0.86; 1.74	0.263
Pooled Analysis	118/332	109/317	0.99	0.76; 1.29	0.966




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Gastrointestinal toxicity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	29/67	41/74	0.76	0.46; 1.24	0.277
ASC4START	34/107	39/124	1.01	0.64; 1.60	0.960
Pooled Analysis	63/174	80/198	0.88	0.63; 1.24	0.481
Male					
ASC4FIRST	48/129	46/116	0.82	0.55; 1.23	0.344
ASC4START	50/177	38/158	1.19	0.78; 1.81	0.430
Pooled Analysis	98/306	84/274	0.98	0.73; 1.32	0.903




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	10/152	12/148	0.76	0.33; 1.77	0.526
ASC4START	12/237	17/246	0.67	0.32; 1.40	0.280
Pooled Analysis	22/389	29/394	0.71	0.41; 1.23	0.218
65 - < 75 years					
ASC4FIRST	1/34	6/29	0.13	0.02; 1.12	0.032
ASC4START	4/38	2/24	1.01	0.18; 5.52	0.992
Pooled Analysis	5/72	8/53	0.41	0.13; 1.28	0.113
>= 75 years					
ASC4FIRST	2/10	0/13	2.92	0.07; 121.64	0.281
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	2/19	0/25	2.92	0.07; 121.64	0.281




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	0/23	0/19	N.E.	N.E.; N.E.	N.E.
ASC4START	2/38	5/37	0.35	0.07; 1.79	0.186
Pooled Analysis	2/61	5/56	0.35	0.07; 1.79	0.186
Intermediate					
ASC4FIRST	6/54	7/52	0.64	0.21; 1.93	0.426
ASC4START	5/75	3/73	1.50	0.36; 6.27	0.578
Pooled Analysis	11/129	10/125	0.89	0.37; 2.09	0.782
Low					
ASC4FIRST	7/119	11/119	0.60	0.23; 1.54	0.283
ASC4START	9/171	11/172	0.79	0.33; 1.91	0.601
Pooled Analysis	16/290	22/291	0.69	0.36; 1.32	0.264




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	2/63	6/61	0.31	0.06; 1.53	0.127
ASC4START	6/138	9/140	0.60	0.21; 1.69	0.327
Pooled Analysis	8/201	15/201	0.48	0.20; 1.14	0.091
Germany					
ASC4FIRST	1/19	1/15	0.79	0.05; 12.65	0.868
ASC4START	3/72	3/53	0.75	0.15; 3.79	0.725
Pooled Analysis	4/91	4/68	0.76	0.19; 3.08	0.699
Others					
ASC4FIRST	10/114	11/114	0.79	0.34; 1.87	0.596
ASC4START	7/74	7/89	1.24	0.43; 3.60	0.689
Pooled Analysis	17/188	18/203	0.95	0.48; 1.85	0.871




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	2/41	7/42	0.27	0.06; 1.34	0.087
Pooled Analysis	2/41	7/42	0.27	0.06; 1.34	0.087
Imatinib					
ASC4FIRST	6/100	9/100	0.58	0.21; 1.64	0.299
Pooled Analysis	6/100	9/100	0.58	0.21; 1.64	0.299
Nilotinib					
ASC4FIRST	5/55	2/48	2.03	0.39; 10.46	0.390
ASC4START	16/284	19/282	0.78	0.40; 1.52	0.471
Pooled Analysis	21/339	21/330	0.91	0.50; 1.67	0.757




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	1/40	4/45	0.28	0.03; 2.53	0.228
Pooled Analysis	5/128	11/130	0.39	0.13; 1.15	0.078
Asian/Others					
ASC4FIRST	4/91	8/89	0.40	0.12; 1.36	0.129
Others					
ASC4START	3/17	1/21	5.09	0.48; 54.08	0.144
Pooled Analysis	3/20	2/25	5.09	0.48; 54.08	0.144
White					
ASC4FIRST	9/105	10/101	0.83	0.33; 2.05	0.682
ASC4START	12/227	14/216	0.76	0.35; 1.65	0.488
Pooled Analysis	21/332	24/317	0.79	0.44; 1.42	0.428




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hemorrhage

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	9/67	11/74	0.79	0.33; 1.92	0.605
ASC4START	12/107	7/124	1.91	0.75; 4.86	0.166
Pooled Analysis	21/174	18/198	1.21	0.64; 2.28	0.552
Male					
ASC4FIRST	4/129	7/116	0.42	0.12; 1.44	0.155
ASC4START	4/177	12/158	0.27	0.09; 0.83	0.014
Pooled Analysis	8/306	19/274	0.32	0.14; 0.74	0.005




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	6/152	3/148	1.84	0.46; 7.38	0.382
ASC4START	3/237	10/246	0.30	0.08; 1.09	0.053
Pooled Analysis	9/389	13/394	0.67	0.29; 1.57	0.351
65 - < 75 years					
ASC4FIRST	0/34	1/29	0.17	0.00; 15.37	0.157
ASC4START	1/38	1/24	0.66	0.04; 11.22	0.773
Pooled Analysis	1/72	2/53	0.29	0.03; 3.35	0.297
>= 75 years					
ASC4FIRST	0/10	0/13	N.E.	N.E.; N.E.	N.E.
ASC4START	0/9	1/12	0.53	0.01; 51.67	0.439
Pooled Analysis	0/19	1/25	0.53	0.01; 51.67	0.439




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	0/23	1/19	0.29	0.00; 26.38	0.280
ASC4START	0/38	3/37	0.13	0.00; 3.89	0.066
Pooled Analysis	0/61	4/56	0.10	0.00; 2.57	0.033
Intermediate					
ASC4FIRST	3/54	0/52	5.09	0.16; 158.08	0.141
ASC4START	1/75	0/73	2.64	0.03; 254.86	0.358
Pooled Analysis	4/129	0/125	6.81	0.26; 180.38	0.083
Low					
ASC4FIRST	3/119	3/119	0.93	0.19; 4.60	0.925
ASC4START	3/171	9/172	0.32	0.09; 1.19	0.073
Pooled Analysis	6/290	12/291	0.48	0.18; 1.27	0.128




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	1/63	1/61	1.19	0.07; 19.00	0.903
ASC4START	3/138	5/140	0.57	0.14; 2.40	0.437
Pooled Analysis	4/201	6/201	0.66	0.19; 2.36	0.522
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	0/72	0/53	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/91	0/68	N.E.	N.E.; N.E.	N.E.
Others					
ASC4FIRST	5/114	3/114	1.36	0.32; 5.80	0.673
ASC4START	1/74	7/89	0.19	0.02; 1.54	0.081
Pooled Analysis	6/188	10/203	0.61	0.22; 1.72	0.348




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	1/41	0/42	2.99	0.03; 275.43	0.317
Pooled Analysis	1/41	0/42	2.99	0.03; 275.43	0.317
Imatinib					
ASC4FIRST	3/100	1/100	2.46	0.25; 23.90	0.424
Pooled Analysis	3/100	1/100	2.46	0.25; 23.90	0.424
Nilotinib					
ASC4FIRST	2/55	3/48	0.56	0.09; 3.43	0.528
ASC4START	4/284	12/282	0.31	0.10; 0.97	0.034
Pooled Analysis	6/339	15/330	0.37	0.14; 0.95	0.031




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	1/40	7/45	0.17	0.02; 1.35	0.056
Pooled Analysis	6/128	10/130	0.57	0.20; 1.61	0.287
Asian/Others					
ASC4FIRST	5/91	3/89	1.36	0.32; 5.91	0.676
Others					
ASC4START	0/17	0/21	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/20	0/25	N.E.	N.E.; N.E.	N.E.
White					
ASC4FIRST	1/105	1/101	1.10	0.07; 17.56	0.947
ASC4START	3/227	5/216	0.55	0.13; 2.31	0.409
Pooled Analysis	4/332	6/317	0.63	0.18; 2.25	0.478




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (clinical events)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	0/67	2/74	0.21	0.01; 8.63	0.167
ASC4START	1/107	7/124	0.15	0.02; 1.20	0.038
Pooled Analysis	1/174	9/198	0.11	0.01; 0.91	0.013
Male					
ASC4FIRST	6/129	2/116	2.20	0.44; 10.98	0.326
ASC4START	3/177	5/158	0.52	0.12; 2.18	0.363
Pooled Analysis	9/306	7/274	1.02	0.38; 2.75	0.969




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	33/152	41/148	0.73	0.46; 1.16	0.188
ASC4START	28/237	72/246	0.35	0.23; 0.54	<0.001
Pooled Analysis	61/389	113/394	0.49	0.36; 0.67	<0.001
65 - < 75 years					
ASC4FIRST	6/34	6/29	0.84	0.27; 2.63	0.758
ASC4START	5/38	6/24	0.37	0.11; 1.27	0.111
Pooled Analysis	11/72	12/53	0.57	0.24; 1.33	0.200
>= 75 years					
ASC4FIRST	0/10	1/13	0.33	0.00; 30.79	0.317
ASC4START	1/9	4/12	0.29	0.03; 2.62	0.228
Pooled Analysis	1/19	5/25	0.23	0.03; 1.95	0.130




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	6/23	5/19	0.91	0.28; 3.00	0.895
ASC4START	6/38	12/37	0.43	0.16; 1.14	0.081
Pooled Analysis	12/61	17/56	0.58	0.27; 1.21	0.144
Intermediate					
ASC4FIRST	11/54	10/52	0.96	0.41; 2.27	0.935
ASC4START	5/75	17/73	0.24	0.09; 0.66	0.003
Pooled Analysis	16/129	27/125	0.50	0.27; 0.93	0.027
Low					
ASC4FIRST	22/119	33/119	0.60	0.35; 1.02	0.061
ASC4START	23/171	53/172	0.38	0.23; 0.61	<0.001
Pooled Analysis	45/290	86/291	0.46	0.32; 0.66	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	7/63	4/61	1.24	0.34; 4.50	0.743
ASC4START	16/138	31/140	0.47	0.26; 0.86	0.013
Pooled Analysis	23/201	35/201	0.56	0.33; 0.96	0.033
Germany					
ASC4FIRST	2/19	3/15	0.48	0.08; 2.93	0.421
ASC4START	10/72	17/53	0.34	0.15; 0.74	0.005
Pooled Analysis	12/91	20/68	0.36	0.17; 0.74	0.004
Others					
ASC4FIRST	30/114	41/114	0.64	0.40; 1.02	0.065
ASC4START	8/74	34/89	0.24	0.11; 0.52	<0.001
Pooled Analysis	38/188	75/203	0.47	0.32; 0.69	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	7/41	9/42	0.68	0.25; 1.86	0.448
Pooled Analysis	7/41	9/42	0.68	0.25; 1.86	0.448
Imatinib					
ASC4FIRST	21/100	20/100	0.98	0.53; 1.81	0.951
Pooled Analysis	21/100	20/100	0.98	0.53; 1.81	0.951
Nilotinib					
ASC4FIRST	11/55	19/48	0.43	0.20; 0.90	0.024
ASC4START	34/284	82/282	0.35	0.24; 0.53	<0.001
Pooled Analysis	45/339	101/330	0.37	0.26; 0.53	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	7/40	17/45	0.40	0.16; 0.96	0.034
Pooled Analysis	33/128	53/130	0.54	0.35; 0.84	0.005
Asian/Others					
ASC4FIRST	26/91	37/89	0.61	0.36; 1.00	0.051
Others					
ASC4START	1/17	7/21	0.13	0.02; 1.07	0.026
Pooled Analysis	1/20	8/25	0.13	0.02; 1.07	0.026
White					
ASC4FIRST	13/105	11/101	1.10	0.49; 2.50	0.816
ASC4START	26/227	58/216	0.37	0.24; 0.60	<0.001
Pooled Analysis	39/332	69/317	0.48	0.32; 0.71	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	11/67	17/74	0.61	0.28; 1.31	0.200
ASC4START	17/107	38/124	0.43	0.24; 0.76	0.003
Pooled Analysis	28/174	55/198	0.48	0.31; 0.77	0.002
Male					
ASC4FIRST	28/129	31/116	0.68	0.41; 1.15	0.155
ASC4START	17/177	44/158	0.31	0.18; 0.54	<0.001
Pooled Analysis	45/306	75/274	0.46	0.32; 0.67	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	44/152	58/148	0.63	0.42; 0.93	0.019
ASC4START	43/237	71/246	0.54	0.37; 0.80	0.001
Pooled Analysis	87/389	129/394	0.58	0.44; 0.76	<0.001
65 - < 75 years					
ASC4FIRST	5/34	17/29	0.17	0.06; 0.48	<0.001
ASC4START	5/38	6/24	0.38	0.12; 1.27	0.104
Pooled Analysis	10/72	23/53	0.24	0.11; 0.51	<0.001
>= 75 years					
ASC4FIRST	2/10	8/13	0.23	0.05; 1.11	0.046
ASC4START	1/9	2/12	1.12	0.07; 17.96	0.937
Pooled Analysis	3/19	10/25	0.32	0.08; 1.21	0.078




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	3/23	5/19	0.39	0.09; 1.64	0.181
ASC4START	4/38	11/37	0.29	0.09; 0.92	0.026
Pooled Analysis	7/61	16/56	0.33	0.13; 0.80	0.010
Intermediate					
ASC4FIRST	14/54	18/52	0.58	0.29; 1.17	0.126
ASC4START	16/75	19/73	0.69	0.35; 1.34	0.265
Pooled Analysis	30/129	37/125	0.63	0.39; 1.03	0.063
Low					
ASC4FIRST	34/119	60/119	0.45	0.29; 0.68	<0.001
ASC4START	29/171	49/172	0.52	0.33; 0.82	0.005
Pooled Analysis	63/290	109/291	0.48	0.35; 0.65	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	13/63	30/61	0.34	0.17; 0.66	<0.001
ASC4START	17/138	30/140	0.52	0.28; 0.94	0.027
Pooled Analysis	30/201	60/201	0.42	0.27; 0.66	<0.001
Germany					
ASC4FIRST	3/19	5/15	0.58	0.13; 2.61	0.472
ASC4START	14/72	15/53	0.60	0.29; 1.26	0.173
Pooled Analysis	17/91	20/68	0.60	0.31; 1.16	0.124
Others					
ASC4FIRST	35/114	48/114	0.58	0.37; 0.90	0.014
ASC4START	18/74	34/89	0.51	0.29; 0.91	0.021
Pooled Analysis	53/188	82/203	0.55	0.39; 0.78	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	11/41	19/42	0.56	0.26; 1.21	0.136
Pooled Analysis	11/41	19/42	0.56	0.26; 1.21	0.136
Imatinib					
ASC4FIRST	23/100	43/100	0.41	0.24; 0.68	<0.001
Pooled Analysis	23/100	43/100	0.41	0.24; 0.68	<0.001
Nilotinib					
ASC4FIRST	17/55	21/48	0.51	0.27; 0.97	0.039
ASC4START	49/284	79/282	0.53	0.37; 0.76	<0.001
Pooled Analysis	66/339	100/330	0.52	0.38; 0.72	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	6/40	17/45	0.30	0.12; 0.76	0.008
Pooled Analysis	34/128	54/130	0.49	0.31; 0.75	<0.001
Asian/Others					
ASC4FIRST	29/91	40/89	0.55	0.34; 0.89	0.014
Others					
ASC4START	5/17	5/21	1.47	0.41; 5.22	0.550
Pooled Analysis	6/20	8/25	1.46	0.46; 4.64	0.519
White					
ASC4FIRST	22/105	43/101	0.40	0.24; 0.67	<0.001
ASC4START	38/227	57/216	0.55	0.37; 0.83	0.004
Pooled Analysis	60/332	100/317	0.48	0.35; 0.67	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hypersensitivity

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	16/67	40/74	0.32	0.18; 0.57	<0.001
ASC4START	20/107	46/124	0.39	0.23; 0.66	<0.001
Pooled Analysis	36/174	86/198	0.35	0.24; 0.52	<0.001
Male					
ASC4FIRST	35/129	43/116	0.63	0.40; 0.98	0.041
ASC4START	29/177	33/158	0.73	0.44; 1.20	0.207
Pooled Analysis	64/306	76/274	0.67	0.48; 0.94	0.018




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	7/152	9/148	0.71	0.26; 1.91	0.494
ASC4START	6/237	10/246	0.59	0.22; 1.63	0.307
Pooled Analysis	13/389	19/394	0.65	0.32; 1.32	0.227
65 - < 75 years					
ASC4FIRST	1/34	1/29	0.76	0.05; 12.29	0.847
ASC4START	1/38	1/24	0.46	0.03; 7.32	0.570
Pooled Analysis	2/72	2/53	0.59	0.08; 4.27	0.596
>= 75 years					
ASC4FIRST	3/10	2/13	1.60	0.26; 9.82	0.608
ASC4START	0/9	1/12	0.39	0.00; 38.92	0.371
Pooled Analysis	3/19	3/25	1.09	0.22; 5.48	0.920




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	0/23	0/19	N.E.	N.E.; N.E.	N.E.
ASC4START	1/38	1/37	0.94	0.06; 15.05	0.966
Pooled Analysis	1/61	1/56	0.94	0.06; 15.05	0.966
Intermediate					
ASC4FIRST	8/54	4/52	1.76	0.53; 5.83	0.351
ASC4START	2/75	4/73	0.43	0.08; 2.33	0.311
Pooled Analysis	10/129	8/125	1.09	0.43; 2.75	0.861
Low					
ASC4FIRST	3/119	8/119	0.33	0.09; 1.25	0.087
ASC4START	4/171	7/172	0.56	0.16; 1.91	0.348
Pooled Analysis	7/290	15/291	0.43	0.18; 1.07	0.061




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	3/63	1/61	3.16	0.33; 30.41	0.294
ASC4START	4/138	3/140	1.28	0.29; 5.77	0.745
Pooled Analysis	7/201	4/201	1.74	0.51; 5.98	0.371
Germany					
ASC4FIRST	2/19	3/15	0.55	0.09; 3.29	0.485
ASC4START	1/72	3/53	0.31	0.03; 3.06	0.292
Pooled Analysis	3/91	6/68	0.44	0.11; 1.76	0.219
Others					
ASC4FIRST	6/114	8/114	0.66	0.23; 1.91	0.440
ASC4START	2/74	6/89	0.35	0.07; 1.76	0.183
Pooled Analysis	8/188	14/203	0.54	0.22; 1.29	0.156




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	3/41	4/42	0.90	0.20; 4.04	0.891
Pooled Analysis	3/41	4/42	0.90	0.20; 4.04	0.891
Imatinib					
ASC4FIRST	5/100	6/100	0.73	0.22; 2.39	0.599
Pooled Analysis	5/100	6/100	0.73	0.22; 2.39	0.599
Nilotinib					
ASC4FIRST	3/55	2/48	1.02	0.17; 6.17	0.983
ASC4START	7/284	12/282	0.54	0.21; 1.38	0.195
Pooled Analysis	10/339	14/330	0.62	0.28; 1.41	0.250




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	1/40	3/45	0.37	0.04; 3.72	0.379
Pooled Analysis	7/128	10/130	0.58	0.22; 1.54	0.266
Asian/Others					
ASC4FIRST	6/91	7/89	0.64	0.22; 1.93	0.430
Others					
ASC4START	2/17	0/21	4.25	0.10; 175.93	0.193
Pooled Analysis	2/20	0/25	4.25	0.10; 175.93	0.193
White					
ASC4FIRST	5/105	5/101	1.06	0.30; 3.75	0.929
ASC4START	4/227	9/216	0.40	0.12; 1.29	0.111
Pooled Analysis	9/332	14/317	0.61	0.26; 1.43	0.249




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	1/67	5/74	0.20	0.02; 1.70	0.101
ASC4START	0/107	4/124	0.13	0.00; 3.35	0.062
Pooled Analysis	1/174	9/198	0.12	0.01; 0.92	0.014
Male					
ASC4FIRST	10/129	7/116	1.17	0.45; 3.09	0.744
ASC4START	7/177	8/158	0.74	0.27; 2.04	0.558
Pooled Analysis	17/306	15/274	0.94	0.47; 1.89	0.870




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	19/152	33/148	0.52	0.29; 0.91	0.020
ASC4START	18/237	22/246	0.83	0.44; 1.54	0.548
Pooled Analysis	37/389	55/394	0.64	0.42; 0.96	0.032
65 - < 75 years					
ASC4FIRST	3/34	7/29	0.46	0.12; 1.78	0.243
ASC4START	2/38	1/24	1.41	0.12; 15.84	0.782
Pooled Analysis	5/72	8/53	0.60	0.19; 1.86	0.371
>= 75 years					
ASC4FIRST	2/10	7/13	0.22	0.03; 1.85	0.124
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	2/19	7/25	0.22	0.03; 1.85	0.124




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	8/19	0.08	0.01; 0.64	0.002
ASC4START	3/38	4/37	0.68	0.15; 3.02	0.609
Pooled Analysis	4/61	12/56	0.25	0.08; 0.77	0.009
Intermediate					
ASC4FIRST	10/54	12/52	0.79	0.34; 1.83	0.582
ASC4START	7/75	5/73	1.28	0.41; 4.05	0.667
Pooled Analysis	17/129	17/125	0.94	0.48; 1.84	0.853
Low					
ASC4FIRST	13/119	27/119	0.45	0.23; 0.87	0.015
ASC4START	10/171	14/172	0.72	0.32; 1.61	0.413
Pooled Analysis	23/290	41/291	0.54	0.32; 0.90	0.016




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	2/63	15/61	0.12	0.03; 0.52	0.001
ASC4START	8/138	7/140	1.16	0.42; 3.20	0.779
Pooled Analysis	10/201	22/201	0.44	0.21; 0.94	0.030
Germany					
ASC4FIRST	1/19	4/15	0.22	0.02; 2.16	0.157
ASC4START	2/72	3/53	0.50	0.08; 3.01	0.437
Pooled Analysis	3/91	7/68	0.35	0.09; 1.43	0.128
Others					
ASC4FIRST	21/114	28/114	0.71	0.40; 1.26	0.251
ASC4START	10/74	13/89	0.91	0.39; 2.08	0.818
Pooled Analysis	31/188	41/203	0.77	0.48; 1.23	0.281




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	3/41	15/42	0.15	0.04; 0.52	<0.001
Pooled Analysis	3/41	15/42	0.15	0.04; 0.52	<0.001
Imatinib					
ASC4FIRST	11/100	25/100	0.42	0.20; 0.85	0.013
Pooled Analysis	11/100	25/100	0.42	0.20; 0.85	0.013
Nilotinib					
ASC4FIRST	10/55	7/48	1.20	0.45; 3.17	0.712
ASC4START	20/284	23/282	0.84	0.46; 1.52	0.555
Pooled Analysis	30/339	30/330	0.92	0.56; 1.53	0.759




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	3/40	4/45	0.79	0.18; 3.57	0.779
Pooled Analysis	22/128	29/130	0.70	0.40; 1.22	0.211
Asian/Others					
ASC4FIRST	19/91	26/89	0.67	0.37; 1.22	0.191
Others					
ASC4START	3/17	5/21	0.82	0.19; 3.57	0.790
Pooled Analysis	3/20	6/25	0.82	0.19; 3.57	0.790
White					
ASC4FIRST	5/105	21/101	0.20	0.07; 0.54	<0.001
ASC4START	14/227	14/216	0.94	0.45; 1.97	0.865
Pooled Analysis	19/332	35/317	0.49	0.28; 0.86	0.011




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	7/67	27/74	0.28	0.12; 0.66	0.002
ASC4START	12/107	13/124	1.05	0.48; 2.30	0.908
Pooled Analysis	19/174	40/198	0.53	0.31; 0.92	0.022
Male					
ASC4FIRST	17/129	20/116	0.76	0.40; 1.46	0.426
ASC4START	8/177	10/158	0.67	0.26; 1.70	0.396
Pooled Analysis	25/306	30/274	0.73	0.43; 1.25	0.254




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	44/152	52/148	0.86	0.57; 1.28	0.455
ASC4START	30/237	24/246	1.26	0.74; 2.16	0.394
Pooled Analysis	74/389	76/394	0.98	0.71; 1.36	0.935
65 - < 75 years					
ASC4FIRST	9/34	11/29	0.60	0.23; 1.56	0.260
ASC4START	1/38	2/24	0.37	0.03; 4.13	0.401
Pooled Analysis	10/72	13/53	0.56	0.23; 1.36	0.173
>= 75 years					
ASC4FIRST	3/10	6/13	0.79	0.18; 3.52	0.753
ASC4START	1/9	0/12	3.71	0.04; 338.14	0.264
Pooled Analysis	4/19	6/25	1.07	0.27; 4.29	0.921




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	6/19	0.24	0.05; 1.20	0.061
ASC4START	6/38	8/37	0.67	0.23; 1.93	0.459
Pooled Analysis	8/61	14/56	0.47	0.20; 1.13	0.087
Intermediate					
ASC4FIRST	19/54	19/52	1.04	0.55; 1.96	0.910
ASC4START	8/75	4/73	1.86	0.56; 6.17	0.302
Pooled Analysis	27/129	23/125	1.18	0.68; 2.07	0.544
Low					
ASC4FIRST	35/119	44/119	0.80	0.51; 1.25	0.322
ASC4START	18/171	14/172	1.30	0.65; 2.62	0.455
Pooled Analysis	53/290	58/291	0.92	0.64; 1.34	0.668




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	12/63	11/61	1.31	0.57; 2.97	0.530
ASC4START	9/138	5/140	1.84	0.62; 5.50	0.270
Pooled Analysis	21/201	16/201	1.48	0.77; 2.85	0.240
Germany					
ASC4FIRST	7/19	7/15	0.86	0.29; 2.59	0.793
ASC4START	7/72	7/53	0.72	0.25; 2.05	0.533
Pooled Analysis	14/91	14/68	0.78	0.37; 1.67	0.526
Others					
ASC4FIRST	37/114	51/114	0.70	0.46; 1.07	0.099
ASC4START	16/74	14/89	1.49	0.72; 3.08	0.273
Pooled Analysis	53/188	65/203	0.85	0.59; 1.22	0.376




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	8/41	21/42	0.40	0.17; 0.92	0.025
Pooled Analysis	8/41	21/42	0.40	0.17; 0.92	0.025
Imatinib					
ASC4FIRST	29/100	34/100	0.88	0.54; 1.45	0.604
Pooled Analysis	29/100	34/100	0.88	0.54; 1.45	0.604
Nilotinib					
ASC4FIRST	19/55	14/48	1.19	0.59; 2.37	0.615
ASC4START	32/284	26/282	1.19	0.71; 2.00	0.508
Pooled Analysis	51/339	40/330	1.19	0.78; 1.80	0.406




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	4/40	5/45	0.82	0.22; 3.09	0.767
Pooled Analysis	40/128	46/130	0.81	0.53; 1.24	0.340
Asian/Others					
ASC4FIRST	36/91	43/89	0.79	0.50; 1.23	0.299
Others					
ASC4START	7/17	6/21	1.92	0.62; 5.93	0.218
Pooled Analysis	7/20	8/25	1.92	0.62; 5.93	0.218
White					
ASC4FIRST	20/105	26/101	0.85	0.47; 1.55	0.594
ASC4START	21/227	15/216	1.29	0.67; 2.51	0.446
Pooled Analysis	41/332	41/317	1.03	0.66; 1.60	0.904




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	21/67	30/74	0.77	0.44; 1.36	0.371
ASC4START	14/107	10/124	1.56	0.69; 3.52	0.276
Pooled Analysis	35/174	40/198	0.97	0.62; 1.54	0.915
Male					
ASC4FIRST	35/129	39/116	0.84	0.53; 1.33	0.473
ASC4START	18/177	16/158	0.98	0.50; 1.93	0.957
Pooled Analysis	53/306	55/274	0.89	0.61; 1.29	0.533




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	40/152	45/148	0.90	0.59; 1.38	0.619
ASC4START	48/237	39/246	1.26	0.83; 1.93	0.272
Pooled Analysis	88/389	84/394	1.07	0.79; 1.44	0.660
65 - < 75 years					
ASC4FIRST	8/34	10/29	0.57	0.21; 1.50	0.258
ASC4START	3/38	3/24	0.75	0.15; 3.77	0.731
Pooled Analysis	11/72	13/53	0.61	0.27; 1.40	0.251
>= 75 years					
ASC4FIRST	2/10	4/13	1.13	0.16; 8.06	0.903
ASC4START	2/9	0/12	6.13	0.15; 252.58	0.118
Pooled Analysis	4/19	4/25	2.33	0.43; 12.74	0.316




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	6/23	10/19	0.42	0.15; 1.17	0.082
ASC4START	15/38	9/37	1.63	0.71; 3.72	0.243
Pooled Analysis	21/61	19/56	0.95	0.51; 1.77	0.871
Intermediate					
ASC4FIRST	20/54	20/52	1.04	0.56; 1.93	0.878
ASC4START	14/75	9/73	1.52	0.66; 3.51	0.318
Pooled Analysis	34/129	29/125	1.19	0.73; 1.95	0.465
Low					
ASC4FIRST	24/119	29/119	0.80	0.47; 1.37	0.416
ASC4START	24/171	24/172	1.02	0.58; 1.79	0.949
Pooled Analysis	48/290	53/291	0.90	0.61; 1.33	0.587




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	9/63	11/61	0.79	0.32; 1.94	0.607
ASC4START	15/138	8/140	1.84	0.78; 4.36	0.160
Pooled Analysis	24/201	19/201	1.24	0.67; 2.28	0.488
Germany					
ASC4FIRST	2/19	8/15	0.17	0.03; 0.85	0.020
ASC4START	15/72	12/53	0.91	0.42; 1.96	0.830
Pooled Analysis	17/91	20/68	0.63	0.32; 1.21	0.180
Others					
ASC4FIRST	39/114	40/114	0.99	0.64; 1.55	0.972
ASC4START	23/74	22/89	1.28	0.71; 2.30	0.406
Pooled Analysis	62/188	62/203	1.09	0.77; 1.55	0.637




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	9/41	15/42	0.54	0.23; 1.26	0.148
Pooled Analysis	9/41	15/42	0.54	0.23; 1.26	0.148
Imatinib					
ASC4FIRST	24/100	29/100	0.80	0.47; 1.38	0.434
Pooled Analysis	24/100	29/100	0.80	0.47; 1.38	0.434
Nilotinib					
ASC4FIRST	17/55	15/48	1.06	0.53; 2.14	0.878
ASC4START	53/284	42/282	1.26	0.84; 1.89	0.261
Pooled Analysis	70/339	57/330	1.21	0.85; 1.71	0.293




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	8/40	8/45	0.98	0.37; 2.63	0.974
Pooled Analysis	44/128	43/130	1.05	0.69; 1.62	0.843
Asian/Others					
ASC4FIRST	36/91	35/89	1.06	0.66; 1.70	0.853
Others					
ASC4START	5/17	5/21	2.00	0.51; 7.79	0.311
Pooled Analysis	5/20	5/25	2.00	0.51; 7.79	0.311
White					
ASC4FIRST	14/105	24/101	0.48	0.24; 0.94	0.029
ASC4START	40/227	29/216	1.34	0.83; 2.16	0.230
Pooled Analysis	54/332	53/317	0.94	0.64; 1.38	0.754




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	18/67	19/74	1.03	0.54; 1.99	0.922
ASC4START	18/107	14/124	1.38	0.69; 2.78	0.364
Pooled Analysis	36/174	33/198	1.18	0.73; 1.91	0.489
Male					
ASC4FIRST	32/129	40/116	0.68	0.43; 1.09	0.106
ASC4START	35/177	28/158	1.14	0.69; 1.87	0.598
Pooled Analysis	67/306	68/274	0.87	0.62; 1.22	0.423




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

QTc prolongation

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	0/41	2/42	0.22	0.01; 8.88	0.165
Pooled Analysis	0/41	2/42	0.22	0.01; 8.88	0.165
Imatinib					
ASC4FIRST	1/100	0/100	3.09	0.03; 283.80	0.310
Pooled Analysis	1/100	0/100	3.09	0.03; 283.80	0.310
Nilotinib					
ASC4FIRST	1/55	1/48	1.32	0.08; 21.27	0.843
ASC4START	4/284	4/282	0.95	0.24; 3.81	0.946
Pooled Analysis	5/339	5/330	1.02	0.29; 3.53	0.978




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.11.1: Forest-Plot for Grade 1/2 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

QTc prolongation

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	0/45	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	1/128	1/130	1.26	0.08; 20.93	0.871
Asian/Others					
ASC4FIRST	1/91	1/89	1.16	0.07; 18.74	0.918
Others					
ASC4START	0/17	1/21	0.64	0.01; 62.05	0.480
Pooled Analysis	0/20	1/25	0.64	0.01; 62.05	0.480
White					
ASC4FIRST	1/105	2/101	0.50	0.04; 6.21	0.595
ASC4START	4/227	3/216	1.23	0.28; 5.50	0.785
Pooled Analysis	5/332	5/317	0.96	0.27; 3.39	0.964



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Acute pancreatitis (including isolated pancreatic enzyme elevations)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.417)								
Low	6/290 (2.1)	N.E. [N.E.; N.E.]	14/291 (4.8)	N.E. [N.E.; N.E.]	0.41	[0.16; 1.07]	0.059	0.346
Intermediate	2/129 (1.6)	N.E. [N.E.; N.E.]	7/125 (5.6)	N.E. [N.E.; N.E.]	0.27	[0.06; 1.28]	0.076	0.994
High	3/61 (4.9)	N.E. [N.E.; N.E.]	2/56 (3.6)	N.E. [N.E.; N.E.]	1.23	[0.20; 7.45]	0.818	0.602
Sex (Interaction test: p = 0.559)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Female	3/174 (1.7)	N.E. [N.E.; N.E.]	10/198 (5.1)	N.E. [N.E.; N.E.]	0.33	[0.09; 1.18]	0.072	0.993
Male	8/306 (2.6)	N.E. [N.E.; N.E.]	13/274 (4.7)	N.E. [N.E.; N.E.]	0.49	[0.20; 1.18]	0.106	0.769
Race								
(Interaction test: p = 0.563)								
Asian	4/128 (3.1)	N.E. [N.E.; N.E.]	6/130 (4.6)	N.E. [N.E.; N.E.]	0.74	[0.21; 2.64]	0.641	0.571
White	6/332 (1.8)	N.E. [N.E.; N.E.]	16/317 (5.0)	N.E. [N.E.; N.E.]	0.37	[0.14; 0.95]	0.031	0.035
Others	1/20 (5.0)	N.E. [N.E.; N.E.]	1/25 (4.0)	N.E. [N.E.; N.E.]	2.24	[0.14; 35.90]	0.560	N.E.
Age groups								
(Interaction test: p = 0.807)								
18 - < 65 years	9/389 (2.3)	N.E. [N.E.; N.E.]	18/394 (4.6)	N.E. [N.E.; N.E.]	0.48	[0.21; 1.06]	0.063	0.470

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
65 - < 75 years	1/72 (1.4)	N.E. [N.E.; N.E.]	3/53 (5.7)	N.E. [N.E.; N.E.]	0.27	[0.03; 2.72]	0.236	0.997
>= 75 years	1/19 (5.3)	N.E. [N.E.; N.E.]	2/25 (8.0)	N.E. [N.E.; N.E.]	0.53	[0.05; 5.86]	0.599	0.998
Pre-randomization selection of TKI								
(Interaction test: p = 0.036)								
Imatinib	6/100 (6.0)	N.E. [N.E.; N.E.]	3/100 (3.0)	N.E. [N.E.; N.E.]	1.87	[0.47; 7.52]	0.369	N.E.
Nilotinib	4/339 (1.2)	N.E. [N.E.; N.E.]	20/330 (6.1)	N.E. [N.E.; N.E.]	0.18	[0.06; 0.52]	<0.001	0.991
Dasatinib	1/41 (2.4)	N.E. [N.E.; N.E.]	0/42	N.E. [N.E.; N.E.]	3.51	[0.04; 321.37]	0.277	N.E.
Geographic region								
(Interaction test: p = 0.531)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Europe excluding Germany	4/201 (2.0)	N.E. [N.E.; N.E.]	11/201 (5.5)	N.E. [N.E.; N.E.]	0.36	[0.11; 1.13]	0.068	0.587
Germany	0/91	N.E. [N.E.; N.E.]	3/68 (4.4)	N.E. [N.E.; N.E.]	0.06	[0.00; 2.25]	0.017	N.E.
Others	7/188 (3.7)	N.E. [N.E.; N.E.]	9/203 (4.4)	N.E. [N.E.; N.E.]	0.85	[0.31; 2.29]	0.743	0.735
Arterial-occlusive events (AOE)								
Pre-randomization selection of TKI (Interaction test: p = 1.000)								
Imatinib	1/100 (1.0)	N.E. [N.E.; N.E.]	0/100	N.E. [N.E.; N.E.]	3.09	[0.03; 283.80]	0.310	N.E.
Nilotinib	4/339 (1.2)	N.E. [N.E.; N.E.]	6/330 (1.8)	N.E. [N.E.; N.E.]	0.58	[0.16; 2.06]	0.396	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	0/41	N.E. [N.E.; N.E.]	1/42 (2.4)	N.E. [N.E.; N.E.]	0.36	[0.00; 33.17]	0.335	N.E.
Hepatotoxicity (including laboratory terms)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.688)								
Low	11/290 (3.8)	N.E. [N.E.; N.E.]	24/291 (8.2)	N.E. [N.E.; N.E.]	0.44	[0.22; 0.90]	0.020	0.885
Intermediate	0/129	N.E. [N.E.; N.E.]	7/125 (5.6)	N.E. [N.E.; N.E.]	0.06	[0.00; 1.24]	0.005	N.E.
High	2/61 (3.3)	N.E. [N.E.; N.E.]	8/56 (14.3)	N.E. [N.E.; N.E.]	0.21	[0.04; 0.99]	0.030	0.534
Sex (Interaction test: p = 0.761)								
Female	6/174	N.E. [N.E.; N.E.]	19/198	N.E. [N.E.; N.E.]	0.34	[0.13; 0.85]	0.015	0.476

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(3.4)		(9.6)					
Male	7/306 (2.3)	N.E. [N.E.; N.E.]	20/274 (7.3)	N.E. [N.E.; N.E.]	0.28	[0.12; 0.66]	0.002	0.570
Race								
(Interaction test: p = 0.998)								
Asian	3/128 (2.3)	N.E. [N.E.; N.E.]	10/130 (7.7)	N.E. [N.E.; N.E.]	0.31	[0.08; 1.13]	0.061	0.505
White	10/332 (3.0)	N.E. [N.E.; N.E.]	25/317 (7.9)	N.E. [N.E.; N.E.]	0.34	[0.16; 0.70]	0.002	0.340
Others	0/20	N.E. [N.E.; N.E.]	4/25 (16.0)	N.E. [N.E.; N.E.]	0.15	[0.01; 4.41]	0.096	N.E.
Age groups								
(Interaction test: p = 0.898)								
18 - < 65 years	10/389 (2.6)	N.E. [N.E.; N.E.]	31/394 (7.9)	N.E. [N.E.; N.E.]	0.31	[0.15; 0.64]	<0.001	0.952
65 - < 75 years	3/72	N.E. [N.E.; N.E.]	4/53	N.E. [N.E.; N.E.]	0.42	[0.09; 1.98]	0.277	0.996

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(4.2)		(7.5)					
>= 75 years	0/19	N.E. [N.E.; N.E.]	4/25 (16.0)	N.E. [N.E.; N.E.]	0.18	[0.01; 5.51]	0.123	N.E.
Pre-randomization selection of TKI								
(Interaction test: p = 0.234)								
Imatinib	3/100 (3.0)	N.E. [N.E.; N.E.]	4/100 (4.0)	N.E. [N.E.; N.E.]	0.73	[0.16; 3.27]	0.681	N.E.
Nilotinib	8/339 (2.4)	N.E. [N.E.; N.E.]	33/330 (10.0)	N.E. [N.E.; N.E.]	0.22	[0.10; 0.49]	<0.001	0.989
Dasatinib	2/41 (4.9)	N.E. [N.E.; N.E.]	2/42 (4.8)	N.E. [N.E.; N.E.]	0.75	[0.10; 5.67]	0.779	N.E.
Geographic region								
(Interaction test: p = 0.222)								
Europe excluding Germany	8/201	N.E. [N.E.; N.E.]	15/201	N.E. [N.E.; N.E.]	0.49	[0.20; 1.17]	0.103	0.107

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(4.0)		(7.5)					
Germany	1/91	N.E. [N.E.; N.E.]	10/68	N.E. [N.E.; N.E.]	0.08	[0.01; 0.63]	0.002	N.E.
	(1.1)		(14.7)					
Others	4/188	N.E. [N.E.; N.E.]	14/203	N.E. [N.E.; N.E.]	0.33	[0.11; 1.01]	0.041	0.258
	(2.1)		(6.9)					
Ischemic heart and CNS conditions								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.821)								
Low	3/290	N.E. [N.E.; N.E.]	4/291	N.E. [N.E.; N.E.]	0.72	[0.16; 3.23]	0.669	0.638
	(1.0)		(1.4)					
Intermediate	6/129	N.E. [N.E.; N.E.]	5/125	N.E. [N.E.; N.E.]	1.06	[0.32; 3.47]	0.925	0.138
	(4.7)		(4.0)					
High	2/61	N.E. [N.E.; N.E.]	1/56	N.E. [N.E.; N.E.]	1.72	[0.16; 18.98]	0.654	0.996
	(3.3)		(1.8)					

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Sex								
(Interaction test: p = 0.780)								
Female	3/174 (1.7)	N.E. [N.E.; N.E.]	4/198 (2.0)	N.E. [N.E.; N.E.]	0.85	[0.19; 3.83]	0.829	0.240
Male	8/306 (2.6)	N.E. [N.E.; N.E.]	6/274 (2.2)	N.E. [N.E.; N.E.]	1.05	[0.36; 3.03]	0.932	0.609
Race								
(Interaction test: p = 0.971)								
Asian	4/128 (3.1)	N.E. [N.E.; N.E.]	4/130 (3.1)	N.E. [N.E.; N.E.]	0.77	[0.19; 3.15]	0.719	0.620
White	7/332 (2.1)	N.E. [N.E.; N.E.]	6/317 (1.9)	N.E. [N.E.; N.E.]	1.05	[0.35; 3.15]	0.930	0.300
Others	0/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Age groups								
(Interaction test: p = 0.720)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
18 - < 65 years	8/389 (2.1)	N.E. [N.E.; N.E.]	7/394 (1.8)	N.E. [N.E.; N.E.]	1.13	[0.41; 3.11]	0.817	0.090
65 - < 75 years	2/72 (2.8)	N.E. [N.E.; N.E.]	0/53	N.E. [N.E.; N.E.]	2.42	[0.06; 103.05]	0.328	N.E.
>= 75 years	1/19 (5.3)	N.E. [N.E.; N.E.]	3/25 (12.0)	N.E. [N.E.; N.E.]	0.42	[0.04; 4.02]	0.434	0.998
Pre-randomization selection of TKI								
(Interaction test: p = 0.970)								
Imatinib	2/100 (2.0)	N.E. [N.E.; N.E.]	0/100	N.E. [N.E.; N.E.]	4.99	[0.12; 205.81]	0.158	N.E.
Nilotinib	7/339 (2.1)	N.E. [N.E.; N.E.]	8/330 (2.4)	N.E. [N.E.; N.E.]	0.74	[0.27; 2.03]	0.552	0.635
Dasatinib	2/41 (4.9)	N.E. [N.E.; N.E.]	2/42 (4.8)	N.E. [N.E.; N.E.]	0.84	[0.11; 6.29]	0.867	N.E.
Geographic region								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 0.867)								
Europe excluding Germany	4/201 (2.0)	N.E. [N.E.; N.E.]	3/201 (1.5)	N.E. [N.E.; N.E.]	1.05	[0.22; 4.86]	0.955	0.995
Germany	2/91 (2.2)	N.E. [N.E.; N.E.]	0/68	N.E. [N.E.; N.E.]	2.91	[0.07; 125.90]	0.285	1.000
Others	5/188 (2.7)	N.E. [N.E.; N.E.]	7/203 (3.4)	N.E. [N.E.; N.E.]	0.69	[0.22; 2.19]	0.522	0.660
Myelosuppression (Erythropenia)								
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.781)								
Low	6/290 (2.1)	N.E. [N.E.; N.E.]	8/291 (2.7)	N.E. [N.E.; N.E.]	0.74	[0.26; 2.13]	0.574	0.043
Intermediate	5/129	N.E. [N.E.; N.E.]	5/125	N.E. [N.E.; N.E.]	0.84	[0.24; 2.94]	0.788	0.436

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(3.9)		(4.0)					
High	5/61	N.E. [N.E.; N.E.]	3/56	N.E. [N.E.; N.E.]	1.44	[0.34; 6.06]	0.620	0.994
	(8.2)		(5.4)					
Sex								
(Interaction test: p = 0.451)								
Female	9/174	N.E. [N.E.; N.E.]	8/198	N.E. [N.E.; N.E.]	1.30	[0.49; 3.41]	0.600	0.993
	(5.2)		(4.0)					
Male	7/306	N.E. [N.E.; N.E.]	8/274	N.E. [N.E.; N.E.]	0.73	[0.26; 2.03]	0.546	0.799
	(2.3)		(2.9)					
Race								
(Interaction test: p = 0.021)								
Asian	3/128	N.E. [N.E.; N.E.]	12/130	N.E. [N.E.; N.E.]	0.21	[0.06; 0.77]	0.010	0.103
	(2.3)		(9.2)					
White	11/332	N.E. [N.E.; N.E.]	4/317	N.E. [N.E.; N.E.]	2.25	[0.71; 7.16]	0.157	0.073
	(3.3)		(1.3)					
Others	2/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	7.38	[0.17; 328.40]	0.095	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(10.0)							
Age groups								
(Interaction test: p = 0.955)								
18 - < 65 years	14/389	N.E. [N.E.; N.E.]	14/394	N.E. [N.E.; N.E.]	0.97	[0.46; 2.03]	0.927	0.010
	(3.6)		(3.6)					
65 - < 75 years	1/72	N.E. [N.E.; N.E.]	1/53	N.E. [N.E.; N.E.]	1.12	[0.07; 18.42]	0.938	0.998
	(1.4)		(1.9)					
>= 75 years	1/19	N.E. [30.1; N.E.]	1/25	N.E. [N.E.; N.E.]	0.33	[0.00; 30.79]	0.317	N.E.
	(5.3)		(4.0)					
Pre-randomization selection of TKI								
(Interaction test: p = 0.016)								
Imatinib	1/100	N.E. [N.E.; N.E.]	5/100	N.E. [N.E.; N.E.]	0.20	[0.02; 1.73]	0.105	N.E.
	(1.0)		(5.0)					
Nilotinib	14/339	N.E. [N.E.; N.E.]	6/330	N.E. [N.E.; N.E.]	2.14	[0.82; 5.59]	0.111	0.230
	(4.1)		(1.8)					

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Dasatinib	1/41 (2.4)	N.E. [N.E.; N.E.]	5/42 (11.9)	N.E. [N.E.; N.E.]	0.11	[0.01; 1.05]	0.029	N.E.
Geographic region (Interaction test: p = 0.261)								
Europe excluding Germany	7/201 (3.5)	N.E. [N.E.; N.E.]	3/201 (1.5)	N.E. [N.E.; N.E.]	1.84	[0.47; 7.29]	0.375	0.058
Germany	2/91 (2.2)	N.E. [N.E.; N.E.]	0/68	N.E. [N.E.; N.E.]	2.71	[0.07; 111.86]	0.299	1.000
Others	7/188 (3.7)	N.E. [N.E.; N.E.]	13/203 (6.4)	N.E. [N.E.; N.E.]	0.55	[0.22; 1.40]	0.204	0.019
Myelosuppression (Leukopenia)								
Stratification factor: ELTS based on randomization data from IRT (Interaction test: p = 0.954)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Low	23/290 (7.9)	N.E. [N.E.; N.E.]	32/291 (11.0)	N.E. [N.E.; N.E.]	0.71	[0.42; 1.22]	0.217	0.844
Intermediate	15/129 (11.6)	N.E. [N.E.; N.E.]	17/125 (13.6)	N.E. [N.E.; N.E.]	0.78	[0.39; 1.57]	0.492	0.265
High	11/61 (18.0)	N.E. [N.E.; N.E.]	11/56 (19.6)	N.E. [N.E.; N.E.]	0.89	[0.38; 2.06]	0.773	0.037
Sex								
(Interaction test: p = 0.801)								
Female	21/174 (12.1)	N.E. [N.E.; N.E.]	28/198 (14.1)	N.E. [N.E.; N.E.]	0.78	[0.44; 1.38]	0.374	0.470
Male	28/306 (9.2)	N.E. [N.E.; N.E.]	32/274 (11.7)	N.E. [N.E.; N.E.]	0.76	[0.46; 1.27]	0.294	0.166
Race								
(Interaction test: p = 0.982)								
Asian	20/128 (15.6)	N.E. [N.E.; N.E.]	24/130 (18.5)	N.E. [N.E.; N.E.]	0.75	[0.41; 1.38]	0.357	0.517

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
White	26/332 (7.8)	N.E. [N.E.; N.E.]	31/317 (9.8)	N.E. [N.E.; N.E.]	0.76	[0.45; 1.29]	0.309	0.041
Others	3/20 (15.0)	N.E. [N.E.; N.E.]	5/25 (20.0)	N.E. [N.E.; N.E.]	0.92	[0.21; 3.99]	0.927	N.E.
Age groups (Interaction test: p = 0.172)								
18 - < 65 years	42/389 (10.8)	N.E. [N.E.; N.E.]	45/394 (11.4)	N.E. [N.E.; N.E.]	0.92	[0.61; 1.41]	0.709	0.128
65 - < 75 years	6/72 (8.3)	N.E. [N.E.; N.E.]	11/53 (20.8)	N.E. [N.E.; N.E.]	0.29	[0.09; 0.94]	0.027	0.979
>= 75 years	1/19 (5.3)	N.E. [N.E.; N.E.]	4/25 (16.0)	N.E. [N.E.; N.E.]	0.49	[0.04; 5.47]	0.557	N.E.
Pre-randomization selection of TKI (Interaction test: p = 0.039)								
Imatinib	11/100	N.E. [N.E.; N.E.]	23/100	N.E. [N.E.; N.E.]	0.44	[0.21; 0.90]	0.020	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
	(11.0)		(23.0)					
Nilotinib	33/339	N.E. [N.E.; N.E.]	26/330	N.E. [N.E.; N.E.]	1.21	[0.72; 2.03]	0.461	0.687
	(9.7)		(7.9)					
Dasatinib	5/41	N.E. [N.E.; N.E.]	11/42	N.E. [N.E.; N.E.]	0.41	[0.14; 1.21]	0.097	N.E.
	(12.2)		(26.2)					
Geographic region								
(Interaction test: p = 0.357)								
Europe excluding Germany	19/201	N.E. [N.E.; N.E.]	16/201	N.E. [N.E.; N.E.]	1.23	[0.63; 2.41]	0.546	0.166
	(9.5)		(8.0)					
Germany	4/91	N.E. [N.E.; N.E.]	6/68	N.E. [N.E.; N.E.]	0.68	[0.17; 2.72]	0.579	0.472
	(4.4)		(8.8)					
Others	26/188	N.E. [N.E.; N.E.]	38/203	N.E. [N.E.; N.E.]	0.69	[0.42; 1.14]	0.151	0.591
	(13.8)		(18.7)					
Myelosuppression (Thrombocytopenia)								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.993)								
Low	20/290 (6.9)	N.E. [N.E.; N.E.]	16/291 (5.5)	N.E. [N.E.; N.E.]	1.25	[0.65; 2.41]	0.505	0.993
Intermediate	17/129 (13.2)	N.E. [N.E.; N.E.]	13/125 (10.4)	N.E. [N.E.; N.E.]	1.24	[0.60; 2.56]	0.552	0.766
High	17/61 (27.9)	N.E. [N.E.; N.E.]	12/56 (21.4)	N.E. [N.E.; N.E.]	1.33	[0.64; 2.80]	0.445	0.356
Sex								
(Interaction test: p = 0.166)								
Female	22/174 (12.6)	N.E. [N.E.; N.E.]	14/198 (7.1)	N.E. [N.E.; N.E.]	1.84	[0.94; 3.62]	0.075	0.823
Male	32/306 (10.5)	N.E. [N.E.; N.E.]	27/274 (9.9)	N.E. [N.E.; N.E.]	1.01	[0.60; 1.69]	0.974	0.697

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Race								
(Interaction test: p = 0.850)								
Asian	21/128 (16.4)	N.E. [N.E.; N.E.]	19/130 (14.6)	N.E. [N.E.; N.E.]	1.19	[0.63; 2.25]	0.593	0.910
White	29/332 (8.7)	N.E. [N.E.; N.E.]	18/317 (5.7)	N.E. [N.E.; N.E.]	1.52	[0.84; 2.74]	0.165	0.724
Others	4/20 (20.0)	N.E. [N.E.; N.E.]	4/25 (16.0)	N.E. [N.E.; N.E.]	3.60	[0.64; 20.24]	0.122	N.E.
Age groups								
(Interaction test: p = 0.971)								
18 - < 65 years	48/389 (12.3)	N.E. [N.E.; N.E.]	37/394 (9.4)	N.E. [N.E.; N.E.]	1.28	[0.83; 1.97]	0.253	0.415
65 - < 75 years	6/72 (8.3)	N.E. [N.E.; N.E.]	4/53 (7.5)	N.E. [N.E.; N.E.]	1.10	[0.29; 4.10]	0.878	0.316
>= 75 years	0/19	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.


	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI								
(Interaction test: p = 0.396)								
Imatinib	12/100 (12.0)	N.E. [N.E.; N.E.]	6/100 (6.0)	N.E. [N.E.; N.E.]	2.07	[0.77; 5.51]	0.135	N.E.
Nilotinib	37/339 (10.9)	N.E. [N.E.; N.E.]	29/330 (8.8)	N.E. [N.E.; N.E.]	1.25	[0.77; 2.03]	0.378	0.524
Dasatinib	5/41 (12.2)	N.E. [N.E.; N.E.]	6/42 (14.3)	N.E. [N.E.; N.E.]	0.74	[0.22; 2.48]	0.622	N.E.
Geographic region								
(Interaction test: p = 0.066)								
Europe excluding Germany	19/201 (9.5)	N.E. [N.E.; N.E.]	7/201 (3.5)	N.E. [N.E.; N.E.]	2.60	[1.09; 6.21]	0.026	0.419
Germany	5/91 (5.5)	N.E. [N.E.; N.E.]	8/68 (11.8)	N.E. [N.E.; N.E.]	0.45	[0.15; 1.40]	0.171	0.992

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Others	30/188 (16.0)	N.E. [N.E.; N.E.]	26/203 (12.8)	N.E. [N.E.; N.E.]	1.29	[0.76; 2.20]	0.330	0.920

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	100 (0)	91 (4)	87 (8)	83 (11)	61 (33)	13 (81)	0 (94)
Investigator Selected TKI	100 (0)	86 (13)	72 (26)	56 (41)	40 (57)	4 (93)	0 (97)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	318 (19)	286 (49)	171 (164)	86 (249)	14 (321)	0 (335)
Investigator Selected TKI	330 (0)	287 (29)	242 (72)	142 (170)	62 (249)	9 (301)	0 (310)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Acute pancreatitis (including isolated pancreatic enzyme elevations): Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Myelosuppression (Erythropenia): Race: Asian



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Myelosuppression (Erythropenia): Race: White



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Myelosuppression (Erythropenia): Race: Others



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Myelosuppression (Erythropenia): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	100 (0)	92 (7)	88 (11)	85 (14)	62 (37)	13 (86)	0 (99)
Investigator Selected TKI	100 (0)	83 (13)	70 (25)	55 (40)	38 (57)	4 (91)	0 (95)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Myelosuppression (Erythropenia): Pre-randomization selection of TKI: Nilotinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)


Myelosuppression (Erythropenia): Pre-randomization selection of TKI: Dasatinib



Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Myelosuppression (Leukopenia): Pre-randomization selection of TKI: Imatinib




Pts at Risk (censored)

Asciminib	100 (0)	84 (5)	80 (9)	77 (12)	56 (33)	11 (78)	0 (89)
Investigator Selected TKI	100 (0)	67 (11)	59 (18)	48 (29)	31 (46)	3 (74)	0 (77)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Myelosuppression (Leukopenia): Pre-randomization selection of TKI: Nilotinib




Pts at Risk (censored)

Asciminib	339 (0)	293 (13)	268 (38)	162 (144)	76 (230)	12 (294)	0 (306)
Investigator Selected TKI	330 (0)	273 (33)	232 (72)	141 (163)	62 (242)	8 (296)	0 (304)

Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12 Time to first grade >=3 AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Kaplan-Meier plot by subgroups (Safety Analysis Set)

Myelosuppression (Leukopenia): Pre-randomization selection of TKI: Dasatinib




Note: o = Censored observations
Kaplan-Meier curves are only presented for subgroup analyses with a statistically significant interaction term ($p < 0.05$).
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	5/152	7/148	0.65	0.21; 2.06	0.463
ASC4START	4/237	11/246	0.36	0.11; 1.13	0.067
Pooled Analysis	9/389	18/394	0.48	0.21; 1.06	0.063
65 - < 75 years					
ASC4FIRST	1/34	1/29	1.44	0.08; 25.64	0.802
ASC4START	0/38	2/24	0.11	0.00; 4.45	0.054
Pooled Analysis	1/72	3/53	0.27	0.03; 2.72	0.236
>= 75 years					
ASC4FIRST	1/10	1/13	1.00	0.06; 15.99	1.000
ASC4START	0/9	1/12	0.39	0.00; 37.18	0.361
Pooled Analysis	1/19	2/25	0.53	0.05; 5.86	0.599




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	1/19	0.69	0.04; 11.21	0.793
ASC4START	2/38	1/37	1.84	0.17; 20.27	0.614
Pooled Analysis	3/61	2/56	1.23	0.20; 7.45	0.818
Intermediate					
ASC4FIRST	2/54	2/52	0.92	0.13; 6.55	0.934
ASC4START	0/75	5/73	0.09	0.00; 2.04	0.021
Pooled Analysis	2/129	7/125	0.27	0.06; 1.28	0.076
Low					
ASC4FIRST	4/119	6/119	0.63	0.18; 2.24	0.474
ASC4START	2/171	8/172	0.24	0.05; 1.14	0.051
Pooled Analysis	6/290	14/291	0.41	0.16; 1.07	0.059




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	2/63	4/61	0.52	0.09; 2.86	0.444
ASC4START	2/138	7/140	0.27	0.06; 1.32	0.083
Pooled Analysis	4/201	11/201	0.36	0.11; 1.13	0.068
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	0/72	3/53	0.06	0.00; 2.25	0.017
Pooled Analysis	0/91	3/68	0.06	0.00; 2.25	0.017
Others					
ASC4FIRST	5/114	5/114	0.96	0.28; 3.33	0.953
ASC4START	2/74	4/89	0.67	0.12; 3.70	0.642
Pooled Analysis	7/188	9/203	0.85	0.31; 2.29	0.743




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	1/41	0/42	3.51	0.04; 321.37	0.277
Pooled Analysis	1/41	0/42	3.51	0.04; 321.37	0.277
Imatinib					
ASC4FIRST	6/100	3/100	1.87	0.47; 7.52	0.369
Pooled Analysis	6/100	3/100	1.87	0.47; 7.52	0.369
Nilotinib					
ASC4FIRST	0/55	6/48	0.06	0.00; 1.28	0.005
ASC4START	4/284	14/282	0.27	0.09; 0.82	0.014
Pooled Analysis	4/339	20/330	0.18	0.06; 0.52	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	2/40	2/45	1.15	0.16; 8.26	0.889
Pooled Analysis	4/128	6/130	0.74	0.21; 2.64	0.641
Asian/Others					
ASC4FIRST	2/91	4/89	0.54	0.10; 2.98	0.475
Others					
ASC4START	1/17	1/21	2.24	0.14; 35.90	0.560
Pooled Analysis	1/20	1/25	2.24	0.14; 35.90	0.560
White					
ASC4FIRST	5/105	5/101	1.09	0.31; 3.81	0.887
ASC4START	1/227	11/216	0.08	0.01; 0.65	0.002
Pooled Analysis	6/332	16/317	0.37	0.14; 0.95	0.031




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	3/67	2/74	1.59	0.27; 9.52	0.609
ASC4START	0/107	8/124	0.06	0.00; 1.33	0.007
Pooled Analysis	3/174	10/198	0.33	0.09; 1.18	0.072
Male					
ASC4FIRST	4/129	7/116	0.43	0.13; 1.48	0.170
ASC4START	4/177	6/158	0.56	0.16; 1.99	0.366
Pooled Analysis	8/306	13/274	0.49	0.20; 1.18	0.106




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arterial-occlusive events (AOE)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	0/41	1/42	0.36	0.00; 33.17	0.335
Pooled Analysis	0/41	1/42	0.36	0.00; 33.17	0.335
Imatinib					
ASC4FIRST	1/100	0/100	3.09	0.03; 283.80	0.310
Pooled Analysis	1/100	0/100	3.09	0.03; 283.80	0.310
Nilotinib					
ASC4FIRST	0/55	0/48	N.E.	N.E.; N.E.	N.E.
ASC4START	4/284	6/282	0.58	0.16; 2.06	0.396
Pooled Analysis	4/339	6/330	0.58	0.16; 2.06	0.396




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	3/152	9/148	0.30	0.08; 1.12	0.057
ASC4START	7/237	22/246	0.32	0.14; 0.74	0.005
Pooled Analysis	10/389	31/394	0.31	0.15; 0.64	<0.001
65 - < 75 years					
ASC4FIRST	2/34	0/29	5.63	0.14; 233.39	0.134
ASC4START	1/38	4/24	0.11	0.01; 0.97	0.019
Pooled Analysis	3/72	4/53	0.42	0.09; 1.98	0.277
>= 75 years					
ASC4FIRST	0/10	1/13	N.E.	N.E.; N.E.	N.E.
ASC4START	0/9	3/12	0.18	0.01; 5.51	0.123
Pooled Analysis	0/19	4/25	0.18	0.01; 5.51	0.123




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	2/19	0.40	0.04; 4.41	0.437
ASC4START	1/38	6/37	0.14	0.02; 1.20	0.037
Pooled Analysis	2/61	8/56	0.21	0.04; 0.99	0.030
Intermediate					
ASC4FIRST	0/54	0/52	N.E.	N.E.; N.E.	N.E.
ASC4START	0/75	7/73	0.06	0.00; 1.24	0.005
Pooled Analysis	0/129	7/125	0.06	0.00; 1.24	0.005
Low					
ASC4FIRST	4/119	8/119	0.47	0.14; 1.57	0.211
ASC4START	7/171	16/172	0.42	0.17; 1.03	0.050
Pooled Analysis	11/290	24/291	0.44	0.22; 0.90	0.020




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	4/63	2/61	1.68	0.29; 9.74	0.556
ASC4START	4/138	13/140	0.30	0.10; 0.93	0.027
Pooled Analysis	8/201	15/201	0.49	0.20; 1.17	0.103
Germany					
ASC4FIRST	0/19	1/15	N.E.	N.E.; N.E.	N.E.
ASC4START	1/72	9/53	0.08	0.01; 0.63	0.002
Pooled Analysis	1/91	10/68	0.08	0.01; 0.63	0.002
Others					
ASC4FIRST	1/114	7/114	0.14	0.02; 1.12	0.030
ASC4START	3/74	7/89	0.58	0.15; 2.28	0.434
Pooled Analysis	4/188	14/203	0.33	0.11; 1.01	0.041




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	2/41	2/42	0.75	0.10; 5.67	0.779
Pooled Analysis	2/41	2/42	0.75	0.10; 5.67	0.779
Imatinib					
ASC4FIRST	3/100	4/100	0.73	0.16; 3.27	0.681
Pooled Analysis	3/100	4/100	0.73	0.16; 3.27	0.681
Nilotinib					
ASC4FIRST	0/55	4/48	0.10	0.00; 2.65	0.036
ASC4START	8/284	29/282	0.26	0.12; 0.56	<0.001
Pooled Analysis	8/339	33/330	0.22	0.10; 0.49	<0.001




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	2/40	5/45	0.46	0.09; 2.40	0.345
Pooled Analysis	3/128	10/130	0.31	0.08; 1.13	0.061
Asian/Others					
ASC4FIRST	1/91	5/89	0.19	0.02; 1.65	0.094
Others					
ASC4START	0/17	4/21	0.15	0.01; 4.41	0.096
Pooled Analysis	0/20	4/25	0.15	0.01; 4.41	0.096
White					
ASC4FIRST	4/105	5/101	0.58	0.15; 2.23	0.427
ASC4START	6/227	20/216	0.27	0.11; 0.66	0.002
Pooled Analysis	10/332	25/317	0.34	0.16; 0.70	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Hepatotoxicity (including laboratory terms)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	1/67	2/74	0.81	0.06; 10.19	0.868
ASC4START	5/107	17/124	0.30	0.11; 0.81	0.012
Pooled Analysis	6/174	19/198	0.34	0.13; 0.85	0.015
Male					
ASC4FIRST	4/129	8/116	0.36	0.11; 1.24	0.092
ASC4START	3/177	12/158	0.22	0.06; 0.77	0.009
Pooled Analysis	7/306	20/274	0.28	0.12; 0.66	0.002




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	6/152	2/148	2.93	0.59; 14.56	0.169
ASC4START	2/237	5/246	0.40	0.08; 2.07	0.259
Pooled Analysis	8/389	7/394	1.13	0.41; 3.11	0.817
65 - < 75 years					
ASC4FIRST	0/34	0/29	N.E.	N.E.; N.E.	N.E.
ASC4START	2/38	0/24	2.42	0.06; 103.05	0.328
Pooled Analysis	2/72	0/53	2.42	0.06; 103.05	0.328
>= 75 years					
ASC4FIRST	0/10	1/13	0.33	0.00; 30.79	0.317
ASC4START	1/9	2/12	0.68	0.06; 7.50	0.748
Pooled Analysis	1/19	3/25	0.42	0.04; 4.02	0.434




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	1/23	0/19	2.68	0.03; 259.50	0.355
ASC4START	1/38	1/37	0.86	0.05; 13.79	0.916
Pooled Analysis	2/61	1/56	1.72	0.16; 18.98	0.654
Intermediate					
ASC4FIRST	4/54	1/52	3.56	0.40; 31.89	0.225
ASC4START	2/75	4/73	0.44	0.08; 2.39	0.326
Pooled Analysis	6/129	5/125	1.06	0.32; 3.47	0.925
Low					
ASC4FIRST	1/119	2/119	0.47	0.04; 5.17	0.526
ASC4START	2/171	2/172	0.98	0.14; 6.99	0.987
Pooled Analysis	3/290	4/291	0.72	0.16; 3.23	0.669




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	2/63	0/61	3.68	0.07; 189.69	0.245
ASC4START	2/138	3/140	0.57	0.09; 3.48	0.536
Pooled Analysis	4/201	3/201	1.05	0.22; 4.86	0.955
Germany					
ASC4FIRST	1/19	0/15	2.37	0.02; 233.45	0.386
ASC4START	1/72	0/53	1.27	0.01; 123.94	0.524
Pooled Analysis	2/91	0/68	2.91	0.07; 125.90	0.285
Others					
ASC4FIRST	3/114	3/114	0.88	0.18; 4.38	0.878
ASC4START	2/74	4/89	0.52	0.09; 2.91	0.450
Pooled Analysis	5/188	7/203	0.69	0.22; 2.19	0.522



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	1/40	2/45	0.48	0.04; 5.38	0.540
Pooled Analysis	4/128	4/130	0.77	0.19; 3.15	0.719
Asian/Others					
ASC4FIRST	3/91	2/89	0.99	0.16; 6.02	0.987
Others					
ASC4START	0/17	0/21	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/20	0/25	N.E.	N.E.; N.E.	N.E.
White					
ASC4FIRST	3/105	1/101	2.89	0.29; 28.98	0.346
ASC4START	4/227	5/216	0.71	0.19; 2.65	0.610
Pooled Analysis	7/332	6/317	1.05	0.35; 3.15	0.930




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Ischemic heart and CNS conditions

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	2/67	1/74	2.56	0.23; 29.12	0.433
ASC4START	1/107	3/124	0.35	0.04; 3.37	0.340
Pooled Analysis	3/174	4/198	0.85	0.19; 3.83	0.829
Male					
ASC4FIRST	4/129	2/116	1.47	0.27; 8.09	0.657
ASC4START	4/177	4/158	0.83	0.21; 3.31	0.789
Pooled Analysis	8/306	6/274	1.05	0.36; 3.03	0.932




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	3/152	10/148	0.28	0.08; 1.02	0.039
ASC4START	11/237	4/246	2.74	0.87; 8.60	0.072
Pooled Analysis	14/389	14/394	0.97	0.46; 2.03	0.927
65 - < 75 years					
ASC4FIRST	0/34	1/29	0.47	0.00; 46.61	0.414
ASC4START	1/38	0/24	2.60	0.03; 250.43	0.361
Pooled Analysis	1/72	1/53	1.12	0.07; 18.42	0.938
>= 75 years					
ASC4FIRST	1/10	1/13	0.33	0.00; 30.79	0.317
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	1/19	1/25	0.33	0.00; 30.79	0.317




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	0/23	2/19	0.13	0.00; 5.38	0.079
ASC4START	5/38	1/37	4.70	0.55; 40.24	0.120
Pooled Analysis	5/61	3/56	1.44	0.34; 6.06	0.620
Intermediate					
ASC4FIRST	3/54	4/52	0.60	0.13; 2.73	0.506
ASC4START	2/75	1/73	1.86	0.17; 20.52	0.607
Pooled Analysis	5/129	5/125	0.84	0.24; 2.94	0.788
Low					
ASC4FIRST	1/119	6/119	0.16	0.02; 1.32	0.051
ASC4START	5/171	2/172	2.54	0.49; 13.07	0.249
Pooled Analysis	6/290	8/291	0.74	0.26; 2.13	0.574




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	1/63	2/61	0.22	0.02; 2.85	0.216
ASC4START	6/138	1/140	5.49	0.66; 45.74	0.077
Pooled Analysis	7/201	3/201	1.84	0.47; 7.29	0.375
Germany					
ASC4FIRST	1/19	0/15	1.57	0.02; 152.79	0.480
ASC4START	1/72	0/53	1.84	0.02; 179.94	0.446
Pooled Analysis	2/91	0/68	2.71	0.07; 111.86	0.299
Others					
ASC4FIRST	2/114	10/114	0.18	0.04; 0.81	0.012
ASC4START	5/74	3/89	2.18	0.52; 9.22	0.276
Pooled Analysis	7/188	13/203	0.55	0.22; 1.40	0.204




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	1/41	5/42	0.11	0.01; 1.05	0.029
Pooled Analysis	1/41	5/42	0.11	0.01; 1.05	0.029
Imatinib					
ASC4FIRST	1/100	5/100	0.20	0.02; 1.73	0.105
Pooled Analysis	1/100	5/100	0.20	0.02; 1.73	0.105
Nilotinib					
ASC4FIRST	2/55	2/48	0.72	0.10; 5.18	0.747
ASC4START	12/284	4/282	2.91	0.94; 9.03	0.053
Pooled Analysis	14/339	6/330	2.14	0.82; 5.59	0.111




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	2/40	3/45	0.79	0.13; 4.73	0.794
Pooled Analysis	3/128	12/130	0.21	0.06; 0.77	0.010
Asian/Others					
ASC4FIRST	1/91	9/89	0.08	0.01; 0.64	0.003
Others					
ASC4START	2/17	0/21	7.38	0.17; 328.40	0.095
Pooled Analysis	2/20	0/25	7.38	0.17; 328.40	0.095
White					
ASC4FIRST	3/105	3/101	0.65	0.12; 3.37	0.601
ASC4START	8/227	1/216	7.31	0.91; 58.52	0.028
Pooled Analysis	11/332	4/317	2.25	0.71; 7.16	0.157




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Erythropenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	0/67	7/74	0.08	0.00; 1.84	0.020
ASC4START	9/107	1/124	9.35	1.18; 74.02	0.010
Pooled Analysis	9/174	8/198	1.30	0.49; 3.41	0.600
Male					
ASC4FIRST	4/129	5/116	0.65	0.17; 2.47	0.529
ASC4START	3/177	3/158	0.86	0.17; 4.26	0.852
Pooled Analysis	7/306	8/274	0.73	0.26; 2.03	0.546




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	20/152	28/148	0.68	0.38; 1.22	0.191
ASC4START	22/237	17/246	1.33	0.71; 2.50	0.372
Pooled Analysis	42/389	45/394	0.92	0.61; 1.41	0.709
65 - < 75 years					
ASC4FIRST	5/34	8/29	0.30	0.08; 1.14	0.060
ASC4START	1/38	3/24	0.29	0.03; 2.75	0.238
Pooled Analysis	6/72	11/53	0.29	0.09; 0.94	0.027
>= 75 years					
ASC4FIRST	1/10	4/13	0.49	0.04; 5.47	0.557
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	1/19	4/25	0.49	0.04; 5.47	0.557




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	2/23	6/19	0.23	0.05; 1.16	0.052
ASC4START	9/38	5/37	1.83	0.61; 5.46	0.275
Pooled Analysis	11/61	11/56	0.89	0.38; 2.06	0.773
Intermediate					
ASC4FIRST	11/54	15/52	0.64	0.30; 1.40	0.265
ASC4START	4/75	2/73	1.87	0.34; 10.19	0.463
Pooled Analysis	15/129	17/125	0.78	0.39; 1.57	0.492
Low					
ASC4FIRST	13/119	19/119	0.68	0.34; 1.38	0.283
ASC4START	10/171	13/172	0.76	0.33; 1.73	0.521
Pooled Analysis	23/290	32/291	0.71	0.42; 1.22	0.217




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	8/63	11/61	0.80	0.32; 1.99	0.613
ASC4START	11/138	5/140	2.14	0.74; 6.18	0.150
Pooled Analysis	19/201	16/201	1.23	0.63; 2.41	0.546
Germany					
ASC4FIRST	1/19	4/15	0.34	0.03; 3.76	0.354
ASC4START	3/72	2/53	1.01	0.17; 6.13	0.987
Pooled Analysis	4/91	6/68	0.68	0.17; 2.72	0.579
Others					
ASC4FIRST	17/114	25/114	0.63	0.34; 1.16	0.136
ASC4START	9/74	13/89	0.84	0.36; 1.97	0.704
Pooled Analysis	26/188	38/203	0.69	0.42; 1.14	0.151




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	5/41	11/42	0.41	0.14; 1.21	0.097
Pooled Analysis	5/41	11/42	0.41	0.14; 1.21	0.097
Imatinib					
ASC4FIRST	11/100	23/100	0.44	0.21; 0.90	0.020
Pooled Analysis	11/100	23/100	0.44	0.21; 0.90	0.020
Nilotinib					
ASC4FIRST	10/55	6/48	1.45	0.52; 4.03	0.473
ASC4START	23/284	20/282	1.14	0.62; 2.07	0.669
Pooled Analysis	33/339	26/330	1.21	0.72; 2.03	0.461




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	4/40	4/45	1.15	0.28; 4.62	0.848
Pooled Analysis	20/128	24/130	0.75	0.41; 1.38	0.357
Asian/Others					
ASC4FIRST	16/91	20/89	0.68	0.35; 1.32	0.254
Others					
ASC4START	3/17	5/21	0.92	0.21; 3.99	0.927
Pooled Analysis	3/20	5/25	0.92	0.21; 3.99	0.927
White					
ASC4FIRST	10/105	20/101	0.44	0.20; 0.94	0.030
ASC4START	16/227	11/216	1.36	0.63; 2.93	0.432
Pooled Analysis	26/332	31/317	0.76	0.45; 1.29	0.309




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Leukopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	13/67	20/74	0.67	0.33; 1.37	0.257
ASC4START	8/107	8/124	1.05	0.39; 2.79	0.946
Pooled Analysis	21/174	28/198	0.78	0.44; 1.38	0.374
Male					
ASC4FIRST	13/129	20/116	0.55	0.27; 1.10	0.086
ASC4START	15/177	12/158	1.13	0.53; 2.42	0.740
Pooled Analysis	28/306	32/274	0.76	0.46; 1.27	0.294




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	20/152	18/148	1.05	0.55; 1.99	0.872
ASC4START	28/237	19/246	1.51	0.84; 2.70	0.165
Pooled Analysis	48/389	37/394	1.28	0.83; 1.97	0.253
65 - < 75 years					
ASC4FIRST	5/34	2/29	1.82	0.33; 10.01	0.464
ASC4START	1/38	2/24	0.40	0.04; 4.48	0.445
Pooled Analysis	6/72	4/53	1.10	0.29; 4.10	0.878
>= 75 years					
ASC4FIRST	0/10	0/13	N.E.	N.E.; N.E.	N.E.
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/19	0/25	N.E.	N.E.; N.E.	N.E.




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	5/23	5/19	0.83	0.24; 2.87	0.767
ASC4START	12/38	7/37	1.72	0.68; 4.38	0.249
Pooled Analysis	17/61	12/56	1.33	0.64; 2.80	0.445
Intermediate					
ASC4FIRST	10/54	7/52	1.37	0.52; 3.60	0.519
ASC4START	7/75	6/73	1.10	0.37; 3.26	0.867
Pooled Analysis	17/129	13/125	1.24	0.60; 2.56	0.552
Low					
ASC4FIRST	10/119	8/119	1.25	0.49; 3.16	0.642
ASC4START	10/171	8/172	1.25	0.50; 3.18	0.634
Pooled Analysis	20/290	16/291	1.25	0.65; 2.41	0.505




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	6/63	1/61	5.56	0.66; 47.01	0.078
ASC4START	13/138	6/140	2.11	0.80; 5.56	0.124
Pooled Analysis	19/201	7/201	2.60	1.09; 6.21	0.026
Germany					
ASC4FIRST	0/19	4/15	0.08	0.00; 2.18	0.016
ASC4START	5/72	4/53	0.95	0.25; 3.57	0.940
Pooled Analysis	5/91	8/68	0.45	0.15; 1.40	0.171
Others					
ASC4FIRST	19/114	15/114	1.32	0.67; 2.61	0.416
ASC4START	11/74	11/89	1.25	0.54; 2.90	0.589
Pooled Analysis	30/188	26/203	1.29	0.76; 2.20	0.330




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	5/41	6/42	0.74	0.22; 2.48	0.622
Pooled Analysis	5/41	6/42	0.74	0.22; 2.48	0.622
Imatinib					
ASC4FIRST	12/100	6/100	2.07	0.77; 5.51	0.135
Pooled Analysis	12/100	6/100	2.07	0.77; 5.51	0.135
Nilotinib					
ASC4FIRST	8/55	8/48	0.94	0.35; 2.54	0.895
ASC4START	29/284	21/282	1.36	0.78; 2.39	0.279
Pooled Analysis	37/339	29/330	1.25	0.77; 2.03	0.378




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	5/40	4/45	1.27	0.34; 4.79	0.721
Pooled Analysis	21/128	19/130	1.19	0.63; 2.25	0.593
Asian/Others					
ASC4FIRST	16/91	15/89	1.08	0.53; 2.22	0.825
Others					
ASC4START	4/17	4/21	3.60	0.64; 20.24	0.122
Pooled Analysis	4/20	4/25	3.60	0.64; 20.24	0.122
White					
ASC4FIRST	9/105	5/101	1.79	0.59; 5.41	0.288
ASC4START	20/227	13/216	1.41	0.70; 2.85	0.332
Pooled Analysis	29/332	18/317	1.52	0.84; 2.74	0.165




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.12.1: Forest-Plot for Grade >=3 AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	11/67	8/74	1.71	0.68; 4.31	0.250
ASC4START	11/107	6/124	2.00	0.74; 5.42	0.170
Pooled Analysis	22/174	14/198	1.84	0.94; 3.62	0.075
Male					
ASC4FIRST	14/129	12/116	0.90	0.41; 1.96	0.789
ASC4START	18/177	15/158	1.10	0.56; 2.19	0.783
Pooled Analysis	32/306	27/274	1.01	0.60; 1.69	0.974



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.13 Time to first serious AESI: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Acute pancreatitis (including isolated pancreatic enzyme elevations)								
Race								
(Interaction test: p = 1.000)								
Asian	0/128	N.E. [N.E.; N.E.]	1/130 (0.8)	N.E. [N.E.; N.E.]	0.28	[0.00; 25.64]	0.273	N.E.
White	4/332 (1.2)	N.E. [N.E.; N.E.]	7/317 (2.2)	N.E. [N.E.; N.E.]	0.57	[0.17; 1.97]	0.371	0.150
Others	0/20	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.
Arterial-occlusive events (AOE)								
Pre-randomization selection of TKI								

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
(Interaction test: p = 1.000)								
Imatinib	1/100 (1.0)	N.E. [N.E.; N.E.]	0/100	N.E. [N.E.; N.E.]	3.09	[0.03; 283.80]	0.310	N.E.
Nilotinib	6/339 (1.8)	N.E. [N.E.; N.E.]	4/330 (1.2)	N.E. [N.E.; N.E.]	1.35	[0.38; 4.79]	0.640	N.E.
Dasatinib	0/41	N.E. [N.E.; N.E.]	1/42 (2.4)	N.E. [N.E.; N.E.]	0.36	[0.00; 33.17]	0.335	N.E.
Myelosuppression (Thrombocytopenia)								
Age groups								
(Interaction test: p = 1.000)								
18 - < 65 years	4/389 (1.0)	N.E. [N.E.; N.E.]	6/394 (1.5)	N.E. [N.E.; N.E.]	0.64	[0.18; 2.26]	0.481	0.773
65 - < 75 years	0/72	N.E. [N.E.; N.E.]	1/53 (1.9)	N.E. [N.E.; N.E.]	0.30	[0.00; 27.98]	0.294	N.E.
>= 75 years	0/19	N.E. [N.E.; N.E.]	0/25	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Pre-randomization selection of TKI (Interaction test: p = 1.000)								
Imatinib	0/100	N.E. [N.E.; N.E.]	1/100 (1.0)	N.E. [N.E.; N.E.]	0.35	[0.00; 31.86]	0.326	N.E.
Nilotinib	4/339 (1.2)	N.E. [N.E.; N.E.]	6/330 (1.8)	N.E. [N.E.; N.E.]	0.61	[0.17; 2.15]	0.433	0.824
Dasatinib	0/41	N.E. [N.E.; N.E.]	0/42	N.E. [N.E.; N.E.]	N.E.	[N.E.; N.E.]	N.E.	N.E.


	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.13.1: Forest-Plot for Serious AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Acute pancreatitis (including isolated pancreatic enzyme elevations)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	0/40	1/45	0.28	0.00; 25.64	0.273
Pooled Analysis	0/128	1/130	0.28	0.00; 25.64	0.273
Asian/Others					
ASC4FIRST	0/91	0/89	N.E.	N.E.; N.E.	N.E.
Others					
ASC4START	0/17	0/21	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/20	0/25	N.E.	N.E.; N.E.	N.E.
White					
ASC4FIRST	2/105	1/101	2.56	0.23; 28.45	0.427
ASC4START	2/227	6/216	0.31	0.06; 1.52	0.126
Pooled Analysis	4/332	7/317	0.57	0.17; 1.97	0.371




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.13.1: Forest-Plot for Serious AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Arterial-occlusive events (AOE)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	0/41	1/42	0.36	0.00; 33.17	0.335
Pooled Analysis	0/41	1/42	0.36	0.00; 33.17	0.335
Imatinib					
ASC4FIRST	1/100	0/100	3.09	0.03; 283.80	0.310
Pooled Analysis	1/100	0/100	3.09	0.03; 283.80	0.310
Nilotinib					
ASC4FIRST	0/55	0/48	N.E.	N.E.; N.E.	N.E.
ASC4START	6/284	4/282	1.35	0.38; 4.79	0.640
Pooled Analysis	6/339	4/330	1.35	0.38; 4.79	0.640




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.13.1: Forest-Plot for Serious AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	1/152	1/148	0.92	0.06; 14.65	0.951
ASC4START	3/237	5/246	0.58	0.14; 2.42	0.449
Pooled Analysis	4/389	6/394	0.64	0.18; 2.26	0.481
65 - < 75 years					
ASC4FIRST	0/34	1/29	0.30	0.00; 27.98	0.294
ASC4START	0/38	0/24	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/72	1/53	0.30	0.00; 27.98	0.294
>= 75 years					
ASC4FIRST	0/10	0/13	N.E.	N.E.; N.E.	N.E.
ASC4START	0/9	0/12	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/19	0/25	N.E.	N.E.; N.E.	N.E.




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.13.1: Forest-Plot for Serious AESI: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Myelosuppression (Thrombocytopenia)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Pre-randomization selection of TKI	**n/N**	**n/N**			
Dasatinib					
ASC4FIRST	0/41	0/42	N.E.	N.E.; N.E.	N.E.
Pooled Analysis	0/41	0/42	N.E.	N.E.; N.E.	N.E.
Imatinib					
ASC4FIRST	0/100	1/100	0.35	0.00; 31.86	0.326
Pooled Analysis	0/100	1/100	0.35	0.00; 31.86	0.326
Nilotinib					
ASC4FIRST	1/55	1/48	0.80	0.05; 12.83	0.876
ASC4START	3/284	5/282	0.56	0.13; 2.36	0.425
Pooled Analysis	4/339	6/330	0.61	0.17; 2.15	0.433



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.14 Time to first AE leading to discontinuation of treatment: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.245)								
Low	21/290 (7.2)	N.E. [N.E.; N.E.]	34/291 (11.7)	N.E. [N.E.; N.E.]	0.59	[0.34; 1.02]	0.055	0.586
Intermediate	9/129 (7.0)	N.E. [32.4; N.E.]	25/125 (20.0)	N.E. [N.E.; N.E.]	0.30	[0.14; 0.65]	0.001	0.964
High	3/61 (4.9)	N.E. [N.E.; N.E.]	10/56 (17.9)	N.E. [N.E.; N.E.]	0.27	[0.07; 0.97]	0.032	0.995
Sex								
(Interaction test: p = 0.577)								
Female	11/174 (6.3)	N.E. [N.E.; N.E.]	31/198 (15.7)	N.E. [N.E.; N.E.]	0.38	[0.19; 0.75]	0.004	0.302

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Male	22/306 (7.2)	N.E. [N.E.; N.E.]	38/274 (13.9)	N.E. [N.E.; N.E.]	0.48	[0.28; 0.82]	0.005	0.124
Race								
(Interaction test: p = 0.615)								
Asian	5/128 (3.9)	N.E. [N.E.; N.E.]	12/130 (9.2)	N.E. [N.E.; N.E.]	0.37	[0.13; 1.07]	0.057	0.791
White	25/332 (7.5)	N.E. [N.E.; N.E.]	53/317 (16.7)	N.E. [N.E.; N.E.]	0.41	[0.26; 0.67]	<0.001	0.736
Others	3/20 (15.0)	N.E. [N.E.; N.E.]	4/25 (16.0)	N.E. [N.E.; N.E.]	1.44	[0.27; 7.59]	0.664	N.E.
Age groups								
(Interaction test: p = 0.964)								
18 - < 65 years	22/389 (5.7)	N.E. [N.E.; N.E.]	49/394 (12.4)	N.E. [N.E.; N.E.]	0.44	[0.27; 0.73]	0.001	0.380
65 - < 75 years	8/72 (11.1)	N.E. [N.E.; N.E.]	11/53 (20.8)	N.E. [26.4; N.E.]	0.54	[0.21; 1.40]	0.197	0.558


	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
>= 75 years	3/19 (15.8)	32.4 [N.E.; N.E.]	9/25 (36.0)	N.E. [10.3; N.E.]	0.27	[0.06; 1.29]	0.079	0.811
Pre-randomization selection of TKI (Interaction test: p = 0.918)								
Imatinib	6/100 (6.0)	N.E. [N.E.; N.E.]	13/100 (13.0)	N.E. [N.E.; N.E.]	0.43	[0.16; 1.14]	0.080	N.E.
Nilotinib	24/339 (7.1)	N.E. [N.E.; N.E.]	48/330 (14.5)	N.E. [N.E.; N.E.]	0.46	[0.28; 0.75]	0.001	0.456
Dasatinib	3/41 (7.3)	N.E. [32.4; N.E.]	8/42 (19.0)	N.E. [N.E.; N.E.]	0.31	[0.08; 1.25]	0.086	N.E.
Geographic region (Interaction test: p = 0.272)								
Europe excluding Germany	12/201 (6.0)	N.E. [N.E.; N.E.]	35/201 (17.4)	N.E. [N.E.; N.E.]	0.33	[0.17; 0.63]	<0.001	0.600

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Germany	6/91 (6.6)	N.E. [N.E.; N.E.]	10/68 (14.7)	N.E. [N.E.; N.E.]	0.41	[0.15; 1.14]	0.077	N.E.
Others	15/188 (8.0)	N.E. [32.4; N.E.]	24/203 (11.8)	N.E. [N.E.; N.E.]	0.66	[0.35; 1.27]	0.213	0.352

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.14.1: Forest-Plot for AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	5/152	16/148	0.30	0.11; 0.82	0.013
ASC4START	17/237	33/246	0.51	0.28; 0.91	0.021
Pooled Analysis	22/389	49/394	0.44	0.27; 0.73	0.001
65 - < 75 years					
ASC4FIRST	3/34	4/29	0.77	0.17; 3.55	0.741
ASC4START	5/38	7/24	0.43	0.13; 1.44	0.161
Pooled Analysis	8/72	11/53	0.54	0.21; 1.40	0.197
>= 75 years					
ASC4FIRST	2/10	5/13	0.23	0.03; 2.04	0.148
ASC4START	1/9	4/12	0.33	0.04; 2.97	0.299
Pooled Analysis	3/19	9/25	0.27	0.06; 1.29	0.079



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.14.1: Forest-Plot for AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
ELTS (IRT)	**n/N**	**n/N**			
High					
ASC4FIRST	0/23	2/19	0.17	0.00; 7.02	0.125
ASC4START	3/38	8/37	0.34	0.09; 1.27	0.093
Pooled Analysis	3/61	10/56	0.27	0.07; 0.97	0.032
Intermediate					
ASC4FIRST	4/54	11/52	0.30	0.09; 0.94	0.028
ASC4START	5/75	14/73	0.31	0.11; 0.86	0.017
Pooled Analysis	9/129	25/125	0.30	0.14; 0.65	0.001
Low					
ASC4FIRST	6/119	12/119	0.47	0.18; 1.26	0.125
ASC4START	15/171	22/172	0.66	0.34; 1.26	0.205
Pooled Analysis	21/290	34/291	0.59	0.34; 1.02	0.055



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 4-2.14.1: Forest-Plot for AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	3/63	12/61	0.25	0.07; 0.88	0.020
ASC4START	9/138	23/140	0.37	0.17; 0.80	0.008
Pooled Analysis	12/201	35/201	0.33	0.17; 0.63	<0.001
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	6/72	10/53	0.41	0.15; 1.14	0.077
Pooled Analysis	6/91	10/68	0.41	0.15; 1.14	0.077
Others					
ASC4FIRST	7/114	13/114	0.49	0.20; 1.24	0.124
ASC4START	8/74	11/89	0.91	0.36; 2.29	0.847
Pooled Analysis	15/188	24/203	0.66	0.35; 1.27	0.213



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 4-2.14.1: Forest-Plot for AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.14.1: Forest-Plot for AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)


Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Race	**n/N**	**n/N**			
Asian					
ASC4START	2/40	5/45	0.44	0.09; 2.31	0.323
Pooled Analysis	5/128	12/130	0.37	0.13; 1.07	0.057
Asian/Others					
ASC4FIRST	3/91	8/89	0.29	0.08; 1.12	0.057
Others					
ASC4START	3/17	3/21	1.44	0.27; 7.59	0.664
Pooled Analysis	3/20	4/25	1.44	0.27; 7.59	0.664
White					
ASC4FIRST	7/105	17/101	0.36	0.15; 0.88	0.020
ASC4START	18/227	36/216	0.44	0.25; 0.77	0.003
Pooled Analysis	25/332	53/317	0.41	0.26; 0.67	<0.001



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.14.1: Forest-Plot for AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	5/67	9/74	0.61	0.20; 1.84	0.375
ASC4START	6/107	22/124	0.29	0.12; 0.71	0.004
Pooled Analysis	11/174	31/198	0.38	0.19; 0.75	0.004
Male					
ASC4FIRST	5/129	16/116	0.25	0.09; 0.70	0.004
ASC4START	17/177	22/158	0.65	0.34; 1.22	0.177
Pooled Analysis	22/306	38/274	0.48	0.28; 0.82	0.005



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.15 Time to first severe AE leading to discontinuation of treatment: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.414)								
Low	14/290 (4.8)	N.E. [N.E.; N.E.]	18/291 (6.2)	N.E. [N.E.; N.E.]	0.75	[0.37; 1.51]	0.424	0.446
Intermediate	7/129 (5.4)	N.E. [N.E.; N.E.]	16/125 (12.8)	N.E. [N.E.; N.E.]	0.39	[0.16; 0.94]	0.030	0.360
High	3/61 (4.9)	N.E. [N.E.; N.E.]	7/56 (12.5)	N.E. [N.E.; N.E.]	0.39	[0.10; 1.52]	0.160	0.994
Sex								
(Interaction test: p = 0.829)								
Female	10/174 (5.7)	N.E. [N.E.; N.E.]	21/198 (10.6)	N.E. [N.E.; N.E.]	0.52	[0.24; 1.10]	0.083	0.085

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Male	14/306 (4.6)	N.E. [N.E.; N.E.]	20/274 (7.3)	N.E. [N.E.; N.E.]	0.59	[0.30; 1.17]	0.129	0.132
Race								
(Interaction test: p = 0.556)								
Asian	3/128 (2.3)	N.E. [N.E.; N.E.]	8/130 (6.2)	N.E. [N.E.; N.E.]	0.31	[0.08; 1.18]	0.071	0.878
White	19/332 (5.7)	N.E. [N.E.; N.E.]	31/317 (9.8)	N.E. [N.E.; N.E.]	0.54	[0.30; 0.95]	0.030	0.880
Others	2/20 (10.0)	N.E. [N.E.; N.E.]	2/25 (8.0)	N.E. [N.E.; N.E.]	1.47	[0.19; 11.16]	0.709	N.E.
Age groups								
(Interaction test: p = 0.656)								
18 - < 65 years	17/389 (4.4)	N.E. [N.E.; N.E.]	29/394 (7.4)	N.E. [N.E.; N.E.]	0.58	[0.32; 1.06]	0.073	0.605
65 - < 75 years	6/72 (8.3)	N.E. [N.E.; N.E.]	6/53 (11.3)	N.E. [26.4; N.E.]	0.89	[0.26; 3.01]	0.851	0.123


	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
>= 75 years	1/19 (5.3)	N.E. [N.E.; N.E.]	6/25 (24.0)	N.E. [N.E.; N.E.]	0.24	[0.03; 2.06]	0.157	0.997
Pre-randomization selection of TKI								
(Interaction test: p = 0.851)								
Imatinib	3/100 (3.0)	N.E. [N.E.; N.E.]	7/100 (7.0)	N.E. [N.E.; N.E.]	0.42	[0.11; 1.61]	0.191	N.E.
Nilotinib	19/339 (5.6)	N.E. [N.E.; N.E.]	31/330 (9.4)	N.E. [N.E.; N.E.]	0.56	[0.32; 1.00]	0.046	0.850
Dasatinib	2/41 (4.9)	N.E. [N.E.; N.E.]	3/42 (7.1)	N.E. [N.E.; N.E.]	0.63	[0.10; 3.93]	0.620	N.E.
Geographic region								
(Interaction test: p = 0.411)								
Europe excluding Germany	10/201 (5.0)	N.E. [N.E.; N.E.]	23/201 (11.4)	N.E. [N.E.; N.E.]	0.42	[0.20; 0.87]	0.017	0.699

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Germany	4/91 (4.4)	N.E. [N.E.; N.E.]	5/68 (7.4)	N.E. [N.E.; N.E.]	0.59	[0.16; 2.28]	0.443	N.E.
Others	10/188 (5.3)	N.E. [N.E.; N.E.]	13/203 (6.4)	N.E. [N.E.; N.E.]	0.87	[0.38; 1.99]	0.734	0.742

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 4-2.15.1: Forest-Plot for Severe AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	3/152	7/148	0.42	0.11; 1.65	0.201
ASC4START	14/237	22/246	0.63	0.32; 1.24	0.177
Pooled Analysis	17/389	29/394	0.58	0.32; 1.06	0.073
65 - < 75 years					
ASC4FIRST	3/34	1/29	3.59	0.37; 34.97	0.240
ASC4START	3/38	5/24	0.42	0.09; 1.90	0.244
Pooled Analysis	6/72	6/53	0.89	0.26; 3.01	0.851
>= 75 years					
ASC4FIRST	0/10	3/13	0.20	0.00; 8.24	0.157
ASC4START	1/9	3/12	0.44	0.05; 4.26	0.467
Pooled Analysis	1/19	6/25	0.24	0.03; 2.06	0.157



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 4-2.15.1: Forest-Plot for Severe AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 4-2.15.1: Forest-Plot for Severe AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	2/63	6/61	0.31	0.06; 1.57	0.138
ASC4START	8/138	17/140	0.45	0.19; 1.05	0.057
Pooled Analysis	10/201	23/201	0.42	0.20; 0.87	0.017
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	4/72	5/53	0.59	0.16; 2.28	0.443
Pooled Analysis	4/91	5/68	0.59	0.16; 2.28	0.443
Others					
ASC4FIRST	4/114	5/114	0.73	0.20; 2.72	0.638
ASC4START	6/74	8/89	0.97	0.33; 2.84	0.956
Pooled Analysis	10/188	13/203	0.87	0.38; 1.99	0.734




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.15.1: Forest-Plot for Severe AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 4-2.15.1: Forest-Plot for Severe AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.15.1: Forest-Plot for Severe AE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Sex	**n/N**	**n/N**			
Female					
ASC4FIRST	4/67	3/74	1.70	0.37; 7.87	0.496
ASC4START	6/107	18/124	0.35	0.14; 0.89	0.020
Pooled Analysis	10/174	21/198	0.52	0.24; 1.10	0.083
Male					
ASC4FIRST	2/129	8/116	0.22	0.05; 1.03	0.035
ASC4START	12/177	12/158	0.84	0.37; 1.86	0.660
Pooled Analysis	14/306	20/274	0.59	0.30; 1.17	0.129



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Table 4-2.16 Time to first SAE leading to discontinuation of treatment: Time to event analysis by subgroups - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Stratification factor: ELTS based on randomization data from IRT								
(Interaction test: p = 0.099)								
Low	14/290 (4.8)	N.E. [N.E.; N.E.]	11/291 (3.8)	N.E. [N.E.; N.E.]	1.23	[0.56; 2.71]	0.609	0.261
Intermediate	2/129 (1.6)	N.E. [N.E.; N.E.]	7/125 (5.6)	N.E. [N.E.; N.E.]	0.25	[0.05; 1.22]	0.065	0.852
High	1/61 (1.6)	N.E. [N.E.; N.E.]	4/56 (7.1)	N.E. [N.E.; N.E.]	0.23	[0.03; 2.08]	0.154	0.996
Sex								
(Interaction test: p = 0.782)								
Female	6/174 (3.4)	N.E. [N.E.; N.E.]	10/198 (5.1)	N.E. [N.E.; N.E.]	0.69	[0.25; 1.93]	0.480	0.147

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Male	11/306 (3.6)	N.E. [N.E.; N.E.]	12/274 (4.4)	N.E. [N.E.; N.E.]	0.79	[0.35; 1.80]	0.580	0.693
Race (Interaction test: p = 0.747)								
Asian	0/128	N.E. [N.E.; N.E.]	5/130 (3.8)	N.E. [N.E.; N.E.]	0.08	[0.00; 1.88]	0.017	1.000
White	15/332 (4.5)	N.E. [N.E.; N.E.]	16/317 (5.0)	N.E. [N.E.; N.E.]	0.83	[0.41; 1.68]	0.606	0.401
Others	2/20 (10.0)	N.E. [N.E.; N.E.]	1/25 (4.0)	N.E. [N.E.; N.E.]	1.70	[0.15; 18.72]	0.663	N.E.
Age groups (Interaction test: p = 0.333)								
18 - < 65 years	10/389 (2.6)	N.E. [N.E.; N.E.]	18/394 (4.6)	N.E. [N.E.; N.E.]	0.56	[0.26; 1.21]	0.134	0.929
65 - < 75 years	5/72 (6.9)	N.E. [N.E.; N.E.]	1/53 (1.9)	N.E. [N.E.; N.E.]	4.43	[0.50; 39.25]	0.148	0.996


	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
>= 75 years	2/19 (10.5)	N.E. [N.E.; N.E.]	3/25 (12.0)	N.E. [N.E.; N.E.]	1.11	[0.16; 7.88]	0.919	0.919
Pre-randomization selection of TKI								
(Interaction test: p = 0.938)								
Imatinib	3/100 (3.0)	N.E. [N.E.; N.E.]	3/100 (3.0)	N.E. [N.E.; N.E.]	0.93	[0.19; 4.63]	0.931	N.E.
Nilotinib	13/339 (3.8)	N.E. [N.E.; N.E.]	17/330 (5.2)	N.E. [N.E.; N.E.]	0.72	[0.35; 1.49]	0.376	0.991
Dasatinib	1/41 (2.4)	N.E. [N.E.; N.E.]	2/42 (4.8)	N.E. [N.E.; N.E.]	0.41	[0.03; 4.83]	0.466	N.E.
Geographic region								
(Interaction test: p = 0.863)								
Europe excluding Germany	7/201 (3.5)	N.E. [N.E.; N.E.]	11/201 (5.5)	N.E. [N.E.; N.E.]	0.64	[0.25; 1.64]	0.345	0.320

	Treatment groups				Comparison			
	Asciminib (N=480)		Investigator Selected TKI (N=472)		HR	[95% CI]	p-value	Test for Heterogeneity p-value
	n/N* (%)	Median (months) [95% CI]	n/N* (%)	Median (months) [95% CI]				
Germany	4/91 (4.4)	N.E. [N.E.; N.E.]	3/68 (4.4)	N.E. [N.E.; N.E.]	0.88	[0.19; 4.01]	0.866	N.E.
Others	6/188 (3.2)	N.E. [N.E.; N.E.]	8/203 (3.9)	N.E. [N.E.; N.E.]	0.81	[0.28; 2.35]	0.697	0.733

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
HR: Hazard Ratio
IPD: Individual Patient Data
.....
If there are not at least 10 patients in every subgroup or not at least 10 events in at least one subgroup, no subgroup analyses were performed for the corresponding attribute.
Two-sided 95% CI for KM percentiles are computed by the Brookmeyer and Crowley method (log log transformation).
The HR and 95% CI values are from a stratified Cox proportional hazard model with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
The model for the interaction p-values includes additionally subgroup and treatment arm*subgroup as covariates.
P-Values are from a stratified logrank test with stratification variables ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the heterogeneity test is based on a stratified Cox proportional hazard model with an additional interaction term between study and treatment arm.
For the subgroups of Stratification factor: ELTS based on IRT randomisation data only the stratification variables Pre-randomisation selection TKI (IRT) and study were used and for the subgroups of Pre-randomisation selection TKI only the stratification variables ELTS score (IRT) and study were used.
The reference group in the stratified Cox proportional hazard model is Investigator Selected TKI.
Firth correction is used in the proportional hazard model if indicated by extreme values of the hazard ratio in case of few/zero events.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 4-2.16.1: Forest-Plot for SAE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Age groups	**n/N**	**n/N**			
18 - < 65 years					
ASC4FIRST	1/152	2/148	0.50	0.05; 5.55	0.567
ASC4START	9/237	16/246	0.57	0.25; 1.28	0.165
Pooled Analysis	10/389	18/394	0.56	0.26; 1.21	0.134
65 - < 75 years					
ASC4FIRST	3/34	1/29	3.43	0.35; 33.48	0.261
ASC4START	2/38	0/24	2.16	0.05; 90.36	0.353
Pooled Analysis	5/72	1/53	4.43	0.50; 39.25	0.148
>= 75 years					
ASC4FIRST	1/10	2/13	1.00	0.06; 15.99	1.000
ASC4START	1/9	1/12	1.22	0.08; 19.58	0.886
Pooled Analysis	2/19	3/25	1.11	0.16; 7.88	0.919



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 4-2.16.1: Forest-Plot for SAE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Figure 4-2.16.1: Forest-Plot for SAE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)

Attribute/Subgroup/Study	Asciminib	Inv. Selected TKI	HR	95% CL	P-value
Geographic region	**n/N**	**n/N**			
Europe excluding Germany					
ASC4FIRST	2/63	1/61	1.93	0.17; 21.74	0.587
ASC4START	5/138	10/140	0.50	0.17; 1.48	0.203
Pooled Analysis	7/201	11/201	0.64	0.25; 1.64	0.345
Germany					
ASC4FIRST	0/19	0/15	N.E.	N.E.; N.E.	N.E.
ASC4START	4/72	3/53	0.88	0.19; 4.01	0.866
Pooled Analysis	4/91	3/68	0.88	0.19; 4.01	0.866
Others					
ASC4FIRST	3/114	4/114	0.67	0.15; 3.03	0.605
ASC4START	3/74	4/89	0.98	0.22; 4.41	0.975
Pooled Analysis	6/188	8/203	0.81	0.28; 2.35	0.697




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.16.1: Forest-Plot for SAE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)




n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.16.1: Forest-Plot for SAE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-2.16.1: Forest-Plot for SAE leading to discontinuation of treatment: time to first occurrence - Subgroup analysis - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits.
p-value from a stratified log-rank test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)


Table 4-4.1 Discontinuation of treatment due to AE - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Competing risks analysis (Safety Analysis Set)

	Treatment groups		Comparison			
	Asciminib (N = 480)	Investigator Selected TKI (N = 472)	sHR	[95%-CI]	P-Value	Test for Heterogeneity p-Value
N*	480	472				
Number of patients with events, n (%)	34 (7.1)	70 (14.8)	0.46	[0.31; 0.69]	<0.001	0.984
Number of patients with competing risk, n (%)	52 (10.8)	85 (18.0)				
Number of patients censored, n (%)	394 (82.1)	317 (67.2)				
Cumulative incidence (%) [95%-CI]						
Month 4	3.8 [2.3; 5.7]	5.9 [4.0; 8.3]				
Month 8	5.2 [3.5; 7.5]	8.5 [6.2; 11.2]				
Month 12	5.6 [3.8; 7.9]	10.6 [8.0; 13.6]				
Month 16	6.1 [4.2; 8.5]	12.5 [9.7; 15.7]				
Month 20	7.3 [5.1; 10.0]	14.9 [11.7; 18.4]				
Month 24	7.3 [5.1; 10.0]	16.1 [12.7; 19.8]				
Month 28	7.3 [5.1; 10.0]	16.8 [13.2; 20.9]				
Month 32	7.3 [5.1; 10.0]	16.8 [13.2; 20.9]				
Month 36	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]				

	Treatment groups		Comparison			
	Asciminib (N = 480)	Investigator Selected TKI (N = 472)	sHR	[95%-CI]	P-Value	Test for Heterogeneity p-Value


sHR: Sub-distribution Hazard Ratio
CI: Confidence Interval
N*: Number of patients included in the analysis
n (%): Number and percentage of patients
.....
Competing risk for the event of interest is the premature discontinuation of study medication for any reason except AE.
Two-sided 95% CI for the cumulative incidence functions are computed by Kaplan-Meier methods.
The sub-distribution HR and 95% CI values are from a stratified Fine-Gray proportional hazard model for competing risk analysis with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study and covariate treatment arm.
P-Values are from a stratified Gray test for competing risks with stratification factors ELTS Score (IRT), Pre-Randomization selection TKI (IRT) and study.
The p-value for the hetereogeneity test is based on a stratified Fine-Gray proportional hazard model with an additional interaction term between study and treatment arm.
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-4.1 Discontinuation of treatment due to AE - Metaanalysis based on IPD from ASC4FIRST and ASC4START: Competing risks analysis: Plot of cumulative incidence functions (Safety Analysis Set)



Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)

Figure 4-4.1.1: Forest-Plot for competing risks analysis of Time to discontinuation of treatment due to AE - Metaanalysis based on IPD from ASC4FIRST and ASC4START (Safety Analysis Set)



n/N: Number of patients with event/number of patients included in the analysis, CL: Confidence limits, sHR: Sub-distribution hazard ratio.
p-value from a stratified Gray test for treatment difference
Data Cut/22OCT2024 (ASC4FIRST), 15MAY2025 (ASC4START)